<SEC-DOCUMENT>0001566044-20-000011.txt : 20200806
<SEC-HEADER>0001566044-20-000011.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806072939
ACCESSION NUMBER:		0001566044-20-000011
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Menlo Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		201079822

	BUSINESS ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		800-775-7936

	MAIL ADDRESS:	
		STREET 1:		520 U.S. HIGHWAY 22, SUITE 204
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mnlo-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355,d:b921aa21f1ac4534b8499c259d3bc7e0--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:mnlo="http://www.menlotherapeutics.com/20200630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mnlo-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV81LTEtMS0xLTA_7c0bc2c7-4d52-46c7-8c59-b7bdd6dc5536">0001566044</ix:nonNumeric><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV82LTEtMS0xLTA_70053a8c-9c0e-4a3f-8aac-b2c77045cf61">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV83LTEtMS0xLTA_c1d1db00-a116-4849-a39d-23547b24217b">2020</ix:nonNumeric><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV84LTEtMS0xLTA_9f146117-4ca6-4642-ad3f-79bb565ac2f5">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV85LTEtMS0xLTA_f0519d6e-6266-42a2-9774-49ec920f61d7">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9e7382c919584b5a9708af3049536ae3_D20200803-20200803" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzQzL2ZyYWc6MGY5ZjA4YWZlMmMwNDU2MWIzMGMyZGM4ZmNjNjQ3ZjYvdGV4dHJlZ2lvbjowZjlmMDhhZmUyYzA0NTYxYjMwYzJkYzhmY2M2NDdmNl8zMjk4NTM0ODgzNDA1_241c30ca-d435-42a5-ba69-6ccdd937a810">2</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i17830450592d46a684d1bad07edf6adc_D20200803-20200803" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzQzL2ZyYWc6MGY5ZjA4YWZlMmMwNDU2MWIzMGMyZGM4ZmNjNjQ3ZjYvdGV4dHJlZ2lvbjowZjlmMDhhZmUyYzA0NTYxYjMwYzJkYzhmY2M2NDdmNl8zMjk4NTM0ODgzNDA4_38b10915-4011-4006-bf4d-9968a4d12618">7</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mnlo-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i6192338baf694a57931b00fdf1208402_I20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i55514fe802bc4047841713151110e3e1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ef5e665bd14d8f848bbea621063a27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic53c293513a3411988e3f82450bc2600_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89212e9395d543b584178d191c5a52df_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ac8ecea9da46f18647e4055ba4c2bf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e10a9cdb13646a5b01897e039b29eb1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23934cfba1c34fb59943833e025eb17f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9988a3e0ca4c50b6d4ebe101481b7b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3031d6ad8c4ebebd28af76579e5a58_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115874d2c71d4965a64a283d45279d4b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99638830588b43439d03faa00fafb735_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f696343f7b4319b954654fee16542a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ec0b6d315d42bf984266ae09cc24f0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10f110e89794a328cd6dff889719d0f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fddccdca3294d4e9d00f89b822119c3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd4960891c34721acc23f0da145dc30_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab607da61e54796b75a8649d120f305_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968d104d31de4459a96511fbf90c1f1d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a66f541efd4f15931ae16609a79908_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3163028e034d0a88324b9af3624248_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3eae89d05b4922b7037525a28870c3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i183126c41cc449dbba13257e8dea4ace_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4fe139b2cc48aaa7444cf89368196d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50df20b4b873412e8222bce987ca55c7_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8caa6a61613a445594a114cf0db71d79_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2f04cbef3845e28d047be6ae20e735_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9778e0408b1f42deaf3632925439e4b0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6feda25267a14e1e9087b4289d642160_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95e4afe75e94206bc731058ea393dba_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7973a9b2e41c4011a66ad0e37aa68515_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib820da2007bf41dba9549a9c8a93db1f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b992755b2b4a5ba58755071de873b4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b02388b48f440649017facfc2fec45b_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b661c91124c4db18890eb501396ac7e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9558e2deebc4ba3a4cbcf4217d7e051_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3f4643a51a41288e8ccd0e60759c97_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101055c62f9d45799bf1500fe791edc4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74604aa6bc2461cb5df34b326723115_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a497140cb264e87a5545a4066bd9ccd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e49138bc604905a6e1fb9cb99008d0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74810c4013404762b66d6ab7950a6c2a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3359148f5b174e9d9dbd7205f678bc8d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004a8f9abfde49159237ec2532aff25c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b89a0f42154a88be72ee1ba1cc8faf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5214fa97c5fa453fa43fa4fe0908ef99_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5439508597d54228b44eb110a0163531_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>mnlo:segments</xbrli:measure></xbrli:unit><xbrli:context id="i27310920890a449ca2694d53e047a675_D20200423-20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-23</xbrli:startDate><xbrli:endDate>2020-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da754f4e94e4544b609a323172766eb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a470217c3a4272adc3535da6eb3922_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fba894574f6426bb988c61b2df7510c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49710f5b3cb5425584627e0e1bcc3521_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f3259df41a745da91e614f0f535fe16_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf5e963873a4e6982e47201cb3ff7f8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29ad7a578cf43a6acb996ff258f0c7c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc2826b77413461d84519a6b754cb004_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c758c8f421d4ae5a44d89c91a01007d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62991dd9b59d4f20932a6cc542870ab2_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d2dac9a2a445dfae26312379d3050b_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fe41f20f4947e2a6b7466a16a798d9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475935ac417d417b95b57d209280bd42_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6ecbab924a41ee8267c4ae3a55f162_I20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64bfe9f3e6894c12a9573e9ba7298549_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363b390923d44002aea9667a68a52c10_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739bb757f1734242959f7c1f7cabb3dd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0c3f02a2d0451fb10bb5af69b6fe95_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf481a0bc8d434eba2737a7b1854201_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb682629e2c14d16967faab5132bce3d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e9d51a1cbf04ecfa836c93c8fcf8b60_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d8a0654d2c844fab4d30cbe0f737b93_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddecf24382d740b79c3744ff4ae84e96_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35eb5a8b86fc4928a2d78dfe2c2b62c4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b5c2e12f42a4c42ab17af5707fd15c0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedfd359d21884ac0b9588367562b5816_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8222d051b543688377451564f533a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186f34938c484be6bd6c29ddc7b7009a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23a57fa3ccf4cc3b6bcee3e98135a78_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mnlo:IsraeliMutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264f53d270b5492d9f34a2d7a650ab3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mnlo:IsraeliMutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a6fc18eac5e4db28a62b77aad463b0d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01876072bcc04580b5f7c62f8637951e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c5efb4fbad4902aaac65636b3fac52_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfa5ee44fb64997893890be476e59ae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5885b910649487099b87fd418a15dde_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d53f792aa942e79e0908f016e0b6ac_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie41f84f7e3ef4b8a9a94c1a9b121dd36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i621dc5363bfa40e3ab7836027e3273ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11306223e6aa4bbc98552eff8183e5d6_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shareholders"><xbrli:measure>mnlo:shareholders</xbrli:measure></xbrli:unit><xbrli:unit id="lenders"><xbrli:measure>mnlo:lenders</xbrli:measure></xbrli:unit><xbrli:context id="ia3617748d41e46a8bfedb32f0d650a74_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423fa226d79249718ae35ed0e4fd377b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f85dcc728e248d98e63a19af7ced4ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranches"><xbrli:measure>mnlo:tranches</xbrli:measure></xbrli:unit><xbrli:context id="i4fa0d91fe20746dc801522cdb641699a_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8232e19d10a4519b9a3cd10a5721fb1_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench1LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a65c85354904beda1b2323ac7ec07cd_I20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1adb6f4952624c32ba9efdccfaadf065_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench3LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52154cb6d81246b2b19b393816177d95_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7a8db7397904657874b01bbee72d568_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665aac50c21e4c9382a4dedf21e3a6d4_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec71e92949949a9a5cbf85570f5b1c2_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4fd37970a64213b591edc27d8201a8_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647408d71ea94b9aacbdfd5eea1f5f10_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="votes"><xbrli:measure>mnlo:votes</xbrli:measure></xbrli:unit><xbrli:context id="i21624033d4ac4fff8c601a26fb4f4cd2_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c8813e111447bda5117bdf5d6a2b26_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45c461b63af4f079fa025d92a11ec36_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a4e94dab8049848e6d72417f3fbe51_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d9ecc3914e54a259847aa543d67e621_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:CSRAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-09</xbrli:startDate><xbrli:endDate>2020-06-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92c1d7c7352a4dca951e1bcd7cb06a55_I20200609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if23f7b87177b47a08e6248caeff2b802_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd250813f00419fbd2e80392e7e0172_D20190729-20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-29</xbrli:startDate><xbrli:endDate>2019-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70cb25f8075540d79ea2d6581691f94f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd59a6ce5690423f839a46a944f522ff_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0047714113804cad9c16bdab5627a1ea_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7afa2c35824eb99e24ca41f2a6b35f_I20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5244e3d9cde04b82806e7986585ce214_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1ae53396f194b79aee91b06e1fcfc53_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128638d8b51d4c5e8740fccfe8bb54e9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf13670f3fa4285a1f4d963e62abc74_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de299f068754a7abc7d85f9a74d1a52_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fdbbba6e7d4d6c8f6192df59a0b3e1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158cc30187ca4219a42536fd98d5fdbd_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7da630ee23404cb0c42917365732be_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6a6702cbe1405fae1d4152caf10cf8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4b715adc284a418c6a708ee727979b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b9c626f5cc4797874b2b7b5b559927_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea5dbcf0c124143b148b23cc686ff50_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic46c960fd7f2441389d418c74a68bbd1_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c1a034475f46eb968fab88c0b84296_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086c3c739539445da6ad056f578caedb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-09</xbrli:startDate><xbrli:endDate>2020-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib290ea8b639941c0865b91b70ea01d50_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b1bb38c09694860a74fca4cb02b7fd2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875e9e1345164d94bc58815365779517_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82863cbbff6145f2bedee6a09e97f8bc_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466f28e0d85348cab9cc5df9627c2a21_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a8e4626ad948338081011de428c56a_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282c323ee4fd405f9b9276a665217e6f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6103d5338e747d3863548470494ec95_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eabf77585034e158ba10a9768877f29_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb9a4f704626440cb634b11d52f4e479_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="if2a66420fa684fbea1eee87e6abdd8e4_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:OriginalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88fbd3af56884c12ae3c30505c83a2f9_D20190313-20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:AdditionalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-13</xbrli:startDate><xbrli:endDate>2019-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4760e6ad58b548bfa055202c3d8cd2e7_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:OriginalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8c08728edb45bd9ea6a6f0fc6e5a20_I20190313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:AdditionalSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e404bead2e4f94b38bf24b66089cdf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:RedwoodCityCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuits"><xbrli:measure>mnlo:lawsuits</xbrli:measure></xbrli:unit><xbrli:context id="id3d0a4c5350e4cbd93b8042046be79d5_I20181108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:InitialPublicOfferingLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mnlo:OfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c399325c504de1963cfc9cabc42c2c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:MergerLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241af8b663f1455bb67c14d739a9fee6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7382c919584b5a9708af3049536ae3_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17830450592d46a684d1bad07edf6adc_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_1"></div><div style="min-height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1NzAw_ed64bfbc-e34d-411a-863e-86015a5cb0a9">10-Q</ix:nonNumeric></span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg5_1658654f-20a7-47cb-b362-25e6ec9a94aa">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8xNjQ5MjY3NDQ0MjA0_a23d5205-c101-4b92-b523-593bf8646960">JUNE&#160;30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg4_32b7fbc2-411c-46db-9673-b2109da5a259">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">FOR THE TRANSITION PERIOD FROM ___ TO ___.</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1NzAx_ba786627-8cb0-4dbb-957e-010a55b6c6d5">001-38356</ix:nonNumeric></span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg3_a3d9fd29-b3fd-4c9d-84b3-dbc6847094b3">MENLO THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:46.169%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.660%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.171%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6ZmVhMWNkOTlhYzdkNDNiYWJhMjBiOGFmMDQ4MTc1MGYvdGFibGVyYW5nZTpmZWExY2Q5OWFjN2Q0M2JhYmEyMGI4YWYwNDgxNzUwZl8wLTAtMS0xLTE5OQ_8600d52b-5eba-4d72-8dac-ce6f287776d3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6ZmVhMWNkOTlhYzdkNDNiYWJhMjBiOGFmMDQ4MTc1MGYvdGFibGVyYW5nZTpmZWExY2Q5OWFjN2Q0M2JhYmEyMGI4YWYwNDgxNzUwZl8wLTItMS0xLTIwMQ_efe6942e-587a-476c-aea4-7bcb11cea810">45-3757789</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgz_202bc2a8-cf12-4088-a580-b61b9ae6957e">520 U.S. Highway 22, Suite 204</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg0_798766bc-471b-43ca-b739-b3502988bf1d">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg1_323c1878-d191-414a-be86-dee561974ad4">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg2_4c93f814-7197-4578-8e6d-b18714e9fa1f">08807</ix:nonNumeric></span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Address of principal executive offices including zip code)</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgx_571c5dbd-248e-4187-9cdf-9ce198b396e7">800</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgy_fecdf2bd-4218-40ed-8d1f-b871c1d424e6">755-7936</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:30.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.452%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:30.454%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTAtMS0xLTIxOQ_59979d36-0468-461a-a25b-b4b5de51d536">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTItMS0xLTIyMA_ac2d4640-d0e1-4166-bb63-0c30624e27e5">MNLO</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTQtMS0xLTIyNQ_5406b1a5-81d8-48d6-bdd7-e455ed4fafc0">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk1_2a86225d-621b-430f-9e2a-bc0216ff0a75">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk2_65d07186-222c-43c8-9f6a-8f2ae1b5b848">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:20.693%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.513%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.437%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.693%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Large accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8wLTMtMS0xLTIzNQ_87da58b1-57c4-4aa3-afb0-d3c4e72596b9">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Smaller reporting company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8xLTQtMS0xLTIzMQ_ef4c939d-ee95-4b3a-8b05-74da0f0c022c">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8yLTQtMS0xLTIzMQ_aac99dbd-db9d-456f-974f-c7acbeda225a">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1ODQ0_71f7f725-35a0-4f43-b094-95a8cd837ee1">&#9746;</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk3_db5985ad-c54e-4c11-ab66-dc0cb718d247">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of July&#160;30, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i6192338baf694a57931b00fdf1208402_I20200730" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8xNjQ5MjY3NDQ0MDQ5_230621fa-f7c7-41c7-b466-38a623672d69">167,690,615</ix:nonFraction> shares of the registrant&#8217;s Common Stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:78.380%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.811%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Page</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_10">Part I</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_10">Financial Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_10">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_13">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_13">Unaudited Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_13">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_16">Unaudited Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_16">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_22">Unaudited Condensed Consolidated Statements Of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_22">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_25">Unaudited Condensed Consolidated Statements Of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_25">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_28">Unaudited Condensed Consolidated Statements Of Changes In Stockholders' Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_28">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_31">Unaudited Condensed Consolidated Statements Of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_31">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_34">Notes to Unaudited Interim Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_34">14</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_91">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_91">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_91">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_127">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_127">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_127">46</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_130">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_130">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_130">46</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_133">Part II</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_133">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_133">47</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_136">Item 1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_136">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_136">47</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_139">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_139">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_139">47</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_142">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_142">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_142">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_145">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_145">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_145">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_148">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_148">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_148">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_151">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_151">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_151">48</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_154">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_154">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_154">49</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_157">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_157">51</a></span></div></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries, including AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, ZILXI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">,</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Molecule Stabilizing Technology (MST)&#8482; and MST&#8482;. This report also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are statements that could be deemed forward-looking statements reflecting the current beliefs and expectations of management with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These statements are often identified by the use of words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;until,&#8221; &#8220;if&#8221; and similar expressions or variations.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following factors, among others, including those described in the section titled &#8220;Risk Factors&#8221; included in this Quarterly Report on Form 10-Q, could cause our future results to differ materially from those expressed in the forward-looking information:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully commercialize AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and ZILXI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">  and our other product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disruptions related to a pandemic, epidemic or outbreak of a contagious disease, such as COVID-19, on the ability of our suppliers to provide materials for our products and product candidates, initiating and retaining patients in our clinical trials, distribution of our products and business sales execution, operating results, liquidity and financial condition;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the regulatory approval process for our product candidates, including any delay or failure in obtaining requisite approvals;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the potential market size of treatments for any diseases and market adoption of our products, if approved or cleared for commercial use, by physicians and patients;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing, cost or other aspects of the commercialization of AMZEEQ, ZILXI and product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to achieve favorable pricing for AMZEEQ, ZILXI and product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">third-party payor reimbursement for AMZEEQ, ZILXI and any future products;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">developments and projections relating to our competitors and our industry, including competing drugs and therapies, particularly if we are unable to receive exclusivity;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">risks related to our indebtedness, including our ability to comply with the covenants in our loan documents;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing of commencement of future non-clinical studies and clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully complete, and receive favorable results in, clinical trials for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our intentions and our ability to establish collaborations or obtain additional funding;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing or likelihood of regulatory filings and approvals or clearances for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to comply with various regulations applicable to our business;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding the commercial supply of AMZEEQ, ZILXI and product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to create intellectual property and the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the timing, costs or results of litigation, including litigation to protect our intellectual property;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital on acceptable terms or at all;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to attract and retain key scientific or management personnel;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our defense of current and any future litigation that may be initiated against us;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our expectations regarding licensing, business transactions and strategic operations; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our future financial performance and liquidity.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_13"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Unaudited Condensed Consolidated Financial Statements</span></div><div style="margin-top:10pt;"><span><br/></span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_16"></div><div style="text-indent:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands, except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">A s s e t s</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNS0xLTEtMS0w_c136fa89-81f1-4049-b6cd-490d4e7e98b5">96,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNS0zLTEtMS0w_ee701bf4-7d06-4e1a-af4c-c3ba5f5db13e">43,759</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNi0xLTEtMS0w_c55e1cc9-53d9-4a3c-a9a1-82a5db9e547a">855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNi0zLTEtMS0w_fa72e4b8-dce1-4ca9-8e71-88c93856c0a0">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term bank deposits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNy0xLTEtMS0w_3f0f6f1f-69c6-4086-813a-c864c53c04ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNy0zLTEtMS0w_378362e3-c503-4fac-bd6e-1d1dc5c24693">12,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in marketable securities (Note 6)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOC0xLTEtMS0w_5acf6ed7-5648-46a3-a318-62fd28358d1e">2,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOC0zLTEtMS0w_744e1c6e-5e69-4223-9eb2-b5ccae221e6f">16,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted investment in marketable securities (Note 6)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:RestrictedInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOS0xLTEtMS0w_b384c1d4-3ebb-41e6-bd4d-1ab6558a7d1a">435</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:RestrictedInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOS0zLTEtMS0w_e0c34940-044f-429e-873f-294ce7ad143c">434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade receivables, net of allowances</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTAtMS0xLTEtMA_4e322f21-589c-449b-8f08-b7b03706ee89">6,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTAtMy0xLTEtMA_a7c6162c-4602-437a-bfe6-36e53375ae55">135</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMS0xLTEtMzkxOQ_579b8875-65b1-489b-b517-92c33d02251d">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMy0xLTEtMzkyMg_689512a5-fd38-4b00-bb46-ee74183f4c5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMS0xLTEtMA_41ca8570-ddd4-4f51-9d07-24112730b832">2,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMy0xLTEtMA_2def48bc-6c89-42b6-94d2-1dcc184765a6">1,557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory (Note 7)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTItMS0xLTEtMA_d92e02d8-2afd-4b0a-9aa5-3a85fc3ae095">5,801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTItMy0xLTEtMA_f761b55e-79ba-42f2-a6c2-09f7150a0e92">1,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL CURRENT ASSETS</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTMtMS0xLTEtMA_037e787a-214b-4642-97a1-51996a72a527">119,290</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTMtMy0xLTEtMA_408f9c39-d06a-422f-beb3-b97ec3788d5f">76,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NON-CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTctMS0xLTEtMA_74371d35-d5df-4de7-92a8-aedc108e24f8">2,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTctMy0xLTEtMA_cb837f9d-9949-45e9-a855-5c1885c4e0c1">2,885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets (Note 10)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTgtMS0xLTEtMA_5617bab7-e571-47d7-a8e6-94565012bae1">2,558</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTgtMy0xLTEtMA_dcab6da3-be9f-451c-9bbe-6d5fc5429ecc">1,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjEtMS0xLTEtMA_b77a743e-bd7a-4e8f-aa51-9420b54135e8">6,183</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjEtMy0xLTEtMA_2f75065b-a2fc-4209-8e39-bf3bf7ef2f3f">166</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL NON-CURRENT ASSETS</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjItMS0xLTEtMA_1fc950cd-278e-4370-bd7d-e3534d5c8823">11,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjItMy0xLTEtMA_a51045ac-23c4-40bb-a727-ac974f18c72a">4,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL ASSETS</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjQtMS0xLTEtMA_c0dc6a41-df79-43a8-a961-2de1b50a1182">130,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjQtMy0xLTEtMA_f5a0aa12-f74a-4b3e-9100-3ae27150462d">81,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands, except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trade payables</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNS0xLTEtMS0w_293ec322-6f20-4846-aea7-adb86cca43a3">9,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNS0zLTEtMS0w_6e418724-2fd7-4b9b-b4d9-21d20595609d">19,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNi0xLTEtMS0w_a8a4057b-529a-422e-b1e9-97b433c06eed">8,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNi0zLTEtMS0w_5b9ac58e-29e9-46b2-a21b-0ed50c1b96a2">3,381</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee related obligations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNy0xLTEtMS0w_4120f6ea-8835-4011-bab5-fda6900c22ff">4,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNy0zLTEtMS0w_0f8e643c-b87d-4c52-94da-ac733e0969e6">5,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities (Note 10)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfOC0xLTEtMS0w_0bef0e93-179e-46b3-99f0-2431261d90a4">1,245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfOC0zLTEtMS0w_88349091-2b09-49c2-ab4c-2474156adc57">1,092</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTEtMS0xLTEtMA_caa95b38-c5a6-411e-81bd-9d1a57c89a05">142</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTEtMy0xLTEtMA_b515c27a-84a3-4447-b88d-061394789486">270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL CURRENT LIABILITIES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTItMS0xLTEtMA_0f5028cd-64b8-49bb-a962-474174a8b901">24,232</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTItMy0xLTEtMA_0960b6a4-0900-413c-bbb9-7ab1e1a3f80e">29,326</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LONG-TERM LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liability for employee severance benefits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTYtMS0xLTEtMA_087803d6-5170-45e2-842c-35e2e86e1950">403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTYtMy0xLTEtMA_098d6a24-834f-4ba0-9b9e-f4f9081f1dd1">424</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities (Note 10)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTctMS0xLTEtMA_2d671540-68b7-441e-ad05-7cf340bfd40c">1,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTctMy0xLTEtMA_27485858-6392-444e-ae65-de0ce4472d1a">653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt (Note 8)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTgtMS0xLTEtMA_197a25a1-45aa-4f51-b9ec-ce519fa8e883">32,915</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTgtMy0xLTEtMA_20e7893b-d718-4b6b-807b-2677c588b06d">32,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTktMS0xLTEtMA_e300afb1-42e7-4bfc-ae14-9c3ea71e1516">456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTktMy0xLTEtMA_816f116c-01f0-4a35-ac4d-5872bc1f28f3">456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL LONG-TERM LIABILITIES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjAtMS0xLTEtMA_1d6a78a4-c590-41af-9db4-18f0c2c36ab6">35,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjAtMy0xLTEtMA_0c130944-3963-47cd-be42-dbcf4cf3f71e">34,258</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL LIABILITIES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjEtMS0xLTEtMA_efaf068d-c849-4ab5-94fa-19a1d0627160">59,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjEtMy0xLTEtMA_1fc8df3e-e57b-414e-8314-e4cf5257ab25">63,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">COMMITMENTS (Note 11)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMS0xLTEtMA_d912d312-0935-4a81-86b8-238be27b2ec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMy0xLTEtMA_e48b184b-9ec6-4b60-83f2-8c2e0acea58b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">STOCKHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MTg_d66c39d4-0cfc-40a6-b668-557d33df08a5"><ix:nonFraction unitRef="usdPerShare" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MTg_e31b6412-1287-4ead-958c-9dd3431b7065">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MjE_940dffff-e0df-4863-a03d-b891ea7d9fc7"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MjE_c3d80902-0570-4d9e-aaa0-44a90b254482">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_0324312a-7f31-44b3-becc-16d50134820f"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_1ebb4442-fece-4da0-b02a-ee43f13e8594"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_a850a1b1-db00-404a-aeb9-0838844ef78f"><ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_fc00f036-8259-4746-b8f6-95e53c69fd50">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMS0xLTEtNDE5OQ_0d537a2f-f7ed-4a17-8b23-6f53c4f146d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMy0xLTEtNDE5Ng_6c924dd8-93e5-4e5d-bb44-4de7e2fa8399">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:22.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk2NA_45a31046-9dfa-412c-9d68-fc9cabc8cb03"><ix:nonFraction unitRef="usdPerShare" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk2NA_6a3fc58f-2d61-468d-b104-2dd62e70d338">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk1NQ_23835869-0064-4ab6-94cd-d5c637507d94"><ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk1NQ_b3e5dba4-39d6-4478-92ca-463e7ad1bc6d">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; <ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAxMQ_4f2a5a0b-b41c-46d8-b56d-a5c48acfc7fd"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAxMQ_fbd8a405-aaf3-4ce3-bbfe-7336d751be1f">167,683,814</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAyMw_89096f41-2579-448b-9081-16ace16b77b4"><ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAyMw_994c027a-7586-4448-873d-02f2ddf5a327">36,480,314</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMS0xLTEtMA_764779fb-308f-462c-8457-296b87e17489">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMy0xLTEtMA_2968ea89-ff1e-4e1f-b3fd-19711f4735c4">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjUtMS0xLTEtMA_558483e0-c4a5-4c4b-9b35-ad4028d30762">589,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjUtMy0xLTEtMA_4dc8fab5-591f-4738-9b52-a0e078195e80">328,154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjYtMS0xLTEtMA_5ded50be-6784-4929-83ce-8680e35203eb">518,301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjYtMy0xLTEtMA_b606d035-c974-4f83-9bf9-01e966b4acb5">310,587</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjctMS0xLTEtMA_c4fbf479-592a-4916-86a9-12c59f956687">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjctMy0xLTEtMA_f9fb4d75-6365-45a9-9ffa-ed8ea9776a1b">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjgtMS0xLTEtMA_9546ba92-d7d2-407d-ace5-1e5fba233359">71,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjgtMy0xLTEtMA_60f69b23-5830-4ec9-ae42-94c27b2eaf26">17,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjktMS0xLTEtMA_121e48c7-f1bd-4571-af3b-3f15fabacaec">130,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjktMy0xLTEtMA_58d7e3ff-936c-47bd-b519-4d2c8e9da23f">81,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands, except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:42.313%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.703%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended<br/>June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended <br/>June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">REVENUES (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic53c293513a3411988e3f82450bc2600_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy0xLTEtMS0w_5d7f8558-0d7b-4f1e-b2aa-fe4b0b86153c">1,483</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89212e9395d543b584178d191c5a52df_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy0zLTEtMS0w_25831d93-b006-4b1c-906b-42431ca3be69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i89ac8ecea9da46f18647e4055ba4c2bf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy01LTEtMS01MA_63563914-9d8a-400f-aaab-dcf29d41197a">3,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e10a9cdb13646a5b01897e039b29eb1_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy03LTEtMS00Ng_9258b0cc-76bf-4cfd-86b8-ef6d4bbe6009">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">License revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23934cfba1c34fb59943833e025eb17f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0xLTEtMS0xODM0_65156261-4f27-4f8c-b1d1-697cda7ab5f7">10,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9c9988a3e0ca4c50b6d4ebe101481b7b_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0zLTEtMS0zNDEz_db663bd7-c8cf-4c22-ac61-0ccd9c80d223">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c3031d6ad8c4ebebd28af76579e5a58_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC01LTEtMS0xODM0_e26f0833-d341-4c08-a5dc-ba75cdf0f685">10,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i115874d2c71d4965a64a283d45279d4b_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC03LTEtMS0zNDEz_e97e30b3-b257-49bb-afbb-4fce357b35bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty revenues</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0xLTEtMS0w_5cf00d91-1fac-4c5c-9675-5ebeee5c028f">205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0zLTEtMS0w_f88a6988-681a-4945-8a66-c9a52abb31b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i99638830588b43439d03faa00fafb735_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC01LTEtMS01MA_e9610c19-afc2-4f00-aed6-b3c06448c7d9">205</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC03LTEtMS00Ng_8e52cf94-c5cb-4873-aaa9-ef07314e7a54">308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL REVENUES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS0xLTEtMS0w_bf84d308-2a83-45dc-82a8-c002d707a2c9">11,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS0zLTEtMS0w_846c270a-bafa-4e8b-8bef-278527f7b750">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS01LTEtMS00Ng_44deba92-6463-44a5-add1-9a6b3f40ab39">13,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS03LTEtMS00Ng_03386235-0205-483e-b20e-56f9cee24509">308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXPENSES</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy0xLTEtMS0w_1e707d4f-be5d-4deb-bc68-a0bc119a7b6d">216</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy0zLTEtMS0w_4ae5797a-fa83-47fc-a5ac-bedf63e05276">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy01LTEtMS01MA_7528ec84-e123-416d-bf36-d7bada857aab">487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy03LTEtMS00Ng_f66615c8-a636-4006-909b-58b8eaaf73c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC0xLTEtMS0w_a9ea651b-5e30-4033-8c37-08710770790f">13,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC0zLTEtMS0w_5b581ede-1d96-4e9f-9b31-a7ab650e6dcb">12,556</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC01LTEtMS01MA_d50f487a-4783-4c25-9d15-3a5c40ba0b81">29,072</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC03LTEtMS00Ng_b84e18c4-f05a-48b6-8d2f-61f4af3f28f8">23,404</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS0xLTEtMS0w_787f6a10-3bf3-453e-a910-5f9cb9b7fb6a">26,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS0zLTEtMS0w_2c42c2fc-3387-44b7-918a-7133be7dd373">6,803</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS01LTEtMS01MA_ef6e5080-f944-4a74-b376-b1056563615e">51,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS03LTEtMS00Ng_8a9c087e-3002-46ce-a6ab-ea08f2ec13c6">12,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill and in-process research &amp; development impairments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMS0xLTEtMTg1MA_01230842-d134-4c1d-b097-1cfbe49519d6">54,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMy0xLTEtMTg1MA_aebcd396-98ad-42b2-a853-7b5e0a65ae55">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNS0xLTEtMTg1MA_3257c229-6c46-4c93-9e85-0263175691d2">54,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNy0xLTEtMTg1MA_237c3bec-452a-4c98-96eb-0798b39cedc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent Stock Right Remeasurement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMS0xLTEtNDIxMA_816bf9d3-130f-44cd-8097-2fe966335e1c">84,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMy0xLTEtNDIxNA_4fa2c90a-23aa-4d74-8f6d-f88a073b6aa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNS0xLTEtNDIxNw_c58dde9a-b92c-470d-a601-35fe0d21cd9b">84,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNy0xLTEtNDIyMA_4e27751e-ccda-4dca-94a6-c07c88153f9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL EXPENSES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtMS0xLTEtMA_08bef76d-22bb-4938-886f-ca43ed5d2e99">178,865</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtMy0xLTEtMA_2d26e809-5b9e-4dfb-a80e-20ddbcf56c9b">19,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtNS0xLTEtNDY_8064ddd8-c0ac-4fa3-b8c2-9941a8c4e315">220,504</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtNy0xLTEtNDY_09294b49-fdf4-4bb9-bc46-db1a17143190">35,551</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OPERATING LOSS</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMS0xLTEtMA_cd76bce0-9149-4e04-86ce-ca53766b7a6f">167,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMy0xLTEtMA_a03f938a-a53b-45f9-9922-310d5fadeefc">19,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNS0xLTEtNDY_6e0006cc-684d-477c-aae5-831074a47e2d">207,066</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNy0xLTEtNDY_e99fde50-a2b3-458f-ae86-43003725c92b">35,243</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FINANCE INCOME</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" name="mnlo:FinancialIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMS0xLTEtMA_330888e0-6002-4854-972d-ee527e5d9bc5">564</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" name="mnlo:FinancialIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMy0xLTEtMA_79ef0bd3-6c38-41bf-bc11-0c7e73cfc1e1">468</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:FinancialIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNS0xLTEtNTA_f8fdccd7-6526-4f80-af7e-9465660a6efd">1,292</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:FinancialIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNy0xLTEtNDY_cf096dee-0028-4b33-885b-b608091b0116">1,004</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FINANCE EXPENSES</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:FinancialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtMS0xLTEtMA_8b78afbd-851c-4de4-a221-aab03d183147">1,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" name="mnlo:FinancialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtMy0xLTEtMA_0c8fc086-2715-4a2b-95ae-e8cb866cc15c">102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:FinancialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtNS0xLTEtNTA_4a96f0c3-3bd1-44ca-80a6-bc971fd71b31">2,158</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="mnlo:FinancialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtNy0xLTEtMzI1_eab9d256-bb87-4768-9bb9-4ff5f6f9c1c1">134</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LOSS BEFORE INCOME TAX</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtMS0xLTEtMA_64a7a7a4-e26b-4bca-ac75-ab8bb4edcfd3">167,699</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtMy0xLTEtMA_4fb36c80-88cc-45dd-958e-8922c9439ccd">18,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtNS0xLTEtNDY_88bfea9c-e8a6-4329-aaca-0c81e51c210d">207,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtNy0xLTEtNDY_dfda904f-f426-4546-9ec5-d8da7550f913">34,373</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">INCOME TAX</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtMS0xLTEtMA_b7ea74e8-6dd6-44e0-b99c-a9ccabaec1b4">259</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtMy0xLTEtMA_e4427121-4821-4cb1-9089-f3200f41f5fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtNS0xLTEtNTA_889f76da-4a68-49d0-ab73-81dcbfa4eda4">259</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtNy0xLTEtNDY_3a03e208-d8b9-429d-bfa7-6144bce84149">176</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NET LOSS FOR THE PERIOD</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtMS0xLTEtMA_514586cb-36ba-4271-a431-27baf2a889cc">167,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtMy0xLTEtMA_8acb1e4d-a779-417d-96ae-1bf3ed4de049">18,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtNS0xLTEtNDY_6be5580b-a643-4a01-8411-7c473443891f">207,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtNy0xLTEtNDY_938deafd-ca41-42e4-abb9-f43606f32c63">34,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LOSS PER SHARE BASIC AND DILUTED</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtMS0xLTEtMA_ec8bc643-3dfe-4e42-a2b8-e4f27eec0aa8">1.21</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtMy0xLTEtMA_77f42929-cd29-4cd3-89da-cef8fb1e31fa">0.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtNS0xLTEtNDY_d03d0d1a-5fb9-4d61-978b-b9a73c55ac58">2.29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtNy0xLTEtNDY_08b450a0-c586-4704-a864-677d84d0ce85">0.35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtMS0xLTEtMA_9fc80f31-aed1-4b90-8ece-547a2a745365">138,653</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtMy0xLTEtMA_abd01f18-5a10-442a-b3b9-fcd7c60688da">97,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtNS0xLTEtNTA_0d1563df-93ea-4694-aeaa-13da09b746d8">90,627</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtNy0xLTEtNTA_96e24e96-c8dc-4027-8e8f-a37b9c8c1c94">97,954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended<br/>June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NET LOSS</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi0xLTEtMS0w_3ef6670d-3a69-46fe-8506-43dc2f959c47">167,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi0zLTEtMS0w_ffc10dd8-da36-4604-9c77-d71fecf362ef">18,993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi01LTEtMS02Nw_13ac5392-8a17-4e9c-8a64-c6b5633430e4">207,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi03LTEtMS02Nw_43ec338c-3539-40cc-8d1d-56c09d267eba">34,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OTHER COMPREHENSIVE LOSS (INCOME):</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized (gains) losses from marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC0xLTEtMS0w_c7dc107f-96a0-4c25-98f5-219808f5f064">43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC0zLTEtMS0w_33a86251-f5df-462f-8308-fa19ec543f58">4</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC01LTEtMS02Nw_53b6d64d-4a08-4a38-8c63-3b667ab67f93">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC03LTEtMS02Nw_03dd34a7-1bc9-48f0-be69-5f1cda9a3ee2">40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses on marketable securities reclassified into net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS0xLTEtMS0w_25661f16-92ca-4698-ad96-adc2156a0bc6">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS0zLTEtMS0w_1d3feac8-d77a-44b5-b3be-84bc2da89556">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS01LTEtMS02Nw_b8f78ccc-95f8-457d-aaaf-0dae5037fe49">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS03LTEtMS02Nw_63591fd4-d4ae-4f78-b781-883ff3f036d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized losses (gains) on derivative financial instruments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi0xLTEtMS0w_df97dea3-b015-4396-9b2b-7c9947e904f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi0zLTEtMS0w_b6f36771-3311-43b3-a8c2-a8d8f093eda5">13</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi01LTEtMS02Nw_a12119a4-f040-49ee-8e46-dca0dccf97b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi03LTEtMS02Nw_087e817c-4e73-4602-b525-a9cf3d664ebb">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL OTHER COMPREHENSIVE (INCOME) LOSS</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy0xLTEtMS0w_eebfa242-8205-4dda-9b31-25bebc70fcd6">40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy0zLTEtMS0w_f695ee5c-285c-4220-affc-c73aea76cd51">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy01LTEtMS02Nw_ac4dd964-835b-4068-a1e6-c5a1cd194bc8">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy03LTEtMS02Nw_4b7f4a73-b03f-46e9-b621-85fdb826919e">42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TOTAL COMPREHENSIVE LOSS</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC0xLTEtMS0w_87222b2d-d00a-4251-a848-daf5d03d6b7c">167,400</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC0zLTEtMS0w_1445c6c9-e03d-4c27-b621-c7171ab8109e">19,002</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC01LTEtMS02Nw_5ca8f2d9-31da-4d1d-89e7-32290e585ccd">207,678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC03LTEtMS02Nw_f3c678bb-88cd-40d1-9a2d-2e4505e0ad6d">34,155</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands, except share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:29.764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.445%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Common stock</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Additional paid-in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Accumulated deficit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">comprehensive</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Income (loss)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amounts</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amounts</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JANUARY 1, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i58ec0b6d315d42bf984266ae09cc24f0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0xLTEtMS0w_d86b4906-77f5-4e81-90f4-3019880736e9">97,864,663</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58ec0b6d315d42bf984266ae09cc24f0_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0zLTEtMS0w_1e2fa083-9997-4a07-91be-5973c4474e72">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib10f110e89794a328cd6dff889719d0f_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi01LTEtMS0w_00521afd-2c00-45cb-9806-1f599c1aff5e">307,624</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6fddccdca3294d4e9d00f89b822119c3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi03LTEtMS0w_bb931d12-7236-47f4-a88a-71dbf2a2a733">215,409</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0bd4960891c34721acc23f0da145dc30_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi05LTEtMS0w_c125ee5b-b3a8-4221-a871-b37e845f1d6d">43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0xMS0xLTEtMA_0ae43293-dacb-4055-a845-6b0b012540e0">92,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaab607da61e54796b75a8649d120f305_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC03LTEtMS0w_138f2876-1d15-4b73-bd43-f74c8efca150">34,197</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i968d104d31de4459a96511fbf90c1f1d_D20190101-20190630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC05LTEtMS0w_75e8df4f-be9f-4a7c-a9b5-49551754b2f0">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC0xMS0xLTEtMA_041d6549-f02b-4022-a5ad-55fd4f1f1569">34,155</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Exercise of options and vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i44a66f541efd4f15931ae16609a79908_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS0xLTEtMS0w_8167a10e-b754-4442-912c-a69114605928">188,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d3163028e034d0a88324b9af3624248_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS01LTEtMS0w_ed96e763-87c8-4f6a-8878-8148c65d1697">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS0xMS0xLTEtMA_37dd85e5-9e80-44e1-95fc-d20a6037b1aa">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8d3163028e034d0a88324b9af3624248_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNi01LTEtMS0w_9b2889d9-a68e-47b0-bc89-bccd8868ac9a">2,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNi0xMS0xLTEtMA_700f3d4e-7f32-45f0-be1c-138294725585">2,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JUNE 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0xLTEtMS0w_3cd20eea-e484-40a0-bca3-a2594fbd94b0">98,053,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0zLTEtMS0w_c9d4910d-2b56-45dc-b997-6c6d604fadf4">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i183126c41cc449dbba13257e8dea4ace_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy01LTEtMS0w_26533c6d-dff3-462b-9f40-ff4b9ba6feb2">309,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6c4fe139b2cc48aaa7444cf89368196d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy03LTEtMS0w_e949424b-d1a1-44cf-9410-44181239f75b">249,606</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy05LTEtMS0w_3beccd1d-4ffe-412c-96d8-e70fb0ab1e55">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0xMS0xLTEtMA_150c68ba-34c5-49ad-ac31-071d7a7fed93">60,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JANUARY 1, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8caa6a61613a445594a114cf0db71d79_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0xLTEtMS0w_2df3cb0f-b0ac-4b6c-add4-4a100052e807">36,480,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8caa6a61613a445594a114cf0db71d79_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0zLTEtMS0w_d64c40b1-15e2-4381-a405-608676aa9595">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a2f04cbef3845e28d047be6ae20e735_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS01LTEtMS0w_201bf9c6-4e9a-4452-8bb5-fdada3fcefd6">328,154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9778e0408b1f42deaf3632925439e4b0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS03LTEtMS0w_cf0edd5e-950e-4e81-8027-fab6014c7acf">310,587</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6feda25267a14e1e9087b4289d642160_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS05LTEtMS0w_b698a9a6-2591-493c-817e-0aaa8421c7e2">5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0xMS0xLTEtMA_822e4857-8a67-4e4e-8874-c22acf0ba24b">17,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if95e4afe75e94206bc731058ea393dba_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtNy0xLTEtMA_168d0126-d0c0-46ee-9f69-208046884cd7">207,673</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7973a9b2e41c4011a66ad0e37aa68515_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtOS0xLTEtMA_f2af6662-690c-49c1-b5b5-5d60c1acd01b">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtMTEtMS0xLTA_34c34691-8c71-4877-b0ef-d2cb051a2522">207,678</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItMS0xLTEtMA_5f2befc2-c1f9-437e-a7d0-0cacdcef2f1b">1,032,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItNS0xLTEtMA_33391ab6-58d9-4309-9437-e080586dc10d">260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItMTEtMS0xLTA_4d5db907-036e-4ab3-bda0-6dbaac83f3da">260</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTMtNS0xLTEtMA_6ab9247e-3729-440b-ba6a-e001f80c88d8">12,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTMtMTEtMS0xLTA_a3814526-2989-4c07-abb0-b4bd46a90968">12,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Deemed dividend to warrants holders due to warrant modification</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630" decimals="-3" sign="-" name="mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtNS0xLTEtMA_3ee9fa34-e2bd-47c6-a734-0da192f94209">41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if95e4afe75e94206bc731058ea393dba_D20200101-20200630" decimals="-3" name="mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtNy0xLTEtMA_941be3e4-9424-49a3-8903-e9d3a9c838fc">41</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtMTEtMS0xLTA_177f7836-c86b-4706-8787-999f2337a02b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Classification of stock awards to derivative liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630" decimals="-3" name="mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTUtNS0xLTEtMA_c5a2565f-c381-4756-be79-c0039879d3ff">975</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTUtMTEtMS0xLTA_4e66c306-701c-411c-ba62-ec89a3d6b05b">975</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Issuance of Ordinary Shares through a public offering, net of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMC0xLTEtNjA4L3RleHRyZWdpb246YTc2NzkxYzBhOWRlNGEzZjk2MjdkNjM3MzgxMWM1MjJfMTY0OTI2NzQ0MTg5Mw_bcd86cd9-7bd6-46d8-8d20-88087fdef147">3,903</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMS0xLTEtNjUy_711469e5-cd6f-4f83-ba51-cbff714ea0bf">31,107,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMy0xLTEtNjUy_9c73d630-c690-4cdb-b6f3-2341725ab6c5">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtNS0xLTEtNjUy_fb58c062-4ebb-4468-885e-cf1009b40d2c">53,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMTEtMS0xLTY1Mg_06bd10a7-36b7-482d-9bcb-b2eb78da041a">53,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Issuance of stock related to merger</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMS0xLTEtMA_a841f0b1-5ecf-4ca9-9f07-bdceb56c6ea0">99,063,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMy0xLTEtMA_e3579779-7095-464b-8b50-338e375c9fdf">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtNS0xLTEtMA_574be71b-57d6-4bd1-82d5-f7d3f93b64bf">196,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMTEtMS0xLTA_71471f74-cd87-4a3a-ae21-24f0dcfe7009">196,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JUNE 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMS0xLTEtMA_deb7d5a0-7644-46e9-a981-47da07716970">167,683,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMy0xLTEtMA_63488b9f-df17-4b82-8f97-cd0222001849">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctNS0xLTEtMA_ef6b4f03-c517-40b0-a39f-20ca6bf6d8b2">589,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie0b992755b2b4a5ba58755071de873b4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctNy0xLTEtMA_589e1143-7627-4ae3-82f7-08cd97ce03b9">518,301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctOS0xLTEtMA_6140fb92-af3a-4be9-92f0-317c93faba21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMTEtMS0xLTA_fb383c86-a24d-4376-b63a-5bef6f9e2009">71,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;padding-left:18pt;text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_1319"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(U.S. dollars in thousands, except share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:29.764%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.176%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.445%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Common stock</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Additional paid-in</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">capital</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Accumulated deficit</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Accumulated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">comprehensive</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Income (loss)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of Shares</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amounts</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amounts</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT APRIL 1, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTEtMS0xLTEwOQ_b08623ff-820c-4b85-9487-e14e691a8725">97,987,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTMtMS0xLTEwOQ_04dec6dc-424e-4ca6-a72d-2d7a75dd2742">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b02388b48f440649017facfc2fec45b_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTUtMS0xLTEwOQ_b0b77f2f-5993-42cc-a7db-aec5b89e745f">308,590</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b661c91124c4db18890eb501396ac7e_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTctMS0xLTEwOQ_93049c75-9c9f-47a1-aaf1-945c723168f7">230,613</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9558e2deebc4ba3a4cbcf4217d7e051_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTktMS0xLTEwOQ_1e3e0a1f-52dc-4a57-841d-a6a040bebb1c">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d3f4643a51a41288e8ccd0e60759c97_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTExLTEtMS0xMDk_b03dfa29-4888-4348-9666-d3c797d56581">77,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i101055c62f9d45799bf1500fe791edc4_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTctMS0xLTEwOQ_c9bda4fa-35a5-4382-a223-f633e95f6fd5">18,993</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib74604aa6bc2461cb5df34b326723115_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTktMS0xLTEwOQ_fc848b75-ecc9-4623-b70b-7770504c974b">9</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTExLTEtMS0xMDk_772d6a16-57ed-4eef-9d2f-f897b36baee8">19,002</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Exercise of options and vesting of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8a497140cb264e87a5545a4066bd9ccd_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTEtMS0xLTEwOQ_41e46479-3429-47b7-ac56-f76d9f125532">65,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTUtMS0xLTEwOQ_d22062c4-53a4-4238-8206-07c8c56ffba8">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTExLTEtMS0xMDk_3cb4fd00-41b1-4d85-9369-2522573316ad">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV82LTUtMS0xLTEwOQ_649f631f-0a76-4269-a8dc-c456ffbaf7b9">1,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV82LTExLTEtMS0xMDk_03042aa1-0025-40b3-b4dd-3926963731fb">1,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JUNE 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTEtMS0xLTEwOQ_69f108bc-afc9-4d4b-a82d-c1f202eb830a">98,053,418</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTMtMS0xLTEwOQ_d35094d3-78e3-4d91-b0aa-dc61842cd8be">10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i183126c41cc449dbba13257e8dea4ace_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTUtMS0xLTEwOQ_6e2b0faa-c09d-4f88-80f6-666dc0e58c95">309,979</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6c4fe139b2cc48aaa7444cf89368196d_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTctMS0xLTEwOQ_ffd856a7-7216-4afc-8e55-907248f5c3ce">249,606</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTktMS0xLTEwOQ_b5787bc7-e84c-48a7-8394-517a7fd003e0">1</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTExLTEtMS0xMDk_b0574f11-0cb6-4fd7-9b18-51b45da623d1">60,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT APRIL 1, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib4e49138bc604905a6e1fb9cb99008d0_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTEtMS0xLTEwOQ_1fcd8ca9-efdf-44d1-8c47-3ab96b1e3a82">61,501,130</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib4e49138bc604905a6e1fb9cb99008d0_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTMtMS0xLTEwOQ_766bbbd9-2c3e-4199-b290-18dcd32d3b65">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74810c4013404762b66d6ab7950a6c2a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTUtMS0xLTEwOQ_d74822d9-ef8f-404a-8a8e-39c3cd7aa127">420,430</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3359148f5b174e9d9dbd7205f678bc8d_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTctMS0xLTEwOQ_422147be-c269-4832-a8aa-180964e7b029">350,861</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i004a8f9abfde49159237ec2532aff25c_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTktMS0xLTEwOQ_54e3ebc5-d881-4a0b-bf5d-c9607726db7f">40</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie8b89a0f42154a88be72ee1ba1cc8faf_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTExLTEtMS0xMDk_2d2e3255-0ffb-4037-bebc-1cd086fc8ef2">69,535</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">CHANGES DURING THE PERIOD:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive (loss) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5214fa97c5fa453fa43fa4fe0908ef99_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS03LTEtMS0xMDk_477b0ab8-016a-46c2-896f-2155c205ec86">167,440</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5439508597d54228b44eb110a0163531_D20200401-20200630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS05LTEtMS0xMDk_a82948b1-2966-4c0c-98e4-6fa7fff73caf">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS0xMS0xLTEtMTA5_faa0abce-2b07-4d38-a344-c4f44b709498">167,400</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi0xLTEtMS0xMDk_f28ad1a5-db5e-47d9-b84e-3ad6a862bb59">530,771</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi01LTEtMS0xMDk_66b0fe48-72fd-422b-8fc6-c8d7adc1d9d7">43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi0xMS0xLTEtMTA5_937969ec-8e8b-4f36-9a69-b7e388507abb">43</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Stock-based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMy01LTEtMS0xMDk_09a907e2-1877-42b6-a21f-4d64079915cf">10,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMy0xMS0xLTEtMTA5_b91f52ae-c8fa-4635-a675-f0548a4bffa6">10,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Classification of stock awards to derivative liability</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" sign="-" name="mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNS01LTEtMS0xMDk_887cebdb-c7ad-4441-9a44-dea01ddc8461">657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" name="mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNS0xMS0xLTEtMTA5_bdb432d6-23d8-4ec9-b13c-34a5cb514f8c">657</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Issuance of Ordinary Shares through a public offering, net of $<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0wLTEtMS02MTAvdGV4dHJlZ2lvbjphMGFjZDI3ZmY4Y2U0MjgxOWQ5OTM2MjJlMjE0OTVhOV8xNjQ5MjY3NDQxNzYy_82aeadee-0331-4495-8f9e-67e874797be2">3,903</ix:nonFraction> issuance costs</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xLTEtMS02NTc_711469e5-cd6f-4f83-ba51-cbff714ea0bf">31,107,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0zLTEtMS02NTc_9c73d630-c690-4cdb-b6f3-2341725ab6c5">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi01LTEtMS02NTc_fb58c062-4ebb-4468-885e-cf1009b40d2c">53,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xMS0xLTEtNjU3_06bd10a7-36b7-482d-9bcb-b2eb78da041a">53,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Issuance of stock related to merger</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xLTEtMS0xMDk_267b0e38-cd58-4763-a723-c89ca25d1bf8">74,544,413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0zLTEtMS0xMDk_81107f40-78b0-45ec-9ed1-def8d27c0c63">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi01LTEtMS0xMDk_58254ce5-1f74-4d24-bbbb-ba3147cc348f">104,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xMS0xLTEtMTA5_c276eca3-14ea-4d21-9a3b-cd628d83a283">104,362</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BALANCE AT JUNE 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0xLTEtMS0xMDk_0442277c-0294-4012-9284-60c44fe0fd1b">167,683,814</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0zLTEtMS0xMDk_7b939a94-24b1-4fbf-b08d-96481c64455a">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy01LTEtMS0xMDk_a33b19c7-d4a1-48e7-9ea0-8229bfd3d9e4">589,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie0b992755b2b4a5ba58755071de873b4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy03LTEtMS0xMDk_c97ed36b-c74b-431a-9106-77c462aa7535">518,301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy05LTEtMS0xMDk_60c9f2ae-5b6b-4ae2-b3c6-dc7435b7a4da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0xMS0xLTEtMTA5_e5d7e02f-e285-41e8-ad33-185820f8949c">71,528</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:36pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">MENLO THERAPEUTICS INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(U.S. dollars in thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">(Unaudited)</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMy0xLTEtMS0w_6a2ac86b-d95e-4d19-95df-fa3b831c039e">207,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMy0zLTEtMS0w_82a485d2-d938-41fa-b9ee-ba3a2752c251">34,197</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:15.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Adjustments required to reconcile net loss to net cash used in</span></div><div style="text-indent:-9pt;padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNS0xLTEtMS0w_797e5aa3-e550-4b01-a05d-140e28a66ace">187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNS0zLTEtMS0w_3da01ee5-d580-4a32-823e-f43633977012">163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill and in-process research &amp; development impairments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0xODY1_3931d459-e9cf-4efb-9c27-59e61e9bce13">54,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0xODY1_470c6f36-b48f-47f1-a790-56990f341385">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent stock right remeasurement</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0xLTEtMS0xODY1_7b82d614-7311-4dc5-8823-351aeb0fde93">84,726</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0zLTEtMS0xODY1_bc2d4da2-13ca-4e23-a485-5a82224140bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from disposal and sale of fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0xMzk_d147c9b0-0285-4384-bc3e-0d1a4819ec49">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0xMzk_625e0432-8a5d-45c3-8e8a-d8db3d5b0a59">29</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in marketable securities and bank deposits, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0w_c32458d9-d41c-4dde-8d4f-ed3f6ee7f3c7">142</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0w_78e3e631-d6cf-49c4-ae59-80df9d45dcf7">358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in accrued liability for employee severance benefits, net of retirement fund profit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" name="mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0xLTEtMS0w_04cf0c74-dd81-4469-8dd4-0a6e25367c4a">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0zLTEtMS0w_e71bc345-13b2-4eec-a5ba-f6f48941a817">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOC0xLTEtMS0w_4a85df85-05ba-464a-9cb1-c073ba14108a">12,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOC0zLTEtMS0w_255da730-b943-47d2-b70c-27e1afa65065">2,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash finance (income) expenses, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOS0xLTEtMS0w_1ecca7f0-e0ef-4368-9fe9-ffb72942a114">833</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOS0zLTEtMS0w_05fce8dc-a545-4757-bf83-e5f83c8754f9">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities, net of effects of businesses acquired:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in trade receivables, prepaid and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTEtMS0xLTEtMA_c796a70a-503b-4817-a632-88d4093508de">9,807</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTEtMy0xLTEtMA_38f9ac13-a614-4c09-8c07-f7b94c394150">246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTItMS0xLTEtMA_910fa109-026a-4c9b-a101-1cfb20360c81">6,026</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTItMy0xLTEtMA_2ca81db1-f2fd-4db4-8950-caf02e063937">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Decrease) increase in accounts payable and accruals</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTMtMS0xLTEtMA_b2b96fad-3910-43bb-b303-f6eb00d06916">10,908</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTMtMy0xLTEtMA_ea87315f-8730-4a99-b162-b9b21eeffdaa">2,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTQtMS0xLTEtMA_48bbb899-c579-442f-b1ba-c18bd3277b23">4,445</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTQtMy0xLTEtMA_01c7d892-a266-4bfb-bde4-0f1c7d397886">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTUtMS0xLTEtMA_e0b606fc-dbee-494b-8879-0ef5c1172789">88,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTUtMy0xLTEtMA_a3939575-d438-479c-9ef4-283e28ce3d5b">29,361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of fixed assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTctMS0xLTEtMA_d7dbc426-dc3d-405a-89e7-750b6632041a">113</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTctMy0xLTEtMA_c8c59c27-7137-4404-92a8-a9ccbf8884fa">454</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investment in bank deposits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTgtMS0xLTEtMA_8b5d6395-8734-40de-97e3-ee33ac1a0f9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTgtMy0xLTEtMA_bb955a7f-5f17-4fc5-8935-c0e51369fe63">16,048</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash acquired through merger</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:ProceedsFromBusinessMerger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTktMS0xLTEtMA_f4a689ba-e7b3-4d11-b569-5d4aabba41bb">38,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:ProceedsFromBusinessMerger" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTktMy0xLTEtMA_af01f852-89b6-433c-9907-657235a03421">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale and maturity of marketable securities and bank deposits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjAtMS0xLTEtMA_d943b9b5-1686-4fac-8d48-3db4a6eb2911">48,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjAtMy0xLTEtMA_e690ec37-a5a6-46b9-862b-d173855de37e">57,014</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjEtMS0xLTEtMA_03c832b4-13ce-459c-a1dc-afe2683a25b4">87,105</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjEtMy0xLTEtMA_43b2aaf5-33b3-47cd-ae68-4d46e89fffe3">40,512</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds related to issuance of ordinary shares through offerings, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMS0xLTEtMTg3OA_f4fe77b4-816e-41b5-9cbe-84aa0d94cae6">53,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMy0xLTEtMTg3OA_9cc0a169-f11e-4cf1-afe9-788ab8f4fbe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds related to issuance of stock for stock-based compensation arrangements, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjMtMS0xLTEtMA_12a653dc-ac59-450a-8c84-9d36a44da80f">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjMtMy0xLTEtMA_37f9ea9d-c602-4d2d-940b-282c2fddbd32">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjQtMS0xLTEtMA_a3863c7f-de14-4d71-9bea-a76b813c8448">53,746</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjQtMy0xLTEtMA_558ee6cf-b9c2-4f64-8fe0-ca4dad2a2ee5">18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjUtMS0xLTEtMA_36fc445c-bfe1-47e0-b1f4-c9d18eb99175">52,781</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjUtMy0xLTEtMA_67a93ce4-23cf-4b6b-b809-9a572502fdd2">11,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjYtMS0xLTEtMA_472563d5-4e8f-4a32-8861-e6fcf1ec2a25">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjYtMy0xLTEtMA_892effc3-67e4-47e8-b1e7-83cb906b4fe2">48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMS0xLTEtMA_fb6151ff-3a84-4b19-a82f-57dc549f42cf">44,584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMy0xLTEtMA_e41d6117-1d38-43d9-a8b4-aa4b67e54972">28,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjgtMS0xLTEtMA_4c56e2ce-bfc4-4e6b-8723-7a38490d5f71">97,366</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjgtMy0xLTEtMA_1c6b2c51-3af5-4fa2-b08f-a3b9ce65bbb4">39,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjktMS0xLTEtMA_23c8ce11-fcbd-41af-8aea-4ee538f470fc">96,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjktMy0xLTEtMA_9ae06873-93d6-4607-8efd-4e6a07fe1e88">39,085</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzAtMS0xLTEtMA_a6eba595-689e-4461-b17c-cd257d49a557">855</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzAtMy0xLTEtMA_e1ecf34c-aefb-45ca-ab94-f861f0198435">250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzEtMS0xLTEtMA_51801d4a-4c21-4b91-8729-a4abce189ed7">97,366</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzEtMy0xLTEtMA_7855eb1e-3f13-429d-aa7d-ee6d1befdf28">39,335</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS -</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cashless exercise of warrants and restricted stock units</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzMtMy0xLTEtMA_5852399c-a3f4-47be-9e6d-5e4938e6d95d">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of shares under employee stock purchase plan</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzQtMS0xLTEtMA_7af47463-d34c-46b6-a9df-b89280ff9105">163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzQtMy0xLTEtMA_254b63b5-84d6-4561-9feb-2ac386eae08e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to operating lease right of use assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzUtMS0xLTEtMA_e97475ed-d90c-4164-b387-3579bbd666a2">1,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzUtMy0xLTEtMA_14a6b13c-8b33-4b2e-87d9-9c08e6636953">867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzctMS0xLTEtMTQ2_35875d85-d429-4bc5-a740-31bb8dc52933">1,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:CapitalLeaseObligationsIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzctMy0xLTEtMTQ2_f8ccf839-c0d3-4782-a250-5f05cfdb7297">850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest received</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" name="mnlo:InterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzgtMS0xLTEtMA_a01e2fad-45af-4163-9a5b-fe72ad90aca9">298</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="mnlo:InterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzgtMy0xLTEtMA_6ee07ef0-8cf4-4732-b786-5987389b3352">666</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest paid</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzktMS0xLTEtMA_2b3caaab-f141-4a83-977d-f195e27e7bdd">1,946</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzktMy0xLTEtMA_bce79f6c-5f55-4bcd-aa28-b713178c14d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDEtMS0xLTEtMA_eed28e22-b29f-4436-946e-9d48b7737ccf">117,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDEtMy0xLTEtMA_b5e6672b-4dcc-40e9-a3cf-0d454192022a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDItMS0xLTEtMA_ed727bbb-dca3-47a8-b019-e1e64f4204f4">5,827</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDItMy0xLTEtMA_042c410c-e3c3-49ac-9e04-1989301f1067">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net acquired (See &#8220;Note 3- Business combination&#8221;)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDMtMS0xLTEtMA_9a350ec5-4f58-4fd3-be93-cec2a0d8cbb0">111,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDMtMy0xLTEtMA_46da4c23-96c1-4247-95b1-2cbe922745ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less cash acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:NonCashAcquisitionOfBusinessCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDQtMS0xLTEtMA_e1f70edf-e3f6-473b-a10c-7d19cf9943bc">38,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:NonCashAcquisitionOfBusinessCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDQtMy0xLTEtMA_068bc735-3e97-4e5c-83ac-0a2800a23e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Merger net of cash acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDUtMS0xLTEtMA_c9e58209-8997-4a32-bfa6-9e3baa0f8e9d">72,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDUtMy0xLTEtMA_7114568d-b6bf-499d-a545-8970c05b27c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">*</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt;">Represents an amount less than one thousand</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Menlo Therapeutics Inc.</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Unaudited Interim Condensed Consolidated Financial Statements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;"><span><br/></span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_37"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1 - <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDkwMDU5NA_1e392d36-550f-432a-ac9a-b1088201bfb8" continuedAt="idf833aec6c1244c4a52cc2774f77ef1b" escape="true">NATURE OF OPERATIONS</ix:nonNumeric></span></div><ix:continuation id="idf833aec6c1244c4a52cc2774f77ef1b" continuedAt="ifbb64db2215c434bb203b41567548d4c"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Menlo Therapeutics Inc. (the &#8220;Company,&#8221; &#8220;Menlo&#8221; or the &#8220;combined company&#8221;) is a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;<ix:nonFraction unitRef="segments" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzQ4_bdf51a42-bfdc-42a9-8bd8-13df59715ae0">one</ix:nonFraction>&#160;business segment.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:ReverseMergerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDg5NTk4Mg_c4545cfb-202f-47df-b214-c6e220020f98" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Reverse Merger</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;) and Giants Merger Subsidiary Ltd. (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020 (the &#8220;Effective Date&#8221;).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#8220;Note 3 &#8211; Business Combination&#8221; for more information on the Merger.</span></div></ix:nonNumeric><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Products, Product Candidates and Licenses</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, in January 2020, Foamix launched AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical foam, 4% (&#8220;AMZEEQ&#8221;), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical form, 1.5% (formerly FMX103, "ZILXI"), for the treatment of inflammatory lesions of rosacea in adults.  AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMZEEQ and ZILXI utilize the Company&#8217;s proprietary Molecule Stabilizing Technology (MST)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that is also being used in the development of the Company&#8217;s other product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.  The Company has begun preparations to conduct an end-of-Phase II meeting with the FDA before the end of 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to pursue serlopitant. As a result, the Company recorded a full impairment charge related to the IPR&amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June&#160;30, 2020. See "Note 3 - Business Combination" for more information.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States, and recently entered into a license agreement with Cutia Therapeutics (HK) Limited (&#8220;Cutia&#8221;).  See "Note 4 - Revenue Recognition."  The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company&#8217;s foam technology with the licensee&#8217;s proprietary drugs.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:LiquidityAndCapitalResourcesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDg5NTk4MQ_76279583-ca3f-4a44-ac54-068c785637a3" continuedAt="icdb748dfb7704b96b0e794e26d4a76d6" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company launched AMZEEQ&#160;in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company&#8217;s activities prior to the commercial launch of AMZEEQ&#160;had primarily consisted of </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="ifbb64db2215c434bb203b41567548d4c" continuedAt="i5d258ee1a3e44e6eb0c9ff6a82e3cd8c"><ix:continuation id="icdb748dfb7704b96b0e794e26d4a76d6"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June&#160;30, 2020, the Company incurred a net loss of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDM5Mg_3a95a90b-1faa-4351-9e95-0c7005b657d0">207.7</ix:nonFraction> million and used&#160;$<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDQwNA_c8fd7420-f7af-4a0f-a7ce-b6954719c85d">88.1</ix:nonFraction> million of cash in operations. As of June&#160;30, 2020, the Company had cash, cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDQ5OA_55d3887b-b31d-46d6-897d-027870567e79">100.4</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDUzMQ_8179931d-905c-4517-945c-eef033ee5bca">518.3</ix:nonFraction> million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates.  The Company does not currently intend to pursue serlopitant further.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash, cash equivalents and investments as of June&#160;30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.</span></div></ix:continuation></ix:continuation><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i5d258ee1a3e44e6eb0c9ff6a82e3cd8c">As a result of the COVID-19 pandemic, the Company suspended the vast majority of its in-person interactions by its customer-facing professionals in healthcare settings and have engaged with these customers remotely as the Company seeks to continue to support healthcare professionals and patient care.  During the second quarter of 2020, the Company began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates.  However, during the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures.  As a result of the negative impact on the Company's product sales, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement.  See "Note 8 - Long-Term Debt." The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict.  An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI, and have a material adverse effect on the Company's liquidity, as well as the Company's ability to remain in compliance with the minimum net revenue covenants contained in the Company's loan documents.</ix:continuation>  </span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_40"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2 - <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMzI5ODUzNDkwMTMwOA_02e89c88-0e6e-4c19-96d9-a6b7dc6b25a3" continuedAt="if0b374c478054c068b523e866d070309" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="if0b374c478054c068b523e866d070309" continuedAt="ic4684e4e17644047995db2779c193386"><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTA_72d2e482-fdde-4d16-b5bf-84a6b89d2d68" continuedAt="if00d0d6cd8d9429da0d92f570b744cba" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="if00d0d6cd8d9429da0d92f570b744cba"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited interim condensed consolidated financial statements should be read in conjunction with Foamix&#8217;s audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company&#8217;s Current Report on Form 8-K/A filed with the Securities and Exchange Commission ("SEC") on May 7, 2020, and the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results expected for the year ending December&#160;31, 2020.</span></div></ix:continuation><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTE_73c49ced-dba0-455a-8b88-161ff9b958e8" continuedAt="ibe395866796a41249d8f23d43e8c14a8" escape="true">Principles of Consolidation</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="ic4684e4e17644047995db2779c193386" continuedAt="i7dc61f09c5994f718d585f096bad1026"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibe395866796a41249d8f23d43e8c14a8">The consolidated financial statements include the accounts of Menlo and its subsidiaries. Intercompany balances and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.</ix:continuation></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">c.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc4MDE_b2c22107-5552-40e4-b1a8-542c29aff3b8" continuedAt="i9a3aa73d6cc445798006afa1456b01b3" escape="true">Use of Estimates</ix:nonNumeric></span></div><ix:continuation id="i9a3aa73d6cc445798006afa1456b01b3"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic.  In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.  The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).  The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:continuation><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">d.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTg_a57a24ea-b910-416d-802c-f543a768b5ff" continuedAt="ic9627d3bc6ff43f7a858ee7b0a71d9ad" escape="true">Business Acquisition</ix:nonNumeric></span></div><ix:continuation id="ic9627d3bc6ff43f7a858ee7b0a71d9ad" continuedAt="i7322f09379384410ba9939cdf7319754"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our fair value methodologies depend on the following types of inputs:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i7dc61f09c5994f718d585f096bad1026" continuedAt="i3a4f05ec2b1f4f0d9708edf49b37e5c8"><ix:continuation id="i7322f09379384410ba9939cdf7319754"><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset Impairment</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div></ix:continuation><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTI_e7af27ee-a0a6-4198-83c3-714561e3f05d" continuedAt="idd7a9a26850c40a2911cb70add295154" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="idd7a9a26850c40a2911cb70add295154" continuedAt="i8fad3965fa644d65b1a3ce88a69b1742"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the distributors. The Company evaluates the creditworthiness of each of its distributors to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 90 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net product revenues through&#160;June&#160;30, 2020&#160;were generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i3a4f05ec2b1f4f0d9708edf49b37e5c8" continuedAt="i605ea71d6b1a4fd3b378a1df885f08e3"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8fad3965fa644d65b1a3ce88a69b1742">products to Cutia for clinical and commercial use.  The Company will receive an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-5" format="ixt:numdotdecimal" name="mnlo:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTA2NQ_910f1773-7828-4b12-b782-31ea57993de2">10.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i5da754f4e94e4544b609a323172766eb_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="mnlo:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTA2OQ_cd9b39fb-d1f3-4add-b0f5-b80815c79e6c">6.0</ix:nonFraction> million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-6" format="ixt:numdotdecimal" name="mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTE1NA_703f27fb-ee10-4e26-a607-b1da3c17d764">1.0</ix:nonFraction> million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognizes the revenues from the upfront license fee when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</ix:continuation></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">f.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;"><ix:nonNumeric contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTM_9096f0f9-b340-4cfd-b73c-ff2fdf17ee22" continuedAt="ie7d4143e52e945e7975a2ef88100bfbb" escape="true">Allowance for credit losses</ix:nonNumeric></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie7d4143e52e945e7975a2ef88100bfbb">An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2020.</ix:continuation></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">g.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTk_e0a3cb02-53d2-4ce1-bd87-43209a6f9986" continuedAt="i6a47eea27a994b6ca8c58dc41c0d044c" escape="true">Derivative instruments</ix:nonNumeric></span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6a47eea27a994b6ca8c58dc41c0d044c">The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as a finance expense (income) in the accompanying condensed consolidated statements of operations.</ix:continuation></span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">h.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc4MDA_e1ff0a73-18ba-44ba-a7c2-2544eb07c75a" continuedAt="if4cb9662028e4ff1b75da35416ffa03f" escape="true">Fair value measurement</ix:nonNumeric></span></div><ix:continuation id="if4cb9662028e4ff1b75da35416ffa03f"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1:&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div></ix:continuation><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">i.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.73pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTQ_8105a80e-0ddb-4637-9ec1-e7bb64545be6" continuedAt="i33c44fd02f6742359a9c8b9b0bf61df0" escape="true">Loss per share</ix:nonNumeric></span></div><ix:continuation id="i33c44fd02f6742359a9c8b9b0bf61df0" continuedAt="i44634216ab374443bc9c1cf5b42e0754"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The basic and diluted loss per share for each comparative period before the acquisition date presented in the consolidated financial statements following the reverse merger was calculated by dividing (a) by (b):</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The loss of the legal acquiree attributable to common stockholders in each of those periods.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The legal acquiree's historical weighted-average number of common stock outstanding multiplied by the exchange ratio established in the merge agreement</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary shares outstanding during the period. Diluted net loss per share is based upon the weighted average number </span></div></ix:continuation></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i605ea71d6b1a4fd3b378a1df885f08e3"><ix:continuation id="i44634216ab374443bc9c1cf5b42e0754"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMzI5ODUzNDkwMTMwOQ_b2e1c1fb-49e2-4f0d-b259-23e255dbea15" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.859%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i80a470217c3a4272adc3535da6eb3922_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi0xLTEtMS0w_8544116b-e2dd-45ab-a1a9-6f7191fc4b20">14,975,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9fba894574f6426bb988c61b2df7510c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi0zLTEtMS0w_833e4e8b-2165-4c43-983a-81e2aa6e3330">11,037,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i49710f5b3cb5425584627e0e1bcc3521_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi01LTEtMS03ODk_18fa0e6d-b44d-4ba6-a42e-fafaafb5f579">12,082,037</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5f3259df41a745da91e614f0f535fe16_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi03LTEtMS03OTM_3f440f08-4c8f-4b65-9d66-ce4bca996f0e">10,576,229</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4bf5e963873a4e6982e47201cb3ff7f8_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy0xLTEtMS0w_9c110769-2310-4bf7-9986-90f041f7ef1e">1,893,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if29ad7a578cf43a6acb996ff258f0c7c_D20190401-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy0zLTEtMS0w_9687a511-c8e4-4c09-9ea4-84d231b917c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc2826b77413461d84519a6b754cb004_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy01LTEtMS03ODk_d870379f-2121-444f-af52-b83bff994048">1,272,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9c758c8f421d4ae5a44d89c91a01007d_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy03LTEtMS03OTM_ddb7a819-809b-4f1c-9257-a2ce1b5e981d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the above, the CSR was excluded from the calculation of the diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTU1ODI_36ab6eff-9529-419e-94b4-e0a6fbe6a12c">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:BusinessCombinationEffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTU2NzM_6ab21fb3-5575-459a-bfa4-e70acaf1bad4">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div></ix:continuation><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">j.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTY_fc4a7d13-f229-4536-97e6-401d13203e55" continuedAt="i4eebc4cec509427a9f47fcd3067ed447" escape="true">Newly issued and recently adopted accounting pronouncements</ix:nonNumeric></span></div><ix:continuation id="i4eebc4cec509427a9f47fcd3067ed447"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div></ix:continuation></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_43"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 3 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3Mw_e256e579-91ba-4543-805d-d6139c26ceb9" continuedAt="i58348038a6974b4b9e2ee5fb7c586554" escape="true">BUSINESS COMBINATION</ix:nonNumeric></span></div><ix:continuation id="i58348038a6974b4b9e2ee5fb7c586554" continuedAt="i3c14058d64154567b84967ac98918c35"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the Effective Date, each ordinary share of Foamix was exchanged for <ix:nonFraction unitRef="number" contextRef="i62991dd9b59d4f20932a6cc542870ab2_I20200309" decimals="INF" name="mnlo:ExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzQ5_9d668637-9a9f-4d6d-ba35-e798927a952e">0.5924</ix:nonFraction> shares of common stock of Menlo (the &#8220;Exchange Ratio&#8221;). In addition, on the Effective Date, Foamix shareholders received <ix:nonFraction unitRef="number" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDcz_808b7500-e844-4e0e-9d54-f97d72f565a3">one</ix:nonFraction> contingent stock right (a &#8220;CSR&#8221;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#8220;CSR Agreement&#8221;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#8220;Phase III PN Trials&#8221;).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i3c14058d64154567b84967ac98918c35" continuedAt="i270de9c5e1e04331a40e8107f75e0ead"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDkzNA_80c0a3db-3960-4972-8a01-a1dad76c9445">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="INF" name="mnlo:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk0Mg_f565a22a-b9e6-4e85-8eb9-2c6412c9cc31">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of <ix:nonFraction unitRef="shares" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk1NA_9e6aaab0-41aa-45d8-81bf-80b9985f5644">74,544,413</ix:nonFraction> shares of Menlo common stock underlying the CSRs.  Following the delivery, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="2" name="mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk1OQ_b3234e1e-a882-43e5-a1ad-c943d93683d2">82</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="2" name="mnlo:PostMergerParentOwnershipByPreMergerParentStockholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk2NA_4467d1b3-692b-4eca-9fc8-5a4d9abb9c32">18</ix:nonFraction>% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#8217;s ordinary shares.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i01fe41f20f4947e2a6b7466a16a798d9_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjI1Mw_da939d0c-6376-4594-8b12-884ff56c779c">11.7</ix:nonFraction> million, which are recorded in the consolidated statements of operations and comprehensive income. This amount includes $<ix:nonFraction unitRef="usd" contextRef="i475935ac417d417b95b57d209280bd42_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjM2OA_4173f967-e596-4d1f-a609-03299016cef1">8.1</ix:nonFraction> million of severance benefits for employees terminated after the Effective Date. The total transaction costs and other non-recurring costs related to the Merger were $<ix:nonFraction unitRef="usd" contextRef="iaa6ecbab924a41ee8267c4ae3a55f162_I20200511" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjU2OQ_7c2fef74-f9b4-4567-bc7b-586db7a19e45">21.8</ix:nonFraction> million.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Purchase Price</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3OA_1b712b2e-f991-448f-aa88-14e5f4b18706" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:84.363%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMS0xLTEtMS0w_6a6381c8-0af7-4d73-84a4-7b03217d06d6">123,757</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMi0xLTEtMS0w_27aa4ee7-f6a2-4c20-b0b4-345360023c2f">7,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total consideration*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationConsiderationTransferredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMy0xLTEtMS0w_09c59a8c-730e-41e9-bc0b-598deea3c179">131,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $<ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTAxMQ_fb4d679a-c5e0-4220-a70f-7caf10ad76f8">19.6</ix:nonFraction> million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzEyOA_3e73ed01-5307-4dd4-942f-1e103cec056d">111.4</ix:nonFraction> million, as shown in the purchase price allocation table below.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on Foamix&#8217;s closing share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzIyOA_6dffcc52-8bc4-41d7-a3db-86b5407e6555">2.99</ix:nonFraction> as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationConsiderationTransferredGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzMzMg_6554bc2b-5518-40a0-a389-81819bb22fc4">131.1</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzM1MA_46b86cef-68d1-44ec-bafa-6540c3818d1b">123.8</ix:nonFraction> million for the deemed (for accounting purposes only) issuance of <ix:nonFraction unitRef="shares" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationSharesDeemedIssuedForAccountingPurposes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzQxMQ_fd27bace-6937-4427-9806-b68a894a269b">41.4</ix:nonFraction> million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzUyMA_dc76061e-c7a4-422a-868c-0b180b1b19bb">7.3</ix:nonFraction> million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzgwNA_2c38f427-ba44-4926-8352-a508ba1708bf">2.99</ix:nonFraction> as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Purchase Price Allocation</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3Nw_ad42b36a-e7f6-4404-8d3c-de7226b74f22" continuedAt="i47472f0b868840babe5c7db5398b4ebb" escape="true">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:</ix:nonNumeric></span></div></ix:continuation><ix:nonNumeric contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfOTU0MQ_b6069441-fad1-491f-856a-66b1f4e0a03b" continuedAt="iac433c2cd3674103ad9a2bc97f127401" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i270de9c5e1e04331a40e8107f75e0ead" continuedAt="i151a46545c934000b31cc5937c0d7c24"><ix:continuation id="i47472f0b868840babe5c7db5398b4ebb"><ix:continuation id="iac433c2cd3674103ad9a2bc97f127401"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:84.363%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMS0xLTEtMS0w_57d06e87-6b31-44d1-b6e2-bb2fbe7f2146">38,641</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investment in marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMi0xLTEtMS0w_969d26cb-648d-46f1-9e9a-40f719366c3f">22,703</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMy0xLTEtMS0w_e8b558dd-3546-439e-9aef-e6acf2bf5db5">1,581</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In-process research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNC0xLTEtMS0w_85eb8659-a7b8-4769-b026-41d5d8709280">50,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNS0xLTEtMS0w_b4d2ed14-aa0a-4610-a3b6-e7e0a243bfec">4,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNi0xLTEtMS0w_056a299f-24ba-437f-bd33-5a08a4434951">117,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNy0xLTEtMS0w_76d05278-96a7-4b22-a12f-62d3b296f726">5,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfOC0xLTEtMS0w_0dbe6f98-c1fd-4d3b-bc0f-461f43540527">5,827</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated purchase price*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfOS0xLTEtMS0w_5bab2dfe-edc3-42fd-b028-6a6dd7d72307">111,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $<ix:nonFraction unitRef="usd" contextRef="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDI0Ng_8b5a33ee-4cd9-49c9-92b4-5c349e4bf647">19.6</ix:nonFraction> million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div></ix:continuation></ix:continuation><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. <ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDg1MQ_1dbf0fd0-5221-4674-a0fe-8d7a16b855c8">None</ix:nonFraction> of the Goodwill recognized is expected to be deductible for income tax purposes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:ScheduleOfBusinessCombinationGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDkwMzM1NA_767606e6-3808-4f8c-b0a6-4f725e82b4db" continuedAt="i5469567ee6474a9a953a0a29e342071b" escape="true">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i5469567ee6474a9a953a0a29e342071b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:84.363%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 9, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase price</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMS0xLTEtMS0w_3285b107-d9c7-45fb-8be4-6a66fe1e067b">111,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMi0xLTEtMS0w_5082ad92-ad99-474a-8cf8-2cdde0456f77">107,398</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMy0xLTEtMS0w_0f544b4d-9b7b-474c-a00a-e209f2fba077">4,045</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE0Mw_5e52e15d-3f74-411e-a216-621d1aa789ef"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE0Mw_a905565c-edb8-489b-8479-795f85ab065e">4.0</ix:nonFraction></ix:nonFraction> million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">In-Process Research and Development (&#8220;IPR&amp;D")</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3NQ_23aecbe9-cd8a-4ad2-82d8-e2387fad11be" continuedAt="i19e431db308e4244a7d7c2dfae74e987" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:83.630%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intangible asset</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJjODNjNGI5ODM2ZDQwMmRiOWIzM2YwMzYwNWIwNjhkL3RhYmxlcmFuZ2U6MmM4M2M0Yjk4MzZkNDAyZGI5YjMzZjAzNjA1YjA2OGRfMS0yLTEtMS0w_a41fb74f-8f63-4283-b429-ca96485c095d">50,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJjODNjNGI5ODM2ZDQwMmRiOWIzM2YwMzYwNWIwNjhkL3RhYmxlcmFuZ2U6MmM4M2M0Yjk4MzZkNDAyZGI5YjMzZjAzNjA1YjA2OGRfMi0yLTEtMS0w_2b4bba3e-306c-431e-840e-4ef13e3ab30a">50,300</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i19e431db308e4244a7d7c2dfae74e987">* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.</ix:continuation> </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of IPR&amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i151a46545c934000b31cc5937c0d7c24" continuedAt="i33a1e3e1b3aa44a5a1c958192c5584e6"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i64bfe9f3e6894c12a9573e9ba7298549_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE2MQ_2e543201-a346-47fb-a396-91da16727ba8"><ix:nonFraction unitRef="usd" contextRef="i363b390923d44002aea9667a68a52c10_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE2MQ_370c3fde-50b8-4693-bf14-ac2cf8ca0720">50.3</ix:nonFraction></ix:nonFraction> million related to the IPR&amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CSR</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s Phase III PN Trials. The Company recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNjU1NA_eff7e50f-3f61-4dbc-adb1-f11adaa81706">19.6</ix:nonFraction> million in the unaudited condensed consolidated balance sheet as of March 31, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ5Mw_80c0a3db-3960-4972-8a01-a1dad76c9445">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="INF" name="mnlo:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ4NQ_f565a22a-b9e6-4e85-8eb9-2c6412c9cc31">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of <ix:nonFraction unitRef="shares" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ3Nw_9e6aaab0-41aa-45d8-81bf-80b9985f5644">74,544,413</ix:nonFraction> shares of Menlo common stock underlying the CSRs.  Following the delivery pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="2" name="mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ5OA_b3234e1e-a882-43e5-a1ad-c943d93683d2">82</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="2" name="mnlo:PostMergerParentOwnershipByPreMergerParentStockholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTUwMw_4467d1b3-692b-4eca-9fc8-5a4d9abb9c32">18</ix:nonFraction>% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mnlo:ContingentStockConsiderationRemeasurementGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE5Ng_cdde13fb-e193-495a-90d7-062e575d6e5e">84.7</ix:nonFraction> million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $<ix:nonFraction unitRef="usd" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDIzOQ_4f2a6471-5301-43a3-be0d-ba053bd71fee">104.4</ix:nonFraction> million (calculated based on <ix:nonFraction unitRef="shares" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="INF" format="ixt:numdotdecimal" name="mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ2NA_9e6aaab0-41aa-45d8-81bf-80b9985f5644">74,544,413</ix:nonFraction> shares issued and a share price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTU3Nw_4a38cfa4-83f2-4874-9e61-51200271e541">1.40</ix:nonFraction> on April 6, 2020) and then settled in connection with the issuance of shares. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pro Forma</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The actual Menlo net loss included in the Company&#8217;s consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3NA_2583c12c-b47d-4754-b9c1-07ccc9c3540c" continuedAt="ic4972c4dcd4d4acdaf7140e56a8217db" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:70.222%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.598%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMC0xLTEtMS0w_ecfb2dfe-6278-4c1f-8fc5-41f00fd7051e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMi0zLTEtMS04ODQ_57d4f8a2-6b30-45c2-aae6-848297c07da7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to Menlo</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMS0xLTEtMS0w_33ec89ec-feed-4bea-b80c-50d2a945c506">7,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMy0zLTEtMS04ODQ_1c1222c9-75d6-4f5f-a22e-6b3a29030891">19,637</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i33a1e3e1b3aa44a5a1c958192c5584e6"><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="ic4972c4dcd4d4acdaf7140e56a8217db"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.713%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.596%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.601%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC0xLTEtMS0w_eaff48ce-f028-4b46-9f4c-d0617657730d">11,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC0zLTEtMS0w_c5b943c9-a3df-4e54-b460-648a78aeae12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC01LTEtMS05MTQ_878877fb-79a2-40df-a420-cf6ca9ba0d2c">13,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC03LTEtMS05MjA_f8266b22-2430-4518-8818-76d95c962efa">308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS0xLTEtMS0w_4b1aa1ea-be8e-4b6d-870e-33a44d468314">167,441</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS0zLTEtMS0w_c31c9a34-a443-4ec1-87bc-b50485d02cbc">35,470</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS01LTEtMS05MTQ_994d9ee2-ac35-47e5-b575-f7015b290892">205,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS03LTEtMS05MjA_5545b34d-c8b4-4687-988a-a38c4c5f0757">69,547</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss per share - basic and diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0xLTEtMS0w_00efbc47-6a95-4ee1-9b6f-ae31fc6b8a2e"><ix:nonFraction unitRef="usdPerShare" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0xLTEtMS0w_db871975-59b7-452c-adc1-d237a86eed99">1.21</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0zLTEtMS0w_931feb25-2e91-4698-a1ad-086a8068c3e2"><ix:nonFraction unitRef="usdPerShare" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0zLTEtMS0w_c0fc85fb-9c24-43ab-b96b-627ba1f0f2e8">0.59</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi01LTEtMS05MTQ_4371620a-df7b-46d2-af03-e317e3df7c90"><ix:nonFraction unitRef="usdPerShare" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi01LTEtMS05MTQ_f5546d8b-4608-4444-9033-9d95bd9725cc">1.23</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi03LTEtMS05MjA_088fea0f-db37-47ca-aa91-44e62b92ff06"><ix:nonFraction unitRef="usdPerShare" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi03LTEtMS05MjA_876c63de-d414-4fec-841f-8784ef44c92c">1.16</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction costs</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS0xLTEtMS0w_a68d7209-fdc0-4281-a517-5c12594e6fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS0zLTEtMS0w_a1ca1b47-4076-4668-88a5-164369f0034f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS01LTEtMS05MTc_08c91356-daa5-4e63-af9d-9e18c2605336">14,931</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS03LTEtMS05MjM_9025f69a-34c8-4c84-b0ef-0843cf0b10ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acceleration of stock based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtMS0xLTEtMA_cd61a497-a4c5-4bfa-bfe8-a3cf00cfd36f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtMy0xLTEtMA_0b9cfad0-583b-4598-b8a1-4511f10ab0f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtNS0xLTEtOTE3_70a49767-9da6-4bc7-a3bd-96d9a29a2736">7,199</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtNy0xLTEtOTIz_52cdbc26-edad-4892-9ed5-c2dd572d31b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total Adjustments</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtMS0xLTEtMA_b4dec2f2-3455-4925-bc79-9019020b0a91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtMy0xLTEtMA_33da9087-6f40-44cb-9ee1-6ed023479af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtNS0xLTEtOTE3_65dbd3e5-6825-4460-aede-447da91ea6c0">22,130</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:zerodash" name="mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtNy0xLTEtOTIz_36b6bad2-5104-4a6d-8adc-0c8606e93ab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_46"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMzI5ODUzNDg4OTkyNw_1eb5cef8-25da-469c-9d71-191f2e09fbdc" continuedAt="ic8aa633fb37e46a5aa0ff506e35e4d0d" escape="true">REVENUE RECOGNITION</ix:nonNumeric></span></div><ix:continuation id="ic8aa633fb37e46a5aa0ff506e35e4d0d" continuedAt="i44737f1263854dfbbd0b50bc33bc78e9"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Sales</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues for the three and six months ended&#160;June&#160;30, 2020&#160;were generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020. The Company&#8217;s customers include a limited number of national and select regional distributors. These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the distributors. For the three months ended June&#160;30, 2020,&#160;three&#160;distributors accounted for&#160;<ix:nonFraction unitRef="number" contextRef="i739bb757f1734242959f7c1f7cabb3dd_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjY2_c9a70836-5f75-4265-b1b7-fb7aad65e226">42</ix:nonFraction>%,&#160;<ix:nonFraction unitRef="number" contextRef="idb0c3f02a2d0451fb10bb5af69b6fe95_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjcw_00411aae-afe7-4fb7-96e1-a70943348eed">43</ix:nonFraction>%&#160;and&#160;<ix:nonFraction unitRef="number" contextRef="iabf481a0bc8d434eba2737a7b1854201_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjc3_7097e093-139d-4cf2-aa95-3a63d8638bad">15</ix:nonFraction>%&#160;of product revenue, respectively.  For the six months ended June&#160;30, 2020, three distributors accounted for <ix:nonFraction unitRef="number" contextRef="icb682629e2c14d16967faab5132bce3d_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk0Mg_57786b6a-7d67-40e1-9977-05d7b03c6846">46</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7e9d51a1cbf04ecfa836c93c8fcf8b60_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk0OA_5a73bc98-093e-478b-b9a6-ec30c2e1fe60">39</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9d8a0654d2c844fab4d30cbe0f737b93_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk1NA_4f562df6-190e-4734-b889-fc60bce0471d">14</ix:nonFraction>% of product revenue, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Sales Provisions</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its distributors less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to Third-party Payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to Trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within Accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTczNw_6c3ac3a2-0402-403e-8084-e471ca4e2b92">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0ODExNQ_282e90a4-a9a3-46be-950e-42ffe82e8b9d">14.1</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Distribution Fees and Trade Discounts and Allowances: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates, Chargebacks and Other Discounts: </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i44737f1263854dfbbd0b50bc33bc78e9" continuedAt="i202158ff2bb74305977fbfc5172bc808"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#8217;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product Returns: </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">he information utilized to estimate the returns provision includes: (i)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> historical industry information regarding rates for comparable pharmaceutical products and product portfolios</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">demand</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="2" name="mnlo:EstimateOfProductReturnRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNDgwNw_9a388891-be45-4f27-9a2b-2837e6990b25">2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="2" name="mnlo:EstimateOfProductReturnRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNDgxMw_f1016b7d-b165-4203-9238-066155186555">3</ix:nonFraction>% of product will be returned.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License Revenues</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commerical use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company will receive an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-5" format="ixt:numdotdecimal" name="mnlo:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQyNg_910f1773-7828-4b12-b782-31ea57993de2">10.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i5da754f4e94e4544b609a323172766eb_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="mnlo:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQzOQ_cd9b39fb-d1f3-4add-b0f5-b80815c79e6c">6.0</ix:nonFraction> million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-6" format="ixt:numdotdecimal" name="mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQ3NA_703f27fb-ee10-4e26-a607-b1da3c17d764">1.0</ix:nonFraction> million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-5" format="ixt:numdotdecimal" name="mnlo:UpfrontRoyaltyReceipt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTY4OQ_910f1773-7828-4b12-b782-31ea57993de2">10.0</ix:nonFraction> million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $<ix:nonFraction unitRef="usd" contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423" decimals="-6" format="ixt:numdotdecimal" name="mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ1MDYzMw_703f27fb-ee10-4e26-a607-b1da3c17d764">1.0</ix:nonFraction> million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contract Assets and Contract Liabilities&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2020, as customer invoicing generally occurs before or at the time of revenue recognition. The Company has a $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTYyMw_b1224dab-42c5-44a3-8ca4-438aa39e9242">4.0</ix:nonFraction> million receivable, recorded as an Other receivable on the consolidated balance sheet, due from Cutia as of June&#160;30, 2020 which is expected to be paid in Q3 2020.  The Company did not have any contract liabilities as of&#160;June&#160;30, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Commissions</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing Component</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 90 days.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalty Revenues&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNTkyNA_1b5f8abb-b99d-4b05-851b-708db897fc9c"><ix:nonFraction unitRef="usd" contextRef="i99638830588b43439d03faa00fafb735_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNTkyNA_5d659803-3394-4e5b-b0ce-887b24e793de">0.2</ix:nonFraction></ix:nonFraction> million were recorded during the three and six months ending </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i202158ff2bb74305977fbfc5172bc808">June&#160;30, 2020 and revenues in the amount of $<ix:nonFraction unitRef="usd" contextRef="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0ODE2MA_2a53de93-feb9-4fdf-84f5-4e2a67dc017d">0.3</ix:nonFraction> million were recorded during the six months ending June&#160;30, 2019.  There was <ix:nonFraction unitRef="usd" contextRef="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMzI5ODUzNDg4OTkzMA_8bfdff1c-7eb5-4b63-990d-b1d75dc8f5f8">no</ix:nonFraction> revenue for the three months ending June&#160;30, 2019.</ix:continuation></span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_52"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5 - <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMzI5ODUzNDg4NTMyNQ_37d06a54-911d-43cc-8dc5-de13befe7a11" continuedAt="ic9cc28365a93441e9aa33aa9c13969bc" escape="true">FAIR VALUE MEASUREMENT</ix:nonNumeric></span></div><ix:continuation id="ic9cc28365a93441e9aa33aa9c13969bc"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMzI5ODUzNDg4NTMyNg_d6b939a4-361f-47bc-9d9b-9a7f520fa8c2" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s assets and liabilities that are measured at fair value as of June&#160;30, 2020 and December&#160;31, 2019, are classified in the tables below in one of the three categories described in note 2H above:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddecf24382d740b79c3744ff4ae84e96_I20200630" decimals="-3" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi0xLTEtMS0w_cd240e08-ec63-42a2-a2aa-4c113fc76394">591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35eb5a8b86fc4928a2d78dfe2c2b62c4_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi0zLTEtMS0w_d524fe1e-af66-46d4-83b8-5da711a97f11">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b5c2e12f42a4c42ab17af5707fd15c0_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi01LTEtMS0w_e553af2c-1a58-4d43-a335-4c5dcdf38d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi03LTEtMS0w_06c60e39-1853-428c-af44-0044721ba472">2,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.879%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.730%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.732%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedfd359d21884ac0b9588367562b5816_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi0xLTEtMS0w_1ba2487f-5679-45c5-826e-fee425e1e303">1,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c8222d051b543688377451564f533a2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi0zLTEtMS0w_7179d168-ff6f-4dac-a5dc-2f690e9a4e41">15,660</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i186f34938c484be6bd6c29ddc7b7009a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi01LTEtMS0w_4107a23b-1841-47c4-be4d-2a4ce5fc9f92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi03LTEtMS0w_f2d08734-e262-4e69-ac31-dd71e30cd6f5">16,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:27pt;margin-top:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.43pt;">The Company&#8217;s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Foreign exchange risk management</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Occasionally, the Company purchases and writes non-functional currency options in order to hedge the currency exposure on the Company&#8217;s cash flow. The currency hedged items are denominated in New Israeli Shekels (&#8220;NIS&#8221;). The purchasing and writing of options is part of a comprehensive currency hedging strategy with respect to salary and rent expenses denominated in NIS. These transactions are at <ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:DerivateCostsForYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTYyMQ_677ed6db-e1d2-4a58-9121-1125281e080e">zero</ix:nonFraction> cost for periods of up to <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:durwordsen" name="mnlo:DerivativeMaximumTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTY1MA_091b7a82-bad0-4b0b-b1e9-5f51c01c46e0">one year</ix:nonNumeric>. The counterparties to the derivatives are major banks in Israel. As of June&#160;30, 2020, there were <ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeAmountOfHedgedItem" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTc0MA_c5eb6aed-c7ee-409b-9846-6eb8dfd097ca">no</ix:nonFraction> hedged amounts.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company has a lien in the amount of $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTgwOQ_8a6d95e5-7f05-4342-9b09-cb68062c3b04">0.3</ix:nonFraction> million on the Company&#8217;s marketable securities and a lien in the amount $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="mnlo:ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTg3Ng_845f067c-0e12-4749-be73-bd3fc87a0520">0.3</ix:nonFraction> million on the Company&#8217;s checking account, in respect of bank guarantees granted in order to secure the hedging transactions.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_55"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6 - <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5Nw_2280c990-3c99-4b55-8233-379dd88464b2" continuedAt="i10677dffe6cd43869a8cc881a230bdad" escape="true">MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i10677dffe6cd43869a8cc881a230bdad" continuedAt="i602a2e6d75a44fee9fb6c5e79b8d0183"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities as of June&#160;30, 2020, and December&#160;31, 2019 consist mainly of debt and mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the consolidated statement of operations as finance income or expenses.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through finance (income) expense in the condensed consolidated statements of operations.  </span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5OQ_e9a12c17-26f7-41d4-812a-8705cb147455" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israeli mutual funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia23a57fa3ccf4cc3b6bcee3e98135a78_I20200630" decimals="-3" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMi0xLTEtMS0w_91def9f3-44a3-4410-ad79-16644d4af0c3">591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i264f53d270b5492d9f34a2d7a650ab3f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMi0zLTEtMS0w_fb038296-7684-48df-8d7e-55e7fde9946a">1,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a6fc18eac5e4db28a62b77aad463b0d_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMy0xLTEtMS0w_1e980cb7-6016-4e85-8508-771f003aae80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231" decimals="-3" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMy0zLTEtMS0w_739009a8-6473-4019-a5bf-70bc0d801b78">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i28c5efb4fbad4902aaac65636b3fac52_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNC0xLTEtMS0w_db7b8850-1e8e-45ed-aa49-b7475b3e76dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNC0zLTEtMS0w_40bdf437-5b34-4e5f-a5ff-781f0c345150">6,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cfa5ee44fb64997893890be476e59ae_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNS0xLTEtMS0w_ca6f2754-5c24-45f5-8b2e-214ffbab03d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5885b910649487099b87fd418a15dde_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNS0zLTEtMS0w_9cedbf76-2b11-4f83-b396-535f1acf8dee">9,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNi0xLTEtMS0w_eff80422-4977-4ecd-9e4b-d70966a58ecb">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie41f84f7e3ef4b8a9a94c1a9b121dd36_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNi0zLTEtMS0w_35bf890c-bcfe-4d51-b167-bc166f94e0aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfOC0xLTEtMS0w_a22136d9-316d-476d-8727-c878459a2913">2,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfOC0zLTEtMS0w_c966c1fa-a70a-4027-a168-6b00ebe260d5">16,680</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5OA_4ed95268-2167-4ea1-9f5b-1b88ebba12af" continuedAt="i298400e6acec4359a371411149924c34" escape="true">As of June&#160;30, 2020 and December&#160;31, 2019 the fair value, cost and gross unrealized holding gains and losses of the debt marketable securities owned by the Company were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i602a2e6d75a44fee9fb6c5e79b8d0183"><ix:continuation id="i298400e6acec4359a371411149924c34"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC0xLTEtMS0w_3bfa09c9-2441-4d1c-bcc2-ef2cbdc29499">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC0zLTEtMS0w_70c187f1-366d-4e23-9ab7-321690871e95">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC01LTEtMS0w_83e40342-4a07-4ba4-aefc-52f309d0d2a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC03LTEtMS0w_5daeb245-0ebd-42c9-97c0-760340578799">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi0xLTEtMS0w_46961107-882a-4b59-8bcb-8b0b08527b47">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi0zLTEtMS0w_d767b5b1-1812-4e30-b637-d3e3b71a77ae">2,018</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi01LTEtMS0w_9ff283ba-0e67-4a20-aa13-e0e4de5820ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi03LTEtMS0w_6a8ffe94-b58b-46ed-a5b5-91406d740a2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi0xLTEtMS0w_2ec267d3-562f-486e-93b7-5d9da81ce818">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi0zLTEtMS0w_acaee44b-5e28-41d5-be4f-e98421593b52">151</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi01LTEtMS0w_0ece2099-e9fa-4e4f-b0ab-417ffbe6cf39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi03LTEtMS0w_435c8558-31ea-40fa-b395-062fbbe698a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government and agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy0xLTEtMS0w_28e69f8b-40fe-4d1a-a6e2-62d4d42b519a">6,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy0zLTEtMS0w_f9e647c4-daa0-48f5-a389-fd79d3a069da">6,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy01LTEtMS0w_cd9a7913-067e-4782-a171-0bf832741669">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy03LTEtMS0w_50c40c03-5e9d-4c8b-9ba0-eaf142fd4228">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5885b910649487099b87fd418a15dde_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC0xLTEtMS0w_5b01188f-65c7-4d27-99eb-e0d8706e7147">9,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5885b910649487099b87fd418a15dde_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC0zLTEtMS0w_5c94db83-682f-4ace-8ae8-a0fd29815aec">9,475</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5885b910649487099b87fd418a15dde_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC01LTEtMS0w_fecc2c18-30ce-45ed-bea8-9c1dab1cb84c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5885b910649487099b87fd418a15dde_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC03LTEtMS0w_b60d6234-3e77-42f8-b4c8-83da086935fb">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS0xLTEtMS0w_4f4ae819-0505-4a97-8190-4bdafd80cea8">15,660</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS0zLTEtMS0w_d7a596f7-1467-4694-9226-1736fb969814">15,656</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS01LTEtMS0w_d0a50130-d2e7-4487-9593-228f678ec834">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS03LTEtMS0w_b59221c6-a6a0-4949-a025-36a268d8700b">4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:continuation><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has considered factors regarding other than temporary impaired securities and determined that there are <ix:nonFraction unitRef="usd" contextRef="i621dc5363bfa40e3ab7836027e3273ea_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTE2Mw_1514914c-10cc-424c-bb97-0afdb3dab103"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTE2Mw_919b4644-66b4-4eac-a479-4ee50ec30624">no</ix:nonFraction></ix:nonFraction> securities with impairment that is other than temporary as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019 all of the Company&#8217;s debt securities were due within one year.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and June&#160;30, 2019 the Company received aggregate proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTM5Mw_f1cb602d-2a1d-4413-ad89-928c17a43593">36.4</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTQwMA_c127f30e-6ffd-44e5-82c7-f76d876cfdb8">33.0</ix:nonFraction> million, respectively, upon sale and maturity of marketable securities.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019, the Company&#8217;s restricted marketable securities were $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTUzNw_f09e9b1f-d878-404f-b67f-e5d6b447fdad">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTU0NA_738402de-16d1-4ee2-a953-6617e00df7f9">0.4</ix:nonFraction> million, respectively, due to a lien in respect of bank guarantees granted to secure hedging transaction and the Company&#8217;s rent agreements. See &#8220;Note 5- Fair Value Measurement&#8221; and &#8220;Note 10-Operating Lease&#8221; for more information.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_61"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfMzI5ODUzNDg4NDIzNA_d6b05385-a1d4-40c2-bf32-39cf8a3c48e1" continuedAt="ie39fdef2a8874031b147d2ed793191bd" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="ie39fdef2a8874031b147d2ed793191bd"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ upon FDA approval of AMZEEQ on October 18, 2019 and ZILXI on May 29, 2020. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were <ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfNzkx_0e720d7c-ad2e-462b-8468-1f4b24eba076"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfNzkx_fca2e9f6-9805-4f95-b82f-846b0c9f9133">no</ix:nonFraction></ix:nonFraction> inventory write-downs during the three and six months ended June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfMzI5ODUzNDg4NDIzNQ_ad06f4d2-1cee-4f5c-8849-dd8b6a5b2242" escape="true"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMi0xLTEtMS0w_ee66dcfa-283b-4200-a105-7d8089570ff4">3,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSupplies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMi0zLTEtMS0w_40e0a54d-6090-48ff-b471-5bc1db46c595">500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMy0xLTEtMS0w_5495b1f0-2be0-40bb-8d21-ade48de017e5">954</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMy0zLTEtMS0w_e03b2c8e-13df-484e-8809-a986c120a143">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNC0xLTEtMS0w_c1fd5920-63d8-4460-8d52-80f297e8b0bb">1,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNC0zLTEtMS0w_14f4bc7d-af36-4a58-a1a5-f287d6c0bba5">856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNS0xLTEtMS0w_71cb593b-fa32-408e-8f4f-9920f5b59620">5,801</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNS0zLTEtMS0w_982194ff-46b0-4fc7-b7be-7e5755620505">1,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_64"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8 - <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzI5ODUzNDg5MDEyOQ_57575bf5-be11-43dc-a04b-72220e24da0d" continuedAt="i07b0fa03a5e54981aeeabf445d1a2902" escape="true">LONG-TERM DEBT</ix:nonNumeric></span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i07b0fa03a5e54981aeeabf445d1a2902" continuedAt="i374fb01d0baa4e4f9ca43faa715129d7">On July 29, 2019 (the &#8220;Closing Date&#8221;) the Company secured up to $<ix:nonFraction unitRef="usd" contextRef="i11306223e6aa4bbc98552eff8183e5d6_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTM_d3d0b123-1d40-4714-bb0b-b586f065a801">50</ix:nonFraction> million in debt under a credit agreement &#8220;the Credit Agreement&#8221;) from <ix:nonFraction unitRef="shareholders" contextRef="i11306223e6aa4bbc98552eff8183e5d6_I20190729" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:NumberOfLenders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTU4_0fed430e-0c1e-4fc4-b49b-ada8dd560d5e">two</ix:nonFraction> of its current shareholders, who are considered related parties (the &#8220;lenders&#8221;) and entered into a Securities Purchase Agreement with <ix:nonFraction unitRef="lenders" contextRef="ia3617748d41e46a8bfedb32f0d650a74_I20190729" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:NumberOfLenders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjk1_fd9c05d2-7bfb-45c0-adfe-f25b49ee49d2">one</ix:nonFraction> of the lenders for gross proceeds of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ia3617748d41e46a8bfedb32f0d650a74_I20190729" decimals="-6" format="ixt:numdotdecimal" name="mnlo:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzQ5_3c31506f-e296-425f-bdb3-661092292579">14</ix:nonFraction> million, before deducting offering expenses (see &#8220;Note 9- Share Capital&#8221; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (the &#8220;Amended and Restated Credit Agreement&#8221;), whereby the Company has guaranteed the indebtedness obligation of Foamix Pharmaceuticals Inc. and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. The Amended and Restated Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTM4_d0fa313b-1936-4405-baa4-84e02fa00221">50.0</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i423fa226d79249718ae35ed0e4fd377b_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTUx_47001ef9-a936-42d5-95fc-9eeedfc83302"><ix:nonFraction unitRef="usd" contextRef="i5f85dcc728e248d98e63a19af7ced4ed_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTUx_b2d1562e-cb94-4c62-bc24-5115ed67c79f">35.0</ix:nonFraction></ix:nonFraction> million was drawn as June&#160;30, 2020 and December&#160;31, 2019.</ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i374fb01d0baa4e4f9ca43faa715129d7" continuedAt="i4b07259bb2b04720831adc1fc6309fa4"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Amended and Restated Credit Agreement, the debt comprises of <ix:nonFraction unitRef="tranches" contextRef="i4fa0d91fe20746dc801522cdb641699a_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:CreditAgreementNumberOfTrenches" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTA0NQ_7ddb72d7-583d-4907-a3f8-22901787a165">three</ix:nonFraction> tranches: (a) $<ix:nonFraction unitRef="usd" contextRef="ie8232e19d10a4519b9a3cd10a5721fb1_I20190729" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTA2Mg_8ab33199-4fa9-461a-b02f-136b85c3af6f">15</ix:nonFraction> million funded at closing (the &#8220;Tranche 1 Loan&#8221;), (b) $<ix:nonFraction unitRef="usd" contextRef="i5a65c85354904beda1b2323ac7ec07cd_I20191217" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTExMQ_eff5b049-aa63-4410-b8e3-85d6fd2d875a">20</ix:nonFraction> million funded on December 17, 2019 (the &#8220;Tranche 2 Loan&#8221;) and (c) up to $<ix:nonFraction unitRef="usd" contextRef="i1adb6f4952624c32ba9efdccfaadf065_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTE3OQ_5c756295-10cb-4ca0-bdcc-5b2762f1c1ce">15</ix:nonFraction> million available after the closing date and prior to September 30, 2020 (the &#8220;Tranche 3 Loan&#8221;). The Tranche 2 Loan was borrowed following the FDA&#8217;s approval of the Company&#8217;s NDA for AMZEEQ (formerly known as FMX101) and listing of AMZEEQ in the FDA&#8217;s &#8220;Orange Book,&#8221; in addition to maintaining its arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company shall be permitted to borrow the Tranche 3 Loan only following the achievement of certain revenue targets prior to September 30, 2020. Subject to any acceleration as provided in the Credit Agreement, including upon an event of default (as defined in the Amended and Restated Credit Agreement), the credit facility will mature on July 29, 2024 and bear interest equal to the sum of (A) <ix:nonFraction unitRef="number" contextRef="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTkyNQ_1a1d2dc8-f84b-43d9-a341-d65322e03496">8.25</ix:nonFraction>% (subject to increase in accordance with the terms of the Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) <ix:nonFraction unitRef="number" contextRef="i52154cb6d81246b2b19b393816177d95_D20200309-20200309" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjI2NA_cfc66aeb-309c-419c-99e7-eb5e0ad86722">2.75</ix:nonFraction>%. A fee in an amount equal to <ix:nonFraction unitRef="number" contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309" decimals="3" name="mnlo:DebtInstrumentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjI5Ng_60cefc3b-eef0-488f-9785-8331e84e6c1f">1.0</ix:nonFraction>% of the aggregate principal amount of all loans made on any given borrowing date shall be payable to the lenders.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amended and Restated Credit Agreement contains certain financial covenants, including that the Company at all times after the date of FDA approval of AMZEEQ maintain a minimum aggregate compensating cash balance of $<ix:nonFraction unitRef="usd" contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:MinimumAggregateCashBalanceMaintainAfterFdaApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjYzNQ_1238df28-3fdb-4427-a618-a8947b26c5d1">2.5</ix:nonFraction> million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as a result of the negative impact on the Company's product sales of AMZEEQ due to the COVID-19 pandemic, the parties entered into Amendment No. 1 to Amended and Restated Credit Agreement (the "Amendment") on August&#160;5, 2020.  The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $<ix:nonFraction unitRef="usd" contextRef="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231" decimals="-5" format="ixt:numdotdecimal" name="mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfODc5NjA5MzAzMzY2OA_2e865583-c280-4795-9b0d-4ebea3d1eacc">6.0</ix:nonFraction>&#160;million for the fiscal quarter ending December 31, 2020 to $<ix:nonFraction unitRef="usd" contextRef="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfODc5NjA5MzAzMzY4Mw_447a96dd-08e4-482b-9bfb-3ad85f7df572">97.0</ix:nonFraction>&#160;million for the fiscal quarter ending June 30, 2024. The Amendment does not modify any of the conditions precedent to borrowing the Tranche 3 Loan, as described above and as set forth in the Amended and Restated Credit Agreement. See "Note 12 - Subsequent Events."</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company is in compliance with all covenants, including&#160;maintaining a minimum aggregate compensating cash balance as mentioned above. In the event where the Company fails to observe or perform any of the financial covenants the lenders may, by notice to the Company, declare the Term Loans then outstanding to be due and payable in whole, together with accrued interest and a Prepayment Premium (as defined in the Amended and Restated Credit Agreement ). Additionally, the Company will continue to monitor ongoing developments in connection with the COVID-19 pandemic, which may have an adverse impact on the Company&#8217;s commercial prospects, projected cash position and ability to remain in compliance with these covenants.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Amended and Restated Credit Agreement, there are no required payments of principal amounts until July 2023. Afterwards, the Company will pay <ix:nonFraction unitRef="number" contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309" decimals="3" name="mnlo:DebtInstrumentPeriodicPaymentPrincipalPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzg2MQ_7f8a5a18-9090-4379-a45d-c472cd377193">1.5</ix:nonFraction>% of the aggregate principal amount each month. The outstanding amount will be paid in full on July 2024.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, on the Closing Date, Foamix issued to the lenders warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDA3NA_0884f7a6-846a-492c-a690-9f0ce41a49c7">1,100,000</ix:nonFraction> of its ordinary shares, at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDEyNQ_32df1a99-bd59-4d8a-b064-156183f4ce56">2.09</ix:nonFraction> per share (the &#8220;Warrant&#8221;), which represents the five-day volume weighted average price of the ordinary shares as of the trading day immediately prior to the Closing Date. Following the Merger, the Warrants were exchanged, based on the Exchange Ratio, to <ix:nonFraction unitRef="shares" contextRef="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309" decimals="INF" format="ixt:numdotdecimal" name="mnlo:StockIssuedDuringPeriodSharesWarrantExchange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDM4Mg_368fb410-b2b9-4df2-af2d-d31e6c35a022">651,640</ix:nonFraction> of the Company&#8217;s common stock, and adjusted the exercise price to $<ix:nonFraction unitRef="usdPerShare" contextRef="i665aac50c21e4c9382a4dedf21e3a6d4_I20200309" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDQ1MQ_72543965-483e-4ce9-b704-cc0f353d0af3">3.53</ix:nonFraction> (See &#8220;Note 3 &#8211; Business Combinations&#8221; for more information relating to subsequent adjustment of warrant following the Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106)). Payment of the exercise price will be made, at the option of the lender, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company incurred offering expenses of $<ix:nonFraction unitRef="usd" contextRef="idec71e92949949a9a5cbf85570f5b1c2_D20190729-20190729" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjE5OTAyMzI2MjU5Ng_3fcfb49d-9e5d-41dd-ad39-f38433078c6a">1.1</ix:nonFraction> million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $<ix:nonFraction unitRef="usd" contextRef="iea4fd37970a64213b591edc27d8201a8_D20190729-20190729" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjE5OTAyMzI2MjYwMw_d3a71eb3-51b2-49db-9f56-8780e4047218">0.3</ix:nonFraction> million from the borrowing of Tranche 2 Loan, allocated only to the debt.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i4b07259bb2b04720831adc1fc6309fa4"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the debt as of June&#160;30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i647408d71ea94b9aacbdfd5eea1f5f10_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjAxNw_04fb88d9-1d8c-4800-baff-c699498b6b23">35.8</ix:nonFraction> million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June&#160;30, 2020 the company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjQwNA_020b5a65-b9a5-4d47-b259-35536f0fa575">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjQxMQ_ab425486-8edf-4097-ac81-1206ef21e672">0.1</ix:nonFraction> million relating to the interest and discount cost, respectively.  During the six months ended June&#160;30, 2020 the company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTY0OTI2NzQ0ODQ2MA_bd07ce7b-af38-40ec-bd1f-084c55e6be83">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTY0OTI2NzQ0ODQ2Mw_6263c2b1-9663-48a0-b448-0ae13879ab21">0.2</ix:nonFraction> million relating to the interest and discount cost, respectively.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_70"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1MQ_63be8717-a057-475b-9175-0c0e832d8797" continuedAt="i1a1bdffd127b4f5f8107b1eafa87effb" escape="true">SHARE CAPITAL</ix:nonNumeric></span></div><ix:continuation id="i1a1bdffd127b4f5f8107b1eafa87effb" continuedAt="i8dacd69a73004e6bb78035dfb77f488b"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Preferred stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkxOA_8caa43d5-2457-4234-80bc-26b519bbc54c">20,000,000</ix:nonFraction> of shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyMQ_0f80e21f-927d-486b-ba97-06cde5000f22">0.0001</ix:nonFraction> par value preferred stock.  There were <ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_0cb3014e-1bdb-4858-962c-4a69bab4fd65"><ix:nonFraction unitRef="shares" contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_8d03870f-13ce-4a83-a67a-e6a77a66cb78"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_cc73ac65-dd44-4225-ac8c-12e72c7cc760"><ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_ffae20a6-f5d6-4f49-ad1c-8b8ea209b12d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Common stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company&#8217;s Certificate of Incorporation, as amended, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkzMA_c86908fe-a6a2-4771-b918-9c8205f78b16">300,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkzMw_d333f4a7-5fa7-4809-b5e2-bce04a27c14d">0.0001</ix:nonFraction> par value common stock. See Note 12&#8212;Subsequent Events. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each share of common stock is entitled to <ix:nonFraction unitRef="votes" contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:CommonStockVotingRightsNumberPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjIx_1661528c-e013-40f1-92ed-16b6ea77d2e7">one</ix:nonFraction> vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Issuance of stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 29, 2019, pursuant to the Credit Agreement and Securities Purchase Agreement, Foamix issued and sold, in a registered offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i21624033d4ac4fff8c601a26fb4f4cd2_D20190729-20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzA0_68d6531d-88a3-4db0-87cc-6eb0d3113b4a">6,542,057</ix:nonFraction> ordinary shares at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8c8813e111447bda5117bdf5d6a2b26_I20190729" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzQ2_1d7835fe-5f79-477d-8dbf-15028a96d4bb">2.14</ix:nonFraction> per share, later exchanged to <ix:nonFraction unitRef="shares" contextRef="ib45c461b63af4f079fa025d92a11ec36_D20200309-20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzc5_546eefbc-aeea-499f-9c05-1d85e3a65cfa">3,875,514</ix:nonFraction> Menlo common stock at the closing of the Merger. The aggregate gross proceeds of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ie7a4e94dab8049848e6d72417f3fbe51_I20190729" decimals="-6" format="ixt:numdotdecimal" name="mnlo:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc3_5e421b37-dcc8-4497-832c-d5388d9856de">14</ix:nonFraction> million, before deducting issuance costs allocated as described in Note 8-Long Term Debt, in the amount of $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2Nzc5Ng_65e32596-fcce-44b3-9c6b-64a51ed28111">0.3</ix:nonFraction> million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the completion of the merger, on March 9, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7d9ecc3914e54a259847aa543d67e621_D20200309-20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTA2Mg_61ddbe4d-59b1-4d4d-96c6-ef05e5bdbfed">36,550,335</ix:nonFraction> shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTUxNQ_34c061ff-8c98-4f0e-9206-c2c53be903e6">74,544,413</ix:nonFraction> shares to Foamix shareholders.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 9, 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTQ3Nw_ac32a22b-1fae-4bb1-a45e-d0b70b2e6260">31,107,500</ix:nonFraction> shares of common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i92c1d7c7352a4dca951e1bcd7cb06a55_I20200609" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTQ4NA_858eb7c0-f47c-448e-910d-33b9a6ab41e8">1.85</ix:nonFraction> per share.  The net proceeds of the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTUwMA_2ad1c81c-7476-4441-ad24-bf0a35c1bae4">53.6</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Warrants</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the Credit Agreement signed on July 29, 2019, on the Closing Date, Foamix issued to the lender Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="if23f7b87177b47a08e6248caeff2b802_I20190729" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTM4NQ_50ba926e-89cd-469d-a4d9-2859aac9084d">1,100,000</ix:nonFraction> of its ordinary shares, later exchanged to <ix:nonFraction unitRef="shares" contextRef="i0cd250813f00419fbd2e80392e7e0172_D20190729-20190729" decimals="0" format="ixt:numdotdecimal" name="mnlo:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MzQ2Nw_19327b57-0f09-4582-9827-68eca8431876">1,980,660</ix:nonFraction> of Menlo&#8217;s common stock. Upon the closing of the Merger, each Warrant received <ix:nonFraction unitRef="number" contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:BusinessAcquisitionContingentStockRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTUxMw_8ac93b06-75a4-4a8e-9d0b-0661234f6593">one</ix:nonFraction> CSR as described in Note 3- Business Combinations.  The warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants&#8217; expiration date, if in the money.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR, was accounted for as a modification, by analogy, from the modification&#8217;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i8dacd69a73004e6bb78035dfb77f488b" continuedAt="i1924eced12bc4ed493bfbcf7c7439963"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">significant. Therefore, the incremental fair value, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309" decimals="-3" format="ixt:numdotdecimal" name="mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjQ4MQ_fafe58b1-8380-4af1-9667-df8b86bc9de6">41,000</ix:nonFraction>, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share-based compensation</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Equity incentive plans:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the Merger, the company adopted Foamix&#8217;s 2019 Equity incentive plan (the &#8220;2019 Plan&#8221;). As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i70cb25f8075540d79ea2d6581691f94f_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjc5MA_0af3b215-4b56-4427-963a-d55501d48e95">2,849,843</ix:nonFraction> shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan"), effective January 2018.  Pursuant to the terms of the 2018 Plan in January 2020, the 2018 share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="idd59a6ce5690423f839a46a944f522ff_I20200630" decimals="INF" format="ixt:numdotdecimal" name="mnlo:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mzc2NQ_7d81b57d-080a-459f-af76-7d12446db0a6">976,105</ix:nonFraction> shares of common stock issuable.  As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="idd59a6ce5690423f839a46a944f522ff_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MzMzMA_8a546b82-1d9f-42ac-9b2e-496ff3fc1669">2,184,769</ix:nonFraction> shares remain issuable under the 2018 Plan.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee Share Purchase Plan:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the Merger, the company adopted Foamix&#8217;s ESPP pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#8217;s common stock at a price equal to&#160;<ix:nonFraction unitRef="number" contextRef="i0047714113804cad9c16bdab5627a1ea_D20200309-20200309" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzE4OA_b0db36d0-8604-41fd-b720-0db0324a2aef">85</ix:nonFraction>%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#8220;Purchase Period&#8221;). Employees are permitted to purchase the number of shares purchasable with up to <ix:nonFraction unitRef="number" contextRef="i6e7afa2c35824eb99e24ca41f2a6b35f_I20200309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzQxNw_db21f971-f8bc-4b23-af74-f7cb4c5a3644">15</ix:nonFraction>% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i5244e3d9cde04b82806e7986585ce214_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzY0MA_c173db2a-9915-4d0a-9c13-d9011432fe8c">9,371,258</ix:nonFraction> shares remain available for grant under the ESPP.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="ic1ae53396f194b79aee91b06e1fcfc53_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzcyNA_a488c109-9f5d-4462-820e-3380d2b4dff4">61,031</ix:nonFraction> Foamix ordinary shares, later exchanged to <ix:nonFraction unitRef="shares" contextRef="i128638d8b51d4c5e8740fccfe8bb54e9_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzc3MA_7cad30f7-e39c-4e63-8f1f-bccdece8510e">109,892</ix:nonFraction> Menlo common stock, were issued to the employees.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Options and RSUs granted to employees and directors:</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1MA_bc6811f9-d134-49b0-aef5-5784919d43ff" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the six months ended June&#160;30, 2020 and 2019, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0xLTEtMS0w_f1b0e662-2e7d-48c1-9e38-6fab129125be">4,782,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0zLTEtMS0zODU0L3RleHRyZWdpb246YTY5NTkxNzA4MjA2NGNhZjhjOWVmYzYxMjc3YmU4YTNfMTY0OTI2NzQ0MTY4NA_30769427-b4ef-4a08-9b1a-dc018a188b87">1.95</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0zLTEtMS0zODU0L3RleHRyZWdpb246YTY5NTkxNzA4MjA2NGNhZjhjOWVmYzYxMjc3YmU4YTNfMTY0OTI2NzQ0MTY5MQ_fa85eb9e-a193-4e5c-b4f8-fb73f8e476af">3.13</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="iacf13670f3fa4285a1f4d963e62abc74_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy01LTEtMS0zODU3L3RleHRyZWdpb246Njc1MTMxNWUzOGY4NGQxOWI3MDVkODI4Y2QxYzYwMDhfMTY0OTI2NzQ0MTY4OQ_ff4ea2fe-6d84-4ff5-96ca-809ec3d7982a">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="i2de299f068754a7abc7d85f9a74d1a52_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy01LTEtMS0zODU3L3RleHRyZWdpb246Njc1MTMxNWUzOGY4NGQxOWI3MDVkODI4Y2QxYzYwMDhfMTY0OTI2NzQ0MTY5OA_43404f3b-31ba-4c9a-94d6-204f1276536f">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy03LTEtMS0w_3fb1f8cf-bf07-415f-b514-0e062d841fcb">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i52fdbbba6e7d4d6c8f6192df59a0b3e1_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC0xLTEtMS0w_2c357bce-335d-461f-b814-827bf1ad7541">2,589,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i158cc30187ca4219a42536fd98d5fdbd_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC01LTEtMS0zODYxL3RleHRyZWdpb246MmRhYjhiNmE3MjkwNGNhNzg4OWZlZGY0MWM0Y2E1NzRfMTY0OTI2NzQ0MTY4OQ_6fb92a5c-fdbd-45ea-81f8-d298bcb44701">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="iea7da630ee23404cb0c42917365732be_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC01LTEtMS0zODYxL3RleHRyZWdpb246MmRhYjhiNmE3MjkwNGNhNzg4OWZlZGY0MWM0Y2E1NzRfMTY0OTI2NzQ0MTY5OA_08a7b6fd-ad9a-4880-a202-b5117ba986b3">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:41.088%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.676%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.679%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0xLTEtMS0w_ae286b22-f206-4d4c-bc9a-1bb3cab56a47">2,299,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$<ix:nonFraction unitRef="usdPerShare" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0zLTEtMS0xMjA2L3RleHRyZWdpb246YmQyNDM3ODAzNmIxNGEzZjkyMDQ3NWIyYWUyZTI4MTFfMTY0OTI2NzQ0MTY4NA_925fc804-82d0-42da-9543-3c6c155fd556">1.48</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0zLTEtMS0xMjA2L3RleHRyZWdpb246YmQyNDM3ODAzNmIxNGEzZjkyMDQ3NWIyYWUyZTI4MTFfMTY0OTI2NzQ0MTY5Mg_274fbe67-89e8-4004-a9b8-8d7d4d4f35bd">2.12</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i2a6a6702cbe1405fae1d4152caf10cf8_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy01LTEtMS0wL3RleHRyZWdpb246NDEyNDg0NjdiMTk4NGRiMzg1MDA5YjYwMmI0ZDU4NzVfMTY0OTI2NzQ0MTY4OQ_6ef9c203-a3b1-4a02-bc78-8080b344e0f9">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="i7d4b715adc284a418c6a708ee727979b_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy01LTEtMS0wL3RleHRyZWdpb246NDEyNDg0NjdiMTk4NGRiMzg1MDA5YjYwMmI0ZDU4NzVfMTY0OTI2NzQ0MTY5OA_5a051e74-e480-4fa7-9a23-ba98422ee245">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy03LTEtMS0w_647c7e03-5cea-40c4-9029-f68331c58719">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia7b9c626f5cc4797874b2b7b5b559927_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC0xLTEtMS0w_e094b365-9370-43ca-8fa7-6cedb5b895d4">748,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i1ea5dbcf0c124143b148b23cc686ff50_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC01LTEtMS0wL3RleHRyZWdpb246NjkyODU3YmMyNDhjNDk0MDlmOTlkOWJhY2EyZDdhN2VfMTY0OTI2NzQ0MTY4OQ_7e1ede12-5b9e-4d4b-8b07-8f632ee48442">1</ix:nonNumeric> year -<ix:nonNumeric contextRef="ic46c960fd7f2441389d418c74a68bbd1_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC01LTEtMS0wL3RleHRyZWdpb246NjkyODU3YmMyNDhjNDk0MDlmOTlkOWJhY2EyZDdhN2VfMTY0OTI2NzQ0MTY5OA_de7d74eb-2aba-4167-bd71-caeb26a13484">4</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* All amounts and exercise prices for pre-Merge grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2020, and the six months ended June&#160;30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNDI3Nw_e62126aa-9238-4ba5-ba5d-54e2a2a97281">11.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNDI4NA_751a0473-2c64-427b-bc95-2b71fadec275">3.7</ix:nonFraction> million, respectively.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of RSUs granted is based on the share price on the grant date.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1Mw_c5e71499-9ce2-45e1-9809-bf4139287ac4" continuedAt="i36bf361d890548f99a33f43a4f43f288" escape="true">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:</ix:nonNumeric></span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i1924eced12bc4ed493bfbcf7c7439963"><div style="margin-top:5pt;margin-bottom:5pt;"><ix:continuation id="i36bf361d890548f99a33f43a4f43f288"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMi0xLTEtMS0w_6fb92525-f4f2-4ec0-8d65-477784648d71">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMi0zLTEtMS0w_f0a04fb1-5e7c-4ad0-a66c-41aa536f56cc">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0xLTEtMS0zNTY0L3RleHRyZWdpb246MTY2MTVmZWVkY2RjNDI3Y2JkYzAzMTcxM2MwZmRhNjlfMTY0OTI2NzQ0MTY5MA_c087d3a3-2fc9-4738-93d0-1ffece7c20d1">60.44</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0xLTEtMS0zNTY0L3RleHRyZWdpb246MTY2MTVmZWVkY2RjNDI3Y2JkYzAzMTcxM2MwZmRhNjlfMTY0OTI2NzQ0MTY5OA_c0718f27-3d73-4fe0-8b55-e2a5a0f1291c">69.83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0zLTEtMS0zNTcxL3RleHRyZWdpb246NmY3NDAyZGIzMDFkNGYyNzg0MGVlMmMxMDFhODAzY2NfMTY0OTI2NzQ0MTY4NA_f7e545a5-16d9-4e41-828f-98cb2cbaa3b8">60.40</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0zLTEtMS0zNTcxL3RleHRyZWdpb246NmY3NDAyZGIzMDFkNGYyNzg0MGVlMmMxMDFhODAzY2NfMTY0OTI2NzQ0MTY5MQ_c9c9c355-7bf5-445c-a799-c312aeeacfea">61.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0xLTEtMS0zNTY4L3RleHRyZWdpb246MDEwMGQzMmI2NDczNDMzYzk0NmE1ZjY5Y2EzN2Q0MjFfMTY0OTI2NzQ0MTY4NA_0e17c10c-89c4-402f-b111-924846f46635">0.44</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0xLTEtMS0zNTY4L3RleHRyZWdpb246MDEwMGQzMmI2NDczNDMzYzk0NmE1ZjY5Y2EzN2Q0MjFfMTY0OTI2NzQ0MTY5MQ_6500c34e-face-4ade-be4d-fbae0cfb51f2">1.26</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"><ix:nonFraction unitRef="number" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0zLTEtMS0zNTc0L3RleHRyZWdpb246ZmUwODVlZTM1OWZiNDc4ZmFjNjMzOWZiYTgxOGI0OTRfMTY0OTI2NzQ0MTY4NA_f7b7ac68-d6b4-43a6-bff7-95ec7ac9f09a">2.20</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0zLTEtMS0zNTc0L3RleHRyZWdpb246ZmUwODVlZTM1OWZiNDc4ZmFjNjMzOWZiYTgxOGI0OTRfMTY0OTI2NzQ0MTY5MQ_29757063-5fd1-498f-8587-5d866eb65af2">2.62</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNS0xLTEtMS0w_98af894f-ab87-48a8-b19e-58ef10fe0738">6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNS0zLTEtMS0w_99b2a119-ca06-4747-9ca0-40b50b1793ac">6</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged to stock options and RSUs of Menlo&#8217;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i50c1a034475f46eb968fab88c0b84296_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNTE0Ng_31786fd2-8475-4a1e-9a5f-b0796e43bd28">60,000</ix:nonFraction> related to the modification in the consolidated statement of operations for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzMzk4Ng_55f9f2f9-3c32-4116-a2bf-39d5c8bc9c0a">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="4" name="mnlo:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzNDAwMg_032d1c45-5365-4a8a-8c3b-8c79cbc35858">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $<ix:nonFraction unitRef="usd" contextRef="i086c3c739539445da6ad056f578caedb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mjg0Ng_3488941a-2025-4cb1-a9e6-e264e9aae1f1">9.3</ix:nonFraction> million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2020 there is $<ix:nonFraction unitRef="usd" contextRef="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630" decimals="-4" format="ixt:numdotdecimal" name="mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mjk2MA_3c073d76-bcd0-4887-bc82-0fe8d6b535ff">6.6</ix:nonFraction> million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next <ix:nonNumeric contextRef="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630" format="ixt-sec:duryear" name="mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2Nzc1OQ_32c59990-364d-4579-9c7c-bc1f4e4f4996">2</ix:nonNumeric> years.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Awards granted to options and RSU holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $<ix:nonFraction unitRef="usd" contextRef="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNTU3OQ_73623ad9-f1a7-4b31-a096-d0c26db273f0">1.6</ix:nonFraction> million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2NzkxOQ_b8a8c01e-494c-4f1a-904f-3017aaf385ce">0.6</ix:nonFraction> million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ib290ea8b639941c0865b91b70ea01d50_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MDE4OQ_f43a4d77-bbac-478e-a603-74585dc5f87d">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5b1bb38c09694860a74fca4cb02b7fd2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MDIxMw_de4bc990-f51c-4f7f-9b49-7de5791d091d">1.0</ix:nonFraction> million for the three and six months ended June&#160;30, 2020, respectively.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into <ix:nonFraction unitRef="number" contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406" decimals="INF" name="mnlo:ContingentStockRightSharesConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzNTYyNQ_55f9f2f9-3c32-4116-a2bf-39d5c8bc9c0a">1.2082</ix:nonFraction> shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of <ix:nonFraction unitRef="number" contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406" decimals="4" name="mnlo:EffectiveExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzMzk5NA_a76f1c09-5696-4e43-8e8b-67175f8afe9a">1.8006</ix:nonFraction> shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1Mg_263be75b-f593-449e-b331-de9e70162cbc" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:41.548%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.386%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.639%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i875e9e1345164d94bc58815365779517_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi0xLTEtMS0w_be4940f2-fc60-46ce-b02b-256db1eb5ffc">3,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i82863cbbff6145f2bedee6a09e97f8bc_D20190401-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi0zLTEtMS0w_8a8206ba-9abc-4d5b-b7e0-bf54aef57309">384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i466f28e0d85348cab9cc5df9627c2a21_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi01LTEtMS0xMjQw_25637df6-4c1e-4b27-84fb-1119792c246f">3,566</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16a8e4626ad948338081011de428c56a_D20190101-20190630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi03LTEtMS0xMjQz_570113de-2db1-4a3d-9668-10286b8e4b67">738</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i282c323ee4fd405f9b9276a665217e6f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy0xLTEtMS0w_5bcedb6d-d9d6-4f89-8304-02e0975bf01c">7,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6103d5338e747d3863548470494ec95_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy0zLTEtMS0w_6f5fde93-8962-4435-a64e-60530a18874f">1,004</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5eabf77585034e158ba10a9768877f29_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy01LTEtMS0xMjQw_5ac9f603-3819-44bc-af93-3252fe576896">8,961</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb9a4f704626440cb634b11d52f4e479_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy03LTEtMS0xMjQz_ead75647-29be-457f-9b9d-43e6eaaac0f2">1,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC0xLTEtMS0w_918b4cdc-d6d5-4e39-9317-4d8bcc952d46">10,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC0zLTEtMS0w_f47d3797-b43a-41e9-8cb0-d07ea886a54b">1,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC01LTEtMS0xMjQw_986c7a56-25ac-4d3b-8c59-51e1f4dc9a5a">12,527</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC03LTEtMS0xMjQz_41c17992-a691-4510-99ab-b0786d5f422d">2,337</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_76"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTgwMg_fa0e21a1-b52a-4295-8b07-69043043aa2b" continuedAt="i3cfea1cd9b8c4fd09d39746eead4818c" escape="true">OPERATING LEASE</ix:nonNumeric></span></div><ix:continuation id="i3cfea1cd9b8c4fd09d39746eead4818c" continuedAt="i0ac9c493593f4a2f997379f5a3888165"><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating lease agreements</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has operating leases for corporate offices, research and development facilities, and vehicles. The properties primarily relate to the Company&#8217;s principal executive office in Bridgewater, New Jersey, corporate offices in Redwood City, California and research and development facility in Israel.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="i0ac9c493593f4a2f997379f5a3888165"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (&#8220;The Amendment&#8221;). The Amendment includes an extension of the lease period of the <ix:nonFraction unitRef="sqft" contextRef="if2a66420fa684fbea1eee87e6abdd8e4_D20190313-20190313" decimals="0" format="ixt:numdotdecimal" name="mnlo:FacilitySpaceUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfNTkx_1f14b7ab-ed94-4e82-adb2-953e2c60f437">10,000</ix:nonFraction> square feet previously leased under the original agreement (the &#8220;Original Space&#8221;) and an addition of <ix:nonFraction unitRef="sqft" contextRef="i88fbd3af56884c12ae3c30505c83a2f9_D20190313-20190313" decimals="0" format="ixt:numdotdecimal" name="mnlo:FacilitySpaceUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfNjk1_6f687c90-69ff-485d-ad07-4290f707836c">4,639</ix:nonFraction> square feet (the &#8220;Additional Space&#8221;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#8220;Commencement Date&#8221;). The Amendment is due to expire on August 31, 2022.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to The Amendment of the lease on the Current Space, the Company recognized an additional right of use asset and liability in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4760e6ad58b548bfa055202c3d8cd2e7_I20190313" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTA4Mw_7494d523-5755-4780-afc8-32d7da30e944">0.7</ix:nonFraction> million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $<ix:nonFraction unitRef="usd" contextRef="i9a8c08728edb45bd9ea6a6f0fc6e5a20_I20190313" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTIyMA_6eacc8ff-2268-468c-816b-1a2eb79cdf3d">0.3</ix:nonFraction> million, on the Commencement Date.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s corporate offices in Redwood City, California are under lease through December&#160;31, 2020 with a base rent of approximately $<ix:nonFraction unitRef="usd" contextRef="i74e404bead2e4f94b38bf24b66089cdf_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTM3MQ_b047818b-7814-417b-9244-ee22430c2b17">60,000</ix:nonFraction> per month. Given the short-term nature of the remaining lease period, the combined company did not recognize a right-of-use asset and liability and expects to recognize the lease payments in its statements of operations and comprehensive loss on a straight-line basis over the remaining lease term.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease agreement for the research and development facility in Israel is linked to the Israeli consumer price index (&#8220;CPI&#8221;) and due to expire in December 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the Company has entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for <ix:nonNumeric contextRef="i55514fe802bc4047841713151110e3e1_I20200630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTg1NQ_0f878951-f847-4575-a7a6-546437b2b0c4">three-year</ix:nonNumeric> terms. To secure the terms of certain of the vehicle lease agreements, the Company has made prepayments to the leasing company, representing approximately <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" format="ixt-sec:durmonth" name="mnlo:VehicleLeasePrepaymentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMjEzNw_5219541c-a7ac-4981-8602-28b9f6324b56">3</ix:nonNumeric> months of lease payments. These amounts have been recorded as part of the operating lease right-of-use assets.</span></div><ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTgwMw_45b0a438-7945-4eeb-8054-18664df19b53" escape="true"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:84.363%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMC0xLTEtMS0w_fa387438-1484-4037-9583-9f63cea7c320">1,267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMS0xLTEtMS0w_8596a3c1-ae1d-4d20-aa14-fb84d0701b5b">993</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMi0xLTEtMS0w_92d330f8-3329-4fdf-adc8-8676d7bcd892">768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMy0xLTEtMS0w_c5c560de-8928-4d1d-ad2c-32cd9ce31934">90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNC0xLTEtMS0w_c623cb38-a700-4a6b-a1d6-3cf7e6ead21b">3,118</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNS0xLTEtMS0w_2c43ae12-92ef-41a7-b166-14cb4330be93">565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNi0xLTEtMS0w_215254ad-28e0-44c7-a11f-a157bdba1b58">2,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company has a lien in the amount of $<ix:nonFraction unitRef="usd" contextRef="i55514fe802bc4047841713151110e3e1_I20200630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:RestrictedInvestmentsToSecureLeaseAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMjM0NA_6dffb162-beec-43a3-911f-0940973d0970">0.7</ix:nonFraction> million on the Company&#8217;s cash and marketable securities in respect of bank guarantees granted in order to secure the lease agreements.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_82"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 11 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMzI5ODUzNDg4NzQxOQ_35ab3237-1e43-4bbd-b8c8-0972bbed22b1" continuedAt="iccc6523d15b94040a23d97ccade29a0c" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iccc6523d15b94040a23d97ccade29a0c" continuedAt="ia0e612ad1c9e4916949861c6cea340bc"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2020, no claims or actions pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IPO Lawsuits</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018 and January 28, 2019, <ix:nonFraction unitRef="lawsuits" contextRef="id3d0a4c5350e4cbd93b8042046be79d5_I20181108" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:NumberOfClassActions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMzcz_19790cdf-98aa-45e5-882f-2b8d970e1a03">two</ix:nonFraction> purported class actions were filed in the Superior Court of California, San Mateo County, against the Company and certain of our officers and directors. The actions are entitled Savelstrov v. Menlo Therapeutics Inc., et al., and McKay v. Menlo Therapeutics Inc., et al. The underwriters for our initial public offering were also named as defendants in these lawsuits. The complaints contain identical allegations against the same defendants. Both complaints alleged&#160;that the Registration Statement and prospectus for our initial public offering contained false and misleading statements in violation of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 due to allegedly false and misleading statements in connection with our initial public offering. The complaints seek, among other things, an award of damages in an amount to be proven at trial, along with reimbursement of reasonable costs and expenses, including attorneys&#8217; fees and expert fees. The McKay action has been consolidated with the Savelstrov action and the claim for violations of Section 12(a)(2) has been dismissed.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The parties have mediated the consolidated lawsuit and reached a settlement, providing for payment to the class of plaintiffs in the amount of $<ix:nonFraction unitRef="usd" contextRef="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMTYxMw_a1af994b-5b92-4536-b32c-94d01b609de1">9.5</ix:nonFraction> million, the vast majority of which will be paid by the Company's insurance carriers, in return for a release of all claims against the defendants, including the Company and its current and former officers and directors. The </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><ix:continuation id="ia0e612ad1c9e4916949861c6cea340bc"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">settlement is subject to final documentation and Court approval. The Court preliminarily approved the settlement on April 24, 2020, and will consider whether to grant final approval of the settlement at a hearing scheduled for August 14, 2020. Menlo accrued for the remaining settlement amount that is not covered by insurance carriers as of December&#160;31, 2019, which did not have a material impact on its financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Merger Lawsuits</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="lawsuits" contextRef="ib1c399325c504de1963cfc9cabc42c2c_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:NumberOfClassActions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMjA5MA_0039b92d-22d4-493b-96a2-8f2be0aaa009">Seven</ix:nonFraction> lawsuits (collectively, the &#8220;Merger Lawsuits&#8221;) were filed in various U.S. federal district courts against Foamix and certain other defendants in connection with the Merger. The lawsuits generally alleged that the registration statement on Form S-4 and the prospectus/joint proxy statement included therein included false or misleading information regarding the Merger in violations of Section 14(a) and Section 20(a) of the Exchange Act and/or Rule 14a 9 promulgated under the Exchange Act. In addition, <ix:nonFraction unitRef="lawsuits" contextRef="i241af8b663f1455bb67c14d739a9fee6_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="mnlo:NumberOfClassActions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMjU5Nw_4e1bd659-996b-444c-952f-4eccc4d1f174">one</ix:nonFraction> of the lawsuits alleged that the members of Foamix&#8217;s board of directors breached their fiduciary duties in connection with the Merger. The plaintiffs sought, among other things, to enjoin consummation of the Merger, or alternatively rescission or rescissory damages; to compel the individual defendants to disseminate a joint proxy statement/prospectus that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; a declaration that defendants violated Sections 14(a) and/or 20(a) of the Exchange Act; a declaration that the Merger Agreement was entered into in breach of fiduciary duty and is therefore invalid and unenforceable; an order directing the individual defendants to commence a sale process for Foamix and obtain a transaction; and an award of costs, including attorneys&#8217; and experts&#8217; fees and expenses, as well as an accounting of damages allegedly suffered by the plaintiffs. The plaintiffs have agreed the Lawsuits were rendered moot by subsequent disclosure, and on April 22, 2020, each of the plaintiffs and defendants named in the Merger Lawsuits entered into a mootness resolution agreement pursuant to which the plaintiffs agreed to dismiss their lawsuits with prejudice as to the named plaintiff and Foamix agreed to pay a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">de minimis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mootness fee to plaintiffs&#8217; counsel. As of May 4, 2020, each of the Merger Lawsuits has been dismissed.</span></div></ix:continuation><div id="ib921aa21f1ac4534b8499c259d3bc7e0_88"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 12 &#8211; <ix:nonNumeric contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMzI5ODUzNDg5MjY5Ng_13d71cbf-559f-4773-a122-d8935b7452f2" continuedAt="i351979951fcd47cbbac9b652d708bbdd" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="text-indent:36pt;"><span><br/></span></div><ix:continuation id="i351979951fcd47cbbac9b652d708bbdd" continuedAt="i41d972604ae24a619425ca0727b69507"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;">Reverse Stock Split Proposal</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Company's annual meeting of stockholders held on August 3, 2020, the Company's stockholders voted to approve a proposal to adopt an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect (a) a reverse stock split of the Company&#8217;s outstanding shares of common stock, at a reverse stock split ratio ranging from 1-for-2 shares to 1-for-7 shares, which may be determined by the Board at a later date, and (b) a reduction in the number of authorized shares of the Company&#8217;s common stock by a corresponding ratio. The exact timing for selection of the reverse stock split ratio and the effective date of the reverse stock split will be determined by the Board based upon its evaluation as to when such action will be most advantageous to the Company and its stockholders. The Board may delay or abandon the reverse stock split at any time prior to the effective time of the reverse stock split, if the Board determines that the reverse stock split is no longer in the best interests of the Company or its stockholders. The reverse stock split, if implemented, would become effective upon the filing of a charter amendment with the Delaware Secretary of State. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amendment to Amended and Restated Credit Agreement</span></div></ix:continuation><div style="text-indent:36pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i41d972604ae24a619425ca0727b69507">On August&#160;5, 2020, the Company and the lenders entered into the Amendment. The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant in the Amended and Restated Credit Agreement, such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing on the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $<ix:nonFraction unitRef="usd" contextRef="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231" decimals="-5" format="ixt:numdotdecimal" name="mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMTY0OTI2NzQ1MDk1OQ_2e865583-c280-4795-9b0d-4ebea3d1eacc">6.0</ix:nonFraction>&#160;million for the fiscal quarter ending December 31, 2020 to $<ix:nonFraction unitRef="usd" contextRef="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630" decimals="-5" format="ixt:numdotdecimal" name="mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMTY0OTI2NzQ1MDk3Nw_447a96dd-08e4-482b-9bfb-3ad85f7df572">97.0</ix:nonFraction>&#160;million for the fiscal quarter ending June 30, 2024.</ix:continuation>  </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q, our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019, our Current Report on Form 8-K/A filed with the SEC on May 7, 2020 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on May 11, 2020. In this Quarterly Report on Form 10-Q, unless otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; or similar terms refer to Menlo Therapeutics Inc. after giving effect to the Merger.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_94"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Company Overview</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology. On March 9, 2020, we combined with Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;). In January 2020, Foamix (now our wholly-owned subsidiary) launched AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical foam, 4% (&#8220;AMZEEQ&#8221;), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the Food and Drug Administration (&#8220;FDA&#8221;) approved ZILXI&#8482; (minocycline) topical foam, 1.5% (formerly FMX103, &#8220;ZILXI&#8221;), for the treatment of inflammatory lesions of rosacea in adults. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA and serve as a springboard for our potential commercialization of additional innovative products in dermatology.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMZEEQ and ZILXI utilize our proprietary Molecule Stabilizing Technology&#8482;, or MST, that we also use in the development of our product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, we announced positive topline results from our Phase II clinical trial, Study FX2016-40, to evaluate the efficacy and safety of FCD105. Pending a successful development program, we intend to file a new drug application (&#8220;NDA&#8221;) for FCD105 under the 505(b)(2) regulatory pathway, which is the same regulatory pathway we have pursued for AMZEEQ and ZILXI. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to MST</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and our emulsion platform which is a different technology, we have a number of proprietary delivery platforms in development that enable topical delivery of other APIs, each having unique pharmacological features and characteristics designed to keep the API stable when delivered and directed to the target site. We believe our MST vehicle and other topical delivery platforms may offer significant advantages over alternative delivery options, including emulsions, and are suitable for multiple application sites across a range of conditions. We are also actively pursuing opportunities to out-license our product and product candidates to third parties for development and commercialization outside the United States.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_97"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Key Developments</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Below is a summary of selected key developments affecting our business that have occurred since December 31, 2019:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On November 10, 2019, the Company, Foamix and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of Menlo (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020. Foamix was deemed the &#8220;accounting acquirer&#8221; in the Merger and the Merger was accounted for as a reverse acquisition, with Foamix allocating the purchase price consideration to the tangible and intangible assets acquired and liabilities assumed from Menlo, and the excess purchase price recorded as goodwill. In accordance with reverse acquisition accounting, Foamix&#8217;s consolidated financial statements are deemed those of the predecessor entity.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On March 9, 2020, we entered into an Amended and Restated Credit Agreement and Guaranty, whereby we have guaranteed the indebtedness obligation of Foamix Pharmaceuticals Inc. and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. The Amended and Restated Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $50.0 million, of which $35.0 million was drawn as of December 31, 2019 and June 30, 2020.  On August&#160;5, 2020, the parties amended the minimum net revenue covenant contained in the Amended and Restated Credit Agreement and Guaranty as a result of the negative impact of the COVID-19 pandemic on the Company's product sales of AMZEEQ.  See "Part II - Other Information - Part 5. Other Information."</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On March 24, 2020, we announced that Andrew Saik has joined the Company as our Chief Financial Officer and Treasurer.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On April 2, 2020, we announced that we have entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> foam.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">LEO Pharma A/S, or LEO, has remedied the supply chain issues related to Finacea foam that Foamix previously disclosed in April 2019 and has resumed commercial sales of Finacea foam.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On April 6, 2020, we announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of pruritus (itch) associated with prurigo nodularis (PN), studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. We currently do not intend to further pursue the development of serlopitant, other than to assess and explore opportunities, if any, to license out and or monetize other aspects of the serlopitant asset. As such, the Company recorded a full impairment charge related to the IPR&amp;D and Goodwill assets of $50.3 million and $4.0 million, respectively, in its unaudited consolidated condensed statement of operations and comprehensive loss for the three and six months ending June&#160;30, 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On April 23, 2020, we announced that we entered into a license agreement with Cutia Therapeutics (HK) Limited (&#8220;Cutia&#8221;) for AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical foam, 4% as well as certain of our other topical minocycline product candidates,&#160;once approved, on an exclusive basis in&#160;Greater China. Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and, if approved in the&#160;U.S., FMX103 and FCD105 in the&#160;Greater China&#160;territory. Foamix will supply the finished licensed products to Cutia for clinical and commercial use. Foamix will receive an upfront cash payment of&#160;$10 million&#160;and will be eligible to receive an additional&#160;$1 million&#160;payment upon the receipt of marketing approval in&#160;China&#160;of the first licensed product. Foamix will also receive royalties on net sales of any licensed products.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">During the first quarter of 2020, an outbreak of respiratory illness caused by a strain of novel coronavirus, COVID-19, that began in China spread throughout the globe. There are many uncertainties regarding the COVID-19 pandemic, and we are closely monitoring the impact of the pandemic on all aspects of our business, including how it will impact our patients, employees, suppliers, vendors, business partners and distribution channels. For the three and six months ended June 30, 2020, the Company's product sales from AMZEEQ were negatively impacted due to office closures as a result of the pandemic.  We are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to numerous uncertainties, including duration, scope and severity of the pandemic, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the development of treatments or vaccines, and the resumption of widespread economic activity. An extended duration of the pandemic could have a material adverse effect on our product sales for AMZEEQ, and any future sales of ZILXI.  In addition, any prolonged material disruption of the Company&#8217;s employees, suppliers, manufacturing, or customers could further materially negatively impact our consolidated financial position, consolidated results of operations and consolidated cash flows. We will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to our operations as necessary. See &#8220;Part II Other Information&#8212;Item 1A. Risk Factors&#8212;Risks Related to Our Business and Industry&#8212;We face risks related to health epidemics and other widespread outbreaks of contagious disease, including COVID-19, which have disrupted, and may continue to significantly disrupt, our operations and impact our financial results.&#8221;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ and its other topical minocycline product candidates. In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On May 28, 2020, the FDA approved ZILXI for the treatment of inflammatory lesions of rosacea in adults. ZILXI is the first minocycline product of any kind to be approved by the FDA for use in rosacea. We anticipate having ZILXI available for prescribing in the fourth quarter of 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On June 2, 2020, we announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3% minocycline foam, 0.3% adapalene foam, or vehicle foam. We have begun preparations to conduct an end-of-Phase II meeting with the FDA before the end of 2020. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">On June 9, 2020, we completed an underwritten public offering of 31,107,500 shares of common stock at a price to the public of $1.85 per share.  The net proceeds of the offering were approximately $53.6&#160;million, after deducting underwriting discounts and commissions and other offering expenses. We intend to use the net proceeds from this offering for (i) a Phase III clinical trial for FCD105 for the potential treatment of acne vulgaris, (ii) supporting the commercial launch of ZILXI, (iii) the continued development of our product candidates and (iv) the remainder, if any, for general corporate purposes. </span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_100"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Overview</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our cash and cash equivalents and investments totaled&#160;$100.4&#160;million&#160;as of&#160;June&#160;30, 2020. We believe that our cash and cash equivalents and investments, projected cash flows from revenues and the funds that we are entitled to receive under our license agreement with Cutia, will provide sufficient resources for our current ongoing needs through at least the next twelve months from the issuance of these financial statements, though there may be need for additional financing activity as a result of the on-going COVID-19 pandemic and as we continue to grow. See &#8220;&#8212;Liquidity and Capital Resources&#8221; below.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred net losses since our inception. Until the first quarter of 2020, when we commenced commercial operations, our business activities were primarily limited to developing product candidates, raising capital and performing research and development activities. As of&#160;June&#160;30, 2020, we had an accumulated deficit of $518.3 million. We recorded net losses of $167.4 million and $19.0 million for the three months ended June&#160;30, 2020 and 2019, respectively, and $207.7 million and $34.2 million for the six months ended June&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our capital resources and business efforts are largely focused on activities relating to the commercialization of AMZEEQ and ZILXI and advancing our product candidates and pipeline. We expect to continue to incur operating losses until our products generate adequate commercial revenue to reach profitability. If we do not successfully commercialize AMZEEQ, ZILXI&#160;or any current or future product candidates, if approved, we may be unable to generate adequate product revenues to achieve such profitability. We may be required to obtain further funding through debt or equity offerings or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce or eliminate our research and development programs or commercialization or manufacturing efforts. Additionally, we are closely monitoring ongoing developments in connection with the COVID-19 pandemic, which may have an adverse impact on our commercial prospects and projected cash position.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_103"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Components of Operating Results</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenues</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have generated limited revenues from sales of AMZEEQ, ZILXI or any of our other product candidates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2019, we were engaged in pre-launch sales and marketing planning activities and other pre-commercialization efforts in order to support the commercialization of AMZEEQ in the United States. We received FDA approval for AMZEEQ on October 18, 2019, launched AMZEEQ in the United States in January 2020 and have generated product revenue of $3.2 million for the six months ended June 30, 2020. We expect to commercially launch ZILXI in the fourth quarter of 2020 and we will not commercially launch our other product candidates in the United States or generate any revenues from sales of any of our product candidates unless and until we obtain marketing approval. Our ability to generate revenues from sales will depend on the successful commercialization of our drug products AMZEEQ and ZILXI and any other product candidates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Historically, we have generated revenues under development and license agreements including royalty payments in relation to Finacea, the prescription foam product that we developed in collaboration with Bayer, which later assigned it to LEO. In the three months ended March 31, 2020, we did not receive or become entitled to any royalty payments due to the ongoing suspension of the manufacturing of Finacea by LEO, following inadequate supply of quality-compliant batches of the API used in such product. In April 2020, LEO informed us that it had reestablished the supply of Finacea foam and resumed commercial sale in the United States. In the three months ended June&#160;30, 2020 we received royalties of $0.2 million.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may become entitled to additional contingent payments in the future, subject to achievement of the applicable clinical results by our other licensees. However, in light of the current phase of development and associated milestone schedules under these agreements, we do not expect to receive significant payments in the near term, if at all. We are also entitled to additional royalties from net sales or net profits generated by other products to be developed under these agreements, if they are successfully commercialized. In those development and license agreements in which royalties are based on net sales, their rate ranges from 3% to 8.5%, and in the agreement in which royalties are based on net profits, their rate is 6%.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, as described in &#8220;Key Developments,&#8221; on April 23, 2020, we announced that we entered into a licensing agreement with Cutia for AMZEEQ as well as certain of our other topical minocycline product candidates,&#160;once approved, on an exclusive basis in&#160;Greater China. Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ and, if approved in the&#160;U.S., FMX103 and FCD105 in the&#160;Greater China&#160;territory. Foamix will supply the finished licensed products to Cutia for clinical and commercial use. Foamix will receive an upfront cash payment of&#160;$10 million&#160;and will be eligible to receive an additional&#160;$1 million&#160;payment upon the receipt of marketing approval in&#160;China&#160;of the first licensed product. Foamix will also receive royalties on net sales of any licensed products.  In the six months ended June&#160;30, 2020 we recognized license revenue of $10.0 million.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Goods Sold</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold was $0.5 million for the six months ended June&#160;30, 2020. There was no cost of goods sold in the six months ended June 30, 2019 because the revenues in that period consisted solely of royalties, which do not bear related cost of goods sold.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our gross margin percentage of&#160;85%&#160;was favorably impacted during the six months ended&#160;June&#160;30, 2020&#160;by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the six months ended&#160;June&#160;30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been&#160;81%.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold expenses consist primarily of:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">third party expenses incurred in manufacturing product for sale;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">transportation costs incurred in shipping manufacturing materials between third parties.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">other costs associated with delivery and manufacturing of product.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Expenses</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development expenses to date relate primarily to the development of AMZEEQ, ZILXI and FCD105. Our total research and development expenses for the six months ended June 30, 2020 and 2019 were approximately $29.1 million and $23.4 million, respectively. We charge all research and development expenses to operations as they are incurred.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expenses consist primarily of:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">employee-related expenses, including salaries, benefits and related expenses, including share-based compensation expenses;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">expenses incurred under agreements with third parties, including subcontractors, suppliers and consultants that conduct regulatory activities, clinical trials and preclinical studies;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">expenses incurred to acquire, develop and manufacture clinical trial materials;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other operating costs;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">costs associated with the creation, development and protection of intellectual property;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9702;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt;">other costs associated with preclinical and clinical activities and regulatory operations; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">materials and manufacturing costs related to commercial production prior to FDA approval.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our selling, general and administrative expenses for the six months ended June&#160;30, 2020 and 2019 were approximately $51.9 million and $12.1 million, respectively. This increase was primarily associated with the expansion of our employee base, including sales force, to support the growth of our operations, severance expenses for Menlo employees, stock based compensation awards, merger expenses and sales and marketing expenses incurred in connection with the commercialization of AMZEEQ.&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our selling, general and administrative expenses consist principally of:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">employee-related expenses, including salaries, benefits and related expenses, including share-based compensation expenses;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs associated with selling, marketing and shipping and handling costs;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">legal and professional fees for auditors and other consulting expenses; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">facility, information technology and depreciation expenses.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Income and Expenses</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial income primarily consist of gains from interest earned from our bank deposits, financial income on our marketable securities and a revaluation of our derivative liability. Financial expenses primarily consist of interest expense on our long-term debt.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes and Net Operating Loss Carryforwards</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant net operating losses (&#8220;NOLs&#8221;) since our inception. We expect to continue to incur NOLs until such a time when AMZEEQ, ZILXI&#160;or any other product, if approved in the future, generates adequate revenues for us to reach profitability. As of December 31, 2019, we had federal and state net operating loss carryforwards of $165.8 million and $17.6&#160;million, respectively, of which $44.3 million and $16.8 million of these carryforwards will begin to expire in 2031 for federal and state purposes, respectively. As of December 31, 2019, we had federal and state research and development tax credit carryforwards of $7.1 million and $2.1 million, respectively. The federal credits begin to expire in 2031 and the California research credits have no expiration dates. As of December 31, 2019, Foamix had foreign NOL carryforwards of&#160;$224.4 million, which are available solely to offset taxable income of our foreign subsidiary, subject to any applicable limitations under foreign law and $27.3 million in federal and state NOLs with no limited period of use.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of our company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. State NOLs and tax credit carryforwards may be subject to similar limitations under state laws. We have not determined if we have experienced Section&#160;382 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Sections&#160;382 or 383. We may have experienced ownership changes in the past, including in connection to our initial public offering (&#8220;IPO&#8221;), and as a result of the Merger and/or subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use the NOL and tax credit carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_106"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three-Month Periods Ended June&#160;30, 2020 and 2019</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Revenues totaled $11.7 million for the three months ended June&#160;30, 2020.  There were no revenues for the three months ended June&#160;30, 2019. For the three months ended June&#160;30, 2020, $1.5 million revenues were generated from product sales of AMZEEQ, which was launched in January 2020, $10.0 million came from the upfront payment associated with the Cutia license agreement and $0.2 million of royalty revenue.  </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lack of supply of Finacea resulted in no royalty revenues from the sale of Finacea for the three months ended March 31, 2020. In April 2020, LEO informed us that it had reestablished the supply of Finacea foam and resumed commercial sales in the United States. For the three months ended June&#160;30, 2020 we recognized royalty revenue of $0.2 million, compared to $0.3 million for three months ended June&#160;30, 2019. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in license revenue for the three months ended June 30, 2020 as compared to license revenue for the three months ended June 30, 2019 is due to the upfront cash payment paid to us under the licensing agreement with Cutia for the sale and marketing of AMZEEQ in China.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the COVID-19 pandemic, we suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings and have engaged with these customers remotely as we seek to continue to support healthcare professionals and patient care. During the second quarter of 2020, we began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates. However, during the three months ended June 30, 2020, the Company&#8217;s product sales for AMZEEQ were negatively impacted by office closures. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of Goods Sold</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold was $0.2 million for the three months ended June&#160;30, 2020. There was no cost of goods sold in the three months ended June&#160;30, 2019 because the revenues in that period consisted solely of royalties, which do not bear related cost of goods sold.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our gross margin percentage of&#160;85%&#160;was favorably impacted during the three months&#160;ended June&#160;30, 2020&#160;by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the three months ended&#160;June&#160;30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been&#160;80%.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development expenses for the three months ended June&#160;30, 2020 were $13.1 million, representing an increase of $0.6 million, or 4%, compared to $12.6 million for the three months ended June&#160;30, 2019. Employee-related expenses increased by $4.5 million, of which $3.0 million related to stock based compensation. In addition, clinical and manufacturing costs related to serlopitant increased by $4.1 million which was acquired in the merger, offset by a decrease of $8.0 million related to clinical and manufacturing expenses for AMZEEQ and ZILXI.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our selling, general and administrative expenses for the three months ended June&#160;30, 2020 were $26.5 million, representing an increase of $19.7 million, or 289%, compared to $6.8 million for the three months ended June&#160;30, 2019. Employee-related expenses increased by $11.9 million, consisting of $3.7 million primarily due to the expansion of our employee base, including sales force, to support the growth of our operations and $7.7 million of stock based compensation. We incurred $3.4 million expenses relating to the Merger included in selling, general and administrative expenses. Sales and marketing expenses increased by $4.4 million related to the commercialization of AMZEEQ.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill and in-process research &amp; development impairments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill and in-process research &amp; development impairments for the three months ended June&#160;30, 2020 were $54.3 million.  There were no impairments for the three months ended June&#160;30, 2019. In the three months ended June 30, 2020, we recorded impairments of $4.0 million for Goodwill and $50.3 million for in process research and development due to the failed clinical trials for serlopitant for the treatment of prurigo nodularis.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CSR Remeasurement&#160;</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent Stock Right Remeasurement for the three months ended June&#160;30, 2020 was $84.7 million. For the three months ended June 30, 2020 we incurred $84.7 million of expense due to the remeasurement of the CSR to fair value which was driven by the result of the failed serlopitant trials.  At the time of the merger, Foamix and Menlo entered into a contingent stock right agreement that called for the issuance of additional Menlo common stock to legacy Foamix shareholders upon negative data from both phase III serlopitant trials.  Since the trials did not meet the milestones outlined per the agreement, the contingent stock rights were remeasured during the three months ended June 30, 2020, resulting in an expense of $84.7 million.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Finance Income and Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance expenses and income are as follows:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands of U.S. dollars)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest on bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(162)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance gains on derivative liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(533)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from marketable securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(306)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(564)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(468)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance expenses on loans interest and discount</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">102&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our tax benefit for the three months ended June&#160;30, 2020 was $0.3 million.  During the three months ended June&#160;30, 2019 we had no tax expenses.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Loss</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net loss for the three months ended June&#160;30, 2020 was $167.4 million, as compared to $19.0 million for the three months ended June&#160;30, 2019, representing an increase of $148.4 million, or 782%. The increase was primarily due to Goodwill impairment, In process research and development impairment, and Contingent Stock Right Remeasurement as a result of the failed clinical trials for serlopitant.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Six-Month Periods Ended June&#160;30, 2020 and 2019</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues totaled $13.4 million and $0.3 million for the six months ended June&#160;30, 2020 and 2019, respectively. For the six months ended June&#160;30, 2020, $3.2 million of  revenues were generated from product sales of AMZEEQ, which was launched in January 2020, $10.0 million of  license revenue, and $0.2 million of royalty revenue. For the six months ended June&#160;30, 2019, revenues consisted solely of royalty revenues.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The increase in license revenue for the six months ended June 30, 2020 as compared to license revenue for the six months ended June 30, 2019 is due to the upfront payment received under the Cutia license agreement for the marketing and sale of AMZEEQ in China.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the COVID-19 pandemic, we suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings and have engaged with these customers remotely as we seek to continue to support healthcare professionals and patient care. During the second quarter of 2020, we began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates. However, during the six months ended June 30, 2020, the Company&#8217;s product sales for AMZEEQ were negatively impacted by office closures. The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of Goods Sold</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold was $0.5 million for the six months ended June&#160;30, 2020. There was no cost of goods sold in the six months ended June&#160;30, 2019 because the revenues in that period consisted solely of royalties, which do not bear related cost of goods sold.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our gross margin percentage of&#160;85%&#160;was favorably impacted during the six months ended June&#160;30, 2020&#160;by product sales with certain materials produced prior to FDA approval and therefore expensed in prior periods. If inventory sold during the six months ended June&#160;30, 2020&#160;was valued at cost, our gross margin for the period then ended would have been&#160;80%.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expenses</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development expenses for the six months ended June&#160;30, 2020 were $29.1 million, representing an increase of $5.7 million, or 24%, compared to $23.4 million for the six months ended June&#160;30, 2019. Employee-related expenses increased by $8.4 million, including $3.8 million related to severance expenses payable to Menlo employees, and stock based compensation of $3.6 million. In addition, clinical and manufacturing costs related to serlopitant increased by $7.4 million which was acquired in the Merger, offset by a decrease of $10.1 million related to clinical and manufacturing expenses for AMZEEQ and ZILXI.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General and Administrative Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our selling, general and administrative expenses for the six months ended June&#160;30, 2020 were $51.9 million, representing an increase of $39.7 million, or 327%, compared to $12.1 million for the six months ended June&#160;30, 2019. Employee-related expenses increased by $13.9 million consisting of $9.6 million primarily due to the expansion of our employee base, including sales force, to support the growth of our operations and $4.3 million related to severance expenses payable to Menlo employees. We incurred $8.9 million of employee award stock compensation.  Sales and marketing expenses increased by $9.3 million related to the commercialization of AMZEEQ. We incurred $7.7 million expenses relating to the merger included in selling, general and administrative expenses.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill and in-process research &amp; development impairments</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill and in-process research &amp; development impairments for the six months ended June&#160;30, 2020 were $54.3 million.  There were no impairments for the six months ended June&#160;30, 2019. In the six months ended June 30, 2020, we recorded impairments of $4.0 million for Goodwill and $50.3 million for in process research and development due to the failed clinical trials for serlopitant for the treatment of prurigo nodularis.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CSR Remeasurement&#160;</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent Stock Right Remeasurement for the six months ended June&#160;30, 2020 was $84.7 million. For the six months ended June&#160;30, 2020 we incurred $84.7&#160;million of expense due to the remeasurement of the CSR to fair value which was driven by the result of the failed serlopitant trials.  At the time of the merger, Foamix and Menlo entered into a contingent stock right agreement that called for the issuance of additional Menlo common stock to legacy Foamix shareholders upon negative data from both Phase III serlopitant trials.  Since the trials did not meet the milestones outlined per the agreement, the contingent stock rights were remeasured during the six months ended June 30, 2020, resulting in an expense of $84.7&#160;million.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Finance Income and Expenses</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the six months ended June&#160;30, 2020 and 2019, our financial income was primarily attributable to gains from marketable securities, interest earned on our bank deposits and revaluation of our derivative liability. Our financial expenses included interest expense on our long-term debt.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Finance expenses and income are as follows:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands of U.S. dollars)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest on bank deposits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(341)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance gains on derivative liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(975)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange gains</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(71)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from marketable securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(663)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,292)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,004)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finance expenses on loans interest and discount</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,158&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">134&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our tax benefit for the six months ended June&#160;30, 2020 was $0.3 million, representing an increase of $0.1 million, or 47%, compared to $0.2 million for the six months ended June&#160;30, 2019.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Loss</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our net loss for the six months ended June&#160;30, 2020 was $207.7 million, as compared to $34.2 million for the six months ended June&#160;30, 2019, representing an increase of $173.5 million, or 507%. The increase was primarily due to an increase in expenses incurred in connection with our commercial launch of AMZEEQ, Merger expenses and severance expenses for Menlo employees, Goodwill impairment, In process research and development impairment, and Contingent Stock Right Remeasurement.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_109"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have funded operations primarily through private and public placements of our equity, debt, warrants and through fees, cost reimbursements and royalties received from our licensees. We commenced generating product revenues related to sales of AMZEEQ&#160;in the first quarter of 2020.&#160;We have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses until such a time when our product and product candidates, if approved, are commercially successful, if at all. We will not generate any revenue from any current or future product candidates unless and until we obtain regulatory approval and commercialize such products.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, we had cash, cash equivalents and investments of $100.4 million. Our cash, cash equivalents and investments are held in money market accounts and marketable securities.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Foamix Pharmaceuticals Inc., a Delaware corporation (the &#8220;Borrower&#8221;), Foamix and Menlo, each as a guarantor, the lenders party thereto, and Perceptive Credit Holdings II, LP, as administrative agent for the lenders, entered into an Amended and Restated Credit Agreement and Guaranty, dated as of March 9, 2020 (the &#8220;Credit Agreement&#8221;). We have guaranteed the indebtedness obligation of the Borrower under the Credit Agreement and in connection with the Credit Agreement also granted a first priority security interest in substantially all of our assets for the benefit of the lenders. The Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $50.0 million, and as of June&#160;30, 2020, approximately $35.0 million was drawn under the Credit Agreement. The Borrower will be permitted to borrow an additional $15 million before September 30, 2020 provided that the Borrower achieves certain revenue targets set forth in the Credit Agreement.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant transaction-related expenses in connection with negotiating and completing the Merger. Transaction-related expenses, which include legal, accounting and financial advisor fees and other service provider costs, were approximately $21.8 million. We incurred $11.7 million of these costs during the six months ended June&#160;30, 2020 in our statements of operations and comprehensive loss, and we do not expect to incur any additional significant costs relating to the Merger in future periods.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant for pruritic conditions. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ and its other topical minocycline product candidates.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our cash and cash equivalents and investments, projected cash flows from revenues and the funds that we are entitled to receive under our license agreement with Cutia, will provide sufficient resources for our current ongoing needs through at least the next twelve months from the issuance of these financial statements, though there may be need for additional financing activity as a result of the on-going COVID-19 pandemic and as we continue to grow. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of the COVID-19 pandemic, we suspended the vast majority of our in-person interactions by our customer-facing professionals in healthcare settings and have engaged with these customers remotely as we seek to continue to support healthcare professionals and patient care. During the second quarter of 2020, we began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates. However, during the three and six months ended June&#160;30, 2020, the Company&#8217;s product sales for AMZEEQ were negatively impacted by office closures. As a result of the negative impact on the Company's product sales, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement. See "Part II&#8212;Other Information&#8212;Part 5. Other Information." The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI, and have a material adverse effect on our liquidity.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary Statement of Cash Flows</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our statement of cash flows for the six months ended June&#160;30, 2020 and 2019:</span></div><div style="text-align:justify;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands of U.S. dollars)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) / provided by:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(88,070)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(29,361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,105&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,512&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53,746&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Used in Operating Activities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Adjustments to net income for non-cash items mainly include depreciation and amortization, share-based compensation, goodwill and in-process research and development impairment, and contingent stock right remeasurement.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $88.1 million in the six months ended June&#160;30, 2020, compared to $29.4 million in the six months ended June&#160;30, 2019. The increase was attributable primarily to the growth in operations and the Merger.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Provided by Investing Activities</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities was $87.1 million in the six months ended June&#160;30, 2020, compared to $40.5 million in the six months ended June&#160;30, 2019. The increase was attributable primarily to the cash acquired through the Merger.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cash Provided by Financing Activities</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There was $53.7 million provided by financing activities in the six months ended June&#160;30, 2020, compared to $18,000 in the six months ended June&#160;30, 2019. The increase was attributable to proceeds from the offering of common stock in June 2020, along with  the exercise of options and issuance of shares under our equity incentive plan.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash and Funding Sources</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sources of liquidity in the six months ended June&#160;30, 2020 consisted primarily of cash and investments acquired in the Merger, proceeds from an underwritten public offering of common stock completed in June 2020, sales of AMZEEQ and the portion of the upfront cash payment paid to us under the Cutia license. </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sources of liquidity in the six months ended June&#160;30, 2019 consisted mainly of proceeds from a share offering and payments from licensees.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no ongoing material financial commitments (such as lines of credit) that may affect our liquidity over the next five years other than our commitments under the Credit Agreement.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our present and future funding requirements will depend on many factors, including, inter alia:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our drug products AMZEEQ and ZILXI and any other pipeline product that is commercialized;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">selling, marketing and patent-related activities undertaken in connection with the commercialization of AMZEEQ, ZILXI and any other product candidates, as well as costs involved in the development of an effective sales and marketing organization;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the progress, timing and completion of preclinical testing and clinical trials for pipeline product candidates;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the time and costs involved in obtaining regulatory approval for our other pipeline product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the efforts necessary to institute post-approval regulatory compliance requirements for AMZEEQ and ZILXI;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number of potential new products we identify and decide to develop; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operating plan may change as a result of many factors currently unknown to us, and any such change may affect our funding requirements. We may therefore need to seek additional capital sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or additional license arrangements. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_112"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our critical accounting policies are described on our Current Report on Form 8-K/A filed with the SEC on May 7, 2020.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While our significant accounting policies are described in the Notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. These policies relate to the more significant areas involving management&#8217;s judgments and estimates and they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">COVID-19</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June&#160;30, 2020, the Company&#8217;s product sales for AMZEEQ were negatively impacted by office closures due to the pandemic. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition. The Company recorded impairments of goodwill and certain indefinite-lived intangibles; however, these impairments were unrelated to the impact of COVID-19 (See &#8220;Note 3 &#8211; Business Combination&#8221; for more information). The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical Trial Accruals</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Clinical trial costs are charged to research and development expense as incurred. We accrue for expenses resulting from obligations under contracts with clinical research organizations, or CROs. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided. Our objective is to reflect the appropriate trial expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">advance payments are made to a CRO, the payments will be recorded as other assets, which will be recognized as expenses as services are rendered. The CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs and other miscellaneous costs. We estimate our clinical accruals based on reports from and discussion with clinical personnel and the CRO as to the progress or state of completion of the trials. We estimate accrued expenses as of each balance sheet date in the consolidated financial statements based on the facts and circumstances known at that time. Our clinical trial accrual is dependent, in part, upon the receipt of timely and accurate reporting from the CROs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record revenue based on a five-step model in accordance with Accounting Standards Codification ("ASC") 606,&#160;Revenue from Contracts with Customers&#160;("ASC 606"). For the Collaboration Agreement under ASC 606, we identify the performance obligations, determine the transaction price, allocate the contract transaction price to the performance obligations, and recognize the revenue when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We identify the performance obligations included within the agreement and evaluate which performance obligations are distinct. Upfront payments for licenses are evaluated to determine if the license is capable of being distinct from the obligations to participate on certain&#160;development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. For performance obligations that are satisfied over time, we utilize the input method and revenue is recognized by consistently applying a method of measuring progress toward complete satisfaction of that performance obligation. We periodically review our estimated periods of performance based on the progress under each arrangement and account for the impact of any changes in estimated periods of performance on a prospective basis.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Milestone payments are a form of variable consideration as the payments are contingent upon achievement of a substantive event. Milestone payments are estimated and included in the transaction price when we determine that it is probable that there will not be a significant reversal of cumulative revenue recognized in future periods.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development revenues and cost reimbursements are based upon negotiated rates for our full-time employee equivalents (&#8220;FTE&#8221;) and actual out-of-pocket costs. FTE rates are set based upon our costs, and which we believe approximate fair value. None of the revenues recognized to date are refundable if the relevant research effort is not successful.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business Acquisition</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our financial statements include the operations of an acquired business after the completion of the acquisition. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet. Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, we use fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our fair value methodologies depend on the following types of inputs:</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Asset Impairment</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_115"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not party to any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_118"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Indemnification</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As permitted under Delaware law and in accordance with our bylaws, we are required to indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of June&#160;30, 2020 and December 31, 2019.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_121"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">JOBS Act Accounting Election</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_124"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See &#8220;Recent Accounting Pronouncements&#8221; in Note&#160;2, &#8220;Significant Accounting Policies&#8221; in the Notes to Unaudited Interim Condensed Consolidated Financial Statements for a discussion of recently adopted accounting pronouncements and accounting pronouncements not yet adopted, and their expected impact on our financial position and results of operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and Item 10 of Regulation S-K. As such, we are not required to provide the information set forth in this item.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_130"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, with the participation of our chief executive and financial officers, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June&#160;30, 2020. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2020 our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no changes in our internal controls over financial reporting during the six months ended June&#160;30, 2020 identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Part II. OTHER INFORMATION</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_136"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1. Legal Proceedings.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018 and January 28, 2019, two purported class actions were filed in the Superior Court of California, San Mateo County, against the Company and certain of our officers and directors. The actions are entitled Savelstrov v. Menlo Therapeutics Inc., et al., and McKay v. Menlo Therapeutics Inc., et al. The underwriters for our initial public offering were also named as defendants in these lawsuits. The complaints contain identical allegations against the same defendants. Both complaints alleged&#160;that the Registration Statement and prospectus for our initial public offering contained false and misleading statements in violation of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 due to allegedly false and misleading statements in connection with our initial public offering. The complaints seek, among other things, an award of damages in an amount to be proven at trial, along with reimbursement of reasonable costs and expenses, including attorneys&#8217; fees and expert fees. The McKay action has been consolidated with the Savelstrov action and the claim for violations of Section 12(a)(2) has been dismissed.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The parties have mediated the consolidated lawsuit and reached a settlement, providing for payment to the class of plaintiffs in the amount of $<ix:nonFraction unitRef="usd" contextRef="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzYvZnJhZzpmM2Q3Yzc4ZTE2YmY0YjQxYjZlMTUzNmMzNDI5Njc5Yi90ZXh0cmVnaW9uOmYzZDdjNzhlMTZiZjRiNDFiNmUxNTM2YzM0Mjk2NzliXzgyNDYzMzcyMTA4OTE_a1af994b-5b92-4536-b32c-94d01b609de1">9.5</ix:nonFraction> million, the vast majority of which will be paid by the Company's insurance carriers, in return for a release of all claims against the defendants, including the Company and its current and former officers and directors. The settlement is subject to final documentation and Court approval. The Court preliminarily approved the settlement on April 24, 2020, and will consider whether to grant final approval of the settlement at a hearing scheduled for August 14, 2020. Menlo accrued for the remaining settlement amount that is not covered by insurance carriers as of December&#160;31, 2019, which did not have a material impact on its financial statements.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_139"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1A. Risk Factors.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to various risks and uncertainties, including those described below, that we believe apply to our business and the industry in which we operate. You should carefully consider these risks, as well as the other information in our Annual Report on Form 10-K, the Current Report on Form 8-K/A filed with the SEC on May 7, 2020, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020, and this Quarterly Report on Form 10-Q, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We face risks related to health epidemics and other widespread outbreaks of contagious disease, including COVID-19, which have disrupted, and may continue to significantly disrupt, our operations and impact our financial results.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, an outbreak of respiratory illness caused by a strain of novel coronavirus, COVID-19, began in China. As of July 2020, that outbreak has led to numerous confirmed cases worldwide, including in the United States and other countries where we or our business partners conduct operations. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, including our own operations. For example, our product sales for AMZEEQ during the three and six months ended June 30, 2020 were negatively impacted by office closures as a result of the pandemic.  The future progression of the outbreak and its effects on our business and operations are uncertain. Many patients have chosen not to visit or contact their healthcare providers which has limited new patient access and conversion. In response to the outbreak, we have taken certain steps to safeguard our employees, healthcare professionals and our other partners. For example, our sales force and marketing team were removed from the field and adopted remote and virtual sales activities, including tele-detailing, web-based speaker programs and virtual product education sessions, in order to meet patients&#8217; needs. During the second quarter of 2020, certain members of our sales force have resumed in-person meetings with healthcare professionals while taking appropriate precautions in locations that have eased restrictions. However, as a precautionary measure, such sales representatives are still prohibited from engaging in certain activities that were available before the pandemic. No assurance can be made that these sales tactics will be as effective as those used prior to the outbreak of COVID-19 or when the remainder of our sales force will be redeployed. If the activities of our sales force continue to be disrupted or such tele-detailing and virtual-based tactics are not accepted by healthcare professionals, we may continue to generate less revenue than expected which would have a material adverse effect on our financial results as well as hinder our ability to satisfy certain covenants contained in our Credit Agreement, which have been amended as of August&#160;5, 2020. See "Item 5. Other Information" for additional discussion regarding the amendment to the Credit Agreement.  In addition, if the pandemic persists for an extended duration, no assurance can be made that the Company will be able to further amend the revenue covenants in the Credit Agreement.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are currently unaware of any material disruptions to the supply of AMZEEQ and any material impact on our primary suppliers. We believe we have a sufficient amount of product in the trade and safety stock of our raw materials to support the current demand for AMZEEQ. While we are currently unaware of any material disruptions to our supply, our primary suppliers or our anticipated timelines for clinical results and other key milestones, we cannot guarantee that we will not experience such disruptions in the future as a result of the COVID-19 pandemic. If the outbreak of COVID-19 persists, we and our third-party contract manufacturers, contract research organizations and clinical sites may experience disruptions in supply of our product and product candidates and/or procuring items that are essential for our commercialization and research and development activities, including, for example, raw materials used in the manufacturing of our products and product candidates, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. Any negative impact that the outbreak has on the ability of our suppliers to provide materials for our product and product candidates or on retaining patients in our clinical trials could disrupt our commercialization efforts and clinical trial activities, which could adversely affect our ability to earn revenue, obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.</span></div><div style="text-align:justify;margin-top:10pt;"><span><br/></span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_142"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_145"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_148"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_151"></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5.&#160;Other Information.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On August&#160;5, 2020, the Company, Foamix, Foamix Pharmaceuticals Inc., the lenders party thereto, and Perceptive Credit Holdings II, LP, as administrative agent to the lenders, amended the existing Amended and Restated Credit Agreement and Guaranty, dated as of March 9, 2020, pursuant to that certain Amendment No. 1 to Amended and Restated Credit Agreement and Guaranty (the &#8220;Amendment&#8221;). The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant contained in the Amended and Restated Credit Agreement, such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $6.0 million for the fiscal quarter ending December 31, 2020 to $97.0 million for the fiscal quarter ending June 30, 2024. The parties entered into the Amendment following an analysis of the negative impact of the COVID-19 pandemic on the Company&#8217;s product sales of AMZEEQ for the three and six months ended June 30, 2020. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">              </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is attached to this Quarterly Report on Form 10-Q as Exhibit 10.2. </span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:10pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.&#160; Exhibits.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following documents are filed, or furnished as applicable, as part of this Quarterly Report on Form 10-Q:</span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit Index</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:41.401%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.826%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporated by Reference</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Form</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Herewith</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000648/exhibit31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1/29/2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000110465920059152/tm2015937d1_ex3-2.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-Q</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5/11/2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex101cutia-licenseagre.htm">License Agreement, dated as of April 21, 2020, by and between Foamix Pharmaceuticals Ltd. and Cutia Therapeutics (HK) Limited.</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="ex102agreementno1toarc.htm">Amendment No. 1 to Amended and Restated Credit Agreement and Guaranty, dated August 5, 2020, by and among Menlo Therapeutics Inc., Foamix Pharmaceuticals Ltd., Foamix Pharmaceuticals Inc., the lenders party thereto and Perceptive Credit Holdings II, LP as administrative agent.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mnlo-20200630xexx311.htm">Certification of Chief Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mnlo-20200630xexx312.htm">Certification of Chief Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mnlo-20200630xexx321.htm">Certification of Chief Executive Officer required by Rule&#160;13a-14(b)&#160;or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="mnlo-20200630xexx322.htm">Certification of Chief Financial Officer required by Rule&#160;13a-14(b) or Rule 15d-14(b)&#160;and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:41.401%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.824%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:7.826%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page of Menlo Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL (included within Exhibit 101 attachments)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_______________________________________________________</span></div><div style="text-indent:-18pt;padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">#&#160;Indicates management contract or compensatory plan.</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">**&#160;The certifications attached as Exhibit&#160;32.1 that accompany this Quarterly Report on Form&#160;10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Menlo Therapeutics&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form&#160;10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><div id="ib921aa21f1ac4534b8499c259d3bc7e0_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#ib921aa21f1ac4534b8499c259d3bc7e0_7">Table of contents</a></span></div></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Signatures</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dated: August&#160;6, 2020 </span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:47.853%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:43.309%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Menlo Therapeutics Inc.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David Domzalski</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">David Domzalski</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Chief Executive Officer</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Andrew Saik</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Andrew Saik</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">Chief&#160;Financial&#160;Officer and Treasurer</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101cutia-licenseagre.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i20edfcbad05f4cf6bdbde2ee63725d4c_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSE AGREEMENT</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">License Agreement </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is entered into as of April 21, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) by and between </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Pharmaceuticals Ltd.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a company organized and existing under the laws of the State of Israel and having a place of business at 2 Holzman Street, Rehovot Science Park, Rehovot, Israel (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Therapeutics (HK) Limited</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a company organized and existing under the laws of Companies Ordinance (Chapter 622 of the laws of Hong Kong) and having a place of business at Unit 402, 4&#47;F Fairmont Hse No 8 Cotton Tree Drive Admiralty Hong Kong (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Foamix and Cutia are sometimes referred to herein individually as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Foamix is currently conducting research, development, and commercialization of certain topical minocycline products&#59; </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Cutia is a biopharmaceutical company with experience in developing pharmaceutical products in the greater China region&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Whereas</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Cutia desires to obtain from Foamix an exclusive license to Develop and Commercialize Licensed Products in the Cutia Territory (with each capitalized term as respectively defined below), and Foamix is willing to grant such license to Cutia, all under the terms and conditions of this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Now, Therefore</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows&#58;</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 1</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEFINITIONS</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Adverse</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Event</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any untoward medical occurrence in a patient or subject who is administered a Licensed Product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease temporally associated with the use of Licensed Products. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.2&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Adverse Risk</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any risk of a material adverse effect on the Development, procurement or maintenance of Regulatory Approval, Manufacture, or Commercialization of Licensed Products outside the Cutia Territory.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.3&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Accounting Standards</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means U.S. generally accepted accounting principles (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">GAAP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or, to the extent that Cutia adopts International Financial Reporting Standards (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">IFRS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then &#8220;Accounting Standards&#8221; means IFRS, in either case consistently applied.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.4&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167;301 et seq., and&#47;or the Public Health Service Act, 42 U.S.C. &#167;&#167;262 et seq., as such may be amended from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a particular Party, a Person that controls, is controlled by, or is under common control with such Party. For the purposes of this definition, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract, or otherwise. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.6&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Anti-Corruption Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means laws, regulations, or orders prohibiting the provision of a financial or other advantage for a corrupt purpose or otherwise in connection with the improper performance of a relevant function, including without limitation, the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">Corruption of Foreign Public Officials Act (CFPOA)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">US Foreign Corrupt Practices Act (FCPA)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">UK Bribery Act 2010</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and similar laws governing corruption and bribery, whether public, commercial or both, to the extent applicable. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Background Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a Party, any and all Information, inventions, and discoveries, in each case whether or not patentable, and any Patents or other intellectual property rights therein, in each case Controlled by such Party as of the Effective Date or acquired, made, conceived, or reduced to practice during the Term independent of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.8&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a day other than Saturday, Sunday or any day that banks in Bridgewater, New Jersey, USA or Hong Kong, China are required or permitted to be closed. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.9&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Calendar Quarter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30, or December 31.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.10&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Change of Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to either Party&#58; (a) the sale of all or substantially all of such Party&#8217;s assets or business relating to (i) this Agreement in its entirety or (ii) any Product or Products (other than to an Affiliate of such Party)&#59; (b) a merger, reorganization, or consolidation involving such Party in which the voting securities of such Party outstanding immediately prior thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization, or consolidation&#59; or (c) a Person, or group of Persons, acting in concert acquire more than fifty percent (50%) of the voting equity securities or management control of such Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.11&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Phase 4 Clinical Trial, or Pivotal Clinical Trial, or any combination thereof.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.12&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CMC Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Information related to the chemistry, manufacturing and controls of the Licensed Products, as specified by the FDA, NMPA and other applicable Regulatory Authorities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.13&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercialization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all activities undertaken before and after obtaining Regulatory Approvals relating to the pre-launch, launch, promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, distribution and disposition of Licensed Products, including strategic marketing, sales force detailing, advertising, market Licensed Product support, all customer support, Licensed Product distribution, and invoicing and sales activities&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercialization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall exclude any activities relating to the Manufacture of Licensed Product. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercialize</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercializing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; have the correlative meanings. For clarity, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercialization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall exclude all activities undertaken in connection with Voluntary Phase 4 Clinical Trials.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.14&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Commercially Reasonable Efforts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to either Party&#8217;s obligations under this Agreement, the carrying out of such obligations with a level of efforts and resources consistent with the commercially reasonable practices of a similarly situated company in the pharmaceutical industry for the active and diligent commercialization of a similarly situated branded pharmaceutical product as the Licensed Product at a similar stage of commercialization, taking into account efficacy, safety, present and future market potential, competitive market conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors (but not taking in account any payment owed to Foamix under this Agreement or any other pharmaceutical product that Cutia is then researching, developing or commercializing, alone or with one or more collaborators). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.15&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Competing Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a pharmaceutical product, other than a Licensed Product, that contains minocycline, alone or in combination with other ingredients, formulated for topical delivery.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.16&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidential Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of a Party means any and all Information of such Party or its Affiliates that is disclosed to the other Party or its Affiliates under this Agreement, whether in oral, written, graphic, or electronic form. In addition, all Information disclosed by a Party or its Affiliates pursuant to the confidentiality agreement between the Parties dated as of January 23, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidentiality Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) is the Confidential Information of such Party disclosed hereunder&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that any use or disclosure of any such Information that is authorized under Article 12 shall not be restricted by, or be deemed a violation of, the Confidentiality Agreement. For clarity, Foamix Licensed Know-How is the Confidential Information of Foamix.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.17&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any material, Information, Patent or other intellectual property right, possession of the right, whether directly or indirectly, and whether by ownership, license, or otherwise, to grant a license, sublicense, or other right to or under, such material, Information, Patent, or intellectual property right without violating the terms of any existing agreement or other arrangement with any Third Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, with respect to any material, Information, Patent or other intellectual property right obtained by Foamix after the Effective Date from a Third Party, Foamix shall be deemed to Control such material, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">3</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Information, Patent or other intellectual property right only if it possesses the right to grant such license, sublicense, or other right thereto without being obligated to pay any royalties or other consideration therefor, unless Cutia agrees in advance of any grant of rights thereto to pay such royalties or other consideration. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Controlled</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has a correlative meaning.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.18&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cover</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a Patent and a Licensed Product, that the Manufacture, use, offer for sale, sale or import of a Licensed Product, absent a license to such Patent or Licensed Product, would infringe a Valid Claim in such Patent&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that in determining whether a claim of a pending Patent application would be infringed, it shall be treated as if issued in the form then currently being prosecuted. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Covered</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Covering</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; have the correlative meanings.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.19&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, collectively, mainland China, Taiwan, Hong Kong and Macau (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Region</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.20&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all data, non-clinical data, preclinical data and clinical data, generated by or on behalf of a Party or its Affiliates or their respective sublicensees pursuant to activities conducted under this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Data excludes CMC Information. For clarity, Data does not include any patentable inventions. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.21&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all activities conducted after the Effective Date relating to preclinical and clinical trials, toxicology testing, statistical analysis, publication and presentation of study results with respect to Licensed Products, and the reporting, preparation and submission of regulatory applications (including any CMC Information) for obtaining, registering and maintaining Regulatory Approval of Licensed Products, including the conduct of Phase 4 Clinical Trials&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; excludes any activities relating to the Manufacture of Licensed Product. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Develop</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Developing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; have the correlative meanings.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.22&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Divest</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the sale or transfer of rights to the Competing Program to a Third Party where neither the assigning Party nor its assignee have the right to engage, and neither the assigning Party nor its assignee in fact engage, in any management, governance or decision-making activities in connection with such Competing Program. &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Divestiture</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the correlative meaning.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.23&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Executive Officers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Chief Executive Officer of Foamix and Chief Executive Officer of Cutia or their respective designees. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.24&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the U.S. Food and Drug Administration or any successor entity thereto. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.25&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Field</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to each Licensed Product, (a) each dermatological Indication for which such Licensed Product receives Regulatory Approval in the United States and (b) with respect to FCD105, any other Indications agreed by the Parties pursuant to Section&#160;4.8.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">4</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.26&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">First Commercial Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the first sale of a Licensed Product in the Cutia Territory to a Third Party after Regulatory Approval has been obtained in the Cutia Territory. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.27&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Fiscal Year</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Cutia&#8217;s fiscal year that starts on January 1 and ends on December 31. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.28&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Licensed Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Information (including Data and Regulatory Materials) that (a) is Controlled by Foamix and&#47;or its Affiliates (i) as of the Effective Date or (ii) during the Term, and (b) is necessary or reasonably useful for the Development or Commercialization of Licensed Products in the Field in the Cutia Territory.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.29&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Licensed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Patents that (a) are Controlled by Foamix and&#47;or its Affiliates (i) as of the Effective Date or (ii) during the Term, and (b) Cover the Development or Commercialization of Licensed Products in the Field in the Cutia Territory, including Foamix&#8217;s interest in any Patents claiming any Foamix Inventions and Joint Inventions. Foamix Licensed Patents existing as of the Effective Date are set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.30&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Foamix Licensed Know-How and Foamix Licensed Patents. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.31&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the world except for the Cutia Territory. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.32&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">GCP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Good Clinical Practices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guidelines entitled &#8220;Guidance for Industry E6 Good Clinical Practice&#58; Consolidated Guidance,&#8221; including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the NMPA or other Regulatory Authority applicable to the Cutia Territory, as they may be updated from time to time, including applicable quality guidelines promulgated under the ICH.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.33&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Generic</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a Licensed Product in a Region, any pharmaceutical product that (a) (i) contains the same active pharmaceutical ingredients as such Licensed Product, (ii) is in the same form and format as such Licensed Product, and (iii) is approved by the Regulatory Authority in such Region based on reference to data contained in an earlier regulatory filing&#59; and (b) is sold in such Region by a Third Party that is not a sublicensee and did not purchase such product or its active pharmaceutical ingredients from Cutia or its Affiliates or sublicensees.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.34&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">GLP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Good Laboratory Practices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by NMPA or other Regulatory Authority applicable to the Cutia Territory, as may be updated from time to time, including applicable quality guidelines promulgated under the ICH.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.35&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Government Official</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) any official or employee of any Governmental Authority, or any department, agency, or instrumentality thereof (including without limitation </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">5</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">commercial entities owned or controlled, directly or indirectly, by a Governmental Authority), (b) any political party or official thereof, or any candidate for political office, or (c) any official or employee of any public international organization. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.36&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governmental Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any multi-national, national, federal, state, local, municipal, provincial or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.37&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ICH</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.38&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a separately defined, well-categorized class of human disease or condition for which a separate MAA (including any extensions or supplements) is required to be filed with a Regulatory Authority. For clarity, if an MAA is approved for a Licensed Product in a particular Indication and patient population, a label expansion for such Licensed Product to include such Indication in a different patient population shall not be considered a separate Indication. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.39&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, copyrights, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting from non-clinical studies), stability data and other study data and procedures.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.40&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any inventions or discoveries, including processes, manufacture, composition of matter, Information, methods, assays, designs, protocols, and formulas, and improvements or modifications thereof, patentable or otherwise, that are generated, developed, conceived or reduced to practice (constructively or actually) by or on behalf of a Party or its Affiliates or their respective sublicensees (a) pursuant to activities conducted under this Agreement, or (b) in connection with the Development, Manufacture, and Commercialization of Licensed Product, in each case of (a) and (b), including all rights, title and interest in and to the intellectual property rights therein and thereto&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Inventions exclude Data. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.41&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a given country, the applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, municipal, city or other political subdivision, domestic or foreign that may be in effect from time to time in such country and that relate to a Party&#8217;s activities under this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.42&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensed Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means each of&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">6</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix&#8217;s minocycline topical foam product referred to as Amzeeq&#8482;, 4%, in the form and format described in NDA 212379 approved by the FDA on October 18, 2019 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amzeeq&#8482;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix&#8217;s minocycline topical foam product referred to as FMX103, 1.5%, and in the form and format described in NDA N050808 for such product (i) submitted by or on behalf of Foamix in the United States and (ii) approved by the FDA (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FMX103</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix&#8217;s combination minocycline and adapalene foam product referred to as FCD105 and in the form and format described in the first MAA for such product (i) submitted by or on behalf of Foamix in the United States and (ii) approved by the FDA (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FCD105</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.43&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Manufacture</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Manufacturing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management, storing and transporting any Licensed Product, including oversight and management of vendors therefor.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.44</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Manufacturing Cost</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to a particular Licensed Product (whether as active pharmaceutical ingredient or finished form) supplied by Foamix pursuant to Section 7.1&#58; (a) if Foamix or its Affiliate Manufactures the applicable Licensed Product, &#91;***&#93;&#59; or (b) if a Third Party Manufactures such Licensed Product, &#91;***&#93;.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.45</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Marketing Authorization Application</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means a New Drug Application (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NDA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) or any other application to the appropriate Regulatory Authority for approval to market a Licensed Product, but excluding pricing approvals. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.46&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the gross amounts billed or invoiced by Cutia, its Affiliates and their respective sublicensees for sales of Licensed Products to Third Parties, less the following deductions to the extent reasonable, customary, and actually allowed and taken with respect to such sales&#58; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;trade, cash or quantity discounts not already reflected in the amount invoiced, to the extent related to the gross amount billed or invoiced&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;price reductions, rebates&#160;and administrative fees (including those paid or credited to pharmacy benefit managers, governmental authorities or otherwise)&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;shipping costs, including freight, insurance and other transportation charges or costs incurred in shipping of Licensed Products to Third Parties (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, such shipping costs shall not be in excess of one percent (1%) of Net Sales with respect to any given Calendar Quarter)&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;sales, use, excise, value-added or similar taxes, customs duties and other governmental fees, charges and surcharges imposed on the sale of Licensed Products&#59; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">7</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;amounts repaid or credited by reason of rejections, defects, recalls or returns&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;amounts paid or credited for wholesaler chargebacks&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;any receivables that have been included in gross sales and are deemed to be uncollectible according to Accounting Standards (any such bad debt deductions shall be applied to Net Sales in the period in which such receivables are written off) (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, the amount of such receivables shall not be in excess of two percent (2%) of Net Sales with respect to any given Calendar Quarter).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, amounts received or invoiced by Cutia, its Affiliates, or their respective sublicensees for the sale of Licensed Product among Cutia, its Affiliates or their respective sublicensees shall not be included in the computation of Net Sales hereunder unless the purchasing entity is the end-user. For purposes of determining Net Sales, the Licensed Product shall be deemed to be sold when billed or invoiced. Net Sales shall be accounted for in accordance with standard Cutia practices for operation by Cutia, its Affiliates or their respective sublicensees, as practiced in the Cutia Territory, but in any event in accordance with Accounting Standards consistently applied in the Cutia Territory. For clarity, a particular item may only be deducted once in the calculation of Net Sales. Notwithstanding anything to the contrary in the foregoing, to the extent any amounts deducted pursuant to subsections (d) or (g) above are subsequently recovered by Cutia, its Affiliates, or their respective sublicensees during the Term, such recovered amounts shall be deemed &#8220;Net Sales&#8221; for the subsequent Calendar Quarter&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, if no royalties are owed by Cutia for such subsequent Calendar Quarter Cutia shall promptly refund such recovered amounts to Foamix.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The transfer of any Licensed Product to an Affiliate, sublicensee, or other Third Party (x)&#160;in connection with the research, development or testing of a Licensed Product (including the conduct of Clinical Trials), (y) for purposes of distribution as promotional samples, or (z) at no charge for indigent or similar public support or compassionate use programs, will not, in any case, be considered a Net Sale of a Licensed Product under this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">With respect to any transfer of any Licensed Product in the Cutia Territory for any substantive consideration other than monetary consideration on arm&#8217;s length terms, for the purposes of calculating the Net Sales under this Agreement, such Licensed Product shall be deemed to be sold exclusively for money at the average Net Sales price charged to Third Parties for cash sales in the Cutia Territory during the applicable reporting period (or if there were only de minimus cash sales in the Cutia Territory, at the fair market value as determined by comparable markets). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Cutia, its Affiliates, and their respective sublicensees shall sell the Licensed Product as a standalone product and will not sell the Licensed Product in combination with other pharmaceutical or biologics products, diagnostic products, or active ingredients or as part of a bundle with other products or offer packaged arrangements to customers that include the Licensed Product, except with Foamix&#8217;s prior written consent.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">8</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.47</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">NMPA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the National Medical Product Administration of the People&#8217;s Republic of China, formerly known as the China National Drug Administration, or any successor agency or authority thereto. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.48</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a) pending patent applications, issued patents, utility models and designs&#59; (b) reissues, substitutions, confirmations, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing&#59; and (c) extensions, renewals or restorations of any of the foregoing by existing or future extension, renewal or restoration mechanisms, including supplementary protection certificate, patent term additions, patent term extensions or the equivalent thereof. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.49</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means an individual, corporation, partnership, limited liability company, limited partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.50</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase&#8239;1 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any human clinical trial of a Licensed Product conducted mainly to evaluate the safety of chemical or biologic agents or other types of interventions (e.g., a new radiation therapy technique) that would satisfy the requirements of 21&#8239;C.F.R. &#167;&#8239;312.21(a) or its non-United States equivalents.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.51</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase&#8239;2 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any human clinical trial of a Licensed Product conducted mainly to test the effectiveness of chemical or biologic agents or other types of interventions for purposes of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular Indication or Indications that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(b) or its non-United States equivalents.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.52</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase&#8239;3 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any human clinical trial of a Licensed Product designed to&#58; (a) establish that such Licensed Product is safe and efficacious for its intended use&#59; (b) define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed&#59; and (c) support regulatory approval of such Licensed Product, that would satisfy the requirements of 21&#8239;CFR &#167;&#8239;312.21(c) or its non-United States equivalents. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.53</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Phase 4 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any human clinical trial of a Licensed Product that is&#58; (a) designed to satisfy a requirement of a Regulatory Authority in order to maintain a Regulatory Approval for such Licensed Product or (b) conducted after the first Regulatory Approval of a Licensed Product in the same Indication for which a Licensed Product received Regulatory Approval.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.54</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Pivotal Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a pivotal clinical trial of a Licensed Product in human patients (whether or not designated a Phase 3 Clinical Trial) in any Region with a defined dose or a set of defined doses of a Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of submitting applications for MAA approval to the competent Regulatory Authorities.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">9</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.55</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Proper Conduct Practices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means, with respect to a Party, each of its Representatives not, directly or indirectly, (a) making, offering, authorizing, providing or paying anything of value in any form, whether in money, property, services or otherwise to any Government Official, or other Person charged with similar public or quasi-public duties, or to any customer, supplier, or any other Person, or to any employee thereof, or failing to disclose fully any such payments in violation of the laws of any relevant jurisdiction to (i) obtain favorable treatment in obtaining or retaining business for it or any of its Affiliates, (ii) pay for favorable treatment for business secured, (iii) obtain special concessions or for special concessions already obtained, for or in respect of it or any of its Affiliates, in each case which would have been in violation of any Law, (iv) influence an act or decision of the recipient (including a decision not to act) in connection with the Person&#8217;s or its Affiliate&#8217;s business, (v) induce the recipient to use his or her influence to affect any government act or decision in connection with the Person&#8217;s or its Affiliate&#8217;s business or (vi) induce the recipient to violate his or her duty of loyalty to his or her organization, or as a reward for having done so&#59; (b)&#160;engaging in any transactions, establishing or maintaining any fund or assets in which it or any of its Affiliates will have proprietary rights that have not been recorded in the books and records of it or any of its Affiliates&#59; (c) making any unlawful payment to any agent, employee, officer or director of any Person with which it or any of its Affiliates does business for the purpose of influencing such agent, employee, officer or director to do business with it or any of its Affiliates&#59; (d) violating any provision of applicable Anti-Corruption Laws&#59; (e) making any payment in the nature of bribery, fraud, or any other unlawful payment under the Law of any jurisdiction where it or any of its Affiliates conducts business or is registered&#59; or, (f) if such Person or any of its Representatives is a Government Official, improperly using his or her position as a Government Official to influence the award of business or regulatory approvals to or for the benefit of such Person, its Representatives or any of their business operations, or failing to recuse himself or herself from any participation as a Government Official in decisions relating to such Person, its Representatives or any of their business operations. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.56</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Regulatory Approval</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all approvals (including marketing authorization approvals, supplements, amendments, pre- and post-approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the Manufacture, distribution, use or commercial sale of a Licensed Product in a given country or regulatory jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.57</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Regulatory Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, in a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.58</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Regulatory Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means regulatory applications (including MAA), submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop, Manufacture, market, sell or otherwise Commercialize Licensed Products in a particular country or jurisdiction.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">10</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.59</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Representatives</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, as to any Person, such Person&#8217;s Affiliates and its and their successors, controlling Persons, directors, officers and employees. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.60</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Person other than a Party or an Affiliate of a Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.61</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">U.S. Dollar</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a U.S. dollar, and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">US$</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall be interpreted accordingly. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.62</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">U.S.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">USA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the United States of America, including all possessions and territories thereof. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.63</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Valid Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means a claim (including a process, use, or composition of matter claim) of (a) an issued and unexpired patent that has not (i) irretrievably lapsed or been revoked, dedicated to the public or disclaimed or (ii) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal, or (b) a pending patent application that has been pending for no more than seven (7) years since its earliest priority date and has not been abandoned or finally disallowed without the possibility of appeal. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.64</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Voluntary Phase 4 Clinical Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a Phase 4 Clinical Trial that is not conducted to satisfy a requirement of a Regulatory Authority in order to maintain a Regulatory Approval for such Licensed Product.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">1.65&#160;Additional Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#58; The following table identifies the location of definitions set forth in various Sections of the Agreement&#58;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:79.699%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.301%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Defined Terms</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Product</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.5</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Tax</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.8(b)(i)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Agreement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preamble</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Alliance Manager</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amzeeq&#8482;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.42(a)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Claims</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Competing Program</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.6(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confidentiality Agreement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.16</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">CRC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.3</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preamble</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia Data</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia Indemnitees</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia Inventions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1(d)(ii)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia Sublicense</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.1(c)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cutia Withholding Tax Action</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.8(b)(i)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development Plan</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.2</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dispute</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">14.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effective Date</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preamble</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">11</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:79.699%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:16.301%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FCD105</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.42(c)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FMX103</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.42(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foamix</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preamble</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foamix Indemnitees</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.2</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foamix Inventions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1(d)(i)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foamix Partner</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.2</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GAAP</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">IFRS</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.3</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indemnified Party</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.3</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indemnifying Party</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.3</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Infringement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.4(a)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Initial Development Plan</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.2</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Initial Transfer</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.7</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">JDC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.2(a)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Joint Inventions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.1(d)(iii)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Licensed Mark</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.6(a)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Losses</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">NDA</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.45</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Party</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preamble</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product Marks</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.6(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Product Materials</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.6</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Region</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.19</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Remedial Action</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.9</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Royalty Term</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.3(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Rules</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2(a)</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Safety Agreement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.8(a)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SEC</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">12.3(c)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supply Agreement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">7.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Term</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">13.1</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Party Infringement Actions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">9.5</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax Withholding</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.8(b)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">VAT</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="margin-top:3pt;margin-bottom:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">8.8(d)</font></div></td></tr></table></div><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 2</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LICENSE</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.1&#160;License to Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;License Grant</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Agreement, Foamix hereby grants Cutia an exclusive (even as to Foamix and its Affiliates, except as provided in Section 2.1(b) below), royalty-bearing license, with the right to sublicense (solely as provided in Section 2.1(c)), under the Foamix Technology, to Develop, use, have used, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">12</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Commercialize Licensed Products in the Field in the Cutia Territory, including to act as the local agent for Foamix to fulfil its obligations as the MAH (Marketing Authorization Holder) of the Licensed Products in the Cutia Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Foamix Retained Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding the exclusive rights granted to Cutia in Section 2.1(a), Foamix and its Affiliates shall retain&#58; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;the right to practice the Foamix Technology within the scope of the license granted to Cutia under Section 2.1(a) in order to perform, or have performed by a Third Party, Foamix&#8217;s obligations under this Agreement&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that Foamix shall remain solely responsible for such Third Party&#8217;s performance of or failures to perform any obligations of Foamix under this Agreement&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;the right to practice and license the Foamix Technology outside the scope of the license granted to Cutia under Section 2.1(a).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Sublicense Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia may grant sublicenses of the license granted in Section 2.1(a) and Section&#160;9.6(a) (i) to its Affiliates, including through multiple tiers, without requiring Foamix&#8217;s prior consent&#59; and (ii) to Third Parties with Foamix&#8217;s prior written consent, such consent not to be unreasonably withheld, conditioned, or delayed&#59; provided, that (x) Foamix shall respond within thirty (30) days of receiving Cutia&#8217;s written notice containing the name of the sublicensee and the material terms of a proposed sublicense, (y) that such consent shall be deemed granted by Foamix if Foamix fails to respond within such thirty (30)-day period, and (z) Cutia shall not enter into a proposed sublicense with material terms different than those presented to Foamix without first notifying Foamix of such changes and obtaining Foamix&#8217;s prior written consent pursuant to this Section&#160;2.1(c). Cutia shall, within thirty (30) days after granting any sublicense under Section 2.1(c), notify Foamix of the execution of such sublicense and provide Foamix with a summary of the sublicense agreement (each, an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Sublicense</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Cutia shall ensure that each Cutia Sublicense is consistent with the terms and conditions of this Agreement, and Cutia shall be solely responsible for all of its sublicensees&#8217; activities and any and all failures by its sublicensees to comply with the terms of this Agreement. Without limiting the foregoing, each Cutia Sublicense shall include the following additional terms and conditions&#58; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the sublicensee shall be bound by confidentiality obligations no less stringent than those set forth in this Agreement&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">he sublicensee shall not have any right to prosecute or maintain or enforce any Foamix Licensed Patents&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the sublicensee shall assign or license to Cutia all Data and Inventions generated by or on behalf of such sublicensee, and shall grant Cutia all of the rights necessary for Cutia to fulfill its obligations under Section 9.1&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iv)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Cutia shall use Commercially Reasonable Efforts to include in each Cutia Sublicense a provision that, if this Agreement terminates, Foamix may assume Cutia&#8217;s rights and obligations under the Cutia Sublicense.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">13</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.2&#160;Foamix Partner</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix may enter into one (1) or more agreements with Third Parties and may grant such Third Parties the right to Develop, Manufacture, and Commercialize Licensed Products in one or more countries in the Foamix Territory (each such Third Party, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Partner</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). In addition, Foamix may exercise any or all of its rights and may fulfill any or all of its obligations under this Agreement through one (1) or more Foamix Partners&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that (a) any such Foamix Partner is not actively developing, manufacturing or commercializing a Competing Product in the Cutia Territory, and (b) Foamix shall remain solely responsible for any Foamix Partner&#8217;s performance of or failures to perform any obligations of Foamix under this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.3&#160;Negative Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall not, and shall not permit any of its Affiliates or sublicensees to, use or practice any Foamix Technology outside the scope of the license granted to it under Section 2.1(a). Cutia shall not, and shall not permit any Affiliate or sublicensee to, directly or indirectly, Develop, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize Licensed Products in the Cutia Territory for any use outside the Field. Foamix shall not, and shall not permit any of its Affiliates to, directly or indirectly, Develop, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize Licensed Products in the Cutia Territory for any use outside the Field unless (a) Foamix has first offered such rights to Cutia pursuant to Section&#160;2.5 and the Parties have failed to reach agreement under Section&#160;2.5 or (b) Foamix obtains Cutia&#8217;s prior written consent. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.4&#160;No Implied Licenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as explicitly set forth in this Agreement, neither Party shall be deemed by estoppel, implication, or otherwise to have granted the other Party any license or other right to any intellectual property of such Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.5&#160;Right of First Offer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix hereby grants to Cutia a right of first offer to obtain an exclusive or non-exclusive license, as the Parties mutually agree, with the right to sublicense through multiple tiers, to Develop, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise Commercialize any topical minocycline product of Foamix, other than the Licensed Products, for any dermatological Indication in the Cutia Territory (an &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Additional Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Foamix shall notify Cutia in writing of its desire to out-license such Additional Product. Together with such notice, Foamix shall provide Cutia with all material information in Foamix&#8217;s control relating to the applicable Additional Product. Cutia shall have fifteen (15) days from receipt of such written notice to notify Foamix in writing as to whether Cutia desires to negotiate for a license for such Additional Product. If Cutia so notifies Foamix that it does desire to negotiate for such rights for such Additional Product, then for forty-five (45) days the Parties shall negotiate in good faith a definitive agreement for such rights for such Additional Product. For clarity, Foamix may only enter into discussions, exchange information, and negotiate with a Third Party with respect to an agreement related to the transfer of or grant of rights for such Additional Product after the foregoing sixty (60)-day notice and negotiation period.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.6&#160;Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">14</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Obligations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. During the Term, Cutia shall not, directly or indirectly, either by itself or with or through any of its Affiliates or any Third Party (including via any arrangement or series of arrangements with a Third Party), Develop, Manufacture or Commercialize any Competing Product in the Cutia Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Acquisition of Competing Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If a Third Party becomes an Affiliate of Cutia after the Effective Date through merger, acquisition, consolidation or other similar transactions and, as of the closing date of such transaction, such Third Party is engaged in the research, development, manufacture or commercialization of a Competing Product such that, if conducted by such Third Party, it would cause Cutia to be in breach of its exclusivity obligations set forth above (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Competing Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) then Cutia and its new Affiliate will have twelve (12) months from the closing date of such transaction to wind down or complete the Divestiture of such Competing Program, and Cutia&#8217;s new Affiliate&#8217;s conduct of such Competing Program during such twelve (12)-month period will not be deemed a breach of Cutia&#8217;s exclusivity obligations set forth above&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that such new Affiliate conducts such Competing Program during such twelve (12)-month period independently of the activities of this Agreement and does not use or access any of Foamix&#8217;s intellectual property rights or Confidential Information in the conduct of such Competing Program.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">2.7&#160;Transfer of Foamix Licensed Know-How</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Promptly after the Effective Date and no later than one hundred (100) Business Days thereafter, Foamix shall, to the extent expressly provided for in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, provide Cutia with complete and accurate copies through the Intralinks data room of the Foamix Licensed Know-How set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (such transfer the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Initial Transfer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The JDC shall establish a reasonable process and schedule for the transfer of any additional Foamix Licensed Know-How that subsequently becomes Controlled by Foamix or its Affiliates during the Term. Foamix shall reasonably cooperate with Cutia in providing Cutia with copies of such Foamix Licensed Know-How in accordance with the process and schedule agreed upon through the JDC. Notwithstanding anything to the contrary, Foamix is not obligated to transfer to Cutia any CMC Information as part of the Initial Transfer or any subsequent transfer. For clarity, all Licensed Know-How, including the Initial Transfer, will be provided by Foamix in English and in such editable PDF form and format then in Foamix&#8217;s possession. </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 3</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">GOVERNANCE</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.1&#160;Alliance Managers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Within thirty (30) days after the Effective Date, each Party shall appoint and notify the other Party of the identity of a representative having the appropriate qualifications, including a general understanding of pharmaceutical development, manufacturing, and commercialization issues, to act as its alliance manager under this Agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Alliance Manager</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing each Party with information on the progress and results of Cutia&#8217;s Development, Manufacturing, and Commercialization of Licensed Products. The Alliance Managers shall also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the Parties with </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">15</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">respect to Licensed Products. Each Party may replace its Alliance Manager at any time upon written notice to the other Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.2&#160;Joint Development Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Formation&#59; Purpose</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Within thirty (30) days after the Effective Date, the Parties shall establish a joint development committee (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) for the overall coordination and oversight of the Parties&#8217; activities under this Agreement. The role of the JDC is&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;to review, discuss and coordinate the overall strategy for the Development, Manufacturing, and Commercialization of Licensed Products in the Cutia Territory, including related regulatory activities&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;to review, discuss and approve any proposed amendments or revisions to the Development Plan, including those with respect to clinical Development activities set forth in Section 4.3, and to review, discuss and approve the conduct of any Development activities by Cutia&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;to perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined by the Parties in writing.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Members</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The JDC shall be comprised of an equal number of representatives from each Party. Each Party&#8217;s representatives shall be an officer or employee of such Party or its Affiliate having sufficient seniority within the applicable Party to make decisions arising within the scope of the JDC&#8217;s responsibilities. Each Party shall initially appoint two (2) representatives to the JDC. Each Party may replace its representatives at any time upon written notice to the other Party. Each Party shall appoint one (1) of its representatives on the JDC to act as the co-chairperson. The role of the co-chairpersons is to convene and preside at the JDC meetings and to ensure the circulation of meeting agendas at least five (5) days in advance of JDC meetings and the preparation of meeting minutes and any pre-read materials in accordance with Section 3.2(c), but the co-chairpersons have no additional powers or rights beyond those held by other JDC representatives. Employees or consultants of either Party that are not representatives of the Parties on the JDC may attend meetings of the JDC, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that such attendees shall not vote or otherwise participate in the decision-making process of the JDC and are subject to obligations of confidentiality substantially similar to the provisions set forth in Section 12.1.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Meetings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The JDC shall meet at least every six (6) months during the Term, and at least one (1) such meeting per calendar year shall be in-person, unless the Parties mutually agree in writing to a different frequency for such meetings. Either Party may also call a special JDC meeting (by videoconference or teleconference) with reasonable advanced written notice to the other Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall promptly provide the JDC prior to the special meeting with materials reasonably adequate to enable an informed decision. All JDC meetings shall be conducted in English, and all communications </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">16</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">under this Agreement shall be in English. The location of each in-person JDC meeting shall alternate between locations reasonably selected by each of the Parties. The co-chairpersons shall be responsible for preparing reasonably detailed written minutes of the JDC meetings that reflect all material decisions made at such meetings. The co-chairpersons shall send draft meeting minutes to each representative of the JDC for review and approval within ten (10) Business Days after the JDC meeting. Such minutes shall be deemed approved unless one or more JDC representatives object to the accuracy of such minutes within ten (10) Business Days of receipt.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.3&#160;Decision Making</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The JDC shall strive to seek consensus in its actions and decision making process, and all decisions by the JDC shall be made by consensus, with each Party having collectively one (1) vote in all decisions. If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter before the JDC, the representatives of the Parties cannot reach an agreement as to such matter (to the extent that such matter requires the agreement of the Parties hereunder) within ten (10) Business Days after such matter was brought to the JDC for resolution or after such matter has been referred to the JDC, such disagreement shall be referred to the Executive Officers for resolution. If the Executive Officers cannot resolve such matter within thirty (30) days after such matter has been referred to them, then&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;the Cutia Executive Officer has the final decision making authority with respect to the Development or Commercialization of Licensed Products in the Field in the Cutia Territory to the extent such Development and Commercialization activities primarily arise within the Cutia Territory and would be reasonably expected to primarily affect the Development, Commercialization, and Manufacture of Licensed Products in the Cutia Territory&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Cutia Executive Officer shall consider in good faith Foamix&#8217;s comments and suggestions with respect to such matter&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Cutia Executive Officer may not exercise such final decision making authority in a manner that creates an Adverse Risk&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;the Foamix Executive Officer has the final decision making authority with respect to all other matters not allocated to Cutia in Section&#160;3.3(a). </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, the Parties shall resolve in accordance with Section 14.2 any Dispute concerning whether the Cutia Executive Officer or the Foamix Executive Officer has the final decision making authority, including a Dispute as to whether a decision by the Cutia Executive Officer creates an Adverse Risk. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.4&#160;Limitation of JDC Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The JDC shall only have the powers expressly assigned to it in this Article 3 and elsewhere in this Agreement and shall not have the authority to&#58; (a) modify or amend the terms and conditions of this Agreement&#59; (b) waive or determine either Party&#8217;s compliance with the terms and conditions of under this Agreement&#59; or (c) decide any issue in a manner that would conflict with the express terms and conditions of this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.5&#160;Discontinuation of the JDC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The activities to be performed by the JDC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. The JDC shall continue to exist until the first to occur of&#58; (a) the Parties </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">17</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">agree to disband the JDC&#59; or (b) Foamix provides written notice to Cutia of its intention to disband and no longer participate in the JDC. Thereafter, the JDC will have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information relevant to the JDC under this Agreement and decisions of the JDC shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.6&#160;Notification of Threatened Action</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall immediately notify the other Party (including by providing notice to the other Party&#8217;s Alliance Manager) of any information it receives regarding any threatened or pending action, inspection or communication by or from any Third Party, including a Regulatory Authority, which has an Adverse Risk. Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">3.7&#160;No Harmful Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Foamix believes that Cutia is taking or intends to take any action (or inaction) with respect to any Licensed Product that could reasonably be expected to create Adverse Risk, then Foamix may bring the matter to the attention of the JDC and the Parties shall discuss in good faith to promptly resolve such concern.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 4</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEVELOPMENT</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.1&#160;Overview&#59; Diligence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Cutia shall be solely responsible for the Development of Licensed Products in the Field in the Cutia Territory, at its own cost and expense (except as otherwise expressly set forth herein), including all non-clinical and clinical studies, as</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">necessary to obtain Regulatory Approval for Licensed Products in any Region in the Cutia Territory. Cutia shall use Commercially Reasonable Efforts to Develop and to obtain Regulatory Approval for each Licensed Product in each Region in the Cutia Territory and in each Indication for which such Licensed Product has received Regulatory Approval in the United States.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.2&#160;Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Without limiting the generality of the other provisions in this Article 4, Cutia shall conduct its Development activities under and in accordance with the Development Plan and shall be solely responsible for all decisions regarding the day-to-day conduct of Development within the Cutia Territory. An initial, mutually agreed Development Plan is attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit&#160;C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Initial Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and together with any subsequent updates pursuant to this Section 4.2, collectively the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Development Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Development Plan shall include among other things, (a) the Indications in the Field for which the Licensed Products are to be Developed, (b) critical activities to be undertaken under this Agreement, (c)&#160;go&#47;no-go decision points and relevant decision criteria, (d) solely to the extent expressly agreed by Foamix with respect to any responsibilities allocated to Cutia, certain allocations of responsibilities between the Parties under the Development Plan, and (e) all non-clinical and clinical studies, CMC Information collection activities, and regulatory activities with respect to the Licensed Products to be conducted by or on behalf of Cutia or its Affiliates or their </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">18</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">respective sublicensees in the Cutia Territory. From time to time during the Term, Cutia may prepare written amendments and updates, as appropriate, to the then-current Development Plan, and shall submit such amendments and updates to the JDC in accordance with Section 3.2. Such Development Plan and the contents therein shall be Confidential Information of Cutia.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.3&#160;Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix shall provide such technical assistance and cooperation to Cutia as Cutia may reasonably request, as necessary or reasonably useful for Cutia to Develop or Commercialize Licensed Products in the Field in the Cutia Territory, without additional charge to Cutia. For clarity, Foamix is not obligated to provide Cutia with any CMC Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.4&#160;Development Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall maintain complete, current and accurate records of all activities conducted pursuant to the Development Plan by Cutia, its Affiliates and their respective sublicensees, and all Data and other Information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Cutia shall document all non-clinical studies and clinical trials in formal written study records in accordance with all Law, including applicable national and international guidelines such as ICH, GCP and GLP. Cutia shall, to the extent permitted by applicable Laws, permit Foamix to review and copy such records at reasonable times and to obtain access to the original to the extent necessary or useful for regulatory or patent purposes.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.5&#160;Development Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall keep Foamix reasonably informed as to the progress and results of its and its Affiliates&#8217; and their respective sublicensees&#8217; work under the Development Plan (including prompt reporting of available clinical data). Without limiting the foregoing, at each regularly scheduled JDC meeting, Cutia shall provide Foamix with a written report summarizing the Development activities performed since the last JDC meeting and the results thereof, and comparing such activities with the Development Plan for such time period. Such reports shall be provided in English and at a level of detail reasonably requested by Foamix and sufficient to enable Foamix to determine Cutia&#8217;s compliance with its diligence obligations under Section 4.1. At such JDC meeting, the Parties shall discuss the status, progress and results of Cutia&#8217;s Development activities. Cutia shall promptly respond to Foamix&#8217;s reasonable questions or requests for additional information relating to such Development activities. In addition, within thirty (30) days after the end of each Fiscal Year, Cutia shall provide Foamix with a detailed written annual report in English regarding the progress under the Development Plan and results thereof (or upon Foamix&#8217;s reasonable request, on a more frequent basis). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.6&#160;Data Exchange</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In addition to Foamix&#8217;s obligation with respect to the transfer of Foamix Licensed Know-How set forth under Section 2.7 and each Party&#8217;s adverse event, safety data, and product quality complaint reporting obligations pursuant to Section 5.8, but subject to the remainder of this Section 4.6, each Party shall, at its sole cost and expense, solely to the extent permitted by applicable Laws, promptly provide the other Party with copies of all Data and Regulatory Materials related to all Licensed Products generated by or on behalf of such Party or its Affiliates or sublicensees in the performance of Development activities of the Licensed Products in their respective territories (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The JDC may establish </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">19</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">reasonable policies to effectuate such exchange of Product Materials between the Parties. For clarity, Product Materials exclude CMC Information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.7&#160;Subcontractors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia may engage subcontractors to conduct any activities necessary for Development of Licensed Products, including non-clinical studies, clinical studies, CMC activities (subject to Foamix&#8217;s prior written consent), and regulatory services for Licensed Products, under this Agreement, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that such subcontractors are bound by written obligations of confidentiality consistent with this Agreement and have agreed in writing to assign to Cutia all Data, Information, inventions or other intellectual property generated by such subcontractor in the course of performing such subcontracted work. Cutia shall remain responsible for any obligations that have been delegated or subcontracted to any subcontractor, and shall be responsible for the performance of its subcontractors. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">4.8&#160;Development of FCD105</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;If Foamix decides, in its sole discretion, to conduct a global Clinical Trial for FCD105 (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Global Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and wishes to include Clinical Trial sites in the Cutia Territory as part of such Global Trial, Foamix shall notify Cutia in writing. Cutia and Foamix shall discuss in good faith the terms of Cutia&#8217;s participation in any such Global Trial. If the Parties agree to collaborate with respect to such Global Trial, the Parties shall enter into a separate clinical trial agreement that is negotiated in good faith and contains commercially reasonable terms and conditions. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;In the event Foamix decides to cease, abandon or discontinue the Development of FCD105 prior to receiving Regulatory Approval therefor in the United States within five (5) years from the Effective Date (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Abandoned FCD105</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Foamix shall notify Cutia of such cessation, abandonment or discontinuance. Upon Cutia&#8217;s request within sixty (60) days after such notice, the Parties shall discuss in good faith including such Abandoned FCD105, in its then-current form and format at the time of the cessation, abandonment or discontinuance, as a Licensed Product under this Agreement. If the Parties agree to include Abandoned FCD105 as a Licensed Product under this Agreement, the Parties shall amend and modify this Agreement as necessary to adjust the rights and obligations of the Parties hereunder with respect to the Abandoned FCD105.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 5</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REGULATORY MATTERS</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.1&#160;Holder of Regulatory Approvals and Regulatory Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix shall initially be the holder of Regulatory Approvals and Regulatory Material for Licensed Products in the Cutia Territory to the extent required by Law in the Cutia Territory. As soon as is practicable during the Term, the Parties shall cooperate in good faith to enable Cutia to hold all Regulatory Approvals and Regulatory Materials, whether by transfer to Cutia of such Regulatory Approvals and Regulatory Materials or through the submission by Cutia of a new application for Regulatory Approval in a Region in the Cutia Territory, to the extent permitted by Law and in accordance therewith. Cutia shall reimburse Foamix&#8217;s actual costs and expenses related to Foamix&#8217;s cooperation to enable Cutia to hold all such Regulatory Approvals and Regulatory Materials.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">20</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.2&#160;Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Responsibilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia shall conduct all regulatory activities delegated to Cutia in this Agreement in connection with the Development and Commercialization of Licensed Products in the Cutia Territory at Cutia&#8217;s sole cost and expense. During such time that Foamix is the holder of Regulatory Approvals and Regulatory Materials for Licensed Products in the Cutia Territory, Cutia shall act as the express and authorized regulatory agent of record for Foamix in the Cutia Territory, and shall carry out specific activities delegated to Cutia by Foamix that are within the scope of this Agreement. Promptly after the Effective Date, the Parties shall execute such documents as are required for Cutia to act as Foamix&#8217;s express and authorized regulatory agent of record in the Cutia Territory. Cutia shall, and shall ensure that its Affiliates and sublicensees, comply with all Laws in its conduct of regulatory activities under this Agreement, and Cutia shall use Commercially Reasonable Efforts, in its capacity as a regulatory agent of record for Foamix in the Cutia Territory, to comply with guidelines in the United States applicable to regulatory agents of record to the extent that equivalent guidelines do not exist in the Cutia Territory, and only to the extent that such guidelines do not conflict with Laws in the Cutia Territory. Subject to Section 5.1, Cutia shall use Commercially Reasonable Efforts to obtain and maintain all Regulatory Approvals and Regulatory Materials necessary to Manufacture Licensed Products in the Cutia Territory as soon as practicable during the Term and to the extent permitted by Law and in accordance therewith. After Regulatory Approvals and Regulatory Materials necessary for the Development and Commercialization of Licensed Products in the Cutia Territory are held by Cutia, Cutia shall be solely responsible for all regulatory activities, including making additional Regulatory Materials and obtaining additional Regulatory Approvals for Licensed Products from the Regulatory Authorities in the Cutia Territory, at its sole cost and expense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, Cutia undertakes any such activities in compliance with this Agreement to the same extent as if Cutia were acting as Foamix&#8217;s authorized regulatory agent under this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia, either itself or on behalf of Foamix in accordance with the foregoing Section&#160;5.1, shall apply for Regulatory Approval of Licensed Products in each Region in the Cutia Territory, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Cutia has obtained, or has been provided with access by Foamix to, Data sufficient for such Regulatory Material. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Except as required by Law, Cutia, its Affiliates and sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Foamix Territory regarding any Licensed Products. If such submission or communication is required by Law, Cutia shall immediately notify Foamix in writing of such requirement and the content of such submission or communication.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.3&#160;Foamix</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Responsibilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix shall use Commercially Reasonable Efforts to maintain Regulatory Approvals in the U.S. for Licensed Products. Foamix shall keep Cutia promptly informed of material notices and communications issued by the FDA in connection with Regulatory Approvals for Licensed Products in the U.S. Foamix shall reasonably cooperate with Cutia in obtaining any Regulatory Approvals for Licensed Products in the Field in the Cutia Territory by providing, to the extent Controlled by Foamix, access to Regulatory Approvals, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">21</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Regulatory Materials, Data, Information, and documentation for Licensed Products outside of the Cutia Territory. The Parties shall establish a reasonable process and schedule for Foamix to provide CMC Information to the applicable Regulatory Authority for purposes of the MAA. With respect to CMC Information and regardless of which Party is then holding the Regulatory Materials and Regulatory Approvals for Licensed Products in the Cutia Territory, Foamix shall reasonably cooperate with Cutia, at Cutia&#8217;s cost and expense, in directly providing to Regulatory Authorities the CMC Information required to obtain Regulatory Approvals for Licensed Products in the applicable Region in the Cutia Territory. Cutia shall reimburse Foamix&#8217;s reasonable costs and expenses incurred in connection with the submission of CMC Information. Foamix shall provide all other regulatory assistance at Foamix&#8217;s cost and expense. Except as expressly permitted under this Agreement or required by Law, Foamix, its Affiliates and sublicensees shall not submit any Regulatory Materials to, or communicate with, any Regulatory Authority in the Cutia Territory regarding any Licensed Products. If such submission or communication is required by Law, Foamix shall immediately notify Cutia in writing of such requirement and the content of such submission or communication. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.4&#160;Right</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">of</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Reference</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party hereby grants to the other Party the right of reference to all Regulatory Materials pertaining to Licensed Products in the Field submitted by or on behalf of such Party. Cutia may use such right of reference to Foamix&#8217;s Regulatory Materials in the Field solely for the purpose of seeking, obtaining and maintaining Regulatory Approval of Licensed Products in Field in the Cutia Territory. Foamix may use the right of reference to Cutia&#8217;s Regulatory Materials in the Field solely for the purpose of seeking, obtaining and maintaining Regulatory Approval of Licensed Products in the Foamix Territory. Each Party shall support the other Party, as reasonably requested by such other Party and at such other Party&#8217;s expense (except as otherwise provided in Section&#160;5.3), in obtaining Regulatory Approvals in such other Party&#8217;s territory, including providing necessary documents or other materials required by Law to obtain Regulatory Approval in such territory, all in accordance with the terms and conditions of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.5&#160;Regulatory Information Sharing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall notify Foamix of any material verbal or written communication or question relating to Licensed Products received by Cutia from the Regulatory Authority in the Cutia Territory and shall promptly notify Foamix in writing of any decision by any Regulatory Authority in the Cutia Territory regarding Licensed Products. Cutia shall provide Foamix with all Regulatory Materials containing or requesting CMC Information upon receipt, and Foamix shall provide any responses or written communications relating to the request for submission directly to the applicable Regulatory Authority. In addition, Cutia shall notify Foamix of any Regulatory Materials received from any Regulatory Authority in the Cutia Territory and shall provide Foamix with copies thereof within five (5) days after receipt. If any such Regulatory Material is not in the English language, Cutia shall also provide Foamix with both the original document and an English summary thereof. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.6&#160;Regulatory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Audits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Inspection</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Upon reasonable notice, Foamix may conduct, once every other year or at any time upon reasonable cause, an audit of safety and regulatory systems, procedures, and practices of Cutia, including on site evaluations. Cutia shall promptly notify Foamix of any inspections relating to the Development or Commercialization of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">22</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Licensed Products by any Regulatory Authority in the Cutia Territory, including the NMPA, of which it becomes aware. Unless prohibited by Laws, Cutia shall permit Foamix&#8217;s representative to observe such inspection. Cutia shall also provide Foamix with copies of all correspondences submitted to or received from the Regulatory Authority relating to such inspection.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.7&#160;Meetings with Regulatory Authorities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall provide the other Party with at least fifteen (15) days&#8217; prior written notice (or, to the extent such meeting or discussion is scheduled in less than fifteen (15) days, notice as quickly as practicable) of any meeting or discussion with any Regulatory Authority in the Cutia Territory related to Licensed Products. Cutia shall lead all interactions with Regulatory Authorities in the Cutia Territory with respect to Licensed Products. To the extent permitted by Law and by the Regulatory Authorities, Foamix may participate (whether directly or through a representative) in all such meetings and discussions, at Foamix&#8217;s cost (except as otherwise provided in Section&#160;5.3). If Foamix elects not to attend such meeting or discussion, Cutia shall provide Foamix with a written summary thereof in English promptly following such meeting or discussion. Cutia shall keep Foamix reasonably informed of any material regulatory developments related to Licensed Products in the Field in the Cutia Territory. At each regularly scheduled JDC meeting, Cutia shall provide Foamix with a list and schedule of any meeting or discussion with the applicable Regulatory Authorities (or related advisory committees) in the Cutia Territory planned for the next Calendar Quarter that relates to any Licensed Product in the Field. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.8&#160;Adverse</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Reporting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Promptly following the Effective Date, but in no event later than sixty (60) days before the commencement of a clinical study with respect to Development of any Licensed Product by Cutia in the Cutia Territory, Cutia and Foamix shall develop and agree to the worldwide safety and pharmacovigilance procedures for the Parties with respect to Licensed Products, such as safety data sharing and exchange, Adverse Events reporting and prescription events monitoring in a written agreement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Safety</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Such Safety Agreement shall describe the coordination of collection, investigation, reporting, and exchange of information concerning Adverse Events or any other safety problem of any significance, and product quality and product complaints involving Adverse Events, sufficient to permit each Party, its Affiliates, or sublicensees to comply with its legal obligations. The Parties shall promptly update the Safety Agreement if required by changes in legal requirements. Each Party shall comply with its respective obligations under the Safety Agreement and to cause its Affiliates and sublicensees to comply with such obligations.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia shall maintain an Adverse Event database for Licensed Products in the Cutia Territory, at its sole cost and expense, and, to the extent required by Laws, shall report quality complaints, Adverse Events and safety data related to Licensed Products to the applicable Regulatory Authorities in the Cutia Territory, as well as responding to safety issues and to all requests of Regulatory Authorities related to Licensed Products in the Cutia Territory. Cutia shall provide to Foamix access to Cutia&#8217;s Adverse Event database for the Cutia Territory. Foamix shall maintain a global Adverse Event database at its sole cost and expense, and, except as prohibited by applicable Law, shall provide Cutia with information contained in such global </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">23</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adverse Event database at JDC meetings, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Foamix shall promptly provide Cutia with any material Adverse Event information that arises between any such JDC meetings. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Each Party shall comply with all Laws governing Adverse Events in its respective territory, and shall notify the other Party on a timely basis of any Adverse Events occurring in its respective territory. Each Party shall submit copies of reports of Adverse Events to the other Party simultaneously with submission to the applicable Regulatory Authorities. Each Party shall notify the other in a timely manner and in any event within twenty-four (24) hours of receiving any serious Adverse Event reports from Clinical Trials that each Party is monitoring, notice from a Regulatory Authority, independent review committee, data safety monitoring board or another similar Clinical Trial or post-marketing monitoring body alleging significant concern regarding a patient safety issue or other material information relevant to the safety or efficacy of Licensed Products. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.9&#160;Remedial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating that any Licensed Product may be subject to any recall, corrective action, or other regulatory action by any Governmental Authority or Regulatory Authority (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Remedial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Action</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Parties shall assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Cutia has sole discretion with respect to any matters relating to any Remedial Action in the Cutia Territory, including the decision to commence such Remedial Action and the control over such Remedial Action in the Cutia Territory&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> if Foamix determines in good faith that any Remedial Action with respect to any Licensed Product in the Cutia Territory should be commenced or is required by Law or Regulatory Authority, (a) Foamix shall discuss such Remedial Action with Cutia and (b) Cutia shall consider in good faith such Remedial Action upon Foamix&#8217;s request. The cost and expenses of any Remedial Action in the Cutia Territory shall be borne solely by Cutia. Cutia shall, and shall ensure that its Affiliates and sublicensees will, maintain adequate records to permit the Parties to trace the distribution, sale and use of Licensed Products in the Cutia Territory. Each Party shall provide the other Party, at the other Party&#8217;s expense, with such assistance in connection with a Remedial Action as may be reasonably requested by such other Party. Notwithstanding the foregoing, any Remedial Action that relates to the manufacture and supply of Licensed Products by Foamix to Cutia shall be governed by the terms and conditions of the applicable Supply Agreement.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 6</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COMMERCIALIZATION </font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.1&#160;Overview&#59; Diligence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Agreement (including the diligence obligations set forth below), Cutia has the sole right and responsibility for all aspects of the Commercialization of Licensed Products in the Field in the Cutia Territory, including&#58; (a) developing and executing a commercial launch and pre-launch plan, (b)&#160;negotiating with applicable Governmental Authorities regarding the price and reimbursement status of Licensed Products&#59; (c) marketing, advertising and promotion&#59; (d) booking sales and distribution and performance of related services&#59; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables&#59; (f) providing customer support, including </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">24</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">handling medical queries, and performing other related functions&#59; and (g) conforming its practices and procedures to Laws relating to the marketing, detailing and promotion of Licensed Products in the Field in the Cutia Territory. Cutia shall bear all of the costs and expenses incurred in connection with such Commercialization activities. Cutia shall use Commercially Reasonable Efforts to Commercialize the Licensed Products in the Cutia Territory.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.2&#160;Commercialization Report</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. For each Fiscal Year following Regulatory Approval for each Licensed Product, Cutia shall provide to Foamix within sixty (60) days after the end of such Fiscal Year a high-level annual report summarizing (a) Cutia&#8217;s activities with respect to the Commercialization of Licensed Products in such Fiscal Year and (b) Cutia&#8217;s anticipated activities with respect to the Commercialization of Licensed Products in the next Fiscal Year. Such reports and the contents therein shall be Confidential Information of Cutia.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.3&#160;Data Exchange</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall keep Foamix reasonably informed of Cutia&#8217;s, its Affiliates&#8217; and their respective sublicensees&#8217; Commercialization activities with respect to the Licensed Products in the Field in the Cutia Territory. Foamix shall provide to Cutia, upon Cutia&#8217;s request, and no more than once each Calendar Quarter, at Foamix&#8217;s cost, access to materials prepared by or on behalf of Foamix that are approved and authorized to be distributed as promotional materials pursuant to Foamix&#8217;s internal commercial review committee (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CRC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that are necessary or reasonably useful in connection with Cutia&#8217;s Commercialization of Licensed Products in the Field in the Cutia Territory (including relevant final and CRC-approved training materials, and any final global brand and global market research materials, in each case, with respect to Licensed Products). Until Cutia has received Regulatory Approval for a Licensed Product in a Region in the Cutia Territory, Foamix shall provide such promotional materials in read-only access format.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">6.4&#160;No Diversion</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party hereby covenants and agrees that it shall not, and shall ensure that its Affiliates and sublicensees will not, directly or indirectly, promote, market, distribute, import, sell or have sold the Licensed Products, including via internet or mail order, in the other Party&#8217;s territory. With respect to any country in the other Party&#8217;s territory, a Party shall not, and shall ensure that its Affiliates and their respective sublicensees will not&#58; (a) establish or maintain any branch, warehouse or distribution facility for Licensed Products in such countries, (b) knowingly engage in any advertising or promotional activities relating to Licensed Products that are directed primarily to customers or other purchaser or users of Licensed Products located in such countries, (c) actively solicit orders for Licensed Products from any prospective purchaser located in such countries, or (d) knowingly sell or distribute Licensed Products to any person in such Party&#8217;s territory who intends to sell or has in the past sold Licensed Products in such countries. If either Party receives any order for any Licensed Product from a prospective purchaser reasonably believed to be located in a country in the other Party&#8217;s territory, such Party shall immediately refer that order to the other Party and such Party shall not accept any such orders. Each Party shall not deliver or tender (or cause to be delivered or tendered) Licensed Products into a country in the other Party&#8217;s territory. Each Party shall not, and shall ensure that its Affiliates and their respective sublicensees will not, knowingly restrict or impede in any manner the other Party&#8217;s exercise of its retained exclusive rights in the other Party&#8217;s territory. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">25</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 7 </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MANUFACTURE AND SUPPLY</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.1&#160;Foamix Manufacture and Supply</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as otherwise provided for in this Agreement or a Supply Agreement, Cutia shall purchase from Foamix, and Foamix shall use Commercially Reasonable Efforts to supply to Cutia, all of Cutia&#8217;s requirements for the Licensed Products, subject to the terms and conditions of each Supply Agreement. &#91;***&#93;. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.2&#160;Cutia Supply&#59; Manufacturing Technology Transfer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix may require that Cutia, and Cutia shall, assume the Manufacture of all of Cutia&#8217;s requirements for the Licensed Products for use in the Cutia Territory in accordance with the procedures set forth in this Section&#160;7.2. At any time after twelve (12) months after the First Commercial Sale of a Licensed Product in the Cutia Territory, Foamix may provide written notice to Cutia of its transfer of the Manufacture of such Licensed Product to Cutia. The commercial Supply Agreement shall set forth the applicable time periods and mechanics of a technology transfer that is reasonably necessary for Cutia, itself or through an Affiliate or Third Party, to Manufacture such Licensed Product for use in the Cutia Territory, including the transfer to Cutia relevant documents and information to the extent Controlled and actually used in the Manufacture of Licensed Products by Foamix as of such transfer date, and the provision of technical assistance and support. Cutia shall pay Foamix&#8217;s external and internal costs incurred in connection with providing such information or assistance, as further set forth in the commercial Supply Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.3&#160;Distribution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia will be solely responsible for the distribution of Licensed Products in the Field in the Cutia Territory.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">7.4&#160;Brand Security and Anti-Counterfeiting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Parties will establish contacts for communication regarding brand security issues, and each Party shall reasonably cooperate with the other Party with respect thereto. </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 8</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COMPENSATION</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.1&#160;Initial Upfront Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. As partial consideration for the licenses granted under this Agreement and as reimbursement of Foamix&#8217;s certain research and development expenses and activities conducted prior to the Effective Date, Cutia shall pay Foamix a one-time, non-refundable, non-creditable payment of ten million U.S. Dollars (US$10,000,000) as follows&#58; (a)&#160;six million U.S. Dollars (US$6,000,000) within twenty-five (25) Business Days after the Effective Date, and (b)&#160;four million U.S. Dollars (US$4,000,000) within one hundred (100) Business Days after the Effective Date, provided that Foamix has provided Cutia with the Foamix Licensed Know-How set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.2&#160;Milestone Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall pay to Foamix a one-time, non-refundable, non-creditable milestone payment of one million U.S. Dollars (US$1,000,000) within thirty (30) Business Days after the first Regulatory Approval of the first Licensed Product by the NMPA, whether achieved by or on behalf of Cutia, its Affiliate, or their respective sublicensees. For </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">26</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">clarity, such milestone payment shall be due only once for all Licensed Products and shall not exceed one million U.S. Dollars (US$1,000,000).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.3&#160;Royalties on Net Sales</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Royalty Rate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Section 8.3, within sixty (60) days after the end of each Calendar Quarter during the Royalty Term, Cutia shall pay to Foamix non-creditable, non-refundable royalties on the Net Sales in the Cutia Territory during such Calendar Quarter, &#91;***&#93;. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Royalties payable under Section 8.3(a) shall be paid by Cutia (on a Licensed Product-by-Licensed Product and Region-by-Region basis) beginning on the date of the First Commercial Sale of each Licensed Product in a Region in the Cutia Territory and continuing until the later of&#58; (i) ten (10) years from the date of First Commercial Sale of such Licensed Product in such Region, and (ii) expiration of the last Valid Claim of a Foamix Licensed Patent Covering such Licensed Product in such Region (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Royalty Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). For clarity, if a Valid Claim of a Foamix Licensed Patent Covers the Manufacture of such Licensed Product in such Region, then regardless of whether such Licensed Product is actually manufactured in such Region, such Licensed Product shall be deemed to be Covered by a Valid Claim of a Foamix Licensed Patent in such Region.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Generic Competition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If, in a Region within the Territory during the Royalty Term for a Licensed Product, sales of all Generic Products to such Licensed Product in such Region in a Calendar Quarter exceed &#91;***&#93; of the unit volume of all sales of such Licensed Product plus the unit volume of all sales of such Generic Products to such Licensed Product in such country, then the royalty rate payable by Cutia to Foamix with respect to Net Sales of the Licensed Product in such Region for such Calendar Quarter shall be reduced by &#91;***&#93; of the otherwise applicable rate. If, in a Region within the Territory during the Royalty Term for a Licensed Product, sales of all Generic Products to such Licensed Product in such Region in a Calendar Quarter exceed &#91;***&#93; of the unit volume of all sales of such Licensed Product plus the unit volume of all sales of such Generic Products to such Licensed Product in such country, then the royalty rate payable by Cutia to Foamix with respect to Net Sales of the Licensed Product in such Region for such Calendar Quarter shall be &#91;***&#93;. All such determinations of the unit volume of sales shall be based upon a mutually acceptable calculation method using market share data provided by a reputable and mutually agreed upon provider, such as IMS Health.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;Third Party License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. To the extent a Third Party license is necessary to make, use, import, sell, have sold, offer for sale or otherwise Commercialize a Licensed Product in a particular Region, the royalties payable by Cutia to Foamix shall be &#91;***&#93;.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)&#160;Floor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In no circumstances will the royalties payable to Foamix under this Section 8.3 in any Calendar Quarter be reduced, as a result of Section 8.3(c)&#8211;(d) below &#91;***&#93; otherwise payable under Section 8.3. Cutia may carry forward to subsequent Calendar Quarters any deductions that it was not able to deduct as a result of the foregoing provision.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">27</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.4&#160;Royalty Payments&#59; Reports</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Royalties under Section 8.3 shall be calculated and reported for each Calendar Quarter during the Royalty Term and shall be paid within sixty (60)&#160;days after the end of the applicable Calendar Quarter, commencing with the Calendar Quarter in which the First Commercial Sale of a Licensed Product occurs&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if, after further review of its books and records of Net Sales for the Calendar Quarter for which Cutia last paid Foamix royalties, Cutia determines that the royalty rate paid during such Calendar Quarter was (i)&#160;more than &#91;***&#93;, the corresponding overpayment received by Foamix shall be credited to Cutia against royalty payments due for the next Calendar Quarter or (ii) less than &#91;***&#93;, Cutia shall pay the amount owed within sixty (60) days after the determination of such underpayment. Each payment or adjustment of royalties shall be accompanied by a report of Net Sales of Licensed Products by Cutia, its Affiliates and their respective sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including&#58; (a) the amount of gross sales and Net Sales of Licensed Products in the Cutia Territory on a Licensed Product-by-Licensed Product and Region-by-Region basis, (b) an itemized calculation showing the deductions from gross sales (by each major category as set forth in the definition of Net Sales herein) to determine Net Sales, and (c) a calculation of the amount of royalties due to Foamix in U.S. Dollars, including the application of any exchange rate used. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.5&#160;Payment Method&#59; Foreign Exchange</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. All payments owed by Cutia under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Foamix. For clarity, all payments by Cutia to Foamix under this Agreement shall be in U.S. Dollars. The rate of exchange to be used in computing the amount of currency equivalent in U.S. Dollars of any amounts payable in U.S. Dollars by Cutia to Foamix under this Agreement shall be determined and calculated using the average rate of exchange based on OANDA rates for the Calendar Quarter in which the applicable payment is due. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.6&#160;Interest on Late Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Foamix does not receive payment of any sum due to it on or before the due date, interest shall thereafter accrue on the sum due to Foamix until the date of payment at the per annum rate of one percent (1%) over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by Law, whichever is lower, with such interest compounded quarterly. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.7&#160;Records&#59; Audits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia shall, and shall cause its Affiliates and their respective sublicensees to, maintain complete and accurate records in accordance with Accounting Standards and in sufficient detail to permit Foamix to confirm the accuracy of the calculation of royalty payments and the achievement of the milestone event. All payments and other amounts under this Agreement shall be accounted for in accordance with Accounting Standards. Upon reasonable prior notice, such records shall be available for examination during regular business hours for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by an independent certified public accountant selected by Foamix and reasonably acceptable to Cutia, for the sole purpose of verifying the accuracy of the financial reports furnished by Cutia pursuant to this Agreement and any payments with respect thereto. Any such auditor shall not disclose Cutia&#8217;s Confidential Information, except to the extent </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">28</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such disclosure is necessary to verify the accuracy of the financial reports furnished by Cutia or the amount of payments due under this Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.6) from the original due date. Any amount overpaid by Cutia shall be returned to Cutia within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.6) from the original payment date. Foamix shall bear the full cost of such audit&#59; provided, however, if the audit discovers that the royalties payable by Cutia for such period are more than one hundred ten percent&#160;(110%) of the royalties actually paid for such period, then Cutia shall pay the reasonable fees and expenses of such audit.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix shall, and shall cause its Affiliates to, maintain complete and accurate records in accordance with Accounting Standards and in sufficient detail to permit Cutia to confirm the accuracy of the calculation of the Manufacturing Cost of the Licensed Products. All such amounts under this Agreement shall be accounted for in accordance with Accounting Standards. Upon reasonable prior notice, such records shall be available for examination during regular business hours for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by an independent certified public accountant selected by Cutia and reasonably acceptable to Foamix, for the sole purpose of verifying the accuracy of the Manufacturing Cost of the Licensed Products furnished by Foamix. Any such auditor shall not disclose Foamix&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the Manufacturing Cost of the Licensed Products furnished by Foamix. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.6) from the original due date. Any amount overpaid by Cutia shall be returned to Cutia within thirty (30) days from the accountant&#8217;s report, plus interest (as set forth in Section 8.6) from the original payment date. Cutia shall bear the full cost of such audit&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, however, if the audit discovers that the Manufacturing Cost furnished by Foamix over the course of a Fiscal Year is more than one hundred ten percent&#160;(110%) of the Manufacturing Cost actually incurred in such Fiscal Year, then Foamix shall pay the reasonable fees and expenses of such audit.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix shall, and shall cause its Affiliates and its and their respective employees, agents and contractors, maintain complete and accurate records with respect to Foamix&#8217;s pharmacovigilance-related obligations set forth in Section 5.8. Upon reasonable prior notice, such records shall be available for examination during regular business hours for a period of three (3) years from the end of the Fiscal Year to which they pertain, and not more often than once each Fiscal Year, by Cutia or its designee that is reasonably acceptable to Foamix, for the sole purpose of ensuring compliance with NMPA and other Regulatory Authority regulations. Any such records shall be deemed Confidential Information of Foamix.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">8.8&#160;Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Taxes on Income</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">29</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Withholding Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Cutia is required by Laws to make any tax deduction, tax withholding or similar payment from any amount paid or payable by Cutia to Foamix (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) under this Agreement, then (1) in the case of payments to be made by Cutia to Foamix under Section 8.1, Cutia shall pay Foamix the actual stated amount set forth under this Agreement in full and shall also pay any such Tax Withholding (including any additional Tax Withholding required with respect to Cutia&#8217;s additional payments under this Section 8.8) directly to the proper Governmental Authority so that Foamix receives the full amount it would have received had no withholding tax applied and (2) in the case of all other payments to be made by Cutia to Foamix under this Agreement (including Sections 8.2 and 8.3), Cutia shall deduct such Tax Withholding, shall pay Foamix such remaining amount after deduction, and shall pay any such Tax Withholding directly to the proper Governmental Authority. If (A) a Tax Withholding is required, but some or all of the tax required to be withheld and remitted by Cutia is not withheld and&#47;or is not remitted by Cutia, and (B) instead Foamix pays the relevant amount to a Governmental Authority, Cutia shall indemnify Foamix for the full amount of any such tax paid by Foamix and any liability (including penalties, interest and reasonable expenses) arising therefrom or with respect thereto.</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)&#160;Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Resulting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">from</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Action</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Cutia is required to make a payment to Foamix subject to Tax Withholding, then (A) if such Tax Withholding arises as a result of any action by Cutia, including payment of amounts owed under this Agreement by through Cutia&#8217;s Affiliates, an assignment or transfer of this Agreement (or the rights and obligations hereunder), a change in Cutia&#8217;s tax domicile, or any failure on the part of Cutia to comply with applicable Law, (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Withholding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Action</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then subject to Section&#160;8.8(b)(ii), the payment by Cutia (in respect of which such deduction or withholding of Tax is required to be made) shall be increased by the amount necessary (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Additional</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to ensure that Foamix receives an amount equal to the amount that it would have received had no such Cutia Withholding Tax Action occurred, and. All Tax deducted and withheld from any payment made by Cutia, shall be timely remitted to the proper Governmental Authority for the account of Foamix in accordance with applicable Law.</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)&#160;Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Credits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">and</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Repayments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Foamix determines that it has derived full use and benefit from a credit (arising with respect to any Additional Tax) against the payment of any other Tax owed by Foamix, or if Foamix receives a refund of any Additional Tax from the Hong Kong Tax Authority, then Foamix shall, to the extent that it can do so without prejudice to financial or tax position of Foamix, refund to Cutia an amount that, after payment to Cutia, will leave Foamix in no worse of an after-Tax position than it would have been in had it not made the payment to Cutia provided that Cutia has not previously obtained a refund or payment of any such amount from the applicable Tax authority. Nothing in this Agreement shall obligate Foamix to make available to Cutia any Tax returns, financial information, or other documents reasonably determined by Foamix to be confidential.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Tax Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Parties shall cooperate with one another and use reasonable efforts to reduce or eliminate Tax Withholding, VAT, or similar obligations in respect of payments made by Cutia to Foamix under this Agreement (including pursuant to Section 8.1 and Section&#160;8.2). To the extent Cutia is required to deduct and withhold taxes from any payment </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">30</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">to Foamix, Cutia shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Foamix an official tax certificate or other evidence of such withholding sufficient to enable the other Party to claim such payment of taxes from any applicable Government Authority. Foamix shall use Commercially Reasonable Efforts to provide Cutia any tax forms that may be necessary in order for Cutia not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty to the extent Foamix is able to do so. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes, VAT or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or VAT. Specifically, in the event that any tax has been withheld upon a payment made under this Agreement and been remitted by Cutia to a Governmental Authority, if requested by Cutia and if, and for so long as, the Parties acting in good faith mutually agree that there is a reasonable prospect of successfully obtaining a refund of such tax, then Cutia may, at its sole cost and expense, seek a refund of such tax from the proper Governmental Authority. Foamix shall reasonably cooperate with Cutia in the pursuit of such tax refund (including, if required by Law or by the applicable Governmental Authority, permitting Cutia to seek such tax refund in Foamix&#8217;s name and participating in any application or appeal that requires that Foamix be the party applying for such tax refund, solely with Foamix&#8217;s prior written consent)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, (i) Cutia shall assume responsibility for direct payment of lawyers&#8217; and other advisors&#8217; fees and any other costs associated with seeking such refund, and (ii) to the extent that Foamix is ever the party making such payment, Cutia agrees that forthwith upon presentation by Foamix of the applicable invoice(s), Cutia shall refund Foamix&#8217;s reasonable expenses in cooperating in the pursuit of such tax refund. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. All payments due to Foamix from Cutia pursuant to this Agreement shall be paid exclusive of, and without reduction for, any value-added tax (including, for greater certainty, any goods and services tax, harmonized sales tax and any similar provincial sales tax) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">VAT</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) (which, if applicable, shall be payable by Cutia upon receipt of a valid VAT invoice). If Foamix determines that it is required to report any such tax, Cutia shall promptly provide Foamix with applicable receipts and other documentation necessary or appropriate for such report. For clarity, this Section 8.8(d) is not intended to limit Cutia&#8217;s right to deduct VAT in determining Net Sales. Cutia shall and hereby does indemnify Foamix for any VAT that is the responsibility of Cutia pursuant to this Section 8.8(d).</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 9</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INTELLECTUAL PROPERTY MATTERS</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.1&#160;Ownership&#59; License Grants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Background IP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall own and retain all right, title, and interest in and to all Background Intellectual Property Controlled by such Party. For clarity, Foamix&#8217;s Background Intellectual Property excludes Foamix Technology, Foamix Inventions, and Joint Inventions.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">31</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix shall solely own all Data generated by or on behalf of Foamix. Cutia shall solely own all Data generated by or on behalf of Cutia in the Development, Manufacture, and Commercialization of Licensed Products in the Field in the Cutia Territory (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). For good and valuable consideration, the receipt of which is hereby acknowledged, to the maximum extent permitted by Law, Cutia hereby grants to Foamix a perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses through multiple tiers, to use the Cutia Data to Develop, Manufacture, and Commercialize the Licensed Products in the Foamix Territory, and, to the extent the foregoing exclusive license is not permitted by Law, Cutia hereby grants to Foamix a perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses through multiple tiers, to use the Cutia Data to Develop, Manufacture, and Commercialize the Licensed Products in the Foamix Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Product Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions of this Agreement, each Party hereby grants to the other Party a fully paid-up, royalty-free license, with the right to grant sublicenses through multiple tiers, to use Product Materials generated and owned by such Party, for the Development, Manufacture (with respect to Cutia, solely to the extent applicable under Section 7.2 or a Supply Agreement) and Commercialization of Licensed Products in the other Party&#8217;s respective territory during the Term.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Inventorship of any Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws. </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)&#160;Foamix Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Foamix, its Affiliates and their respective sublicensees, including their employees, agents and contractors (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be solely and exclusively owned by Foamix. </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)&#160;Cutia Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any Inventions, including Manufacturing improvements, generated, developed, conceived or reduced to practice (constructively or actually) solely by or on behalf of Cutia, its Affiliates and their respective sublicensees, including their employees, agents and contractors (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be solely and exclusively owned by Cutia. For good and valuable consideration, the receipt of which is hereby acknowledged, to the maximum extent permitted by Law, Cutia shall and hereby does grant to Foamix a perpetual, royalty-free, fully paid-up, exclusive license, with the right to grant sublicenses through multiple tiers, under the Cutia Inventions and all of Cutia&#8217;s intellectual property rights therein and thereto, to Develop, Manufacture, and Commercialize the Licensed Products in the Foamix Territory, and, to the extent the foregoing exclusive license is not permitted by Law, Cutia hereby grants to Foamix a perpetual, royalty-free, fully paid-up, non-exclusive license, with the right to grant sublicenses through multiple tiers, under the Cutia Inventions and all of Cutia&#8217;s intellectual property rights therein and thereto, to Develop, Manufacture, and Commercialize the Licensed Products in the Foamix Territory. </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)&#160;Joint Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any Inventions generated, developed, conceived or reduced to practice (constructively or actually) jointly by or on behalf of Cutia and Foamix, their Affiliates and respective sublicensees, including their employees, agents and contractors </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">32</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Joint Inventions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be jointly owned by Foamix and Cutia. Each Party may use, or allow Third Parties to use, the Joint Inventions without the duty to account to the other Party.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)&#160;Affiliates, Sublicensees and Subcontractors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall ensure that each of its Affiliates, sublicensees and subcontractors under this Agreement has a contractual obligation to disclose to such Party all Data, Product Materials and Inventions generated, invented, discovered, developed, made or otherwise created by them or their employees, agents or independent contractors, and to provide sufficient rights with respect thereto, so that such Party can comply with its obligations under this Article 9. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.2&#160;Patent Prosecution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Definition</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. For the purpose of this Article 9, &#8220;prosecution&#8221; (and all correlative forms of &#8220;prosecution&#8221;) of Patents includes all communication and other interaction with any patent office or patent authority having jurisdiction over a Patent application throughout the world in connection with any pre-grant proceedings and post-grant proceeding, including opposition proceedings. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Foamix Licensed Patents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. As between the Parties, Foamix has the first right, but not obligation, to prepare, file, prosecute and maintain or abandon the Foamix Licensed Patents on a worldwide basis. Foamix shall use Commercially Reasonable Efforts to prepare, file, prosecute, defend and maintain all Foamix Licensed Patents in the Cutia Territory&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Foamix does not represent or warrant that any patent will issue or be granted based on patent applications contained in the Foamix Licensed Patents. After the Effective Date, Foamix shall provide Cutia reasonable opportunity to review and comment on such prosecution efforts regarding the Foamix Licensed Patents in the Cutia Territory, including, (i) promptly providing Cutia with copies of all material communications from any patent authority in the Cutia Territory with respect thereto&#59; (ii)&#160;providing Cutia, for its review and comment, with drafts of any material filings or responses to be made to such patent authorities in a reasonable amount of time in advance of submitting such filings or responses&#59; and (iii)&#160;considering in good faith comments thereto provided by Cutia in connection with the prosecution thereof. Cutia shall reimburse Foamix for all out-of-pocket patent expenses incurred on or after the Effective Date in connection with the preparation, filing, prosecution, and maintenance of all Foamix Licensed Patents in the Cutia Territory. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Step-In Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If Foamix elects to cease prosecution or maintenance of a Foamix Licensed Patent in a Region in the Cutia Territory, Cutia may, at its cost, continue prosecution or maintenance of such Foamix Licensed Patent in such Region. If Cutia elects to continue prosecution or maintenance or elects to file additional applications following Foamix&#8217;s election to cease prosecution or maintenance pursuant to this Section 9.2, Foamix shall transfer the applicable patent files to Cutia or its designee and execute such documents and perform such acts at Foamix&#8217;s expense as may be reasonably necessary to allow Cutia to initiate or continue such filing, prosecution or maintenance at Cutia&#8217;s sole expense. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall provide the other Party with all reasonable assistance and cooperation in the patent prosecution efforts set forth in this Section 9.2, including </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">33</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.3&#160;Patent Term Extensions in the Cutia Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The JDC will discuss and recommend for which, if any, of the Patents within the Foamix Licensed Patents in the Cutia Territory the Parties should seek patent term extensions. Cutia has final decision-making authority with respect to applying for any such patent term extension in the Cutia Territory, and shall act with reasonable promptness in light of the development stage of Licensed Products to apply for any such patent term extension, where it so elects&#59;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> provided, however, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that if only one such Patent can obtain a patent term extension, then the Parties shall consult in good faith to determine which such Patent(s) should be the subject of efforts to obtain a patent term extension. Cutia shall cooperate fully with Foamix in making such filings or actions, including making available all required regulatory Data and Information and executing any required authorizations to apply for such patent term extension. All expenses incurred in connection with activities of Foamix with respect to the Foamix Licensed Patents for which Foamix seeks patent term extensions pursuant to this Section 9.3 shall be borne by Foamix.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.4&#160;Patent Enforcement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Notification&#59; Information Sharing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If either Party becomes aware of any existing or threatened infringement of any Foamix Licensed Patent by the use, offer for sale or sale of a Product or a Competing Product (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), it shall promptly notify the other Party in writing to that effect, and the Parties shall consult with each other regarding any actions to be taken with respect to such Infringement. Each Party shall share with the other Party all Information available to it regarding such alleged Infringement, pursuant to a mutually agreeable &#8220;common interest agreement&#8221; executed by the Parties under which the Parties agree to their shared, mutual interest in the outcome of any suit to enforce the Foamix Licensed Patents against such Infringement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Enforcement Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia has the first right, but not the obligation, to bring an appropriate suit or other action against any Person engaged in Infringement in the Cutia Territory. If Cutia elects to commence a suit to enforce such patent rights against such Infringement, then Foamix may join such enforcement action upon notice to Cutia, and in this case the Parties shall share the cost and expense of such enforcement action equally. If Cutia notifies Foamix that it does not intend to commence a suit to enforce the applicable Foamix Licensed Patent against such Infringement or to take other action to secure the abatement of such Infringement, or fails to take any such action after a period of one hundred twenty (120) days, then Foamix may commence such a suit or take such action, at its sole cost and expense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, in no event shall Cutia take any action that is likely to materially or adversely impact the scope or enforceability of the Foamix Licensed Patents in the Foamix Territory. If Foamix believes in good faith that the commencement of any such suit or action by Cutia would reasonably be likely to have such an impact, then Cutia shall not commence or continue such suit or action without the prior written consent of Foamix. In addition, neither Party shall settle any such suit or action in any manner that would limit or restrict the ability of the other Party to sell the Licensed Products in its respective Territory without the prior written consent of such Party. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">34</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, Foamix has the sole right to bring an appropriate suit or other action against any Person engaged in Infringement in the Foamix Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Collaboration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall provide the other Party with reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense (unless a Party elects to join an enforcement action when the other Party is the enforcing Party, in which case the expenses will be shared equally by the Parties), including joining such action as a party plaintiff if required by Law to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, and shall reasonably consider the other Party&#8217;s comments on any such efforts. The non-Enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;Expenses and Recoveries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The enforcing Party shall be solely responsible for any expenses it incurs as a result of such enforcement action, except that the Parties shall share equally the cost and expense of the enforcement action when the non-enforcing Party elects to join the enforcement action. If the enforcing Party recovers monetary damages in such claim, suit or action brought under Section 9.4(a), such recovery shall be allocated first to the reimbursement of any documented expenses incurred by the Parties in such enforcement action, and any remaining amounts shall be shared by the Parties as follows&#58; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;if Foamix is the enforcing Party&#58; one hundred percent (100%) of the remaining amounts shall be retained by Foamix&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;if Cutia is the enforcing Party and Foamix does not elect to join the enforcement action and share the cost and expense of the enforcement action&#58; one hundred percent (100%) of the remaining amounts shall be retained by Cutia (</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that, such remaining amounts shall be treated as Net Sales)&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;if Cutia is the enforcing Party and Foamix elects to join the enforcement action and share the cost and expense of the enforcement action&#58; fifty percent (50%) of the remaining amounts shall be retained by Cutia, and fifty percent (50%) of the remaining amounts shall be paid to Foamix.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, Foamix shall retain all amounts recovered under any suit or action with respect to Infringement of any Foamix Licensed Patent in the Foamix Territory.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.5&#160;Third Party Infringement Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If the Development, Manufacture, or Commercialization of any Licensed Product in the Field in the Cutia Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against Foamix or Cutia (or their respective Affiliates, licensees or sublicensees) (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party Infringement Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), such Party shall promptly notify the other Party hereto in writing. Foamix may direct and control the defense of such Third Party Infringement Action, at its own expense with counsel of its choice&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Cutia may participate in the defense and settlement thereof, at its own expense with counsel of its choice. In any event, Foamix shall keep Cutia reasonably informed of all material developments in connection with any such Third </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">35</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Party Infringement Action for which Foamix exercises its right to direct and control the defense. Foamix agrees not to settle such Third Party Infringement Action, or make any admissions or assert any position in such Third Party Infringement Action, in a manner that would materially adversely affect the rights or interests of Cutia, without the prior written consent of Cutia, which shall not be unreasonably withheld or delayed. If Foamix does not exercise its right to direct and control the defense of a Third Party Infringement Action that is brought against Cutia, then Cutia may exercise such right and it shall keep Foamix reasonably informed of all material developments in connection with such Third Party Infringement Action, and it shall not settle such Third Party Infringement Action, or make any admissions or assert any position in such Third Party Infringement Action, in a manner that would materially adversely affect the rights or interests of Foamix, without the prior written consent of Foamix, which shall not be unreasonably withheld or delayed. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">9.6&#160;Trademarks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix shall own and retain all right, title, and interest in and to all trademarks associated with any Licensed Product that are owned or Controlled by Foamix worldwide (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensed Mark</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Foamix shall register and maintain all Licensed Marks at Foamix cost and expense, and all goodwill in any such Licensed Mark shall accrue to Foamix. Foamix hereby grants Cutia an exclusive (even as to Foamix), sublicensable right to use all Licensed Marks to Develop, Commercialize, and Manufacture Licensed Products in the Field in the Cutia Territory. Cutia shall, and shall ensure that its Affiliates and its and their respective sublicensees, use the Licensed Marks solely in connection with the Development, Commercialization, and Manufacture of Licensed Products in the Field in the Cutia Territory. For clarity, Foamix has no obligation to register or maintain any trademark in the Cutia Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia may brand Licensed Products in the Cutia Territory using trademarks, logos, and trade names it determines appropriate for Licensed Products, which may vary by Region or within a Region (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Marks</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Cutia shall own all rights in the Product Marks in the Cutia Territory and shall register and maintain the Product Marks in the Cutia Territory that it determines reasonably necessary, at Cutia&#8217;s cost and expense. Cutia shall consult with Foamix and consider Foamix&#8217;s comments in good faith in the selection and design of the Product Marks.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;During the Term, Cutia may request in writing a transfer of ownership of any Licensed Mark in the Cutia Territory from Foamix to Cutia. Foamix shall review such request in good faith, and within thirty (30) days of receipt of Cutia&#8217;s request to transfer ownership of such Licensed Mark, Foamix may, at its sole discretion, approve such request and submit to Cutia a written invoice for all past preparation, filing, prosecution, and maintenance costs incurred by Foamix with respect to such approved Licensed Mark. Cutia shall pay the invoiced amount to Foamix within thirty (30) days of receipt of such invoice. Upon full payment of the invoiced amount pursuant to this Section 9.6(b), Foamix hereby transfers and assigns all its right, title, and interest in and to such Licensed Mark in the Cutia Territory to Cutia.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Notwithstanding anything to the contrary, to the extent required by Law, (i)&#160;Cutia may include Foamix&#8217;s name and corporate logo on the Licensed Product label, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">36</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">packaging, promotional&#47;marketing materials to indicate that the Licensed Product is in-licensed from Foamix, and shall display Foamix&#8217;s name and corporate logo with equal prominence and comparable size, resolution, print quality, and location, as instructed by Foamix from time to time, as Cutia&#8217;s name and corporate logo is displayed, and (ii) Foamix hereby grants to Cutia a non-exclusive, fully paid-up, royalty free, sublicensable license to use Foamix&#8217;s name and corporate logo for the Commercialization of the Licensed Product in the Cutia Territory to the extent consistent with this Section 9.6(d).</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 10</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS AND WARRANTIES&#59; COVENANTS</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.1&#160;Mutual Representations and Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party hereby represents and warrants to the other Party, as follows&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Corporate Existence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. As of the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Corporate Power, Authority and Binding Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. As of the Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder&#59; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder&#59; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and similar Laws affecting creditors&#8217; rights and remedies generally&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;No Conflict</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The execution and delivery of this Agreement, the performance of such Party&#8217;s obligations in the conduct of the Development Plan and the license granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of Law existing as of the Effective Date&#59; (ii) do not and will not conflict with or violate the certificate of incorporation or by-laws (or other constating documents) of such Party&#59; and (iii) do not and will not conflict with, violate, breach or constitute a material default under any contractual obligations of such Party or any of its Affiliates existing as of the Effective Date&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;No Violation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Neither such Party nor any of its Affiliates is under any obligation to any Person, contractual or otherwise, that is in violation of the terms of this Agreement or that would impede the fulfillment of such Party&#8217;s obligations hereunder&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)&#160;No Debarment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Neither such Party nor any of its Affiliates is debarred or disqualified under the Act or comparable Laws outside the U.S.&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(f)&#160;No Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. No authorization, consent, approval of a Third Party, nor to such Party&#8217;s knowledge, any license, permit, exemption of or filing or registration with or notification to any court or Governmental Authority is or will be necessary for the (i) valid </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">37</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">execution and delivery of this Agreement by such Party&#59; or (ii) the consummation by such Party of the transactions contemplated hereby.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.2&#160;Additional Representations and Warranties of Foamix</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix represents and warrants to Cutia, as of the Effective Date, as follows&#58; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Title&#59; Encumbrances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. (i) It has sufficient legal or beneficial title or ownership or license, free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreement, encumbrances, charges or claim of any kind, of the Foamix Technology to grant the licenses to Cutia as purported to be granted pursuant to this Agreement&#59; (ii) to Foamix&#8217;s knowledge, no Third Party has taken any action before the United States Patent and Trademark Office or a court, or any counterpart thereof outside the U.S., claiming legal or beneficial title or ownership or license of any Foamix Technology&#59; and (iii) it has not received any written notice from any Third Party claiming legal or beneficial title or ownership or license of any Foamix Technology&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Compliance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. To Foamix&#8217;s knowledge, Foamix has complied in all respects with and is not in breach, violation or noncompliance of any applicable Laws with respect to its ownership, use, or Manufacture of the Licensed Products. To Foamix&#8217;s knowledge, no employee of Foamix has breached any non-use or confidentiality obligations under any agreement with his or her respective prior employers, or has otherwise misappropriated any trade secret or confidential information of such prior employers, in each case relating to the Foamix Technology&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Intellectual Property Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Foamix Technology includes all intellectual property rights Controlled by Foamix that (i) are necessary or reasonably useful for the Development or Commercialization of the Licensed Product by Cutia in the Cutia Territory in accordance with the terms of this Agreement as contemplated on the Effective Date or (ii) were generated, developed, conceived, reduced to practice (constructively or actually) or used by or on behalf of Foamix or its Affiliates in the Development or Commercialization of Licensed Product. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;The Information that Foamix has disclosed to Cutia, together with the Foamix Licensed Know-How set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, constitute all material Information (other than CMC Information) in its or its Affiliates&#8217; possession regarding the Foamix Technology and Licensed Products (including all clinical trial and safety data, databases and analyses)&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;To Foamix&#8217;s knowledge (without any inquiry or requirement to conduct any freedom-to-operate patent search), (i) the Development of Amzeeq&#8482; in the manner contemplated by the Initial Development Plan and (ii) the Commercialization of Amzeeq&#8482; in the same manner as Amzeeq&#8482; is commercialized by Foamix in the U.S., in each case of (i) and (ii) does not infringe or misappropriate any intellectual property rights of any Third Party in the Cutia Territory.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(f)&#160;Notice of Infringement or Misappropriation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. To Foamix&#8217;s knowledge, the Development, Manufacture and Commercialization of the Licensed Products ongoing as of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">38</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Effective Date does not infringe or misappropriate any intellectual property rights of any Third Party in the Foamix Territory. It has not received any written notice from any Third Party asserting or alleging that (i) any research, development, manufacture, or commercialization of a Licensed Product by Foamix prior to the Effective Date infringed or misappropriated the intellectual property rights of such Third Party, or (ii) the Development, Manufacture, or Commercialization of the Licensed Products in the Cutia Territory would infringe or misappropriate the intellectual property rights of such Third Party&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(g)&#160;Non-Infringement of Rights by Third Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. To Foamix&#8217;s knowledge, no Third Party is infringing or misappropriating, or has infringed or misappropriated the Foamix Technology as of the Effective Date&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(h)&#160;No Proceeding</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. There is no pending, and to Foamix&#8217;s knowledge, no threatened, adverse action, suit or proceeding against Foamix involving any Foamix Technology or a Licensed Product&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(i)&#160;No Conflicts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix has not entered, and shall not enter, into any agreement with any Third Party that is in conflict with the rights granted to Cutia under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting the rights granted to Cutia under this Agreement, or that would otherwise materially conflict with or adversely affect Cutia&#8217;s rights under this Agreement&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(j)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix hereby covenants to Cutia that neither Foamix nor any of its Affiliates or it or their respective contractors will employ or use the services of any Person who is debarred or disqualified under the Act, or comparable Laws outside the U.S., in connection with activities relating to any Licensed Product&#59; and in the event that Foamix becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to Foamix or any of its Affiliates with respect to any activities relating to any Licensed Product, Foamix will immediately notify Cutia in writing and Foamix will cease, or cause its Affiliate or it or their respective contractors to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to any Licensed Product&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(k)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Foamix hereby covenants to Cutia that neither Foamix nor any of its Affiliates, nor any of their respective employees, agents or contractors shall use any confidential information obtained from any Third Party (including any prior employer), directly or indirectly, whether obtained prior to the Effective Date or during the Term, in connection with activities performed under this Agreement, and Foamix shall be solely responsible and liable for, and shall indemnify Cutia pursuant to Section 11.1 in connection with, any breach of this covenant by Foamix, any of its Affiliates, or their respective employees, agents or contractors. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.3&#160;Additional Representations, Warranties and Covenants of Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia represents and warrants to Foamix that, as of the Effective Date, to Cutia&#8217;s knowledge as of the Effective Date, Cutia does not Control any Patent that is necessary to make, use, import, offer for sale or sell Licensed Products.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">39</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia hereby covenants to Foamix that neither Cutia nor any of its Affiliates or it or their respective sublicensees will employ or use the services of any Person who is debarred or disqualified under the Act, or comparable Laws outside the U.S., in connection with activities relating to any Licensed Product&#59; and in the event that Cutia becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to Cutia or any of its Affiliates with respect to any activities relating to any Licensed Product, Cutia will immediately notify Foamix in writing and Cutia will cease, or cause its Affiliate or it or their respective sublicensee to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to any Licensed Product.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia hereby covenants to Foamix that neither Cutia nor any of its Affiliates, or its or their sublicensees, shall exploit in any manner any Licensed Product outside of the scope of the licenses expressly granted to Cutia under this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Cutia hereby covenants to Foamix that neither Cutia nor any of its Affiliates, nor any of their respective employees, agents or contractors shall use any confidential information obtained from any Third Party (including any prior employer), directly or indirectly, whether obtained prior to the Effective Date or during the Term, in connection with activities performed under this Agreement, and Cutia shall be solely responsible and liable for, and shall indemnify Foamix pursuant to Section 11.2 in connection with, any breach of this covenant by Cutia, any of its Affiliates, or their respective employees, agents or contractors.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.4&#160;Compliance with Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Each Party shall, and shall ensure that its Affiliates and their respective sublicensees will, comply in all respects with Anti-Corruption Laws, Proper Conduct Practices and all Law in the Development, Manufacturing, and Commercialization of Licensed Products and performance of its obligations under this Agreement, including the ICH, GCP, GLP and any Regulatory Authority and Governmental Authority health care programs having jurisdiction in such Party&#8217;s respective territory, each as may be amended from time to time. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Each Party shall immediately notify the other Party if it has any information or suspicion that there may be a violation of any Laws (including Anti-Corruption Laws) in connection with its performance under this Agreement or the Development or Commercialization of any Licensed Product hereunder. In the event that either Party has violated or been suspected of violating any of its obligations, representations, warranties or covenants in Section 10.4(a), such Party will take reasonable actions to remedy such breach and to prevent further such breaches from occurring. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Notwithstanding the foregoing, each Party will have the right, upon reasonable prior written notice and during the other Party&#8217;s regular business hours, to audit the other Party&#8217;s books and records in the event that a suspected violation of any Anti-Corruption Law needs to be investigated (in such Party&#8217;s reasonable, good-faith discretion). Such audit shall be conducted by such Party&#8217;s audit team comprised of qualified auditors who have received anticorruption training.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, a credible finding, after a reasonable investigation, of any breach of Section 10.4(a) or 10.4(b) with respect to any Anti-Corruption Law, shall be deemed a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">40</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">material breach of this Agreement and allow the non-breaching Party to terminate this Agreement in accordance with Section 13.4.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.5&#160;No Other Representations or Warranties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY OR ITS AFFILIATES, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. FOR CLARITY AND WITHOUT LIMITING THE FOREGOING, FOAMIX MAKES NO REPRESENTATION OR WARRANTY CONCERNING THE LICENSED PRODUCTS OR FOAMIX TECHNOLOGY EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10. </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 11</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INDEMNIFICATION</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.1&#160;Indemnification by Foamix</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix shall defend, indemnify, and hold Cutia and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) harmless from and against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys&#8217; fees (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Losses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to which any Cutia Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of Licensed Products in the Foamix Territory (except to the extent that any such activities are conducted by or on behalf of Cutia or its Affiliates as permitted under this Agreement), (b) the breach of any of Foamix&#8217;s obligations under this Agreement, including Foamix&#8217;s representations, warranties or covenants set forth herein, or (c)&#160;the willful misconduct or negligent acts of any Foamix Indemnitee. The foregoing indemnity obligation shall not apply to the extent that (i) the Cutia Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Foamix&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Cutia is obligated to indemnify the Foamix Indemnitees under Section&#160;11.2.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.2&#160;Indemnification by Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall defend, indemnify, and hold Foamix and its Affiliates and their respective officers, directors, employees, and agents (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) harmless from and against any and all Losses to which any Foamix Indemnitee may become subject as a result of any Claims arising out of, based on, or resulting from (a) the Development, Manufacture, or Commercialization of Licensed Products by or on behalf of Cutia or its Affiliates or sublicensees on or after the Effective Date (except to the extent that any such activities are conducted by or on behalf of Foamix or its Affiliates as permitted under this Agreement) (including any Third Party Infringement Actions), (b) the breach of any of Cutia&#8217;s obligations under this Agreement, including Cutia&#8217;s representations, warranties, or covenants set forth herein, (c) actions taken by Cutia as Foamix&#8217;s local regulatory agent in the Cutia Territory, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">41</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or (d) the willful misconduct or negligent acts of any Cutia Indemnitee. The foregoing indemnity obligation shall not apply to the extent that (i) the Foamix Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Cutia&#8217;s defense of the relevant Claim is materially prejudiced by such failure, or (ii) any Claim arises from, is based on, or results from any activity or occurrence for which Foamix is obligated to indemnify the Cutia Indemnitees under Section&#160;11.1.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.3&#160;Indemnification Procedures</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Party claiming indemnity under this Article 11 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnifying Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) promptly after learning of such Claim and shall offer control of the defense of such Claim to the Indemnifying Party. The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Indemnifying Party may assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle or compromise any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b)&#160;the Indemnifying Party shall remain responsible to indemnify the Indemnified Party as provided in this Article 11. Notwithstanding anything contained in the foregoing to the contrary, the provisions of Section 9.5 shall govern the defense of any Third Party Infringement Actions. Additionally, in the event that Foamix has elected to defend any such Third Party Infringement Action, then Cutia shall not be obligated to indemnify Foamix for any Claims related to such Third Party Infringement Action&#59; rather, the Parties shall share such Claims equally.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.4&#160;Limitation of Liability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT WILL EITHER PARTY&#8217;S TOTAL LIABILITY UNDER THIS AGREEMENT EXCEED THE AMOUNT PAID OR PAYABLE BY CUTIA TO FOAMIX UNDER THIS AGREEMENT. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION&#160;11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION&#160;11.1 OR 11.2, A PARTY&#8217;S GROSSLY NEGLIGENT OR INTENTIONAL BREACH OF THIS AGREEMENT, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF ITS EXCLUSIVITY OBLIGATIONS IN SECTION 2.6 OR ITS CONFIDENTIALITY OBLIGATIONS IN SECTION&#160;12.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">42</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">11.5&#160;Insurance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated. Such insurance shall not be construed to create a limit of either Party&#8217;s liability with respect to its indemnification obligations under this Article 11. Each Party shall provide the other Party with written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30) days prior to the cancellation, non&#30;renewal or material change in such insurance.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 12</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONFIDENTIALITY</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.1&#160;Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party agrees that, during the Term and for a period of ten (10) years thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential Information of the other Party, except to the extent expressly agreed in writing by the Parties. The foregoing confidentiality and non-use obligations shall not apply to any portion of the other Party&#8217;s Confidential Information that the receiving Party can demonstrate by competent written proof&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;was disclosed to the receiving Party or its Affiliate without any confidentiality obligations by a Third Party who, to the Party&#8217;s knowledge, had a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;was independently discovered or developed by the receiving Party or its Affiliate without use of or reference to the other Party&#8217;s Confidential Information, as evidenced by a contemporaneous writing.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For purposes of this Section 12.1(b)&#8211;(c), Confidential Information disclosed under this Agreement shall not be deemed to be within such exceptions unless such information is readily accessible to the public in a written publication, and such exceptions shall not include information the substance of which must be pieced together from a number of different publications or other sources.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">43</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.2&#160;Authorized Disclosure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding the obligations set forth in Section 12.1, a Party may disclose the other Party&#8217;s Confidential Information and the terms of this Agreement to the extent&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;such disclosure is reasonably necessary (i) for the filing or prosecuting of Patent rights as contemplated herein&#59; (ii) to comply with the requirements of Regulatory Authorities with respect to obtaining and maintaining Regulatory Approval of Licensed Product&#59; or (iii) for the prosecuting or defending litigation as contemplated herein&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;such disclosure is reasonably necessary to its or its Affiliate&#8217;s employees, agents, consultants, contractors, licensees or sublicensees on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights hereunder&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that in each case, the disclosees are bound by written obligations of confidentiality consistent with those contained in this Agreement&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other financial or commercial partner for the sole purpose of evaluating or carrying out an actual or potential investment, acquisition or other business relationship&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that in connection with such disclosure, such Party shall inform each disclosee of the confidential nature of such Confidential Information and require each disclosee to treat such Confidential Information as confidential&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;such disclosure is reasonably necessary to comply with Laws, including regulations or rules promulgated by applicable securities commissions (or other securities regulatory authorities), security exchanges, court order, administrative subpoena or order.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 12.2(a) or 12.2(d), such Party shall promptly notify the other Party of such required disclosure, to the extent that it is legally authorized or permitted to so, and shall use reasonable efforts to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.3&#160;Publicity&#59; Terms of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;The Parties agree that the terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in this Section 12.3. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;The Parties have agreed upon in principle the initial press release to announce the execution of this Agreement in substantially the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit E, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">which shall be finalized upon mutual agreement by the Parties before release. After such initial press release, if either Party desires to make a public disclosure concerning the terms of this Agreement, such Party shall give reasonable prior advance notice of the proposed text of such disclosure to the other Party for its prior review and approval (except as otherwise provided herein), which approval shall not be unreasonably withheld, conditioned, or delayed. A Party commenting on such a proposed disclosure shall provide its comments, if any, within ten (10) </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">44</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Business Days after receiving the proposed disclosure for review (or such shorter period of time as necessitated by regulatory requirements). Each Party may make a press release or other public disclosure regarding the achievement of the milestone, the achievements of Regulatory Approval in the Cutia Territory as they occur or the occurrence of other events that affect either Party&#8217;s rights or obligations under this Agreement, in each case subject only to the review procedure set forth in the preceding sentences. In relation to the other Party&#8217;s review of such an announcement, such other Party may make specific, reasonable comments on such proposed press release within the prescribed time for commentary. Neither Party is required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 12.3. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Either or both Parties or their Affiliates may be obligated to file under Laws a copy of this Agreement with Governmental Authorities, including the U.S. Securities and Exchange Commission (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SEC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Each Party and its Affiliates may make such a required filing, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that it requests confidential treatment of the commercial terms and sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party or its Affiliate intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s timely comments thereon to the extent consistent with the legal requirements, with respect to the filing Party or Affiliate, governing disclosure of material agreements and material information that must be publicly filed.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;Each Party may disclose the existence and terms of this Agreement to bona fide potential or actual investors, advisors, lenders, and research collaborators, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">each such entity is bound by confidentiality obligations no less stringent than this Article 12.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.4&#160;Technical Publication</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia may not publish peer reviewed manuscripts, or provide other forms of public disclosure, including abstracts and presentations, of results of studies carried out under the Development Plan, or otherwise pertaining to the Licensed Products or Foamix Licensed Know-How, without the prior written consent of Foamix. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">12.5&#160;Equitable Relief</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party acknowledges that its breach of this Article 12 will cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in an action at law. By reasons thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to seek preliminary and permanent injunctive and other equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential Information set forth in this Article 12 by the other Party. </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 13</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TERM AND TERMINATION</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.1&#160;Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 13, shall remain in effect until the expiration of the Royalty Term of the last Licensed Product on a Region-by-Region basis (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Term</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Upon </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">45</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the expiration (but not early termination) of this Agreement for all Licensed Products in a Region, the licenses granted hereunder by Foamix to Cutia shall become non-exclusive, fully paid-up, royalty-free, and perpetual for such Region. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.2&#160;Termination by Cutia</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia may terminate this Agreement in its entirety (a) at any time for convenience upon ninety (90) days&#8217; prior written notice given to Foamix, or (b) upon prior written notice given to Foamix if a Regulatory Authority in the Cutia Territory has ordered Cutia to stop all sales of Licensed Products in the Cutia Territory due to a safety concern&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Cutia has, for a period of ninety (90) days prior to the provision of such notice by Cutia, used Commercially Reasonable Efforts to resolve such safety concern.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.3&#160;Termination by Foamix</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Foamix may terminate this Agreement in its entirety upon sixty (60) days&#8217; prior written notice to Cutia, if Cutia or its Affiliates or their respective sublicensees (directly or indirectly, individually or in association with any other Person) challenges the validity, enforceability or scope of any Foamix Licensed Patent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in a litigation or other court proceeding, unless during such sixty (60)-day period the subject challenge is permanently dismissed or withdrawn and is not thereafter reinstituted or continued&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that in the event Cutia&#8217;s sublicensee initiates such challenge, Foamix may not terminate this Agreement if (i) Cutia successfully causes such sublicensee to withdraw such challenge within such sixty (60)-day period, or (ii) Cutia successfully terminates such sublicense and provides written evidence of such termination to Foamix within such sixty (60)-day period.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.4&#160;Termination for Breach</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party may terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material breach within sixty (60) days from the date of such notice&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that, such cure period shall be extended for up to an additional sixty (60) days upon the breaching Party providing a written plan that reasonably demonstrates the need for such additional time and continuing to use Commercially Reasonable Efforts to cure such breach. If either Party disputes (a) whether such material breach has occurred, or (b)&#160;whether the defaulting Party has cured such material breach, the Parties shall promptly resolve the Dispute under Article 14. During the pendency of such a Dispute, all of the terms and conditions of this Agreement remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.5&#160;Termination Due to Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof, or if the other Party proposes or becomes a Party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">46</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.6&#160;Effect of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Upon any termination of this Agreement, the following shall apply (in addition to any other rights and obligations under this Agreement with respect to such termination)&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Licenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. All licenses and other rights granted by Foamix to Cutia under this Agreement shall terminate, including all sublicenses granted by Cutia unless such sublicenses are assumed by Foamix pursuant to Section 2.1(c), which shall survive such termination. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Wind-Down</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Cutia shall (i) responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced and (ii) at Foamix&#8217;s written election, (A) transfer to Foamix or its designee any such clinical studies to the extent permitted under Laws and accepted pharmaceutical industry norms and ethical practices, or (B) if reasonably practicable and not adverse to patient safety, complete such trials and Foamix shall reimburse Cutia its reasonable, out-of-pocket costs associated therewith. For clarity, except as provided for above, Cutia may transfer to Foamix or its designee or wind-down any ongoing clinical trials prior to the date of termination in accordance with accepted pharmaceutical industry norms and ethical practices and Cutia will be responsible for any costs associated with such transfer or wind-down.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Regulatory Materials&#59; Data</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Unless this Agreement is terminated by Cutia pursuant to Section 13.4 or Section 13.5, Cutia shall (i) provide and assign to Foamix or its designee all Regulatory Materials, including Regulatory Approvals, for the Licensed Products to the extent possible under Law in the Cutia Territory, (ii) promptly provide and assign to Foamix all Data, including pharmacovigilance data, generated by or on behalf of Cutia, and (iii) promptly return or destroy (and certify such destruction in writing), at Foamix&#8217;s election, all Confidential Information of Foamix. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(d)&#160;Transition Assistance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Upon Foamix&#8217;s reasonable request, (i) Cutia shall provide such assistance as may be reasonably necessary or useful for Foamix to continue the Development, Manufacture, and Commercialization of Licensed Products in the Cutia Territory, to the extent Cutia or its Affiliate is then performing or having performed such activities, including upon the reasonable request of Foamix, assigning (or using Commercially Reasonable Efforts to amend as appropriate) any agreements or arrangements Cutia or its Affiliate have with any Third Party for the Development, Manufacture, distribution, or Commercialization of Licensed Products&#59; and (ii) Cutia shall provide Foamix with copies of any promotional and marketing materials generated by or on behalf of Cutia with respect to Licensed Products prior to the effective date of termination. Cutia shall reimburse Foamix&#8217;s costs and expenses in connection with such transition assistance, unless this Agreement is terminated by Cutia pursuant to Section 13.4 or Section 13.5.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(e)&#160;Inventory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In the event that this Agreement is terminated in its entirety, Foamix may purchase any and all of the inventory of Licensed Products held by Cutia or its Affiliates or sublicensees as of the date of termination, at a price equal to the transfer price paid by Cutia to Foamix for such inventory. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">47</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(f)&#160;Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Unless this Agreement is terminated by Cutia pursuant to Section 13.4 or Section 13.5, with respect to all Patents, Product Marks, and other intellectual property rights Controlled by Cutia that are necessary for the Development, Manufacture, or Commercialization of Licensed Products prior to the effective date of termination, for good and valuable consideration, the receipt of which is hereby acknowledged, Cutia hereby grants to Foamix, effective upon the effective date of termination&#58; (i) to the maximum extent permitted by Law, a worldwide, exclusive, perpetual, royalty-free license, with the right to sublicense through multiple tiers, under such Patents, Product Marks, and other intellectual property rights to make, have made, import, use, offer for sale, sell, or otherwise exploit the Licensed Products, and (ii) to the extent the foregoing exclusive license is not permitted by Law, a worldwide, non-exclusive, perpetual, royalty-free license, with the right to sublicense through multiple tiers, under such Patents, Product Marks, and other intellectual property rights to make, have made, import, use, offer for sale, sell, or otherwise exploit the Licensed Products.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.7&#160;Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any expiration or termination of this Agreement shall not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of expiration or termination. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Agreement&#58; Sections 2.4 (No Implied Licenses), 8.5 (Payment Method&#59; Foreign Exchange), 8.6 (Interest on Late Payments), 8.7 (Records&#59; Audits), 8.8 (Taxes), 9.1 (Ownership&#59; License Grants), 10.5 (No Other Representations or Warranties), 13.6 (Effects of Termination), 13.7 (Survival), and 13.8 (Termination Not Sole Remedy), and Articles 1 (Definitions) (to the extent such terms are used in other surviving provisions), 11 (Indemnification) (to the extent the cause of action for such indemnification obligation arose prior to the effective date of expiration or termination), 12 (Confidentiality), 14 (Dispute Resolution), and 15 (Miscellaneous).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">13.8&#160;Termination Not Sole Remedy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. </font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 14</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DISPUTE RESOLUTION</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.1&#160;Disputes&#59; Internal Resolution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. It is the objective of the Parties to establish procedures to facilitate the resolution of any and all disputes that may arise out of or in connection with this Agreement (each a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Dispute</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) in an expedient manner by mutual cooperation. To accomplish this objective, the Parties agree that, except as otherwise provided in Section 3.3, in the event of such a Dispute, including any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, and the Parties are unable to resolve such Dispute within thirty (30) days after such Dispute is first identified by either Party in writing to the other, the Parties shall refer such Dispute to the Executive Officers for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. If the dispute is not resolved within such thirty (30) days, either Party may commence </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">48</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">arbitration with respect to the subject matter of the Dispute and with respect to any other claims it may have and thereafter neither Party will have any further obligation under this Section 14.1. Any Dispute concerning the propriety of the commencement of the arbitration or the applicability of the Agreement to arbitrate shall be finally settled by the arbitral tribunal. Notwithstanding the foregoing, and without waiting for the expiration of any such thirty (30)-day periods, Foamix and Cutia may each apply to any court of competent jurisdiction for appropriate interim or provisional relief, as necessary to protect the rights or property of that Party. </font></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">14.2&#160;Arbitration&#59; Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(a)&#160;Arbitration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to Section 14.1, all Disputes, including existence, validity, interpretation, performance, breach or termination thereof, shall be submitted to and finally resolved by arbitration administered by the International Court of Arbitration of the International Chamber of Commerce (ICC) under the Rules of Arbitration of the International Chamber of Commerce (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Rules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The seat, or legal place, of arbitration shall be Hong Kong. The language of the arbitration shall be English. The arbitration shall be conducted by a tribunal of three (3) arbitrators. Each Party shall nominate one (1) arbitrator, and the two (2) party nominated arbitrators shall jointly nominate, within fifteen (15) days of the second arbitrator&#8217;s appointment, the third arbitrator who shall serve as the presiding arbitrator and shall be of neutral nationality. Each arbitrator must have significant business or legal experience in the pharmaceutical business. An arbitrator shall be deemed to meet this qualification unless a Party objects within ten (10) days after the arbitrator is nominated. The Parties shall engage in discovery of information and evidence that is or might be relevant to the claims, defenses, and issues in the Dispute, including by means of discovery in the form of requests for documents (including electronically stored information). After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators shall render their award within six (6) months of the final arbitration hearing or the final post-hearing submissions unless the Parties jointly request an extension, or the arbitral tribunal determines in a reasoned decision that the interest of justice or the complexity of the case requires that such a limit be extended. The arbitral tribunal shall not have the power to award damages excluded pursuant to Section 11.4 of this Agreement, and any arbitral award that purports to award such damages is expressly prohibited. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(b)&#160;Arbitral Award. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The award shall be final and binding, and the Parties undertake to carry out the award without delay. Judgment on the award so rendered may be entered in any court of competent jurisdiction. Each Party shall bear one-half (&#189;) of all ICC administrative costs and the fees and costs of the arbitrators. Notwithstanding the foregoing, each Party shall bear its own attorneys&#8217; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party. The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (i) to the extent that disclosure may be required of a party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (ii) with the consent of all Parties, (iii) where needed for the preparation or presentation of a claim or defense in this arbitration, (iv) </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">49</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">where such information is already in the public domain other than as a result of a breach of this clause, or (v) by order of the arbitral tribunal upon application of a Party.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">(c)&#160;Governing Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement and all Disputes shall be governed by and construed in accordance with the laws of the State of New York, USA, without giving effect to any choice of law rules or principles.</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE 15</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MISCELLANEOUS</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.1&#160;Entire Agreement&#59; Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the Confidentiality Agreement. The foregoing shall not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under the Confidentiality Agreement. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.2&#160;Force Majeure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued only for so long as (a) the condition constituting force majeure continues and (b) the nonperforming Party takes all reasonable efforts to remove the condition. For purposes of this Agreement, force majeure includes conditions beyond the reasonable control of the applicable Party, which may include an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, action or inaction of any Governmental Authority, and failure of plant or machinery. Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure persists for more than ninety (90) days, then the Parties will discuss in good faith the modification of the Parties&#8217; obligations under this Agreement in order to mitigate the delays caused by such force majeure.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.3&#160;Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and shall be deemed to have been given for all purposes (a) when received, if hand-delivered or a reputable courier service, (b) five (5) Business </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">50</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Days after mailing, if mailed by first class certified or registered airmail, postage prepaid, return receipt requested, (c) or upon receipt if sent by electronic mail, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that such notice is also sent by a reputable courier service or first class certified or registered airmail, postage prepaid, return receipt requested. </font></div><div style="text-indent:31.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Foamix&#58; &#160;&#160;&#160;Foamix Pharmaceuticals Ltd. </font></div><div style="padding-left:172.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> 2 Holzman Street,</font></div><div style="padding-left:172.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Rehovot Science Park</font></div><div style="padding-left:172.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Rehovot Israel</font></div><div style="text-indent:27pt;padding-left:144pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Attn&#58; General Counsel</font></div><div><font><br></font></div><div style="padding-left:31.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">with copies to (which shall not constitute notice)&#58; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-171.35pt;padding-left:171.35pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cooley LLP</font></div><div style="padding-left:171pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">11951 Freedom Drive #1500 </font></div><div style="text-indent:-171.35pt;padding-left:171.35pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reston, VA 20190</font></div><div style="text-indent:-171.35pt;padding-left:171.35pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; Kenneth Krisko</font></div><div style="text-indent:-171.35pt;padding-left:171.35pt;text-align:justify;"><font><br></font></div><div style="text-indent:-139.5pt;padding-left:172.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Cutia&#58; &#160;&#160;          Cutia Therapeutics (HK) Limited</font></div><div style="text-indent:-36pt;padding-left:172.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNIT 402, 4&#47;F FAIRMONT HSE </font></div><div style="padding-left:172.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NO 8 COTTON TREE DRIVE ADMIRALTY </font></div><div style="padding-left:172.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">HONG KONG</font></div><div style="text-indent:171pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attn&#58; CEO</font></div><div style="text-indent:-136.1pt;padding-left:172.1pt;"><font><br></font></div><div style="text-indent:-139.5pt;padding-left:172.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">with copies to (which shall not constitute notice)&#58;</font></div><div style="padding-left:171pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Greenberg Traurig LLP</font></div><div style="padding-left:171pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">One International Place, Suite 2000</font></div><div style="padding-left:171pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Boston, MA 02110 </font></div><div style="padding-left:171pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Fang Xie</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.4&#160;No Strict Construction&#59; Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is disjunctive but not necessarily exclusive. The term &#8220;including&#8221; as used herein means including, without limiting the generality of any description preceding such term.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.5&#160;Assignment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that either Party may make such an assignment, in whole or in part, without the other Party&#8217;s consent (a) to an Affiliate of such Party or (b) to a Third Party in connection with a Change of Control. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">51</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">assignment or attempted assignment by either Party in violation of the terms of this Section&#160;15.5 shall be null, void and of no legal effect.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.6&#160;Performance by Affiliates</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.7&#160;Further Actions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.8&#160;Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.9&#160;No Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Any delay in enforcing a Party&#8217;s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.10&#160;Independent Contractors</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.11&#160;English Language</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.12&#160;Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Agreement may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The signatures of all the Parties do not need to be on the same counterpart for it to be effective. Delivery of an executed counterpart&#8217;s signature page of this Agreement, by electronic mail in portable document format (.pdf) or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, has the same effect as delivery of an executed original of this Agreement.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">52</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">15.13&#160;Rights in Bankruptcy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. All rights and licenses granted under or pursuant to this Agreement by one Party to the other Party are, and otherwise will be deemed to be, for purposes of Section&#160;365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, licenses of right to &#8220;intellectual property&#8221; as defined under Section&#160;101 of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. Each Party will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party to this Agreement under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and same, if not already in its possession, will be promptly delivered to it (i)&#160;upon any such commencement of a bankruptcy or insolvency proceeding upon its written request therefor, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii)&#160;if not delivered under (i) above, following the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#123;Signature Page Follows&#125;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;">53</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><div id="i20edfcbad05f4cf6bdbde2ee63725d4c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">In Witness Whereof, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Parties have executed this License Agreement in duplicate originals by their duly authorized officers as of the Effective Date.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Pharmaceuticals Ltd.</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#47;s&#47; David Domzalski</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; David Domzalski</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; Chief Executive Officer</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Cutia Therapeutics (HK) Limited</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; &#47;s&#47; Chung Sau Yin</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Chung Sau Yin</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; Director</font></div></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">By&#58;&#47;s&#47; David Domzalski&#160;By&#58; &#47;s&#47; Chung Sau Yin</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Name&#58; David Domzalski&#160;Name&#58; Chung Sau Yin&#160;</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Title&#58; Chief Executive Officer&#160;Title&#58; Director</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit A</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Foamix Licensed Patents</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit B</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Initial Transfer of Foamix Licensed Know-How</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><div id="i20edfcbad05f4cf6bdbde2ee63725d4c_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit C</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Initial Development Plan</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><div id="i20edfcbad05f4cf6bdbde2ee63725d4c_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit D</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Supply Agreement Terms</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit E</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Press Release</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">222330578 v11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102agreementno1toarc.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1f3c3afd13c0485c8cc7cdc30b611bc4_36"></div><div style="min-height:72pt;width:100%;"><div style="padding-right:6pt;text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.2</font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">AMENDMENT NO. 1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">TO AMENDED AND RESTATED </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">CREDIT AGREEMENT AND GUARANTY</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT AND GUARANTY, dated as of August 5, 2020 (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is by and among Foamix Pharmaceuticals Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Borrower</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Foamix Pharmaceuticals Ltd., an Israeli limited liability company (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Israeli Guarantor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Menlo Therapeutics Inc., a Delaware corporation (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Parent Guarantor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), the Lenders signatory hereto (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Lenders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and Perceptive Credit Holdings II, LP, a Delaware limited partnership, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Administrative Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Reference is made to the Amended and Restated Credit Agreement and Guaranty, dated as of March 9, 2020, among the Borrower, the Israeli Guarantor, the Parent Guarantor, certain subsidiaries of the Parent Guarantor from time to time party thereto, the Lenders from time to time party thereto and the Administrative Agent (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Credit Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement, as amended by this Amendment (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Amended Credit Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">A.&#160;WHEREAS, the Borrower has requested that the Administrative Agent and Majority Lenders agree to certain amendments and modifications of Section 10.02 of the Credit Agreement&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">B. &#160;WHEREAS, the Lenders party hereto constitute Majority Lenders&#59; and</font></div><div style="text-indent:36pt;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">C.&#160;WHEREAS, the Administrative Agent and the Majority Lenders have agreed to allow for the amendments and modifications to Section 10.02 of the Credit Agreement set forth herein on the terms and subject to the conditions set forth herein.</font></div><div><font><br></font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, the parties hereto hereby agree as follows&#58;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE I</font></div><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDMENTS TO CREDIT AGREEMENT</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 1.01.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendments to the Credit Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160; As of the Amendment Effective Date (as defined below), the Credit Agreement shall be amended as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;The following new defined terms shall be added to Section 1.01 of the Credit Agreement and inserted in appropriate alphabetical order&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Amendment No. 1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that certain Amendment No. 1 to Amended and Restated Credit Agreement and Guaranty, dated as of August 5, 2020, by and among the Borrower, the Parent Guarantor, the Israeli Guarantor, the Administrative Agent and the Lenders party thereto.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:108%;">Amendment No. 1 Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:108%;">&#8221; means August 5, 2020. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">1271711.03-NYCSR01A - MSW</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Section 10.02 of the Credit Agreement is hereby deleted in its entirety and replaced by inserting the following new text&#58;</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">10.02&#160;Minimum Net Revenue.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> As of the last day of each fiscal quarter set forth below, the Parent Guarantor and its Subsidiaries, determined on a consolidated basis, shall have generated Net Revenue, for the twelve (12) consecutive month period ending on the last day of such fiscal quarter, in an aggregate amount not less than the corresponding amount set forth opposite such fiscal quarter&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:77.564%;"><tr><td style="width:1.0%;"></td><td style="width:73.206%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.794%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Fiscal Quarter Ending</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Revenue</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$6,000,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2021</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$10,500,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2021</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$16,400,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2021</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$25,800,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2021</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$34,900,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2022</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$43,500,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2022</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$49,300,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2022</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$53,400,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2022</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$56,600,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2023</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$59,900,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2023</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$64,100,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2023</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$72,000,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2023</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$80,300,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2024</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$88,800,000</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2024</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$97,000,000</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE II</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ACKNOWLEDGEMENT, AGREEMENT AND CONSENT AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS AND WARRANTIES</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 2.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Each Obligor confirms and agrees that, notwithstanding the effectiveness of this Amendment, the obligations of such Obligor under each Loan Document to which such Obligor is a party shall not be impaired and each Loan Document to which such Obligor is a party is, and shall continue to be, in full force and effect and is hereby confirmed and ratified in all respects.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 2.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  Each Obligor hereby acknowledges and agrees that the Guaranteed Obligations will include all Obligations under, and as defined in, the Amended Credit Agreement.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 2.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  To induce the Administrative Agent and the Lenders to execute and deliver this Amendment, each Obligor party hereto represents and warrants to the Administrative Agent and the Lenders party hereto that as of the date hereof, the following statements are true, correct and complete&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;the representations and warranties made by each Obligor party hereto in each Loan Document are true and correct in all material respects as if made on and as of such date (or in the case of any representation or warranty qualified by materiality, Material Adverse Effect or similar qualification, true and correct in all respects) unless stated to relate solely to an earlier date, in which case such representations or warranties shall be true and correct in all material respects as of such earlier date&#59;&#160;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;the execution, delivery and performance of this Amendment by each Obligor party hereto has been duly authorized by all necessary corporate or other organizational action on the part of such Obligor and this Amendment constitutes a legal, valid and binding agreement of such Obligor, enforceable against such Obligor in accordance with its terms, except as enforcement may be limited by (i) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors&#8217; rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law)&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;the execution, delivery and performance of this Amendment by any Obligor party hereto does not constitute a violation of any Law to which such Obligor or any of its Subsidiaries is subject, and does not result in the creation of any Lien (other than Permitted Liens) on any asset of such Obligor or any of its Subsidiaries, or violate, or result in a material default under any Material Agreement binding upon such Obligor or any of its Subsidiaries&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;no authorization or approval or other action by, and no notice or filing with, any Governmental Authority or any other Person (other than those that have been duly obtained or made and which are in full force and effect) is required for the due execution, delivery and performance by any Obligor party to this Amendment&#59; and</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;immediately after giving effect to this Amendment, no event has occurred and is continuing that constitutes a Default or an Event of Default. </font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE III</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDITIONS PRECEDENT</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 3.01.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Effectiveness of this Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment shall become effective only upon, and shall be subject to, the prior or simultaneous satisfaction or waiver of each of the following conditions precedent in a manner reasonably satisfactory to the Administrative Agent (the date satisfaction of such conditions being referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Amendment Effective Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;Executed Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The Administrative Agent shall have received this Amendment, duly executed by the Borrower, the Parent Guarantor, the Israeli Guarantor and each of the Majority Lenders. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Representations and Warranties&#59; No Default</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. (1) Each of the representations and warranties set forth in this Amendment and each other Loan Document (including the Credit Agreement both immediately before and after giving effect to this Amendment) that are qualified </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">by materiality, Material Adverse Effect or the like are, in each case, true and correct, (2) each of the representations and warranties set forth in this Amendment and each other Loan Document (including the Credit Agreement both immediately before and after giving effect to this Amendment) that are not qualified by materiality, Material Adverse Effect or the like are, in each case, true and correct in all material respects and (3) no Default or Event of Default has occurred and is continuing, or could reasonably be expected to result from the execution, delivery and performance of this Amendment or the transactions contemplated hereby.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;Amendment Effective Date Certificate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160;The Administrative Agent shall have received a certificate of the Borrower confirming that the conditions precedent described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">clause (b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 3.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> have been satisfied.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;Costs and Expenses, Etc</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Administrative Agent shall have received for its account and the account of each Lender all fees, costs and expenses due and payable to them pursuant to Section 14.03 of the Credit Agreement (including the Administrative Agent&#8217;s and each Lender&#8217;s reasonable and documented legal fees and out-of-pocket expenses) to the extent invoiced at least two (2) Business Days prior to the Amendment Effective Date.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MISCELLANEOUS</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.01.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law&#59; Jurisdiction&#59; Jury Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Amendment shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction.  The jurisdiction and waiver of jury trial provisions set forth in Sections 14.10 and 14.11 of the Credit Agreement, respectively, are incorporated herein by reference </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">mutatis mutandis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.02.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Effect of Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;On and after the Amendment Effective Date, each reference in the Credit Agreement to &#8220;this Agreement&#8221;, &#8220;hereunder&#8221;, &#8220;hereof&#8221;, &#8220;herein&#8221;, or words of like import, and each reference to the Credit Agreement in any other Loan Document shall be deemed a reference to the Amended Credit Agreement.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;This Amendment shall constitute a Loan Document for all purposes of the Amended Credit Agreement.  The Obligors party hereto agree that all of the representations, warranties, terms, covenants, conditions and other provisions of the Credit Agreement and other Loan Documents shall, except as expressly set forth in this Amendment, remain unchanged and shall continue to be, and shall remain, in full force and effect in accordance with their respective terms.  The amendments, consents and modifications set forth herein shall be limited precisely as provided for herein to the provisions expressly amended herein or otherwise modified or consented to hereby and shall not be deemed to be an amendment to, waiver of, consent to or modification of any other term or provision of the Credit Agreement or any other Loan Document or of any transaction or further or future action on the part of any Obligor which would require the consent of the Lenders or the Administrative Agent under the Credit </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Agreement or any other Loan Document, or a waiver of any Default or Event of Default or non-compliance with any term or condition contained in the Credit Agreement.  Except as expressly set forth in this Amendment, the Credit Agreement and the other Loan Documents are and shall continue to be in full force and effect and are hereby in all respects ratified and confirmed.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any holder of the Administrative Agent or any Lender under any Loan Document or applicable Law, nor constitute a waiver of any provision of the Credit Agreement except as expressly set forth herein. </font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.03.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Novation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment is not intended by the parties to be, and shall not be construed to be, a novation of the Credit Agreement or the other Loan Documents.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.04.  Costs and Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each Obligor party hereto agrees to pay or reimburse the Administrative Agent and the Lenders for all of their reasonable and documented out-of-pocket costs in connection with the negotiation, preparation, execution and delivery of this Amendment, including, without limitation, the reasonable and documented out-of-pocket fees and expenses of outside counsel for the Administrative Agent and the Lenders,.</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.05.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart. Delivery of an executed signature page of this Amendment by facsimile transmission or electronic transmission (including PDF format) shall be effective as delivery of a manually executed counterpart hereof. Any signature (including, without limitation, (x) any electronic symbol or process attached to, or associated with, a contract or other record and adopted by a person with the intent to sign, authenticate or accept such contract or record and (y) any facsimile or .pdf signature) hereto or to any other certificate, agreement or document related to this transaction, and any contract formation or record-keeping, in each case, through electronic means, shall have the same legal validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act, and the parties hereto hereby waive any objection to the contrary. The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.06.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Binding Nature</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.07.  Captions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Amendment.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.08.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In case any provision of or obligation under this Amendment shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.09.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Integration</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Amendment, together with the other Loan Documents, sets forth the entire understanding of the parties with respect to the matters set forth herein, and shall supersede any prior negotiations or agreements, whether written or oral, with respect thereto.</font></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECTION 4.10. Waiver and Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  TO INDUCE THE ADMINISTRATIVE AGENT AND THE LENDERS TO AGREE TO THE TERMS OF THIS AMENDMENT, PARENT GUARANTOR, Israeli Guarantor and the Borrower AND THEIR AFFILIATES (COLLECTIVELY, THE &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">RELEASING PARTIES</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) REPRESENT AND WARRANT THAT, AS OF THE DATE HEREOF, THERE ARE NO CLAIMS OR OFFSETS AGAINST, OR RIGHTS OF RECOUPMENT WITH RESPECT TO, OR DISPUTES OF, OR DEFENSES OR COUNTERCLAIMS TO, THEIR OBLIGATIONS UNDER THIS AMENDMENT OR THE OTHER LOAN DOCUMENTS, AND IN ACCORDANCE THEREWITH THEY&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;WAIVE ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DISPUTES, DEFENSES AND COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING PRIOR TO THE DATE HEREOF&#59; AND</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;FOREVER RELEASE, RELIEVE, AND DISCHARGE THE ADMINISTRATIVE AGENT AND EACH LENDER AND THEIR RESPECTIVE OFFICERS, DIRECTORS, SHAREHOLDERS, MEMBERS, PARTNERS, PREDECESSORS, SUCCESSORS, ASSIGNS, ATTORNEYS, ACCOUNTANTS, AGENTS, EMPLOYEES, AND REPRESENTATIVES (COLLECTIVELY, THE &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">RELEASED PARTIES</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), AND EACH OF THEM, FROM ANY AND ALL CLAIMS, LIABILITIES, DEMANDS, CAUSES OF ACTION, DEBTS, OBLIGATIONS, PROMISES, ACTS, AGREEMENTS, AND DAMAGES, OF WHATEVER KIND OR NATURE, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR UNSUSPECTED, CONTINGENT OR FIXED, LIQUIDATED OR UNLIQUIDATED, MATURED OR UNMATURED, WHETHER ARISING AT LAW OR IN EQUITY, WHICH THE RELEASING PARTIES EVER HAD, NOW HAVE, OR MAY, SHALL, OR CAN HEREAFTER HAVE, DIRECTLY OR INDIRECTLY ARISING OUT OF OR IN ANY WAY BASED UPON, CONNECTED WITH, OR RELATED TO MATTERS, THINGS, ACTS, CONDUCT, AND&#47;OR OMISSIONS AT ANY TIME FROM THE DATE THAT WAS NINETY (90) DAYS PRIOR TO THE DATE HEREOF THROUGH AND INCLUDING THE DATE HEREOF, INCLUDING WITHOUT LIMITATION ANY AND ALL CLAIMS AGAINST THE RELEASED PARTIES ARISING UNDER OR RELATED TO ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;IN CONNECTION WITH THE RELEASE CONTAINED HEREIN, THE RELEASING PARTIES ACKNOWLEDGE THAT THEY ARE AWARE THAT THEY MAY HEREAFTER DISCOVER CLAIMS PRESENTLY UNKNOWN OR UNSUSPECTED, OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH THEY KNOW OR BELIEVE TO BE TRUE, WITH RESPECT TO THE MATTERS RELEASED HEREIN. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NEVERTHELESS, IT IS THE INTENTION OF THE RELEASING PARTIES, THROUGH THIS AMENDMENT AND WITH ADVICE OF COUNSEL, FULLY, FINALLY, AND FOREVER TO RELEASE ALL SUCH MATTERS, AND ALL CLAIMS RELATED THERETO, WHICH DO NOW EXIST, OR HERETOFORE HAVE EXISTED.  IN FURTHERANCE OF SUCH INTENTION, THE RELEASES HEREIN GIVEN SHALL BE AND REMAIN IN EFFECT AS A FULL AND COMPLETE RELEASE OF SUCH MATTERS NOTWITHSTANDING THE DISCOVERY OR EXISTENCE OF ANY SUCH ADDITIONAL OR DIFFERENT CLAIMS OR FACTS RELATED THERETO.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;THE RELEASING PARTIES COVENANT AND AGREE NOT TO BRING ANY CLAIM, ACTION, SUIT, OR PROCEEDING AGAINST THE RELEASED PARTIES, DIRECTLY OR INDIRECTLY, REGARDING OR RELATED IN ANY MANNER TO THE MATTERS RELEASED HEREBY, AND FURTHER COVENANT AND AGREE THAT THIS AMENDMENT IS A BAR TO ANY SUCH CLAIM, ACTION, SUIT, OR PROCEEDING.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;THE RELEASING PARTIES REPRESENT AND WARRANT TO THE RELEASED PARTIES THAT THEY HAVE NOT HERETOFORE ASSIGNED OR TRANSFERRED, OR PURPORTED TO ASSIGN OR TRANSFER, TO ANY PERSON OR ENTITY ANY CLAIMS OR OTHER MATTERS HEREIN RELEASED.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;THE RELEASING PARTIES ACKNOWLEDGE THAT THEY HAVE HAD THE BENEFIT OF INDEPENDENT LEGAL ADVICE WITH RESPECT TO THE ADVISABILITY OF ENTERING INTO THIS RELEASE AND HEREBY KNOWINGLY, AND UPON SUCH ADVICE OF COUNSEL, WAIVE ANY AND ALL APPLICABLE RIGHTS AND BENEFITS UNDER, AND PROTECTIONS OF, CALIFORNIA CIVIL CODE SECTION 1542, AND ANY AND ALL STATUTES AND PRINCIPLES OF COMMON LAW THAT HAVE SIMILAR EFFECT.  CALIFORNIA CIVIL CODE SECTION 1542 PROVIDES AS FOLLOWS&#58;</font></div><div style="padding-left:81pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, and that if known by him or her, would have materially affected his or her settlement with the debtor or released party.</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%;"> &#91;Signature pages to follow&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date hereof.</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">FOAMIX PHARMACEUTICALS INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as Borrower</font></div><div style="padding-left:216pt;"><font><br></font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; David Domzalski__________________</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; David Domzalski </font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;   Chief Executive Officer</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Andrew Saik </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_____________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Andrew Saik</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Chief Financial Officer</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MENLO THERAPEUTICS INC.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as Parent Guarantor</font></div><div style="padding-left:216pt;"><font><br></font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; David Domzalski__________________</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; David Domzalski </font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;   Chief Executive Officer</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Andrew Saik </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_____________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Andrew Saik</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Chief Financial Officer</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> FOAMIX PHARMACEUTICALS LTD.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as Israeli Guarantor</font></div><div style="padding-left:216pt;"><font><br></font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; David Domzalski__________________</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; David Domzalski </font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;   Chief Executive Officer</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Andrew Saik </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">_____________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Andrew Saik</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;  Chief Financial Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><div id="i1f3c3afd13c0485c8cc7cdc30b611bc4_39"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="padding-right:6pt;text-align:right;"><font><br></font></div></div><div><font><br></font></div><div style="text-indent:36pt;padding-left:180pt;"><font><br></font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PERCEPTIVE CREDIT HOLDINGS II, LP, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">as Administrative Agent and a Lender</font></div><div style="padding-left:216pt;padding-right:-18pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  PERCEPTIVE CREDIT OPPORTUNITIES GP, LLC</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> its general partner</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By _</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Sandeep Dixit </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">______________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Sandeep Dixit</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;   Chief Credit Officer</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By _</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Sam Chawla</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">________________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; Sam Chawla</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;   Portfolio Manager</font></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div><div><font><br></font></div></div></div><div id="i1f3c3afd13c0485c8cc7cdc30b611bc4_42"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font><br></font></div></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ORBIMED ROYALTY &#38; CREDIT OPPORTUNITIES III, LP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as a Lender</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  ORBIMED ROF III LLC, its general partner</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;  ORBIMED ADVISORS LLC, its managing member</font></div><div style="padding-left:216pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; W. Carter Neild_____________________</font></div><div style="padding-left:234pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58; W. Carter Neild</font></div><div style="padding-left:234pt;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58; Member</font></div><div style="padding-left:216pt;margin-bottom:12pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mnlo-20200630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4f9217ea747a403baf8047ce41907525_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David Domzalski, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Menlo Therapeutics Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.327%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David Domzalski</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Domzalski<br>Principal Executive Officer</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mnlo-20200630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7f9d8d283865428683fc408e4d28a048_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Andrew Saik, certify that&#58;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">I have reviewed this Quarterly Report on Form 10-Q of Menlo Therapeutics Inc.&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:63.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.327%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Andrew Saik<br>Principal Financial Officer</font></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mnlo-20200630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic23734b332ac4611a5c7ce3faab5087d_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Menlo Therapeutics Inc. (the &#8220;Company&#8221;), for the quarterly period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, David Domzalski, President and Chief Executive Officer and principal executive officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:15pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:334.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:22.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David Domzalski</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David Domzalski<br>Principal Executive Officer</font></td></tr></table></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>mnlo-20200630xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i98aee55dc8744c9cba80386a44a4d55f_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Menlo Therapeutics Inc. (the &#8220;Company&#8221;), for the quarterly period ended June&#160;30, 2020 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Andrew Saik, Chief Financial Officer, Treasurer and principal financial officer, hereby certify as of the date hereof, solely for purposes of 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:15pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:511.50pt;"><tr><td style="width:1.0pt;"></td><td style="width:334.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:22.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:148.00pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; August 6, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Andrew Saik<br>Principal Financial Officer</font></td></tr></table></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mnlo-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlo="http://www.menlotherapeutics.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.menlotherapeutics.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.menlotherapeutics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONS" roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSDetails" roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails">
        <link:definition>2402401 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATION" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION">
        <link:definition>2107103 - Disclosure - BUSINESS COMBINATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONTables" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables">
        <link:definition>2308302 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails">
        <link:definition>2409403 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails">
        <link:definition>2410404 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONPurchasePriceAllocationDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails">
        <link:definition>2411405 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONGoodwillDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails">
        <link:definition>2412406 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONIPRDandCSRDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails">
        <link:definition>2413407 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONProFormaDetails" roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails">
        <link:definition>2414408 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION">
        <link:definition>2115104 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONDetails" roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails">
        <link:definition>2416409 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENT" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT">
        <link:definition>2117105 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTTables" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables">
        <link:definition>2318303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2419410 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails">
        <link:definition>2420411 - Disclosure - FAIR VALUE MEASUREMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIES" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES">
        <link:definition>2121106 - Disclosure - MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESTables" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables">
        <link:definition>2322304 - Disclosure - MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESMarketableSecuritiesDetails" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails">
        <link:definition>2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails">
        <link:definition>2424413 - Disclosure - MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails">
        <link:definition>2425414 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://www.menlotherapeutics.com/role/INVENTORY">
        <link:definition>2126107 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables">
        <link:definition>2327305 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYDetails" roleURI="http://www.menlotherapeutics.com/role/INVENTORYDetails">
        <link:definition>2428415 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBT" roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBT">
        <link:definition>2129108 - Disclosure - LONG-TERM DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTCreditagreementDetails" roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails">
        <link:definition>2430416 - Disclosure - LONG-TERM DEBT - Credit agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMDEBTWarrantsDetails" roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails">
        <link:definition>2431417 - Disclosure - LONG-TERM DEBT - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITAL" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL">
        <link:definition>2132109 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALTables" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables">
        <link:definition>2333306 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALNarrativeDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails">
        <link:definition>2434418 - Disclosure - SHARE CAPITAL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALOptionsandRSUGrantsDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails">
        <link:definition>2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALFairvalueassumptionsDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails">
        <link:definition>2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALScheduleofSharebasedCompensationDetails" roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails">
        <link:definition>2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASE" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE">
        <link:definition>2138110 - Disclosure - OPERATING LEASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASETables" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables">
        <link:definition>2339307 - Disclosure - OPERATING LEASE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASEOperatingleasecostsDetails" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails">
        <link:definition>2440422 - Disclosure - OPERATING LEASE - Operating lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2443424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS">
        <link:definition>2144112 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2445425 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench1LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ReverseMergerPolicyTextBlock" abstract="false" name="ReverseMergerPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_GrossProceedsFromIssuanceOfCommonStock" abstract="false" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_EstimateOfProductReturnRateMaximum" abstract="false" name="EstimateOfProductReturnRateMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_StockIssuedDuringPeriodSharesWarrantExchange" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExchange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" abstract="false" name="ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" abstract="false" name="BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_EstimateOfProductReturnRateMinimum" abstract="false" name="EstimateOfProductReturnRateMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_RedwoodCityCaliforniaMember" abstract="true" name="RedwoodCityCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_EffectiveExchangeRatio" abstract="false" name="EffectiveExchangeRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlo_VehicleLeasePrepaymentPeriod" abstract="false" name="VehicleLeasePrepaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mnlo_ProceedsFromBusinessMerger" abstract="false" name="ProceedsFromBusinessMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_FinancialIncomeNet" abstract="false" name="FinancialIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" abstract="false" name="AdjustmentsToSupplementalProformaCombinedResultsOfOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" abstract="false" name="MinimumAggregateCashBalanceMaintainAfterFdaApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_DebtCovenantsAbstract" abstract="true" name="DebtCovenantsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" abstract="true" name="MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" abstract="true" name="FairValueMeasurmentsNarrativeDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlo_CreditAgreementNumberOfTrenches" abstract="false" name="CreditAgreementNumberOfTrenches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlo_RestrictedInvestmentsToSecureLeaseAgreements" abstract="false" name="RestrictedInvestmentsToSecureLeaseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" abstract="false" name="ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_OfficersAndDirectorsMember" abstract="true" name="OfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" abstract="false" name="AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_NonCashAcquisitionOfBusinessCashAcquired" abstract="false" name="NonCashAcquisitionOfBusinessCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_AdjustmentsToSupplementalProformaTransactionCosts" abstract="false" name="AdjustmentsToSupplementalProformaTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" abstract="false" name="ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" abstract="false" name="BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_ClassOfWarrantAbstract" abstract="true" name="ClassOfWarrantAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlo_MergerLawsuitsMember" abstract="true" name="MergerLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_UpfrontRoyaltyReceipt" abstract="false" name="UpfrontRoyaltyReceipt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_FoamixMember" abstract="true" name="FoamixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_CommonStockVotingRightsNumberPerShare" abstract="false" name="CommonStockVotingRightsNumberPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlo_OriginalSpaceMember" abstract="true" name="OriginalSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_FinancialExpenses" abstract="false" name="FinancialExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" abstract="false" name="AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_ShareholderLenderMember" abstract="true" name="ShareholderLenderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" abstract="false" name="ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" abstract="false" name="BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_IsraeliMutualFundsMember" abstract="true" name="IsraeliMutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ContingentStockConsiderationRemeasurementGainLoss" abstract="false" name="ContingentStockConsiderationRemeasurementGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_DerivateCostsForYear" abstract="false" name="DerivateCostsForYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_FacilitySpaceUnderLease" abstract="false" name="FacilitySpaceUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" abstract="false" name="DeemedDividendToWarrantsHoldersDueToWarrantModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_OrdinarySharesMember" abstract="true" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlo_RegisteredOfferingMember" abstract="true" name="RegisteredOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ContingentStockRightSharesConversion" abstract="false" name="ContingentStockRightSharesConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlo_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" abstract="false" name="SharesIssuedUponConversionOfCommonStockRightsPerAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlo_NumberOfClassActions" abstract="false" name="NumberOfClassActions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" abstract="false" name="ScheduleOfBusinessCombinationGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" abstract="false" name="RevenueRecognitionDistributionTradeDiscountsAndAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_AmendedAndRestatedCreditAgreementMember" abstract="true" name="AmendedAndRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_DistributorThreeMember" abstract="true" name="DistributorThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" abstract="false" name="ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" abstract="false" name="IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_A2018PlanMember" abstract="true" name="A2018PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_BusinessCombinationConsiderationTransferredGross" abstract="false" name="BusinessCombinationConsiderationTransferredGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" abstract="false" name="DebtCovenantMinimumQuarterlyRevenueCompliance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" abstract="false" name="PostMergerParentOwnershipByPreMergerParentStockholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench3LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_CSRAgreementMember" abstract="true" name="CSRAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" abstract="false" name="PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" abstract="false" name="NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_DebtInstrumentFeePercent" abstract="false" name="DebtInstrumentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_InterestReceived" abstract="false" name="InterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_AdditionalSpaceMember" abstract="true" name="AdditionalSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_NumberOfLenders" abstract="false" name="NumberOfLenders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" abstract="false" name="LiquidityAndCapitalResourcesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mnlo_DerivativeMaximumTermOfContract" abstract="false" name="DerivativeMaximumTermOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" abstract="true" name="AmendedAndRestatedCreditAgreementTrench2LoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_BusinessAcquisitionContingentStockRightIssued" abstract="false" name="BusinessAcquisitionContingentStockRightIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlo_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" abstract="true" name="ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_InitialPublicOfferingLawsuitsMember" abstract="true" name="InitialPublicOfferingLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" abstract="false" name="ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mnlo_BridgewaterNewJerseyMember" abstract="true" name="BridgewaterNewJerseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mnlo_ExchangeRatio" abstract="false" name="ExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" abstract="false" name="BusinessCombinationSharesDeemedIssuedForAccountingPurposes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" abstract="false" name="DebtInstrumentPeriodicPaymentPrincipalPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mnlo_BusinessCombinationEffectiveExchangeRatio" abstract="false" name="BusinessCombinationEffectiveExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mnlo-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/Cover" xlink:type="simple" xlink:href="mnlo-20200630.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_df4a7f95-2c9f-4ddc-9c5f-0a5236abeb33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44641505-e01a-4a1e-9505-1de56457a67d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df4a7f95-2c9f-4ddc-9c5f-0a5236abeb33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_44641505-e01a-4a1e-9505-1de56457a67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e8393280-238b-4765-b77e-66655f90d0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df4a7f95-2c9f-4ddc-9c5f-0a5236abeb33" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_e8393280-238b-4765-b77e-66655f90d0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9bde697a-4063-4859-aa16-4d5e9102435b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_df4a7f95-2c9f-4ddc-9c5f-0a5236abeb33" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9bde697a-4063-4859-aa16-4d5e9102435b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_3bc9d35e-afa1-4316-a73f-b2f0dc763a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_3bc9d35e-afa1-4316-a73f-b2f0dc763a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ef01909-9848-4673-99b5-bf65b6f5b863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ef01909-9848-4673-99b5-bf65b6f5b863" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2faf0265-6109-4a31-bbea-68bf86088b41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2faf0265-6109-4a31-bbea-68bf86088b41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8b1bd9-fd66-4cb8-bfa7-a91b829e437d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5f8b1bd9-fd66-4cb8-bfa7-a91b829e437d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_703e2654-0b64-4540-a6c3-92797e35231a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fe3cec77-022e-4580-af11-927a2c3c394a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_703e2654-0b64-4540-a6c3-92797e35231a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d3e1b156-4f57-4915-842e-9b22ad55ccda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_3805d11c-a658-45b6-9b56-f51899b0b70d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d3e1b156-4f57-4915-842e-9b22ad55ccda" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_3805d11c-a658-45b6-9b56-f51899b0b70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a776bdf8-dd98-427a-be85-bc9889ccc9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d3e1b156-4f57-4915-842e-9b22ad55ccda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a776bdf8-dd98-427a-be85-bc9889ccc9c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8731d519-ab20-42c4-bd08-15cbd594ec89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d3e1b156-4f57-4915-842e-9b22ad55ccda" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8731d519-ab20-42c4-bd08-15cbd594ec89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_47f50681-d33f-4473-b334-23f9d1d794a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d3e1b156-4f57-4915-842e-9b22ad55ccda" xlink:to="loc_us-gaap_OtherLiabilities_47f50681-d33f-4473-b334-23f9d1d794a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b08fcb20-3106-43de-8f86-74a64637ba1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_35c839e4-26f5-43db-9ead-512cabe7d6b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b08fcb20-3106-43de-8f86-74a64637ba1c" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_35c839e4-26f5-43db-9ead-512cabe7d6b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_26f77e1a-c4e0-4808-8594-6ad9bb4355d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b08fcb20-3106-43de-8f86-74a64637ba1c" xlink:to="loc_us-gaap_LiabilitiesCurrent_26f77e1a-c4e0-4808-8594-6ad9bb4355d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c3ca5e4e-e8e6-4d9b-b8ea-5bea413ebe40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:to="loc_us-gaap_CommonStockValue_c3ca5e4e-e8e6-4d9b-b8ea-5bea413ebe40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9a55f30b-2684-4115-a0e2-3c6bcca4b3de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9a55f30b-2684-4115-a0e2-3c6bcca4b3de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_987f63cd-26c0-4921-8066-695dadab7c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_987f63cd-26c0-4921-8066-695dadab7c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b099612a-5d90-4cbc-8931-38ebf49198d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b099612a-5d90-4cbc-8931-38ebf49198d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_971191f9-d727-420f-992c-ccc35855c998" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_733ac99c-8f82-400c-b2b8-e7e79186ce73" xlink:to="loc_us-gaap_PreferredStockValue_971191f9-d727-420f-992c-ccc35855c998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ffdc6ad-5d2a-488f-83e6-5eada98f52c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_81fcad77-b6da-43d4-adbb-61c2a54097f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ffdc6ad-5d2a-488f-83e6-5eada98f52c9" xlink:to="loc_us-gaap_Liabilities_81fcad77-b6da-43d4-adbb-61c2a54097f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9431e5f4-af8e-4428-8e10-b9871a71e0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ffdc6ad-5d2a-488f-83e6-5eada98f52c9" xlink:to="loc_us-gaap_StockholdersEquity_9431e5f4-af8e-4428-8e10-b9871a71e0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_40943b9d-3e2f-4b24-909f-12a105864248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ffdc6ad-5d2a-488f-83e6-5eada98f52c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_40943b9d-3e2f-4b24-909f-12a105864248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2876a4e8-f69f-47ee-a2bb-82036fee69fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fde06237-d7d8-4845-8bfe-1b6f7fac38b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2876a4e8-f69f-47ee-a2bb-82036fee69fe" xlink:to="loc_us-gaap_AssetsCurrent_fde06237-d7d8-4845-8bfe-1b6f7fac38b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_10621755-3aa1-46c5-86bc-6dbcdd883546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2876a4e8-f69f-47ee-a2bb-82036fee69fe" xlink:to="loc_us-gaap_AssetsNoncurrent_10621755-3aa1-46c5-86bc-6dbcdd883546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b2b443-f56a-46e8-983d-176104f1fa0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6b2b443-f56a-46e8-983d-176104f1fa0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e49a5d2-f51e-4acf-a90a-baafa2937ecc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3e49a5d2-f51e-4acf-a90a-baafa2937ecc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_29f604d1-1c80-4c20-9bf4-efa2c64d0f2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_29f604d1-1c80-4c20-9bf4-efa2c64d0f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_861a4fe8-ac5b-4b4d-af24-99e4f12dd0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_861a4fe8-ac5b-4b4d-af24-99e4f12dd0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d5b13d95-a914-4a09-8db5-92f142f89124" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d5b13d95-a914-4a09-8db5-92f142f89124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2c42ac46-8ba8-4470-85e5-0dbc7b73f3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_InventoryNet_2c42ac46-8ba8-4470-85e5-0dbc7b73f3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4be47fa7-a235-4928-9dbd-54f25da815d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4be47fa7-a235-4928-9dbd-54f25da815d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_218e7f38-ec0f-4e6d-bf37-ae04834e1533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_OtherShortTermInvestments_218e7f38-ec0f-4e6d-bf37-ae04834e1533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_a20ec486-747b-4eca-be3b-07412c654651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4c663617-2389-4e11-8176-f365919acfba" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_a20ec486-747b-4eca-be3b-07412c654651" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b24f016d-cfce-4184-8855-0afe35a91a35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b24f016d-cfce-4184-8855-0afe35a91a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6727819f-d6ae-4cc6-b94b-80cdb40481af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6727819f-d6ae-4cc6-b94b-80cdb40481af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b9908b5d-d1f3-4d9b-9b75-801fe7c459fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b9908b5d-d1f3-4d9b-9b75-801fe7c459fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f9f5c06b-bc86-46ce-9e0d-f07e60e414e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f9f5c06b-bc86-46ce-9e0d-f07e60e414e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_1c36b8f0-6b66-4f85-866c-0b850410a0de" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_eeb1a439-fc00-48ca-b470-9cca9d81975c" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_1c36b8f0-6b66-4f85-866c-0b850410a0de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_964b8f7c-97ad-4bf6-b858-28526e9cee19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialExpenses_014be7f8-1bf2-4c39-8c5a-7b67e28ac481" xlink:href="mnlo-20200630.xsd#mnlo_FinancialExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_964b8f7c-97ad-4bf6-b858-28526e9cee19" xlink:to="loc_mnlo_FinancialExpenses_014be7f8-1bf2-4c39-8c5a-7b67e28ac481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialIncomeNet_945179b2-762d-40d6-93dc-427bffeb0634" xlink:href="mnlo-20200630.xsd#mnlo_FinancialIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_964b8f7c-97ad-4bf6-b858-28526e9cee19" xlink:to="loc_mnlo_FinancialIncomeNet_945179b2-762d-40d6-93dc-427bffeb0634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d355a04c-7c93-43fb-8ccf-dd4d59371cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_964b8f7c-97ad-4bf6-b858-28526e9cee19" xlink:to="loc_us-gaap_OperatingIncomeLoss_d355a04c-7c93-43fb-8ccf-dd4d59371cd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_55dc5304-dc5d-4450-9f98-d7f0c32cea45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c8061466-7aca-4334-b977-388c81a9f9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_55dc5304-dc5d-4450-9f98-d7f0c32cea45" xlink:to="loc_us-gaap_CostsAndExpenses_c8061466-7aca-4334-b977-388c81a9f9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_01ddf151-5535-480e-9224-f4df0331cc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_55dc5304-dc5d-4450-9f98-d7f0c32cea45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_01ddf151-5535-480e-9224-f4df0331cc6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fdefc870-dcfc-4e3b-9f1f-398f736cdb78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f867824-5364-4f7f-afb2-9654cad8f1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fdefc870-dcfc-4e3b-9f1f-398f736cdb78" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f867824-5364-4f7f-afb2-9654cad8f1b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_76b7e979-df14-4bec-866d-50706b05be29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fdefc870-dcfc-4e3b-9f1f-398f736cdb78" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_76b7e979-df14-4bec-866d-50706b05be29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d1d03a1b-4b6f-46bd-8eba-d4767396ac96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a4966dd-837b-47eb-aa05-450693239374" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d1d03a1b-4b6f-46bd-8eba-d4767396ac96" xlink:to="loc_us-gaap_NetIncomeLoss_3a4966dd-837b-47eb-aa05-450693239374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_acecb964-6365-4012-901d-1b199f304572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d1d03a1b-4b6f-46bd-8eba-d4767396ac96" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_acecb964-6365-4012-901d-1b199f304572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_56d63043-0113-41c3-8fc2-f393a9c45394" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95264213-408b-47a3-9420-844062855d01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_56d63043-0113-41c3-8fc2-f393a9c45394" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95264213-408b-47a3-9420-844062855d01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c6390603-09f3-4353-a21b-03409766a3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_56d63043-0113-41c3-8fc2-f393a9c45394" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c6390603-09f3-4353-a21b-03409766a3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_734b345c-456e-4a27-a1c3-ddfdb4354beb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_56d63043-0113-41c3-8fc2-f393a9c45394" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_734b345c-456e-4a27-a1c3-ddfdb4354beb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3e10062c-39e4-406e-b33f-25d41308b014" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e161e02f-1d3b-4200-aa03-eeeb707c806a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3e10062c-39e4-406e-b33f-25d41308b014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e161e02f-1d3b-4200-aa03-eeeb707c806a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1205453d-47e8-4c48-9ea2-5d37ce39e079" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3e10062c-39e4-406e-b33f-25d41308b014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1205453d-47e8-4c48-9ea2-5d37ce39e079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c19c046b-1552-47d0-9c97-718c7fcc971b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3e10062c-39e4-406e-b33f-25d41308b014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c19c046b-1552-47d0-9c97-718c7fcc971b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4974d5f-5d4e-479c-a105-fa3368f25b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_1db85f6d-53f3-479e-8733-f24ddb46598a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4974d5f-5d4e-479c-a105-fa3368f25b3c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_1db85f6d-53f3-479e-8733-f24ddb46598a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35e100c4-58f4-47ef-baad-8b2c7c0eee6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4974d5f-5d4e-479c-a105-fa3368f25b3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35e100c4-58f4-47ef-baad-8b2c7c0eee6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbc9572d-f8c5-4a7b-b406-f80cf7e3d9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_60f58fd7-8c41-4408-a433-dd3b9044c63a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbc9572d-f8c5-4a7b-b406-f80cf7e3d9ae" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_60f58fd7-8c41-4408-a433-dd3b9044c63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_90fb9a5b-5e29-4821-87e7-166631d96e53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbc9572d-f8c5-4a7b-b406-f80cf7e3d9ae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_90fb9a5b-5e29-4821-87e7-166631d96e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ProceedsFromBusinessMerger_3c973933-7215-4244-bdf4-6892cff753ed" xlink:href="mnlo-20200630.xsd#mnlo_ProceedsFromBusinessMerger"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbc9572d-f8c5-4a7b-b406-f80cf7e3d9ae" xlink:to="loc_mnlo_ProceedsFromBusinessMerger_3c973933-7215-4244-bdf4-6892cff753ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e24cc66-1986-47e7-a308-e5d73c4d9984" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cbc9572d-f8c5-4a7b-b406-f80cf7e3d9ae" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9e24cc66-1986-47e7-a308-e5d73c4d9984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_c2d8840c-de10-47f2-b709-8def4a3b5fb2" xlink:href="mnlo-20200630.xsd#mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_c2d8840c-de10-47f2-b709-8def4a3b5fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_319f32cd-267a-440e-a82e-bee6578c7730" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_319f32cd-267a-440e-a82e-bee6578c7730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3791bfd9-3567-4cb2-ad3f-350ff05c2494" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_3791bfd9-3567-4cb2-ad3f-350ff05c2494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b0aed3d6-9e8b-4dc6-8e81-96b400b3504b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b0aed3d6-9e8b-4dc6-8e81-96b400b3504b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5b49d4ce-3a3c-45c8-a60d-539d71c1476e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_5b49d4ce-3a3c-45c8-a60d-539d71c1476e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c63ff032-2ee2-4df7-a495-33169843c29e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_NetIncomeLoss_c63ff032-2ee2-4df7-a495-33169843c29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_425791d6-4176-4db7-b9dd-a9393bcbcff2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_ShareBasedCompensation_425791d6-4176-4db7-b9dd-a9393bcbcff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d6371c19-5ad5-4cbd-b2f7-54177cbd937f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d6371c19-5ad5-4cbd-b2f7-54177cbd937f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c84eb715-7c24-4503-a00a-577c74b6d921" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c84eb715-7c24-4503-a00a-577c74b6d921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6635e0d2-42f8-468d-9519-75fb3d2c288a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6635e0d2-42f8-468d-9519-75fb3d2c288a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b01937a-d18e-4622-9de8-77308c5058f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b01937a-d18e-4622-9de8-77308c5058f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cf9b6b87-5e43-417d-8b4a-68e3299493fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cf9b6b87-5e43-417d-8b4a-68e3299493fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_d2774a6a-6299-4437-9295-7362391b89ef" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd04ed94-4812-4495-b487-7d5f6528e90f" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_d2774a6a-6299-4437-9295-7362391b89ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_62d539b5-6ca7-4dac-9d24-cfeed0d82350" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired_ad13500f-2b0c-4e0c-9ac7-f046f0347db4" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_62d539b5-6ca7-4dac-9d24-cfeed0d82350" xlink:to="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired_ad13500f-2b0c-4e0c-9ac7-f046f0347db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_e94d147c-bb31-43a5-a2ed-6aa70b0a6b53" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_62d539b5-6ca7-4dac-9d24-cfeed0d82350" xlink:to="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_e94d147c-bb31-43a5-a2ed-6aa70b0a6b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f2153c0-6bb2-4183-b20e-e92d7fd3d430" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a91b7100-7f7f-4c4a-9341-e78c2c5bbc9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f2153c0-6bb2-4183-b20e-e92d7fd3d430" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a91b7100-7f7f-4c4a-9341-e78c2c5bbc9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b923d753-3568-4ebc-8487-d689cbc80a01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f2153c0-6bb2-4183-b20e-e92d7fd3d430" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b923d753-3568-4ebc-8487-d689cbc80a01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONSDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATION"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross_4621c2f4-bfea-484e-9379-1017053ad123" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_3953c5db-3f84-463b-a2e9-c81f0b3e0fb2" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_BusinessCombinationConsiderationTransferredGross_4621c2f4-bfea-484e-9379-1017053ad123" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_3953c5db-3f84-463b-a2e9-c81f0b3e0fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_628d0cbf-fe5e-4e17-968a-b6756d0d38bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_BusinessCombinationConsiderationTransferredGross_4621c2f4-bfea-484e-9379-1017053ad123" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_628d0cbf-fe5e-4e17-968a-b6756d0d38bd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b69ba8a4-7145-4297-b0c5-423f4651c10a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b69ba8a4-7145-4297-b0c5-423f4651c10a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_1168869b-8dbc-4628-aae1-fe4aee0aec23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_1168869b-8dbc-4628-aae1-fe4aee0aec23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_622f931e-072e-4b76-9222-fde6a1d63acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_622f931e-072e-4b76-9222-fde6a1d63acc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3dd6989c-9848-43cc-a350-b550930cd8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_3dd6989c-9848-43cc-a350-b550930cd8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31397f8d-c0ec-419b-94b2-337f6f594be4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_925e7e8c-fa78-4718-a817-3222b657afde" xlink:to="loc_us-gaap_Goodwill_31397f8d-c0ec-419b-94b2-337f6f594be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6c8e2fc5-ea0d-43fc-b4d1-11ce007e15a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20631dd7-ce23-496c-8469-f1e33d451a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6c8e2fc5-ea0d-43fc-b4d1-11ce007e15a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20631dd7-ce23-496c-8469-f1e33d451a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6d1e19c6-2a9d-474b-bffa-44a892f0fcb7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6c8e2fc5-ea0d-43fc-b4d1-11ce007e15a4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6d1e19c6-2a9d-474b-bffa-44a892f0fcb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99591423-037a-42ea-8eb2-c701e7b5c10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1358a57f-96d9-4add-bc8f-9e3f202be79a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99591423-037a-42ea-8eb2-c701e7b5c10d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_1358a57f-96d9-4add-bc8f-9e3f202be79a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_341878ec-6bb3-4516-b23e-b760be81ccb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_a5af0d55-5b53-40e5-ae1d-d425510739ec" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_341878ec-6bb3-4516-b23e-b760be81ccb9" xlink:to="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_a5af0d55-5b53-40e5-ae1d-d425510739ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_287d23bc-8c20-40f3-abea-68b600749a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_341878ec-6bb3-4516-b23e-b760be81ccb9" xlink:to="loc_us-gaap_Goodwill_287d23bc-8c20-40f3-abea-68b600749a4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6ab7e157-c380-4bc3-ae15-84c7c168e642" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b8e3fe03-540a-4e21-a99b-e421f940920b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_6ab7e157-c380-4bc3-ae15-84c7c168e642" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b8e3fe03-540a-4e21-a99b-e421f940920b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_47f92f39-f856-4b37-9ef3-7829400a0000" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_07e15234-0a6b-411d-b1ee-7b7de43e01ee" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_47f92f39-f856-4b37-9ef3-7829400a0000" xlink:to="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_07e15234-0a6b-411d-b1ee-7b7de43e01ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_d63dcaa0-8c23-42d3-8e94-07191e200d44" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_47f92f39-f856-4b37-9ef3-7829400a0000" xlink:to="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_d63dcaa0-8c23-42d3-8e94-07191e200d44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITION"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITIONDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENT"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIES"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5f3355d-23c1-41a1-bf71-ef3899f2d590" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4f8ef29-ea40-40e9-853e-b3ddc8ae3ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5f3355d-23c1-41a1-bf71-ef3899f2d590" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4f8ef29-ea40-40e9-853e-b3ddc8ae3ca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1308a6e3-e60a-47f4-ae2e-7ecc94260d49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5f3355d-23c1-41a1-bf71-ef3899f2d590" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1308a6e3-e60a-47f4-ae2e-7ecc94260d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f76b487-915a-47a9-ad93-fc5d49a54df3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5f3355d-23c1-41a1-bf71-ef3899f2d590" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7f76b487-915a-47a9-ad93-fc5d49a54df3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORY"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_38bba0e1-d894-4d0e-83e5-0ad116cd3d15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_6b5b2bfe-7e83-436e-a3c6-db39b863ee2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_38bba0e1-d894-4d0e-83e5-0ad116cd3d15" xlink:to="loc_us-gaap_InventoryFinishedGoods_6b5b2bfe-7e83-436e-a3c6-db39b863ee2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_4e084ddf-18db-43d6-b1e2-0e21e956ddb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_38bba0e1-d894-4d0e-83e5-0ad116cd3d15" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_4e084ddf-18db-43d6-b1e2-0e21e956ddb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_6de8a6d9-a2a7-4da3-82d2-31f3245dedbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_38bba0e1-d894-4d0e-83e5-0ad116cd3d15" xlink:to="loc_us-gaap_InventoryWorkInProcess_6de8a6d9-a2a7-4da3-82d2-31f3245dedbe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBT"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTCreditagreementDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITAL"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALTables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALOptionsandRSUGrantsDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALFairvalueassumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALScheduleofSharebasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASE"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASETables"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEOperatingleasecostsDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8637590-dea0-47b9-9e64-87a138a44f12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6741b7fb-d51b-44c5-9102-739738cb5bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8637590-dea0-47b9-9e64-87a138a44f12" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6741b7fb-d51b-44c5-9102-739738cb5bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a59fd12f-9394-41e7-87a8-cbdc1a499d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8637590-dea0-47b9-9e64-87a138a44f12" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a59fd12f-9394-41e7-87a8-cbdc1a499d4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_97d139d8-d911-4d80-a8b8-3678d517c6dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8637590-dea0-47b9-9e64-87a138a44f12" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_97d139d8-d911-4d80-a8b8-3678d517c6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_231385b4-029d-48ce-a668-1cded47661ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8637590-dea0-47b9-9e64-87a138a44f12" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_231385b4-029d-48ce-a668-1cded47661ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_193a3f6c-30b7-4115-8e9e-6e05df269e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_113655de-7d34-4b5c-aed7-cd89968390d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_193a3f6c-30b7-4115-8e9e-6e05df269e14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_113655de-7d34-4b5c-aed7-cd89968390d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c172773e-47f7-4ad2-9e0c-6391f61018ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_193a3f6c-30b7-4115-8e9e-6e05df269e14" xlink:to="loc_us-gaap_OperatingLeaseLiability_c172773e-47f7-4ad2-9e0c-6391f61018ea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mnlo-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/Cover" xlink:type="simple" xlink:href="mnlo-20200630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/Cover" xlink:type="extended" id="i2f121dedb016416482c76ccf7b79cce1_Cover"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i089e1590d5214f599b709a626e182fb6_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ic0943471ce1642e79a9672e5547d22b9_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="iea137bce3abb49f69ba2327f6bebbac1_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ffdf12-3b51-4845-94b4-6481b34fdb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ffdf12-3b51-4845-94b4-6481b34fdb4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3e1a8058-e6b8-4a5a-8a01-e3a7d0f957c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3e1a8058-e6b8-4a5a-8a01-e3a7d0f957c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec187ba2-fce1-48bf-8ba3-ac72e3ecc459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec187ba2-fce1-48bf-8ba3-ac72e3ecc459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5723a63b-95c3-4eb4-9cc4-51df599667e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5723a63b-95c3-4eb4-9cc4-51df599667e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_33b8d31c-6f1b-4cdc-9f30-d57136b4a227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_33b8d31c-6f1b-4cdc-9f30-d57136b4a227" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_a7a119c5-548c-426e-b902-386d88363651" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_a7a119c5-548c-426e-b902-386d88363651" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1167aafe-e91d-482f-93b8-6f0ae6bb406e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_CostsAndExpenses_1167aafe-e91d-482f-93b8-6f0ae6bb406e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3e83fb1e-832a-4cfe-9bd5-f2a658a0f454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_OperatingIncomeLoss_3e83fb1e-832a-4cfe-9bd5-f2a658a0f454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialIncomeNet_e1e96f39-4e48-4c26-bc9a-42d4f8ea5563" xlink:href="mnlo-20200630.xsd#mnlo_FinancialIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_mnlo_FinancialIncomeNet_e1e96f39-4e48-4c26-bc9a-42d4f8ea5563" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialExpenses_1c5ddcbd-56a3-4bf5-9bfc-e03b6eaaeab2" xlink:href="mnlo-20200630.xsd#mnlo_FinancialExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_mnlo_FinancialExpenses_1c5ddcbd-56a3-4bf5-9bfc-e03b6eaaeab2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0dc348a-9517-4c6f-ba4a-efb1a23a286f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0dc348a-9517-4c6f-ba4a-efb1a23a286f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_702a7716-4f03-4561-aaa2-ece34dd09ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_702a7716-4f03-4561-aaa2-ece34dd09ddd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d288c200-6489-4d1f-975e-be318cb86115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_NetIncomeLoss_d288c200-6489-4d1f-975e-be318cb86115" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_251ca071-0c08-4db6-a6ee-8637ad843317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_251ca071-0c08-4db6-a6ee-8637ad843317" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a91b0d28-5067-4c4a-9816-c8890686783e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a91b0d28-5067-4c4a-9816-c8890686783e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:to="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f9445358-8c71-4609-8620-ad1d484a688f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:to="loc_srt_ProductsAndServicesDomain_f9445358-8c71-4609-8620-ad1d484a688f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:to="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_023c3177-df10-446b-a152-54b7cf6068d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_ProductMember_023c3177-df10-446b-a152-54b7cf6068d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_240b2841-0f2d-4997-bfe6-b2588f7f02d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_LicenseMember_240b2841-0f2d-4997-bfe6-b2588f7f02d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_74fca27b-9cc0-4924-aa5d-856a3dbdf9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_RoyaltyMember_74fca27b-9cc0-4924-aa5d-856a3dbdf9fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="i093852ead1704fc7a493f8c2bbb14d6f_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="id9c0953a0c314dc0804bb77b66a83a47_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd4c8c25-0c83-4e8d-91b7-4c1351aa56ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockholdersEquity_dd4c8c25-0c83-4e8d-91b7-4c1351aa56ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_313e3192-deeb-42df-a3f8-91bd0c85442c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_313e3192-deeb-42df-a3f8-91bd0c85442c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a3f3f6fb-6bbb-40ae-89b5-d042ef850cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a3f3f6fb-6bbb-40ae-89b5-d042ef850cb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3cabfe02-6f4a-4589-8558-d539c8c074e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3cabfe02-6f4a-4589-8558-d539c8c074e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06945a6d-b60f-41dd-aa18-eee216db59ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06945a6d-b60f-41dd-aa18-eee216db59ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_0480e528-bbe7-4b5b-a81f-f47d645b7a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_0480e528-bbe7-4b5b-a81f-f47d645b7a3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6a82663c-b0a4-444f-a524-d4a0aa6265b2" xlink:href="mnlo-20200630.xsd#mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6a82663c-b0a4-444f-a524-d4a0aa6265b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_cc9e1367-fd02-4ae2-b042-bc8ddda74bda" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_cc9e1367-fd02-4ae2-b042-bc8ddda74bda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_78916af7-124a-488f-9994-d8901e55bbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_78916af7-124a-488f-9994-d8901e55bbb3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_202255c4-c1fa-4779-8ca5-56f3494c2594" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_202255c4-c1fa-4779-8ca5-56f3494c2594" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa0133e8-738c-4649-b2aa-5fda3f864df4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa0133e8-738c-4649-b2aa-5fda3f864df4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_25e7c9ba-d294-4242-803a-d6f8da6a2006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_25e7c9ba-d294-4242-803a-d6f8da6a2006" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22b5a923-a4c5-4782-ad3f-54b7eee2dac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ebc32070-6fc0-4c29-aceb-17a09564c952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:to="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b0f0beb-18ff-41f9-94bb-774240c8b006_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:to="loc_us-gaap_EquityComponentDomain_2b0f0beb-18ff-41f9-94bb-774240c8b006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:to="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a8002d3-0c10-490e-8bcb-618b0e124da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_CommonStockMember_3a8002d3-0c10-490e-8bcb-618b0e124da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5e82583a-f43f-461d-b877-6829c683b950" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5e82583a-f43f-461d-b877-6829c683b950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5bfce31e-7984-4953-94df-ed4262259771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_RetainedEarningsMember_5bfce31e-7984-4953-94df-ed4262259771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ab73414e-5196-4062-b1b6-6381a64cf0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ab73414e-5196-4062-b1b6-6381a64cf0e3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="ib4ed6c4b457747439f80fcbe265eb91b_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i519f3fe5dc20473ca7cf6b76a6d1f4ac_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="extended" id="i74a63fc9745e4ca3822ebb48c27e5dcd_NATUREOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONSDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="extended" id="i7fc723ba15ab4684bf20ccd1811db97b_NATUREOFOPERATIONSDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i6ee4ef9e8eca44b9b22f1a376af247a3_SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i3018c093480a4d68bb79092900ff2d40_SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="i9d88b61a565c401c95bbac0d6aa82a44_SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="ic7692cd2e133497d9a483aed7eeed87e_SIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_UpfrontRoyaltyReceipt_783570f4-bd78-49e3-b3b7-21feab910d2e" xlink:href="mnlo-20200630.xsd#mnlo_UpfrontRoyaltyReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_UpfrontRoyaltyReceipt_783570f4-bd78-49e3-b3b7-21feab910d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_cd196fa5-83ea-4715-bb1c-b35dbf7ad284" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_cd196fa5-83ea-4715-bb1c-b35dbf7ad284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d19eb1e5-4735-456b-9886-16b3d186436b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d19eb1e5-4735-456b-9886-16b3d186436b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_a67396b2-5df1-4e3a-b374-5baf7ea91146" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_a67396b2-5df1-4e3a-b374-5baf7ea91146" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_c2c7333f-1ef4-4990-aec3-ac84b1a771b1" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationEffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_c2c7333f-1ef4-4990-aec3-ac84b1a771b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_406ba68a-9f4b-4b1f-bae3-423c5343023d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_406ba68a-9f4b-4b1f-bae3-423c5343023d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_5f0cc1b1-66c1-41f5-8505-1ad11f84a44c" xlink:href="mnlo-20200630.xsd#mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:to="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_5f0cc1b1-66c1-41f5-8505-1ad11f84a44c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0c11fd9f-9849-4c50-bc6d-4cee4972a3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:to="loc_us-gaap_WarrantMember_0c11fd9f-9849-4c50-bc6d-4cee4972a3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:to="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2f088283-60df-4252-bf90-75c5e2628310_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:to="loc_dei_EntityDomain_2f088283-60df-4252-bf90-75c5e2628310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:to="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_684b2cef-6d3c-4f3b-9bae-97b3cf653dbe" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:to="loc_mnlo_FoamixMember_684b2cef-6d3c-4f3b-9bae-97b3cf653dbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATION"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="extended" id="ia26296eff03f4ef48bd2434f58d8d7b7_BUSINESSCOMBINATION"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="extended" id="iaf0d92ff65394043a03f4de762de64ce_BUSINESSCOMBINATIONTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended" id="ic8b43773fe054599a256752396225919_BUSINESSCOMBINATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ExchangeRatio_66220aab-9ff4-4c9f-8dfd-f97515d16439" xlink:href="mnlo-20200630.xsd#mnlo_ExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ExchangeRatio_66220aab-9ff4-4c9f-8dfd-f97515d16439" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_9b90d861-fc5d-4bcc-a44e-fcc42d0648a1" xlink:href="mnlo-20200630.xsd#mnlo_BusinessAcquisitionContingentStockRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_9b90d861-fc5d-4bcc-a44e-fcc42d0648a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_692fe23a-52c9-4902-817b-a529069db1df" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_692fe23a-52c9-4902-817b-a529069db1df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EffectiveExchangeRatio_d851d181-258e-46fb-91f8-5c2b570c6fc3" xlink:href="mnlo-20200630.xsd#mnlo_EffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_EffectiveExchangeRatio_d851d181-258e-46fb-91f8-5c2b570c6fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_dc9df128-acf3-4c93-b68c-6a6fbfb1de17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_dc9df128-acf3-4c93-b68c-6a6fbfb1de17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_7b5487a8-23dd-4904-bf00-83a897f19a26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_7b5487a8-23dd-4904-bf00-83a897f19a26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_a9342da2-30bd-4a69-83dd-fba5c74277dc" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_a9342da2-30bd-4a69-83dd-fba5c74277dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_1d359623-df67-446f-9a7e-311a4bb89dd8" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_1d359623-df67-446f-9a7e-311a4bb89dd8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_68eb2706-7ac4-419d-9297-d77e45723704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_68eb2706-7ac4-419d-9297-d77e45723704" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_709b1116-876d-4cc8-b058-730a31025b0f" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_709b1116-876d-4cc8-b058-730a31025b0f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross_8e87a27a-0212-41bf-af16-0c1d804ae2a3" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredGross_8e87a27a-0212-41bf-af16-0c1d804ae2a3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84b1a1f5-ea51-40dd-95a3-dba82d371ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_SharePrice_84b1a1f5-ea51-40dd-95a3-dba82d371ae1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_4f6dab12-3ee4-4b35-beaa-5286d1839d8a" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_4f6dab12-3ee4-4b35-beaa-5286d1839d8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_997a0e76-dca2-4117-87a1-9c363180edd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_997a0e76-dca2-4117-87a1-9c363180edd0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dcbadaad-b8c5-4a26-ae70-4fb456f4219f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dcbadaad-b8c5-4a26-ae70-4fb456f4219f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_c15a9508-52c2-4045-8305-562383679101" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_c15a9508-52c2-4045-8305-562383679101" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_8faa1280-8e7a-4322-b960-415a1446039a" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_8faa1280-8e7a-4322-b960-415a1446039a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_797d6401-7f54-4bf3-8ada-99f624112d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_797d6401-7f54-4bf3-8ada-99f624112d7e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_f5857652-0fe3-446b-88e5-77021737efdb" xlink:href="mnlo-20200630.xsd#mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_f5857652-0fe3-446b-88e5-77021737efdb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a05f0356-27e7-4eed-b892-946231868b0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:to="loc_us-gaap_EquityComponentDomain_a05f0356-27e7-4eed-b892-946231868b0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:to="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48a6284f-e14a-4006-b14d-47396e66cff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:to="loc_us-gaap_CommonStockMember_48a6284f-e14a-4006-b14d-47396e66cff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_211bb1d3-f676-464a-a011-9808189717c3" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:to="loc_mnlo_FoamixMember_211bb1d3-f676-464a-a011-9808189717c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_37709cfa-982d-40e5-b0fb-5004fe2ff799_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_37709cfa-982d-40e5-b0fb-5004fe2ff799_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77918d5a-2bf6-48f5-8ab0-456764e476fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77918d5a-2bf6-48f5-8ab0-456764e476fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_eda03fbb-180a-4b40-be0f-fecaae58f79e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_eda03fbb-180a-4b40-be0f-fecaae58f79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2914604d-78c1-48be-8beb-146d9095aff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2914604d-78c1-48be-8beb-146d9095aff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c6c545e-915e-4b06-95c9-4530fa5599ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6c6c545e-915e-4b06-95c9-4530fa5599ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6fe7c8a5-2f2a-4298-946f-b219bb3bf991" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6fe7c8a5-2f2a-4298-946f-b219bb3bf991" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended" id="i6896cc581f4c46adb918dce0c22e0472_BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8daefecd-89c7-42ce-b1d7-1fc5dcf6f963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8daefecd-89c7-42ce-b1d7-1fc5dcf6f963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_7e5ff231-486d-4bfe-ba91-ca0482d7a483" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_7e5ff231-486d-4bfe-ba91-ca0482d7a483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross_7f40729f-e655-4867-848a-00033af4c8ed" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredGross_7f40729f-e655-4867-848a-00033af4c8ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c9e1676-b97a-4bfd-b2a3-5d594ddb4c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c9e1676-b97a-4bfd-b2a3-5d594ddb4c00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30cf1710-e7ac-40e1-9203-4cdaf7662a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30cf1710-e7ac-40e1-9203-4cdaf7662a6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3243c065-b4b4-4d78-814b-f0fa4c0e42e2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3243c065-b4b4-4d78-814b-f0fa4c0e42e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_21424dd9-4678-49d9-af03-31466c8d489f" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:to="loc_mnlo_FoamixMember_21424dd9-4678-49d9-af03-31466c8d489f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended" id="i8b63e397a89d47679c24a5c0508fbd55_BUSINESSCOMBINATIONPurchasePriceAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3242f1bd-0863-4f4e-ad91-15280d2992b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3242f1bd-0863-4f4e-ad91-15280d2992b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ada42923-53d3-4f7a-a1f5-ed8c0004aad5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ada42923-53d3-4f7a-a1f5-ed8c0004aad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d6f8f619-df0c-44f9-8cdb-1d4e24652adc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d6f8f619-df0c-44f9-8cdb-1d4e24652adc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_28ca261b-d7f5-4fb3-8330-e17d152545c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_28ca261b-d7f5-4fb3-8330-e17d152545c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7742952a-43cf-4122-9a0a-b66f6988828c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_Goodwill_7742952a-43cf-4122-9a0a-b66f6988828c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_be82dbf9-eb79-4800-8bbc-9dfd773df177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_be82dbf9-eb79-4800-8bbc-9dfd773df177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_da21d1a0-8e6e-4d1c-ab52-1bb7a287464f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_da21d1a0-8e6e-4d1c-ab52-1bb7a287464f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a46acbd-7450-4401-8658-6f168ca4e191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a46acbd-7450-4401-8658-6f168ca4e191" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d20e4230-b368-4295-926a-5f9f62a9891b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d20e4230-b368-4295-926a-5f9f62a9891b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_cb4b5489-bf49-4e89-9664-0efc727e08ab" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_cb4b5489-bf49-4e89-9664-0efc727e08ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa119f4d-589c-4baa-8101-174fff9aab70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa119f4d-589c-4baa-8101-174fff9aab70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_19629568-2ead-4d26-9274-af0f1bb71926" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:to="loc_mnlo_FoamixMember_19629568-2ead-4d26-9274-af0f1bb71926" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended" id="i8b9cd0830748459c8152b502b47f1b61_BUSINESSCOMBINATIONGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:to="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_03ac17dc-b1a8-420d-9796-7bf5cdb99335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_03ac17dc-b1a8-420d-9796-7bf5cdb99335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_37ffe518-e8ad-4017-b2db-8f794829f81f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_37ffe518-e8ad-4017-b2db-8f794829f81f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_d7414da6-a2f0-4a12-a01d-a3adca51d3b5" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_d7414da6-a2f0-4a12-a01d-a3adca51d3b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25f2a094-b310-4f4e-b642-f549682fe29b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_Goodwill_25f2a094-b310-4f4e-b642-f549682fe29b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_e094d27f-9529-4ddb-9f0f-9a8922f5b74f" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:to="loc_mnlo_FoamixMember_e094d27f-9529-4ddb-9f0f-9a8922f5b74f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended" id="i6627ad38c264485390862b410682b94b_BUSINESSCOMBINATIONIPRDandCSRDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_55fd279f-8e8e-41a9-bc37-9f4adc859b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_55fd279f-8e8e-41a9-bc37-9f4adc859b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_26de5298-62b1-4c6c-917d-7e56a20dc4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_26de5298-62b1-4c6c-917d-7e56a20dc4d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e12e8008-767a-4a85-b4d5-47aef320bab1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e12e8008-767a-4a85-b4d5-47aef320bab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_a1808cb7-7c44-44e2-9d24-86541a6420de" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:to="loc_mnlo_FoamixMember_a1808cb7-7c44-44e2-9d24-86541a6420de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended" id="i979eda42347e4c53a7cb2e90dc18ad07_BUSINESSCOMBINATIONProFormaDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITION"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="extended" id="i9a86635a06c94142b983267e4086c7af_REVENUERECOGNITION"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITIONDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended" id="i969ead33b94141c1a237c1466f4f81e9_REVENUERECOGNITIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f2afd489-3607-4675-890a-f737d8207708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f2afd489-3607-4675-890a-f737d8207708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_4a381e4b-8618-4112-ba9b-6ec15682dfd5" xlink:href="mnlo-20200630.xsd#mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_4a381e4b-8618-4112-ba9b-6ec15682dfd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMinimum_4de65934-b2d8-4b41-834a-1bef4304a010" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_EstimateOfProductReturnRateMinimum_4de65934-b2d8-4b41-834a-1bef4304a010" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMaximum_4cdce2ef-4a88-4b7a-b1f6-892beb6811a3" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_EstimateOfProductReturnRateMaximum_4cdce2ef-4a88-4b7a-b1f6-892beb6811a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_UpfrontRoyaltyReceipt_7c2c47fc-f16e-4b6e-9e5a-e76cb77f4519" xlink:href="mnlo-20200630.xsd#mnlo_UpfrontRoyaltyReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_UpfrontRoyaltyReceipt_7c2c47fc-f16e-4b6e-9e5a-e76cb77f4519" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_0000080f-8021-473a-8ee2-5a5451ed15a4" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_0000080f-8021-473a-8ee2-5a5451ed15a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f1ee32bf-da26-430d-9fa8-20eaff68e997" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f1ee32bf-da26-430d-9fa8-20eaff68e997" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0332526-310d-438d-8632-e342e8bd66eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0332526-310d-438d-8632-e342e8bd66eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4a5e906e-a435-416b-8a66-c59f80ef66b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4a5e906e-a435-416b-8a66-c59f80ef66b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3f02a4b9-0d77-44f3-a883-18bd63a77796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3f02a4b9-0d77-44f3-a883-18bd63a77796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91d81155-ae3b-43a4-9e7a-ff83ae572b6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_91d81155-ae3b-43a4-9e7a-ff83ae572b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_b7e245ff-4021-458e-a31a-69e3ef02d058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_b7e245ff-4021-458e-a31a-69e3ef02d058" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a0277546-ccf6-4734-8b64-bfee25d5db81_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:to="loc_srt_NameOfMajorCustomerDomain_a0277546-ccf6-4734-8b64-bfee25d5db81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:to="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorOneMember_480c5667-c05f-47a2-b657-62097f8a4abe" xlink:href="mnlo-20200630.xsd#mnlo_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorOneMember_480c5667-c05f-47a2-b657-62097f8a4abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorTwoMember_c24fe83e-dcda-4826-9a24-282e9f338f46" xlink:href="mnlo-20200630.xsd#mnlo_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorTwoMember_c24fe83e-dcda-4826-9a24-282e9f338f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorThreeMember_4a18e68d-35c7-4163-9c82-3026ebff6475" xlink:href="mnlo-20200630.xsd#mnlo_DistributorThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorThreeMember_4a18e68d-35c7-4163-9c82-3026ebff6475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a6e60e7-e500-442f-a2be-9beda8873093_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:to="loc_srt_ProductsAndServicesDomain_1a6e60e7-e500-442f-a2be-9beda8873093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:to="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_70c428e7-55b4-4a95-ad03-231685f5360a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:to="loc_us-gaap_RoyaltyMember_70c428e7-55b4-4a95-ad03-231685f5360a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_080e1ffb-3046-44b1-bae2-724fd3879dc2_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:to="loc_dei_EntityDomain_080e1ffb-3046-44b1-bae2-724fd3879dc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:to="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_0faebf34-4d0f-444a-88d3-54fd4db87fe8" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:to="loc_mnlo_FoamixMember_0faebf34-4d0f-444a-88d3-54fd4db87fe8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENT"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="extended" id="i154a95e620254b3a947c924549cb9e7a_FAIRVALUEMEASUREMENT"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="extended" id="ia65cb56645df40cd8813704f3536f84b_FAIRVALUEMEASUREMENTTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i385ad2c6dce54bc4a9a63581193af5ff_FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_eefbf7d0-72aa-4b26-b8c1-6f182c65efd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:to="loc_us-gaap_MarketableSecurities_eefbf7d0-72aa-4b26-b8c1-6f182c65efd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b6a6333-72bc-48c5-b830-b3f56c082cbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3b6a6333-72bc-48c5-b830-b3f56c082cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_97d859a7-cdb5-470e-b148-14f937d6c7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_97d859a7-cdb5-470e-b148-14f937d6c7d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4745704b-4862-4694-acb9-e71be9f15b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4745704b-4862-4694-acb9-e71be9f15b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ca8699d9-4783-4ae1-9c73-a10e27d09d32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ca8699d9-4783-4ae1-9c73-a10e27d09d32" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="extended" id="i80364df8dfa94dbdbe945e2dc0d95b89_FAIRVALUEMEASUREMENTNarrativeDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIES"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="extended" id="ibaa35bee466a4b159065ae8abdb3b7f5_MARKETABLESECURITIES"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="extended" id="ia0a7dd6922a94b5e98508a348c9d83ed_MARKETABLESECURITIESTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="extended" id="ic051077c37f34384afca103b57f25497_MARKETABLESECURITIESMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1d8e5aaf-9eec-48da-93f0-efd6c40cf78e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:to="loc_us-gaap_ShortTermInvestments_1d8e5aaf-9eec-48da-93f0-efd6c40cf78e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:to="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c65af340-ae5f-4b2f-a35e-5c116ff67cdc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c65af340-ae5f-4b2f-a35e-5c116ff67cdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IsraeliMutualFundsMember_47c8d35d-18be-4d99-b478-aafbdb9615d1" xlink:href="mnlo-20200630.xsd#mnlo_IsraeliMutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_mnlo_IsraeliMutualFundsMember_47c8d35d-18be-4d99-b478-aafbdb9615d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7a918f19-3c22-4879-be1b-16a3e145e102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7a918f19-3c22-4879-be1b-16a3e145e102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_56fec657-945e-4185-a5b2-009a42ba6690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_56fec657-945e-4185-a5b2-009a42ba6690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_2b3963c0-7125-4be6-b798-5b47e00259e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_2b3963c0-7125-4be6-b798-5b47e00259e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_1ba16c3d-6c39-420d-b530-836aba913299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_1ba16c3d-6c39-420d-b530-836aba913299" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="extended" id="ic14b0fef23244848906d121507f9855b_MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9456ef-a94b-4f8d-9618-e0530725da0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9456ef-a94b-4f8d-9618-e0530725da0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b78e8a4-e563-47c8-b6be-d3ddbc556476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b78e8a4-e563-47c8-b6be-d3ddbc556476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37708b80-d103-42b7-a7a6-a02e57715f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37708b80-d103-42b7-a7a6-a02e57715f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b56e44b6-1088-4fc4-88e4-0da30848997d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b56e44b6-1088-4fc4-88e4-0da30848997d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:to="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f94e760d-a2c7-482c-8cb5-989a55399401_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f94e760d-a2c7-482c-8cb5-989a55399401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_5d56583d-6400-4038-843b-a269e6311475" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_5d56583d-6400-4038-843b-a269e6311475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_12d2f835-0c62-4065-952d-c8d302452cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_12d2f835-0c62-4065-952d-c8d302452cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_6795ee20-a8ff-4b13-98ae-926f74c9dcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_6795ee20-a8ff-4b13-98ae-926f74c9dcc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8255fb18-e2dd-46f5-9b27-52d0aaefcbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8255fb18-e2dd-46f5-9b27-52d0aaefcbfa" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="extended" id="ie2c287dd78e24ae496d33de54e93ea5a_MARKETABLESECURITIESNarrativeDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORY"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="extended" id="i53aafadbfcb84db3a19a167f65d8bc16_INVENTORY"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="extended" id="i8ddc6f382c254f5490d3e0027e5f2aaf_INVENTORYTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="extended" id="i3f3f68d79fb048f7b4d2cdbc7b71b4aa_INVENTORYDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBT"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="extended" id="i9ad04fa2882f40b884c3c6b4ed9e1f03_LONGTERMDEBT"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTCreditagreementDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="extended" id="i20439c72a48d4c2ea60212d41fbe0c19_LONGTERMDEBTCreditagreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da9b76f7-5008-4934-b5ce-56232b88b20e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da9b76f7-5008-4934-b5ce-56232b88b20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8b9e0e1a-012e-4ddb-b649-0cfaa2fccf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8b9e0e1a-012e-4ddb-b649-0cfaa2fccf8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfLenders_282f1494-e3b7-4fd2-b3b6-b98e93780570" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfLenders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_NumberOfLenders_282f1494-e3b7-4fd2-b3b6-b98e93780570" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_464761a4-04b6-4e26-aa61-b0d9aa7df952" xlink:href="mnlo-20200630.xsd#mnlo_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_464761a4-04b6-4e26-aa61-b0d9aa7df952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e18a8d2e-79a1-4b71-8025-70d378456535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e18a8d2e-79a1-4b71-8025-70d378456535" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CreditAgreementNumberOfTrenches_f5cd3cfc-9f17-4190-8e7d-9c7be5eca159" xlink:href="mnlo-20200630.xsd#mnlo_CreditAgreementNumberOfTrenches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_CreditAgreementNumberOfTrenches_f5cd3cfc-9f17-4190-8e7d-9c7be5eca159" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f8fd8c6-20e5-4db9-9443-3fd290f25af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f8fd8c6-20e5-4db9-9443-3fd290f25af4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd4caf93-98b6-499f-8510-b17791677a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd4caf93-98b6-499f-8510-b17791677a38" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentFeePercent_4c3ca54a-ebb4-4ca7-a718-57de440e5880" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtInstrumentFeePercent_4c3ca54a-ebb4-4ca7-a718-57de440e5880" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_2c562767-74f5-4858-a897-97bb8fd19b9f" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_2c562767-74f5-4858-a897-97bb8fd19b9f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_58aa52c6-7d5e-40ac-92f2-7809527785aa" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_58aa52c6-7d5e-40ac-92f2-7809527785aa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_105ceff4-1733-44fe-a4ab-87246f8042a2" xlink:href="mnlo-20200630.xsd#mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:to="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_105ceff4-1733-44fe-a4ab-87246f8042a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_763a3c80-a506-4c1c-bfec-bf6144d5ea0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_763a3c80-a506-4c1c-bfec-bf6144d5ea0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RegisteredOfferingMember_ef2e2b46-c5fb-45cc-8e7a-7e0cd36eeb7e" xlink:href="mnlo-20200630.xsd#mnlo_RegisteredOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:to="loc_mnlo_RegisteredOfferingMember_ef2e2b46-c5fb-45cc-8e7a-7e0cd36eeb7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:to="loc_us-gaap_RelatedPartyDomain_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:to="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareholderLenderMember_2e593dd6-e0b4-4b70-a80c-bd1106ef5a8c" xlink:href="mnlo-20200630.xsd#mnlo_ShareholderLenderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:to="loc_mnlo_ShareholderLenderMember_2e593dd6-e0b4-4b70-a80c-bd1106ef5a8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b156834f-c34d-49be-b120-045d098b5d59_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b156834f-c34d-49be-b120-045d098b5d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_4291eab5-041b-43a8-aed5-8fadcab0c566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:to="loc_us-gaap_SecuredDebtMember_4291eab5-041b-43a8-aed5-8fadcab0c566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_16fd7aad-169b-4c1c-8832-fc0bcbdcc72b" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_16fd7aad-169b-4c1c-8832-fc0bcbdcc72b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_9d42595b-1a42-4e3f-b6ca-8897f399d615" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_9d42595b-1a42-4e3f-b6ca-8897f399d615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_0bf24754-b7d1-483c-8be3-07e2c87fc75a" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_0bf24754-b7d1-483c-8be3-07e2c87fc75a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5a667104-d727-41a9-bb1c-58bfdd6c7f6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:to="loc_us-gaap_VariableRateDomain_5a667104-d727-41a9-bb1c-58bfdd6c7f6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:to="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3c2041ed-92aa-4944-9535-25afc5af47de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3c2041ed-92aa-4944-9535-25afc5af47de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_99a220a0-c09a-4aea-b5bd-9c7a870c93d9_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_99a220a0-c09a-4aea-b5bd-9c7a870c93d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9372368a-92b2-4feb-8dfd-de574361326a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:to="loc_srt_ScenarioForecastMember_9372368a-92b2-4feb-8dfd-de574361326a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0c51ea9-05b8-470f-88ae-187eb763d9a2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0c51ea9-05b8-470f-88ae-187eb763d9a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cfa1e141-9106-425c-b745-cf6e8dbd3987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:to="loc_us-gaap_SubsequentEventMember_cfa1e141-9106-425c-b745-cf6e8dbd3987" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="extended" id="ib8f770a5275e4323bd35174b9ca19693_LONGTERMDEBTWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_54786f8d-6394-469a-8a0c-e21d75eec213" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_54786f8d-6394-469a-8a0c-e21d75eec213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:href="mnlo-20200630.xsd#mnlo_ClassOfWarrantAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a42346bc-df2a-4e2a-a004-37c9fd7bb17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a42346bc-df2a-4e2a-a004-37c9fd7bb17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60a7b077-2932-4d82-9c96-16677877ca05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60a7b077-2932-4d82-9c96-16677877ca05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_99da0197-1757-4d66-b488-f68fb8454a94" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_99da0197-1757-4d66-b488-f68fb8454a94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_9eab91f2-8071-43b5-bea4-1914eb8b39dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_9eab91f2-8071-43b5-bea4-1914eb8b39dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ead9d28c-63e9-41f4-a80a-34d0f303a4de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_InterestExpenseDebt_ead9d28c-63e9-41f4-a80a-34d0f303a4de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7eb0e583-96a7-4c4c-b880-108ce039cb6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7eb0e583-96a7-4c4c-b880-108ce039cb6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0c6bc304-e4c3-4376-809b-53a0d55669d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0c6bc304-e4c3-4376-809b-53a0d55669d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:to="loc_dei_EntityDomain_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:to="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_88bba2ce-45dd-4bdc-9c02-ad32e179a0c9" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:to="loc_mnlo_FoamixMember_88bba2ce-45dd-4bdc-9c02-ad32e179a0c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_082cfe51-9566-4524-aff7-94d2d4ea22b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:to="loc_us-gaap_RelatedPartyDomain_082cfe51-9566-4524-aff7-94d2d4ea22b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:to="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareholderLenderMember_4b757dfb-355c-49cc-8c3e-a51e03ff416b" xlink:href="mnlo-20200630.xsd#mnlo_ShareholderLenderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:to="loc_mnlo_ShareholderLenderMember_4b757dfb-355c-49cc-8c3e-a51e03ff416b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8e650af-6ac9-4757-8c3c-ccd2c894a81d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8e650af-6ac9-4757-8c3c-ccd2c894a81d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_d5d1cd9a-fae7-4de5-b574-ba895e16aab5" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_d5d1cd9a-fae7-4de5-b574-ba895e16aab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_1d53469b-2698-45e7-95e1-32d105931d6a" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_1d53469b-2698-45e7-95e1-32d105931d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e94b596b-5755-4d6a-9ffa-2c2ccaa250ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_us-gaap_SecuredDebtMember_e94b596b-5755-4d6a-9ffa-2c2ccaa250ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f6079f1-209a-42ab-b317-75f9c904d555_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f6079f1-209a-42ab-b317-75f9c904d555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bdb0240e-9753-437a-8261-a8511c3f73a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bdb0240e-9753-437a-8261-a8511c3f73a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f290a8b3-0341-43e8-8e94-b7e77f348ba0_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:to="loc_srt_RangeMember_f290a8b3-0341-43e8-8e94-b7e77f348ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:to="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61ac449e-df60-47c8-a3d5-63f69000d312" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:to="loc_srt_MaximumMember_61ac449e-df60-47c8-a3d5-63f69000d312" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITAL"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="extended" id="i52982e17db3345848015f5fec006e708_SHARECAPITAL"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALTables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="extended" id="ib878db70ab784fa1bb308461e19ec520_SHARECAPITALTables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="extended" id="i367524ee4227426bb90f93ad16300604_SHARECAPITALNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5a1379fa-369e-4624-bab9-e00ee5b67e49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5a1379fa-369e-4624-bab9-e00ee5b67e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6534bfec-75ae-41cd-8eea-d2fd5b493bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6534bfec-75ae-41cd-8eea-d2fd5b493bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6c9b878a-b130-4ece-b6a1-24890cbdb5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6c9b878a-b130-4ece-b6a1-24890cbdb5d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4da035d5-98a8-4287-bc2d-57314b207ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4da035d5-98a8-4287-bc2d-57314b207ec6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_46946fff-0d3e-42d7-af97-6a67e01351b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_46946fff-0d3e-42d7-af97-6a67e01351b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_456e0d0b-35ea-4258-9090-c173ad7b03ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_456e0d0b-35ea-4258-9090-c173ad7b03ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockVotingRightsNumberPerShare_31e6eb13-c262-4e1e-8cc4-dfff5ec601a5" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockVotingRightsNumberPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_CommonStockVotingRightsNumberPerShare_31e6eb13-c262-4e1e-8cc4-dfff5ec601a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5431dcb4-a336-45c7-b75b-8786833e2b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5431dcb4-a336-45c7-b75b-8786833e2b97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_97a6cfa9-65bd-463e-ad6c-2bcc5358aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_97a6cfa9-65bd-463e-ad6c-2bcc5358aeba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_87287e49-749f-45ae-9f18-0dfbec910ff5" xlink:href="mnlo-20200630.xsd#mnlo_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_87287e49-749f-45ae-9f18-0dfbec910ff5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_28ede63e-50b9-41ce-8c29-59ca2d599b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_28ede63e-50b9-41ce-8c29-59ca2d599b6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dfcff741-86fa-4486-bcb5-c0fff53793ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dfcff741-86fa-4486-bcb5-c0fff53793ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26482acd-40d5-43ba-b92e-8893f4d90618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26482acd-40d5-43ba-b92e-8893f4d90618" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e70a60e5-7f4a-4110-8f18-5ae8c2e27f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e70a60e5-7f4a-4110-8f18-5ae8c2e27f1b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_123a44b6-5c5b-4131-aef3-1d56af53c33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_123a44b6-5c5b-4131-aef3-1d56af53c33d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_af2b05ea-fcc2-4a8e-a617-d6c5c0cf87cb" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_af2b05ea-fcc2-4a8e-a617-d6c5c0cf87cb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_c4da9942-177d-4c58-a61c-3b6241e7c012" xlink:href="mnlo-20200630.xsd#mnlo_BusinessAcquisitionContingentStockRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_c4da9942-177d-4c58-a61c-3b6241e7c012" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6d172a1f-fcaa-4cfa-a8d2-35fb98c3da8e" xlink:href="mnlo-20200630.xsd#mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6d172a1f-fcaa-4cfa-a8d2-35fb98c3da8e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_5e04c4c3-0506-4198-903b-5a6b772f5779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_5e04c4c3-0506-4198-903b-5a6b772f5779" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_65abcce9-692e-4d94-a969-b74b1c3bf2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_65abcce9-692e-4d94-a969-b74b1c3bf2c1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_998116d5-67b6-4aab-af2c-ead6c755c780" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_998116d5-67b6-4aab-af2c-ead6c755c780" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_fea691aa-b9b8-4f76-873c-195b05b6bb66" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_fea691aa-b9b8-4f76-873c-195b05b6bb66" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d9f2d6c2-b5d6-49c2-b7e6-1b821beeb620" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d9f2d6c2-b5d6-49c2-b7e6-1b821beeb620" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_03537076-6bbf-4098-94cc-54740886ec07" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_03537076-6bbf-4098-94cc-54740886ec07" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b117c72-d814-49c4-b83d-9a57dbbde1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b117c72-d814-49c4-b83d-9a57dbbde1f8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_a7596f1a-7b7a-46e9-8af9-9becb079dddb" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_a7596f1a-7b7a-46e9-8af9-9becb079dddb" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EffectiveExchangeRatio_819c14c6-c42d-454d-8a77-201075637034" xlink:href="mnlo-20200630.xsd#mnlo_EffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_EffectiveExchangeRatio_819c14c6-c42d-454d-8a77-201075637034" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6c3384ce-8f10-4fea-b7fc-96d58adf0b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6c3384ce-8f10-4fea-b7fc-96d58adf0b0e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_c364b08c-cdb6-4fbc-a0f4-970cdfc60a8b" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_c364b08c-cdb6-4fbc-a0f4-970cdfc60a8b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_5bfd971a-6b52-4eb0-a1c9-a36c4c24a630" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_5bfd971a-6b52-4eb0-a1c9-a36c4c24a630" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_50da0ced-ea5d-451d-a71f-6035bd582351" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_50da0ced-ea5d-451d-a71f-6035bd582351" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_6359dc3f-6f5a-4733-802f-3d98af404f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_6359dc3f-6f5a-4733-802f-3d98af404f51" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0837bc72-2140-4832-8506-a64ed24fa758_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:to="loc_us-gaap_EquityComponentDomain_0837bc72-2140-4832-8506-a64ed24fa758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:to="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d457027-44fb-4c5d-920a-fe213c505eab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_us-gaap_CommonStockMember_7d457027-44fb-4c5d-920a-fe213c505eab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OrdinarySharesMember_79918474-2063-4431-962d-db859d00a4b5" xlink:href="mnlo-20200630.xsd#mnlo_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_mnlo_OrdinarySharesMember_79918474-2063-4431-962d-db859d00a4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a6a91526-2a4c-4332-9fdf-c12f9bdd7f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_us-gaap_WarrantMember_a6a91526-2a4c-4332-9fdf-c12f9bdd7f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3545dada-2815-453a-b9a3-5b3531ef10a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3545dada-2815-453a-b9a3-5b3531ef10a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RegisteredOfferingMember_718a5565-964a-4734-8e18-377be5b1582d" xlink:href="mnlo-20200630.xsd#mnlo_RegisteredOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:to="loc_mnlo_RegisteredOfferingMember_718a5565-964a-4734-8e18-377be5b1582d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PublicStockOfferingMember_ec215152-c3ce-49a8-85ce-6cb672429a5a" xlink:href="mnlo-20200630.xsd#mnlo_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:to="loc_mnlo_PublicStockOfferingMember_ec215152-c3ce-49a8-85ce-6cb672429a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_61d9d391-1dcc-47b0-bb2a-fab241ebdb19_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:to="loc_dei_EntityDomain_61d9d391-1dcc-47b0-bb2a-fab241ebdb19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:to="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_d9c3af22-2943-4656-abfe-b58efbedc48d" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:to="loc_mnlo_FoamixMember_d9c3af22-2943-4656-abfe-b58efbedc48d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_de2b33b8-470b-480b-b8b5-601a77dc1e9b" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:to="loc_mnlo_FoamixMember_de2b33b8-470b-480b-b8b5-601a77dc1e9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_c058819d-e510-4612-bdab-339df499ddce" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_c058819d-e510-4612-bdab-339df499ddce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6b423bda-4a3b-4a76-b1a9-f28705cc6b24_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:to="loc_srt_RangeMember_6b423bda-4a3b-4a76-b1a9-f28705cc6b24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:to="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee7d08a6-4996-49f7-aa5a-d562b1e23359" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:to="loc_srt_MaximumMember_ee7d08a6-4996-49f7-aa5a-d562b1e23359" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9fc65106-ee19-4959-9369-88efc4e9b0df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:to="loc_us-gaap_PlanNameDomain_9fc65106-ee19-4959-9369-88efc4e9b0df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:to="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EmployeeStockPurchasePlanMember_c0e6d3f7-3dda-4de3-8b9c-27abb7907847" xlink:href="mnlo-20200630.xsd#mnlo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_EmployeeStockPurchasePlanMember_c0e6d3f7-3dda-4de3-8b9c-27abb7907847" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CSRAgreementMember_3bee4ebe-ab7e-4c39-afe1-a0049ca930a8" xlink:href="mnlo-20200630.xsd#mnlo_CSRAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_CSRAgreementMember_3bee4ebe-ab7e-4c39-afe1-a0049ca930a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2018PlanMember_2caf29f4-0f6f-4e07-8fc9-450490399870" xlink:href="mnlo-20200630.xsd#mnlo_A2018PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_A2018PlanMember_2caf29f4-0f6f-4e07-8fc9-450490399870" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2019PlanMember_724f5c8d-d4dc-4a36-91c5-493959540ce2" xlink:href="mnlo-20200630.xsd#mnlo_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_A2019PlanMember_724f5c8d-d4dc-4a36-91c5-493959540ce2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_fc64ff78-ccae-494c-b163-deb4973fb502_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:to="loc_us-gaap_GranteeStatusDomain_fc64ff78-ccae-494c-b163-deb4973fb502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:to="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_08c3aa98-6204-4c25-865f-c2cf4a428ece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_08c3aa98-6204-4c25-865f-c2cf4a428ece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ec37896d-d78e-4674-958b-a7f1322266ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ec37896d-d78e-4674-958b-a7f1322266ac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALOptionsandRSUGrantsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="extended" id="i512f8a6c38cb4c78b2dbc8f165504388_SHARECAPITALOptionsandRSUGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50399cc0-f3ca-4701-8158-f093b43cec59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50399cc0-f3ca-4701-8158-f093b43cec59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7129a79a-a5d3-4a19-932f-5b9a99eec88c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7129a79a-a5d3-4a19-932f-5b9a99eec88c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_157b9dc4-70e3-4512-9167-8e367cdbd118" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_157b9dc4-70e3-4512-9167-8e367cdbd118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ea46f11a-f559-4005-952d-485390397e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ea46f11a-f559-4005-952d-485390397e9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e5812624-2392-4f4d-a155-fc09c429fcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e5812624-2392-4f4d-a155-fc09c429fcd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d2730a6-e4d7-4f30-8a35-9bf07abbf1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d2730a6-e4d7-4f30-8a35-9bf07abbf1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:to="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c4f112-af4a-4caf-8029-c6041e5a976b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11c4f112-af4a-4caf-8029-c6041e5a976b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96cedf68-5bb0-4216-b6d5-c5754cfe9c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96cedf68-5bb0-4216-b6d5-c5754cfe9c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_424aab7d-dfe1-4344-a433-2a70ba478109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_424aab7d-dfe1-4344-a433-2a70ba478109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:to="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb5fc6c3-141a-436d-b603-105ab5f0663a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:to="loc_srt_RangeMember_fb5fc6c3-141a-436d-b603-105ab5f0663a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:to="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6da1dc8e-ce02-4883-b94e-7879585ef3c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:to="loc_srt_MinimumMember_6da1dc8e-ce02-4883-b94e-7879585ef3c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76b0637a-41b1-436d-9e01-4dc3a485a364" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:to="loc_srt_MaximumMember_76b0637a-41b1-436d-9e01-4dc3a485a364" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALFairvalueassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="extended" id="i0e465d0e311340c8aba36e30dfd040c8_SHARECAPITALFairvalueassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8aeb6d52-f386-42c9-8430-c4845fd33f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8aeb6d52-f386-42c9-8430-c4845fd33f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8ee2a51b-d29b-4b37-a8e4-093fac5865c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8ee2a51b-d29b-4b37-a8e4-093fac5865c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e3130055-6f2e-4840-82fd-07b7ba6c98af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e3130055-6f2e-4840-82fd-07b7ba6c98af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bf674014-f669-4f2f-8459-a067f021c919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bf674014-f669-4f2f-8459-a067f021c919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7d4d582f-991b-463f-ae82-f0009e19663b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7d4d582f-991b-463f-ae82-f0009e19663b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c8f4968-b010-4653-91cd-98d41e330630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c8f4968-b010-4653-91cd-98d41e330630" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:to="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0f7597b0-6acb-417c-9d4c-b63d60e9f70b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0f7597b0-6acb-417c-9d4c-b63d60e9f70b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALScheduleofSharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="extended" id="i51b591b408b44cd08ae55ecc6f81babd_SHARECAPITALScheduleofSharebasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c6925bf0-bd34-4654-ba0d-29c6d05c9633" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c6925bf0-bd34-4654-ba0d-29c6d05c9633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3a995428-f4fd-42b3-a485-dc7ec6d3c91b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3a995428-f4fd-42b3-a485-dc7ec6d3c91b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_843a2699-882f-4e66-814d-1c47357a9426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_843a2699-882f-4e66-814d-1c47357a9426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c7377e55-d599-49cf-9c05-0165959dfe44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c7377e55-d599-49cf-9c05-0165959dfe44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASE"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="extended" id="i568b8acb31564471890c1598e0f88ad9_OPERATINGLEASE"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASETables"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="extended" id="i297ea82ce382444c8f1b2e3f32ab922f_OPERATINGLEASETables"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEOperatingleasecostsDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="extended" id="i355503f60db34b2b8cc351e178751d22_OPERATINGLEASEOperatingleasecostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FacilitySpaceUnderLease_f4319795-a551-4e5b-bb1b-2b4650486415" xlink:href="mnlo-20200630.xsd#mnlo_FacilitySpaceUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_FacilitySpaceUnderLease_f4319795-a551-4e5b-bb1b-2b4650486415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3213b1d1-56a8-45ac-90f3-889522543b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3213b1d1-56a8-45ac-90f3-889522543b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments_f52e31e9-5dc5-4737-b6cd-95301c43d470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_ShortTermLeasePayments_f52e31e9-5dc5-4737-b6cd-95301c43d470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6870c9ac-5403-48eb-b577-1d753be05662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_OperatingLeaseLiability_6870c9ac-5403-48eb-b577-1d753be05662" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e9655783-18ce-4d94-a6db-e67b08e7c7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e9655783-18ce-4d94-a6db-e67b08e7c7ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_VehicleLeasePrepaymentPeriod_4ffde0bc-6aed-438d-9f9c-cacd36701b27" xlink:href="mnlo-20200630.xsd#mnlo_VehicleLeasePrepaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_VehicleLeasePrepaymentPeriod_4ffde0bc-6aed-438d-9f9c-cacd36701b27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_8f2f0459-a02a-4e3b-9d32-4a90d9e35a5b" xlink:href="mnlo-20200630.xsd#mnlo_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_8f2f0459-a02a-4e3b-9d32-4a90d9e35a5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:to="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OriginalSpaceMember_ac438e03-33f2-4541-b064-bf52b98d3246" xlink:href="mnlo-20200630.xsd#mnlo_OriginalSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:to="loc_mnlo_OriginalSpaceMember_ac438e03-33f2-4541-b064-bf52b98d3246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalSpaceMember_55b0b3ca-cc29-47b0-88db-e859217ccd10" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:to="loc_mnlo_AdditionalSpaceMember_55b0b3ca-cc29-47b0-88db-e859217ccd10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:to="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_280a86ee-811c-41d5-aa32-dfa4df48cf42_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:to="loc_srt_SegmentGeographicalDomain_280a86ee-811c-41d5-aa32-dfa4df48cf42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:to="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BridgewaterNewJerseyMember_559e41fd-4c89-455d-a92a-b2ceddc78232" xlink:href="mnlo-20200630.xsd#mnlo_BridgewaterNewJerseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:to="loc_mnlo_BridgewaterNewJerseyMember_559e41fd-4c89-455d-a92a-b2ceddc78232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RedwoodCityCaliforniaMember_82bd8882-46c2-44b9-a3a9-09e255714a74" xlink:href="mnlo-20200630.xsd#mnlo_RedwoodCityCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:to="loc_mnlo_RedwoodCityCaliforniaMember_82bd8882-46c2-44b9-a3a9-09e255714a74" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" id="ic5e53cf6ddb44b4092f1790e48132d9b_OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="ia45eabf0448541339b09658519845041_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i343a1818033941038b231ec30e8a0651_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfClassActions_1186f5bc-eb43-49aa-9583-c4e57cb3ddac" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfClassActions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:to="loc_mnlo_NumberOfClassActions_1186f5bc-eb43-49aa-9583-c4e57cb3ddac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b3bbe695-bb81-4aa3-b86b-9058de5e63fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b3bbe695-bb81-4aa3-b86b-9058de5e63fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:to="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:to="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2883d4d9-6c7f-4846-a26c-3eea81b20b65_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:to="loc_srt_LitigationCaseTypeDomain_2883d4d9-6c7f-4846-a26c-3eea81b20b65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:to="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_InitialPublicOfferingLawsuitsMember_eade1173-e087-4097-add3-d0b6024b3f44" xlink:href="mnlo-20200630.xsd#mnlo_InitialPublicOfferingLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:to="loc_mnlo_InitialPublicOfferingLawsuitsMember_eade1173-e087-4097-add3-d0b6024b3f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:to="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_0f185f99-8ff1-4f76-9691-60a450035f45" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:to="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_0f185f99-8ff1-4f76-9691-60a450035f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:to="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OfficersAndDirectorsMember_8a5cae48-1421-4727-9cff-13f8bcf41f0c" xlink:href="mnlo-20200630.xsd#mnlo_OfficersAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:to="loc_mnlo_OfficersAndDirectorsMember_8a5cae48-1421-4727-9cff-13f8bcf41f0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="extended" id="i737c27e4a15b4b97b9580f621dfed76c_SUBSEQUENTEVENTS"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="ibbda1c7f79e24b33a6b1156652398089_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_33099fdd-8bf9-44dd-8f71-92d694e0cfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_33099fdd-8bf9-44dd-8f71-92d694e0cfb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_0b016f67-e32e-45ec-a1e2-43fab3c6f5bb" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_0b016f67-e32e-45ec-a1e2-43fab3c6f5bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_314d356c-46b6-45b9-a574-7f17ec735487" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationEffectiveExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_314d356c-46b6-45b9-a574-7f17ec735487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_bb1da2fb-a5a1-4f2d-b6df-5afe39dcb169" xlink:href="mnlo-20200630.xsd#mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_bb1da2fb-a5a1-4f2d-b6df-5afe39dcb169" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_da69fd63-149e-409d-b57b-ac546d2f3915" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_da69fd63-149e-409d-b57b-ac546d2f3915" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_974bde5a-ff1f-46d2-968e-222b5cbf2ebb" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_974bde5a-ff1f-46d2-968e-222b5cbf2ebb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb1c99f3-7515-4b19-8fc6-4cb956545a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:to="loc_us-gaap_SubsequentEventMember_eb1c99f3-7515-4b19-8fc6-4cb956545a82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fc22f1b-b07f-48b9-8a9a-145a4812cc90_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:to="loc_srt_RangeMember_2fc22f1b-b07f-48b9-8a9a-145a4812cc90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:to="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94a86a97-1470-435e-aed7-2bb6197ad5d3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:to="loc_srt_MinimumMember_94a86a97-1470-435e-aed7-2bb6197ad5d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c051379-9eca-4015-89c6-ca722bc00f95" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:to="loc_srt_MaximumMember_2c051379-9eca-4015-89c6-ca722bc00f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_76f2c2d1-0da3-4813-9387-c6bbf723c1a0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_76f2c2d1-0da3-4813-9387-c6bbf723c1a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_4a49d5ef-d3b3-4a32-aaa3-816ea8a6933e" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_4a49d5ef-d3b3-4a32-aaa3-816ea8a6933e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7ce3b300-5d4d-48ca-a860-8f93cc113539_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7ce3b300-5d4d-48ca-a860-8f93cc113539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b5692603-ceb0-455f-94cd-ee37f35b5ac0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:to="loc_srt_ScenarioForecastMember_b5692603-ceb0-455f-94cd-ee37f35b5ac0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mnlo-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_TitleOfIndividualAxis_7a7032fc-1d65-4946-a778-e298afaae826_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4b88b97b-4e8e-4eb9-bee2-d6d9edf3a64f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_670f8e11-a8b3-4ef5-9ece-1b6aedbd7651_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_29fbaedf-3604-4ecb-9602-021215b94b1b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_3b4fd36d-29a0-47b8-a0ef-77e6c5ea48c4_terseLabel_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of parent by parent stockholders</link:label>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_label_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Merger Parent Ownership By Pre Merger Parent Stockholders</link:label>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_documentation_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:to="lab_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_12e10dac-8054-4134-88d2-f5d6b83f1603_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_cb7f4368-1d96-4bbd-97ed-03049e8b9f76_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_14406589-8eeb-4185-8a0f-8209ca8857b2_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Government</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Short-term Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_FinancialExpenses_ae9c05ed-c02f-4cf7-a405-af45f2d18a8c_terseLabel_en-US" xlink:label="lab_mnlo_FinancialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCE EXPENSES</link:label>
    <link:label id="lab_mnlo_FinancialExpenses_label_en-US" xlink:label="lab_mnlo_FinancialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Expenses</link:label>
    <link:label id="lab_mnlo_FinancialExpenses_documentation_en-US" xlink:label="lab_mnlo_FinancialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total financial expenses during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialExpenses" xlink:href="mnlo-20200630.xsd#mnlo_FinancialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_FinancialExpenses" xlink:to="lab_mnlo_FinancialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_65c68342-8459-4990-b94e-3af446e89a3c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4666a704-b83c-4f80-b390-6dcc8fb0817b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4ab476e1-a3a9-4c5e-97ff-459a24dcc637_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER COMPREHENSIVE LOSS (INCOME):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2577ef1-5fe1-45cc-a020-eaa4bff9260e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU, award amount</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_ab39ff3c-b167-4cfb-8978-05b7c8ff7014_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b60c0c94-960f-4b21-b17f-5f740a217a2c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5871b33c-fb7e-43f7-9b11-2d994aa8949e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DebtCovenantsAbstract_138f03d6-c218-4393-97b9-d89f6e38b87b_terseLabel_en-US" xlink:label="lab_mnlo_DebtCovenantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenants</link:label>
    <link:label id="lab_mnlo_DebtCovenantsAbstract_label_en-US" xlink:label="lab_mnlo_DebtCovenantsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenants [Abstract]</link:label>
    <link:label id="lab_mnlo_DebtCovenantsAbstract_documentation_en-US" xlink:label="lab_mnlo_DebtCovenantsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantsAbstract" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DebtCovenantsAbstract" xlink:to="lab_mnlo_DebtCovenantsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_16148245-3786-4566-baf2-fdfa79e44954_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_510133b8-ad60-453d-8278-703ba86dac0b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_55f833f1-5038-439f-91bc-5e39efe88796_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range, minimum (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a68bd806-f933-42cc-b626-94eeca037d16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to issuance of ordinary shares through offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_95e85f40-7ae3-4051-91aa-484af156c993_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities (Note 6)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_867ca529-3395-4d7a-991e-79bebd7f4650_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_26eab79f-6d29-45d8-a1be-0b3242057221_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b854eb54-44d9-49f3-9df0-f96ba67cd185_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Ordinary Shares through a public offering, net of $3,903 issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d7a6b63b-6ead-47e4-9d9d-e3643e4abc8c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ccf7e3f2-c628-4351-a8c3-db50e60a069e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_FoamixMember_b7192857-40db-4805-b2c8-f18cbdf0bcb3_terseLabel_en-US" xlink:label="lab_mnlo_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foamix</link:label>
    <link:label id="lab_mnlo_FoamixMember_label_en-US" xlink:label="lab_mnlo_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foamix [Member]</link:label>
    <link:label id="lab_mnlo_FoamixMember_documentation_en-US" xlink:label="lab_mnlo_FoamixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the merger of Foamix.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_FoamixMember" xlink:to="lab_mnlo_FoamixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_8d2172db-0f81-4f15-8bdf-f22518ec77dc_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-month LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_767a1131-0fbd-4f9a-949a-a8e6668c7ddd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd2bb3f1-47d0-4960-a7d6-610cb6d3eb73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96c915ce-9712-451e-9f5b-18901d955c6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ebb8391d-45ab-4bb5-b2b1-3f3a7ed9f8ed_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions_bdeceef4-f6f0-420b-add9-8c9d0314e2fe_terseLabel_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions</link:label>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions_label_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions</link:label>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions_documentation_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:href="mnlo-20200630.xsd#mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:to="lab_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0d1da751-38ba-4767-82f8-fd7f5946db7d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7c7831be-6620-45ca-a3b9-78a75c4186de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_EmployeeStockPurchasePlanMember_bc15b572-9b30-4dc6-ad55-3e20929663d1_terseLabel_en-US" xlink:label="lab_mnlo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_mnlo_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mnlo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mnlo_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mnlo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EmployeeStockPurchasePlanMember" xlink:href="mnlo-20200630.xsd#mnlo_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EmployeeStockPurchasePlanMember" xlink:to="lab_mnlo_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_a245877a-1a98-4fa7-b288-ab474e0a28ae_negatedLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: fair value of net assets acquired, including other identifiable intangibles</link:label>
    <link:label id="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_label_en-US" xlink:label="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Assets Acquired Including Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of net assets acquired including other identifiable intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:to="lab_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4ba7f34c-3a6c-4257-b836-e68e284d71eb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_InterestReceived_7f3f612d-cfec-4765-8c59-53a0b64154ac_terseLabel_en-US" xlink:label="lab_mnlo_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_mnlo_InterestReceived_label_en-US" xlink:label="lab_mnlo_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_mnlo_InterestReceived_documentation_en-US" xlink:label="lab_mnlo_InterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_InterestReceived" xlink:href="mnlo-20200630.xsd#mnlo_InterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_InterestReceived" xlink:to="lab_mnlo_InterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_819a1fc7-de2b-4500-8614-bc80d497d49c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d44b55a4-56c1-4f67-8dba-2f2b4d4d6985_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_360ac31b-3632-4f43-b6ee-cf0f53827bba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_51bda53b-397d-4661-a1bc-15b233eb5d38_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_OrdinarySharesMember_5101ca6c-0dfb-4fdb-9193-061b0f246643_terseLabel_en-US" xlink:label="lab_mnlo_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_mnlo_OrdinarySharesMember_label_en-US" xlink:label="lab_mnlo_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares [Member]</link:label>
    <link:label id="lab_mnlo_OrdinarySharesMember_documentation_en-US" xlink:label="lab_mnlo_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary shares of legal entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OrdinarySharesMember" xlink:href="mnlo-20200630.xsd#mnlo_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OrdinarySharesMember" xlink:to="lab_mnlo_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_a6e5461b-9be5-49e1-a0a3-5b44bfe8290e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_daec3272-9bbe-4d04-aba6-44dcbe05f4c9_terseLabel_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for warrants exercised</link:label>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for warrants exercised during the current period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_673d88ed-b46a-4b09-8c78-6882e9e2faa2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_58514c43-d31c-4be0-8eea-f2ea477a46ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value of liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_2eabbc22-0fc3-4eb9-a589-93cf24d53dd6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_28017ad2-3b2d-45f0-a82f-d21dad19bfa8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_95c38df2-07e9-4bb9-a189-1e1d1b248a06_terseLabel_en-US" xlink:label="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Increase in Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Increase in Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:to="lab_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ContingentStockRightSharesConversion_128796cf-bf2d-43e8-bd9e-56342a45542f_terseLabel_en-US" xlink:label="lab_mnlo_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares issued per CSR (in shares)</link:label>
    <link:label id="lab_mnlo_ContingentStockRightSharesConversion_label_en-US" xlink:label="lab_mnlo_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Right Shares Conversion</link:label>
    <link:label id="lab_mnlo_ContingentStockRightSharesConversion_documentation_en-US" xlink:label="lab_mnlo_ContingentStockRightSharesConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued per each contingent stock right.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ContingentStockRightSharesConversion" xlink:to="lab_mnlo_ContingentStockRightSharesConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_36bd1e70-663b-479c-ae73-743e432a23f5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ad3d671d-e80a-469e-892a-13705d51deeb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DerivativeMaximumTermOfContract_25b53f96-9c84-4c91-800f-79858b479227_terseLabel_en-US" xlink:label="lab_mnlo_DerivativeMaximumTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency hedging transactions, maximum term</link:label>
    <link:label id="lab_mnlo_DerivativeMaximumTermOfContract_label_en-US" xlink:label="lab_mnlo_DerivativeMaximumTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency hedging transactions, maximum term</link:label>
    <link:label id="lab_mnlo_DerivativeMaximumTermOfContract_documentation_en-US" xlink:label="lab_mnlo_DerivativeMaximumTermOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum period the derivative contract is outstanding, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DerivativeMaximumTermOfContract" xlink:href="mnlo-20200630.xsd#mnlo_DerivativeMaximumTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DerivativeMaximumTermOfContract" xlink:to="lab_mnlo_DerivativeMaximumTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_A2018PlanMember_ca7d10cd-4fac-416d-964d-04425f52e4e3_terseLabel_en-US" xlink:label="lab_mnlo_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_mnlo_A2018PlanMember_label_en-US" xlink:label="lab_mnlo_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan [Member]</link:label>
    <link:label id="lab_mnlo_A2018PlanMember_documentation_en-US" xlink:label="lab_mnlo_A2018PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2018PlanMember" xlink:href="mnlo-20200630.xsd#mnlo_A2018PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_A2018PlanMember" xlink:to="lab_mnlo_A2018PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_694aaa38-1ff0-4728-a43d-ab86eb957e73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_c6d72388-7154-4c8b-bd33-4c8adcc8e19b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_67f577f1-dc19-4d20-a024-954d0a273fd2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent impairment loss, debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6aa168ff-9b7d-474f-9e4e-5048c8105e2f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_91efb41d-16e9-438e-b8d7-e8278406d725_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_58585b00-9c14-41a6-8492-c7679c95f652_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DebtInstrumentFeePercent_0e5d0a30-665a-4714-bfca-e657496165b3_terseLabel_en-US" xlink:label="lab_mnlo_DebtInstrumentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument fee as a percent of the aggregate principal amount</link:label>
    <link:label id="lab_mnlo_DebtInstrumentFeePercent_label_en-US" xlink:label="lab_mnlo_DebtInstrumentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fee Percent</link:label>
    <link:label id="lab_mnlo_DebtInstrumentFeePercent_documentation_en-US" xlink:label="lab_mnlo_DebtInstrumentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the fee that accompanies borrowing money under the debt instrument, as a percent of the aggregate principal amount of all loans outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentFeePercent" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DebtInstrumentFeePercent" xlink:to="lab_mnlo_DebtInstrumentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_77af9c69-d731-4eaf-b5a8-85f971852c6f_terseLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares deemed (for accounting purposes only) issued (in shares)</link:label>
    <link:label id="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_label_en-US" xlink:label="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Shares Deemed Issued For Accounting Purposes</link:label>
    <link:label id="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares deemed, for accounting purposes only, to be issued in the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:to="lab_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_49a98ee8-4163-4bcd-98aa-7308d940e58b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_FacilitySpaceUnderLease_b829dfc1-0d5e-4482-a7aa-ec2b4d2b5a69_terseLabel_en-US" xlink:label="lab_mnlo_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility space leased</link:label>
    <link:label id="lab_mnlo_FacilitySpaceUnderLease_label_en-US" xlink:label="lab_mnlo_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Space Under Lease</link:label>
    <link:label id="lab_mnlo_FacilitySpaceUnderLease_documentation_en-US" xlink:label="lab_mnlo_FacilitySpaceUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Size of the facility under lease, in square feet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FacilitySpaceUnderLease" xlink:href="mnlo-20200630.xsd#mnlo_FacilitySpaceUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_FacilitySpaceUnderLease" xlink:to="lab_mnlo_FacilitySpaceUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_33e7f922-2cbf-47d0-b2a5-b14ff2bab087_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_39928983-7c7c-41de-987f-79a22129f5db_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS -</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_64e81670-9c0d-4d89-a98f-17f9fd33bfc0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d0a3bd8-27a6-4fe0-abb9-c00801e1911c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a0983d4a-eb64-4549-9482-91f3c7a901a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4889a3b2-9dda-464d-91e6-d9e766aab916_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7178c359-f90f-49d1-b7a2-1f6b9709f604_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument information</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_CommonStockVotingRightsNumberPerShare_34fbc33e-2224-4e2f-b33f-874b6001e904_terseLabel_en-US" xlink:label="lab_mnlo_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled to each ordinary share</link:label>
    <link:label id="lab_mnlo_CommonStockVotingRightsNumberPerShare_label_en-US" xlink:label="lab_mnlo_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights Number Per Share</link:label>
    <link:label id="lab_mnlo_CommonStockVotingRightsNumberPerShare_documentation_en-US" xlink:label="lab_mnlo_CommonStockVotingRightsNumberPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitled to each ordinary share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockVotingRightsNumberPerShare" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockVotingRightsNumberPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CommonStockVotingRightsNumberPerShare" xlink:to="lab_mnlo_CommonStockVotingRightsNumberPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9f3be4e7-a641-4542-8166-b4e87a797518_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_39a628b8-22dc-4149-9f6a-c511da7f8f67_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_a32a09c8-ce91-4784-a451-5279a74fb7c0_negatedLabel_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acceleration of stock based compensation</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_label_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_documentation_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:to="lab_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_5d16d627-e1ce-4213-a690-86d08af9a8ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessAcquisitionContingentStockRightIssued_2a93fddd-c5d3-4b38-9b22-8fafe507bfd7_terseLabel_en-US" xlink:label="lab_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent stock rights issued (in CSR)</link:label>
    <link:label id="lab_mnlo_BusinessAcquisitionContingentStockRightIssued_label_en-US" xlink:label="lab_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Stock Right Issued</link:label>
    <link:label id="lab_mnlo_BusinessAcquisitionContingentStockRightIssued_documentation_en-US" xlink:label="lab_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of contingent stock right issued in connection with the business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:href="mnlo-20200630.xsd#mnlo_BusinessAcquisitionContingentStockRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:to="lab_mnlo_BusinessAcquisitionContingentStockRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DistributorTwoMember_75476f23-b2d6-4994-8420-bfdf1e503024_terseLabel_en-US" xlink:label="lab_mnlo_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_mnlo_DistributorTwoMember_label_en-US" xlink:label="lab_mnlo_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_mnlo_DistributorTwoMember_documentation_en-US" xlink:label="lab_mnlo_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorTwoMember" xlink:href="mnlo-20200630.xsd#mnlo_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DistributorTwoMember" xlink:to="lab_mnlo_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_92acd082-8196-4f53-a18b-84bcae6259e3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (USD/share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5235f33c-e0c2-4875-ab75-9b5c86a4125e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_977cecc8-4070-49e1-b1e6-df5aef729242_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_InitialPublicOfferingLawsuitsMember_521fdb05-ceb4-4c3f-b6cd-3b7fdc881819_terseLabel_en-US" xlink:label="lab_mnlo_InitialPublicOfferingLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Lawsuits</link:label>
    <link:label id="lab_mnlo_InitialPublicOfferingLawsuitsMember_label_en-US" xlink:label="lab_mnlo_InitialPublicOfferingLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering Lawsuits [Member]</link:label>
    <link:label id="lab_mnlo_InitialPublicOfferingLawsuitsMember_documentation_en-US" xlink:label="lab_mnlo_InitialPublicOfferingLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents initial public offering related lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_InitialPublicOfferingLawsuitsMember" xlink:href="mnlo-20200630.xsd#mnlo_InitialPublicOfferingLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_InitialPublicOfferingLawsuitsMember" xlink:to="lab_mnlo_InitialPublicOfferingLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_34d8ba3e-f71d-49ba-9ca9-1ae41065b72b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationEffectiveExchangeRatio_937ef36d-3abd-4196-84cd-a7cfd71c182e_terseLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)</link:label>
    <link:label id="lab_mnlo_BusinessCombinationEffectiveExchangeRatio_label_en-US" xlink:label="lab_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Effective Exchange Ratio</link:label>
    <link:label id="lab_mnlo_BusinessCombinationEffectiveExchangeRatio_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationEffectiveExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:to="lab_mnlo_BusinessCombinationEffectiveExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_c20ce427-dc6b-4fed-88ec-4232070c8d86_terseLabel_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Merger Consideration to be transferred</link:label>
    <link:label id="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_label_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisition Consideration [Table Text Block]</link:label>
    <link:label id="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_documentation_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of consideration to be transferred to effect the Merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:to="lab_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_b8c335e3-068f-4553-8730-5f415de61efe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ea8143b1-2639-482b-9bb1-76564f6c9bc6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e30d44ac-90b8-4d79-83ce-fdee25bd686b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL OTHER COMPREHENSIVE (INCOME) LOSS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_6f15e55b-bbdf-404b-abf4-8e63b65b8102_terseLabel_en-US" xlink:label="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly payment as a percent of the aggregate principal amount beginning July 2023</link:label>
    <link:label id="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_label_en-US" xlink:label="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Principal Percent</link:label>
    <link:label id="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_documentation_en-US" xlink:label="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required monthly payment as a percent of the aggregate principal amount from Jul 2023 through July 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:to="lab_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_79f47ff6-f9d9-4edd-9033-2c30ba81127f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ce210cd5-6f1b-47e7-8be9-ba235105d3a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses on marketable securities reclassified into net loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_223c65f8-f323-4439-8362-3bbf5d9e9acf_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredGross_7d5ca9c9-3167-4530-9a18-560bf1e87264_terseLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredGross_5ff1da2f-f095-46df-8666-3d4dc8a50026_totalLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredGross_label_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Gross</link:label>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredGross_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:to="lab_mnlo_BusinessCombinationConsiderationTransferredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_81807041-eba4-4f11-b45f-b22c46f35253_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of underlying data used for computing the fair value of the options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_bc9cbe9f-6e9b-44d5-906f-abbb493af5bc_terseLabel_en-US" xlink:label="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales provisions</link:label>
    <link:label id="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_label_en-US" xlink:label="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Distribution, Trade Discounts and Allowances</link:label>
    <link:label id="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_documentation_en-US" xlink:label="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:href="mnlo-20200630.xsd#mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:to="lab_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1dcda28a-d312-4718-8f09-898f49dbb4fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DistributorThreeMember_4edf2fba-5b74-4feb-9348-487da0552075_terseLabel_en-US" xlink:label="lab_mnlo_DistributorThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Three</link:label>
    <link:label id="lab_mnlo_DistributorThreeMember_label_en-US" xlink:label="lab_mnlo_DistributorThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Three [Member]</link:label>
    <link:label id="lab_mnlo_DistributorThreeMember_documentation_en-US" xlink:label="lab_mnlo_DistributorThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents distributor three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorThreeMember" xlink:href="mnlo-20200630.xsd#mnlo_DistributorThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DistributorThreeMember" xlink:to="lab_mnlo_DistributorThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_f9c9a78d-88ed-44c5-89c5-ea3375e54c7f_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_537dd1fd-b8b3-4009-a3ed-f7b72a07e1cc_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING LOSS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock_4102ceab-fa1e-4840-9691-27b5f6234d24_terseLabel_en-US" xlink:label="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock_label_en-US" xlink:label="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources [Policy Text Block]</link:label>
    <link:label id="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock_documentation_en-US" xlink:label="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:to="lab_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_189c37ec-ea9f-4812-b7f1-17d96095cf3e_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0b842f63-b2fb-43ed-881d-1985590b90ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e09148eb-eb3e-4e88-bb1b-505401a40087_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_327215d1-d595-4e95-bd8f-c701c61d1736_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_54d85093-1d31-49a9-9c80-180031b78827_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4f9cca68-e035-4b27-a484-34ef16cd1de4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASURMENTS [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_846fddee-1bd3-4dbc-83ab-ae8f10d9eeb6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_3a737c6d-5828-48e9-990b-aa6f002522a6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:to="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_13473f4f-b4e8-4087-b83c-cbf664a79724_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8b419135-3863-4a0a-8ff1-3faca4a1cf5b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_692f4195-52fd-4835-922e-8596ef08a83b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_750b55d4-9b27-4a8a-aab8-6ee4d711bcf3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c2284a6f-15c9-41c2-9edc-2184b3858a0c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e5519a7c-7031-436e-80ea-32ecf4b16f68_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0041efce-ae27-4f85-bad5-55670869109d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_e630bb5f-956f-42af-b572-1e8c196ffd80_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_fbf8361e-538e-49e1-addd-c2d050192075_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2d584f43-7b81-4b2b-b6a5-442374c96feb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fbf1e0ae-be93-4d5c-b6a9-cf517324c387_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of identified intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2f6ec0ac-2f20-4407-b418-21f17dd7accf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4041fccb-b968-4388-9a02-b1d9aeb321ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_edb1975d-fc43-404c-b2a4-c25f42043d5c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9915486a-6d4f-473b-9e44-9b0f598efe91_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost or amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8c4bd310-05b4-439f-84ff-66618eda7950_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of businesses acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_289d0b4e-43ce-49ce-8a2a-26c8c83f79aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3a7d7176-02fc-45e0-9b69-7659bf45ff31_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_982d8336-809b-461d-9f17-d219d7ecb70c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b6dae20a-45df-4fdd-80c7-78b92985475f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_380e9677-2669-4d47-acd8-1c08d4d6366d_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_96b362ae-8ffc-47bf-b4e8-3787cec6203b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_3ae9cae3-1701-4134-a6d2-48d394f62700_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_9318692c-0267-42fe-927c-054153b2e28d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ad6986e7-e13f-4097-b392-b64384376109_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b521c8ef-39ff-44d8-8e42-5b92d45d93ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e2c1ac41-148a-4df6-b24b-855c55e6bba0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_fa166f2d-c4c9-434a-abd0-8b1008853e4c_negatedTerseLabel_en-US" xlink:label="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend to warrants holders due to warrant modification</link:label>
    <link:label id="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_f5418525-a594-4bd0-925f-2f18567cc59b_terseLabel_en-US" xlink:label="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend to warrants holders due to warrant modification</link:label>
    <link:label id="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_label_en-US" xlink:label="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend To Warrants Holders Due To Warrant Modification</link:label>
    <link:label id="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_documentation_en-US" xlink:label="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:href="mnlo-20200630.xsd#mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:to="lab_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_44aac6cb-c1ab-4402-a85b-c3a4119e2757_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d6d1463c-4d2c-4309-8089-c9a7a151f86a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_417690f8-19e5-4416-96af-053fd7dd4655_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c8da0724-2791-49ff-8065-f6d3b493d809_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8fe43389-d371-4d61-b8ce-d5fc82a30955_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_7cb3642c-23b6-4e66-89d6-f141dada3f4e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for employee severance benefits</link:label>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_84c89d7f-f1f3-4ec3-bdc6-b97e97d5d1bd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_9d345efc-e10c-411b-804f-13a58cd0f47a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM DEBT</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions_846769ab-1c0f-4c2c-94b7-14e0b069d846_terseLabel_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions</link:label>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions_label_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions</link:label>
    <link:label id="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions_documentation_en-US" xlink:label="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:href="mnlo-20200630.xsd#mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:to="lab_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3bf62f96-7818-4dcf-961b-928d03e1da50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_4f14fbba-c56c-4ce3-b97a-dee2ab3e3472_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b866c663-ad31-41cd-a2fa-8bd7f71d633d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c7bc2bdb-4d5e-450d-a0f7-3eca1a3d3ee2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option, award amount</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_211f8adb-a1fd-4912-8831-49c10c0b2b95_negatedLabel_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_label_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Supplemental Proforma Transaction Costs</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_documentation_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:to="lab_mnlo_AdjustmentsToSupplementalProformaTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_143e6669-3d23-4c9d-8cfa-0bf9c21321cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_7e6e9e9c-1430-4cd7-a534-2d56a4af0bd5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_be992b53-7e85-4aa6-a8e1-d72231ccf1a2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c06a6bc9-83f6-4065-a859-62d337df38eb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_16f65541-f432-4dc1-aa7a-4aca27c24576_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_bb023cde-3fff-40e0-8fea-93368e8f5ef2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c71f00c2-21eb-4a5b-b1bb-3cf558f327d8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS FOR THE PERIOD</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_476d240d-0943-42ba-b0ce-6d54aa18b661_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_95bc75a4-e54d-4580-9a27-24ef92ca1016_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d9d35c4a-7d60-442c-8d4c-e41773b26630_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds related to issuance of stock for stock-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_45de6dcc-979e-4eeb-8338-d94a117d58fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f1c737f5-0c19-47ed-85bf-010289605b45_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_63326e48-4271-49aa-9182-63515eb3672b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_428826c3-c5c7-4374-8e17-c95bb5cf10ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a93c6726-d5aa-447a-8b35-7afb8c20f969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_1c2364be-716e-4837-854a-262b2603d8fb_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b9db4f7f-8e1a-42e8-994e-2c62600e0e97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_EffectiveExchangeRatio_56356149-d337-4680-a41a-7092ce93afa3_terseLabel_en-US" xlink:label="lab_mnlo_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Exchange Ratio (CSR per share)</link:label>
    <link:label id="lab_mnlo_EffectiveExchangeRatio_label_en-US" xlink:label="lab_mnlo_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Exchange Ratio</link:label>
    <link:label id="lab_mnlo_EffectiveExchangeRatio_documentation_en-US" xlink:label="lab_mnlo_EffectiveExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EffectiveExchangeRatio" xlink:href="mnlo-20200630.xsd#mnlo_EffectiveExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EffectiveExchangeRatio" xlink:to="lab_mnlo_EffectiveExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_a7d5436e-5c06-4c8b-a16c-1d1276adca4f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_46f26520-ec40-4550-be57-0a021df0cadb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_063b5c19-2743-4956-9f4a-1d4c78ecc697_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_c62ccdde-3766-4658-a293-ae4f3ac76d99_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5216e7e1-2b40-4bf8-bdff-1b0524b9c50a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in bank deposits</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_2f0239c9-c10a-47f1-959b-4a5886c7408e_terseLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed (for accounting purposes only) conversion of Menlo equity awards</link:label>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_label_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Consideration Transferred Conversion Of Acquirer Equity Awards</link:label>
    <link:label id="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of consideration transferred consisting of the conversion of equity awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:to="lab_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_338a803c-d327-4c4c-9a09-95b8a4564752_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_ea162bef-1383-4392-8235-b97e815ecf26_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net acquired (See &#8220;Note 3- Business combination&#8221;)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_UpfrontRoyaltyReceipt_1b3f55d4-3a2c-42ce-a605-30cbaa3bc5e9_terseLabel_en-US" xlink:label="lab_mnlo_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront royalty receipt</link:label>
    <link:label id="lab_mnlo_UpfrontRoyaltyReceipt_label_en-US" xlink:label="lab_mnlo_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Royalty Receipt</link:label>
    <link:label id="lab_mnlo_UpfrontRoyaltyReceipt_documentation_en-US" xlink:label="lab_mnlo_UpfrontRoyaltyReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of upfront royalty receipt upon delivery of licensed products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_UpfrontRoyaltyReceipt" xlink:href="mnlo-20200630.xsd#mnlo_UpfrontRoyaltyReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_UpfrontRoyaltyReceipt" xlink:to="lab_mnlo_UpfrontRoyaltyReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e989e29d-2bab-40d5-a0e9-bae3aba3ba50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fdfaf2e1-c170-4b6a-8b33-058f8dc0d86a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e36acd18-537a-4237-8ab2-5c76d4dbec7d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_b4b03eb8-be7a-4d45-91a5-ea959e8955da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b25259ae-7adf-4806-baee-c56b8f4c7328_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AdditionalSpaceMember_f12eecdb-f61c-43ef-91b6-4d31ae80d9ea_terseLabel_en-US" xlink:label="lab_mnlo_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space</link:label>
    <link:label id="lab_mnlo_AdditionalSpaceMember_label_en-US" xlink:label="lab_mnlo_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Space [Member]</link:label>
    <link:label id="lab_mnlo_AdditionalSpaceMember_documentation_en-US" xlink:label="lab_mnlo_AdditionalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the additional leased facility space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalSpaceMember" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdditionalSpaceMember" xlink:to="lab_mnlo_AdditionalSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_130fabc8-7316-4dde-897e-5176303c242e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_afe95f9b-90b5-4027-b763-348cb9987c1e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_46ab8f4b-a166-4873-9031-84aa89bbedd7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract_11a598bb-ca73-4796-b22a-a1b91adab4af_terseLabel_en-US" xlink:label="lab_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Narrative</link:label>
    <link:label id="lab_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract_label_en-US" xlink:label="lab_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements Narrative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" xlink:href="mnlo-20200630.xsd#mnlo_FairValueMeasurmentsNarrativeDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" xlink:to="lab_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_27d48691-dffd-4f77-a169-ab622323438a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9a2fe4d6-d769-441f-ab77-c43ae5ef356b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_1dcbdede-8339-4210-8f4b-811d1cf8cdc4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-Process Research and Development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_5f637596-ff6c-4133-afd3-c125f521a5c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c83ff068-bd50-42e3-ba91-e18f2a2d8dfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0ac6709d-d87f-485e-9721-a1fbfc3bdc79_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_d7028dee-db87-41cb-9f31-0cbb6a0c5913_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9b607e3d-21f0-4f0f-a965-194651c0b94c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ef0c5f27-a1fa-4c52-b515-2f1952dc301f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received in a transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1714099e-6306-4d80-ae64-ece95b7cda3a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c864d503-8c64-4dbc-b448-6350e7860d03_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fac66fdf-3e13-46f5-8a6f-48e6553020c3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4c5b102b-51a4-46ad-8f09-a66e4ede28bf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a6b9b391-0b3b-404f-b252-ece424022b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_CreditAgreementNumberOfTrenches_d5d60b5d-8887-4f0b-bb5b-264456359857_terseLabel_en-US" xlink:label="lab_mnlo_CreditAgreementNumberOfTrenches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trenches</link:label>
    <link:label id="lab_mnlo_CreditAgreementNumberOfTrenches_label_en-US" xlink:label="lab_mnlo_CreditAgreementNumberOfTrenches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement, Number of Trenches</link:label>
    <link:label id="lab_mnlo_CreditAgreementNumberOfTrenches_documentation_en-US" xlink:label="lab_mnlo_CreditAgreementNumberOfTrenches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trenches of credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CreditAgreementNumberOfTrenches" xlink:href="mnlo-20200630.xsd#mnlo_CreditAgreementNumberOfTrenches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CreditAgreementNumberOfTrenches" xlink:to="lab_mnlo_CreditAgreementNumberOfTrenches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_df31e24e-6595-4271-96ec-82c32b105077_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_ae16c479-129d-4338-a07f-f56216e0a9d6_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_a415a129-b64d-43f2-827a-c2f3d7fa74ea_terseLabel_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger net of cash acquired</link:label>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_label_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Acquisition Of Business, Net Assets After Cash Acquired</link:label>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_documentation_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:to="lab_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_56ff979f-7f27-4f87-b443-afb99ab52530_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares that may be purchased by exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_c7c06062-972e-4a2e-a017-812468728461_terseLabel_en-US" xlink:label="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation awards granted for options and RSUs during the period</link:label>
    <link:label id="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_label_en-US" xlink:label="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation By Share Based Payment Award Grants In Period [Table Text Block]</link:label>
    <link:label id="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_documentation_en-US" xlink:label="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:to="lab_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_OfficersAndDirectorsMember_7c4971d2-b07c-4ed7-9677-2093123d7e14_terseLabel_en-US" xlink:label="lab_mnlo_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and Former Officers and Directors</link:label>
    <link:label id="lab_mnlo_OfficersAndDirectorsMember_label_en-US" xlink:label="lab_mnlo_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officers And Directors [Member]</link:label>
    <link:label id="lab_mnlo_OfficersAndDirectorsMember_documentation_en-US" xlink:label="lab_mnlo_OfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The member pertaining to Officers and Directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OfficersAndDirectorsMember" xlink:href="mnlo-20200630.xsd#mnlo_OfficersAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OfficersAndDirectorsMember" xlink:to="lab_mnlo_OfficersAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f5080a9b-93c4-4c18-af9a-1ac6ea64594b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ad25d263-872b-423e-9e40-89c53df72334_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_563fe2e1-ba25-4a67-b9b9-6760667f76e8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_VehicleLeasePrepaymentPeriod_b9f8df5d-34e0-443f-a371-63dab569a592_terseLabel_en-US" xlink:label="lab_mnlo_VehicleLeasePrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles lease prepaid period</link:label>
    <link:label id="lab_mnlo_VehicleLeasePrepaymentPeriod_label_en-US" xlink:label="lab_mnlo_VehicleLeasePrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicle Lease, Prepayment Period</link:label>
    <link:label id="lab_mnlo_VehicleLeasePrepaymentPeriod_documentation_en-US" xlink:label="lab_mnlo_VehicleLeasePrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of prepaid to secure lease of vehicles.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_VehicleLeasePrepaymentPeriod" xlink:href="mnlo-20200630.xsd#mnlo_VehicleLeasePrepaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_VehicleLeasePrepaymentPeriod" xlink:to="lab_mnlo_VehicleLeasePrepaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DerivateCostsForYear_45ff1d1c-3022-410c-a2cb-c568e3e6f20a_terseLabel_en-US" xlink:label="lab_mnlo_DerivateCostsForYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency hedging cost for a year</link:label>
    <link:label id="lab_mnlo_DerivateCostsForYear_label_en-US" xlink:label="lab_mnlo_DerivateCostsForYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivate Costs For A Year</link:label>
    <link:label id="lab_mnlo_DerivateCostsForYear_documentation_en-US" xlink:label="lab_mnlo_DerivateCostsForYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The transaction cost of currency hedging for year from the time of occurrence of the transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DerivateCostsForYear" xlink:href="mnlo-20200630.xsd#mnlo_DerivateCostsForYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DerivateCostsForYear" xlink:to="lab_mnlo_DerivateCostsForYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_8cacb1e3-a70c-4214-ba3a-5b47f8221298_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_be681ca1-abcb-4157-9093-8db915a46bed_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EXPENSES</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9ef68a2c-c90e-47d7-8185-a06993296936_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_86d3d3be-2020-4cea-9c65-e32ec38e7629_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ee24bc69-fed1-4b98-987d-cf2fc96fc42a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_63d97baa-d057-460a-bed2-c2986719b923_terseLabel_en-US" xlink:label="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of CSR converted into additional shares of the combined company</link:label>
    <link:label id="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_label_en-US" xlink:label="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquiree Common Stock Rights Converted to Common Stock</link:label>
    <link:label id="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_documentation_en-US" xlink:label="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquiree Common Stock Rights Converted to Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:to="lab_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_54874af8-b3ad-4d1e-8d1b-557d8ff85e1f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_99a5aba8-a2da-476c-a47a-4bb7e7ecd785_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss_608e5d6b-199a-457a-83c8-5eac4fe64a08_negatedTerseLabel_en-US" xlink:label="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Right Remeasurement</link:label>
    <link:label id="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss_label_en-US" xlink:label="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Consideration, Remeasurement Gain (Loss)</link:label>
    <link:label id="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss_documentation_en-US" xlink:label="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Stock Consideration, Remeasurement Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:to="lab_mnlo_ContingentStockConsiderationRemeasurementGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4df67bd8-6ba6-43e6-bd5e-6df13bde5bd2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING LEASE</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_91d03bb0-5eb5-4002-a15c-a8457d28c821_terseLabel_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in exchange of warrants</link:label>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_label_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrant Exchange</link:label>
    <link:label id="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_documentation_en-US" xlink:label="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares issued during the period for the exchange of warrants following the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:to="lab_mnlo_StockIssuedDuringPeriodSharesWarrantExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_119886a9-83e2-44fb-925d-e70ee9d3cbe1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a35866f2-2caf-4711-b1ab-eb3435f100ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_5d66513c-3018-4c59-a854-db6b397ba99d_terseLabel_en-US" xlink:label="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible IPRD assets acquired in the merger</link:label>
    <link:label id="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_label_en-US" xlink:label="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of In Process Research And Development Assets Acquired Through Business Combination [Table Text Block]</link:label>
    <link:label id="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_documentation_en-US" xlink:label="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:to="lab_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_95d86de2-8095-412b-a7a7-fb6bde4ad8cc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_200a271d-9d8b-4462-aeed-ce7581ecbb62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_ba83d295-bf22-4607-95de-b0e37263f343_terseLabel_en-US" xlink:label="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options and RSUs granted</link:label>
    <link:label id="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_label_en-US" xlink:label="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options And Equity Instruments Other Than Options Grants in Period Total Grant Date Fair Value</link:label>
    <link:label id="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_documentation_en-US" xlink:label="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total fair value of options and equity instruments other than options granted during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:to="lab_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_bc85a715-b2e6-4482-8341-9a451b63bbe8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and in-process research &amp; development impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock_0947e0dd-5140-4a78-8b01-c72b4bd669ed_terseLabel_en-US" xlink:label="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label id="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label id="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross proceeds from issuance of common stock before deducting offering expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:href="mnlo-20200630.xsd#mnlo_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lab_mnlo_GrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_afa7aae1-b30e-4e0b-a8bf-15c89bb7bf9a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6de26e6b-a727-4124-8cf2-86d45c89e629_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f49cbb36-a2cf-4ddf-bba9-147c8263c09c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2f26049f-dcc5-42dc-ab17-e5b265598080_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8f2adf4b-d4ee-4293-a015-0b32af7dce1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7bea965a-bfe2-43d2-b5de-6fdeff2f33e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_44b79d58-7577-4108-a478-070c59fb0ac3_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_e22f8f47-1888-4dd4-860c-94b9214cf7b0_terseLabel_en-US" xlink:label="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, minimum quarterly revenue compliance</link:label>
    <link:label id="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_label_en-US" xlink:label="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Minimum Quarterly Revenue Compliance</link:label>
    <link:label id="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_documentation_en-US" xlink:label="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Minimum Quarterly Revenue Compliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:to="lab_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f93d0c1-d41b-47a5-8a6b-2ef67cbdffd2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DocumentAndEntityInformationAbstract_21508eb8-e7de-4f34-a5e1-8777b1a60716_terseLabel_en-US" xlink:label="lab_mnlo_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOCUMENT AND ENTITY INFORMATION [Abstract]</link:label>
    <link:label id="lab_mnlo_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_mnlo_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOCUMENT AND ENTITY INFORMATION [Abstract]</link:label>
    <link:label id="lab_mnlo_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_mnlo_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DocumentAndEntityInformationAbstract" xlink:href="mnlo-20200630.xsd#mnlo_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract" xlink:to="lab_mnlo_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementMember_701108d0-99ca-434f-8e43-20b5bb8da195_terseLabel_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementMember_label_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Amended and Restated Credit Agreement entered into on March 9, 2020.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:to="lab_mnlo_AmendedAndRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ac63d999-f90f-482b-9f81-030d7301f63c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ce31e3ed-067a-4cf8-88c3-bf5cf6b061ea_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_04e6e084-f1c4-43d4-b173-1c317436d979_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_BridgewaterNewJerseyMember_1ad5898d-6b0d-46b2-800c-5a1871a75801_terseLabel_en-US" xlink:label="lab_mnlo_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater, New Jersey</link:label>
    <link:label id="lab_mnlo_BridgewaterNewJerseyMember_label_en-US" xlink:label="lab_mnlo_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater New Jersey [Member]</link:label>
    <link:label id="lab_mnlo_BridgewaterNewJerseyMember_documentation_en-US" xlink:label="lab_mnlo_BridgewaterNewJerseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the location in Bridgewater, New Jersey.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BridgewaterNewJerseyMember" xlink:href="mnlo-20200630.xsd#mnlo_BridgewaterNewJerseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_BridgewaterNewJerseyMember" xlink:to="lab_mnlo_BridgewaterNewJerseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0d5b0001-b773-4a48-9047-905acbe0ba13_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_29f637b9-ed79-4857-967a-d01392f5286f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_77d1a4f4-6eed-45ee-8f4c-5979a2b6864a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains) losses from marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_934eefaf-044d-4723-a6b6-be922b9b6a31_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_76b7ae06-503d-4c39-9228-0dd83c57effe_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_132e4e11-8040-4fef-92ec-be356d1b24a2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_438d8c85-f8a0-40a5-b31f-aea784b88319_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allocation of the purchase price to the fair values of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e7a19deb-064f-4bad-b424-04b06517c872_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_bce50beb-5aa8-4010-a335-2dc842e1f38b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_PublicStockOfferingMember_016de3c6-e773-4ac5-a882-0e3e8d67be18_terseLabel_en-US" xlink:label="lab_mnlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_mnlo_PublicStockOfferingMember_label_en-US" xlink:label="lab_mnlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_mnlo_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_mnlo_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PublicStockOfferingMember" xlink:href="mnlo-20200630.xsd#mnlo_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_PublicStockOfferingMember" xlink:to="lab_mnlo_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_61edabff-4c51-463d-be5f-faa6734d6f89_terseLabel_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage of parent by subsidiary stockholders</link:label>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_label_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders</link:label>
    <link:label id="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_documentation_en-US" xlink:label="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:to="lab_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_8fb3a5d1-7861-42e4-a74d-1ada6aff58a5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_677816a9-cbcd-4594-b9c1-5d9fd2876819_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f3c6fe7-f1f9-4137-997a-42c3a249450a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f96200d2-89d6-4e69-b84f-738d68e0d16d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_9508c505-be77-4224-a75f-4c3ed386d24f_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurrred expenses related to Credit Agreement and Securities Purchase Agreement</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7e221a0b-53e1-460e-9214-0bf1a4035a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_fcfccb49-a00f-4a24-8c40-fd96fbb42e75_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_82164331-4a3c-470d-920e-e36c289505af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_be9a9f17-004c-47da-b843-09e8ae7f1243_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAX</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_94a39671-f4cc-4789-bed6-ccdb465c1538_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock related to merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_2b1824ac-6f21-4d30-96fc-62a6dbe172d0_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3bdd6daa-697a-44a6-b9bf-923b5d2820d9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_e5acc3e5-40ee-46dc-bcc7-bfa086ab5930_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair market value used as purchase price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationGoodwillAbstract_95ecc7ec-8732-4dc7-a7e4-93bdd88dbcdb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Goodwill [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_74ec7dfd-0c62-406f-b60e-00ed6c151031_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_CSRAgreementMember_50fc5633-8bbe-45bd-9f0d-b16284c72c85_terseLabel_en-US" xlink:label="lab_mnlo_CSRAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CSR Agreement</link:label>
    <link:label id="lab_mnlo_CSRAgreementMember_label_en-US" xlink:label="lab_mnlo_CSRAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CSR Agreement [Member]</link:label>
    <link:label id="lab_mnlo_CSRAgreementMember_documentation_en-US" xlink:label="lab_mnlo_CSRAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CSR Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CSRAgreementMember" xlink:href="mnlo-20200630.xsd#mnlo_CSRAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CSRAgreementMember" xlink:to="lab_mnlo_CSRAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_03687104-dcd1-45ec-9615-e6f85ed8730b_terseLabel_en-US" xlink:label="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Lawsuits, Breach of Fiduciary Duties Of BOD</link:label>
    <link:label id="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_label_en-US" xlink:label="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Lawsuits Breach Of Fiduciary Duties Of B O D [Member]</link:label>
    <link:label id="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_documentation_en-US" xlink:label="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents lawsuit related to the merger alleging that the members of Foamix's board of directors breached their fiduciary duties in connection with the Merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:to="lab_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1c1f9ea2-29e3-44a0-b93c-c1ab0c955262_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0cce0e43-4c9e-4c41-9dfb-d0a86cf853d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock_9bae5c68-a46f-4df4-89a0-5cddd190f417_terseLabel_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the calculation of goodwill from the merger</link:label>
    <link:label id="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock_label_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Combination Goodwill [Table Text Block]</link:label>
    <link:label id="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the calculation of goodwill from the business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:to="lab_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_5af18a76-be6a-4154-b823-a71121c2671e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f1762d24-7502-4506-adbe-65d490bf7def_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables, prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_02b3955f-6067-4c70-9610-f6429a76da90_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_560f8be8-52b5-4991-8ea7-5e3172d99e8f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ee73b275-013b-4387-9e9f-d8055ff7ecf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued during the period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd7fb106-90f2-4e26-a3cd-bee7fe27e84e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_03520098-23c2-482c-8d6c-a8ca756b5682_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Recognition and Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_OriginalSpaceMember_140fce8e-06c7-40b8-ab85-9f117a28a14f_terseLabel_en-US" xlink:label="lab_mnlo_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Space</link:label>
    <link:label id="lab_mnlo_OriginalSpaceMember_label_en-US" xlink:label="lab_mnlo_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Space [Member]</link:label>
    <link:label id="lab_mnlo_OriginalSpaceMember_documentation_en-US" xlink:label="lab_mnlo_OriginalSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the original leased facility space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OriginalSpaceMember" xlink:href="mnlo-20200630.xsd#mnlo_OriginalSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OriginalSpaceMember" xlink:to="lab_mnlo_OriginalSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_8aeffd03-85b6-4776-8eda-d509aa505df2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6368943c-57d9-41c1-b904-f0cb6502565d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_67f76f2b-0295-4b72-89f0-273ad1703ab9_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash finance (income) expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d178af77-f832-4c34-9811-62cdb2b37c6f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e56fb392-b409-430d-9436-a5fe932c06a1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS BEFORE INCOME TAX</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_499987f7-0ce9-44f5-a3b9-d12376e93ad8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_c7cdd7f2-72d0-4d19-83de-f65062420f4c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c403e7ab-3710-4b20-bad3-aa35aef6f1c9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5efdde18-7069-40d5-b3f2-11c543338155_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f5c71162-5bf2-408c-a83e-09f5a40d5b74_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (USD/share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_38d162db-76cb-447f-9190-f909480b4102_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_6d34d635-4b50-4e57-880e-e728566c5cd0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_8ca48d3e-eda5-4daa-9221-71a6187d5989_terseLabel_en-US" xlink:label="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in accrued liability for employee severance benefits, net of retirement fund profit</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_label_en-US" xlink:label="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_documentation_en-US" xlink:label="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:href="mnlo-20200630.xsd#mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:to="lab_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_887bcf51-4d8e-4a8e-84d8-6d67323284f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for income tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_f655ac09-c59b-4e51-ae07-f23a34d18798_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsIncurred_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Obligation Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsIncurred" xlink:to="lab_us-gaap_CapitalLeaseObligationsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9a7d4dda-04ea-4f28-9ec1-71c6b3ed275d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, consersion ratio (share/share)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_47dcc005-2d77-4fd8-9af2-a1c9cb854b2e_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMaximum_f03ed956-206f-4551-a995-a6ff8fe3c813_terseLabel_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum estimate product return (as a percent)</link:label>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMaximum_label_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Product Return Rate, Maximum</link:label>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMaximum_documentation_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum estimate of product sales return rate at reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMaximum" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EstimateOfProductReturnRateMaximum" xlink:to="lab_mnlo_EstimateOfProductReturnRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_ddffdff0-40f6-4a07-8d79-1ab319805363_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_MergerLawsuitsMember_ea1545ae-fbe6-4203-8d45-4ecec869e8c7_terseLabel_en-US" xlink:label="lab_mnlo_MergerLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Lawsuits</link:label>
    <link:label id="lab_mnlo_MergerLawsuitsMember_label_en-US" xlink:label="lab_mnlo_MergerLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger Lawsuits [Member]</link:label>
    <link:label id="lab_mnlo_MergerLawsuitsMember_documentation_en-US" xlink:label="lab_mnlo_MergerLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents merger related lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsMember" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_MergerLawsuitsMember" xlink:to="lab_mnlo_MergerLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5beeb6b5-2d32-48c3-b06a-882e4666f8e0_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_RedwoodCityCaliforniaMember_c81d47e5-d6ba-48e7-86d0-f0354f514f5c_terseLabel_en-US" xlink:label="lab_mnlo_RedwoodCityCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redwood City, California</link:label>
    <link:label id="lab_mnlo_RedwoodCityCaliforniaMember_label_en-US" xlink:label="lab_mnlo_RedwoodCityCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redwood City California [Member]</link:label>
    <link:label id="lab_mnlo_RedwoodCityCaliforniaMember_documentation_en-US" xlink:label="lab_mnlo_RedwoodCityCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the location in Redwood City, California.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RedwoodCityCaliforniaMember" xlink:href="mnlo-20200630.xsd#mnlo_RedwoodCityCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_RedwoodCityCaliforniaMember" xlink:to="lab_mnlo_RedwoodCityCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ReverseMergerPolicyTextBlock_38091b2a-29b1-456a-aafc-523ffdbe5da2_terseLabel_en-US" xlink:label="lab_mnlo_ReverseMergerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger</link:label>
    <link:label id="lab_mnlo_ReverseMergerPolicyTextBlock_label_en-US" xlink:label="lab_mnlo_ReverseMergerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger [Policy Text Block]</link:label>
    <link:label id="lab_mnlo_ReverseMergerPolicyTextBlock_documentation_en-US" xlink:label="lab_mnlo_ReverseMergerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ReverseMergerPolicyTextBlock" xlink:href="mnlo-20200630.xsd#mnlo_ReverseMergerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ReverseMergerPolicyTextBlock" xlink:to="lab_mnlo_ReverseMergerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_703244cb-6398-4ce1-a977-8267f6f1167c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_4f5a46b8-3ecd-42e8-9670-140ccd3a217b_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_a03b12ec-636c-44ce-9081-9f6504ad9ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment assumptions for computing fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_9a885ab3-c884-4ab4-ab64-916fc129a894_terseLabel_en-US" xlink:label="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share issued and delivered upon CSR conversion (in shares)</link:label>
    <link:label id="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_label_en-US" xlink:label="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Upon Conversion of Common Stock Rights, Per Agreement</link:label>
    <link:label id="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_documentation_en-US" xlink:label="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:href="mnlo-20200630.xsd#mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:to="lab_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_d876821d-5eaf-417f-8ce2-22c5a33aa528_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE BASIC AND DILUTED (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c2e4c3e0-3bb8-43ad-bac9-1a5b2de299e5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsCurrent_63081f08-2e17-4adc-a853-2de53d2c68a3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investment in marketable securities (Note 6)</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b89c8c19-6a3f-4858-ba11-20ffc98c65e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7e05576e-c5ab-47cb-9a5f-6da255fb3e3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7ec81e53-dfef-411b-82f3-4a46bfa975ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHANGES DURING THE PERIOD:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_FinancialIncomeNet_4a54ec3f-16d3-4468-9c92-a8364e11125b_negatedLabel_en-US" xlink:label="lab_mnlo_FinancialIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCE INCOME</link:label>
    <link:label id="lab_mnlo_FinancialIncomeNet_label_en-US" xlink:label="lab_mnlo_FinancialIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Income Net</link:label>
    <link:label id="lab_mnlo_FinancialIncomeNet_documentation_en-US" xlink:label="lab_mnlo_FinancialIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total financial income during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialIncomeNet" xlink:href="mnlo-20200630.xsd#mnlo_FinancialIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_FinancialIncomeNet" xlink:to="lab_mnlo_FinancialIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e340b2e2-72d2-4f5b-94b5-c22782daf8e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f6af4d8a-e082-4f5a-bad1-dd7df51ab2fa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aacc705c-2002-4161-956a-277e0b560fb9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4d8557b3-71e1-4c47-a1d9-327168f74064_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from disposal and sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_IsraeliMutualFundsMember_3c8b6973-922f-4ae1-86c4-fe95782502a6_terseLabel_en-US" xlink:label="lab_mnlo_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli mutual funds</link:label>
    <link:label id="lab_mnlo_IsraeliMutualFundsMember_label_en-US" xlink:label="lab_mnlo_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Mutual Funds [Member]</link:label>
    <link:label id="lab_mnlo_IsraeliMutualFundsMember_documentation_en-US" xlink:label="lab_mnlo_IsraeliMutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Israeli Mutual Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IsraeliMutualFundsMember" xlink:href="mnlo-20200630.xsd#mnlo_IsraeliMutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IsraeliMutualFundsMember" xlink:to="lab_mnlo_IsraeliMutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a447d51d-7030-441b-9c47-8a4aa22c92c2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4279f33d-6728-4023-92b3-2090d771ff02_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_08540e5b-5966-4e70-9e40-771d0f31bcad_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_ded143b8-a205-47da-bd16-386df23721a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs incurred</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_68016166-2efe-4470-9099-e9709d4f68b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of pro forma</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b13212eb-fc6f-4ed1-9e65-f6e08aca9fbf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_26177197-cf38-47e3-bfff-ec3fc05d51b6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_64a45713-e0e2-4158-9426-e7052b55f6e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_9f4917e7-188e-4a14-9b25-2cf6779db82a_negatedTotalLabel_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Adjustments</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_label_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Supplemental Proforma Combined Results of Operations</link:label>
    <link:label id="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_documentation_en-US" xlink:label="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:to="lab_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_12b45198-0c4a-42ba-855c-5c06616923c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized losses (gains) on derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeasePayments_b98ac73e-fe2d-49e3-a6d9-61ce0f54bf48_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent</link:label>
    <link:label id="lab_us-gaap_ShortTermLeasePayments_label_en-US" xlink:label="lab_us-gaap_ShortTermLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeasePayments" xlink:to="lab_us-gaap_ShortTermLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_651f4dd4-c621-4d6c-98f1-583bc87fc021_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e95c36c2-1c7e-4eb0-9a22-a859652b5961_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f751e240-fff9-417d-a311-bef78591e043_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_f3ee0d17-9bba-478b-bfdc-75639bf0b316_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_60128397-3537-4e81-9494-f9ee76ef6766_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_72a91c63-dc42-4082-aa98-66cc919fe5ff_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_25920cea-2fc7-4559-a0d0-91b709721a35_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_ba2a947e-ca81-48c3-ae3b-ac12fa4f0521_terseLabel_en-US" xlink:label="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum aggregate cash balance to maintain after FDA approval</link:label>
    <link:label id="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_label_en-US" xlink:label="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum aggregate cash balance to maintain after FDA approval</link:label>
    <link:label id="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_documentation_en-US" xlink:label="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum aggregate cash balance to maintain after FDA approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:href="mnlo-20200630.xsd#mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:to="lab_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_174d8a67-40ea-4619-8b99-a150aac2d80b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_427164fa-ffab-4a89-9aca-96540f82cc58_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c594d907-18b0-4b92-88dd-58d206d9c0c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a5735cc1-f294-46e3-998f-ec81d3f1ea5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 8)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5790e845-f413-4e18-a8bb-e1eac0abbfb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2ed42449-12f5-43e2-be86-190a87048a56_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_a62d8c7f-59a1-4575-9180-770c4cc4ae6d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued pursuant to the merger (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0c1808b2-f87d-45e6-8521-0ccfac6c5820_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_abe99c2b-0125-4ed8-9fec-00cb0aeb1d50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6adc7030-f96b-45ab-81c9-3d104564949f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_7b06084f-75fe-4c35-9117-3a6c68a15270_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and consultants</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_68a49252-244a-4913-a302-ef56972e0323_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocations of purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_be6a49e9-d996-4dfe-8aa1-fc9089d629a2_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ba5b9a96-7e39-4837-ae83-afba53fdd0a7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c5f74a1a-d0f9-4669-8e6a-5021f65db2bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_NumberOfLenders_55a08f7b-adb6-4088-a997-afc779981690_terseLabel_en-US" xlink:label="lab_mnlo_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lenders involved</link:label>
    <link:label id="lab_mnlo_NumberOfLenders_label_en-US" xlink:label="lab_mnlo_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lenders</link:label>
    <link:label id="lab_mnlo_NumberOfLenders_documentation_en-US" xlink:label="lab_mnlo_NumberOfLenders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of lenders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfLenders" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfLenders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NumberOfLenders" xlink:to="lab_mnlo_NumberOfLenders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_67ac2194-d9e9-45f9-a2e7-9c4f08cbd785_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9dbad7cf-9736-4eef-a5a9-61e1a43473a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f052dbe9-7a7f-4d28-b79b-738445e8fcd9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1317c16c-bb51-4a71-abab-d3c8e14592fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No longer employed or providing services</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6248c9da-1676-4283-9022-ae5dbaa38ca5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b499b7d8-01b8-482f-b4e9-c91ec55a4add_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_97dd92be-575c-4d8d-ba3e-344ccaea6879_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_e2f65143-2981-430a-871b-e7ffbea674ce_terseLabel_en-US" xlink:label="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional royalty upon receipt of marketing approval in China</link:label>
    <link:label id="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_label_en-US" xlink:label="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalty Receipt Upon Occurrence Of Certain Events</link:label>
    <link:label id="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_documentation_en-US" xlink:label="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of additional royalty receipt upon occurrence of certain event related to licensed products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:to="lab_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_01c78385-922f-47d7-9bd6-4d597c7fb9ed_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f56b8260-df79-4e42-ba95-bc3b56d71895_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in accounts payable and accruals</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAmountOfHedgedItem_f249030a-8248-412c-9523-14fe8de4feb8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Hedged Item</link:label>
    <link:label id="lab_us-gaap_DerivativeAmountOfHedgedItem_label_en-US" xlink:label="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Amount of Hedged Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAmountOfHedgedItem" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAmountOfHedgedItem"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAmountOfHedgedItem" xlink:to="lab_us-gaap_DerivativeAmountOfHedgedItem" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_DistributorOneMember_eee8a5fe-0874-4d25-a08e-8904a9c430aa_terseLabel_en-US" xlink:label="lab_mnlo_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_mnlo_DistributorOneMember_label_en-US" xlink:label="lab_mnlo_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_mnlo_DistributorOneMember_documentation_en-US" xlink:label="lab_mnlo_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorOneMember" xlink:href="mnlo-20200630.xsd#mnlo_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DistributorOneMember" xlink:to="lab_mnlo_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_509870d4-1d1a-4d7b-8189-4748a75f864c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e6d8f245-729f-429c-998c-b335f8665045_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4b529c49-1b5f-42e6-bb2d-12afd7455cb5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to Menlo</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4d12d1c5-1726-468b-adff-4a1abd67de48_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_3f447b36-794c-4650-bc20-6c1563b72a9f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in marketable securities and bank deposits, net</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_f2bf6117-8d13-4de7-b3c6-13cbdd36c3fe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_1108b566-8068-4624-9e5f-37f5beebdf8f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_b687f513-7765-460a-9bf6-23e874fa0002_terseLabel_en-US" xlink:label="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lien on marketable securities to secure lease agreements</link:label>
    <link:label id="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_label_en-US" xlink:label="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments To Secure Lease Agreements</link:label>
    <link:label id="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_documentation_en-US" xlink:label="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:href="mnlo-20200630.xsd#mnlo_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:to="lab_mnlo_RestrictedInvestmentsToSecureLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_19ab04f7-a38b-4050-bb41-4fae01ed0f55_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4371e869-0858-4d69-9a25-118672727675_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_26514f49-f498-4326-89ba-5da2cbf4daaf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_32f2cbe7-b718-4a63-a4dd-9182edc61097_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_ad9bf766-7f31-40eb-8db3-ce9efaaeee7f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareholderLenderMember_5f4e4c86-1d2c-46b7-b8d2-5a158035aa7f_terseLabel_en-US" xlink:label="lab_mnlo_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Lender</link:label>
    <link:label id="lab_mnlo_ShareholderLenderMember_label_en-US" xlink:label="lab_mnlo_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Lender [Member]</link:label>
    <link:label id="lab_mnlo_ShareholderLenderMember_documentation_en-US" xlink:label="lab_mnlo_ShareholderLenderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to shareholders that are also lenders of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareholderLenderMember" xlink:href="mnlo-20200630.xsd#mnlo_ShareholderLenderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareholderLenderMember" xlink:to="lab_mnlo_ShareholderLenderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_bec97359-ade6-4790-90e2-66e0bb3b4ead_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock related to merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_59ba196a-d441-4c2a-930d-d8979ef2f97f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</link:label>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:to="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ProceedsFromBusinessMerger_57aa4171-d889-43f6-9339-2f5dbc918d87_terseLabel_en-US" xlink:label="lab_mnlo_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired through merger</link:label>
    <link:label id="lab_mnlo_ProceedsFromBusinessMerger_label_en-US" xlink:label="lab_mnlo_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Business Merger</link:label>
    <link:label id="lab_mnlo_ProceedsFromBusinessMerger_documentation_en-US" xlink:label="lab_mnlo_ProceedsFromBusinessMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash inflow from business merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ProceedsFromBusinessMerger" xlink:href="mnlo-20200630.xsd#mnlo_ProceedsFromBusinessMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ProceedsFromBusinessMerger" xlink:to="lab_mnlo_ProceedsFromBusinessMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_26925597-f0e8-4d4d-be05-3a96f4c0273a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_ef6035e4-7839-4228-88ec-5e736d3e3af5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8ecb7052-170f-4ae7-8e3a-022878f72d17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of annual earnings that may be used to purchase shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_556ec2a6-b81d-444e-9808-dd4fb6d126cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMinimum_b9aea0ac-ad28-47ae-81a1-f6b4bbede284_terseLabel_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum estimate product return (as a percent)</link:label>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMinimum_label_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Product Return Rate, Minimum</link:label>
    <link:label id="lab_mnlo_EstimateOfProductReturnRateMinimum_documentation_en-US" xlink:label="lab_mnlo_EstimateOfProductReturnRateMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum estimate of product sales return rate at reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMinimum" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EstimateOfProductReturnRateMinimum" xlink:to="lab_mnlo_EstimateOfProductReturnRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7e7eff04-6574-4136-b008-2bdb9f04a724_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_d8f8e635-263d-41b5-a1f6-8ead6db7681c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_fc7f7366-c227-4867-b7b3-308f056af9e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_81f3df69-5bb5-4aee-b0e5-e33c7f0a8ed9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ad20c423-b9c1-4f76-9f73-1a204008e877_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6837725c-528a-4b00-aa76-8218fcf3cc86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2e2c81c0-2105-48cf-a612-56a775a0c7b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_bb986973-5536-4680-874e-83f33cfb24cd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customers</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_134d98ef-bb14-435c-8844-e23be888d42a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8263e2ab-8559-42e6-9f4c-13e21f8bfaa4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_065c363b-244e-485b-8206-b5bffe85352d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_01d2a13d-e586-46e8-8a31-c6b49ffb9272_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration net of the effect of CSRs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d1c553ca-1d47-4e4b-b48e-8c4fe697779d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_97cbdd5d-4590-4246-9240-f31d979001ac_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_cc69da34-5a68-4717-b2da-17bddc1dc730_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_c5fa76d2-9cc2-470d-bc8f-3f97b6e873e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_781ffb97-f4ee-4a97-bfda-facf9f8f6819_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract" xlink:to="lab_us-gaap_DeferredFinanceCostsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e4692327-6edd-4b7b-9cd2-4d19a9251c50_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_73a472fb-1143-4076-b5cb-5aaf66612627_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_0e2c8d59-c497-415c-97ae-8ecbc78e8cf2_terseLabel_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs incurred</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_label_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_documentation_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:to="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4e98a3a4-fc82-488e-962e-f08ff0f7c6d1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e4d4e391-efed-4721-8729-c1c2d158d98b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3b9c3a63-d4ea-4ca6-8b80-1b1038901d69_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c639be00-9308-4136-9225-34a810f97984_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL EXPENSES</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_04673e30-99ef-4dcc-9e0e-85cf87c0dedf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock par value (USD/share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e45a0e8-c6a8-405b-98e9-0b84269094c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a1678ffe-bf14-4bf8-b14c-9e4c5d13ff0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestments_e9ac529b-f065-48de-a83b-41f4332bd127_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments" xlink:to="lab_us-gaap_RestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1bc7c474-339c-4b24-913d-1f0ce4762362_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory (Note 7)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_d3e03380-583b-4733-83be-ea7eaac840b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range, maximum (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_38638a7a-744e-494f-99ee-33af76f6be62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aab1e47c-56d4-412a-889e-ae32566690cb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_2e2bd62f-1bc3-4a8a-bd90-9560e39a320a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_eb8b5bb5-9f49-410e-b225-5a8a10aac4bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired indefinite life intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_4e986999-5e24-4db0-a2b0-5fa5d722ca9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_163d6868-4993-44b4-8648-01b981dd2de6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_NumberOfClassActions_355fdfce-cfce-4cd2-bb27-c4b879a30007_terseLabel_en-US" xlink:label="lab_mnlo_NumberOfClassActions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of class actions</link:label>
    <link:label id="lab_mnlo_NumberOfClassActions_label_en-US" xlink:label="lab_mnlo_NumberOfClassActions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Class Actions</link:label>
    <link:label id="lab_mnlo_NumberOfClassActions_documentation_en-US" xlink:label="lab_mnlo_NumberOfClassActions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of class actions lawsuit brought against the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfClassActions" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfClassActions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NumberOfClassActions" xlink:to="lab_mnlo_NumberOfClassActions" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_3a53112b-36b3-4bbb-b4df-16544c92731d_terseLabel_en-US" xlink:label="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options, RSUs and shares under the ESPP</link:label>
    <link:label id="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_label_en-US" xlink:label="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options Restricted Stock Units R S U And Shares Under Espp [Member]</link:label>
    <link:label id="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_documentation_en-US" xlink:label="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share options RSUs and Shares Under ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:href="mnlo-20200630.xsd#mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:to="lab_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea65ee57-884f-445c-8667-ccef44089b18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_83a650e0-66b0-4537-b177-f7174e83643c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ba9cf55-b93b-48cc-8ba3-fd642bbfd5a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Ordinary Shares through public offering, net of $3,903 issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8b205e55-05a2-42a2-9670-a8f9175dd0b4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in usd per share)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_c1055201-45fd-4eaf-bef6-3558d5d91e00_terseLabel_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 1 Loan</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_label_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench1 Loan [Member]</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_documentation_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 1 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:to="lab_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_cd2655ac-f094-4086-9cc3-eb83e6fdfc7b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_08b79cad-bcba-4122-80b8-126c7b24ecfc_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_a1fe8f41-2986-44dd-8f34-ca6e5c1541a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_ac5932cf-eb5b-4a25-8a4e-f2274947fec0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0ff0c79-2f51-4687-9ff9-13135c1cb77d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_830c688e-7166-4c23-b8d2-4316f4b585a1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_dd5171ee-1ee6-47f4-9e34-43b8046a3001_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS COMBINATION</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0d5f8124-5ef8-4df8-a216-888abfd179f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock: $0.0001 par value; 300,000,000 shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; 167,683,814 and 36,480,314 shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_edcd8766-994b-4873-bffa-2c17718b6d96_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_bcdb9e47-7d82-4155-8ace-6eafd95e6fd9_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ExchangeRatio_e0804802-240b-4761-a6db-b061df5be643_terseLabel_en-US" xlink:label="lab_mnlo_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange ratio per ordinary share for common stock (share per share)</link:label>
    <link:label id="lab_mnlo_ExchangeRatio_label_en-US" xlink:label="lab_mnlo_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Ratio</link:label>
    <link:label id="lab_mnlo_ExchangeRatio_documentation_en-US" xlink:label="lab_mnlo_ExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ExchangeRatio" xlink:href="mnlo-20200630.xsd#mnlo_ExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ExchangeRatio" xlink:to="lab_mnlo_ExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_97ca4c68-2c74-4e99-803f-8efcc799a968_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_28fd2e91-2c0b-4c29-b696-10f68674af5a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b051858c-3a31-49c2-983a-15be4e938580_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f13d507d-628c-4dc9-a287-762a06c5bf92_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ClassOfWarrantAbstract_a89fbe4c-577c-4d5d-8fc6-67c4118a8d4f_terseLabel_en-US" xlink:label="lab_mnlo_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued</link:label>
    <link:label id="lab_mnlo_ClassOfWarrantAbstract_label_en-US" xlink:label="lab_mnlo_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant [Abstract]</link:label>
    <link:label id="lab_mnlo_ClassOfWarrantAbstract_documentation_en-US" xlink:label="lab_mnlo_ClassOfWarrantAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ClassOfWarrantAbstract" xlink:href="mnlo-20200630.xsd#mnlo_ClassOfWarrantAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ClassOfWarrantAbstract" xlink:to="lab_mnlo_ClassOfWarrantAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_d21653ba-aa65-4178-b880-810842758a23_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_7e2e73d4-69a7-42e1-ba48-78def33b033a_terseLabel_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation costs, recognition period</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_label_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_documentation_en-US" xlink:label="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:to="lab_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a5971d9d-ae7b-449b-ada5-2a0676af1037_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets (Note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_04c7601c-94ff-43d6-8ea5-c6aa18df08ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fdbd76d3-bfa1-4903-8a3e-c26e6277b549_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_d0d32707-64b5-44ff-a1c1-f68d8167e7b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless exercise of warrants and restricted stock units</link:label>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_2a3498a2-bf31-4099-b556-11f74d4c96ec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_41a0fd7d-2c9a-481b-8239-847569c54feb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3b5461c7-08a8-4e9d-90ea-d5de0a570b1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_063271a7-c999-4c02-88cb-d4311bdc1c06_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_06de0686-3e47-4ac3-a863-750ca39db920_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3e4cf55f-9ad3-4cb7-9c25-02e216a12076_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_d5e514fd-dbe4-4712-8793-028c5a58932d_negatedLabel_en-US" xlink:label="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classification of stock awards to derivative liability</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_e8364b90-ebc6-4851-acad-d621deb142f5_terseLabel_en-US" xlink:label="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid in capital reclassified to derivate liabilities</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_label_en-US" xlink:label="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment, Modification of Terms, Incremental Compensation, Modification of Terms, Incremental Compensation Cost, Reclassified Adjustment</link:label>
    <link:label id="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_documentation_en-US" xlink:label="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:to="lab_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_90f777d3-aa91-4271-adc1-35403e6a0527_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b2c47769-115f-4a6a-bcbb-3bcc8835fb7b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_bd0f6140-7c27-48c2-83be-00ce0a5bec72_terseLabel_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 3 Loan</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_label_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench3 Loan [Member]</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_documentation_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 3 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:to="lab_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_37b1f34b-ab72-482a-ae6c-3811992117d3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSupplies_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6fc0dc42-b4a0-4829-9ac9-507e5650db3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_b32c6b45-1347-4bd2-a736-3f50da563f43_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired_45f1abd4-d345-4898-a66f-f2289faf23a8_terseLabel_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less cash acquired</link:label>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired_label_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Acquisition Of Business, Cash Acquired</link:label>
    <link:label id="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired_documentation_en-US" xlink:label="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash as part of a non-cash business acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:to="lab_mnlo_NonCashAcquisitionOfBusinessCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d7e3cca7-2fa0-45a8-89a4-f58c073c754c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8ff2ac16-07b6-4a4d-b0e8-c97b4763f9e4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_A2019PlanMember_e857792f-ecb5-4b06-a8f7-b5807abd0ce1_terseLabel_en-US" xlink:label="lab_mnlo_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_mnlo_A2019PlanMember_label_en-US" xlink:label="lab_mnlo_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan [Member]</link:label>
    <link:label id="lab_mnlo_A2019PlanMember_documentation_en-US" xlink:label="lab_mnlo_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2019PlanMember" xlink:href="mnlo-20200630.xsd#mnlo_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_A2019PlanMember" xlink:to="lab_mnlo_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_41d0fd1e-4bda-4703-af8b-b13ec15821b7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_700972db-32c9-408e-afa8-67e3d7c5968e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_eebcac71-6e88-4796-9109-80010fc43eb7_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_eb8e1f5e-3391-4900-aeb4-c1f92fbd7c38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9906e8ce-425e-41f9-89b7-93c5a6631199_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; no shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_06f38d80-e192-45ab-b46d-a2ab3a5137c8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_a70958b2-1607-45a9-b3af-ca31ce768a6c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_36ffe65c-4f94-4aa4-9e80-2e010a72b902_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f1cf0e50-fed0-4120-af52-82ae39a1ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_77102b6a-e270-4983-9a04-0d3d67c08d5e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_de9d2e0f-f1a3-4423-ae25-35124a97a0e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2679f4bc-d7c9-48ae-a705-9a10f106d648_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3331dc1f-3969-4e5e-a967-4c881c382a66_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a4fa1e03-14fe-4421-b456-d42462bf96b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cbc5c4cc-bc28-4b95-b1c9-81b77db3b092_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89182827-30f8-467d-a008-863427aee5fa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_2075e613-4667-4b2e-9903-f5458e91abf1_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_633e3950-4179-47ab-83c8-e7768f972ca4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60368f97-be61-4c81-85ab-4a86e1efa9df_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_RegisteredOfferingMember_228921ac-906e-4cdb-8207-42768c0bb190_terseLabel_en-US" xlink:label="lab_mnlo_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered offering per securities purchase agreement</link:label>
    <link:label id="lab_mnlo_RegisteredOfferingMember_label_en-US" xlink:label="lab_mnlo_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Offering [Member]</link:label>
    <link:label id="lab_mnlo_RegisteredOfferingMember_documentation_en-US" xlink:label="lab_mnlo_RegisteredOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of entity stock pursuant to a Securities Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RegisteredOfferingMember" xlink:href="mnlo-20200630.xsd#mnlo_RegisteredOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_RegisteredOfferingMember" xlink:to="lab_mnlo_RegisteredOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_f1d08004-5533-43eb-b5f8-160665f87e08_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_4cce1beb-7d3f-4eaf-84dd-ba05b8118e46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of marketable securities and bank deposits</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_c4cc9f7b-1509-4536-8072-8eaeeaf2d714_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_c1c4e044-0a5b-49fb-bfb0-b5f976c8b261_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_be24f11a-2505-4b99-b96b-21d74296e6d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_1a072a3b-b6a3-41b6-9af7-d6aaf8fcee85_terseLabel_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Credit Agreement, Trench 2 Loan</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_label_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated Credit Agreement Trench2 Loan [Member]</link:label>
    <link:label id="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_documentation_en-US" xlink:label="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents trench 2 loan of the Amended and Restated Credit Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:to="lab_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mnlo-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:276499ea-c77d-48dc-b5fb-05d04991a356,g:3045a758-2748-483f-bb9c-8dc09725d355-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/Cover" xlink:type="simple" xlink:href="mnlo-20200630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:href="mnlo-20200630.xsd#mnlo_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b18282cd-94fe-4ae1-9521-520ed4c58b75" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentType_b18282cd-94fe-4ae1-9521-520ed4c58b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d9a01842-d0d8-4332-abef-51f915e769aa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentPeriodEndDate_d9a01842-d0d8-4332-abef-51f915e769aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b1ac709e-6ef1-4a43-a77e-3bfa405c90c4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentQuarterlyReport_b1ac709e-6ef1-4a43-a77e-3bfa405c90c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_58339772-95dc-4931-a18b-304be57b1a61" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentTransitionReport_58339772-95dc-4931-a18b-304be57b1a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_601f65b1-a2ab-41ab-8e04-c2d94d9fd3c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityFileNumber_601f65b1-a2ab-41ab-8e04-c2d94d9fd3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d37d256a-a79f-4512-892a-f5e23193ca60" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityRegistrantName_d37d256a-a79f-4512-892a-f5e23193ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e3cbf938-08f5-4e26-a630-e71f3be0c104" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e3cbf938-08f5-4e26-a630-e71f3be0c104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bf9ba1b1-8e96-4119-bef6-b9dcb2b66c5f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityTaxIdentificationNumber_bf9ba1b1-8e96-4119-bef6-b9dcb2b66c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2cf0c0a4-f907-425a-8f58-33bdd0782608" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityAddressAddressLine1_2cf0c0a4-f907-425a-8f58-33bdd0782608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f2154d3-76bf-4251-85fa-e4679936c21d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityAddressCityOrTown_8f2154d3-76bf-4251-85fa-e4679936c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_88fabcc7-2194-4512-bc08-be40ae08acb3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityAddressStateOrProvince_88fabcc7-2194-4512-bc08-be40ae08acb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_904afe73-ca4b-43f5-a14e-0a40e0bcd6de" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityAddressPostalZipCode_904afe73-ca4b-43f5-a14e-0a40e0bcd6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2ca49392-541d-44ca-8d69-c268fc20ed5a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_CityAreaCode_2ca49392-541d-44ca-8d69-c268fc20ed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3a0c1f19-2bb3-46c6-9815-88666755407e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_LocalPhoneNumber_3a0c1f19-2bb3-46c6-9815-88666755407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_fa86bf53-d08f-428c-8692-b79810579f58" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_Security12bTitle_fa86bf53-d08f-428c-8692-b79810579f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eb9edabd-874a-466e-9f1a-ab305dea70df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_TradingSymbol_eb9edabd-874a-466e-9f1a-ab305dea70df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_54d9fa9c-7f1e-45f8-8dfd-ab088863a008" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_SecurityExchangeName_54d9fa9c-7f1e-45f8-8dfd-ab088863a008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3ba3f4ab-2096-428a-8eaa-85905794fc2c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityCurrentReportingStatus_3ba3f4ab-2096-428a-8eaa-85905794fc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c3f20f61-0701-433d-8fad-5ff288250ed6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityInteractiveDataCurrent_c3f20f61-0701-433d-8fad-5ff288250ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_06a6d990-dc54-41b3-a8eb-773ef33ca28b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityFilerCategory_06a6d990-dc54-41b3-a8eb-773ef33ca28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_db87f7b7-6135-40c6-90ed-ed603eb18e96" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntitySmallBusiness_db87f7b7-6135-40c6-90ed-ed603eb18e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d78c102f-17e0-49d5-9098-4c56cde392c3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityEmergingGrowthCompany_d78c102f-17e0-49d5-9098-4c56cde392c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_305efa21-e7ca-46b8-94d0-23fdf997331e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityShellCompany_305efa21-e7ca-46b8-94d0-23fdf997331e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8deb18e2-c8ac-432a-803f-cc79028b06d9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityCentralIndexKey_8deb18e2-c8ac-432a-803f-cc79028b06d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b2ade5ea-4f3a-4a38-9618-360c03189ee2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_CurrentFiscalYearEndDate_b2ade5ea-4f3a-4a38-9618-360c03189ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_792da9fa-5576-46fc-b5fd-3ccecea72afa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentFiscalYearFocus_792da9fa-5576-46fc-b5fd-3ccecea72afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6f9289c3-5cf5-474d-957d-b5561aea0cbb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6f9289c3-5cf5-474d-957d-b5561aea0cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_41f77c1a-52e4-40b9-94cf-2d8d2d191166" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_AmendmentFlag_41f77c1a-52e4-40b9-94cf-2d8d2d191166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_1960815c-a781-4983-bc63-ef0bf12f1af2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityExTransitionPeriod_1960815c-a781-4983-bc63-ef0bf12f1af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a34f19c0-9b99-4912-878d-a40a3e071f50" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DocumentAndEntityInformationAbstract_6588b83b-e8c4-43c3-a3be-bea2eae6a149" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a34f19c0-9b99-4912-878d-a40a3e071f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6f434c97-666e-473d-87cb-be4e2c9f61a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_86c43646-9a08-4a26-91db-786cf7c977a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f434c97-666e-473d-87cb-be4e2c9f61a7" xlink:to="loc_us-gaap_AssetsAbstract_86c43646-9a08-4a26-91db-786cf7c977a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86c43646-9a08-4a26-91db-786cf7c977a1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_865a61f7-e92c-49ec-bd4c-d2c7bfd3ea8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_865a61f7-e92c-49ec-bd4c-d2c7bfd3ea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_551c18e2-ed26-4d13-a479-14c7665e869b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_551c18e2-ed26-4d13-a479-14c7665e869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_33cd2dfc-ff8b-4138-9c1a-f7fa105be92f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_OtherShortTermInvestments_33cd2dfc-ff8b-4138-9c1a-f7fa105be92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ac3344aa-923c-4744-bb6d-6b64232fb4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ac3344aa-923c-4744-bb6d-6b64232fb4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsCurrent_8ee3e0fe-db78-4914-81a3-1283d8963ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_RestrictedInvestmentsCurrent_8ee3e0fe-db78-4914-81a3-1283d8963ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_db5746b1-3c76-44b1-b7f8-0f99ac707a79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_db5746b1-3c76-44b1-b7f8-0f99ac707a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_9eb48fc1-0cf0-4271-a406-9d3cae04e9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_9eb48fc1-0cf0-4271-a406-9d3cae04e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e88cc065-e94f-44d2-9e5e-a9059aca089a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e88cc065-e94f-44d2-9e5e-a9059aca089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_88c73761-19f1-43d6-9bc4-01047fc50905" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_InventoryNet_88c73761-19f1-43d6-9bc4-01047fc50905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0edcf267-f604-4a00-a3e0-4a1af5d3b1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c3e24b53-6a75-4c10-967b-0a448a378c69" xlink:to="loc_us-gaap_AssetsCurrent_0edcf267-f604-4a00-a3e0-4a1af5d3b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86c43646-9a08-4a26-91db-786cf7c977a1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9feaaa7f-27a8-46d6-afe4-9f9ee8e5af67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9feaaa7f-27a8-46d6-afe4-9f9ee8e5af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f94f947-d70c-4839-8c30-fe27ad56d757" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f94f947-d70c-4839-8c30-fe27ad56d757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5ce9d9ef-53ba-480d-a668-f49a9caec166" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_5ce9d9ef-53ba-480d-a668-f49a9caec166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_48241025-06da-48c6-8e52-d36728e71163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce20c189-f96d-4c29-b5df-310da7269e63" xlink:to="loc_us-gaap_AssetsNoncurrent_48241025-06da-48c6-8e52-d36728e71163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5c701bb9-e61e-40ca-935e-40d20b0f7e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86c43646-9a08-4a26-91db-786cf7c977a1" xlink:to="loc_us-gaap_Assets_5c701bb9-e61e-40ca-935e-40d20b0f7e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6f434c97-666e-473d-87cb-be4e2c9f61a7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_ec57ee93-ea9e-43b6-abda-eaf7a14ad7af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_ec57ee93-ea9e-43b6-abda-eaf7a14ad7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cb58c090-9ff7-40f2-8e58-897e3da88e04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cb58c090-9ff7-40f2-8e58-897e3da88e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1a195a03-a44f-43d5-a589-ce78a81f5d18" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1a195a03-a44f-43d5-a589-ce78a81f5d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_042dd77d-d082-4c8a-9cbf-60db76d484ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_042dd77d-d082-4c8a-9cbf-60db76d484ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ab47a30d-d09a-4d1c-a1b7-a29d73477378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ab47a30d-d09a-4d1c-a1b7-a29d73477378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1b24789c-f7d2-439a-ba09-9573566c2018" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1286d5a4-dfd1-4c71-8dd5-1587c6273431" xlink:to="loc_us-gaap_LiabilitiesCurrent_1b24789c-f7d2-439a-ba09-9573566c2018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_2b09a0b7-db4b-4c6b-8058-8ca03e1329b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_2b09a0b7-db4b-4c6b-8058-8ca03e1329b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4da7022-af41-43da-863a-94b7e4442d89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4da7022-af41-43da-863a-94b7e4442d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_801dec67-e090-48c5-8527-89d4cae68830" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_801dec67-e090-48c5-8527-89d4cae68830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_e06a7627-ae9e-4d13-ab91-5a25da827972" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_OtherLiabilities_e06a7627-ae9e-4d13-ab91-5a25da827972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_55d3f01c-be9f-4994-a14e-b65b3ec9eaf4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_55d3f01c-be9f-4994-a14e-b65b3ec9eaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_380729f1-bfa9-4009-b7f5-0332bda2234d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_Liabilities_380729f1-bfa9-4009-b7f5-0332bda2234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_52c52c7b-bc7c-4854-b061-e6af1adecd91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a4dbfb60-2121-4455-845e-510d0701ebce" xlink:to="loc_us-gaap_CommitmentsAndContingencies_52c52c7b-bc7c-4854-b061-e6af1adecd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ceea347c-e4d3-4043-a2fe-f2fa005496e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_PreferredStockValue_ceea347c-e4d3-4043-a2fe-f2fa005496e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cc9b9d1a-7572-4047-acd7-e0a221b88ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_CommonStockValue_cc9b9d1a-7572-4047-acd7-e0a221b88ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7f3ba305-2c52-4350-aebc-2631d24d2468" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7f3ba305-2c52-4350-aebc-2631d24d2468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f43927cf-2e09-4ae4-8763-e1403072ec35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f43927cf-2e09-4ae4-8763-e1403072ec35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09f69ae1-b6d5-4e01-9cec-3062f90294a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_09f69ae1-b6d5-4e01-9cec-3062f90294a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_813447aa-eb6c-4ac9-8bf0-b64beb41fb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1bc1bc6e-31af-4a25-9d7a-677d2d00d3c2" xlink:to="loc_us-gaap_StockholdersEquity_813447aa-eb6c-4ac9-8bf0-b64beb41fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d52c8835-b0ac-4457-a9e3-d0a7576330b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_47fe27bc-32ba-4f84-9a1f-e080d123fd6b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d52c8835-b0ac-4457-a9e3-d0a7576330b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_af869ee9-f092-4090-a25d-b87a683583e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_af869ee9-f092-4090-a25d-b87a683583e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6000254c-eeea-4ff7-bfd0-c24f337822ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6000254c-eeea-4ff7-bfd0-c24f337822ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9f371466-d7b4-4feb-b12f-ee5cebbf75f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9f371466-d7b4-4feb-b12f-ee5cebbf75f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c903a047-53c8-4c04-9235-f42db1bfb70a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c903a047-53c8-4c04-9235-f42db1bfb70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c0d7d13-646a-4771-bd0d-9262403a26dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c0d7d13-646a-4771-bd0d-9262403a26dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_17d14a9a-cce4-4dd4-a5c2-2fb84cbd89c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_17d14a9a-cce4-4dd4-a5c2-2fb84cbd89c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_462a171c-d747-495e-9677-11e472a91294" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_CommonStockSharesIssued_462a171c-d747-495e-9677-11e472a91294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98928a51-42c3-4194-b1b6-3c88f2f177fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d11f3230-4e90-48b8-b406-986079e5d875" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98928a51-42c3-4194-b1b6-3c88f2f177fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8472933e-953a-455f-8908-d84ed267a401" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8472933e-953a-455f-8908-d84ed267a401" xlink:to="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:to="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f9445358-8c71-4609-8620-ad1d484a688f" xlink:to="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_023c3177-df10-446b-a152-54b7cf6068d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_ProductMember_023c3177-df10-446b-a152-54b7cf6068d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_240b2841-0f2d-4997-bfe6-b2588f7f02d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_LicenseMember_240b2841-0f2d-4997-bfe6-b2588f7f02d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_74fca27b-9cc0-4924-aa5d-856a3dbdf9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb40003b-3d9e-44a6-a206-b4bad25f7dd8" xlink:to="loc_us-gaap_RoyaltyMember_74fca27b-9cc0-4924-aa5d-856a3dbdf9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_dc2081d7-3dbd-488e-a94c-b7b1f316af3b" xlink:to="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ffdf12-3b51-4845-94b4-6481b34fdb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37ffdf12-3b51-4845-94b4-6481b34fdb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3e1a8058-e6b8-4a5a-8a01-e3a7d0f957c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3e1a8058-e6b8-4a5a-8a01-e3a7d0f957c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ec187ba2-fce1-48bf-8ba3-ac72e3ecc459" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ec187ba2-fce1-48bf-8ba3-ac72e3ecc459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5723a63b-95c3-4eb4-9cc4-51df599667e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5723a63b-95c3-4eb4-9cc4-51df599667e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_33b8d31c-6f1b-4cdc-9f30-d57136b4a227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_33b8d31c-6f1b-4cdc-9f30-d57136b4a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_a7a119c5-548c-426e-b902-386d88363651" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_a7a119c5-548c-426e-b902-386d88363651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1167aafe-e91d-482f-93b8-6f0ae6bb406e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7eb20478-d3d7-4a71-ae38-40c7b06ae1a3" xlink:to="loc_us-gaap_CostsAndExpenses_1167aafe-e91d-482f-93b8-6f0ae6bb406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3e83fb1e-832a-4cfe-9bd5-f2a658a0f454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_OperatingIncomeLoss_3e83fb1e-832a-4cfe-9bd5-f2a658a0f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialIncomeNet_e1e96f39-4e48-4c26-bc9a-42d4f8ea5563" xlink:href="mnlo-20200630.xsd#mnlo_FinancialIncomeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_mnlo_FinancialIncomeNet_e1e96f39-4e48-4c26-bc9a-42d4f8ea5563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FinancialExpenses_1c5ddcbd-56a3-4bf5-9bfc-e03b6eaaeab2" xlink:href="mnlo-20200630.xsd#mnlo_FinancialExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_mnlo_FinancialExpenses_1c5ddcbd-56a3-4bf5-9bfc-e03b6eaaeab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0dc348a-9517-4c6f-ba4a-efb1a23a286f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0dc348a-9517-4c6f-ba4a-efb1a23a286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_702a7716-4f03-4561-aaa2-ece34dd09ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_702a7716-4f03-4561-aaa2-ece34dd09ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d288c200-6489-4d1f-975e-be318cb86115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_NetIncomeLoss_d288c200-6489-4d1f-975e-be318cb86115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_251ca071-0c08-4db6-a6ee-8637ad843317" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_251ca071-0c08-4db6-a6ee-8637ad843317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a91b0d28-5067-4c4a-9816-c8890686783e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d822243a-7051-4117-a75a-584a46e9d716" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a91b0d28-5067-4c4a-9816-c8890686783e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_49e0901d-8f5f-44aa-97a2-f0fb4e9ec34f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42cabbed-2e63-447f-9cb1-2da67eaf39fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_49e0901d-8f5f-44aa-97a2-f0fb4e9ec34f" xlink:to="loc_us-gaap_NetIncomeLoss_42cabbed-2e63-447f-9cb1-2da67eaf39fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_49e0901d-8f5f-44aa-97a2-f0fb4e9ec34f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f045f5ca-c83e-4d28-9aaf-1d4263ffeea0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f045f5ca-c83e-4d28-9aaf-1d4263ffeea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_73596b35-d928-4114-a946-05456781a77b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_73596b35-d928-4114-a946-05456781a77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_94da306c-6d1a-44ca-a4eb-0edbadb970d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_94da306c-6d1a-44ca-a4eb-0edbadb970d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76e21932-b863-4513-a3b5-11c8f79f8d66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2554d18b-32b6-4967-a160-20f7b5c736df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76e21932-b863-4513-a3b5-11c8f79f8d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6d6db66-50cf-4653-9321-0badf4944338" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_49e0901d-8f5f-44aa-97a2-f0fb4e9ec34f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f6d6db66-50cf-4653-9321-0badf4944338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_483575e4-fedd-4118-99df-d3f415374f75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_483575e4-fedd-4118-99df-d3f415374f75" xlink:to="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2b0f0beb-18ff-41f9-94bb-774240c8b006" xlink:to="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3a8002d3-0c10-490e-8bcb-618b0e124da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_CommonStockMember_3a8002d3-0c10-490e-8bcb-618b0e124da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5e82583a-f43f-461d-b877-6829c683b950" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5e82583a-f43f-461d-b877-6829c683b950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_5bfce31e-7984-4953-94df-ed4262259771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_RetainedEarningsMember_5bfce31e-7984-4953-94df-ed4262259771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ab73414e-5196-4062-b1b6-6381a64cf0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6557984-8031-47d8-8126-2e7eafe035c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ab73414e-5196-4062-b1b6-6381a64cf0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e6dacb-21df-4a8d-aaa2-3bb84570de5e" xlink:to="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_aa032b3c-2415-414b-9454-4d0476e34bea" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd4c8c25-0c83-4e8d-91b7-4c1351aa56ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockholdersEquity_dd4c8c25-0c83-4e8d-91b7-4c1351aa56ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_313e3192-deeb-42df-a3f8-91bd0c85442c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_313e3192-deeb-42df-a3f8-91bd0c85442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a3f3f6fb-6bbb-40ae-89b5-d042ef850cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a3f3f6fb-6bbb-40ae-89b5-d042ef850cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3cabfe02-6f4a-4589-8558-d539c8c074e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3cabfe02-6f4a-4589-8558-d539c8c074e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06945a6d-b60f-41dd-aa18-eee216db59ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06945a6d-b60f-41dd-aa18-eee216db59ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_0480e528-bbe7-4b5b-a81f-f47d645b7a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_0480e528-bbe7-4b5b-a81f-f47d645b7a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6a82663c-b0a4-444f-a524-d4a0aa6265b2" xlink:href="mnlo-20200630.xsd#mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6a82663c-b0a4-444f-a524-d4a0aa6265b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_cc9e1367-fd02-4ae2-b042-bc8ddda74bda" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_cc9e1367-fd02-4ae2-b042-bc8ddda74bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_78916af7-124a-488f-9994-d8901e55bbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_78916af7-124a-488f-9994-d8901e55bbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_202255c4-c1fa-4779-8ca5-56f3494c2594" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_202255c4-c1fa-4779-8ca5-56f3494c2594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa0133e8-738c-4649-b2aa-5fda3f864df4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa0133e8-738c-4649-b2aa-5fda3f864df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_25e7c9ba-d294-4242-803a-d6f8da6a2006" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_25e7c9ba-d294-4242-803a-d6f8da6a2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22b5a923-a4c5-4782-ad3f-54b7eee2dac1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_StockholdersEquity_22b5a923-a4c5-4782-ad3f-54b7eee2dac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ebc32070-6fc0-4c29-aceb-17a09564c952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_81e8b87b-73b3-49b5-bba3-6c02639c93a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ebc32070-6fc0-4c29-aceb-17a09564c952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3067a444-7cb6-44ed-8219-203186d22e34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_95372321-543a-435c-a314-2cc78dae5564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3067a444-7cb6-44ed-8219-203186d22e34" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_95372321-543a-435c-a314-2cc78dae5564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c5ea8f7c-e91e-419b-ac76-fd2916467eef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c5ea8f7c-e91e-419b-ac76-fd2916467eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_447f8053-6075-4b02-b12b-e2db81a654d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c5ea8f7c-e91e-419b-ac76-fd2916467eef" xlink:to="loc_us-gaap_NetIncomeLoss_447f8053-6075-4b02-b12b-e2db81a654d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c5ea8f7c-e91e-419b-ac76-fd2916467eef" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_00ccd322-97a5-40c5-b6b7-53345b20baea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_00ccd322-97a5-40c5-b6b7-53345b20baea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7d57c39b-362f-48ea-a76d-6faf2bc45480" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_7d57c39b-362f-48ea-a76d-6faf2bc45480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_5a19f2d7-dd41-4811-a8a8-10f2c20ed6ea" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_5a19f2d7-dd41-4811-a8a8-10f2c20ed6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_62ea86cc-48f0-4740-9f38-002e08c82864" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_62ea86cc-48f0-4740-9f38-002e08c82864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8beeabc5-724a-48a5-b614-aebc9ffc2d93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8beeabc5-724a-48a5-b614-aebc9ffc2d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_e170b873-c685-4efc-b3bc-14e5f0ed5582" xlink:href="mnlo-20200630.xsd#mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits_e170b873-c685-4efc-b3bc-14e5f0ed5582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_518daf6a-c9b8-4dfe-bed6-1949b77aabd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_ShareBasedCompensation_518daf6a-c9b8-4dfe-bed6-1949b77aabd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_18c19338-d60b-490b-813d-ef07df4437cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73ad184d-4eae-485c-be24-dad4bb0ea8f0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_18c19338-d60b-490b-813d-ef07df4437cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c5ea8f7c-e91e-419b-ac76-fd2916467eef" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a8ce0bb-fe6c-42e1-ada6-b72e4b8d08d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a8ce0bb-fe6c-42e1-ada6-b72e4b8d08d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e951e228-7064-467b-a01f-53e25fd6f749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e951e228-7064-467b-a01f-53e25fd6f749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1ca322db-c450-4b10-b561-bc1702219105" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1ca322db-c450-4b10-b561-bc1702219105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1e797af6-201f-409f-99d7-aa43b577e084" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1e797af6-201f-409f-99d7-aa43b577e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b63a6b4-dd0f-4c8f-9834-3b1855d69111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968f8935-03b7-4446-834e-9ecfd007bdeb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b63a6b4-dd0f-4c8f-9834-3b1855d69111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2222f9c1-0d44-427a-a4ef-fa904df94609" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2222f9c1-0d44-427a-a4ef-fa904df94609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_99e2d53f-85d1-4597-afb4-78f5ccd808b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_99e2d53f-85d1-4597-afb4-78f5ccd808b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ProceedsFromBusinessMerger_df07ee1a-a4c4-49ab-a190-144c9320129c" xlink:href="mnlo-20200630.xsd#mnlo_ProceedsFromBusinessMerger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:to="loc_mnlo_ProceedsFromBusinessMerger_df07ee1a-a4c4-49ab-a190-144c9320129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_14593358-58c8-4d40-ba30-d065ed756dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_14593358-58c8-4d40-ba30-d065ed756dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_917cfa2e-5842-4ad4-bd2b-8e2b50a24921" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_b3f2907b-0807-4f3e-a248-9beb289db8d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_917cfa2e-5842-4ad4-bd2b-8e2b50a24921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8d527b73-5e35-4e78-8576-08d115377dee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8d527b73-5e35-4e78-8576-08d115377dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cd9283fc-d53d-47b6-80fe-33b5642388ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8d527b73-5e35-4e78-8576-08d115377dee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cd9283fc-d53d-47b6-80fe-33b5642388ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_af60006c-d603-4b02-993b-eefde5b33159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8d527b73-5e35-4e78-8576-08d115377dee" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_af60006c-d603-4b02-993b-eefde5b33159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_392df8c7-d7b7-4014-9717-9b62144c4a98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8d527b73-5e35-4e78-8576-08d115377dee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_392df8c7-d7b7-4014-9717-9b62144c4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f6982631-87db-44aa-a8f5-33e9223f2bc7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f6982631-87db-44aa-a8f5-33e9223f2bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65cfa8dd-e2a7-4a47-9cde-30f509730f5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65cfa8dd-e2a7-4a47-9cde-30f509730f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca995709-4893-4378-833d-8c68d8ec5e3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca995709-4893-4378-833d-8c68d8ec5e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0c74af6-1bb5-40b4-b939-5a1b8e40a159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0c74af6-1bb5-40b4-b939-5a1b8e40a159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_87824c84-cc96-4e1a-83f3-3c01a022a7dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_87824c84-cc96-4e1a-83f3-3c01a022a7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ede6c741-7197-4ef6-9d55-0edbacf5081a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ede6c741-7197-4ef6-9d55-0edbacf5081a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf651a7c-79dc-4a09-9202-0e644aa61c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf651a7c-79dc-4a09-9202-0e644aa61c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_de06f643-63b2-4251-a8b8-56179b7e95b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_de06f643-63b2-4251-a8b8-56179b7e95b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9a9f00ef-edd7-4a58-90b7-d5a6581f358f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:to="loc_us-gaap_StockIssued1_9a9f00ef-edd7-4a58-90b7-d5a6581f358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_253a1aa1-1865-4e4c-bae0-51a67172e10e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_253a1aa1-1865-4e4c-bae0-51a67172e10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsIncurred_69d9359d-b603-4d6c-85a1-7f827ac3fbad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9754da71-8722-4ad6-a206-697ab8006384" xlink:to="loc_us-gaap_CapitalLeaseObligationsIncurred_69d9359d-b603-4d6c-85a1-7f827ac3fbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_56cc881e-ffaa-4a34-8f00-b61efe82e8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_56cc881e-ffaa-4a34-8f00-b61efe82e8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_InterestReceived_2be90941-a13f-4139-94d4-486facdc24b2" xlink:href="mnlo-20200630.xsd#mnlo_InterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56cc881e-ffaa-4a34-8f00-b61efe82e8d8" xlink:to="loc_mnlo_InterestReceived_2be90941-a13f-4139-94d4-486facdc24b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7d40d183-fd90-4450-a318-97f099bad2dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_56cc881e-ffaa-4a34-8f00-b61efe82e8d8" xlink:to="loc_us-gaap_InterestPaidNet_7d40d183-fd90-4450-a318-97f099bad2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1ab3af96-c657-4169-8eb9-b455713bc3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_1ab3af96-c657-4169-8eb9-b455713bc3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_868d5a13-1271-4148-9340-30ba2d141177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_868d5a13-1271-4148-9340-30ba2d141177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7626a959-7bb6-47dd-8b61-cc6f5ff83693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_7626a959-7bb6-47dd-8b61-cc6f5ff83693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired_1d8093c7-4c05-446c-b30d-4be4315a0f12" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessCashAcquired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_mnlo_NonCashAcquisitionOfBusinessCashAcquired_1d8093c7-4c05-446c-b30d-4be4315a0f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_8f5cea9c-70be-4d38-b934-b49c67093868" xlink:href="mnlo-20200630.xsd#mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_240aeb07-a912-463e-b0f6-1ff1301836db" xlink:to="loc_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired_8f5cea9c-70be-4d38-b934-b49c67093868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f99de42a-73f5-494e-8aec-f1de55d86e30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bd3f9ae6-7c00-4f39-9391-89ee14d88064" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f99de42a-73f5-494e-8aec-f1de55d86e30" xlink:to="loc_us-gaap_NatureOfOperations_bd3f9ae6-7c00-4f39-9391-89ee14d88064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#NATUREOFOPERATIONSDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4827bd7c-6124-4fa2-8c74-d52671f4292d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:to="loc_us-gaap_NumberOfReportableSegments_4827bd7c-6124-4fa2-8c74-d52671f4292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83707f8c-0445-4276-8551-b2907d49efd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:to="loc_us-gaap_NetIncomeLoss_83707f8c-0445-4276-8551-b2907d49efd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7818dd61-5399-49ab-8b15-812a0b71f574" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7818dd61-5399-49ab-8b15-812a0b71f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_40a1eb80-140d-4203-a1ee-1364bf4b2b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_40a1eb80-140d-4203-a1ee-1364bf4b2b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_402b2408-06fb-4e31-853a-87496426caed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4959730-e8a0-4d27-8324-265452711722" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_402b2408-06fb-4e31-853a-87496426caed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_843d9767-799c-4ddf-ae0e-9802e13d67b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_66671290-c84e-49c2-a626-3e8d7aae2b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_843d9767-799c-4ddf-ae0e-9802e13d67b3" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_66671290-c84e-49c2-a626-3e8d7aae2b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ReverseMergerPolicyTextBlock_4016a99c-3f2e-4c3d-a942-b0b2c7a07b74" xlink:href="mnlo-20200630.xsd#mnlo_ReverseMergerPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_mnlo_ReverseMergerPolicyTextBlock_4016a99c-3f2e-4c3d-a942-b0b2c7a07b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock_7f627b75-5d2f-4a69-9489-c8c4ac35e839" xlink:href="mnlo-20200630.xsd#mnlo_LiquidityAndCapitalResourcesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock_7f627b75-5d2f-4a69-9489-c8c4ac35e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0713b88a-d30f-46f6-a2e2-09ffcc05e63b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0713b88a-d30f-46f6-a2e2-09ffcc05e63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_eec94f7f-3cc9-4ccb-a79a-3a444192aec4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_eec94f7f-3cc9-4ccb-a79a-3a444192aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1a8f4738-c33b-4f6b-b06f-ecbb0a4bae70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_UseOfEstimates_1a8f4738-c33b-4f6b-b06f-ecbb0a4bae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_c2bb8129-c8eb-44ea-a015-04411e95701a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_c2bb8129-c8eb-44ea-a015-04411e95701a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1cdeb655-904e-487f-b1d6-c432994eb045" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1cdeb655-904e-487f-b1d6-c432994eb045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_1b16a4e0-0131-494c-bb02-b5f65d08c8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_1b16a4e0-0131-494c-bb02-b5f65d08c8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_245b3756-5acc-48a3-82c5-7bce9a231734" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_245b3756-5acc-48a3-82c5-7bce9a231734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_89306821-f663-4f15-957a-deaaad73b075" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_89306821-f663-4f15-957a-deaaad73b075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2dfbcf8b-de4d-4c0d-be18-7dfc957bbaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2dfbcf8b-de4d-4c0d-be18-7dfc957bbaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_705da083-e1c5-4b7f-98f1-d080c3de5efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f4b25576-53d6-46c6-9e25-c409fd00a3e2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_705da083-e1c5-4b7f-98f1-d080c3de5efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8cb54476-2de8-40d2-8c11-161e650aea00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba590dc6-1b36-4f99-8934-8decf8da43cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cb54476-2de8-40d2-8c11-161e650aea00" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba590dc6-1b36-4f99-8934-8decf8da43cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ed3a6ee-1a19-42cf-9e3a-5539c037419d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ed3a6ee-1a19-42cf-9e3a-5539c037419d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_406ba68a-9f4b-4b1f-bae3-423c5343023d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_5f0cc1b1-66c1-41f5-8505-1ad11f84a44c" xlink:href="mnlo-20200630.xsd#mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:to="loc_mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember_5f0cc1b1-66c1-41f5-8505-1ad11f84a44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_0c11fd9f-9849-4c50-bc6d-4cee4972a3fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d0a8ebb-cfb0-436c-88ab-7ee1129a3c34" xlink:to="loc_us-gaap_WarrantMember_0c11fd9f-9849-4c50-bc6d-4cee4972a3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:to="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2f088283-60df-4252-bf90-75c5e2628310" xlink:to="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_684b2cef-6d3c-4f3b-9bae-97b3cf653dbe" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c1caef01-aa51-42a8-bd88-2ab3d6b4adc0" xlink:to="loc_mnlo_FoamixMember_684b2cef-6d3c-4f3b-9bae-97b3cf653dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58958b96-5850-40e3-8089-d891083bf1dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_UpfrontRoyaltyReceipt_783570f4-bd78-49e3-b3b7-21feab910d2e" xlink:href="mnlo-20200630.xsd#mnlo_UpfrontRoyaltyReceipt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_UpfrontRoyaltyReceipt_783570f4-bd78-49e3-b3b7-21feab910d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_cd196fa5-83ea-4715-bb1c-b35dbf7ad284" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_cd196fa5-83ea-4715-bb1c-b35dbf7ad284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d19eb1e5-4735-456b-9886-16b3d186436b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d19eb1e5-4735-456b-9886-16b3d186436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_a67396b2-5df1-4e3a-b374-5baf7ea91146" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_a67396b2-5df1-4e3a-b374-5baf7ea91146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_c2c7333f-1ef4-4990-aec3-ac84b1a771b1" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationEffectiveExchangeRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b97edda-c4ad-404d-ba30-de715365e8bf" xlink:to="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_c2c7333f-1ef4-4990-aec3-ac84b1a771b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATION"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b6c6a931-3a07-4374-b156-5aa871080050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c9ce37ba-b3d2-401b-b664-d76e09df9090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b6c6a931-3a07-4374-b156-5aa871080050" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c9ce37ba-b3d2-401b-b664-d76e09df9090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_1ff55b18-30a5-40ac-a242-82e602b3ef09" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:to="loc_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock_1ff55b18-30a5-40ac-a242-82e602b3ef09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c9c90fae-f035-4627-aece-e9a939c4bf5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c9c90fae-f035-4627-aece-e9a939c4bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock_f84e8273-32bd-49b7-af9f-b302c8c542bb" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:to="loc_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock_f84e8273-32bd-49b7-af9f-b302c8c542bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_94d32de4-82bd-4bc4-8169-f27d056c73dc" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:to="loc_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock_94d32de4-82bd-4bc4-8169-f27d056c73dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_2ff5aed6-7964-4335-a733-9d5815cc76c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_521aa888-5ac3-4846-a61a-9f13fb33c4f2" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_2ff5aed6-7964-4335-a733-9d5815cc76c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_066f2ed5-7493-4049-a750-946a8f65dcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_066f2ed5-7493-4049-a750-946a8f65dcfd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a05f0356-27e7-4eed-b892-946231868b0c" xlink:to="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48a6284f-e14a-4006-b14d-47396e66cff4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_dfc8b443-4295-45c9-b3e7-96d852843693" xlink:to="loc_us-gaap_CommonStockMember_48a6284f-e14a-4006-b14d-47396e66cff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d44b6ffc-42a4-4b4d-a9d1-5232b6ae1b9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_211bb1d3-f676-464a-a011-9808189717c3" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8e040447-22f6-4bc8-a8bd-f2b7a8aa6ccc" xlink:to="loc_mnlo_FoamixMember_211bb1d3-f676-464a-a011-9808189717c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_37709cfa-982d-40e5-b0fb-5004fe2ff799" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77918d5a-2bf6-48f5-8ab0-456764e476fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_244038ef-e084-44fa-85f6-20a368e863bd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77918d5a-2bf6-48f5-8ab0-456764e476fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_eda03fbb-180a-4b40-be0f-fecaae58f79e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2914604d-78c1-48be-8beb-146d9095aff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_75c8feff-61c4-4761-bb81-374067d3fa14" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2914604d-78c1-48be-8beb-146d9095aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6c6c545e-915e-4b06-95c9-4530fa5599ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_6fe7c8a5-2f2a-4298-946f-b219bb3bf991" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cae5efb5-c2b7-40a2-8969-01b69b64ad49" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_6fe7c8a5-2f2a-4298-946f-b219bb3bf991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2cfd0ff5-7a03-40d9-9e9e-730a86641377" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ExchangeRatio_66220aab-9ff4-4c9f-8dfd-f97515d16439" xlink:href="mnlo-20200630.xsd#mnlo_ExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ExchangeRatio_66220aab-9ff4-4c9f-8dfd-f97515d16439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_9b90d861-fc5d-4bcc-a44e-fcc42d0648a1" xlink:href="mnlo-20200630.xsd#mnlo_BusinessAcquisitionContingentStockRightIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_9b90d861-fc5d-4bcc-a44e-fcc42d0648a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_692fe23a-52c9-4902-817b-a529069db1df" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_692fe23a-52c9-4902-817b-a529069db1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EffectiveExchangeRatio_d851d181-258e-46fb-91f8-5c2b570c6fc3" xlink:href="mnlo-20200630.xsd#mnlo_EffectiveExchangeRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_EffectiveExchangeRatio_d851d181-258e-46fb-91f8-5c2b570c6fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_dc9df128-acf3-4c93-b68c-6a6fbfb1de17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_dc9df128-acf3-4c93-b68c-6a6fbfb1de17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_7b5487a8-23dd-4904-bf00-83a897f19a26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_7b5487a8-23dd-4904-bf00-83a897f19a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_a9342da2-30bd-4a69-83dd-fba5c74277dc" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_a9342da2-30bd-4a69-83dd-fba5c74277dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_1d359623-df67-446f-9a7e-311a4bb89dd8" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerParentStockholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders_1d359623-df67-446f-9a7e-311a4bb89dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_68eb2706-7ac4-419d-9297-d77e45723704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_68eb2706-7ac4-419d-9297-d77e45723704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_709b1116-876d-4cc8-b058-730a31025b0f" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_709b1116-876d-4cc8-b058-730a31025b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross_8e87a27a-0212-41bf-af16-0c1d804ae2a3" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredGross_8e87a27a-0212-41bf-af16-0c1d804ae2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84b1a1f5-ea51-40dd-95a3-dba82d371ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_SharePrice_84b1a1f5-ea51-40dd-95a3-dba82d371ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_4f6dab12-3ee4-4b35-beaa-5286d1839d8a" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes_4f6dab12-3ee4-4b35-beaa-5286d1839d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_997a0e76-dca2-4117-87a1-9c363180edd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_997a0e76-dca2-4117-87a1-9c363180edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dcbadaad-b8c5-4a26-ae70-4fb456f4219f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dcbadaad-b8c5-4a26-ae70-4fb456f4219f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_c15a9508-52c2-4045-8305-562383679101" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_c15a9508-52c2-4045-8305-562383679101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_8faa1280-8e7a-4322-b960-415a1446039a" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockConsiderationRemeasurementGainLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_ContingentStockConsiderationRemeasurementGainLoss_8faa1280-8e7a-4322-b960-415a1446039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_797d6401-7f54-4bf3-8ada-99f624112d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_797d6401-7f54-4bf3-8ada-99f624112d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_f5857652-0fe3-446b-88e5-77021737efdb" xlink:href="mnlo-20200630.xsd#mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_915eb716-19c5-4f03-981b-3f66a71f239b" xlink:to="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_f5857652-0fe3-446b-88e5-77021737efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_4e3aed03-cc0b-4a77-a236-13ebab4b765e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_4e3aed03-cc0b-4a77-a236-13ebab4b765e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3243c065-b4b4-4d78-814b-f0fa4c0e42e2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_21424dd9-4678-49d9-af03-31466c8d489f" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_69a35c55-585b-47d7-b014-a50e89717316" xlink:to="loc_mnlo_FoamixMember_21424dd9-4678-49d9-af03-31466c8d489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_09d4b1da-fe09-41bb-9ccc-edd3c3de611e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8daefecd-89c7-42ce-b1d7-1fc5dcf6f963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_8daefecd-89c7-42ce-b1d7-1fc5dcf6f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_7e5ff231-486d-4bfe-ba91-ca0482d7a483" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards_7e5ff231-486d-4bfe-ba91-ca0482d7a483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationConsiderationTransferredGross_7f40729f-e655-4867-848a-00033af4c8ed" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationConsiderationTransferredGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_mnlo_BusinessCombinationConsiderationTransferredGross_7f40729f-e655-4867-848a-00033af4c8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c9e1676-b97a-4bfd-b2a3-5d594ddb4c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6c9e1676-b97a-4bfd-b2a3-5d594ddb4c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30cf1710-e7ac-40e1-9203-4cdaf7662a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_94f35b3d-afb1-4ad9-8b25-7ae8362f750c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_30cf1710-e7ac-40e1-9203-4cdaf7662a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9aa239d8-0992-4ff9-8b6c-75f217a91ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9aa239d8-0992-4ff9-8b6c-75f217a91ced" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_aa119f4d-589c-4baa-8101-174fff9aab70" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_19629568-2ead-4d26-9274-af0f1bb71926" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_22fd0346-34a5-4a8b-9e9e-b496cf763946" xlink:to="loc_mnlo_FoamixMember_19629568-2ead-4d26-9274-af0f1bb71926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_76d489e9-d227-4844-92e8-6b66a22d26fe" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b7626f73-3c11-447a-98d9-26afb594a72e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3242f1bd-0863-4f4e-ad91-15280d2992b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3242f1bd-0863-4f4e-ad91-15280d2992b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ada42923-53d3-4f7a-a1f5-ed8c0004aad5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ada42923-53d3-4f7a-a1f5-ed8c0004aad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d6f8f619-df0c-44f9-8cdb-1d4e24652adc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d6f8f619-df0c-44f9-8cdb-1d4e24652adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_28ca261b-d7f5-4fb3-8330-e17d152545c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_28ca261b-d7f5-4fb3-8330-e17d152545c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7742952a-43cf-4122-9a0a-b66f6988828c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_Goodwill_7742952a-43cf-4122-9a0a-b66f6988828c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_be82dbf9-eb79-4800-8bbc-9dfd773df177" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_be82dbf9-eb79-4800-8bbc-9dfd773df177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_da21d1a0-8e6e-4d1c-ab52-1bb7a287464f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_da21d1a0-8e6e-4d1c-ab52-1bb7a287464f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a46acbd-7450-4401-8658-6f168ca4e191" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a46acbd-7450-4401-8658-6f168ca4e191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d20e4230-b368-4295-926a-5f9f62a9891b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_d20e4230-b368-4295-926a-5f9f62a9891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_cb4b5489-bf49-4e89-9664-0efc727e08ab" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_4271248c-2f43-45eb-be54-e236e171889e" xlink:to="loc_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock_cb4b5489-bf49-4e89-9664-0efc727e08ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3922dae5-1d29-4ee5-aa00-057cc5569cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3922dae5-1d29-4ee5-aa00-057cc5569cd7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5b2042a3-7e62-4ffa-a7e1-592470b5f7ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_e094d27f-9529-4ddb-9f0f-9a8922f5b74f" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_02c96b8c-dd1d-492c-a8cc-dac6af11ff05" xlink:to="loc_mnlo_FoamixMember_e094d27f-9529-4ddb-9f0f-9a8922f5b74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_598975e7-6bdf-42ca-8de3-0002e4918e86" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_27822ba6-0663-4f3a-9e0a-8809ecc64c00" xlink:to="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_03ac17dc-b1a8-420d-9796-7bf5cdb99335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_03ac17dc-b1a8-420d-9796-7bf5cdb99335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_37ffe518-e8ad-4017-b2db-8f794829f81f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_37ffe518-e8ad-4017-b2db-8f794829f81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_d7414da6-a2f0-4a12-a01d-a3adca51d3b5" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets_d7414da6-a2f0-4a12-a01d-a3adca51d3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25f2a094-b310-4f4e-b642-f549682fe29b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationGoodwillAbstract_8cbc7b59-2d8a-4f26-b0a2-7b34cbe04f09" xlink:to="loc_us-gaap_Goodwill_25f2a094-b310-4f4e-b642-f549682fe29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONIPRDandCSRDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_aa8b6243-2946-431b-ab91-a0a74bf5ad79" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aa8b6243-2946-431b-ab91-a0a74bf5ad79" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e12e8008-767a-4a85-b4d5-47aef320bab1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_a1808cb7-7c44-44e2-9d24-86541a6420de" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_732c65a4-db9c-496c-898c-de5c11cd30c8" xlink:to="loc_mnlo_FoamixMember_a1808cb7-7c44-44e2-9d24-86541a6420de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_25551f16-5f8b-4d2f-9608-490fc46ef404" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ab12b5d7-7a70-49ee-890d-676fb9510675" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_55fd279f-8e8e-41a9-bc37-9f4adc859b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_55fd279f-8e8e-41a9-bc37-9f4adc859b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_26de5298-62b1-4c6c-917d-7e56a20dc4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_377ece6f-6189-4558-9df1-6d1dde4f94c4" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_26de5298-62b1-4c6c-917d-7e56a20dc4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_63d8bcea-a9ad-4c23-a94e-11ad927b71a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_022395ef-bece-4a76-a4cb-2ee9ab4609a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_63d8bcea-a9ad-4c23-a94e-11ad927b71a8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_022395ef-bece-4a76-a4cb-2ee9ab4609a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a0257b10-422d-41f1-a693-c338fa9d542b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_63d8bcea-a9ad-4c23-a94e-11ad927b71a8" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_a0257b10-422d-41f1-a693-c338fa9d542b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_63d8bcea-a9ad-4c23-a94e-11ad927b71a8" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_15d4b8ab-696a-40cb-b241-a12e236f9578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_15d4b8ab-696a-40cb-b241-a12e236f9578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_985f9b78-1eaf-465f-b5e8-004e5771a134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_985f9b78-1eaf-465f-b5e8-004e5771a134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_22af84a5-2547-495b-bfe1-5b1b1cc32f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_22af84a5-2547-495b-bfe1-5b1b1cc32f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_45b38cfe-88d3-47ed-b36b-0143c304fa30" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_21619bd9-abf9-48aa-8d1c-3f1431f2d859" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_45b38cfe-88d3-47ed-b36b-0143c304fa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_a9327945-2780-4db3-bf96-f464eac2dd75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_63d8bcea-a9ad-4c23-a94e-11ad927b71a8" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_a9327945-2780-4db3-bf96-f464eac2dd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_f2676461-5d0c-40e0-9a96-0ddffc658fba" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaTransactionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_a9327945-2780-4db3-bf96-f464eac2dd75" xlink:to="loc_mnlo_AdjustmentsToSupplementalProformaTransactionCosts_f2676461-5d0c-40e0-9a96-0ddffc658fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_49ce068f-2b82-4763-a8de-eed6f5c66bf2" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_a9327945-2780-4db3-bf96-f464eac2dd75" xlink:to="loc_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation_49ce068f-2b82-4763-a8de-eed6f5c66bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_e3a1750c-aafc-4797-9f13-244d673267b3" xlink:href="mnlo-20200630.xsd#mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_a9327945-2780-4db3-bf96-f464eac2dd75" xlink:to="loc_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations_e3a1750c-aafc-4797-9f13-244d673267b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7e447ce7-14c6-4fdc-870f-b9f31eec1ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cd270ddc-4617-446e-a9e9-cea5f6ed6762" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7e447ce7-14c6-4fdc-870f-b9f31eec1ab0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cd270ddc-4617-446e-a9e9-cea5f6ed6762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#REVENUERECOGNITIONDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f409b18-058a-482b-8b96-099955c181e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_2f409b18-058a-482b-8b96-099955c181e1" xlink:to="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4a5e906e-a435-416b-8a66-c59f80ef66b4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3f02a4b9-0d77-44f3-a883-18bd63a77796" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_12ef914c-e4b8-415f-98f4-c6ba04bb97cc" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3f02a4b9-0d77-44f3-a883-18bd63a77796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_91d81155-ae3b-43a4-9e7a-ff83ae572b6d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_b7e245ff-4021-458e-a31a-69e3ef02d058" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2f3a5165-83e8-4401-995c-c7b51092d982" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_b7e245ff-4021-458e-a31a-69e3ef02d058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a0277546-ccf6-4734-8b64-bfee25d5db81" xlink:to="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorOneMember_480c5667-c05f-47a2-b657-62097f8a4abe" xlink:href="mnlo-20200630.xsd#mnlo_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorOneMember_480c5667-c05f-47a2-b657-62097f8a4abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorTwoMember_c24fe83e-dcda-4826-9a24-282e9f338f46" xlink:href="mnlo-20200630.xsd#mnlo_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorTwoMember_c24fe83e-dcda-4826-9a24-282e9f338f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DistributorThreeMember_4a18e68d-35c7-4163-9c82-3026ebff6475" xlink:href="mnlo-20200630.xsd#mnlo_DistributorThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ed38e9b3-9049-4ad1-ae8d-ddcf07678531" xlink:to="loc_mnlo_DistributorThreeMember_4a18e68d-35c7-4163-9c82-3026ebff6475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1a6e60e7-e500-442f-a2be-9beda8873093" xlink:to="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_70c428e7-55b4-4a95-ad03-231685f5360a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b361e0d0-2ffe-481b-93a5-c72fca103fd8" xlink:to="loc_us-gaap_RoyaltyMember_70c428e7-55b4-4a95-ad03-231685f5360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_080e1ffb-3046-44b1-bae2-724fd3879dc2" xlink:to="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_0faebf34-4d0f-444a-88d3-54fd4db87fe8" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_da8a7271-ea4d-4e25-b679-f7160d36d760" xlink:to="loc_mnlo_FoamixMember_0faebf34-4d0f-444a-88d3-54fd4db87fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_53896ba9-6473-4368-8c8b-56a1e847e0f8" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f2afd489-3607-4675-890a-f737d8207708" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f2afd489-3607-4675-890a-f737d8207708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_4a381e4b-8618-4112-ba9b-6ec15682dfd5" xlink:href="mnlo-20200630.xsd#mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances_4a381e4b-8618-4112-ba9b-6ec15682dfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMinimum_4de65934-b2d8-4b41-834a-1bef4304a010" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_EstimateOfProductReturnRateMinimum_4de65934-b2d8-4b41-834a-1bef4304a010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EstimateOfProductReturnRateMaximum_4cdce2ef-4a88-4b7a-b1f6-892beb6811a3" xlink:href="mnlo-20200630.xsd#mnlo_EstimateOfProductReturnRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_EstimateOfProductReturnRateMaximum_4cdce2ef-4a88-4b7a-b1f6-892beb6811a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_UpfrontRoyaltyReceipt_7c2c47fc-f16e-4b6e-9e5a-e76cb77f4519" xlink:href="mnlo-20200630.xsd#mnlo_UpfrontRoyaltyReceipt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_UpfrontRoyaltyReceipt_7c2c47fc-f16e-4b6e-9e5a-e76cb77f4519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_0000080f-8021-473a-8ee2-5a5451ed15a4" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents_0000080f-8021-473a-8ee2-5a5451ed15a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f1ee32bf-da26-430d-9fa8-20eaff68e997" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f1ee32bf-da26-430d-9fa8-20eaff68e997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0332526-310d-438d-8632-e342e8bd66eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e673c093-7d5f-4af4-a029-3e43dbd6342f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b0332526-310d-438d-8632-e342e8bd66eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENT"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_058184c1-fcf8-4f18-a074-e07641478192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_cda397e8-4265-4cc7-a54e-d978302908b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_058184c1-fcf8-4f18-a074-e07641478192" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_cda397e8-4265-4cc7-a54e-d978302908b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eab2d1d9-d263-453b-87ad-3ae4ed87461c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a6a7a934-4b44-49f4-9655-9bfaf5e9a0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eab2d1d9-d263-453b-87ad-3ae4ed87461c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a6a7a934-4b44-49f4-9655-9bfaf5e9a0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb94db69-8ce2-4b08-b8c5-26a23978fa78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb94db69-8ce2-4b08-b8c5-26a23978fa78" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3b6a6333-72bc-48c5-b830-b3f56c082cbe" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_97d859a7-cdb5-470e-b148-14f937d6c7d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_97d859a7-cdb5-470e-b148-14f937d6c7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4745704b-4862-4694-acb9-e71be9f15b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4745704b-4862-4694-acb9-e71be9f15b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ca8699d9-4783-4ae1-9c73-a10e27d09d32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c0bffee9-9156-4767-bdd9-bdebe373c840" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ca8699d9-4783-4ae1-9c73-a10e27d09d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1568568d-5aed-4404-844f-d8e474d12019" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_eefbf7d0-72aa-4b26-b8c1-6f182c65efd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d5127b2-da1f-41dc-a36d-7349f49ab0de" xlink:to="loc_us-gaap_MarketableSecurities_eefbf7d0-72aa-4b26-b8c1-6f182c65efd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#FAIRVALUEMEASUREMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract_c8051a3b-e680-4e35-b7b5-6e10001c82a2" xlink:href="mnlo-20200630.xsd#mnlo_FairValueMeasurmentsNarrativeDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_FairValueMeasurmentsNarrativeDetailsAbstract_c8051a3b-e680-4e35-b7b5-6e10001c82a2" xlink:to="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DerivateCostsForYear_bb5a0a1f-f3c3-46a1-aad6-85ddff41c93f" xlink:href="mnlo-20200630.xsd#mnlo_DerivateCostsForYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:to="loc_mnlo_DerivateCostsForYear_bb5a0a1f-f3c3-46a1-aad6-85ddff41c93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DerivativeMaximumTermOfContract_c4e13e86-b4de-4402-b887-7864146e94c5" xlink:href="mnlo-20200630.xsd#mnlo_DerivativeMaximumTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:to="loc_mnlo_DerivativeMaximumTermOfContract_c4e13e86-b4de-4402-b887-7864146e94c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAmountOfHedgedItem_2908630d-bbe3-432f-aecc-74a805550705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAmountOfHedgedItem"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:to="loc_us-gaap_DerivativeAmountOfHedgedItem_2908630d-bbe3-432f-aecc-74a805550705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions_c542337d-8951-4c09-bd72-e836716a0c72" xlink:href="mnlo-20200630.xsd#mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:to="loc_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions_c542337d-8951-4c09-bd72-e836716a0c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions_e7c46c85-fb0d-45b7-8ea7-16917578ec8c" xlink:href="mnlo-20200630.xsd#mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ea7ba58e-3e9d-496f-86eb-ac52d1f7fc42" xlink:to="loc_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions_e7c46c85-fb0d-45b7-8ea7-16917578ec8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cece4ed1-f6a7-4d10-8da7-d7bfd00a4c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f98822a9-ceb6-4d82-8d72-6509dba20a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cece4ed1-f6a7-4d10-8da7-d7bfd00a4c7c" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f98822a9-ceb6-4d82-8d72-6509dba20a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_30edf6b3-8d7e-4461-895d-7b215a1eb22d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_b06344c5-ddff-47ac-8220-38e979f3d863" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_30edf6b3-8d7e-4461-895d-7b215a1eb22d" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_b06344c5-ddff-47ac-8220-38e979f3d863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_5cfa9c44-aa51-4589-9479-658ffd7618c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_30edf6b3-8d7e-4461-895d-7b215a1eb22d" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_5cfa9c44-aa51-4589-9479-658ffd7618c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e571793-c0a0-4022-8a1a-e3dab4dc328e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e571793-c0a0-4022-8a1a-e3dab4dc328e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:to="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_c65af340-ae5f-4b2f-a35e-5c116ff67cdc" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_IsraeliMutualFundsMember_47c8d35d-18be-4d99-b478-aafbdb9615d1" xlink:href="mnlo-20200630.xsd#mnlo_IsraeliMutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_mnlo_IsraeliMutualFundsMember_47c8d35d-18be-4d99-b478-aafbdb9615d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7a918f19-3c22-4879-be1b-16a3e145e102" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7a918f19-3c22-4879-be1b-16a3e145e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_56fec657-945e-4185-a5b2-009a42ba6690" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_56fec657-945e-4185-a5b2-009a42ba6690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_2b3963c0-7125-4be6-b798-5b47e00259e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_2b3963c0-7125-4be6-b798-5b47e00259e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_1ba16c3d-6c39-420d-b530-836aba913299" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_365e0e84-e492-403f-a623-3776f57edbf0" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_1ba16c3d-6c39-420d-b530-836aba913299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_692ecf85-5065-43d7-bc03-dfdb6bb0c242" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_1d8e5aaf-9eec-48da-93f0-efd6c40cf78e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ba3b9629-7488-48ae-8dcf-f153b3ac2729" xlink:to="loc_us-gaap_ShortTermInvestments_1d8e5aaf-9eec-48da-93f0-efd6c40cf78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d47b1726-782b-47cf-93de-2e80d1a35d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d47b1726-782b-47cf-93de-2e80d1a35d0b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:to="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f94e760d-a2c7-482c-8cb5-989a55399401" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_5d56583d-6400-4038-843b-a269e6311475" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_5d56583d-6400-4038-843b-a269e6311475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_12d2f835-0c62-4065-952d-c8d302452cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_CertificatesOfDepositMember_12d2f835-0c62-4065-952d-c8d302452cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_6795ee20-a8ff-4b13-98ae-926f74c9dcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember_6795ee20-a8ff-4b13-98ae-926f74c9dcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8255fb18-e2dd-46f5-9b27-52d0aaefcbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cf4c4f8c-d226-4b7f-9a35-6a819fdd2bd1" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8255fb18-e2dd-46f5-9b27-52d0aaefcbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a36f24cb-0df4-4b24-9392-f8b3c7c30a8c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9456ef-a94b-4f8d-9618-e0530725da0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9456ef-a94b-4f8d-9618-e0530725da0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b78e8a4-e563-47c8-b6be-d3ddbc556476" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b78e8a4-e563-47c8-b6be-d3ddbc556476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37708b80-d103-42b7-a7a6-a02e57715f49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37708b80-d103-42b7-a7a6-a02e57715f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b56e44b6-1088-4fc4-88e4-0da30848997d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_48df4899-3111-4473-a7da-d9d8c8235bd1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b56e44b6-1088-4fc4-88e4-0da30848997d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#MARKETABLESECURITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425d6911-2f8f-4ae4-b954-23a48278b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e28ffc74-e87f-48bd-b0bc-fdc8f548a681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425d6911-2f8f-4ae4-b954-23a48278b7b4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_e28ffc74-e87f-48bd-b0bc-fdc8f548a681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4140a575-1bcc-4742-bbd8-7248acd0da9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425d6911-2f8f-4ae4-b954-23a48278b7b4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4140a575-1bcc-4742-bbd8-7248acd0da9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_c874a4d9-0b83-4471-966a-6d51ab10d217" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_425d6911-2f8f-4ae4-b954-23a48278b7b4" xlink:to="loc_us-gaap_RestrictedInvestments_c874a4d9-0b83-4471-966a-6d51ab10d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_34fbead5-33ae-438b-8b21-9b0955bebb1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_004d15ba-2362-4d70-b674-48425f1e5a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_34fbead5-33ae-438b-8b21-9b0955bebb1e" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_004d15ba-2362-4d70-b674-48425f1e5a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353394eb-c6ad-43d3-9c7a-b68f3dd68427" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_965b4585-7f43-4536-b2cb-0d5d6d9f3705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353394eb-c6ad-43d3-9c7a-b68f3dd68427" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_965b4585-7f43-4536-b2cb-0d5d6d9f3705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#INVENTORYDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/INVENTORYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_8fdca6e4-fc38-4f28-9b7b-b69f4b379ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:to="loc_us-gaap_InventoryWriteDown_8fdca6e4-fc38-4f28-9b7b-b69f4b379ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSupplies_c7169bde-baed-4e0f-b85b-b3ae86ac32c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSupplies_c7169bde-baed-4e0f-b85b-b3ae86ac32c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_77972062-b11a-4651-9dc6-c190c9864bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:to="loc_us-gaap_InventoryWorkInProcess_77972062-b11a-4651-9dc6-c190c9864bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_77639a1e-622f-4e7c-8950-d6afe4d6465e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:to="loc_us-gaap_InventoryFinishedGoods_77639a1e-622f-4e7c-8950-d6afe4d6465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_8a6201c1-643f-4cfb-826b-7d1782fcfc41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_81dcced2-15b8-4af3-8570-930ce79733a3" xlink:to="loc_us-gaap_InventoryGross_8a6201c1-643f-4cfb-826b-7d1782fcfc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBT"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0a82adda-b82d-46a9-830e-2fbc6f04e802" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_cba5a511-36a2-462b-9861-a16a88d4d9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0a82adda-b82d-46a9-830e-2fbc6f04e802" xlink:to="loc_us-gaap_LongTermDebtTextBlock_cba5a511-36a2-462b-9861-a16a88d4d9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTCreditagreementDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_91cb7f3d-4610-40db-a6aa-8721793b00c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_91cb7f3d-4610-40db-a6aa-8721793b00c4" xlink:to="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_763a3c80-a506-4c1c-bfec-bf6144d5ea0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RegisteredOfferingMember_ef2e2b46-c5fb-45cc-8e7a-7e0cd36eeb7e" xlink:href="mnlo-20200630.xsd#mnlo_RegisteredOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e3722331-c075-47f1-b4ab-99a82b9c73d0" xlink:to="loc_mnlo_RegisteredOfferingMember_ef2e2b46-c5fb-45cc-8e7a-7e0cd36eeb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5a74dd1d-b6e3-43f6-8b2c-feeac11c1444" xlink:to="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareholderLenderMember_2e593dd6-e0b4-4b70-a80c-bd1106ef5a8c" xlink:href="mnlo-20200630.xsd#mnlo_ShareholderLenderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_93f31167-e1b0-482d-9e35-34044af0b626" xlink:to="loc_mnlo_ShareholderLenderMember_2e593dd6-e0b4-4b70-a80c-bd1106ef5a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b156834f-c34d-49be-b120-045d098b5d59" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_4291eab5-041b-43a8-aed5-8fadcab0c566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:to="loc_us-gaap_SecuredDebtMember_4291eab5-041b-43a8-aed5-8fadcab0c566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4993d88c-1070-4c21-8def-ced1973d6210" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_16fd7aad-169b-4c1c-8832-fc0bcbdcc72b" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_16fd7aad-169b-4c1c-8832-fc0bcbdcc72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_9d42595b-1a42-4e3f-b6ca-8897f399d615" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_9d42595b-1a42-4e3f-b6ca-8897f399d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_0bf24754-b7d1-483c-8be3-07e2c87fc75a" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_AmendedAndRestatedCreditAgreementMember_0c99a669-151a-4f3e-b0ac-62a797578135" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember_0bf24754-b7d1-483c-8be3-07e2c87fc75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_5a667104-d727-41a9-bb1c-58bfdd6c7f6d" xlink:to="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3c2041ed-92aa-4944-9535-25afc5af47de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a03ea126-687e-4421-acc6-81710c79f42f" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_3c2041ed-92aa-4944-9535-25afc5af47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_99a220a0-c09a-4aea-b5bd-9c7a870c93d9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_9372368a-92b2-4feb-8dfd-de574361326a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bf45a304-e555-4399-a031-acd6ba175f67" xlink:to="loc_srt_ScenarioForecastMember_9372368a-92b2-4feb-8dfd-de574361326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c0c51ea9-05b8-470f-88ae-187eb763d9a2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cfa1e141-9106-425c-b745-cf6e8dbd3987" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f9b20ad0-392e-4579-b170-e3177d21739f" xlink:to="loc_us-gaap_SubsequentEventMember_cfa1e141-9106-425c-b745-cf6e8dbd3987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_429b3199-76a0-46ac-9867-20f84de5e920" xlink:to="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da9b76f7-5008-4934-b5ce-56232b88b20e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_da9b76f7-5008-4934-b5ce-56232b88b20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8b9e0e1a-012e-4ddb-b649-0cfaa2fccf8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8b9e0e1a-012e-4ddb-b649-0cfaa2fccf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfLenders_282f1494-e3b7-4fd2-b3b6-b98e93780570" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfLenders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_NumberOfLenders_282f1494-e3b7-4fd2-b3b6-b98e93780570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_464761a4-04b6-4e26-aa61-b0d9aa7df952" xlink:href="mnlo-20200630.xsd#mnlo_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_464761a4-04b6-4e26-aa61-b0d9aa7df952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e18a8d2e-79a1-4b71-8025-70d378456535" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e18a8d2e-79a1-4b71-8025-70d378456535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CreditAgreementNumberOfTrenches_f5cd3cfc-9f17-4190-8e7d-9c7be5eca159" xlink:href="mnlo-20200630.xsd#mnlo_CreditAgreementNumberOfTrenches"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_CreditAgreementNumberOfTrenches_f5cd3cfc-9f17-4190-8e7d-9c7be5eca159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f8fd8c6-20e5-4db9-9443-3fd290f25af4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1f8fd8c6-20e5-4db9-9443-3fd290f25af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd4caf93-98b6-499f-8510-b17791677a38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fd4caf93-98b6-499f-8510-b17791677a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentFeePercent_4c3ca54a-ebb4-4ca7-a718-57de440e5880" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentFeePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtInstrumentFeePercent_4c3ca54a-ebb4-4ca7-a718-57de440e5880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_2c562767-74f5-4858-a897-97bb8fd19b9f" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_2c562767-74f5-4858-a897-97bb8fd19b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_58aa52c6-7d5e-40ac-92f2-7809527785aa" xlink:href="mnlo-20200630.xsd#mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent_58aa52c6-7d5e-40ac-92f2-7809527785aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantsAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_294a0976-1fcf-4757-a6b1-9337905e1a29" xlink:to="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_105ceff4-1733-44fe-a4ab-87246f8042a2" xlink:href="mnlo-20200630.xsd#mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_DebtCovenantsAbstract_307e6c7d-0390-48cd-b663-4f6deec6e16c" xlink:to="loc_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval_105ceff4-1733-44fe-a4ab-87246f8042a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#LONGTERMDEBTWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_188351ed-a8d9-4072-873d-5c7419dee8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_188351ed-a8d9-4072-873d-5c7419dee8a0" xlink:to="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bfbd6174-c261-4d2c-8e1a-bc397a6e0f61" xlink:to="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_88bba2ce-45dd-4bdc-9c02-ad32e179a0c9" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_27b0f1ba-835f-4a59-9f77-2f615d8fd28c" xlink:to="loc_mnlo_FoamixMember_88bba2ce-45dd-4bdc-9c02-ad32e179a0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_082cfe51-9566-4524-aff7-94d2d4ea22b9" xlink:to="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareholderLenderMember_4b757dfb-355c-49cc-8c3e-a51e03ff416b" xlink:href="mnlo-20200630.xsd#mnlo_ShareholderLenderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3a1eb2b3-dae5-4659-a840-2c4994b2d10f" xlink:to="loc_mnlo_ShareholderLenderMember_4b757dfb-355c-49cc-8c3e-a51e03ff416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e8e650af-6ac9-4757-8c3c-ccd2c894a81d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_d5d1cd9a-fae7-4de5-b574-ba895e16aab5" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember_d5d1cd9a-fae7-4de5-b574-ba895e16aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_1d53469b-2698-45e7-95e1-32d105931d6a" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_1d53469b-2698-45e7-95e1-32d105931d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e94b596b-5755-4d6a-9ffa-2c2ccaa250ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6cee4e55-9de0-4a2d-9f23-e10b675ff4fa" xlink:to="loc_us-gaap_SecuredDebtMember_e94b596b-5755-4d6a-9ffa-2c2ccaa250ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f6079f1-209a-42ab-b317-75f9c904d555" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bdb0240e-9753-437a-8261-a8511c3f73a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cd676266-ff97-4dff-8485-676636f7f310" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bdb0240e-9753-437a-8261-a8511c3f73a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f290a8b3-0341-43e8-8e94-b7e77f348ba0" xlink:to="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61ac449e-df60-47c8-a3d5-63f69000d312" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6c0c13f-3afb-447e-93d5-df76f87fd871" xlink:to="loc_srt_MaximumMember_61ac449e-df60-47c8-a3d5-63f69000d312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8d1e2e1c-4b68-413d-8cfe-3615fd4b718f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_54786f8d-6394-469a-8a0c-e21d75eec213" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_54786f8d-6394-469a-8a0c-e21d75eec213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:href="mnlo-20200630.xsd#mnlo_ClassOfWarrantAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a42346bc-df2a-4e2a-a004-37c9fd7bb17b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a42346bc-df2a-4e2a-a004-37c9fd7bb17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60a7b077-2932-4d82-9c96-16677877ca05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60a7b077-2932-4d82-9c96-16677877ca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_99da0197-1757-4d66-b488-f68fb8454a94" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantExchange"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_ClassOfWarrantAbstract_29dbe808-5469-4247-a973-8735389be6c3" xlink:to="loc_mnlo_StockIssuedDuringPeriodSharesWarrantExchange_99da0197-1757-4d66-b488-f68fb8454a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f652679c-121c-45bc-bdcb-ff91eb9c13a4" xlink:to="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_9eab91f2-8071-43b5-bea4-1914eb8b39dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_9eab91f2-8071-43b5-bea4-1914eb8b39dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ead9d28c-63e9-41f4-a80a-34d0f303a4de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_InterestExpenseDebt_ead9d28c-63e9-41f4-a80a-34d0f303a4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_7eb0e583-96a7-4c4c-b880-108ce039cb6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_DebtInstrumentFairValue_7eb0e583-96a7-4c4c-b880-108ce039cb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_0c6bc304-e4c3-4376-809b-53a0d55669d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFinanceCostsNetAbstract_3ae2c1fd-3971-4ba5-8157-b11d94b370b0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_0c6bc304-e4c3-4376-809b-53a0d55669d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITAL"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a8c5e565-7816-41d6-bab9-95b679b9e1fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_199103e2-b34d-451a-9fc5-9a95bceb1d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a8c5e565-7816-41d6-bab9-95b679b9e1fb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_199103e2-b34d-451a-9fc5-9a95bceb1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALTables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4f453850-73f6-4cf5-86f8-5f950ecd4858" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_fc9a83e5-2e57-4e25-a55f-b6f89432b43c" xlink:href="mnlo-20200630.xsd#mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4f453850-73f6-4cf5-86f8-5f950ecd4858" xlink:to="loc_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock_fc9a83e5-2e57-4e25-a55f-b6f89432b43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72034114-32f8-4c6f-8c22-2fb03c75520e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4f453850-73f6-4cf5-86f8-5f950ecd4858" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72034114-32f8-4c6f-8c22-2fb03c75520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_38d03a8f-4d3a-4e8c-b974-3d59bce1d650" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4f453850-73f6-4cf5-86f8-5f950ecd4858" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_38d03a8f-4d3a-4e8c-b974-3d59bce1d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3ca58dd0-84ca-4e0a-8489-350b06f9367c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3ca58dd0-84ca-4e0a-8489-350b06f9367c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0837bc72-2140-4832-8506-a64ed24fa758" xlink:to="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7d457027-44fb-4c5d-920a-fe213c505eab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_us-gaap_CommonStockMember_7d457027-44fb-4c5d-920a-fe213c505eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OrdinarySharesMember_79918474-2063-4431-962d-db859d00a4b5" xlink:href="mnlo-20200630.xsd#mnlo_OrdinarySharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_mnlo_OrdinarySharesMember_79918474-2063-4431-962d-db859d00a4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a6a91526-2a4c-4332-9fdf-c12f9bdd7f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fad3f6c-0170-4d1d-ab16-d543affad1d4" xlink:to="loc_us-gaap_WarrantMember_a6a91526-2a4c-4332-9fdf-c12f9bdd7f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3545dada-2815-453a-b9a3-5b3531ef10a0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RegisteredOfferingMember_718a5565-964a-4734-8e18-377be5b1582d" xlink:href="mnlo-20200630.xsd#mnlo_RegisteredOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:to="loc_mnlo_RegisteredOfferingMember_718a5565-964a-4734-8e18-377be5b1582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PublicStockOfferingMember_ec215152-c3ce-49a8-85ce-6cb672429a5a" xlink:href="mnlo-20200630.xsd#mnlo_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0044711a-b40a-455d-85ec-55ec661f6086" xlink:to="loc_mnlo_PublicStockOfferingMember_ec215152-c3ce-49a8-85ce-6cb672429a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_61d9d391-1dcc-47b0-bb2a-fab241ebdb19" xlink:to="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_d9c3af22-2943-4656-abfe-b58efbedc48d" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_652fd025-7aec-4a13-bd69-712b91eb55ba" xlink:to="loc_mnlo_FoamixMember_d9c3af22-2943-4656-abfe-b58efbedc48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_77fc0ec2-7f4d-45f4-b2ce-da87bdb5c27a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FoamixMember_de2b33b8-470b-480b-b8b5-601a77dc1e9b" xlink:href="mnlo-20200630.xsd#mnlo_FoamixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_18f8b959-762d-475b-a43a-7b9601d2593c" xlink:to="loc_mnlo_FoamixMember_de2b33b8-470b-480b-b8b5-601a77dc1e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ad6847b4-ee1b-4f1d-8d82-af959ab20cfe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_c058819d-e510-4612-bdab-339df499ddce" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b241ec8-9b7b-48ad-afba-8826f66b079b" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember_c058819d-e510-4612-bdab-339df499ddce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6b423bda-4a3b-4a76-b1a9-f28705cc6b24" xlink:to="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee7d08a6-4996-49f7-aa5a-d562b1e23359" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c910b0c5-519e-4e6e-95cc-cb7b58a0ce34" xlink:to="loc_srt_MaximumMember_ee7d08a6-4996-49f7-aa5a-d562b1e23359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9fc65106-ee19-4959-9369-88efc4e9b0df" xlink:to="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EmployeeStockPurchasePlanMember_c0e6d3f7-3dda-4de3-8b9c-27abb7907847" xlink:href="mnlo-20200630.xsd#mnlo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_EmployeeStockPurchasePlanMember_c0e6d3f7-3dda-4de3-8b9c-27abb7907847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CSRAgreementMember_3bee4ebe-ab7e-4c39-afe1-a0049ca930a8" xlink:href="mnlo-20200630.xsd#mnlo_CSRAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_CSRAgreementMember_3bee4ebe-ab7e-4c39-afe1-a0049ca930a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2018PlanMember_2caf29f4-0f6f-4e07-8fc9-450490399870" xlink:href="mnlo-20200630.xsd#mnlo_A2018PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_A2018PlanMember_2caf29f4-0f6f-4e07-8fc9-450490399870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_A2019PlanMember_724f5c8d-d4dc-4a36-91c5-493959540ce2" xlink:href="mnlo-20200630.xsd#mnlo_A2019PlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_926a0751-3add-4172-8eaa-f3f2f383f727" xlink:to="loc_mnlo_A2019PlanMember_724f5c8d-d4dc-4a36-91c5-493959540ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_fc64ff78-ccae-494c-b163-deb4973fb502" xlink:to="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_08c3aa98-6204-4c25-865f-c2cf4a428ece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_08c3aa98-6204-4c25-865f-c2cf4a428ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ec37896d-d78e-4674-958b-a7f1322266ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_0ff58450-3ad2-4928-959c-ea2ef5e5344e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ec37896d-d78e-4674-958b-a7f1322266ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_40c3c3dd-28dd-4674-ba97-267762c91f78" xlink:to="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5a1379fa-369e-4624-bab9-e00ee5b67e49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5a1379fa-369e-4624-bab9-e00ee5b67e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6534bfec-75ae-41cd-8eea-d2fd5b493bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6534bfec-75ae-41cd-8eea-d2fd5b493bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6c9b878a-b130-4ece-b6a1-24890cbdb5d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6c9b878a-b130-4ece-b6a1-24890cbdb5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4da035d5-98a8-4287-bc2d-57314b207ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4da035d5-98a8-4287-bc2d-57314b207ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_46946fff-0d3e-42d7-af97-6a67e01351b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_46946fff-0d3e-42d7-af97-6a67e01351b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_456e0d0b-35ea-4258-9090-c173ad7b03ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_456e0d0b-35ea-4258-9090-c173ad7b03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockVotingRightsNumberPerShare_31e6eb13-c262-4e1e-8cc4-dfff5ec601a5" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockVotingRightsNumberPerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_CommonStockVotingRightsNumberPerShare_31e6eb13-c262-4e1e-8cc4-dfff5ec601a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5431dcb4-a336-45c7-b75b-8786833e2b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5431dcb4-a336-45c7-b75b-8786833e2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_97a6cfa9-65bd-463e-ad6c-2bcc5358aeba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_97a6cfa9-65bd-463e-ad6c-2bcc5358aeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_87287e49-749f-45ae-9f18-0dfbec910ff5" xlink:href="mnlo-20200630.xsd#mnlo_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_GrossProceedsFromIssuanceOfCommonStock_87287e49-749f-45ae-9f18-0dfbec910ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_28ede63e-50b9-41ce-8c29-59ca2d599b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_28ede63e-50b9-41ce-8c29-59ca2d599b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dfcff741-86fa-4486-bcb5-c0fff53793ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dfcff741-86fa-4486-bcb5-c0fff53793ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26482acd-40d5-43ba-b92e-8893f4d90618" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26482acd-40d5-43ba-b92e-8893f4d90618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e70a60e5-7f4a-4110-8f18-5ae8c2e27f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_e70a60e5-7f4a-4110-8f18-5ae8c2e27f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_123a44b6-5c5b-4131-aef3-1d56af53c33d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_123a44b6-5c5b-4131-aef3-1d56af53c33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_af2b05ea-fcc2-4a8e-a617-d6c5c0cf87cb" xlink:href="mnlo-20200630.xsd#mnlo_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised_af2b05ea-fcc2-4a8e-a617-d6c5c0cf87cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_c4da9942-177d-4c58-a61c-3b6241e7c012" xlink:href="mnlo-20200630.xsd#mnlo_BusinessAcquisitionContingentStockRightIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_BusinessAcquisitionContingentStockRightIssued_c4da9942-177d-4c58-a61c-3b6241e7c012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6d172a1f-fcaa-4cfa-a8d2-35fb98c3da8e" xlink:href="mnlo-20200630.xsd#mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification_6d172a1f-fcaa-4cfa-a8d2-35fb98c3da8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_5e04c4c3-0506-4198-903b-5a6b772f5779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_5e04c4c3-0506-4198-903b-5a6b772f5779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_65abcce9-692e-4d94-a969-b74b1c3bf2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_65abcce9-692e-4d94-a969-b74b1c3bf2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_998116d5-67b6-4aab-af2c-ead6c755c780" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_998116d5-67b6-4aab-af2c-ead6c755c780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_fea691aa-b9b8-4f76-873c-195b05b6bb66" xlink:href="mnlo-20200630.xsd#mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_fea691aa-b9b8-4f76-873c-195b05b6bb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d9f2d6c2-b5d6-49c2-b7e6-1b821beeb620" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d9f2d6c2-b5d6-49c2-b7e6-1b821beeb620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_03537076-6bbf-4098-94cc-54740886ec07" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue_03537076-6bbf-4098-94cc-54740886ec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b117c72-d814-49c4-b83d-9a57dbbde1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5b117c72-d814-49c4-b83d-9a57dbbde1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_a7596f1a-7b7a-46e9-8af9-9becb079dddb" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_a7596f1a-7b7a-46e9-8af9-9becb079dddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_EffectiveExchangeRatio_819c14c6-c42d-454d-8a77-201075637034" xlink:href="mnlo-20200630.xsd#mnlo_EffectiveExchangeRatio"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_EffectiveExchangeRatio_819c14c6-c42d-454d-8a77-201075637034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6c3384ce-8f10-4fea-b7fc-96d58adf0b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_6c3384ce-8f10-4fea-b7fc-96d58adf0b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_c364b08c-cdb6-4fbc-a0f4-970cdfc60a8b" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost_c364b08c-cdb6-4fbc-a0f4-970cdfc60a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_5bfd971a-6b52-4eb0-a1c9-a36c4c24a630" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod_5bfd971a-6b52-4eb0-a1c9-a36c4c24a630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_50da0ced-ea5d-451d-a71f-6035bd582351" xlink:href="mnlo-20200630.xsd#mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment_50da0ced-ea5d-451d-a71f-6035bd582351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_6359dc3f-6f5a-4733-802f-3d98af404f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c1a9b3e4-dd07-4887-840f-0371e716e68b" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost_6359dc3f-6f5a-4733-802f-3d98af404f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALOptionsandRSUGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1deb59ac-b599-4187-ac18-faf282e72ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1deb59ac-b599-4187-ac18-faf282e72ac3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:to="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11c4f112-af4a-4caf-8029-c6041e5a976b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_96cedf68-5bb0-4216-b6d5-c5754cfe9c17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_96cedf68-5bb0-4216-b6d5-c5754cfe9c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_424aab7d-dfe1-4344-a433-2a70ba478109" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57a07194-914d-4b55-822f-62d04b1437a1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_424aab7d-dfe1-4344-a433-2a70ba478109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:to="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fb5fc6c3-141a-436d-b603-105ab5f0663a" xlink:to="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6da1dc8e-ce02-4883-b94e-7879585ef3c5" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:to="loc_srt_MinimumMember_6da1dc8e-ce02-4883-b94e-7879585ef3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_76b0637a-41b1-436d-9e01-4dc3a485a364" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2e4a05e1-9d65-4a1c-b419-c423b52e60e1" xlink:to="loc_srt_MaximumMember_76b0637a-41b1-436d-9e01-4dc3a485a364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_285bf2ce-45a5-4c12-8784-5960536d36b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50399cc0-f3ca-4701-8158-f093b43cec59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50399cc0-f3ca-4701-8158-f093b43cec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7129a79a-a5d3-4a19-932f-5b9a99eec88c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7129a79a-a5d3-4a19-932f-5b9a99eec88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_157b9dc4-70e3-4512-9167-8e367cdbd118" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_157b9dc4-70e3-4512-9167-8e367cdbd118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ea46f11a-f559-4005-952d-485390397e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_ea46f11a-f559-4005-952d-485390397e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e5812624-2392-4f4d-a155-fc09c429fcd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e5812624-2392-4f4d-a155-fc09c429fcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d2730a6-e4d7-4f30-8a35-9bf07abbf1b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a350fd61-ca9d-4847-8efd-22401f0a04af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d2730a6-e4d7-4f30-8a35-9bf07abbf1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALFairvalueassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_42d36f8b-9d72-4a13-abc1-13e610637258" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_42d36f8b-9d72-4a13-abc1-13e610637258" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:to="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad1e3fdd-d0e9-430e-9954-2c07f9b37a25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0f7597b0-6acb-417c-9d4c-b63d60e9f70b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28555613-1d64-4d2d-a4e5-3e6ea4ef4448" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0f7597b0-6acb-417c-9d4c-b63d60e9f70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7c151723-5281-4c7a-a1cf-8f86c61daead" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98de48aa-d4e2-40c4-915a-030313b01ec5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8aeb6d52-f386-42c9-8430-c4845fd33f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8aeb6d52-f386-42c9-8430-c4845fd33f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8ee2a51b-d29b-4b37-a8e4-093fac5865c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8ee2a51b-d29b-4b37-a8e4-093fac5865c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e3130055-6f2e-4840-82fd-07b7ba6c98af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e3130055-6f2e-4840-82fd-07b7ba6c98af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bf674014-f669-4f2f-8459-a067f021c919" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bf674014-f669-4f2f-8459-a067f021c919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7d4d582f-991b-463f-ae82-f0009e19663b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_7d4d582f-991b-463f-ae82-f0009e19663b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c8f4968-b010-4653-91cd-98d41e330630" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_8bcc8404-b2c1-49ae-8e09-b4c2d44d2fac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9c8f4968-b010-4653-91cd-98d41e330630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SHARECAPITALScheduleofSharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d29d3a83-40d7-4081-82c5-71c5d082b733" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d29d3a83-40d7-4081-82c5-71c5d082b733" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3a995428-f4fd-42b3-a485-dc7ec6d3c91b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_843a2699-882f-4e66-814d-1c47357a9426" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_843a2699-882f-4e66-814d-1c47357a9426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c7377e55-d599-49cf-9c05-0165959dfe44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10ce2bad-55dd-433f-a820-bc8cab8a56c5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c7377e55-d599-49cf-9c05-0165959dfe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5eb56154-7bec-4ca1-bf13-aa4998bdfc6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c6925bf0-bd34-4654-ba0d-29c6d05c9633" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba29abe8-e9ec-42a2-b8db-1b6ceb2f5b35" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c6925bf0-bd34-4654-ba0d-29c6d05c9633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASE"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eacc050c-7678-44a2-93e7-de455d6ed8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_65f08113-a996-4a1a-9c04-efc256c28b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eacc050c-7678-44a2-93e7-de455d6ed8a2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_65f08113-a996-4a1a-9c04-efc256c28b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASETables"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_206a9022-540d-47b1-b659-72c1cadcdb15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f4cee35a-8d85-46ed-ad42-5c8061fa8e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_206a9022-540d-47b1-b659-72c1cadcdb15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f4cee35a-8d85-46ed-ad42-5c8061fa8e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEOperatingleasecostsDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6a707c35-351e-4e9f-a9a6-b28ab9dc5ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a707c35-351e-4e9f-a9a6-b28ab9dc5ede" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6fa978d-ac9b-4eaf-b86c-3e8b9f581b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fb98b4d0-fdf1-442a-b97e-22afc1630d91" xlink:to="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OriginalSpaceMember_ac438e03-33f2-4541-b064-bf52b98d3246" xlink:href="mnlo-20200630.xsd#mnlo_OriginalSpaceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:to="loc_mnlo_OriginalSpaceMember_ac438e03-33f2-4541-b064-bf52b98d3246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AdditionalSpaceMember_55b0b3ca-cc29-47b0-88db-e859217ccd10" xlink:href="mnlo-20200630.xsd#mnlo_AdditionalSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BuildingMember_d29fe81a-0c62-4e03-a2f5-6f5452227bbe" xlink:to="loc_mnlo_AdditionalSpaceMember_55b0b3ca-cc29-47b0-88db-e859217ccd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:to="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_280a86ee-811c-41d5-aa32-dfa4df48cf42" xlink:to="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BridgewaterNewJerseyMember_559e41fd-4c89-455d-a92a-b2ceddc78232" xlink:href="mnlo-20200630.xsd#mnlo_BridgewaterNewJerseyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:to="loc_mnlo_BridgewaterNewJerseyMember_559e41fd-4c89-455d-a92a-b2ceddc78232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RedwoodCityCaliforniaMember_82bd8882-46c2-44b9-a3a9-09e255714a74" xlink:href="mnlo-20200630.xsd#mnlo_RedwoodCityCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f23d4db2-3efa-4651-be2b-637c28458678" xlink:to="loc_mnlo_RedwoodCityCaliforniaMember_82bd8882-46c2-44b9-a3a9-09e255714a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1c707194-709d-4ab8-bb1c-5e38adc3f4ac" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_FacilitySpaceUnderLease_f4319795-a551-4e5b-bb1b-2b4650486415" xlink:href="mnlo-20200630.xsd#mnlo_FacilitySpaceUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_FacilitySpaceUnderLease_f4319795-a551-4e5b-bb1b-2b4650486415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3213b1d1-56a8-45ac-90f3-889522543b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3213b1d1-56a8-45ac-90f3-889522543b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeasePayments_f52e31e9-5dc5-4737-b6cd-95301c43d470" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_ShortTermLeasePayments_f52e31e9-5dc5-4737-b6cd-95301c43d470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6870c9ac-5403-48eb-b577-1d753be05662" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_OperatingLeaseLiability_6870c9ac-5403-48eb-b577-1d753be05662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e9655783-18ce-4d94-a6db-e67b08e7c7ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e9655783-18ce-4d94-a6db-e67b08e7c7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_VehicleLeasePrepaymentPeriod_4ffde0bc-6aed-438d-9f9c-cacd36701b27" xlink:href="mnlo-20200630.xsd#mnlo_VehicleLeasePrepaymentPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_VehicleLeasePrepaymentPeriod_4ffde0bc-6aed-438d-9f9c-cacd36701b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_8f2f0459-a02a-4e3b-9d32-4a90d9e35a5b" xlink:href="mnlo-20200630.xsd#mnlo_RestrictedInvestmentsToSecureLeaseAgreements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b1f5f4e6-6292-425e-8c09-5305250c0e48" xlink:to="loc_mnlo_RestrictedInvestmentsToSecureLeaseAgreements_8f2f0459-a02a-4e3b-9d32-4a90d9e35a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7b412c74-4117-4912-9fc0-23ea0bdb27b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7b412c74-4117-4912-9fc0-23ea0bdb27b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c4148e6d-fe0c-431f-9db1-a8fad20adcda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c4148e6d-fe0c-431f-9db1-a8fad20adcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62b0cd23-7619-4f05-9954-931ace194bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62b0cd23-7619-4f05-9954-931ace194bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_790a3bad-c033-475c-b495-979f2ce0f07f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_790a3bad-c033-475c-b495-979f2ce0f07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a982925-42c7-4132-9f14-cb690a391c87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8a982925-42c7-4132-9f14-cb690a391c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_19642235-389e-47bb-a079-ca16c5af6e42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_19642235-389e-47bb-a079-ca16c5af6e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d7f039e-5508-48bf-af4b-53e4936b867c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a2b7be2-a6b7-4895-bbc1-b9aa945093d9" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d7f039e-5508-48bf-af4b-53e4936b867c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="mnlo-20200630.xsd#OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1249f33c-34b6-4cf4-8524-5b9cb409c011" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eace56a7-5bde-4dc0-aa02-b59b2a26af6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1249f33c-34b6-4cf4-8524-5b9cb409c011" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eace56a7-5bde-4dc0-aa02-b59b2a26af6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a529731d-0de1-4a85-bbe9-becf137d5f74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a529731d-0de1-4a85-bbe9-becf137d5f74" xlink:to="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:to="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2883d4d9-6c7f-4846-a26c-3eea81b20b65" xlink:to="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_InitialPublicOfferingLawsuitsMember_eade1173-e087-4097-add3-d0b6024b3f44" xlink:href="mnlo-20200630.xsd#mnlo_InitialPublicOfferingLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:to="loc_mnlo_InitialPublicOfferingLawsuitsMember_eade1173-e087-4097-add3-d0b6024b3f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d66a2293-eb17-428c-8450-0d69a14d4e2f" xlink:to="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_0f185f99-8ff1-4f76-9691-60a450035f45" xlink:href="mnlo-20200630.xsd#mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_MergerLawsuitsMember_60dd49ea-f5ee-4c6b-a5b8-c149da71a062" xlink:to="loc_mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember_0f185f99-8ff1-4f76-9691-60a450035f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:to="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_fb5dc20a-58c0-4b8b-b3ee-3a955f973c85" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_OfficersAndDirectorsMember_8a5cae48-1421-4727-9cff-13f8bcf41f0c" xlink:href="mnlo-20200630.xsd#mnlo_OfficersAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2bacf6f2-200f-4247-9551-dcf3fdbf6c9d" xlink:to="loc_mnlo_OfficersAndDirectorsMember_8a5cae48-1421-4727-9cff-13f8bcf41f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_07abc85c-1652-4a79-852c-bf097421289a" xlink:to="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_NumberOfClassActions_1186f5bc-eb43-49aa-9583-c4e57cb3ddac" xlink:href="mnlo-20200630.xsd#mnlo_NumberOfClassActions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:to="loc_mnlo_NumberOfClassActions_1186f5bc-eb43-49aa-9583-c4e57cb3ddac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b3bbe695-bb81-4aa3-b86b-9058de5e63fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1a99cf57-a0b0-42b1-8363-ce9f895e3e87" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b3bbe695-bb81-4aa3-b86b-9058de5e63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c18da8b9-ac71-44d6-a7ee-5c93acbc8b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9024c1a9-4603-406b-9475-8901de377661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c18da8b9-ac71-44d6-a7ee-5c93acbc8b1d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9024c1a9-4603-406b-9475-8901de377661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="mnlo-20200630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_adff03c0-5e56-4d41-a764-1bc0268ba6f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_adff03c0-5e56-4d41-a764-1bc0268ba6f7" xlink:to="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_60b2116a-d269-40f0-9ef8-9fd8eefdfbe3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eb1c99f3-7515-4b19-8fc6-4cb956545a82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_844fa166-5d59-4575-ae97-dbfc095b6f53" xlink:to="loc_us-gaap_SubsequentEventMember_eb1c99f3-7515-4b19-8fc6-4cb956545a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2fc22f1b-b07f-48b9-8a9a-145a4812cc90" xlink:to="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_94a86a97-1470-435e-aed7-2bb6197ad5d3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:to="loc_srt_MinimumMember_94a86a97-1470-435e-aed7-2bb6197ad5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c051379-9eca-4015-89c6-ca722bc00f95" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52d8c61d-a412-4bf9-a813-2194aba329ef" xlink:to="loc_srt_MaximumMember_2c051379-9eca-4015-89c6-ca722bc00f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_76f2c2d1-0da3-4813-9387-c6bbf723c1a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_AmendedAndRestatedCreditAgreementMember_4a49d5ef-d3b3-4a32-aaa3-816ea8a6933e" xlink:href="mnlo-20200630.xsd#mnlo_AmendedAndRestatedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9585bfdb-880c-4f77-8570-65763041c115" xlink:to="loc_mnlo_AmendedAndRestatedCreditAgreementMember_4a49d5ef-d3b3-4a32-aaa3-816ea8a6933e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7ce3b300-5d4d-48ca-a860-8f93cc113539" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b5692603-ceb0-455f-94cd-ee37f35b5ac0" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e35dc78a-608e-4e1a-bdaa-2d2bea794d19" xlink:to="loc_srt_ScenarioForecastMember_b5692603-ceb0-455f-94cd-ee37f35b5ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_31b96e78-111b-4be2-bccd-fcb9c33808f1" xlink:to="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_33099fdd-8bf9-44dd-8f71-92d694e0cfb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_33099fdd-8bf9-44dd-8f71-92d694e0cfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_ContingentStockRightSharesConversion_0b016f67-e32e-45ec-a1e2-43fab3c6f5bb" xlink:href="mnlo-20200630.xsd#mnlo_ContingentStockRightSharesConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_ContingentStockRightSharesConversion_0b016f67-e32e-45ec-a1e2-43fab3c6f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_314d356c-46b6-45b9-a574-7f17ec735487" xlink:href="mnlo-20200630.xsd#mnlo_BusinessCombinationEffectiveExchangeRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_BusinessCombinationEffectiveExchangeRatio_314d356c-46b6-45b9-a574-7f17ec735487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_bb1da2fb-a5a1-4f2d-b6df-5afe39dcb169" xlink:href="mnlo-20200630.xsd#mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement_bb1da2fb-a5a1-4f2d-b6df-5afe39dcb169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_da69fd63-149e-409d-b57b-ac546d2f3915" xlink:href="mnlo-20200630.xsd#mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders_da69fd63-149e-409d-b57b-ac546d2f3915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_974bde5a-ff1f-46d2-968e-222b5cbf2ebb" xlink:href="mnlo-20200630.xsd#mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_63988161-8998-4646-9f6c-31e7f2944a2e" xlink:to="loc_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance_974bde5a-ff1f-46d2-968e-222b5cbf2ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>mnlo-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mnlo="http://www.menlotherapeutics.com/20200630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnlo-20200630.xsd" xlink:type="simple"/>
    <context id="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6192338baf694a57931b00fdf1208402_I20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-07-30</instant>
        </period>
    </context>
    <context id="i55514fe802bc4047841713151110e3e1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i52ef5e665bd14d8f848bbea621063a27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic53c293513a3411988e3f82450bc2600_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i89212e9395d543b584178d191c5a52df_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i89ac8ecea9da46f18647e4055ba4c2bf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e10a9cdb13646a5b01897e039b29eb1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i23934cfba1c34fb59943833e025eb17f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c9988a3e0ca4c50b6d4ebe101481b7b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2c3031d6ad8c4ebebd28af76579e5a58_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i115874d2c71d4965a64a283d45279d4b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i99638830588b43439d03faa00fafb735_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i74f696343f7b4319b954654fee16542a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i58ec0b6d315d42bf984266ae09cc24f0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib10f110e89794a328cd6dff889719d0f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6fddccdca3294d4e9d00f89b822119c3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0bd4960891c34721acc23f0da145dc30_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaab607da61e54796b75a8649d120f305_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i968d104d31de4459a96511fbf90c1f1d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i44a66f541efd4f15931ae16609a79908_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8d3163028e034d0a88324b9af3624248_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2c3eae89d05b4922b7037525a28870c3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i183126c41cc449dbba13257e8dea4ace_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6c4fe139b2cc48aaa7444cf89368196d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i50df20b4b873412e8222bce987ca55c7_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8caa6a61613a445594a114cf0db71d79_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a2f04cbef3845e28d047be6ae20e735_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9778e0408b1f42deaf3632925439e4b0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6feda25267a14e1e9087b4289d642160_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if95e4afe75e94206bc731058ea393dba_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7973a9b2e41c4011a66ad0e37aa68515_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib820da2007bf41dba9549a9c8a93db1f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie0b992755b2b4a5ba58755071de873b4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8b02388b48f440649017facfc2fec45b_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6b661c91124c4db18890eb501396ac7e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic9558e2deebc4ba3a4cbcf4217d7e051_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2d3f4643a51a41288e8ccd0e60759c97_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i101055c62f9d45799bf1500fe791edc4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib74604aa6bc2461cb5df34b326723115_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8a497140cb264e87a5545a4066bd9ccd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib4e49138bc604905a6e1fb9cb99008d0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i74810c4013404762b66d6ab7950a6c2a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3359148f5b174e9d9dbd7205f678bc8d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i004a8f9abfde49159237ec2532aff25c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie8b89a0f42154a88be72ee1ba1cc8faf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5214fa97c5fa453fa43fa4fe0908ef99_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5439508597d54228b44eb110a0163531_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i27310920890a449ca2694d53e047a675_D20200423-20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-23</startDate>
            <endDate>2020-04-23</endDate>
        </period>
    </context>
    <context id="i5da754f4e94e4544b609a323172766eb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80a470217c3a4272adc3535da6eb3922_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9fba894574f6426bb988c61b2df7510c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i49710f5b3cb5425584627e0e1bcc3521_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5f3259df41a745da91e614f0f535fe16_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4bf5e963873a4e6982e47201cb3ff7f8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if29ad7a578cf43a6acb996ff258f0c7c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ibc2826b77413461d84519a6b754cb004_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c758c8f421d4ae5a44d89c91a01007d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="i62991dd9b59d4f20932a6cc542870ab2_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="id8d2dac9a2a445dfae26312379d3050b_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="i01fe41f20f4947e2a6b7466a16a798d9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i475935ac417d417b95b57d209280bd42_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaa6ecbab924a41ee8267c4ae3a55f162_I20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-11</instant>
        </period>
    </context>
    <context id="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i64bfe9f3e6894c12a9573e9ba7298549_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i363b390923d44002aea9667a68a52c10_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i739bb757f1734242959f7c1f7cabb3dd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb0c3f02a2d0451fb10bb5af69b6fe95_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iabf481a0bc8d434eba2737a7b1854201_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icb682629e2c14d16967faab5132bce3d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e9d51a1cbf04ecfa836c93c8fcf8b60_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d8a0654d2c844fab4d30cbe0f737b93_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mnlo:DistributorThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iddecf24382d740b79c3744ff4ae84e96_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i35eb5a8b86fc4928a2d78dfe2c2b62c4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4b5c2e12f42a4c42ab17af5707fd15c0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iedfd359d21884ac0b9588367562b5816_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c8222d051b543688377451564f533a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i186f34938c484be6bd6c29ddc7b7009a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia23a57fa3ccf4cc3b6bcee3e98135a78_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mnlo:IsraeliMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i264f53d270b5492d9f34a2d7a650ab3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">mnlo:IsraeliMutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a6fc18eac5e4db28a62b77aad463b0d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i01876072bcc04580b5f7c62f8637951e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28c5efb4fbad4902aaac65636b3fac52_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if1f69ab2ddf8408a8224f655bbd15be5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cfa5ee44fb64997893890be476e59ae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic5885b910649487099b87fd418a15dde_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i72d53f792aa942e79e0908f016e0b6ac_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie41f84f7e3ef4b8a9a94c1a9b121dd36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i621dc5363bfa40e3ab7836027e3273ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11306223e6aa4bbc98552eff8183e5d6_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="ia3617748d41e46a8bfedb32f0d650a74_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i423fa226d79249718ae35ed0e4fd377b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5f85dcc728e248d98e63a19af7ced4ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4fa0d91fe20746dc801522cdb641699a_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="ie8232e19d10a4519b9a3cd10a5721fb1_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench1LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i5a65c85354904beda1b2323ac7ec07cd_I20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-17</instant>
        </period>
    </context>
    <context id="i1adb6f4952624c32ba9efdccfaadf065_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench3LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i52154cb6d81246b2b19b393816177d95_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="id7a8db7397904657874b01bbee72d568_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mnlo:ShareholderLenderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i665aac50c21e4c9382a4dedf21e3a6d4_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="idec71e92949949a9a5cbf85570f5b1c2_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="iea4fd37970a64213b591edc27d8201a8_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mnlo:AmendedAndRestatedCreditAgreementTrench2LoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="i647408d71ea94b9aacbdfd5eea1f5f10_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i21624033d4ac4fff8c601a26fb4f4cd2_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="ia8c8813e111447bda5117bdf5d6a2b26_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:RegisteredOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="ib45c461b63af4f079fa025d92a11ec36_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="ie7a4e94dab8049848e6d72417f3fbe51_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i7d9ecc3914e54a259847aa543d67e621_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:CSRAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-09</startDate>
            <endDate>2020-06-09</endDate>
        </period>
    </context>
    <context id="i92c1d7c7352a4dca951e1bcd7cb06a55_I20200609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mnlo:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-09</instant>
        </period>
    </context>
    <context id="if23f7b87177b47a08e6248caeff2b802_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="i0cd250813f00419fbd2e80392e7e0172_D20190729-20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="i70cb25f8075540d79ea2d6581691f94f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idd59a6ce5690423f839a46a944f522ff_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0047714113804cad9c16bdab5627a1ea_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="i6e7afa2c35824eb99e24ca41f2a6b35f_I20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="i5244e3d9cde04b82806e7986585ce214_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic1ae53396f194b79aee91b06e1fcfc53_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mnlo:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mnlo:FoamixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i128638d8b51d4c5e8740fccfe8bb54e9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iacf13670f3fa4285a1f4d963e62abc74_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2de299f068754a7abc7d85f9a74d1a52_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i52fdbbba6e7d4d6c8f6192df59a0b3e1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i158cc30187ca4219a42536fd98d5fdbd_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iea7da630ee23404cb0c42917365732be_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2a6a6702cbe1405fae1d4152caf10cf8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7d4b715adc284a418c6a708ee727979b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia7b9c626f5cc4797874b2b7b5b559927_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i1ea5dbcf0c124143b148b23cc686ff50_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic46c960fd7f2441389d418c74a68bbd1_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i50c1a034475f46eb968fab88c0b84296_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i086c3c739539445da6ad056f578caedb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-09</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="ib290ea8b639941c0865b91b70ea01d50_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5b1bb38c09694860a74fca4cb02b7fd2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mnlo:FoamixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i875e9e1345164d94bc58815365779517_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i82863cbbff6145f2bedee6a09e97f8bc_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i466f28e0d85348cab9cc5df9627c2a21_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i16a8e4626ad948338081011de428c56a_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i282c323ee4fd405f9b9276a665217e6f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic6103d5338e747d3863548470494ec95_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i5eabf77585034e158ba10a9768877f29_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb9a4f704626440cb634b11d52f4e479_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if2a66420fa684fbea1eee87e6abdd8e4_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:OriginalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i88fbd3af56884c12ae3c30505c83a2f9_D20190313-20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:AdditionalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="i4760e6ad58b548bfa055202c3d8cd2e7_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:OriginalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i9a8c08728edb45bd9ea6a6f0fc6e5a20_I20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:BridgewaterNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mnlo:AdditionalSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="i74e404bead2e4f94b38bf24b66089cdf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mnlo:RedwoodCityCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id3d0a4c5350e4cbd93b8042046be79d5_I20181108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:InitialPublicOfferingLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-08</instant>
        </period>
    </context>
    <context id="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">mnlo:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib1c399325c504de1963cfc9cabc42c2c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:MergerLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i241af8b663f1455bb67c14d739a9fee6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mnlo:MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9e7382c919584b5a9708af3049536ae3_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i17830450592d46a684d1bad07edf6adc_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001566044</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segments">
        <measure>mnlo:segments</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shareholders">
        <measure>mnlo:shareholders</measure>
    </unit>
    <unit id="lenders">
        <measure>mnlo:lenders</measure>
    </unit>
    <unit id="tranches">
        <measure>mnlo:tranches</measure>
    </unit>
    <unit id="votes">
        <measure>mnlo:votes</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="lawsuits">
        <measure>mnlo:lawsuits</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV81LTEtMS0xLTA_7c0bc2c7-4d52-46c7-8c59-b7bdd6dc5536">0001566044</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV82LTEtMS0xLTA_70053a8c-9c0e-4a3f-8aac-b2c77045cf61">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV83LTEtMS0xLTA_c1d1db00-a116-4849-a39d-23547b24217b">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV84LTEtMS0xLTA_9f146117-4ca6-4642-ad3f-79bb565ac2f5">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80L2ZyYWc6ZmJlMWU2ZDI0Y2E5NGM0Zjg2ZjA0YTZlZTk3ZmM1ZWYvdGFibGU6YmM0MmIxOGM0M2MzNDhiNGJiYzA3NmE3YzRmYzhkNjEvdGFibGVyYW5nZTpiYzQyYjE4YzQzYzM0OGI0YmJjMDc2YTdjNGZjOGQ2MV85LTEtMS0xLTA_f0519d6e-6266-42a2-9774-49ec920f61d7">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9e7382c919584b5a9708af3049536ae3_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzQzL2ZyYWc6MGY5ZjA4YWZlMmMwNDU2MWIzMGMyZGM4ZmNjNjQ3ZjYvdGV4dHJlZ2lvbjowZjlmMDhhZmUyYzA0NTYxYjMwYzJkYzhmY2M2NDdmNl8zMjk4NTM0ODgzNDA1_241c30ca-d435-42a5-ba69-6ccdd937a810"
      unitRef="number">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i17830450592d46a684d1bad07edf6adc_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzQzL2ZyYWc6MGY5ZjA4YWZlMmMwNDU2MWIzMGMyZGM4ZmNjNjQ3ZjYvdGV4dHJlZ2lvbjowZjlmMDhhZmUyYzA0NTYxYjMwYzJkYzhmY2M2NDdmNl8zMjk4NTM0ODgzNDA4_38b10915-4011-4006-bf4d-9968a4d12618"
      unitRef="number">7</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1NzAw_ed64bfbc-e34d-411a-863e-86015a5cb0a9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg5_1658654f-20a7-47cb-b362-25e6ec9a94aa">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8xNjQ5MjY3NDQ0MjA0_a23d5205-c101-4b92-b523-593bf8646960">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg4_32b7fbc2-411c-46db-9673-b2109da5a259">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1NzAx_ba786627-8cb0-4dbb-957e-010a55b6c6d5">001-38356</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg3_a3d9fd29-b3fd-4c9d-84b3-dbc6847094b3">MENLO THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6ZmVhMWNkOTlhYzdkNDNiYWJhMjBiOGFmMDQ4MTc1MGYvdGFibGVyYW5nZTpmZWExY2Q5OWFjN2Q0M2JhYmEyMGI4YWYwNDgxNzUwZl8wLTAtMS0xLTE5OQ_8600d52b-5eba-4d72-8dac-ce6f287776d3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6ZmVhMWNkOTlhYzdkNDNiYWJhMjBiOGFmMDQ4MTc1MGYvdGFibGVyYW5nZTpmZWExY2Q5OWFjN2Q0M2JhYmEyMGI4YWYwNDgxNzUwZl8wLTItMS0xLTIwMQ_efe6942e-587a-476c-aea4-7bcb11cea810">45-3757789</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgz_202bc2a8-cf12-4088-a580-b61b9ae6957e">520 U.S. Highway 22, Suite 204</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg0_798766bc-471b-43ca-b739-b3502988bf1d">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg1_323c1878-d191-414a-be86-dee561974ad4">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njg2_4c93f814-7197-4578-8e6d-b18714e9fa1f">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgx_571c5dbd-248e-4187-9cdf-9ce198b396e7">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njgy_fecdf2bd-4218-40ed-8d1f-b871c1d424e6">755-7936</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTAtMS0xLTIxOQ_59979d36-0468-461a-a25b-b4b5de51d536">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTItMS0xLTIyMA_ac2d4640-d0e1-4166-bb63-0c30624e27e5">MNLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6OWU1N2E1MzQxYzFmNGFiNGE2NzZmOGQ5Yjc2ZDNhNTEvdGFibGVyYW5nZTo5ZTU3YTUzNDFjMWY0YWI0YTY3NmY4ZDliNzZkM2E1MV8xLTQtMS0xLTIyNQ_5406b1a5-81d8-48d6-bdd7-e455ed4fafc0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk1_2a86225d-621b-430f-9e2a-bc0216ff0a75">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk2_65d07186-222c-43c8-9f6a-8f2ae1b5b848">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8wLTMtMS0xLTIzNQ_87da58b1-57c4-4aa3-afb0-d3c4e72596b9">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8xLTQtMS0xLTIzMQ_ef4c939d-ee95-4b3a-8b05-74da0f0c022c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGFibGU6MjZkYjBiMGQzNWVjNDI0Zjk3N2VlMWI4MGNlM2FmNDQvdGFibGVyYW5nZToyNmRiMGIwZDM1ZWM0MjRmOTc3ZWUxYjgwY2UzYWY0NF8yLTQtMS0xLTIzMQ_aac99dbd-db9d-456f-974f-c7acbeda225a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1ODQ0_71f7f725-35a0-4f43-b094-95a8cd837ee1">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8zMjk4NTM0ODg1Njk3_db5985ad-c54e-4c11-ab66-dc0cb718d247">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6192338baf694a57931b00fdf1208402_I20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xL2ZyYWc6ZjVlNjlmNDI4NTExNGI3MGExMjFhZjRlY2U0MDY0NzQvdGV4dHJlZ2lvbjpmNWU2OWY0Mjg1MTE0YjcwYTEyMWFmNGVjZTQwNjQ3NF8xNjQ5MjY3NDQ0MDQ5_230621fa-f7c7-41c7-b466-38a623672d69"
      unitRef="shares">167690615</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNS0xLTEtMS0w_c136fa89-81f1-4049-b6cd-490d4e7e98b5"
      unitRef="usd">96511000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNS0zLTEtMS0w_ee701bf4-7d06-4e1a-af4c-c3ba5f5db13e"
      unitRef="usd">43759000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNi0xLTEtMS0w_c55e1cc9-53d9-4a3c-a9a1-82a5db9e547a"
      unitRef="usd">855000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNi0zLTEtMS0w_fa72e4b8-dce1-4ca9-8e71-88c93856c0a0"
      unitRef="usd">825000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNy0xLTEtMS0w_3f0f6f1f-69c6-4086-813a-c864c53c04ec"
      unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfNy0zLTEtMS0w_378362e3-c503-4fac-bd6e-1d1dc5c24693"
      unitRef="usd">12102000</us-gaap:OtherShortTermInvestments>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOC0xLTEtMS0w_5acf6ed7-5648-46a3-a318-62fd28358d1e"
      unitRef="usd">2609000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOC0zLTEtMS0w_744e1c6e-5e69-4223-9eb2-b5ccae221e6f"
      unitRef="usd">16246000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOS0xLTEtMS0w_b384c1d4-3ebb-41e6-bd4d-1ab6558a7d1a"
      unitRef="usd">435000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfOS0zLTEtMS0w_e0c34940-044f-429e-873f-294ce7ad143c"
      unitRef="usd">434000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTAtMS0xLTEtMA_4e322f21-589c-449b-8f08-b7b03706ee89"
      unitRef="usd">6407000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTAtMy0xLTEtMA_a7c6162c-4602-437a-bfe6-36e53375ae55"
      unitRef="usd">135000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMS0xLTEtMzkxOQ_579b8875-65b1-489b-b517-92c33d02251d"
      unitRef="usd">4000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMy0xLTEtMzkyMg_689512a5-fd38-4b00-bb46-ee74183f4c5b"
      unitRef="usd">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMS0xLTEtMA_41ca8570-ddd4-4f51-9d07-24112730b832"
      unitRef="usd">2672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTEtMy0xLTEtMA_2def48bc-6c89-42b6-94d2-1dcc184765a6"
      unitRef="usd">1557000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTItMS0xLTEtMA_d92e02d8-2afd-4b0a-9aa5-3a85fc3ae095"
      unitRef="usd">5801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTItMy0xLTEtMA_f761b55e-79ba-42f2-a6c2-09f7150a0e92"
      unitRef="usd">1356000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTMtMS0xLTEtMA_037e787a-214b-4642-97a1-51996a72a527"
      unitRef="usd">119290000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTMtMy0xLTEtMA_408f9c39-d06a-422f-beb3-b97ec3788d5f"
      unitRef="usd">76414000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTctMS0xLTEtMA_74371d35-d5df-4de7-92a8-aedc108e24f8"
      unitRef="usd">2811000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTctMy0xLTEtMA_cb837f9d-9949-45e9-a855-5c1885c4e0c1"
      unitRef="usd">2885000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTgtMS0xLTEtMA_5617bab7-e571-47d7-a8e6-94565012bae1"
      unitRef="usd">2558000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMTgtMy0xLTEtMA_dcab6da3-be9f-451c-9bbe-6d5fc5429ecc"
      unitRef="usd">1694000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjEtMS0xLTEtMA_b77a743e-bd7a-4e8f-aa51-9420b54135e8"
      unitRef="usd">6183000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjEtMy0xLTEtMA_2f75065b-a2fc-4209-8e39-bf3bf7ef2f3f"
      unitRef="usd">166000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjItMS0xLTEtMA_1fc950cd-278e-4370-bd7d-e3534d5c8823"
      unitRef="usd">11552000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjItMy0xLTEtMA_a51045ac-23c4-40bb-a727-ac974f18c72a"
      unitRef="usd">4745000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjQtMS0xLTEtMA_c0dc6a41-df79-43a8-a961-2de1b50a1182"
      unitRef="usd">130842000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOmRjNzc3M2YxZTkyMjRiZmZiNzJkNzg0N2Q0OWRkMWVlL3RhYmxlcmFuZ2U6ZGM3NzczZjFlOTIyNGJmZmI3MmQ3ODQ3ZDQ5ZGQxZWVfMjQtMy0xLTEtMA_f5a0aa12-f74a-4b3e-9100-3ae27150462d"
      unitRef="usd">81159000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNS0xLTEtMS0w_293ec322-6f20-4846-aea7-adb86cca43a3"
      unitRef="usd">9952000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNS0zLTEtMS0w_6e418724-2fd7-4b9b-b4d9-21d20595609d"
      unitRef="usd">19352000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNi0xLTEtMS0w_a8a4057b-529a-422e-b1e9-97b433c06eed"
      unitRef="usd">8812000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNi0zLTEtMS0w_5b9ac58e-29e9-46b2-a21b-0ed50c1b96a2"
      unitRef="usd">3381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNy0xLTEtMS0w_4120f6ea-8835-4011-bab5-fda6900c22ff"
      unitRef="usd">4081000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfNy0zLTEtMS0w_0f8e643c-b87d-4c52-94da-ac733e0969e6"
      unitRef="usd">5231000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfOC0xLTEtMS0w_0bef0e93-179e-46b3-99f0-2431261d90a4"
      unitRef="usd">1245000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfOC0zLTEtMS0w_88349091-2b09-49c2-ab4c-2474156adc57"
      unitRef="usd">1092000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTEtMS0xLTEtMA_caa95b38-c5a6-411e-81bd-9d1a57c89a05"
      unitRef="usd">142000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTEtMy0xLTEtMA_b515c27a-84a3-4447-b88d-061394789486"
      unitRef="usd">270000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTItMS0xLTEtMA_0f5028cd-64b8-49bb-a962-474174a8b901"
      unitRef="usd">24232000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTItMy0xLTEtMA_0960b6a4-0900-413c-bbb9-7ab1e1a3f80e"
      unitRef="usd">29326000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTYtMS0xLTEtMA_087803d6-5170-45e2-842c-35e2e86e1950"
      unitRef="usd">403000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTYtMy0xLTEtMA_098d6a24-834f-4ba0-9b9e-f4f9081f1dd1"
      unitRef="usd">424000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTctMS0xLTEtMA_2d671540-68b7-441e-ad05-7cf340bfd40c"
      unitRef="usd">1308000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTctMy0xLTEtMA_27485858-6392-444e-ae65-de0ce4472d1a"
      unitRef="usd">653000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTgtMS0xLTEtMA_197a25a1-45aa-4f51-b9ec-ce519fa8e883"
      unitRef="usd">32915000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTgtMy0xLTEtMA_20e7893b-d718-4b6b-807b-2677c588b06d"
      unitRef="usd">32725000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTktMS0xLTEtMA_e300afb1-42e7-4bfc-ae14-9c3ea71e1516"
      unitRef="usd">456000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMTktMy0xLTEtMA_816f116c-01f0-4a35-ac4d-5872bc1f28f3"
      unitRef="usd">456000</us-gaap:OtherLiabilities>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjAtMS0xLTEtMA_1d6a78a4-c590-41af-9db4-18f0c2c36ab6"
      unitRef="usd">35082000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjAtMy0xLTEtMA_0c130944-3963-47cd-be42-dbcf4cf3f71e"
      unitRef="usd">34258000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjEtMS0xLTEtMA_efaf068d-c849-4ab5-94fa-19a1d0627160"
      unitRef="usd">59314000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjEtMy0xLTEtMA_1fc8df3e-e57b-414e-8314-e4cf5257ab25"
      unitRef="usd">63584000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMS0xLTEtMA_d912d312-0935-4a81-86b8-238be27b2ec6"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMy0xLTEtMA_e48b184b-9ec6-4b60-83f2-8c2e0acea58b"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MTg_d66c39d4-0cfc-40a6-b668-557d33df08a5"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MTg_e31b6412-1287-4ead-958c-9dd3431b7065"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MjE_940dffff-e0df-4863-a03d-b891ea7d9fc7"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3MjE_c3d80902-0570-4d9e-aaa0-44a90b254482"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_0324312a-7f31-44b3-becc-16d50134820f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_1ebb4442-fece-4da0-b02a-ee43f13e8594"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_a850a1b1-db00-404a-aeb9-0838844ef78f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMC0xLTEtNDE4Ny90ZXh0cmVnaW9uOmZlNWY3YThkNGQzYTRmMDA4MjNkZTU5ZjFmZTBkNDZkXzIxOTkwMjMyNTU3Mjc_fc00f036-8259-4746-b8f6-95e53c69fd50"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMS0xLTEtNDE5OQ_0d537a2f-f7ed-4a17-8b23-6f53c4f146d2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjItMy0xLTEtNDE5Ng_6c924dd8-93e5-4e5d-bb44-4de7e2fa8399"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk2NA_45a31046-9dfa-412c-9d68-fc9cabc8cb03"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk2NA_6a3fc58f-2d61-468d-b104-2dd62e70d338"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk1NQ_23835869-0064-4ab6-94cd-d5c637507d94"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MTk1NQ_b3e5dba4-39d6-4478-92ca-463e7ad1bc6d"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAxMQ_4f2a5a0b-b41c-46d8-b56d-a5c48acfc7fd"
      unitRef="shares">167683814</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAxMQ_fbd8a405-aaf3-4ce3-bbfe-7336d751be1f"
      unitRef="shares">167683814</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAyMw_89096f41-2579-448b-9081-16ace16b77b4"
      unitRef="shares">36480314</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMC0xLTEtMzEzL3RleHRyZWdpb246MGVjOGI3YTAyODc0NGIzMWJjZTNlOWNlMWY0N2I5N2ZfMTY0OTI2NzQ0MjAyMw_994c027a-7586-4448-873d-02f2ddf5a327"
      unitRef="shares">36480314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMS0xLTEtMA_764779fb-308f-462c-8457-296b87e17489"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjQtMy0xLTEtMA_2968ea89-ff1e-4e1f-b3fd-19711f4735c4"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjUtMS0xLTEtMA_558483e0-c4a5-4c4b-9b35-ad4028d30762"
      unitRef="usd">589812000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjUtMy0xLTEtMA_4dc8fab5-591f-4738-9b52-a0e078195e80"
      unitRef="usd">328154000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjYtMS0xLTEtMA_5ded50be-6784-4929-83ce-8680e35203eb"
      unitRef="usd">-518301000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjYtMy0xLTEtMA_b606d035-c974-4f83-9bf9-01e966b4acb5"
      unitRef="usd">-310587000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjctMS0xLTEtMA_c4fbf479-592a-4916-86a9-12c59f956687"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjctMy0xLTEtMA_f9fb4d75-6365-45a9-9ffa-ed8ea9776a1b"
      unitRef="usd">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjgtMS0xLTEtMA_9546ba92-d7d2-407d-ace5-1e5fba233359"
      unitRef="usd">71528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjgtMy0xLTEtMA_60f69b23-5830-4ec9-ae42-94c27b2eaf26"
      unitRef="usd">17575000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjktMS0xLTEtMA_121e48c7-f1bd-4571-af3b-3f15fabacaec"
      unitRef="usd">130842000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xNi9mcmFnOjMxNmRiODBkNjMzNTQ5MWE4NDliYTgwZTMzZDI1NzU1L3RhYmxlOjdmYmVlM2FmY2M3ZjRjMDhhYTY2ODA2NDFlMTA2YzBlL3RhYmxlcmFuZ2U6N2ZiZWUzYWZjYzdmNGMwOGFhNjY4MDY0MWUxMDZjMGVfMjktMy0xLTEtMA_58d7e3ff-936c-47bd-b519-4d2c8e9da23f"
      unitRef="usd">81159000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic53c293513a3411988e3f82450bc2600_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy0xLTEtMS0w_5d7f8558-0d7b-4f1e-b2aa-fe4b0b86153c"
      unitRef="usd">1483000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89212e9395d543b584178d191c5a52df_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy0zLTEtMS0w_25831d93-b006-4b1c-906b-42431ca3be69"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89ac8ecea9da46f18647e4055ba4c2bf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy01LTEtMS01MA_63563914-9d8a-400f-aaab-dcf29d41197a"
      unitRef="usd">3233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e10a9cdb13646a5b01897e039b29eb1_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMy03LTEtMS00Ng_9258b0cc-76bf-4cfd-86b8-ef6d4bbe6009"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23934cfba1c34fb59943833e025eb17f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0xLTEtMS0xODM0_65156261-4f27-4f8c-b1d1-697cda7ab5f7"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c9988a3e0ca4c50b6d4ebe101481b7b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0zLTEtMS0zNDEz_db663bd7-c8cf-4c22-ac61-0ccd9c80d223"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c3031d6ad8c4ebebd28af76579e5a58_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC01LTEtMS0xODM0_e26f0833-d341-4c08-a5dc-ba75cdf0f685"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i115874d2c71d4965a64a283d45279d4b_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC03LTEtMS0zNDEz_e97e30b3-b257-49bb-afbb-4fce357b35bb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0xLTEtMS0w_5cf00d91-1fac-4c5c-9675-5ebeee5c028f"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC0zLTEtMS0w_f88a6988-681a-4945-8a66-c9a52abb31b0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99638830588b43439d03faa00fafb735_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC01LTEtMS01MA_e9610c19-afc2-4f00-aed6-b3c06448c7d9"
      unitRef="usd">205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNC03LTEtMS00Ng_8e52cf94-c5cb-4873-aaa9-ef07314e7a54"
      unitRef="usd">308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS0xLTEtMS0w_bf84d308-2a83-45dc-82a8-c002d707a2c9"
      unitRef="usd">11688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS0zLTEtMS0w_846c270a-bafa-4e8b-8bef-278527f7b750"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS01LTEtMS00Ng_44deba92-6463-44a5-add1-9a6b3f40ab39"
      unitRef="usd">13438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNS03LTEtMS00Ng_03386235-0205-483e-b20e-56f9cee24509"
      unitRef="usd">308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy0xLTEtMS0w_1e707d4f-be5d-4deb-bc68-a0bc119a7b6d"
      unitRef="usd">216000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy0zLTEtMS0w_4ae5797a-fa83-47fc-a5ac-bedf63e05276"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy01LTEtMS01MA_7528ec84-e123-416d-bf36-d7bada857aab"
      unitRef="usd">487000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfNy03LTEtMS00Ng_f66615c8-a636-4006-909b-58b8eaaf73c9"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC0xLTEtMS0w_a9ea651b-5e30-4033-8c37-08710770790f"
      unitRef="usd">13119000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC0zLTEtMS0w_5b581ede-1d96-4e9f-9b31-a7ab650e6dcb"
      unitRef="usd">12556000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC01LTEtMS01MA_d50f487a-4783-4c25-9d15-3a5c40ba0b81"
      unitRef="usd">29072000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOC03LTEtMS00Ng_b84e18c4-f05a-48b6-8d2f-61f4af3f28f8"
      unitRef="usd">23404000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS0xLTEtMS0w_787f6a10-3bf3-453e-a910-5f9cb9b7fb6a"
      unitRef="usd">26459000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS0zLTEtMS0w_2c42c2fc-3387-44b7-918a-7133be7dd373"
      unitRef="usd">6803000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS01LTEtMS01MA_ef6e5080-f944-4a74-b376-b1056563615e"
      unitRef="usd">51874000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfOS03LTEtMS00Ng_8a9c087e-3002-46ce-a6ab-ea08f2ec13c6"
      unitRef="usd">12147000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMS0xLTEtMTg1MA_01230842-d134-4c1d-b097-1cfbe49519d6"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMy0xLTEtMTg1MA_aebcd396-98ad-42b2-a853-7b5e0a65ae55"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNS0xLTEtMTg1MA_3257c229-6c46-4c93-9e85-0263175691d2"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNy0xLTEtMTg1MA_237c3bec-452a-4c98-96eb-0798b39cedc9"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMS0xLTEtNDIxMA_816bf9d3-130f-44cd-8097-2fe966335e1c"
      unitRef="usd">-84726000</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMy0xLTEtNDIxNA_4fa2c90a-23aa-4d74-8f6d-f88a073b6aa9"
      unitRef="usd">0</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNS0xLTEtNDIxNw_c58dde9a-b92c-470d-a601-35fe0d21cd9b"
      unitRef="usd">-84726000</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNy0xLTEtNDIyMA_4e27751e-ccda-4dca-94a6-c07c88153f9b"
      unitRef="usd">0</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:CostsAndExpenses
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtMS0xLTEtMA_08bef76d-22bb-4938-886f-ca43ed5d2e99"
      unitRef="usd">178865000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtMy0xLTEtMA_2d26e809-5b9e-4dfb-a80e-20ddbcf56c9b"
      unitRef="usd">19359000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtNS0xLTEtNDY_8064ddd8-c0ac-4fa3-b8c2-9941a8c4e315"
      unitRef="usd">220504000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTAtNy0xLTEtNDY_09294b49-fdf4-4bb9-bc46-db1a17143190"
      unitRef="usd">35551000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMS0xLTEtMA_cd76bce0-9149-4e04-86ce-ca53766b7a6f"
      unitRef="usd">-167177000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtMy0xLTEtMA_a03f938a-a53b-45f9-9922-310d5fadeefc"
      unitRef="usd">-19359000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNS0xLTEtNDY_6e0006cc-684d-477c-aae5-831074a47e2d"
      unitRef="usd">-207066000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTEtNy0xLTEtNDY_e99fde50-a2b3-458f-ae86-43003725c92b"
      unitRef="usd">-35243000</us-gaap:OperatingIncomeLoss>
    <mnlo:FinancialIncomeNet
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMS0xLTEtMA_330888e0-6002-4854-972d-ee527e5d9bc5"
      unitRef="usd">564000</mnlo:FinancialIncomeNet>
    <mnlo:FinancialIncomeNet
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItMy0xLTEtMA_79ef0bd3-6c38-41bf-bc11-0c7e73cfc1e1"
      unitRef="usd">468000</mnlo:FinancialIncomeNet>
    <mnlo:FinancialIncomeNet
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNS0xLTEtNTA_f8fdccd7-6526-4f80-af7e-9465660a6efd"
      unitRef="usd">1292000</mnlo:FinancialIncomeNet>
    <mnlo:FinancialIncomeNet
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTItNy0xLTEtNDY_cf096dee-0028-4b33-885b-b608091b0116"
      unitRef="usd">1004000</mnlo:FinancialIncomeNet>
    <mnlo:FinancialExpenses
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtMS0xLTEtMA_8b78afbd-851c-4de4-a221-aab03d183147"
      unitRef="usd">1086000</mnlo:FinancialExpenses>
    <mnlo:FinancialExpenses
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtMy0xLTEtMA_0c8fc086-2715-4a2b-95ae-e8cb866cc15c"
      unitRef="usd">102000</mnlo:FinancialExpenses>
    <mnlo:FinancialExpenses
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtNS0xLTEtNTA_4a96f0c3-3bd1-44ca-80a6-bc971fd71b31"
      unitRef="usd">2158000</mnlo:FinancialExpenses>
    <mnlo:FinancialExpenses
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTMtNy0xLTEtMzI1_eab9d256-bb87-4768-9bb9-4ff5f6f9c1c1"
      unitRef="usd">134000</mnlo:FinancialExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtMS0xLTEtMA_64a7a7a4-e26b-4bca-ac75-ab8bb4edcfd3"
      unitRef="usd">-167699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtMy0xLTEtMA_4fb36c80-88cc-45dd-958e-8922c9439ccd"
      unitRef="usd">-18993000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtNS0xLTEtNDY_88bfea9c-e8a6-4329-aaca-0c81e51c210d"
      unitRef="usd">-207932000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTQtNy0xLTEtNDY_dfda904f-f426-4546-9ec5-d8da7550f913"
      unitRef="usd">-34373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtMS0xLTEtMA_b7ea74e8-6dd6-44e0-b99c-a9ccabaec1b4"
      unitRef="usd">-259000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtMy0xLTEtMA_e4427121-4821-4cb1-9089-f3200f41f5fa"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtNS0xLTEtNTA_889f76da-4a68-49d0-ab73-81dcbfa4eda4"
      unitRef="usd">-259000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTUtNy0xLTEtNDY_3a03e208-d8b9-429d-bfa7-6144bce84149"
      unitRef="usd">-176000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtMS0xLTEtMA_514586cb-36ba-4271-a431-27baf2a889cc"
      unitRef="usd">-167440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtMy0xLTEtMA_8acb1e4d-a779-417d-96ae-1bf3ed4de049"
      unitRef="usd">-18993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtNS0xLTEtNDY_6be5580b-a643-4a01-8411-7c473443891f"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTYtNy0xLTEtNDY_938deafd-ca41-42e4-abb9-f43606f32c63"
      unitRef="usd">-34197000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtMS0xLTEtMA_ec8bc643-3dfe-4e42-a2b8-e4f27eec0aa8"
      unitRef="usdPerShare">1.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtMy0xLTEtMA_77f42929-cd29-4cd3-89da-cef8fb1e31fa"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtNS0xLTEtNDY_d03d0d1a-5fb9-4d61-978b-b9a73c55ac58"
      unitRef="usdPerShare">2.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMTgtNy0xLTEtNDY_08b450a0-c586-4704-a864-677d84d0ce85"
      unitRef="usdPerShare">0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtMS0xLTEtMA_9fc80f31-aed1-4b90-8ece-547a2a745365"
      unitRef="shares">138653000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtMy0xLTEtMA_abd01f18-5a10-442a-b3b9-fcd7c60688da"
      unitRef="shares">97999000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtNS0xLTEtNTA_0d1563df-93ea-4694-aeaa-13da09b746d8"
      unitRef="shares">90627000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yMi9mcmFnOmQ1YjdhMTkwZjg1MjRjMjVhYzUzZGM3OTFmZGU3MmI5L3RhYmxlOjJjNWEzNTkxYzY4OTQ1ZjdiMmMyMWY0ZjM1YWNjODEyL3RhYmxlcmFuZ2U6MmM1YTM1OTFjNjg5NDVmN2IyYzIxZjRmMzVhY2M4MTJfMjAtNy0xLTEtNTA_96e24e96-c8dc-4027-8e8f-a37b9c8c1c94"
      unitRef="shares">97954000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi0xLTEtMS0w_3ef6670d-3a69-46fe-8506-43dc2f959c47"
      unitRef="usd">-167440000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi0zLTEtMS0w_ffc10dd8-da36-4604-9c77-d71fecf362ef"
      unitRef="usd">-18993000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi01LTEtMS02Nw_13ac5392-8a17-4e9c-8a64-c6b5633430e4"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfMi03LTEtMS02Nw_43ec338c-3539-40cc-8d1d-56c09d267eba"
      unitRef="usd">-34197000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC0xLTEtMS0w_c7dc107f-96a0-4c25-98f5-219808f5f064"
      unitRef="usd">43000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC0zLTEtMS0w_33a86251-f5df-462f-8308-fa19ec543f58"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC01LTEtMS02Nw_53b6d64d-4a08-4a38-8c63-3b667ab67f93"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNC03LTEtMS02Nw_03dd34a7-1bc9-48f0-be69-5f1cda9a3ee2"
      unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS0xLTEtMS0w_25661f16-92ca-4698-ad96-adc2156a0bc6"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS0zLTEtMS0w_1d3feac8-d77a-44b5-b3be-84bc2da89556"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS01LTEtMS02Nw_b8f78ccc-95f8-457d-aaaf-0dae5037fe49"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNS03LTEtMS02Nw_63591fd4-d4ae-4f78-b781-883ff3f036d6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi0xLTEtMS0w_df97dea3-b015-4396-9b2b-7c9947e904f7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi0zLTEtMS0w_b6f36771-3311-43b3-a8c2-a8d8f093eda5"
      unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi01LTEtMS02Nw_a12119a4-f040-49ee-8e46-dca0dccf97b6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNi03LTEtMS02Nw_087e817c-4e73-4602-b525-a9cf3d664ebb"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy0xLTEtMS0w_eebfa242-8205-4dda-9b31-25bebc70fcd6"
      unitRef="usd">40000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy0zLTEtMS0w_f695ee5c-285c-4220-affc-c73aea76cd51"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy01LTEtMS02Nw_ac4dd964-835b-4068-a1e6-c5a1cd194bc8"
      unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfNy03LTEtMS02Nw_4b7f4a73-b03f-46e9-b621-85fdb826919e"
      unitRef="usd">42000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC0xLTEtMS0w_87222b2d-d00a-4251-a848-daf5d03d6b7c"
      unitRef="usd">-167400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC0zLTEtMS0w_1445c6c9-e03d-4c27-b621-c7171ab8109e"
      unitRef="usd">-19002000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC01LTEtMS02Nw_5ca8f2d9-31da-4d1d-89e7-32290e585ccd"
      unitRef="usd">-207678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yNS9mcmFnOmY4MDBhOTNlMGFjYjQzY2Y4ZmIxZDE2YmQzNzc5NmUyL3RhYmxlOjBiNjMyODJjZTEyYjQ1YzZhNDlhMmJiZTk3ZmI5ZGE4L3RhYmxlcmFuZ2U6MGI2MzI4MmNlMTJiNDVjNmE0OWEyYmJlOTdmYjlkYThfOC03LTEtMS02Nw_f3c678bb-88cd-40d1-9a2d-2e4505e0ad6d"
      unitRef="usd">-34155000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i58ec0b6d315d42bf984266ae09cc24f0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0xLTEtMS0w_d86b4906-77f5-4e81-90f4-3019880736e9"
      unitRef="shares">97864663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58ec0b6d315d42bf984266ae09cc24f0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0zLTEtMS0w_1e2fa083-9997-4a07-91be-5973c4474e72"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib10f110e89794a328cd6dff889719d0f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi01LTEtMS0w_00521afd-2c00-45cb-9806-1f599c1aff5e"
      unitRef="usd">307624000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6fddccdca3294d4e9d00f89b822119c3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi03LTEtMS0w_bb931d12-7236-47f4-a88a-71dbf2a2a733"
      unitRef="usd">-215409000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bd4960891c34721acc23f0da145dc30_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi05LTEtMS0w_c125ee5b-b3a8-4221-a871-b37e845f1d6d"
      unitRef="usd">-43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMi0xMS0xLTEtMA_0ae43293-dacb-4055-a845-6b0b012540e0"
      unitRef="usd">92182000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaab607da61e54796b75a8649d120f305_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC03LTEtMS0w_138f2876-1d15-4b73-bd43-f74c8efca150"
      unitRef="usd">-34197000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i968d104d31de4459a96511fbf90c1f1d_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC05LTEtMS0w_75e8df4f-be9f-4a7c-a9b5-49551754b2f0"
      unitRef="usd">42000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNC0xMS0xLTEtMA_041d6549-f02b-4022-a5ad-55fd4f1f1569"
      unitRef="usd">-34155000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i44a66f541efd4f15931ae16609a79908_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS0xLTEtMS0w_8167a10e-b754-4442-912c-a69114605928"
      unitRef="shares">188755</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8d3163028e034d0a88324b9af3624248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS01LTEtMS0w_ed96e763-87c8-4f6a-8878-8148c65d1697"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNS0xMS0xLTEtMA_37dd85e5-9e80-44e1-95fc-d20a6037b1aa"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i8d3163028e034d0a88324b9af3624248_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNi01LTEtMS0w_9b2889d9-a68e-47b0-bc89-bccd8868ac9a"
      unitRef="usd">2337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNi0xMS0xLTEtMA_700f3d4e-7f32-45f0-be1c-138294725585"
      unitRef="usd">2337000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0xLTEtMS0w_3cd20eea-e484-40a0-bca3-a2594fbd94b0"
      unitRef="shares">98053418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0zLTEtMS0w_c9d4910d-2b56-45dc-b997-6c6d604fadf4"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i183126c41cc449dbba13257e8dea4ace_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy01LTEtMS0w_26533c6d-dff3-462b-9f40-ff4b9ba6feb2"
      unitRef="usd">309979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c4fe139b2cc48aaa7444cf89368196d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy03LTEtMS0w_e949424b-d1a1-44cf-9410-44181239f75b"
      unitRef="usd">-249606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy05LTEtMS0w_3beccd1d-4ffe-412c-96d8-e70fb0ab1e55"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfNy0xMS0xLTEtMA_150c68ba-34c5-49ad-ac31-071d7a7fed93"
      unitRef="usd">60382000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8caa6a61613a445594a114cf0db71d79_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0xLTEtMS0w_2df3cb0f-b0ac-4b6c-add4-4a100052e807"
      unitRef="shares">36480314</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8caa6a61613a445594a114cf0db71d79_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0zLTEtMS0w_d64c40b1-15e2-4381-a405-608676aa9595"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a2f04cbef3845e28d047be6ae20e735_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS01LTEtMS0w_201bf9c6-4e9a-4452-8bb5-fdada3fcefd6"
      unitRef="usd">328154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9778e0408b1f42deaf3632925439e4b0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS03LTEtMS0w_cf0edd5e-950e-4e81-8027-fab6014c7acf"
      unitRef="usd">-310587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6feda25267a14e1e9087b4289d642160_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS05LTEtMS0w_b698a9a6-2591-493c-817e-0aaa8421c7e2"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfOS0xMS0xLTEtMA_822e4857-8a67-4e4e-8874-c22acf0ba24b"
      unitRef="usd">17575000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if95e4afe75e94206bc731058ea393dba_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtNy0xLTEtMA_168d0126-d0c0-46ee-9f69-208046884cd7"
      unitRef="usd">-207673000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7973a9b2e41c4011a66ad0e37aa68515_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtOS0xLTEtMA_f2af6662-690c-49c1-b5b5-5d60c1acd01b"
      unitRef="usd">-5000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTEtMTEtMS0xLTA_34c34691-8c71-4877-b0ef-d2cb051a2522"
      unitRef="usd">-207678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItMS0xLTEtMA_5f2befc2-c1f9-437e-a7d0-0cacdcef2f1b"
      unitRef="shares">1032003</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItNS0xLTEtMA_33391ab6-58d9-4309-9437-e080586dc10d"
      unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTItMTEtMS0xLTA_4d5db907-036e-4ab3-bda0-6dbaac83f3da"
      unitRef="usd">260000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTMtNS0xLTEtMA_6ab9247e-3729-440b-ba6a-e001f80c88d8"
      unitRef="usd">12527000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTMtMTEtMS0xLTA_a3814526-2989-4c07-abb0-b4bd46a90968"
      unitRef="usd">12527000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtNS0xLTEtMA_3ee9fa34-e2bd-47c6-a734-0da192f94209"
      unitRef="usd">-41000</mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="if95e4afe75e94206bc731058ea393dba_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtNy0xLTEtMA_941be3e4-9424-49a3-8903-e9d3a9c838fc"
      unitRef="usd">41000</mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTQtMTEtMS0xLTA_177f7836-c86b-4706-8787-999f2337a02b"
      unitRef="usd">0</mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTUtNS0xLTEtMA_c5a2565f-c381-4756-be79-c0039879d3ff"
      unitRef="usd">975000</mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTUtMTEtMS0xLTA_4e66c306-701c-411c-ba62-ec89a3d6b05b"
      unitRef="usd">975000</mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMC0xLTEtNjA4L3RleHRyZWdpb246YTc2NzkxYzBhOWRlNGEzZjk2MjdkNjM3MzgxMWM1MjJfMTY0OTI2NzQ0MTg5Mw_bcd86cd9-7bd6-46d8-8d20-88087fdef147"
      unitRef="usd">3903000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMS0xLTEtNjUy_711469e5-cd6f-4f83-ba51-cbff714ea0bf"
      unitRef="shares">31107500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMy0xLTEtNjUy_9c73d630-c690-4cdb-b6f3-2341725ab6c5"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtNS0xLTEtNjUy_fb58c062-4ebb-4468-885e-cf1009b40d2c"
      unitRef="usd">53646000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMTEtMS0xLTY1Mg_06bd10a7-36b7-482d-9bcb-b2eb78da041a"
      unitRef="usd">53649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMS0xLTEtMA_a841f0b1-5ecf-4ca9-9f07-bdceb56c6ea0"
      unitRef="shares">99063997</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i1bb96cb6230f47f5ac20302ff9c75c94_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMy0xLTEtMA_e3579779-7095-464b-8b50-338e375c9fdf"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8196bfc28f4c403c984a0618bb5d85d3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtNS0xLTEtMA_574be71b-57d6-4bd1-82d5-f7d3f93b64bf"
      unitRef="usd">196159000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTYtMTEtMS0xLTA_71471f74-cd87-4a3a-ae21-24f0dcfe7009"
      unitRef="usd">196170000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMS0xLTEtMA_deb7d5a0-7644-46e9-a981-47da07716970"
      unitRef="shares">167683814</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMy0xLTEtMA_63488b9f-df17-4b82-8f97-cd0222001849"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctNS0xLTEtMA_ef6b4f03-c517-40b0-a39f-20ca6bf6d8b2"
      unitRef="usd">589812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0b992755b2b4a5ba58755071de873b4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctNy0xLTEtMA_589e1143-7627-4ae3-82f7-08cd97ce03b9"
      unitRef="usd">-518301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctOS0xLTEtMA_6140fb92-af3a-4be9-92f0-317c93faba21"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8yOC9mcmFnOmM1ZDgzNDNiZGIyYTQ5MGY4NjFiYWQ0NmM1NzZkM2MxL3RhYmxlOmU3MjIwYTk0MjMxMjRjY2FhZTIzYmUzYjRmZDZjNTNkL3RhYmxlcmFuZ2U6ZTcyMjBhOTQyMzEyNGNjYWFlMjNiZTNiNGZkNmM1M2RfMTctMTEtMS0xLTA_fb383c86-a24d-4376-b63a-5bef6f9e2009"
      unitRef="usd">71528000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTEtMS0xLTEwOQ_b08623ff-820c-4b85-9487-e14e691a8725"
      unitRef="shares">97987433</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i21be6e2e185f4c91ae1d09d41ef87fe8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTMtMS0xLTEwOQ_04dec6dc-424e-4ca6-a72d-2d7a75dd2742"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b02388b48f440649017facfc2fec45b_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTUtMS0xLTEwOQ_b0b77f2f-5993-42cc-a7db-aec5b89e745f"
      unitRef="usd">308590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b661c91124c4db18890eb501396ac7e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTctMS0xLTEwOQ_93049c75-9c9f-47a1-aaf1-945c723168f7"
      unitRef="usd">-230613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9558e2deebc4ba3a4cbcf4217d7e051_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTktMS0xLTEwOQ_1e3e0a1f-52dc-4a57-841d-a6a040bebb1c"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d3f4643a51a41288e8ccd0e60759c97_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8yLTExLTEtMS0xMDk_b03dfa29-4888-4348-9666-d3c797d56581"
      unitRef="usd">77995000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i101055c62f9d45799bf1500fe791edc4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTctMS0xLTEwOQ_c9bda4fa-35a5-4382-a223-f633e95f6fd5"
      unitRef="usd">-18993000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib74604aa6bc2461cb5df34b326723115_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTktMS0xLTEwOQ_fc848b75-ecc9-4623-b70b-7770504c974b"
      unitRef="usd">-9000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV80LTExLTEtMS0xMDk_772d6a16-57ed-4eef-9d2f-f897b36baee8"
      unitRef="usd">-19002000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8a497140cb264e87a5545a4066bd9ccd_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTEtMS0xLTEwOQ_41e46479-3429-47b7-ac56-f76d9f125532"
      unitRef="shares">65985</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTUtMS0xLTEwOQ_d22062c4-53a4-4238-8206-07c8c56ffba8"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV81LTExLTEtMS0xMDk_3cb4fd00-41b1-4d85-9369-2522573316ad"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i38828d3a43994d5eb2042a39adbc2a17_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV82LTUtMS0xLTEwOQ_649f631f-0a76-4269-a8dc-c456ffbaf7b9"
      unitRef="usd">1387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV82LTExLTEtMS0xMDk_03042aa1-0025-40b3-b4dd-3926963731fb"
      unitRef="usd">1387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTEtMS0xLTEwOQ_69f108bc-afc9-4d4b-a82d-c1f202eb830a"
      unitRef="shares">98053418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2c3eae89d05b4922b7037525a28870c3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTMtMS0xLTEwOQ_d35094d3-78e3-4d91-b0aa-dc61842cd8be"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i183126c41cc449dbba13257e8dea4ace_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTUtMS0xLTEwOQ_6e2b0faa-c09d-4f88-80f6-666dc0e58c95"
      unitRef="usd">309979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c4fe139b2cc48aaa7444cf89368196d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTctMS0xLTEwOQ_ffd856a7-7216-4afc-8e55-907248f5c3ce"
      unitRef="usd">-249606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1abd32d9d2d4d598ad7e5ab0e9bd4af_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTktMS0xLTEwOQ_b5787bc7-e84c-48a7-8394-517a7fd003e0"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV83LTExLTEtMS0xMDk_b0574f11-0cb6-4fd7-9b18-51b45da623d1"
      unitRef="usd">60382000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib4e49138bc604905a6e1fb9cb99008d0_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTEtMS0xLTEwOQ_1fcd8ca9-efdf-44d1-8c47-3ab96b1e3a82"
      unitRef="shares">61501130</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib4e49138bc604905a6e1fb9cb99008d0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTMtMS0xLTEwOQ_766bbbd9-2c3e-4199-b290-18dcd32d3b65"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74810c4013404762b66d6ab7950a6c2a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTUtMS0xLTEwOQ_d74822d9-ef8f-404a-8a8e-39c3cd7aa127"
      unitRef="usd">420430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3359148f5b174e9d9dbd7205f678bc8d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTctMS0xLTEwOQ_422147be-c269-4832-a8aa-180964e7b029"
      unitRef="usd">-350861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i004a8f9abfde49159237ec2532aff25c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTktMS0xLTEwOQ_54e3ebc5-d881-4a0b-bf5d-c9607726db7f"
      unitRef="usd">-40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8b89a0f42154a88be72ee1ba1cc8faf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV85LTExLTEtMS0xMDk_2d2e3255-0ffb-4037-bebc-1cd086fc8ef2"
      unitRef="usd">69535000</us-gaap:StockholdersEquity>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5214fa97c5fa453fa43fa4fe0908ef99_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS03LTEtMS0xMDk_477b0ab8-016a-46c2-896f-2155c205ec86"
      unitRef="usd">-167440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5439508597d54228b44eb110a0163531_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS05LTEtMS0xMDk_a82948b1-2966-4c0c-98e4-6fa7fff73caf"
      unitRef="usd">40000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMS0xMS0xLTEtMTA5_faa0abce-2b07-4d38-a344-c4f44b709498"
      unitRef="usd">-167400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi0xLTEtMS0xMDk_f28ad1a5-db5e-47d9-b84e-3ad6a862bb59"
      unitRef="shares">530771</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi01LTEtMS0xMDk_66b0fe48-72fd-422b-8fc6-c8d7adc1d9d7"
      unitRef="usd">-43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMi0xMS0xLTEtMTA5_937969ec-8e8b-4f36-9a69-b7e388507abb"
      unitRef="usd">-43000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMy01LTEtMS0xMDk_09a907e2-1877-42b6-a21f-4d64079915cf"
      unitRef="usd">10768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xMy0xMS0xLTEtMTA5_b91f52ae-c8fa-4635-a675-f0548a4bffa6"
      unitRef="usd">10768000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNS01LTEtMS0xMDk_887cebdb-c7ad-4441-9a44-dea01ddc8461"
      unitRef="usd">-657000</mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNS0xMS0xLTEtMTA5_bdb432d6-23d8-4ec9-b13c-34a5cb514f8c"
      unitRef="usd">-657000</mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0wLTEtMS02MTAvdGV4dHJlZ2lvbjphMGFjZDI3ZmY4Y2U0MjgxOWQ5OTM2MjJlMjE0OTVhOV8xNjQ5MjY3NDQxNzYy_82aeadee-0331-4495-8f9e-67e874797be2"
      unitRef="usd">3903000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xLTEtMS02NTc_711469e5-cd6f-4f83-ba51-cbff714ea0bf"
      unitRef="shares">31107500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0zLTEtMS02NTc_9c73d630-c690-4cdb-b6f3-2341725ab6c5"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi01LTEtMS02NTc_fb58c062-4ebb-4468-885e-cf1009b40d2c"
      unitRef="usd">53646000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xMS0xLTEtNjU3_06bd10a7-36b7-482d-9bcb-b2eb78da041a"
      unitRef="usd">53649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xLTEtMS0xMDk_267b0e38-cd58-4763-a723-c89ca25d1bf8"
      unitRef="shares">74544413</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i43f88f199dc643d3b822a7ee0f6555e8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0zLTEtMS0xMDk_81107f40-78b0-45ec-9ed1-def8d27c0c63"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ifc776f6179b94ace80180cdce87f8ff2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi01LTEtMS0xMDk_58254ce5-1f74-4d24-bbbb-ba3147cc348f"
      unitRef="usd">104354000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNi0xMS0xLTEtMTA5_c276eca3-14ea-4d21-9a3b-cd628d83a283"
      unitRef="usd">104362000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0xLTEtMS0xMDk_0442277c-0294-4012-9284-60c44fe0fd1b"
      unitRef="shares">167683814</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0zLTEtMS0xMDk_7b939a94-24b1-4fbf-b08d-96481c64455a"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i565a4d23c5f045cba80ae5bbd9d069f6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy01LTEtMS0xMDk_a33b19c7-d4a1-48e7-9ea0-8229bfd3d9e4"
      unitRef="usd">589812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie0b992755b2b4a5ba58755071de873b4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy03LTEtMS0xMDk_c97ed36b-c74b-431a-9106-77c462aa7535"
      unitRef="usd">-518301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ba7b053810a41f6ba6aa29fa4c66772_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy05LTEtMS0xMDk_60c9f2ae-5b6b-4ae2-b3c6-dc7435b7a4da"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzE5L2ZyYWc6ZTZkZTA5NmEzNTFkNDU5M2JkZWRhOWMzMzEzMjQzZDkvdGFibGU6NWM1YWU2YTU1MjRhNDBiMmFhODQwNmY4ZDkzZWZkN2EvdGFibGVyYW5nZTo1YzVhZTZhNTUyNGE0MGIyYWE4NDA2ZjhkOTNlZmQ3YV8xNy0xMS0xLTEtMTA5_e5d7e02f-e285-41e8-ad33-185820f8949c"
      unitRef="usd">71528000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMy0xLTEtMS0w_6a2ac86b-d95e-4d19-95df-fa3b831c039e"
      unitRef="usd">-207673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMy0zLTEtMS0w_82a485d2-d938-41fa-b9ee-ba3a2752c251"
      unitRef="usd">-34197000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNS0xLTEtMS0w_797e5aa3-e550-4b01-a05d-140e28a66ace"
      unitRef="usd">187000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNS0zLTEtMS0w_3da01ee5-d580-4a32-823e-f43633977012"
      unitRef="usd">163000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0xODY1_3931d459-e9cf-4efb-9c27-59e61e9bce13"
      unitRef="usd">54345000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0xODY1_470c6f36-b48f-47f1-a790-56990f341385"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0xLTEtMS0xODY1_7b82d614-7311-4dc5-8823-351aeb0fde93"
      unitRef="usd">-84726000</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0zLTEtMS0xODY1_bc2d4da2-13ca-4e23-a485-5a82224140bb"
      unitRef="usd">0</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0xMzk_d147c9b0-0285-4384-bc3e-0d1a4819ec49"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0xMzk_625e0432-8a5d-45c3-8e8a-d8db3d5b0a59"
      unitRef="usd">-29000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0xLTEtMS0w_c32458d9-d41c-4dde-8d4f-ed3f6ee7f3c7"
      unitRef="usd">142000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNi0zLTEtMS0w_78e3e631-d6cf-49c4-ae59-80df9d45dcf7"
      unitRef="usd">358000</us-gaap:UnrealizedGainLossOnInvestments>
    <mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0xLTEtMS0w_04cf0c74-dd81-4469-8dd4-0a6e25367c4a"
      unitRef="usd">-21000</mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits>
    <mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNy0zLTEtMS0w_e71bc345-13b2-4eec-a5ba-f6f48941a817"
      unitRef="usd">42000</mnlo:IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits>
    <us-gaap:ShareBasedCompensation
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOC0xLTEtMS0w_4a85df85-05ba-464a-9cb1-c073ba14108a"
      unitRef="usd">12527000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOC0zLTEtMS0w_255da730-b943-47d2-b70c-27e1afa65065"
      unitRef="usd">2337000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOS0xLTEtMS0w_1ecca7f0-e0ef-4368-9fe9-ffb72942a114"
      unitRef="usd">833000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfOS0zLTEtMS0w_05fce8dc-a545-4757-bf83-e5f83c8754f9"
      unitRef="usd">-3000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTEtMS0xLTEtMA_c796a70a-503b-4817-a632-88d4093508de"
      unitRef="usd">9807000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTEtMy0xLTEtMA_38f9ac13-a614-4c09-8c07-f7b94c394150"
      unitRef="usd">-246000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTItMS0xLTEtMA_910fa109-026a-4c9b-a101-1cfb20360c81"
      unitRef="usd">6026000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTItMy0xLTEtMA_2ca81db1-f2fd-4db4-8950-caf02e063937"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTMtMS0xLTEtMA_b2b96fad-3910-43bb-b303-f6eb00d06916"
      unitRef="usd">-10908000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTMtMy0xLTEtMA_ea87315f-8730-4a99-b162-b9b21eeffdaa"
      unitRef="usd">2374000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTQtMS0xLTEtMA_48bbb899-c579-442f-b1ba-c18bd3277b23"
      unitRef="usd">4445000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTQtMy0xLTEtMA_01c7d892-a266-4bfb-bde4-0f1c7d397886"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTUtMS0xLTEtMA_e0b606fc-dbee-494b-8879-0ef5c1172789"
      unitRef="usd">-88070000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTUtMy0xLTEtMA_a3939575-d438-479c-9ef4-283e28ce3d5b"
      unitRef="usd">-29361000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTctMS0xLTEtMA_d7dbc426-dc3d-405a-89e7-750b6632041a"
      unitRef="usd">113000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTctMy0xLTEtMA_c8c59c27-7137-4404-92a8-a9ccbf8884fa"
      unitRef="usd">454000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTgtMS0xLTEtMA_8b5d6395-8734-40de-97e3-ee33ac1a0f9e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTgtMy0xLTEtMA_bb955a7f-5f17-4fc5-8935-c0e51369fe63"
      unitRef="usd">16048000</us-gaap:PaymentsToAcquireInvestments>
    <mnlo:ProceedsFromBusinessMerger
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTktMS0xLTEtMA_f4a689ba-e7b3-4d11-b569-5d4aabba41bb"
      unitRef="usd">38641000</mnlo:ProceedsFromBusinessMerger>
    <mnlo:ProceedsFromBusinessMerger
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMTktMy0xLTEtMA_af01f852-89b6-433c-9907-657235a03421"
      unitRef="usd">0</mnlo:ProceedsFromBusinessMerger>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjAtMS0xLTEtMA_d943b9b5-1686-4fac-8d48-3db4a6eb2911"
      unitRef="usd">48577000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjAtMy0xLTEtMA_e690ec37-a5a6-46b9-862b-d173855de37e"
      unitRef="usd">57014000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjEtMS0xLTEtMA_03c832b4-13ce-459c-a1dc-afe2683a25b4"
      unitRef="usd">87105000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjEtMy0xLTEtMA_43b2aaf5-33b3-47cd-ae68-4d46e89fffe3"
      unitRef="usd">40512000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMS0xLTEtMTg3OA_f4fe77b4-816e-41b5-9cbe-84aa0d94cae6"
      unitRef="usd">53646000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMy0xLTEtMTg3OA_9cc0a169-f11e-4cf1-afe9-788ab8f4fbe7"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjMtMS0xLTEtMA_12a653dc-ac59-450a-8c84-9d36a44da80f"
      unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjMtMy0xLTEtMA_37f9ea9d-c602-4d2d-940b-282c2fddbd32"
      unitRef="usd">18000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjQtMS0xLTEtMA_a3863c7f-de14-4d71-9bea-a76b813c8448"
      unitRef="usd">53746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjQtMy0xLTEtMA_558ee6cf-b9c2-4f64-8fe0-ca4dad2a2ee5"
      unitRef="usd">18000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjUtMS0xLTEtMA_36fc445c-bfe1-47e0-b1f4-c9d18eb99175"
      unitRef="usd">52781000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjUtMy0xLTEtMA_67a93ce4-23cf-4b6b-b809-9a572502fdd2"
      unitRef="usd">11169000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjYtMS0xLTEtMA_472563d5-4e8f-4a32-8861-e6fcf1ec2a25"
      unitRef="usd">1000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjYtMy0xLTEtMA_892effc3-67e4-47e8-b1e7-83cb906b4fe2"
      unitRef="usd">48000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMS0xLTEtMA_fb6151ff-3a84-4b19-a82f-57dc549f42cf"
      unitRef="usd">44584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i25c54cc3ee9d4ef7bbd258d135e18074_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjctMy0xLTEtMA_e41d6117-1d38-43d9-a8b4-aa4b67e54972"
      unitRef="usd">28118000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjgtMS0xLTEtMA_4c56e2ce-bfc4-4e6b-8723-7a38490d5f71"
      unitRef="usd">97366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjgtMy0xLTEtMA_1c6b2c51-3af5-4fa2-b08f-a3b9ce65bbb4"
      unitRef="usd">39335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjktMS0xLTEtMA_23c8ce11-fcbd-41af-8aea-4ee538f470fc"
      unitRef="usd">96511000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMjktMy0xLTEtMA_9ae06873-93d6-4607-8efd-4e6a07fe1e88"
      unitRef="usd">39085000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzAtMS0xLTEtMA_a6eba595-689e-4461-b17c-cd257d49a557"
      unitRef="usd">855000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzAtMy0xLTEtMA_e1ecf34c-aefb-45ca-ab94-f861f0198435"
      unitRef="usd">250000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzEtMS0xLTEtMA_51801d4a-4c21-4b91-8729-a4abce189ed7"
      unitRef="usd">97366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50df20b4b873412e8222bce987ca55c7_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzEtMy0xLTEtMA_7855eb1e-3f13-429d-aa7d-ee6d1befdf28"
      unitRef="usd">39335000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzMtMy0xLTEtMA_5852399c-a3f4-47be-9e6d-5e4938e6d95d"
      unitRef="usd">4000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
    <us-gaap:StockIssued1
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzQtMS0xLTEtMA_7af47463-d34c-46b6-a9df-b89280ff9105"
      unitRef="usd">163000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzQtMy0xLTEtMA_254b63b5-84d6-4561-9feb-2ac386eae08e"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzUtMS0xLTEtMA_e97475ed-d90c-4164-b387-3579bbd666a2"
      unitRef="usd">1120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzUtMy0xLTEtMA_14a6b13c-8b33-4b2e-87d9-9c08e6636953"
      unitRef="usd">867000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzctMS0xLTEtMTQ2_35875d85-d429-4bc5-a740-31bb8dc52933"
      unitRef="usd">1120000</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzctMy0xLTEtMTQ2_f8ccf839-c0d3-4782-a250-5f05cfdb7297"
      unitRef="usd">850000</us-gaap:CapitalLeaseObligationsIncurred>
    <mnlo:InterestReceived
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzgtMS0xLTEtMA_a01e2fad-45af-4163-9a5b-fe72ad90aca9"
      unitRef="usd">298000</mnlo:InterestReceived>
    <mnlo:InterestReceived
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzgtMy0xLTEtMA_6ee07ef0-8cf4-4732-b786-5987389b3352"
      unitRef="usd">666000</mnlo:InterestReceived>
    <us-gaap:InterestPaidNet
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzktMS0xLTEtMA_2b3caaab-f141-4a83-977d-f195e27e7bdd"
      unitRef="usd">1946000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfMzktMy0xLTEtMA_bce79f6c-5f55-4bcd-aa28-b713178c14d2"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDEtMS0xLTEtMA_eed28e22-b29f-4436-946e-9d48b7737ccf"
      unitRef="usd">117270000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDEtMy0xLTEtMA_b5e6672b-4dcc-40e9-a3cf-0d454192022a"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDItMS0xLTEtMA_ed727bbb-dca3-47a8-b019-e1e64f4204f4"
      unitRef="usd">5827000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDItMy0xLTEtMA_042c410c-e3c3-49ac-9e04-1989301f1067"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDMtMS0xLTEtMA_9a350ec5-4f58-4fd3-be93-cec2a0d8cbb0"
      unitRef="usd">111443000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDMtMy0xLTEtMA_46da4c23-96c1-4247-95b1-2cbe922745ee"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <mnlo:NonCashAcquisitionOfBusinessCashAcquired
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDQtMS0xLTEtMA_e1f70edf-e3f6-473b-a10c-7d19cf9943bc"
      unitRef="usd">38641000</mnlo:NonCashAcquisitionOfBusinessCashAcquired>
    <mnlo:NonCashAcquisitionOfBusinessCashAcquired
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDQtMy0xLTEtMA_068bc735-3e97-4e5c-83ac-0a2800a23e34"
      unitRef="usd">0</mnlo:NonCashAcquisitionOfBusinessCashAcquired>
    <mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDUtMS0xLTEtMA_c9e58209-8997-4a32-bfa6-9e3baa0f8e9d"
      unitRef="usd">72802000</mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired>
    <mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zMS9mcmFnOmRkNjlhZDNlMDMwMDRmOGQ5ZjQ3NWMxZjIxNWFlNDEzL3RhYmxlOjQ3OTU5M2E3ZDVkMDQxYTE4ZjFlNTNhZDMwNDc4MmJlL3RhYmxlcmFuZ2U6NDc5NTkzYTdkNWQwNDFhMThmMWU1M2FkMzA0NzgyYmVfNDUtMy0xLTEtMA_7114568d-b6bf-499d-a545-8970c05b27c2"
      unitRef="usd">0</mnlo:NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired>
    <us-gaap:NatureOfOperations
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDkwMDU5NA_1e392d36-550f-432a-ac9a-b1088201bfb8">NATURE OF OPERATIONS&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Menlo Therapeutics Inc. (the &#x201c;Company,&#x201d; &#x201c;Menlo&#x201d; or the &#x201c;combined company&#x201d;) is a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;one&#160;business segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Reverse Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (&#x201c;Foamix&#x201d;) and Giants Merger Subsidiary Ltd. (&#x201c;Merger Sub&#x201d;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#x201c;Merger Agreement&#x201d;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#x201c;Merger&#x201d;) on March 9, 2020 (the &#x201c;Effective Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For accounting purposes, the Merger is treated as a &#x201c;reverse acquisition&#x201d; under generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#x2019;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#x201c;Note 3 &#x2013; Business Combination&#x201d; for more information on the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Products, Product Candidates and Licenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the Merger, in January 2020, Foamix launched AMZEEQ&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (minocycline) topical foam, 4% (&#x201c;AMZEEQ&#x201d;), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#x2122;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (minocycline) topical form, 1.5% (formerly FMX103, "ZILXI"), for the treatment of inflammatory lesions of rosacea in adults.  AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;AMZEEQ and ZILXI utilize the Company&#x2019;s proprietary Molecule Stabilizing Technology (MST)&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#x2122;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; that is also being used in the development of the Company&#x2019;s other product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.  The Company has begun preparations to conduct an end-of-Phase II meeting with the FDA before the end of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to pursue serlopitant. As a result, the Company recorded a full impairment charge related to the IPR&amp;amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June&#160;30, 2020. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States, and recently entered into a license agreement with Cutia Therapeutics (HK) Limited (&#x201c;Cutia&#x201d;).  See "Note 4 - Revenue Recognition."  The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company&#x2019;s foam technology with the licensee&#x2019;s proprietary drugs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company launched AMZEEQ&#160;in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company&#x2019;s activities prior to the commercial launch of AMZEEQ&#160;had primarily consisted of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June&#160;30, 2020, the Company incurred a net loss of $207.7 million and used&#160;$88.1 million of cash in operations. As of June&#160;30, 2020, the Company had cash, cash equivalents and investments of $100.4 million and an accumulated deficit of $518.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates.  The Company does not currently intend to pursue serlopitant further.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its existing cash, cash equivalents and investments as of June&#160;30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.&lt;/span&gt;&lt;/div&gt;As a result of the COVID-19 pandemic, the Company suspended the vast majority of its in-person interactions by its customer-facing professionals in healthcare settings and have engaged with these customers remotely as the Company seeks to continue to support healthcare professionals and patient care.  During the second quarter of 2020, the Company began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates.  However, during the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures.  As a result of the negative impact on the Company's product sales, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement.  See "Note 8 - Long-Term Debt." The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict.  An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI, and have a material adverse effect on the Company's liquidity, as well as the Company's ability to remain in compliance with the minimum net revenue covenants contained in the Company's loan documents.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfReportableSegments
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzQ4_bdf51a42-bfdc-42a9-8bd8-13df59715ae0"
      unitRef="segments">1</us-gaap:NumberOfReportableSegments>
    <mnlo:ReverseMergerPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDg5NTk4Mg_c4545cfb-202f-47df-b214-c6e220020f98">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Reverse Merger&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (&#x201c;Foamix&#x201d;) and Giants Merger Subsidiary Ltd. (&#x201c;Merger Sub&#x201d;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#x201c;Merger Agreement&#x201d;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#x201c;Merger&#x201d;) on March 9, 2020 (the &#x201c;Effective Date&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For accounting purposes, the Merger is treated as a &#x201c;reverse acquisition&#x201d; under generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#x2019;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#x201c;Note 3 &#x2013; Business Combination&#x201d; for more information on the Merger.&lt;/span&gt;&lt;/div&gt;</mnlo:ReverseMergerPolicyTextBlock>
    <mnlo:LiquidityAndCapitalResourcesPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfMzI5ODUzNDg5NTk4MQ_76279583-ca3f-4a44-ac54-068c785637a3">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company launched AMZEEQ&#160;in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company&#x2019;s activities prior to the commercial launch of AMZEEQ&#160;had primarily consisted of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June&#160;30, 2020, the Company incurred a net loss of $207.7 million and used&#160;$88.1 million of cash in operations. As of June&#160;30, 2020, the Company had cash, cash equivalents and investments of $100.4 million and an accumulated deficit of $518.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates.  The Company does not currently intend to pursue serlopitant further.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes that its existing cash, cash equivalents and investments as of June&#160;30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.&lt;/span&gt;&lt;/div&gt;</mnlo:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDM5Mg_3a95a90b-1faa-4351-9e95-0c7005b657d0"
      unitRef="usd">-207700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDQwNA_c8fd7420-f7af-4a0f-a7ce-b6954719c85d"
      unitRef="usd">-88100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDQ5OA_55d3887b-b31d-46d6-897d-027870567e79"
      unitRef="usd">100400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8zNy9mcmFnOmUxNGRhYjExNDRhZDRhMTdiZWNlYzZiNTI3YTIwNTFhL3RleHRyZWdpb246ZTE0ZGFiMTE0NGFkNGExN2JlY2VjNmI1MjdhMjA1MWFfNDUzMQ_8179931d-905c-4517-945c-eef033ee5bca"
      unitRef="usd">-518300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMzI5ODUzNDkwMTMwOA_02e89c88-0e6e-4c19-96d9-a6b7dc6b25a3">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;a.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with Foamix&#x2019;s audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company&#x2019;s Current Report on Form 8-K/A filed with the Securities and Exchange Commission ("SEC") on May 7, 2020, and the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results expected for the year ending December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;b.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The consolidated financial statements include the accounts of Menlo and its subsidiaries. Intercompany balances and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;c.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic.  In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.  The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).  The Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;d.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"&gt;Business Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Income approach, which is based on the present value of a future stream of net cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;e.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s customers include a limited number of national and select regional wholesalers (the &#x201c;distributors&#x201d;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the distributors. The Company evaluates the creditworthiness of each of its distributors to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 90 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#x2019;s product sales are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net product revenues through&#160;June&#160;30, 2020&#160;were generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#x201c;Note 4 &#x2013; Revenue Recognition&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;products to Cutia for clinical and commercial use.  The Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognizes the revenues from the upfront license fee when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;f.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;"&gt;Allowance for credit losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;g.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as a finance expense (income) in the accompanying condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;h.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;"&gt;Fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1:&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;i.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.73pt;"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;a.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;b.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;"&gt;The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The basic and diluted loss per share for each comparative period before the acquisition date presented in the consolidated financial statements following the reverse merger was calculated by dividing (a) by (b):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;a.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;The loss of the legal acquiree attributable to common stockholders in each of those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;b.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;"&gt;The legal acquiree's historical weighted-average number of common stock outstanding multiplied by the exchange ratio established in the merge agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary shares outstanding during the period. Diluted net loss per share is based upon the weighted average number &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,975,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,037,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,082,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,576,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,893,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,272,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the above, the CSR was excluded from the calculation of the diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;j.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;"&gt;Newly issued and recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Guidance Issued:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTA_72d2e482-fdde-4d16-b5bf-84a6b89d2d68">Basis of Presentation&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#x2019;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited interim condensed consolidated financial statements should be read in conjunction with Foamix&#x2019;s audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company&#x2019;s Current Report on Form 8-K/A filed with the Securities and Exchange Commission ("SEC") on May 7, 2020, and the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results expected for the year ending December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTE_73c49ced-dba0-455a-8b88-161ff9b958e8">Principles of ConsolidationThe consolidated financial statements include the accounts of Menlo and its subsidiaries. Intercompany balances and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc4MDE_b2c22107-5552-40e4-b1a8-542c29aff3b8">Use of Estimates&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic.  In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.  The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).  The Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTg_a57a24ea-b910-416d-802c-f543a768b5ff">Business Acquisition&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Income approach, which is based on the present value of a future stream of net cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Asset Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTI_e7af27ee-a0a6-4198-83c3-714561e3f05d">Revenue Recognition&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s customers include a limited number of national and select regional wholesalers (the &#x201c;distributors&#x201d;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the distributors. The Company evaluates the creditworthiness of each of its distributors to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 90 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#x2019;s product sales are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net product revenues through&#160;June&#160;30, 2020&#160;were generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#x201c;Note 4 &#x2013; Revenue Recognition&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed &lt;/span&gt;&lt;/div&gt;products to Cutia for clinical and commercial use.  The Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognizes the revenues from the upfront license fee when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mnlo:UpfrontRoyaltyReceipt
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTA2NQ_910f1773-7828-4b12-b782-31ea57993de2"
      unitRef="usd">10000000.0</mnlo:UpfrontRoyaltyReceipt>
    <mnlo:UpfrontRoyaltyReceipt
      contextRef="i5da754f4e94e4544b609a323172766eb_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTA2OQ_cd9b39fb-d1f3-4add-b0f5-b80815c79e6c"
      unitRef="usd">6000000.0</mnlo:UpfrontRoyaltyReceipt>
    <mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTY0OTI2NzQ2MTE1NA_703f27fb-ee10-4e26-a607-b1da3c17d764"
      unitRef="usd">1000000.0</mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTM_9096f0f9-b340-4cfd-b73c-ff2fdf17ee22">Allowance for credit lossesAn allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2020.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTk_e0a3cb02-53d2-4ce1-bd87-43209a6f9986">Derivative instrumentsThe Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as a finance expense (income) in the accompanying condensed consolidated statements of operations.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc4MDA_e1ff0a73-18ba-44ba-a7c2-2544eb07c75a">Fair value measurement&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1:&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTQ_8105a80e-0ddb-4637-9ec1-e7bb64545be6">Loss per share&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;a.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;b.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;"&gt;The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The basic and diluted loss per share for each comparative period before the acquisition date presented in the consolidated financial statements following the reverse merger was calculated by dividing (a) by (b):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;a.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;"&gt;The loss of the legal acquiree attributable to common stockholders in each of those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;b.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;"&gt;The legal acquiree's historical weighted-average number of common stock outstanding multiplied by the exchange ratio established in the merge agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary shares outstanding during the period. Diluted net loss per share is based upon the weighted average number &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,975,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,037,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,082,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,576,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,893,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,272,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the above, the CSR was excluded from the calculation of the diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMzI5ODUzNDkwMTMwOQ_b2e1c1fb-49e2-4f0d-b259-23e255dbea15">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following average stock options, restricted stock units (&#x201c;RSUs&#x201d;), warrants and incremental shares to be issued under the employee stock purchase plan (&#x201c;ESPP&#x201d;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.859%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding stock options, RSUs and shares under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,975,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,037,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,082,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,576,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,893,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,272,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i80a470217c3a4272adc3535da6eb3922_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi0xLTEtMS0w_8544116b-e2dd-45ab-a1a9-6f7191fc4b20"
      unitRef="shares">14975385</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fba894574f6426bb988c61b2df7510c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi0zLTEtMS0w_833e4e8b-2165-4c43-983a-81e2aa6e3330"
      unitRef="shares">11037802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49710f5b3cb5425584627e0e1bcc3521_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi01LTEtMS03ODk_18fa0e6d-b44d-4ba6-a42e-fafaafb5f579"
      unitRef="shares">12082037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f3259df41a745da91e614f0f535fe16_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMi03LTEtMS03OTM_3f440f08-4c8f-4b65-9d66-ce4bca996f0e"
      unitRef="shares">10576229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4bf5e963873a4e6982e47201cb3ff7f8_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy0xLTEtMS0w_9c110769-2310-4bf7-9986-90f041f7ef1e"
      unitRef="shares">1893032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if29ad7a578cf43a6acb996ff258f0c7c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy0zLTEtMS0w_9687a511-c8e4-4c09-9ea4-84d231b917c2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibc2826b77413461d84519a6b754cb004_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy01LTEtMS03ODk_d870379f-2121-444f-af52-b83bff994048"
      unitRef="shares">1272336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9c758c8f421d4ae5a44d89c91a01007d_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RhYmxlOjUxZDNhMDBmM2Y5NDQ2NzE4YzAwMmM4YzdiNDQxMmZmL3RhYmxlcmFuZ2U6NTFkM2EwMGYzZjk0NDY3MThjMDAyYzhjN2I0NDEyZmZfMy03LTEtMS03OTM_ddb7a819-809b-4f1c-9257-a2ce1b5e981d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <mnlo:ContingentStockRightSharesConversion
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTU1ODI_36ab6eff-9529-419e-94b4-e0a6fbe6a12c"
      unitRef="number">1.2082</mnlo:ContingentStockRightSharesConversion>
    <mnlo:BusinessCombinationEffectiveExchangeRatio
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTU2NzM_6ab21fb3-5575-459a-bfa4-e70acaf1bad4"
      unitRef="number">1.8006</mnlo:BusinessCombinationEffectiveExchangeRatio>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80MC9mcmFnOjU3OWVjYmVmZTBiNjQ5ZGM5MDM4YTVhNzU3ZmFiN2RkL3RleHRyZWdpb246NTc5ZWNiZWZlMGI2NDlkYzkwMzhhNWE3NTdmYWI3ZGRfMTc3OTY_fc4a7d13-f229-4536-97e6-401d13203e55">Newly issued and recently adopted accounting pronouncements&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Guidance Issued:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#x201c;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3Mw_e256e579-91ba-4543-805d-d6139c26ceb9">BUSINESS COMBINATION&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo (the &#x201c;Exchange Ratio&#x201d;). In addition, on the Effective Date, Foamix shareholders received one contingent stock right (a &#x201c;CSR&#x201d;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#x201c;CSR Agreement&#x201d;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp;amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#x2019;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#x201c;Phase III PN Trials&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 shares of Menlo common stock underlying the CSRs.  Following the delivery, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For accounting purposes, the Merger is treated as a &#x201c;reverse acquisition&#x201d; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#x2019;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $11.7 million, which are recorded in the consolidated statements of operations and comprehensive income. This amount includes $8.1 million of severance benefits for employees terminated after the Effective Date. The total transaction costs and other non-recurring costs related to the Merger were $21.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Purchase Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deemed (for accounting purposes only) conversion of Menlo equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total consideration*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#x2019; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on Foamix&#x2019;s closing share price of $2.99 as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $131.1 million, consisting of $123.8 million for the deemed (for accounting purposes only) issuance of 41.4 million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $7.3 million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;March 9, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Investment in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimated purchase price*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#x2019;s outstanding shares being owned by Menlo stockholders following the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. None of the Goodwill recognized is expected to be deductible for income tax purposes&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 9, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: fair value of net assets acquired, including other identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(107,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $4.0 million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D")&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The IPR&amp;amp;D recognized relates to Menlo&#x2019;s once&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Acquired indefinite life intangible assets*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value of identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* Represents acquired IPR&amp;amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of IPR&amp;amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $50.3 million related to the IPR&amp;amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;CSR&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp;amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#x2019;s Phase III PN Trials. The Company recognized a liability of $19.6 million in the unaudited condensed consolidated balance sheet as of March 31, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 6, 2020, the Company announced that each of Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 shares of Menlo common stock underlying the CSRs.  Following the delivery pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $84.7 million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $104.4 million (calculated based on 74,544,413 shares issued and a share price of $1.40 on April 6, 2020) and then settled in connection with the issuance of shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Pro Forma&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The actual Menlo net loss included in the Company&#x2019;s consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to Menlo&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Acceleration of stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <mnlo:ExchangeRatio
      contextRef="i62991dd9b59d4f20932a6cc542870ab2_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzQ5_9d668637-9a9f-4d6d-ba35-e798927a952e"
      unitRef="number">0.5924</mnlo:ExchangeRatio>
    <mnlo:BusinessAcquisitionContingentStockRightIssued
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDcz_808b7500-e844-4e0e-9d54-f97d72f565a3"
      unitRef="number">1</mnlo:BusinessAcquisitionContingentStockRightIssued>
    <mnlo:ContingentStockRightSharesConversion
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDkzNA_80c0a3db-3960-4972-8a01-a1dad76c9445"
      unitRef="number">1.2082</mnlo:ContingentStockRightSharesConversion>
    <mnlo:EffectiveExchangeRatio
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk0Mg_f565a22a-b9e6-4e85-8eb9-2c6412c9cc31"
      unitRef="number">1.8006</mnlo:EffectiveExchangeRatio>
    <mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk1NA_9e6aaab0-41aa-45d8-81bf-80b9985f5644"
      unitRef="shares">74544413</mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk1OQ_b3234e1e-a882-43e5-a1ad-c943d93683d2"
      unitRef="number">0.82</mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders>
    <mnlo:PostMergerParentOwnershipByPreMergerParentStockholders
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDk2NA_4467d1b3-692b-4eca-9fc8-5a4d9abb9c32"
      unitRef="number">0.18</mnlo:PostMergerParentOwnershipByPreMergerParentStockholders>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i01fe41f20f4947e2a6b7466a16a798d9_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjI1Mw_da939d0c-6376-4594-8b12-884ff56c779c"
      unitRef="usd">11700000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i475935ac417d417b95b57d209280bd42_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjM2OA_4173f967-e596-4d1f-a609-03299016cef1"
      unitRef="usd">8100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="iaa6ecbab924a41ee8267c4ae3a55f162_I20200511"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjU2OQ_7c2fef74-f9b4-4567-bc7b-586db7a19e45"
      unitRef="usd">21800000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3OA_1b712b2e-f991-448f-aa88-14e5f4b18706">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Deemed (for accounting purposes only) conversion of Menlo equity awards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total consideration*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;131,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#x2019; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.&lt;/span&gt;&lt;/div&gt;</mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMS0xLTEtMS0w_6a6381c8-0af7-4d73-84a4-7b03217d06d6"
      unitRef="usd">123757000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMi0xLTEtMS0w_27aa4ee7-f6a2-4c20-b0b4-345360023c2f"
      unitRef="usd">7322000</mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards>
    <mnlo:BusinessCombinationConsiderationTransferredGross
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjAyZTJhNzU0OWJmOTRlYzlhZWY5MTIxZjgxMDQzZmQxL3RhYmxlcmFuZ2U6MDJlMmE3NTQ5YmY5NGVjOWFlZjkxMjFmODEwNDNmZDFfMy0xLTEtMS0w_09c59a8c-730e-41e9-bc0b-598deea3c179"
      unitRef="usd">131079000</mnlo:BusinessCombinationConsiderationTransferredGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTAxMQ_fb4d679a-c5e0-4220-a70f-7caf10ad76f8"
      unitRef="usd">19600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzEyOA_3e73ed01-5307-4dd4-942f-1e103cec056d"
      unitRef="usd">111400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SharePrice
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzIyOA_6dffcc52-8bc4-41d7-a3db-86b5407e6555"
      unitRef="usdPerShare">2.99</us-gaap:SharePrice>
    <mnlo:BusinessCombinationConsiderationTransferredGross
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzMzMg_6554bc2b-5518-40a0-a389-81819bb22fc4"
      unitRef="usd">131100000</mnlo:BusinessCombinationConsiderationTransferredGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzM1MA_46b86cef-68d1-44ec-bafa-6540c3818d1b"
      unitRef="usd">123800000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <mnlo:BusinessCombinationSharesDeemedIssuedForAccountingPurposes
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzQxMQ_fd27bace-6937-4427-9806-b68a894a269b"
      unitRef="shares">41400000</mnlo:BusinessCombinationSharesDeemedIssuedForAccountingPurposes>
    <mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzUyMA_dc76061e-c7a4-422a-868c-0b180b1b19bb"
      unitRef="usd">7300000</mnlo:BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards>
    <us-gaap:SharePrice
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzgwNA_2c38f427-ba44-4926-8352-a508ba1708bf"
      unitRef="usdPerShare">2.99</us-gaap:SharePrice>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3Nw_ad42b36a-e7f6-4404-8d3c-de7226b74f22">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;March 9, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Investment in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimated purchase price*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#x2019;s outstanding shares being owned by Menlo stockholders following the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfOTU0MQ_b6069441-fad1-491f-856a-66b1f4e0a03b">&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;March 9, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;38,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Investment in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In-process research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;117,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5,827)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Estimated purchase price*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#x2019;s outstanding shares being owned by Menlo stockholders following the Merger.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMS0xLTEtMS0w_57d06e87-6b31-44d1-b6e2-bb2fbe7f2146"
      unitRef="usd">38641000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMi0xLTEtMS0w_969d26cb-648d-46f1-9e9a-40f719366c3f"
      unitRef="usd">22703000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfMy0xLTEtMS0w_e8b558dd-3546-439e-9aef-e6acf2bf5db5"
      unitRef="usd">1581000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNC0xLTEtMS0w_85eb8659-a7b8-4769-b026-41d5d8709280"
      unitRef="usd">50300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNS0xLTEtMS0w_b4d2ed14-aa0a-4610-a3b6-e7e0a243bfec"
      unitRef="usd">4045000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNi0xLTEtMS0w_056a299f-24ba-437f-bd33-5a08a4434951"
      unitRef="usd">117270000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfNy0xLTEtMS0w_76d05278-96a7-4b22-a12f-62d3b296f726"
      unitRef="usd">5827000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfOC0xLTEtMS0w_0dbe6f98-c1fd-4d3b-bc0f-461f43540527"
      unitRef="usd">5827000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjA4NTg5NTQ2NTBkZDRhMjI5MTVkNjY2OWZjNGQ2NDhhL3RhYmxlcmFuZ2U6MDg1ODk1NDY1MGRkNGEyMjkxNWQ2NjY5ZmM0ZDY0OGFfOS0xLTEtMS0w_5bab2dfe-edc3-42fd-b028-6a6dd7d72307"
      unitRef="usd">111443000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock
      contextRef="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDI0Ng_8b5a33ee-4cd9-49c9-92b4-5c349e4bf647"
      unitRef="usd">19600000</mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNDg1MQ_1dbf0fd0-5221-4674-a0fe-8d7a16b855c8"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <mnlo:ScheduleOfBusinessCombinationGoodwillTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDkwMzM1NA_767606e6-3808-4f8c-b0a6-4f725e82b4db">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 9, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;111,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: fair value of net assets acquired, including other identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(107,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mnlo:ScheduleOfBusinessCombinationGoodwillTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMS0xLTEtMS0w_3285b107-d9c7-45fb-8be4-6a66fe1e067b"
      unitRef="usd">111443000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <mnlo:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMi0xLTEtMS0w_5082ad92-ad99-474a-8cf8-2cdde0456f77"
      unitRef="usd">107398000</mnlo:BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets>
    <us-gaap:Goodwill
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOmEwZDkxODc5ZGM5MDRkYTU4YzRlMmIwYWVmOWVhNDIxL3RhYmxlcmFuZ2U6YTBkOTE4NzlkYzkwNGRhNThjNGUyYjBhZWY5ZWE0MjFfMy0xLTEtMS0w_0f544b4d-9b7b-474c-a00a-e209f2fba077"
      unitRef="usd">4045000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE0Mw_5e52e15d-3f74-411e-a216-621d1aa789ef"
      unitRef="usd">4000000.0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE0Mw_a905565c-edb8-489b-8479-795f85ab065e"
      unitRef="usd">4000000.0</us-gaap:GoodwillImpairmentLoss>
    <mnlo:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3NQ_23aecbe9-cd8a-4ad2-82d8-e2387fad11be">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The IPR&amp;amp;D recognized relates to Menlo&#x2019;s once&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;-&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.630%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Intangible asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Acquired indefinite life intangible assets*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Fair value of identified intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;50,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;* Represents acquired IPR&amp;amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.</mnlo:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJjODNjNGI5ODM2ZDQwMmRiOWIzM2YwMzYwNWIwNjhkL3RhYmxlcmFuZ2U6MmM4M2M0Yjk4MzZkNDAyZGI5YjMzZjAzNjA1YjA2OGRfMS0yLTEtMS0w_a41fb74f-8f63-4283-b429-ca96485c095d"
      unitRef="usd">50300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJjODNjNGI5ODM2ZDQwMmRiOWIzM2YwMzYwNWIwNjhkL3RhYmxlcmFuZ2U6MmM4M2M0Yjk4MzZkNDAyZGI5YjMzZjAzNjA1YjA2OGRfMi0yLTEtMS0w_2b4bba3e-306c-431e-840e-4ef13e3ab30a"
      unitRef="usd">50300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i64bfe9f3e6894c12a9573e9ba7298549_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE2MQ_2e543201-a346-47fb-a396-91da16727ba8"
      unitRef="usd">50300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i363b390923d44002aea9667a68a52c10_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE2MQ_370c3fde-50b8-4693-bf14-ac2cf8ca0720"
      unitRef="usd">50300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfNjU1NA_eff7e50f-3f61-4dbc-adb1-f11adaa81706"
      unitRef="usd">19600000</mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock>
    <mnlo:ContingentStockRightSharesConversion
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ5Mw_80c0a3db-3960-4972-8a01-a1dad76c9445"
      unitRef="number">1.2082</mnlo:ContingentStockRightSharesConversion>
    <mnlo:EffectiveExchangeRatio
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ4NQ_f565a22a-b9e6-4e85-8eb9-2c6412c9cc31"
      unitRef="number">1.8006</mnlo:EffectiveExchangeRatio>
    <mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ3Nw_9e6aaab0-41aa-45d8-81bf-80b9985f5644"
      unitRef="shares">74544413</mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ5OA_b3234e1e-a882-43e5-a1ad-c943d93683d2"
      unitRef="number">0.82</mnlo:PostMergerParentOwnershipByPreMergerSubsidiaryShareholders>
    <mnlo:PostMergerParentOwnershipByPreMergerParentStockholders
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTUwMw_4467d1b3-692b-4eca-9fc8-5a4d9abb9c32"
      unitRef="number">0.18</mnlo:PostMergerParentOwnershipByPreMergerParentStockholders>
    <mnlo:ContingentStockConsiderationRemeasurementGainLoss
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDE5Ng_cdde13fb-e193-495a-90d7-062e575d6e5e"
      unitRef="usd">-84700000</mnlo:ContingentStockConsiderationRemeasurementGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMTY0OTI2NzQ2MDIzOQ_4f2a6471-5301-43a3-be0d-ba053bd71fee"
      unitRef="usd">104400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTQ2NA_9e6aaab0-41aa-45d8-81bf-80b9985f5644"
      unitRef="shares">74544413</mnlo:SharesIssuedUponConversionOfCommonStockRightsPerAgreement>
    <us-gaap:SharePrice
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMjE5OTAyMzI3NTU3Nw_4a38cfa4-83f2-4874-9e61-51200271e541"
      unitRef="usdPerShare">1.40</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RleHRyZWdpb246ZDg3ZDRhMDFiOGRjNGE3NDg5MDI1ZmI4Y2NjMmQ5ZGFfMzI5ODUzNDg5Mjg3NA_2583c12c-b47d-4754-b9c1-07ccc9c3540c">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.222%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.598%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Loss attributable to Menlo&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.713%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.596%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.384%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.601%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;(Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;167,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;205,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(14,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Acceleration of stock based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:11.25pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total Adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(22,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMC0xLTEtMS0w_ecfb2dfe-6278-4c1f-8fc5-41f00fd7051e"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMi0zLTEtMS04ODQ_57d4f8a2-6b30-45c2-aae6-848297c07da7"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMS0xLTEtMS0w_33ec89ec-feed-4bea-b80c-50d2a945c506"
      unitRef="usd">7594000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjJhMDcwN2U1ZGYwOTQ2OTJiNWMzYzU1NGJiMzdmMDcyL3RhYmxlcmFuZ2U6MmEwNzA3ZTVkZjA5NDY5MmI1YzNjNTU0YmIzN2YwNzJfMy0zLTEtMS04ODQ_1c1222c9-75d6-4f5f-a22e-6b3a29030891"
      unitRef="usd">19637000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC0xLTEtMS0w_eaff48ce-f028-4b46-9f4c-d0617657730d"
      unitRef="usd">11688000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC0zLTEtMS0w_c5b943c9-a3df-4e54-b460-648a78aeae12"
      unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC01LTEtMS05MTQ_878877fb-79a2-40df-a420-cf6ca9ba0d2c"
      unitRef="usd">13438000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNC03LTEtMS05MjA_f8266b22-2430-4518-8818-76d95c962efa"
      unitRef="usd">308000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS0xLTEtMS0w_4b1aa1ea-be8e-4b6d-870e-33a44d468314"
      unitRef="usd">-167441000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS0zLTEtMS0w_c31c9a34-a443-4ec1-87bc-b50485d02cbc"
      unitRef="usd">-35470000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS01LTEtMS05MTQ_994d9ee2-ac35-47e5-b575-f7015b290892"
      unitRef="usd">-205082000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNS03LTEtMS05MjA_5545b34d-c8b4-4687-988a-a38c4c5f0757"
      unitRef="usd">-69547000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0xLTEtMS0w_00efbc47-6a95-4ee1-9b6f-ae31fc6b8a2e"
      unitRef="usdPerShare">-1.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0xLTEtMS0w_db871975-59b7-452c-adc1-d237a86eed99"
      unitRef="usdPerShare">-1.21</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0zLTEtMS0w_931feb25-2e91-4698-a1ad-086a8068c3e2"
      unitRef="usdPerShare">-0.59</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi0zLTEtMS0w_c0fc85fb-9c24-43ab-b96b-627ba1f0f2e8"
      unitRef="usdPerShare">-0.59</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi01LTEtMS05MTQ_4371620a-df7b-46d2-af03-e317e3df7c90"
      unitRef="usdPerShare">-1.23</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi01LTEtMS05MTQ_f5546d8b-4608-4444-9033-9d95bd9725cc"
      unitRef="usdPerShare">-1.23</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi03LTEtMS05MjA_088fea0f-db37-47ca-aa91-44e62b92ff06"
      unitRef="usdPerShare">-1.16</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfNi03LTEtMS05MjA_876c63de-d414-4fec-841f-8784ef44c92c"
      unitRef="usdPerShare">-1.16</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <mnlo:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS0xLTEtMS0w_a68d7209-fdc0-4281-a517-5c12594e6fe9"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaTransactionCosts>
    <mnlo:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS0zLTEtMS0w_a1ca1b47-4076-4668-88a5-164369f0034f"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaTransactionCosts>
    <mnlo:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS01LTEtMS05MTc_08c91356-daa5-4e63-af9d-9e18c2605336"
      unitRef="usd">14931000</mnlo:AdjustmentsToSupplementalProformaTransactionCosts>
    <mnlo:AdjustmentsToSupplementalProformaTransactionCosts
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfOS03LTEtMS05MjM_9025f69a-34c8-4c84-b0ef-0843cf0b10ba"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaTransactionCosts>
    <mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtMS0xLTEtMA_cd61a497-a4c5-4bfa-bfe8-a3cf00cfd36f"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtMy0xLTEtMA_0b9cfad0-583b-4598-b8a1-4511f10ab0f4"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtNS0xLTEtOTE3_70a49767-9da6-4bc7-a3bd-96d9a29a2736"
      unitRef="usd">7199000</mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTAtNy0xLTEtOTIz_52cdbc26-edad-4892-9ed5-c2dd572d31b7"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation>
    <mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtMS0xLTEtMA_b4dec2f2-3455-4925-bc79-9019020b0a91"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtMy0xLTEtMA_33da9087-6f40-44cb-9ee1-6ed023479af3"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtNS0xLTEtOTE3_65dbd3e5-6825-4460-aede-447da91ea6c0"
      unitRef="usd">22130000</mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80My9mcmFnOmQ4N2Q0YTAxYjhkYzRhNzQ4OTAyNWZiOGNjYzJkOWRhL3RhYmxlOjZiMDcxOWYzZGVlNzRhMGY4ZTcyMDExOGVmNTFhYWI3L3RhYmxlcmFuZ2U6NmIwNzE5ZjNkZWU3NGEwZjhlNzIwMTE4ZWY1MWFhYjdfMTEtNy0xLTEtOTIz_36b6bad2-5104-4a6d-8adc-0c8606e93ab4"
      unitRef="usd">0</mnlo:AdjustmentsToSupplementalProformaCombinedResultsOfOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMzI5ODUzNDg4OTkyNw_1eb5cef8-25da-469c-9d71-191f2e09fbdc">REVENUE RECOGNITION&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenues for the three and six months ended&#160;June&#160;30, 2020&#160;were generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020. The Company&#x2019;s customers include a limited number of national and select regional distributors. These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#x2019;s products, which occurs at a point in time, typically upon delivery of product to the distributors. For the three months ended June&#160;30, 2020,&#160;three&#160;distributors accounted for&#160;42%,&#160;43%&#160;and&#160;15%&#160;of product revenue, respectively.  For the six months ended June&#160;30, 2020, three distributors accounted for 46%, 39% and 14% of product revenue, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its distributors less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to Third-party Payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to Trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within Accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$5.9 million and $14.1 million for the three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Distribution Fees and Trade Discounts and Allowances: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Rebates, Chargebacks and Other Discounts: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#x2019;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product Returns: &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;he information utilized to estimate the returns provision includes: (i)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; historical industry information regarding rates for comparable pharmaceutical products and product portfolios&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;demand&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately 2% to 3% of product will be returned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commerical use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  The Company recorded $10.0 million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $1.0 million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Contract Assets and Contract Liabilities&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2020, as customer invoicing generally occurs before or at the time of revenue recognition. The Company has a $4.0 million receivable, recorded as an Other receivable on the consolidated balance sheet, due from Cutia as of June&#160;30, 2020 which is expected to be paid in Q3 2020.  The Company did not have any contract liabilities as of&#160;June&#160;30, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Sales Commissions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 90 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Royalty Revenues&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $0.2 million were recorded during the three and six months ending &lt;/span&gt;&lt;/div&gt;June&#160;30, 2020 and revenues in the amount of $0.3 million were recorded during the six months ending June&#160;30, 2019.  There was no revenue for the three months ending June&#160;30, 2019.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i739bb757f1734242959f7c1f7cabb3dd_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjY2_c9a70836-5f75-4265-b1b7-fb7aad65e226"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb0c3f02a2d0451fb10bb5af69b6fe95_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjcw_00411aae-afe7-4fb7-96e1-a70943348eed"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iabf481a0bc8d434eba2737a7b1854201_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNjc3_7097e093-139d-4cf2-aa95-3a63d8638bad"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb682629e2c14d16967faab5132bce3d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk0Mg_57786b6a-7d67-40e1-9977-05d7b03c6846"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7e9d51a1cbf04ecfa836c93c8fcf8b60_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk0OA_5a73bc98-093e-478b-b9a6-ec30c2e1fe60"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9d8a0654d2c844fab4d30cbe0f737b93_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0Nzk1NA_4f562df6-190e-4734-b889-fc60bce0471d"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTczNw_6c3ac3a2-0402-403e-8084-e471ca4e2b92"
      unitRef="usd">5900000</mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0ODExNQ_282e90a4-a9a3-46be-950e-42ffe82e8b9d"
      unitRef="usd">14100000</mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances>
    <mnlo:EstimateOfProductReturnRateMinimum
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNDgwNw_9a388891-be45-4f27-9a2b-2837e6990b25"
      unitRef="number">0.02</mnlo:EstimateOfProductReturnRateMinimum>
    <mnlo:EstimateOfProductReturnRateMaximum
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNDgxMw_f1016b7d-b165-4203-9238-066155186555"
      unitRef="number">0.03</mnlo:EstimateOfProductReturnRateMaximum>
    <mnlo:UpfrontRoyaltyReceipt
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQyNg_910f1773-7828-4b12-b782-31ea57993de2"
      unitRef="usd">10000000.0</mnlo:UpfrontRoyaltyReceipt>
    <mnlo:UpfrontRoyaltyReceipt
      contextRef="i5da754f4e94e4544b609a323172766eb_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQzOQ_cd9b39fb-d1f3-4add-b0f5-b80815c79e6c"
      unitRef="usd">6000000.0</mnlo:UpfrontRoyaltyReceipt>
    <mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTQ3NA_703f27fb-ee10-4e26-a607-b1da3c17d764"
      unitRef="usd">1000000.0</mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <mnlo:UpfrontRoyaltyReceipt
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTY4OQ_910f1773-7828-4b12-b782-31ea57993de2"
      unitRef="usd">10000000.0</mnlo:UpfrontRoyaltyReceipt>
    <mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents
      contextRef="i27310920890a449ca2694d53e047a675_D20200423-20200423"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ1MDYzMw_703f27fb-ee10-4e26-a607-b1da3c17d764"
      unitRef="usd">1000000.0</mnlo:AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0OTYyMw_b1224dab-42c5-44a3-8ca4-438aa39e9242"
      unitRef="usd">4000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0891f287b8734116af48e6399bfbfd3d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNTkyNA_1b5f8abb-b99d-4b05-851b-708db897fc9c"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99638830588b43439d03faa00fafb735_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfNTkyNA_5d659803-3394-4e5b-b0ce-887b24e793de"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i089aabffb9cc48838b8d41e4bf090998_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMTY0OTI2NzQ0ODE2MA_2a53de93-feb9-4fdf-84f5-4e2a67dc017d"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37f865286a5b4ce5a8f34c262f8b5bf0_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF80Ni9mcmFnOmU5MjkwZTIwZTRiNjQ4YjY5NjdlMjkyZjhiZmQ5MjU4L3RleHRyZWdpb246ZTkyOTBlMjBlNGI2NDhiNjk2N2UyOTJmOGJmZDkyNThfMzI5ODUzNDg4OTkzMA_8bfdff1c-7eb5-4b63-990d-b1d75dc8f5f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMzI5ODUzNDg4NTMyNQ_37d06a54-911d-43cc-8dc5-de13befe7a11">FAIR VALUE MEASUREMENT&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value as of June&#160;30, 2020 and December&#160;31, 2019, are classified in the tables below in one of the three categories described in note 2H above:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;margin-top:10pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.43pt;"&gt;The Company&#x2019;s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Foreign exchange risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Occasionally, the Company purchases and writes non-functional currency options in order to hedge the currency exposure on the Company&#x2019;s cash flow. The currency hedged items are denominated in New Israeli Shekels (&#x201c;NIS&#x201d;). The purchasing and writing of options is part of a comprehensive currency hedging strategy with respect to salary and rent expenses denominated in NIS. These transactions are at zero cost for periods of up to one year. The counterparties to the derivatives are major banks in Israel. As of June&#160;30, 2020, there were no hedged amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company has a lien in the amount of $0.3 million on the Company&#x2019;s marketable securities and a lien in the amount $0.3 million on the Company&#x2019;s checking account, in respect of bank guarantees granted in order to secure the hedging transactions.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMzI5ODUzNDg4NTMyNg_d6b939a4-361f-47bc-9d9b-9a7f520fa8c2">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value as of June&#160;30, 2020 and December&#160;31, 2019, are classified in the tables below in one of the three categories described in note 2H above:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:48.879%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.730%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.732%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:-9pt;padding-left:27pt;margin-top:10pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.43pt;"&gt;The Company&#x2019;s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:MarketableSecurities
      contextRef="iddecf24382d740b79c3744ff4ae84e96_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi0xLTEtMS0w_cd240e08-ec63-42a2-a2aa-4c113fc76394"
      unitRef="usd">591000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i35eb5a8b86fc4928a2d78dfe2c2b62c4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi0zLTEtMS0w_d524fe1e-af66-46d4-83b8-5da711a97f11"
      unitRef="usd">2018000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i4b5c2e12f42a4c42ab17af5707fd15c0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi01LTEtMS0w_e553af2c-1a58-4d43-a335-4c5dcdf38d21"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOjIyMzAzZTE4ODkwODRmOWY4ZTZmMWY1ZDQ5YzUzOGNlL3RhYmxlcmFuZ2U6MjIzMDNlMTg4OTA4NGY5ZjhlNmYxZjVkNDljNTM4Y2VfMi03LTEtMS0w_06c60e39-1853-428c-af44-0044721ba472"
      unitRef="usd">2609000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="iedfd359d21884ac0b9588367562b5816_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi0xLTEtMS0w_1ba2487f-5679-45c5-826e-fee425e1e303"
      unitRef="usd">1020000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i3c8222d051b543688377451564f533a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi0zLTEtMS0w_7179d168-ff6f-4dac-a5dc-2f690e9a4e41"
      unitRef="usd">15660000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i186f34938c484be6bd6c29ddc7b7009a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi01LTEtMS0w_4107a23b-1841-47c4-be4d-2a4ce5fc9f92"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RhYmxlOmVhOWUxZGJmMDA4NDRmZDZhNTM1ZWNiOWY2YzA3YTdlL3RhYmxlcmFuZ2U6ZWE5ZTFkYmYwMDg0NGZkNmE1MzVlY2I5ZjZjMDdhN2VfMi03LTEtMS0w_f2d08734-e262-4e69-ac31-dd71e30cd6f5"
      unitRef="usd">16680000</us-gaap:MarketableSecurities>
    <mnlo:DerivateCostsForYear
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTYyMQ_677ed6db-e1d2-4a58-9121-1125281e080e"
      unitRef="usd">0</mnlo:DerivateCostsForYear>
    <mnlo:DerivativeMaximumTermOfContract
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTY1MA_091b7a82-bad0-4b0b-b1e9-5f51c01c46e0">P1Y</mnlo:DerivativeMaximumTermOfContract>
    <us-gaap:DerivativeAmountOfHedgedItem
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTc0MA_c5eb6aed-c7ee-409b-9846-6eb8dfd097ca"
      unitRef="usd">0</us-gaap:DerivativeAmountOfHedgedItem>
    <mnlo:ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTgwOQ_8a6d95e5-7f05-4342-9b09-cb68062c3b04"
      unitRef="usd">300000</mnlo:ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions>
    <mnlo:ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81Mi9mcmFnOmU1ODQxMTVmNDc1NTQ4OWZiYTJhZTFlMjE5NWM4ZTE3L3RleHRyZWdpb246ZTU4NDExNWY0NzU1NDg5ZmJhMmFlMWUyMTk1YzhlMTdfMTg3Ng_845f067c-0e12-4749-be73-bd3fc87a0520"
      unitRef="usd">300000</mnlo:ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5Nw_2280c990-3c99-4b55-8233-379dd88464b2">MARKETABLE SECURITIES&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Marketable securities as of June&#160;30, 2020, and December&#160;31, 2019 consist mainly of debt and mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the consolidated statement of operations as finance income or expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through finance (income) expense in the condensed consolidated statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Israeli mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019 the fair value, cost and gross unrealized holding gains and losses of the debt marketable securities owned by the Company were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost or&lt;br/&gt;amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost or&lt;br/&gt;amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Government and agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has considered factors regarding other than temporary impaired securities and determined that there are no securities with impairment that is other than temporary as of June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, and December&#160;31, 2019 all of the Company&#x2019;s debt securities were due within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020 and June&#160;30, 2019 the Company received aggregate proceeds of $36.4 million&#160;and $33.0 million, respectively, upon sale and maturity of marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, and December&#160;31, 2019, the Company&#x2019;s restricted marketable securities were $0.4 million and $0.4 million, respectively, due to a lien in respect of bank guarantees granted to secure hedging transaction and the Company&#x2019;s rent agreements. See &#x201c;Note 5- Fair Value Measurement&#x201d; and &#x201c;Note 10-Operating Lease&#x201d; for more information.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5OQ_e9a12c17-26f7-41d4-812a-8705cb147455">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s marketable securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Israeli mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="ia23a57fa3ccf4cc3b6bcee3e98135a78_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMi0xLTEtMS0w_91def9f3-44a3-4410-ad79-16644d4af0c3"
      unitRef="usd">591000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i264f53d270b5492d9f34a2d7a650ab3f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMi0zLTEtMS0w_fb038296-7684-48df-8d7e-55e7fde9946a"
      unitRef="usd">1020000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i1a6fc18eac5e4db28a62b77aad463b0d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMy0xLTEtMS0w_1e980cb7-6016-4e85-8508-771f003aae80"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfMy0zLTEtMS0w_739009a8-6473-4019-a5bf-70bc0d801b78"
      unitRef="usd">151000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i28c5efb4fbad4902aaac65636b3fac52_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNC0xLTEtMS0w_db7b8850-1e8e-45ed-aa49-b7475b3e76dd"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNC0zLTEtMS0w_40bdf437-5b34-4e5f-a5ff-781f0c345150"
      unitRef="usd">6031000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i4cfa5ee44fb64997893890be476e59ae_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNS0xLTEtMS0w_ca6f2754-5c24-45f5-8b2e-214ffbab03d7"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ic5885b910649487099b87fd418a15dde_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNS0zLTEtMS0w_9cedbf76-2b11-4f83-b396-535f1acf8dee"
      unitRef="usd">9478000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNi0xLTEtMS0w_eff80422-4977-4ecd-9e4b-d70966a58ecb"
      unitRef="usd">2018000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="ie41f84f7e3ef4b8a9a94c1a9b121dd36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfNi0zLTEtMS0w_35bf890c-bcfe-4d51-b167-bc166f94e0aa"
      unitRef="usd">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfOC0xLTEtMS0w_a22136d9-316d-476d-8727-c878459a2913"
      unitRef="usd">2609000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjE0ZTQ2NTk0ZjhjNjQ5ZGU5ZWFmMDk4ZDk1N2MzNjFlL3RhYmxlcmFuZ2U6MTRlNDY1OTRmOGM2NDlkZTllYWYwOThkOTU3YzM2MWVfOC0zLTEtMS0w_c966c1fa-a70a-4027-a168-6b00ebe260d5"
      unitRef="usd">16680000</us-gaap:ShortTermInvestments>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMzI5ODUzNDg4NTA5OA_4ed95268-2167-4ea1-9f5b-1b88ebba12af">As of June&#160;30, 2020 and December&#160;31, 2019 the fair value, cost and gross unrealized holding gains and losses of the debt marketable securities owned by the Company were as follows:&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost or&lt;br/&gt;amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost or&lt;br/&gt;amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;holding gains&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Government and agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S Treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC0xLTEtMS0w_3bfa09c9-2441-4d1c-bcc2-ef2cbdc29499"
      unitRef="usd">2018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC0zLTEtMS0w_70c187f1-366d-4e23-9ab7-321690871e95"
      unitRef="usd">2018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC01LTEtMS0w_83e40342-4a07-4ba4-aefc-52f309d0d2a0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i72d53f792aa942e79e0908f016e0b6ac_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNC03LTEtMS0w_5daeb245-0ebd-42c9-97c0-760340578799"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi0xLTEtMS0w_46961107-882a-4b59-8bcb-8b0b08527b47"
      unitRef="usd">2018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi0zLTEtMS0w_d767b5b1-1812-4e30-b637-d3e3b71a77ae"
      unitRef="usd">2018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi01LTEtMS0w_9ff283ba-0e67-4a20-aa13-e0e4de5820ab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOjI0OTVjYjQzOWFkNjRjNTM4MTdhNGIyYjViNTM4YzNhL3RhYmxlcmFuZ2U6MjQ5NWNiNDM5YWQ2NGM1MzgxN2E0YjJiNWI1MzhjM2FfNi03LTEtMS0w_6a8ffe94-b58b-46ed-a5b5-91406d740a2f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi0xLTEtMS0w_2ec267d3-562f-486e-93b7-5d9da81ce818"
      unitRef="usd">151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi0zLTEtMS0w_acaee44b-5e28-41d5-be4f-e98421593b52"
      unitRef="usd">151000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi01LTEtMS0w_0ece2099-e9fa-4e4f-b0ab-417ffbe6cf39"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01876072bcc04580b5f7c62f8637951e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMi03LTEtMS0w_435c8558-31ea-40fa-b395-062fbbe698a6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy0xLTEtMS0w_28e69f8b-40fe-4d1a-a6e2-62d4d42b519a"
      unitRef="usd">6031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy0zLTEtMS0w_f9e647c4-daa0-48f5-a389-fd79d3a069da"
      unitRef="usd">6030000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy01LTEtMS0w_cd9a7913-067e-4782-a171-0bf832741669"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if1f69ab2ddf8408a8224f655bbd15be5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfMy03LTEtMS0w_50c40c03-5e9d-4c8b-9ba0-eaf142fd4228"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5885b910649487099b87fd418a15dde_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC0xLTEtMS0w_5b01188f-65c7-4d27-99eb-e0d8706e7147"
      unitRef="usd">9478000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5885b910649487099b87fd418a15dde_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC0zLTEtMS0w_5c94db83-682f-4ace-8ae8-a0fd29815aec"
      unitRef="usd">9475000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5885b910649487099b87fd418a15dde_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC01LTEtMS0w_fecc2c18-30ce-45ed-bea8-9c1dab1cb84c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5885b910649487099b87fd418a15dde_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNC03LTEtMS0w_b60d6234-3e77-42f8-b4c8-83da086935fb"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS0xLTEtMS0w_4f4ae819-0505-4a97-8190-4bdafd80cea8"
      unitRef="usd">15660000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS0zLTEtMS0w_d7a596f7-1467-4694-9226-1736fb969814"
      unitRef="usd">15656000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS01LTEtMS0w_d0a50130-d2e7-4487-9593-228f678ec834"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RhYmxlOmIzYzYxNmFlYzcyODQ2MmRhMjI0YzA4YjVmNDBlNzI4L3RhYmxlcmFuZ2U6YjNjNjE2YWVjNzI4NDYyZGEyMjRjMDhiNWY0MGU3MjhfNS03LTEtMS0w_b59221c6-a6a0-4949-a025-36a268d8700b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i621dc5363bfa40e3ab7836027e3273ea_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTE2Mw_1514914c-10cc-424c-bb97-0afdb3dab103"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTE2Mw_919b4644-66b4-4eac-a479-4ee50ec30624"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTM5Mw_f1cb602d-2a1d-4413-ad89-928c17a43593"
      unitRef="usd">36400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTQwMA_c127f30e-6ffd-44e5-82c7-f76d876cfdb8"
      unitRef="usd">33000000.0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:RestrictedInvestments
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTUzNw_f09e9b1f-d878-404f-b67f-e5d6b447fdad"
      unitRef="usd">400000</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF81NS9mcmFnOjQzNTM1YTlkYzY5NDRjZDlhZDZlZDljMDA4OGUxY2RjL3RleHRyZWdpb246NDM1MzVhOWRjNjk0NGNkOWFkNmVkOWMwMDg4ZTFjZGNfMTU0NA_738402de-16d1-4ee2-a953-6617e00df7f9"
      unitRef="usd">400000</us-gaap:RestrictedInvestments>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfMzI5ODUzNDg4NDIzNA_d6b05385-a1d4-40c2-bf32-39cf8a3c48e1">INVENTORY&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ upon FDA approval of AMZEEQ on October 18, 2019 and ZILXI on May 29, 2020. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were no inventory write-downs during the three and six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s inventory:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfNzkx_0e720d7c-ad2e-462b-8468-1f4b24eba076"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfNzkx_fca2e9f6-9805-4f95-b82f-846b0c9f9133"
      unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RleHRyZWdpb246ZjRlMTJiY2U2ZDI4NDhjMjg5MDk1MWJhNDI2NzBlNGNfMzI5ODUzNDg4NDIzNQ_ad06f4d2-1cee-4f5c-8849-dd8b6a5b2242">&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth the Company&#x2019;s inventory:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMi0xLTEtMS0w_ee66dcfa-283b-4200-a105-7d8089570ff4"
      unitRef="usd">3387000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMi0zLTEtMS0w_40e0a54d-6090-48ff-b471-5bc1db46c595"
      unitRef="usd">500000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMy0xLTEtMS0w_5495b1f0-2be0-40bb-8d21-ade48de017e5"
      unitRef="usd">954000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfMy0zLTEtMS0w_e03b2c8e-13df-484e-8809-a986c120a143"
      unitRef="usd">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNC0xLTEtMS0w_c1fd5920-63d8-4460-8d52-80f297e8b0bb"
      unitRef="usd">1460000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNC0zLTEtMS0w_14f4bc7d-af36-4a58-a1a5-f287d6c0bba5"
      unitRef="usd">856000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNS0xLTEtMS0w_71cb593b-fa32-408e-8f4f-9920f5b59620"
      unitRef="usd">5801000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82MS9mcmFnOmY0ZTEyYmNlNmQyODQ4YzI4OTA5NTFiYTQyNjcwZTRjL3RhYmxlOjgwZGVmZjM4MjRhZTRkMGE5NWIwODM1YmI5MTM4YTA4L3RhYmxlcmFuZ2U6ODBkZWZmMzgyNGFlNGQwYTk1YjA4MzViYjkxMzhhMDhfNS0zLTEtMS0w_982194ff-46b0-4fc7-b7be-7e5755620505"
      unitRef="usd">1356000</us-gaap:InventoryGross>
    <us-gaap:LongTermDebtTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzI5ODUzNDg5MDEyOQ_57575bf5-be11-43dc-a04b-72220e24da0d">LONG-TERM DEBTOn July 29, 2019 (the &#x201c;Closing Date&#x201d;) the Company secured up to $50 million in debt under a credit agreement &#x201c;the Credit Agreement&#x201d;) from two of its current shareholders, who are considered related parties (the &#x201c;lenders&#x201d;) and entered into a Securities Purchase Agreement with one of the lenders for gross proceeds of approximately&#160;$14 million, before deducting offering expenses (see &#x201c;Note 9- Share Capital&#x201d; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (the &#x201c;Amended and Restated Credit Agreement&#x201d;), whereby the Company has guaranteed the indebtedness obligation of Foamix Pharmaceuticals Inc. and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. The Amended and Restated Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $50.0 million, of which $35.0 million was drawn as June&#160;30, 2020 and December&#160;31, 2019.&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Amended and Restated Credit Agreement, the debt comprises of three tranches: (a) $15 million funded at closing (the &#x201c;Tranche 1 Loan&#x201d;), (b) $20 million funded on December 17, 2019 (the &#x201c;Tranche 2 Loan&#x201d;) and (c) up to $15 million available after the closing date and prior to September 30, 2020 (the &#x201c;Tranche 3 Loan&#x201d;). The Tranche 2 Loan was borrowed following the FDA&#x2019;s approval of the Company&#x2019;s NDA for AMZEEQ (formerly known as FMX101) and listing of AMZEEQ in the FDA&#x2019;s &#x201c;Orange Book,&#x201d; in addition to maintaining its arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company shall be permitted to borrow the Tranche 3 Loan only following the achievement of certain revenue targets prior to September 30, 2020. Subject to any acceleration as provided in the Credit Agreement, including upon an event of default (as defined in the Amended and Restated Credit Agreement), the credit facility will mature on July 29, 2024 and bear interest equal to the sum of (A) 8.25% (subject to increase in accordance with the terms of the Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) 2.75%. A fee in an amount equal to 1.0% of the aggregate principal amount of all loans made on any given borrowing date shall be payable to the lenders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Amended and Restated Credit Agreement contains certain financial covenants, including that the Company at all times after the date of FDA approval of AMZEEQ maintain a minimum aggregate compensating cash balance of $2.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, as a result of the negative impact on the Company's product sales of AMZEEQ due to the COVID-19 pandemic, the parties entered into Amendment No. 1 to Amended and Restated Credit Agreement (the "Amendment") on August&#160;5, 2020.  The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $6.0&#160;million for the fiscal quarter ending December 31, 2020 to $97.0&#160;million for the fiscal quarter ending June 30, 2024. The Amendment does not modify any of the conditions precedent to borrowing the Tranche 3 Loan, as described above and as set forth in the Amended and Restated Credit Agreement. See "Note 12 - Subsequent Events."&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company is in compliance with all covenants, including&#160;maintaining a minimum aggregate compensating cash balance as mentioned above. In the event where the Company fails to observe or perform any of the financial covenants the lenders may, by notice to the Company, declare the Term Loans then outstanding to be due and payable in whole, together with accrued interest and a Prepayment Premium (as defined in the Amended and Restated Credit Agreement ). Additionally, the Company will continue to monitor ongoing developments in connection with the COVID-19 pandemic, which may have an adverse impact on the Company&#x2019;s commercial prospects, projected cash position and ability to remain in compliance with these covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the Amended and Restated Credit Agreement, there are no required payments of principal amounts until July 2023. Afterwards, the Company will pay 1.5% of the aggregate principal amount each month. The outstanding amount will be paid in full on July 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, on the Closing Date, Foamix issued to the lenders warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, at an exercise price of $2.09 per share (the &#x201c;Warrant&#x201d;), which represents the five-day volume weighted average price of the ordinary shares as of the trading day immediately prior to the Closing Date. Following the Merger, the Warrants were exchanged, based on the Exchange Ratio, to 651,640 of the Company&#x2019;s common stock, and adjusted the exercise price to $3.53 (See &#x201c;Note 3 &#x2013; Business Combinations&#x201d; for more information relating to subsequent adjustment of warrant following the Menlo&#x2019;s Phase III PN Trials (study MTI-105 and study MTI-106)). Payment of the exercise price will be made, at the option of the lender, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company incurred offering expenses of $1.1 million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $0.3 million from the borrowing of Tranche 2 Loan, allocated only to the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the debt as of June&#160;30, 2020 was $35.8 million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended June&#160;30, 2020 the company recorded interest expense of $1.0 million and $0.1 million relating to the interest and discount cost, respectively.  During the six months ended June&#160;30, 2020 the company recorded interest expense of $1.9 million and $0.2 million relating to the interest and discount cost, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i11306223e6aa4bbc98552eff8183e5d6_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTM_d3d0b123-1d40-4714-bb0b-b586f065a801"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mnlo:NumberOfLenders
      contextRef="i11306223e6aa4bbc98552eff8183e5d6_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTU4_0fed430e-0c1e-4fc4-b49b-ada8dd560d5e"
      unitRef="shareholders">2</mnlo:NumberOfLenders>
    <mnlo:NumberOfLenders
      contextRef="ia3617748d41e46a8bfedb32f0d650a74_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjk1_fd9c05d2-7bfb-45c0-adfe-f25b49ee49d2"
      unitRef="lenders">1</mnlo:NumberOfLenders>
    <mnlo:GrossProceedsFromIssuanceOfCommonStock
      contextRef="ia3617748d41e46a8bfedb32f0d650a74_I20190729"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzQ5_3c31506f-e296-425f-bdb3-661092292579"
      unitRef="usd">14000000</mnlo:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTM4_d0fa313b-1936-4405-baa4-84e02fa00221"
      unitRef="usd">50000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i423fa226d79249718ae35ed0e4fd377b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTUx_47001ef9-a936-42d5-95fc-9eeedfc83302"
      unitRef="usd">35000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5f85dcc728e248d98e63a19af7ced4ed_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfOTUx_b2d1562e-cb94-4c62-bc24-5115ed67c79f"
      unitRef="usd">35000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <mnlo:CreditAgreementNumberOfTrenches
      contextRef="i4fa0d91fe20746dc801522cdb641699a_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTA0NQ_7ddb72d7-583d-4907-a3f8-22901787a165"
      unitRef="tranches">3</mnlo:CreditAgreementNumberOfTrenches>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie8232e19d10a4519b9a3cd10a5721fb1_I20190729"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTA2Mg_8ab33199-4fa9-461a-b02f-136b85c3af6f"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5a65c85354904beda1b2323ac7ec07cd_I20191217"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTExMQ_eff5b049-aa63-4410-b8e3-85d6fd2d875a"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1adb6f4952624c32ba9efdccfaadf065_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTE3OQ_5c756295-10cb-4ca0-bdcc-5b2762f1c1ce"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a4fdb7ec32d4aae957110a79e0ef694_I20200309"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTkyNQ_1a1d2dc8-f84b-43d9-a341-d65322e03496"
      unitRef="number">0.0825</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i52154cb6d81246b2b19b393816177d95_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjI2NA_cfc66aeb-309c-419c-99e7-eb5e0ad86722"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mnlo:DebtInstrumentFeePercent
      contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjI5Ng_60cefc3b-eef0-488f-9785-8331e84e6c1f"
      unitRef="number">0.010</mnlo:DebtInstrumentFeePercent>
    <mnlo:MinimumAggregateCashBalanceMaintainAfterFdaApproval
      contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjYzNQ_1238df28-3fdb-4427-a618-a8947b26c5d1"
      unitRef="usd">2500000</mnlo:MinimumAggregateCashBalanceMaintainAfterFdaApproval>
    <mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance
      contextRef="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfODc5NjA5MzAzMzY2OA_2e865583-c280-4795-9b0d-4ebea3d1eacc"
      unitRef="usd">6000000.0</mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance>
    <mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance
      contextRef="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfODc5NjA5MzAzMzY4Mw_447a96dd-08e4-482b-9bfb-3ad85f7df572"
      unitRef="usd">97000000.0</mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance>
    <mnlo:DebtInstrumentPeriodicPaymentPrincipalPercent
      contextRef="id7a8db7397904657874b01bbee72d568_D20200309-20200309"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMzg2MQ_7f8a5a18-9090-4379-a45d-c472cd377193"
      unitRef="number">0.015</mnlo:DebtInstrumentPeriodicPaymentPrincipalPercent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDA3NA_0884f7a6-846a-492c-a690-9f0ce41a49c7"
      unitRef="shares">1100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id942c8a7476f4e9c8b7d92fc820c5fc1_I20200309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDEyNQ_32df1a99-bd59-4d8a-b064-156183f4ce56"
      unitRef="usdPerShare">2.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mnlo:StockIssuedDuringPeriodSharesWarrantExchange
      contextRef="i4294414ce48b417a90b94bbd93daf454_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDM4Mg_368fb410-b2b9-4df2-af2d-d31e6c35a022"
      unitRef="shares">651640</mnlo:StockIssuedDuringPeriodSharesWarrantExchange>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i665aac50c21e4c9382a4dedf21e3a6d4_I20200309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNDQ1MQ_72543965-483e-4ce9-b704-cc0f353d0af3"
      unitRef="usdPerShare">3.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="idec71e92949949a9a5cbf85570f5b1c2_D20190729-20190729"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjE5OTAyMzI2MjU5Ng_3fcfb49d-9e5d-41dd-ad39-f38433078c6a"
      unitRef="usd">1100000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="iea4fd37970a64213b591edc27d8201a8_D20190729-20190729"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMjE5OTAyMzI2MjYwMw_d3a71eb3-51b2-49db-9f56-8780e4047218"
      unitRef="usd">300000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i647408d71ea94b9aacbdfd5eea1f5f10_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjAxNw_04fb88d9-1d8c-4800-baff-c699498b6b23"
      unitRef="usd">35800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InterestExpenseDebt
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjQwNA_020b5a65-b9a5-4d47-b259-35536f0fa575"
      unitRef="usd">1000000.0</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfNjQxMQ_ab425486-8edf-4097-ac81-1206ef21e672"
      unitRef="usd">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTY0OTI2NzQ0ODQ2MA_bd07ce7b-af38-40ec-bd1f-084c55e6be83"
      unitRef="usd">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF82NC9mcmFnOmU0NGQzMTM5YWExYTQ3NmZhYTBjZWY4M2Y0YzIyMmU1L3RleHRyZWdpb246ZTQ0ZDMxMzlhYTFhNDc2ZmFhMGNlZjgzZjRjMjIyZTVfMTY0OTI2NzQ0ODQ2Mw_6263c2b1-9663-48a0-b448-0ae13879ab21"
      unitRef="usd">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1MQ_63be8717-a057-475b-9175-0c0e832d8797">SHARE CAPITAL&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue 20,000,000 of shares of $0.0001 par value preferred stock.  There were no shares of preferred stock issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company&#x2019;s Certificate of Incorporation, as amended, authorizes the Company to issue 300,000,000 shares of $0.0001 par value common stock. See Note 12&#x2014;Subsequent Events. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Issuance of stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 29, 2019, pursuant to the Credit Agreement and Securities Purchase Agreement, Foamix issued and sold, in a registered offering, an aggregate of 6,542,057 ordinary shares at a purchase price of $2.14 per share, later exchanged to 3,875,514 Menlo common stock at the closing of the Merger. The aggregate gross proceeds of approximately&#160;$14 million, before deducting issuance costs allocated as described in Note 8-Long Term Debt, in the amount of $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the completion of the merger, on March 9, 2020, the Company issued 36,550,335 shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued 74,544,413 shares to Foamix shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On June 9, 2020, the Company completed an underwritten public offering of 31,107,500 shares of common stock at a price to the public of $1.85 per share.  The net proceeds of the offering were approximately $53.6&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition to the Credit Agreement signed on July 29, 2019, on the Closing Date, Foamix issued to the lender Warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, later exchanged to 1,980,660 of Menlo&#x2019;s common stock. Upon the closing of the Merger, each Warrant received one CSR as described in Note 3- Business Combinations.  The warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants&#x2019; expiration date, if in the money.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR, was accounted for as a modification, by analogy, from the modification&#x2019;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;significant. Therefore, the incremental fair value, in the amount of $41,000, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Equity incentive plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon closing of the Merger, the company adopted Foamix&#x2019;s 2019 Equity incentive plan (the &#x201c;2019 Plan&#x201d;). As of June&#160;30, 2020, 2,849,843 shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan"), effective January 2018.  Pursuant to the terms of the 2018 Plan in January 2020, the 2018 share reserve automatically increased by 976,105 shares of common stock issuable.  As of June&#160;30, 2020, 2,184,769 shares remain issuable under the 2018 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Employee Share Purchase Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon closing of the Merger, the company adopted Foamix&#x2019;s ESPP pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#x2019;s common stock at a price equal to&#160;85%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#x201c;Purchase Period&#x201d;). Employees are permitted to purchase the number of shares purchasable with up to 15% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, 9,371,258 shares remain available for grant under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June&#160;30, 2020, 61,031 Foamix ordinary shares, later exchanged to 109,892 Menlo common stock, were issued to the employees.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Options and RSUs granted to employees and directors:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the six months ended June&#160;30, 2020 and 2019, the Company granted options and RSU as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,782,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.95-$3.13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,589,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,299,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.48-$2.12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;748,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* All amounts and exercise prices for pre-Merge grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2020, and the six months ended June&#160;30, 2019 was $11.4 million and $3.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of RSUs granted is based on the share price on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended&lt;br/&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;60.44%-69.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;60.40%-61.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;0.44%-1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;2.20%-2.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged to stock options and RSUs of Menlo&#x2019;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation expense of $60,000 related to the modification in the consolidated statement of operations for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $9.3 million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2020 there is $6.6 million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next 2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Awards granted to options and RSU holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $1.6 million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $0.6 million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $0.5 million and $1.0 million for the three and six months ended June&#160;30, 2020, respectively.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkxOA_8caa43d5-2457-4234-80bc-26b519bbc54c"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyMQ_0f80e21f-927d-486b-ba97-06cde5000f22"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_0cb3014e-1bdb-4858-962c-4a69bab4fd65"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i52ef5e665bd14d8f848bbea621063a27_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_8d03870f-13ce-4a83-a67a-e6a77a66cb78"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_cc73ac65-dd44-4225-ac8c-12e72c7cc760"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkyNQ_ffae20a6-f5d6-4f49-ad1c-8b8ea209b12d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkzMA_c86908fe-a6a2-4771-b918-9c8205f78b16"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1NDkzMw_d333f4a7-5fa7-4809-b5e2-bce04a27c14d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <mnlo:CommonStockVotingRightsNumberPerShare
      contextRef="ib820da2007bf41dba9549a9c8a93db1f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjIx_1661528c-e013-40f1-92ed-16b6ea77d2e7"
      unitRef="votes">1</mnlo:CommonStockVotingRightsNumberPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i21624033d4ac4fff8c601a26fb4f4cd2_D20190729-20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzA0_68d6531d-88a3-4db0-87cc-6eb0d3113b4a"
      unitRef="shares">6542057</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia8c8813e111447bda5117bdf5d6a2b26_I20190729"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzQ2_1d7835fe-5f79-477d-8dbf-15028a96d4bb"
      unitRef="usdPerShare">2.14</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib45c461b63af4f079fa025d92a11ec36_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNzc5_546eefbc-aeea-499f-9c05-1d85e3a65cfa"
      unitRef="shares">3875514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mnlo:GrossProceedsFromIssuanceOfCommonStock
      contextRef="ie7a4e94dab8049848e6d72417f3fbe51_I20190729"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc3_5e421b37-dcc8-4497-832c-d5388d9856de"
      unitRef="usd">14000000</mnlo:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2Nzc5Ng_65e32596-fcce-44b3-9c6b-64a51ed28111"
      unitRef="usd">300000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i7d9ecc3914e54a259847aa543d67e621_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTA2Mg_61ddbe4d-59b1-4d4d-96c6-ef05e5bdbfed"
      unitRef="shares">36550335</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTUxNQ_34c061ff-8c98-4f0e-9206-c2c53be903e6"
      unitRef="shares">74544413</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTQ3Nw_ac32a22b-1fae-4bb1-a45e-d0b70b2e6260"
      unitRef="shares">31107500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i92c1d7c7352a4dca951e1bcd7cb06a55_I20200609"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTQ4NA_858eb7c0-f47c-448e-910d-33b9a6ab41e8"
      unitRef="usdPerShare">1.85</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i217eb440f9434ffd9faa963e5a512f7b_D20200609-20200609"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ0OTUwMA_2ad1c81c-7476-4441-ad24-bf0a35c1bae4"
      unitRef="usd">53600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="if23f7b87177b47a08e6248caeff2b802_I20190729"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTM4NQ_50ba926e-89cd-469d-a4d9-2859aac9084d"
      unitRef="shares">1100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <mnlo:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i0cd250813f00419fbd2e80392e7e0172_D20190729-20190729"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MzQ2Nw_19327b57-0f09-4582-9827-68eca8431876"
      unitRef="shares">1980660</mnlo:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mnlo:BusinessAcquisitionContingentStockRightIssued
      contextRef="id8d2dac9a2a445dfae26312379d3050b_I20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTUxMw_8ac93b06-75a4-4a8e-9d0b-0661234f6593"
      unitRef="number">1</mnlo:BusinessAcquisitionContingentStockRightIssued>
    <mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification
      contextRef="i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjQ4MQ_fafe58b1-8380-4af1-9667-df8b86bc9de6"
      unitRef="usd">41000</mnlo:DeemedDividendToWarrantsHoldersDueToWarrantModification>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i70cb25f8075540d79ea2d6581691f94f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjc5MA_0af3b215-4b56-4427-963a-d55501d48e95"
      unitRef="shares">2849843</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <mnlo:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance
      contextRef="idd59a6ce5690423f839a46a944f522ff_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mzc2NQ_7d81b57d-080a-459f-af76-7d12446db0a6"
      unitRef="shares">976105</mnlo:CommonStockIncreaseInCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="idd59a6ce5690423f839a46a944f522ff_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MzMzMA_8a546b82-1d9f-42ac-9b2e-496ff3fc1669"
      unitRef="shares">2184769</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i0047714113804cad9c16bdab5627a1ea_D20200309-20200309"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzE4OA_b0db36d0-8604-41fd-b720-0db0324a2aef"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i6e7afa2c35824eb99e24ca41f2a6b35f_I20200309"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzQxNw_db21f971-f8bc-4b23-af74-f7cb4c5a3644"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5244e3d9cde04b82806e7986585ce214_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzY0MA_c173db2a-9915-4d0a-9c13-d9011432fe8c"
      unitRef="shares">9371258</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic1ae53396f194b79aee91b06e1fcfc53_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzcyNA_a488c109-9f5d-4462-820e-3380d2b4dff4"
      unitRef="shares">61031</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i128638d8b51d4c5e8740fccfe8bb54e9_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzc3MA_7cad30f7-e39c-4e63-8f1f-bccdece8510e"
      unitRef="shares">109892</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1MA_bc6811f9-d134-49b0-aef5-5784919d43ff">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the six months ended June&#160;30, 2020 and 2019, the Company granted options and RSU as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,782,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.95-$3.13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,589,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.088%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.676%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.679%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Award&lt;br/&gt;amount*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercise price&lt;br/&gt;range*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vesting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employees and Directors:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,299,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;$1.48-$2.12&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;748,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;1 year -4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;* All amounts and exercise prices for pre-Merge grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.&lt;/span&gt;&lt;/div&gt;</mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0xLTEtMS0w_f1b0e662-2e7d-48c1-9e38-6fab129125be"
      unitRef="shares">4782444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0zLTEtMS0zODU0L3RleHRyZWdpb246YTY5NTkxNzA4MjA2NGNhZjhjOWVmYzYxMjc3YmU4YTNfMTY0OTI2NzQ0MTY4NA_30769427-b4ef-4a08-9b1a-dc018a188b87"
      unitRef="usdPerShare">1.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy0zLTEtMS0zODU0L3RleHRyZWdpb246YTY5NTkxNzA4MjA2NGNhZjhjOWVmYzYxMjc3YmU4YTNfMTY0OTI2NzQ0MTY5MQ_fa85eb9e-a193-4e5c-b4f8-fb73f8e476af"
      unitRef="usdPerShare">3.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iacf13670f3fa4285a1f4d963e62abc74_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy01LTEtMS0zODU3L3RleHRyZWdpb246Njc1MTMxNWUzOGY4NGQxOWI3MDVkODI4Y2QxYzYwMDhfMTY0OTI2NzQ0MTY4OQ_ff4ea2fe-6d84-4ff5-96ca-809ec3d7982a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2de299f068754a7abc7d85f9a74d1a52_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy01LTEtMS0zODU3L3RleHRyZWdpb246Njc1MTMxNWUzOGY4NGQxOWI3MDVkODI4Y2QxYzYwMDhfMTY0OTI2NzQ0MTY5OA_43404f3b-31ba-4c9a-94d6-204f1276536f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfMy03LTEtMS0w_3fb1f8cf-bf07-415f-b514-0e062d841fcb">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i52fdbbba6e7d4d6c8f6192df59a0b3e1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC0xLTEtMS0w_2c357bce-335d-461f-b814-827bf1ad7541"
      unitRef="shares">2589710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i158cc30187ca4219a42536fd98d5fdbd_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC01LTEtMS0zODYxL3RleHRyZWdpb246MmRhYjhiNmE3MjkwNGNhNzg4OWZlZGY0MWM0Y2E1NzRfMTY0OTI2NzQ0MTY4OQ_6fb92a5c-fdbd-45ea-81f8-d298bcb44701">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iea7da630ee23404cb0c42917365732be_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjk3ZWZmNzU2YWM4MzRlY2FiYzg0YmE5MjYyNzY4ZDZmL3RhYmxlcmFuZ2U6OTdlZmY3NTZhYzgzNGVjYWJjODRiYTkyNjI3NjhkNmZfNC01LTEtMS0zODYxL3RleHRyZWdpb246MmRhYjhiNmE3MjkwNGNhNzg4OWZlZGY0MWM0Y2E1NzRfMTY0OTI2NzQ0MTY5OA_08a7b6fd-ad9a-4880-a202-b5117ba986b3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0xLTEtMS0w_ae286b22-f206-4d4c-bc9a-1bb3cab56a47"
      unitRef="shares">2299899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0zLTEtMS0xMjA2L3RleHRyZWdpb246YmQyNDM3ODAzNmIxNGEzZjkyMDQ3NWIyYWUyZTI4MTFfMTY0OTI2NzQ0MTY4NA_925fc804-82d0-42da-9543-3c6c155fd556"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy0zLTEtMS0xMjA2L3RleHRyZWdpb246YmQyNDM3ODAzNmIxNGEzZjkyMDQ3NWIyYWUyZTI4MTFfMTY0OTI2NzQ0MTY5Mg_274fbe67-89e8-4004-a9b8-8d7d4d4f35bd"
      unitRef="usdPerShare">2.12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2a6a6702cbe1405fae1d4152caf10cf8_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy01LTEtMS0wL3RleHRyZWdpb246NDEyNDg0NjdiMTk4NGRiMzg1MDA5YjYwMmI0ZDU4NzVfMTY0OTI2NzQ0MTY4OQ_6ef9c203-a3b1-4a02-bc78-8080b344e0f9">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7d4b715adc284a418c6a708ee727979b_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy01LTEtMS0wL3RleHRyZWdpb246NDEyNDg0NjdiMTk4NGRiMzg1MDA5YjYwMmI0ZDU4NzVfMTY0OTI2NzQ0MTY5OA_5a051e74-e480-4fa7-9a23-ba98422ee245">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfMy03LTEtMS0w_647c7e03-5cea-40c4-9029-f68331c58719">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia7b9c626f5cc4797874b2b7b5b559927_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC0xLTEtMS0w_e094b365-9370-43ca-8fa7-6cedb5b895d4"
      unitRef="shares">748337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1ea5dbcf0c124143b148b23cc686ff50_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC01LTEtMS0wL3RleHRyZWdpb246NjkyODU3YmMyNDhjNDk0MDlmOTlkOWJhY2EyZDdhN2VfMTY0OTI2NzQ0MTY4OQ_7e1ede12-5b9e-4d4b-8b07-8f632ee48442">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic46c960fd7f2441389d418c74a68bbd1_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjdiYTA2ZmJiYzRkZjRhYzliYmU5NTYwYzQxMDJkZGEyL3RhYmxlcmFuZ2U6N2JhMDZmYmJjNGRmNGFjOWJiZTk1NjBjNDEwMmRkYTJfNC01LTEtMS0wL3RleHRyZWdpb246NjkyODU3YmMyNDhjNDk0MDlmOTlkOWJhY2EyZDdhN2VfMTY0OTI2NzQ0MTY5OA_de7d74eb-2aba-4167-bd71-caeb26a13484">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNDI3Nw_e62126aa-9238-4ba5-ba5d-54e2a2a97281"
      unitRef="usd">11400000</mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue>
    <mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNDI4NA_751a0473-2c64-427b-bc95-2b71fadec275"
      unitRef="usd">3700000</mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1Mw_c5e71499-9ce2-45e1-9809-bf4139287ac4">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:69.994%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended&lt;br/&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;60.44%-69.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;60.40%-61.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;0.44%-1.26%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:right;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;2.20%-2.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMi0xLTEtMS0w_6fb92525-f4f2-4ec0-8d65-477784648d71"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMi0zLTEtMS0w_f0a04fb1-5e7c-4ad0-a66c-41aa536f56cc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0xLTEtMS0zNTY0L3RleHRyZWdpb246MTY2MTVmZWVkY2RjNDI3Y2JkYzAzMTcxM2MwZmRhNjlfMTY0OTI2NzQ0MTY5MA_c087d3a3-2fc9-4738-93d0-1ffece7c20d1"
      unitRef="number">0.6044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0xLTEtMS0zNTY0L3RleHRyZWdpb246MTY2MTVmZWVkY2RjNDI3Y2JkYzAzMTcxM2MwZmRhNjlfMTY0OTI2NzQ0MTY5OA_c0718f27-3d73-4fe0-8b55-e2a5a0f1291c"
      unitRef="number">0.6983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0zLTEtMS0zNTcxL3RleHRyZWdpb246NmY3NDAyZGIzMDFkNGYyNzg0MGVlMmMxMDFhODAzY2NfMTY0OTI2NzQ0MTY4NA_f7e545a5-16d9-4e41-828f-98cb2cbaa3b8"
      unitRef="number">0.6040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfMy0zLTEtMS0zNTcxL3RleHRyZWdpb246NmY3NDAyZGIzMDFkNGYyNzg0MGVlMmMxMDFhODAzY2NfMTY0OTI2NzQ0MTY5MQ_c9c9c355-7bf5-445c-a799-c312aeeacfea"
      unitRef="number">0.6140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0xLTEtMS0zNTY4L3RleHRyZWdpb246MDEwMGQzMmI2NDczNDMzYzk0NmE1ZjY5Y2EzN2Q0MjFfMTY0OTI2NzQ0MTY4NA_0e17c10c-89c4-402f-b111-924846f46635"
      unitRef="number">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0xLTEtMS0zNTY4L3RleHRyZWdpb246MDEwMGQzMmI2NDczNDMzYzk0NmE1ZjY5Y2EzN2Q0MjFfMTY0OTI2NzQ0MTY5MQ_6500c34e-face-4ade-be4d-fbae0cfb51f2"
      unitRef="number">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0zLTEtMS0zNTc0L3RleHRyZWdpb246ZmUwODVlZTM1OWZiNDc4ZmFjNjMzOWZiYTgxOGI0OTRfMTY0OTI2NzQ0MTY4NA_f7b7ac68-d6b4-43a6-bff7-95ec7ac9f09a"
      unitRef="number">0.0220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNC0zLTEtMS0zNTc0L3RleHRyZWdpb246ZmUwODVlZTM1OWZiNDc4ZmFjNjMzOWZiYTgxOGI0OTRfMTY0OTI2NzQ0MTY5MQ_29757063-5fd1-498f-8587-5d866eb65af2"
      unitRef="number">0.0262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNS0xLTEtMS0w_98af894f-ab87-48a8-b19e-58ef10fe0738">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iccfa93d4f5a147d1b16cdc7636d16ec9_D20190101-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjUxYWEzMGFlZGI0NjRlMTFiZmQzNGI0MjRjZDllNzBlL3RhYmxlcmFuZ2U6NTFhYTMwYWVkYjQ2NGUxMWJmZDM0YjQyNGNkOWU3MGVfNS0zLTEtMS0w_99b2a119-ca06-4747-9ca0-40b50b1793ac">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50c1a034475f46eb968fab88c0b84296_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNTE0Ng_31786fd2-8475-4a1e-9a5f-b0796e43bd28"
      unitRef="usd">60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <mnlo:ContingentStockRightSharesConversion
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzMzk4Ng_55f9f2f9-3c32-4116-a2bf-39d5c8bc9c0a"
      unitRef="number">1.2082</mnlo:ContingentStockRightSharesConversion>
    <mnlo:EffectiveExchangeRatio
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzNDAwMg_032d1c45-5365-4a8a-8c3b-8c79cbc35858"
      unitRef="number">1.8006</mnlo:EffectiveExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i086c3c739539445da6ad056f578caedb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mjg0Ng_3488941a-2025-4cb1-a9e6-e264e9aae1f1"
      unitRef="usd">9300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost
      contextRef="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1Mjk2MA_3c073d76-bcd0-4887-bc82-0fe8d6b535ff"
      unitRef="usd">6600000</mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCost>
    <mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod
      contextRef="i08ac020e83f64755aafa80e2c3d0ec90_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2Nzc1OQ_32c59990-364d-4579-9c7c-bc1f4e4f4996">P2Y</mnlo:ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod>
    <mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment
      contextRef="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfNTU3OQ_73623ad9-f1a7-4b31-a096-d0c26db273f0"
      unitRef="usd">1600000</mnlo:ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
      contextRef="ie4289ef6fa584dcca85d80a110dd70dc_D20200309-20200309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMjE5OTAyMzI2NzkxOQ_b8a8c01e-494c-4f1a-904f-3017aaf385ce"
      unitRef="usd">600000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="ib290ea8b639941c0865b91b70ea01d50_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MDE4OQ_f43a4d77-bbac-478e-a603-74585dc5f87d"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="i5b1bb38c09694860a74fca4cb02b7fd2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMTY0OTI2NzQ1MDIxMw_de4bc990-f51c-4f7f-9b49-7de5791d091d"
      unitRef="usd">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <mnlo:ContingentStockRightSharesConversion
      contextRef="ib1f7bee6f856461cb5df3d54f47f4a78_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzNTYyNQ_55f9f2f9-3c32-4116-a2bf-39d5c8bc9c0a"
      unitRef="number">1.2082</mnlo:ContingentStockRightSharesConversion>
    <mnlo:EffectiveExchangeRatio
      contextRef="i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfODc5NjA5MzAzMzk5NA_a76f1c09-5696-4e43-8e8b-67175f8afe9a"
      unitRef="number">1.8006</mnlo:EffectiveExchangeRatio>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RleHRyZWdpb246ZWNjOTFlY2YwYmQ4NGMzOWI0NjdhNjgwZTJmNmI3YjlfMzI5ODUzNDg4OTk1Mg_263be75b-f593-449e-b331-de9e70162cbc">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table illustrates the effect of share-based compensation on the statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.548%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.636%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.386%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.639%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i875e9e1345164d94bc58815365779517_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi0xLTEtMS0w_be4940f2-fc60-46ce-b02b-256db1eb5ffc"
      unitRef="usd">3050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82863cbbff6145f2bedee6a09e97f8bc_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi0zLTEtMS0w_8a8206ba-9abc-4d5b-b7e0-bf54aef57309"
      unitRef="usd">384000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i466f28e0d85348cab9cc5df9627c2a21_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi01LTEtMS0xMjQw_25637df6-4c1e-4b27-84fb-1119792c246f"
      unitRef="usd">3566000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16a8e4626ad948338081011de428c56a_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMi03LTEtMS0xMjQz_570113de-2db1-4a3d-9668-10286b8e4b67"
      unitRef="usd">738000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i282c323ee4fd405f9b9276a665217e6f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy0xLTEtMS0w_5bcedb6d-d9d6-4f89-8304-02e0975bf01c"
      unitRef="usd">7718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic6103d5338e747d3863548470494ec95_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy0zLTEtMS0w_6f5fde93-8962-4435-a64e-60530a18874f"
      unitRef="usd">1004000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5eabf77585034e158ba10a9768877f29_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy01LTEtMS0xMjQw_5ac9f603-3819-44bc-af93-3252fe576896"
      unitRef="usd">8961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb9a4f704626440cb634b11d52f4e479_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfMy03LTEtMS0xMjQz_ead75647-29be-457f-9b9d-43e6eaaac0f2"
      unitRef="usd">1599000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74f696343f7b4319b954654fee16542a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC0xLTEtMS0w_918b4cdc-d6d5-4e39-9317-4d8bcc952d46"
      unitRef="usd">10768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4799b91cb4364b1f87868804c354c1a5_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC0zLTEtMS0w_f47d3797-b43a-41e9-8cb0-d07ea886a54b"
      unitRef="usd">1388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC01LTEtMS0xMjQw_986c7a56-25ac-4d3b-8c59-51e1f4dc9a5a"
      unitRef="usd">12527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i851e26b02daf42c989107e5e6213ed52_D20190101-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83MC9mcmFnOmVjYzkxZWNmMGJkODRjMzliNDY3YTY4MGUyZjZiN2I5L3RhYmxlOjhlMTcwNDAzYTBlYTQ3YzU5ZjBlMWY1YTIxZTAzNGNjL3RhYmxlcmFuZ2U6OGUxNzA0MDNhMGVhNDdjNTlmMGUxZjVhMjFlMDM0Y2NfNC03LTEtMS0xMjQz_41c17992-a691-4510-99ab-b0786d5f422d"
      unitRef="usd">2337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTgwMg_fa0e21a1-b52a-4295-8b07-69043043aa2b">OPERATING LEASE&lt;div style="text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Operating lease agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has operating leases for corporate offices, research and development facilities, and vehicles. The properties primarily relate to the Company&#x2019;s principal executive office in Bridgewater, New Jersey, corporate offices in Redwood City, California and research and development facility in Israel.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (&#x201c;The Amendment&#x201d;). The Amendment includes an extension of the lease period of the 10,000 square feet previously leased under the original agreement (the &#x201c;Original Space&#x201d;) and an addition of 4,639 square feet (the &#x201c;Additional Space&#x201d;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#x201c;Commencement Date&#x201d;). The Amendment is due to expire on August 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Pursuant to The Amendment of the lease on the Current Space, the Company recognized an additional right of use asset and liability in the amount of $0.7 million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $0.3 million, on the Commencement Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s corporate offices in Redwood City, California are under lease through December&#160;31, 2020 with a base rent of approximately $60,000 per month. Given the short-term nature of the remaining lease period, the combined company did not recognize a right-of-use asset and liability and expects to recognize the lease payments in its statements of operations and comprehensive loss on a straight-line basis over the remaining lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease agreement for the research and development facility in Israel is linked to the Israeli consumer price index (&#x201c;CPI&#x201d;) and due to expire in December 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, the Company has entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for three-year terms. To secure the terms of certain of the vehicle lease agreements, the Company has made prepayments to the leasing company, representing approximately 3 months of lease payments. These amounts have been recorded as part of the operating lease right-of-use assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June&#160;30, 2020, the Company has a lien in the amount of $0.7 million on the Company&#x2019;s cash and marketable securities in respect of bank guarantees granted in order to secure the lease agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <mnlo:FacilitySpaceUnderLease
      contextRef="if2a66420fa684fbea1eee87e6abdd8e4_D20190313-20190313"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfNTkx_1f14b7ab-ed94-4e82-adb2-953e2c60f437"
      unitRef="sqft">10000</mnlo:FacilitySpaceUnderLease>
    <mnlo:FacilitySpaceUnderLease
      contextRef="i88fbd3af56884c12ae3c30505c83a2f9_D20190313-20190313"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfNjk1_6f687c90-69ff-485d-ad07-4290f707836c"
      unitRef="sqft">4639</mnlo:FacilitySpaceUnderLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4760e6ad58b548bfa055202c3d8cd2e7_I20190313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTA4Mw_7494d523-5755-4780-afc8-32d7da30e944"
      unitRef="usd">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9a8c08728edb45bd9ea6a6f0fc6e5a20_I20190313"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTIyMA_6eacc8ff-2268-468c-816b-1a2eb79cdf3d"
      unitRef="usd">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeasePayments
      contextRef="i74e404bead2e4f94b38bf24b66089cdf_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMTM3MQ_b047818b-7814-417b-9244-ee22430c2b17"
      unitRef="usd">60000</us-gaap:ShortTermLeasePayments>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTg1NQ_0f878951-f847-4575-a7a6-546437b2b0c4">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mnlo:VehicleLeasePrepaymentPeriod
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMjEzNw_5219541c-a7ac-4981-8602-28b9f6324b56">P3M</mnlo:VehicleLeasePrepaymentPeriod>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMzI5ODUzNDg4NTgwMw_45b0a438-7945-4eeb-8054-18664df19b53">&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Maturities of lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;margin-bottom:5pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:84.363%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.637%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMC0xLTEtMS0w_fa387438-1484-4037-9583-9f63cea7c320"
      unitRef="usd">1267000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMS0xLTEtMS0w_8596a3c1-ae1d-4d20-aa14-fb84d0701b5b"
      unitRef="usd">993000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMi0xLTEtMS0w_92d330f8-3329-4fdf-adc8-8676d7bcd892"
      unitRef="usd">768000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfMy0xLTEtMS0w_c5c560de-8928-4d1d-ad2c-32cd9ce31934"
      unitRef="usd">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNC0xLTEtMS0w_c623cb38-a700-4a6b-a1d6-3cf7e6ead21b"
      unitRef="usd">3118000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNS0xLTEtMS0w_2c43ae12-92ef-41a7-b166-14cb4330be93"
      unitRef="usd">565000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RhYmxlOjE1N2U1Njg3NWNmYjRiZTg4ZjU4YWUwNzcwMzQ3YzU1L3RhYmxlcmFuZ2U6MTU3ZTU2ODc1Y2ZiNGJlODhmNThhZTA3NzAzNDdjNTVfNi0xLTEtMS0w_215254ad-28e0-44c7-a11f-a157bdba1b58"
      unitRef="usd">2553000</us-gaap:OperatingLeaseLiability>
    <mnlo:RestrictedInvestmentsToSecureLeaseAgreements
      contextRef="i55514fe802bc4047841713151110e3e1_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF83Ni9mcmFnOjBiZGMwYmZjYTVmMDRhZDZiZDQ4ZjRmYjQ3ZGM0N2U5L3RleHRyZWdpb246MGJkYzBiZmNhNWYwNGFkNmJkNDhmNGZiNDdkYzQ3ZTlfMjM0NA_6dffb162-beec-43a3-911f-0940973d0970"
      unitRef="usd">700000</mnlo:RestrictedInvestmentsToSecureLeaseAgreements>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMzI5ODUzNDg4NzQxOQ_35ab3237-1e43-4bbd-b8c8-0972bbed22b1">COMMITMENTS AND CONTINGENCIES&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2020, no claims or actions pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;IPO Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 8, 2018 and January 28, 2019, two purported class actions were filed in the Superior Court of California, San Mateo County, against the Company and certain of our officers and directors. The actions are entitled Savelstrov v. Menlo Therapeutics Inc., et al., and McKay v. Menlo Therapeutics Inc., et al. The underwriters for our initial public offering were also named as defendants in these lawsuits. The complaints contain identical allegations against the same defendants. Both complaints alleged&#160;that the Registration Statement and prospectus for our initial public offering contained false and misleading statements in violation of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 due to allegedly false and misleading statements in connection with our initial public offering. The complaints seek, among other things, an award of damages in an amount to be proven at trial, along with reimbursement of reasonable costs and expenses, including attorneys&#x2019; fees and expert fees. The McKay action has been consolidated with the Savelstrov action and the claim for violations of Section 12(a)(2) has been dismissed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The parties have mediated the consolidated lawsuit and reached a settlement, providing for payment to the class of plaintiffs in the amount of $9.5 million, the vast majority of which will be paid by the Company's insurance carriers, in return for a release of all claims against the defendants, including the Company and its current and former officers and directors. The &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;settlement is subject to final documentation and Court approval. The Court preliminarily approved the settlement on April 24, 2020, and will consider whether to grant final approval of the settlement at a hearing scheduled for August 14, 2020. Menlo accrued for the remaining settlement amount that is not covered by insurance carriers as of December&#160;31, 2019, which did not have a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Merger Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Seven lawsuits (collectively, the &#x201c;Merger Lawsuits&#x201d;) were filed in various U.S. federal district courts against Foamix and certain other defendants in connection with the Merger. The lawsuits generally alleged that the registration statement on Form S-4 and the prospectus/joint proxy statement included therein included false or misleading information regarding the Merger in violations of Section 14(a) and Section 20(a) of the Exchange Act and/or Rule 14a 9 promulgated under the Exchange Act. In addition, one of the lawsuits alleged that the members of Foamix&#x2019;s board of directors breached their fiduciary duties in connection with the Merger. The plaintiffs sought, among other things, to enjoin consummation of the Merger, or alternatively rescission or rescissory damages; to compel the individual defendants to disseminate a joint proxy statement/prospectus that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; a declaration that defendants violated Sections 14(a) and/or 20(a) of the Exchange Act; a declaration that the Merger Agreement was entered into in breach of fiduciary duty and is therefore invalid and unenforceable; an order directing the individual defendants to commence a sale process for Foamix and obtain a transaction; and an award of costs, including attorneys&#x2019; and experts&#x2019; fees and expenses, as well as an accounting of damages allegedly suffered by the plaintiffs. The plaintiffs have agreed the Lawsuits were rendered moot by subsequent disclosure, and on April 22, 2020, each of the plaintiffs and defendants named in the Merger Lawsuits entered into a mootness resolution agreement pursuant to which the plaintiffs agreed to dismiss their lawsuits with prejudice as to the named plaintiff and Foamix agreed to pay a &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;de minimis&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; mootness fee to plaintiffs&#x2019; counsel. As of May 4, 2020, each of the Merger Lawsuits has been dismissed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <mnlo:NumberOfClassActions
      contextRef="id3d0a4c5350e4cbd93b8042046be79d5_I20181108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMzcz_19790cdf-98aa-45e5-882f-2b8d970e1a03"
      unitRef="lawsuits">2</mnlo:NumberOfClassActions>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMTYxMw_a1af994b-5b92-4536-b32c-94d01b609de1"
      unitRef="usd">9500000</us-gaap:PaymentsForLegalSettlements>
    <mnlo:NumberOfClassActions
      contextRef="ib1c399325c504de1963cfc9cabc42c2c_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMjA5MA_0039b92d-22d4-493b-96a2-8f2be0aaa009"
      unitRef="lawsuits">7</mnlo:NumberOfClassActions>
    <mnlo:NumberOfClassActions
      contextRef="i241af8b663f1455bb67c14d739a9fee6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84Mi9mcmFnOmEwMTkzM2FiZTQzYTQ4MDdiMjI2MjY2MDI5NmFlODIyL3RleHRyZWdpb246YTAxOTMzYWJlNDNhNDgwN2IyMjYyNjYwMjk2YWU4MjJfMjU5Nw_4e1bd659-996b-444c-952f-4eccc4d1f174"
      unitRef="lawsuits">1</mnlo:NumberOfClassActions>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMzI5ODUzNDg5MjY5Ng_13d71cbf-559f-4773-a122-d8935b7452f2">SUBSEQUENT EVENTS&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;"&gt;Reverse Stock Split Proposal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the Company's annual meeting of stockholders held on August 3, 2020, the Company's stockholders voted to approve a proposal to adopt an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation to effect (a) a reverse stock split of the Company&#x2019;s outstanding shares of common stock, at a reverse stock split ratio ranging from 1-for-2 shares to 1-for-7 shares, which may be determined by the Board at a later date, and (b) a reduction in the number of authorized shares of the Company&#x2019;s common stock by a corresponding ratio. The exact timing for selection of the reverse stock split ratio and the effective date of the reverse stock split will be determined by the Board based upon its evaluation as to when such action will be most advantageous to the Company and its stockholders. The Board may delay or abandon the reverse stock split at any time prior to the effective time of the reverse stock split, if the Board determines that the reverse stock split is no longer in the best interests of the Company or its stockholders. The reverse stock split, if implemented, would become effective upon the filing of a charter amendment with the Delaware Secretary of State. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;On August&#160;5, 2020, the Company and the lenders entered into the Amendment. The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant in the Amended and Restated Credit Agreement, such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing on the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $6.0&#160;million for the fiscal quarter ending December 31, 2020 to $97.0&#160;million for the fiscal quarter ending June 30, 2024.</us-gaap:SubsequentEventsTextBlock>
    <mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance
      contextRef="if5621f8762eb475d9ed17ae8f1e11e98_D20201031-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMTY0OTI2NzQ1MDk1OQ_2e865583-c280-4795-9b0d-4ebea3d1eacc"
      unitRef="usd">6000000.0</mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance>
    <mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance
      contextRef="i53e6a2df0fcc4338a340314f1088bfc9_D20240401-20240630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF84OC9mcmFnOmNlZTQ3ZDJhYjVjOTRkNGNhYTJkOGZhZmZhMThmY2FjL3RleHRyZWdpb246Y2VlNDdkMmFiNWM5NGQ0Y2FhMmQ4ZmFmZmExOGZjYWNfMTY0OTI2NzQ1MDk3Nw_447a96dd-08e4-482b-9bfb-3ad85f7df572"
      unitRef="usd">97000000.0</mnlo:DebtCovenantMinimumQuarterlyRevenueCompliance>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i62013cb8bd8344108941648a67adfc5b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI5MjFhYTIxZjFhYzQ1MzRiODQ5OWMyNTlkM2JjN2UwL3NlYzpiOTIxYWEyMWYxYWM0NTM0Yjg0OTljMjU5ZDNiYzdlMF8xMzYvZnJhZzpmM2Q3Yzc4ZTE2YmY0YjQxYjZlMTUzNmMzNDI5Njc5Yi90ZXh0cmVnaW9uOmYzZDdjNzhlMTZiZjRiNDFiNmUxNTM2YzM0Mjk2NzliXzgyNDYzMzcyMTA4OTE_a1af994b-5b92-4536-b32c-94d01b609de1"
      unitRef="usd">9500000</us-gaap:PaymentsForLegalSettlements>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660096662776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DocumentAndEntityInformationAbstract', window );"><strong>DOCUMENT AND ENTITY INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MENLO THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3757789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 U.S. Highway 22, Suite 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">755-7936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MNLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001566044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,690,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097398088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 96,511<span></span>
</td>
<td class="nump">$ 43,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities (Note 6)</a></td>
<td class="nump">2,609<span></span>
</td>
<td class="nump">16,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted investment in marketable securities (Note 6)</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net of allowances</a></td>
<td class="nump">6,407<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other assets</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory (Note 7)</a></td>
<td class="nump">5,801<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">119,290<span></span>
</td>
<td class="nump">76,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (Note 10)</a></td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid and other assets</a></td>
<td class="nump">6,183<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">11,552<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">130,842<span></span>
</td>
<td class="nump">81,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">19,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related obligations</a></td>
<td class="nump">4,081<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (Note 10)</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">24,232<span></span>
</td>
<td class="nump">29,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Liability for employee severance benefits</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities (Note 10)</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 8)</a></td>
<td class="nump">32,915<span></span>
</td>
<td class="nump">32,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">35,082<span></span>
</td>
<td class="nump">34,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">59,314<span></span>
</td>
<td class="nump">63,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; no shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value; 300,000,000 shares authorized at June&#160;30, 2020 and December&#160;31, 2019, respectively; 167,683,814 and 36,480,314 shares issued and outstanding at June&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">589,812<span></span>
</td>
<td class="nump">328,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(518,301)<span></span>
</td>
<td class="num">(310,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">71,528<span></span>
</td>
<td class="nump">17,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 130,842<span></span>
</td>
<td class="nump">$ 81,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660096668216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD/share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD/share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">167,683,814<span></span>
</td>
<td class="nump">36,480,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">167,683,814<span></span>
</td>
<td class="nump">36,480,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097289464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUES</a></td>
<td class="nump">$ 11,688,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,438,000<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">13,119,000<span></span>
</td>
<td class="nump">12,556,000<span></span>
</td>
<td class="nump">29,072,000<span></span>
</td>
<td class="nump">23,404,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,459,000<span></span>
</td>
<td class="nump">6,803,000<span></span>
</td>
<td class="nump">51,874,000<span></span>
</td>
<td class="nump">12,147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and in-process research &amp; development impairments</a></td>
<td class="nump">54,345,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,345,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="nump">84,726,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,726,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">TOTAL EXPENSES</a></td>
<td class="nump">178,865,000<span></span>
</td>
<td class="nump">19,359,000<span></span>
</td>
<td class="nump">220,504,000<span></span>
</td>
<td class="nump">35,551,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="nump">167,177,000<span></span>
</td>
<td class="nump">19,359,000<span></span>
</td>
<td class="nump">207,066,000<span></span>
</td>
<td class="nump">35,243,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_FinancialIncomeNet', window );">FINANCE INCOME</a></td>
<td class="num">(564,000)<span></span>
</td>
<td class="num">(468,000)<span></span>
</td>
<td class="num">(1,292,000)<span></span>
</td>
<td class="num">(1,004,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_FinancialExpenses', window );">FINANCE EXPENSES</a></td>
<td class="nump">1,086,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">2,158,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX</a></td>
<td class="nump">167,699,000<span></span>
</td>
<td class="nump">18,993,000<span></span>
</td>
<td class="nump">207,932,000<span></span>
</td>
<td class="nump">34,373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX</a></td>
<td class="num">(259,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(259,000)<span></span>
</td>
<td class="num">(176,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="nump">$ 167,440,000<span></span>
</td>
<td class="nump">$ 18,993,000<span></span>
</td>
<td class="nump">$ 207,673,000<span></span>
</td>
<td class="nump">$ 34,197,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">LOSS PER SHARE BASIC AND DILUTED (in dollars per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 2.29<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (in shares)</a></td>
<td class="nump">138,653<span></span>
</td>
<td class="nump">97,999<span></span>
</td>
<td class="nump">90,627<span></span>
</td>
<td class="nump">97,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUES</a></td>
<td class="nump">$ 1,483,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,233,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUES</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUES</a></td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_FinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total financial expenses during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_FinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_FinancialIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total financial income during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_FinancialIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165640808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 167,440<span></span>
</td>
<td class="nump">$ 18,993<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
<td class="nump">$ 34,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS (INCOME):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (gains) losses from marketable securities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Losses on marketable securities reclassified into net loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net unrealized losses (gains) on derivative financial instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">TOTAL OTHER COMPREHENSIVE (INCOME) LOSS</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="nump">$ 167,400<span></span>
</td>
<td class="nump">$ 19,002<span></span>
</td>
<td class="nump">$ 207,678<span></span>
</td>
<td class="nump">$ 34,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097275208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 92,182<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 307,624<span></span>
</td>
<td class="num">$ (215,409)<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,864,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(34,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,197)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">60,382<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">309,979<span></span>
</td>
<td class="num">(249,606)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,053,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">77,995<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">308,590<span></span>
</td>
<td class="num">(230,613)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,987,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(19,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,993)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">60,382<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">309,979<span></span>
</td>
<td class="num">(249,606)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,053,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 17,575<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">328,154<span></span>
</td>
<td class="num">(310,587)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Dec. 31, 2019</a></td>
<td class="nump">36,480,314<span></span>
</td>
<td class="nump">36,480,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (207,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(207,673)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modification</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Classification of stock awards to derivative liability</a></td>
<td class="num">(975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of stock related to merger</a></td>
<td class="nump">196,170<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">196,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of stock related to merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,063,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 71,528<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">589,812<span></span>
</td>
<td class="num">(518,301)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2020</a></td>
<td class="nump">167,683,814<span></span>
</td>
<td class="nump">167,683,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 69,535<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">420,430<span></span>
</td>
<td class="num">(350,861)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,501,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE PERIOD:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(167,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,440)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options and vesting of restricted stock units</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="nump">10,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Classification of stock awards to derivative liability</a></td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Ordinary Shares through a public offering, net of $3,903 issuance costs</a></td>
<td class="nump">53,649<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">53,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Ordinary Shares through public offering, net of $3,903 issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of stock related to merger</a></td>
<td class="nump">104,362<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">104,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of stock related to merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 71,528<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 589,812<span></span>
</td>
<td class="num">$ (518,301)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (shares) at Jun. 30, 2020</a></td>
<td class="nump">167,683,814<span></span>
</td>
<td class="nump">167,683,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660176184184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 3,903<span></span>
</td>
<td class="nump">$ 3,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097000792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="nump">$ 207,673<span></span>
</td>
<td class="nump">$ 34,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and in-process research &amp; development impairments</a></td>
<td class="nump">54,345<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="nump">84,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal and sale of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Changes in marketable securities and bank deposits, net</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits', window );">Changes in accrued liability for employee severance benefits, net of retirement fund profit</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,527<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash finance (income) expenses, net</a></td>
<td class="num">(833)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of businesses acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in trade receivables, prepaid and other assets</a></td>
<td class="num">(9,807)<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other non-current assets</a></td>
<td class="num">(6,026)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">(Decrease) increase in accounts payable and accruals</a></td>
<td class="num">(10,908)<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(4,445)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88,070)<span></span>
</td>
<td class="num">(29,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investment in bank deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ProceedsFromBusinessMerger', window );">Cash acquired through merger</a></td>
<td class="nump">38,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale and maturity of marketable securities and bank deposits</a></td>
<td class="nump">48,577<span></span>
</td>
<td class="nump">57,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">87,105<span></span>
</td>
<td class="nump">40,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds related to issuance of ordinary shares through offerings, net of issuance costs</a></td>
<td class="nump">53,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds related to issuance of stock for stock-based compensation arrangements, net</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">53,746<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">52,781<span></span>
</td>
<td class="nump">11,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD</a></td>
<td class="nump">44,584<span></span>
</td>
<td class="nump">28,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD</a></td>
<td class="nump">97,366<span></span>
</td>
<td class="nump">39,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS</a></td>
<td class="nump">97,366<span></span>
</td>
<td class="nump">39,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS -</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Cashless exercise of warrants and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares under employee stock purchase plan</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Additions to operating lease right of use assets</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Additions to operating lease liabilities</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_InterestReceived', window );">Interest received</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">117,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Less liabilities assumed</a></td>
<td class="nump">5,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net acquired (See &#8220;Note 3- Business combination&#8221;)</a></td>
<td class="nump">111,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NonCashAcquisitionOfBusinessCashAcquired', window );">Less cash acquired</a></td>
<td class="nump">38,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired', window );">Merger net of cash acquired</a></td>
<td class="nump">$ 72,802<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_InterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_InterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NonCashAcquisitionOfBusinessCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as part of a non-cash business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NonCashAcquisitionOfBusinessCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ProceedsFromBusinessMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from business merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ProceedsFromBusinessMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in lease obligation from new lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093596984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text">NATURE OF OPERATIONS<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Menlo Therapeutics Inc. (the &#8220;Company,&#8221; &#8220;Menlo&#8221; or the &#8220;combined company&#8221;) is a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as&#160;one&#160;business segment.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Reverse Merger</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;) and Giants Merger Subsidiary Ltd. (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020 (the &#8220;Effective Date&#8221;).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#8220;Note 3 &#8211; Business Combination&#8221; for more information on the Merger.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Products, Product Candidates and Licenses</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, in January 2020, Foamix launched AMZEEQ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical foam, 4% (&#8220;AMZEEQ&#8221;), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (minocycline) topical form, 1.5% (formerly FMX103, "ZILXI"), for the treatment of inflammatory lesions of rosacea in adults.  AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMZEEQ and ZILXI utilize the Company&#8217;s proprietary Molecule Stabilizing Technology (MST)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> that is also being used in the development of the Company&#8217;s other product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris.  The Company has begun preparations to conduct an end-of-Phase II meeting with the FDA before the end of 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or&#160;NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to pursue serlopitant. As a result, the Company recorded a full impairment charge related to the IPR&amp;D and Goodwill assets in its unaudited condensed consolidated statement of operations and comprehensive loss for the three and six months ended June&#160;30, 2020. See "Note 3 - Business Combination" for more information.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States, and recently entered into a license agreement with Cutia Therapeutics (HK) Limited (&#8220;Cutia&#8221;).  See "Note 4 - Revenue Recognition."  The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company&#8217;s foam technology with the licensee&#8217;s proprietary drugs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company launched AMZEEQ&#160;in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company&#8217;s activities prior to the commercial launch of AMZEEQ&#160;had primarily consisted of </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June&#160;30, 2020, the Company incurred a net loss of $207.7 million and used&#160;$88.1 million of cash in operations. As of June&#160;30, 2020, the Company had cash, cash equivalents and investments of $100.4 million and an accumulated deficit of $518.3 million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates.  The Company does not currently intend to pursue serlopitant further.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash, cash equivalents and investments as of June&#160;30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.</span></div>As a result of the COVID-19 pandemic, the Company suspended the vast majority of its in-person interactions by its customer-facing professionals in healthcare settings and have engaged with these customers remotely as the Company seeks to continue to support healthcare professionals and patient care.  During the second quarter of 2020, the Company began limited in-person customer meetings and interactions in certain regions, consistent with local government mandates.  However, during the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures.  As a result of the negative impact on the Company's product sales, the Company and its lenders amended the minimum net revenue covenant in the Amended and Restated Credit Agreement.  See "Note 8 - Long-Term Debt." The length of time and extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict.  An extended duration of the COVID-19 pandemic could continue to negatively impact sales of AMZEEQ, and any future sales of ZILXI, and have a material adverse effect on the Company's liquidity, as well as the Company's ability to remain in compliance with the minimum net revenue covenants contained in the Company's loan documents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095018184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;">Basis of Presentation</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited interim condensed consolidated financial statements should be read in conjunction with Foamix&#8217;s audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company&#8217;s Current Report on Form 8-K/A filed with the Securities and Exchange Commission ("SEC") on May 7, 2020, and the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results expected for the year ending December&#160;31, 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;">Principles of Consolidation</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consolidated financial statements include the accounts of Menlo and its subsidiaries. Intercompany balances and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">c.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;">Use of Estimates</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic.  In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.  The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).  The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">d.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;">Business Acquisition</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our fair value methodologies depend on the following types of inputs:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset Impairment</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">e.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt;">Revenue Recognition</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the distributors. The Company evaluates the creditworthiness of each of its distributors to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 90 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net product revenues through&#160;June&#160;30, 2020&#160;were generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">products to Cutia for clinical and commercial use.  The Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognizes the revenues from the upfront license fee when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">f.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;">Allowance for credit losses</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2020.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">g.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt;">Derivative instruments</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as a finance expense (income) in the accompanying condensed consolidated statements of operations.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">h.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt;">Fair value measurement</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1:&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">i.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.73pt;">Loss per share</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The basic and diluted loss per share for each comparative period before the acquisition date presented in the consolidated financial statements following the reverse merger was calculated by dividing (a) by (b):</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The loss of the legal acquiree attributable to common stockholders in each of those periods.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The legal acquiree's historical weighted-average number of common stock outstanding multiplied by the exchange ratio established in the merge agreement</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary shares outstanding during the period. Diluted net loss per share is based upon the weighted average number </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,975,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,037,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,082,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,576,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,893,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,272,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the above, the CSR was excluded from the calculation of the diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">j.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt;">Newly issued and recently adopted accounting pronouncements</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093581192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text">BUSINESS COMBINATION<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, Menlo entered into the Merger Agreement with Foamix, and Merger Sub, a direct and wholly-owned Israeli subsidiary of Menlo. On March 9, 2020, the Merger was completed and Foamix is now a wholly-owned subsidiary of Menlo.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On the Effective Date, each ordinary share of Foamix was exchanged for 0.5924 shares of common stock of Menlo (the &#8220;Exchange Ratio&#8221;). In addition, on the Effective Date, Foamix shareholders received one contingent stock right (a &#8220;CSR&#8221;) for each Foamix ordinary share held by them. The CSRs were issued pursuant to the Contingent Stock Rights Agreement (the &#8220;CSR Agreement&#8221;), dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s phase III clinical trials evaluating the safety and efficacy of once daily oral serlopitant for the treatment of prurigo nodularis (the &#8220;Phase III PN Trials&#8221;).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 shares of Menlo common stock underlying the CSRs.  Following the delivery, pre-Merger Foamix shareholders and pre-Merger Menlo stockholders owned approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under U.S. GAAP and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under reverse acquisition accounting, the U.S. dollar amount for common stock in the financial statements is based on the value and number of shares issued by Menlo (reflecting the legal structure of Menlo as the legal acquirer) on the Merger date plus subsequent shares issued by the Company. The amounts in additional paid-in capital represent that of Foamix and include the fair value of shares deemed for accounting purposes to have been issued by Foamix on the merger date and the fair value of the Menlo equity awards included in the purchase price calculation. The Foamix additional paid-in capital was also adjusted for the difference between the number of common stock and the historical number of shares of Foamix&#8217;s ordinary shares.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, the Company incurred transaction costs of approximately $11.7 million, which are recorded in the consolidated statements of operations and comprehensive income. This amount includes $8.1 million of severance benefits for employees terminated after the Effective Date. The total transaction costs and other non-recurring costs related to the Merger were $21.8 million.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Purchase Price</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total consideration*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on Foamix&#8217;s closing share price of $2.99 as of March 9, 2020, the Merger Consideration under reverse acquisition accounting was approximately $131.1 million, consisting of $123.8 million for the deemed (for accounting purposes only) issuance of 41.4 million Foamix shares assuming that no upwards adjustment was made to the Exchange Ratio relating to the CSR, and $7.3 million for the fair value of Menlo equity awards deemed (for accounting purposes only) to be converted into Foamix equity awards. The converted stock options represent the fair value of such options attributable to service prior to the Merger date using the Foamix closing share price of $2.99 as of March 9, 2020 as an input to the Black Scholes valuation model to determine the fair value of the options.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Purchase Price Allocation</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investment in marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In-process research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated purchase price*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Goodwill</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually. None of the Goodwill recognized is expected to be deductible for income tax purposes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 9, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase price</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(107,398)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $4.0 million related to goodwill in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2020.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">In-Process Research and Development (&#8220;IPR&amp;D")</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:83.630%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intangible asset</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of IPR&amp;D has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. The Company does not intend to pursue the development of serlopitant.  As such, the Company recorded a full impairment charge of $50.3 million related to the IPR&amp;D asset in its unaudited condensed consolidated statements of operations and comprehensive loss for the three and six months ended June&#160;30, 2020.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CSR</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The CSR was issued pursuant to the CSR Agreement, dated as of March 9, 2020, by and between Menlo and American Stock Transfer &amp; Trust Company, LLC, and represented the non-transferable contractual right to receive shares of common stock of Menlo depending on the results of Menlo&#8217;s Phase III PN Trials. The Company recognized a liability of $19.6 million in the unaudited condensed consolidated balance sheet as of March 31, 2020. The liability was measured at fair value and categorized as level 3 as of the acquisition date in accordance with ASC 805-31-25-5 and subsequently at each reporting date thereafter. The fair value of the CSR was estimated as the incremental value that Foamix would be able to achieve on a probability weighted basis assuming three different potential probabilities of the following scenarios: (a) serlopitant significance was achieved in both Phase III PN Trials (b) serlopitant significance was achieved in only one Phase III PN Trial and (c) serlopitant significance was not achieved or was not determined on or before May 31, 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The CSR conversion resulted in the issuance and delivery of 74,544,413 shares of Menlo common stock underlying the CSRs.  Following the delivery pre-Merger Foamix shareholders and pre-Merger Menlo stockholders own approximately 82% and 18% of post-Merger Menlo, respectively, each calculated on a fully diluted basis.  The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020 and increased the awards available for grant under the Company's equity plan.    </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration associated with the CSR was recognized and measured at fair value as of the acquisition date in accordance with ASC 805-30-25-5. An acquirer's obligation to pay contingent consideration should be classified as a liability or equity in accordance with ASC 480, Distinguishing Liabilities from Equity, ASC 815 Derivatives and Hedging, and other applicable U.S. GAAP.&#160;The contingent consideration associated with the CSR was initially measured at fair value and will subsequently be measured at fair value at each reporting date. The CSR was classified as a liability, as it is settled by issuing a variable number of the Company's common stock.  On April 6, 2020, the Company recorded $84.7 million of expense in its unaudited condensed consolidated statements of operations and comprehensive loss to remeasure the CSR liability in its consolidated balance sheet to its fair value of $104.4 million (calculated based on 74,544,413 shares issued and a share price of $1.40 on April 6, 2020) and then settled in connection with the issuance of shares. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Pro Forma</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The actual Menlo net loss included in the Company&#8217;s consolidated statements of operations and comprehensive income for the three and six months ended June&#160;30, 2020 (for the period from the March 9, 2020, the Effective Date, through June&#160;30, 2020, which are not indicative of the results to be expected for a full year) and the supplemental unaudited pro forma revenue and net loss of the combined entity had the acquisition been completed on January 1, 2019 are as follows:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to Menlo</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss per share - basic and diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction costs</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acceleration of stock based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,199)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total Adjustments</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,130)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the Merger.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095087032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Sales</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenues for the three and six months ended&#160;June&#160;30, 2020&#160;were generated from sales of AMZEEQ&#160;which was commercially launched in the United States in January 2020. The Company&#8217;s customers include a limited number of national and select regional distributors. These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the distributors. For the three months ended June&#160;30, 2020,&#160;three&#160;distributors accounted for&#160;42%,&#160;43%&#160;and&#160;15%&#160;of product revenue, respectively.  For the six months ended June&#160;30, 2020, three distributors accounted for 46%, 39% and 14% of product revenue, respectively.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Sales Provisions</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, chargebacks, estimated returns and other incentives, described below. </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company calculates its net product revenue based on the wholesale acquisition cost that the Company charges its distributors less provisions for (i) trade discounts and allowances, such as distributor fees and discounts for prompt payment, (ii) estimated rebates to Third-party Payers, patient co-pay assistance programs, chargebacks and other discount programs and (iii) reserves for expected product returns.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions for distribution fees, trade discounts and chargebacks are reflected as a reduction to Trade receivables, net on the condensed consolidated balance sheet. All other provisions, including rebates, other discounts and return provisions are reflected as a liability within Accrued expenses on the condensed consolidated balance sheet. Provisions for revenue reserves described below reduced product revenues by&#160;$5.9 million and $14.1 million for the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Distribution Fees and Trade Discounts and Allowances: The Company pays fees for distribution services and for certain data that distributors provide to the Company and generally provides discounts on sales to its distributors for prompt payment. These fees and discounts are contractual in nature and the Company expects its distributors to earn these fees and discounts, and accordingly deducts the full amount of these fees and discounts from its gross product revenues at the time such revenues are recognized.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rebates, Chargebacks and Other Discounts: </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales made under managed-care and governmental pricing programs in the U.S. are subject to rebates.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share. Chargebacks relate to contractual agreements to sell products to government agencies and other indirect </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these government agencies or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers. The Company estimates the rebates and chargebacks it expects to be obligated to provide and deducts these estimated amounts from its gross product revenue at the time the revenue is recognized. The Company estimates the rebates and chargebacks that it expects to be obligated to provide based upon (i) the Company's current contracts and negotiations, (ii) estimates regarding the payer mix&#160;based on third-party data and utilization, (iii) inventory held by distributors and (iv) estimates of inventory held at the retail channel. Other discounts include the Company&#8217;s co-pay assistance coupon programs for commercially-insured patients meeting certain eligibility requirements. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to pay associated with product that has been recognized as revenue.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product Returns: </span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Consistent with industry practice, customers are generally allowed to return products within a specified period of time before and after its expiration date.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company estimates the amount of product&#160;that will be returned and deducts these estimated amounts from its gross revenue at the time the revenue is recognized. T</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">he information utilized to estimate the returns provision includes: (i)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> historical industry information regarding rates for comparable pharmaceutical products and product portfolios</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">demand</span><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for products and (iv) remaining shelf lives of products at the date of sale. The Company estimates that approximately 2% to 3% of product will be returned.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License Revenues</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed products to Cutia for clinical and commerical use.  Outside of the license transferred, the Company does not have any additional performance obligations under the arrangement.  In exchange for the license, the Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The license is considered functional IP as the licensee is able to use and benefit from the license without the continued involvement of the Company.  The Company recorded $10.0 million of license revenue in the three and six months ended June&#160;30, 2020.  The Company will also receive royalties on net sales of any licensed products, such royalties will be recognized in the period the sales or usage occurs under the royalties sales-and usage based exception.  The Company has not recorded revenue related to the $1.0 million payment due upon receipt of marketing approval for the licensed product as such amount is constrained under the variable consideration guidance under ASC 606, Revenue from Contracts with Customers.  </span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Contract Assets and Contract Liabilities&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any contract assets (unbilled receivables) related to product sales as of&#160;June&#160;30, 2020, as customer invoicing generally occurs before or at the time of revenue recognition. The Company has a $4.0 million receivable, recorded as an Other receivable on the consolidated balance sheet, due from Cutia as of June&#160;30, 2020 which is expected to be paid in Q3 2020.  The Company did not have any contract liabilities as of&#160;June&#160;30, 2020, as the Company did not receive payments in advance of fulfilling its performance obligations to its customers.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Sales Commissions</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financing Component</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.&#160;Standard credit terms do not exceed 90 days.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Royalty Revenues&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is entitled to royalty payments with respect to sales of a product developed by a customer in collaboration with the Company. Revenues in the amount of $0.2 million were recorded during the three and six months ending </span></div>June&#160;30, 2020 and revenues in the amount of $0.3 million were recorded during the six months ending June&#160;30, 2019.  There was no revenue for the three months ending June&#160;30, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093664600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text">FAIR VALUE MEASUREMENT<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s assets and liabilities that are measured at fair value as of June&#160;30, 2020 and December&#160;31, 2019, are classified in the tables below in one of the three categories described in note 2H above:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:27pt;margin-top:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.43pt;">The Company&#8217;s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.</span></div><div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Foreign exchange risk management</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Occasionally, the Company purchases and writes non-functional currency options in order to hedge the currency exposure on the Company&#8217;s cash flow. The currency hedged items are denominated in New Israeli Shekels (&#8220;NIS&#8221;). The purchasing and writing of options is part of a comprehensive currency hedging strategy with respect to salary and rent expenses denominated in NIS. These transactions are at zero cost for periods of up to one year. The counterparties to the derivatives are major banks in Israel. As of June&#160;30, 2020, there were no hedged amounts.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company has a lien in the amount of $0.3 million on the Company&#8217;s marketable securities and a lien in the amount $0.3 million on the Company&#8217;s checking account, in respect of bank guarantees granted in order to secure the hedging transactions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093307560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">MARKETABLE SECURITIES</a></td>
<td class="text">MARKETABLE SECURITIES<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities as of June&#160;30, 2020, and December&#160;31, 2019 consist mainly of debt and mutual funds securities. The debt securities are classified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in other comprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in the consolidated statement of operations as finance income or expenses.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Equity securities with readily determinable fair value are measured at fair value. The changes in the fair value of equity investments are recognized through finance (income) expense in the condensed consolidated statements of operations.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israeli mutual funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020 and December&#160;31, 2019 the fair value, cost and gross unrealized holding gains and losses of the debt marketable securities owned by the Company were as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government and agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has considered factors regarding other than temporary impaired securities and determined that there are no securities with impairment that is other than temporary as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019 all of the Company&#8217;s debt securities were due within one year.</span></div><div style="text-indent:36pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020 and June&#160;30, 2019 the Company received aggregate proceeds of $36.4 million&#160;and $33.0 million, respectively, upon sale and maturity of marketable securities.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, and December&#160;31, 2019, the Company&#8217;s restricted marketable securities were $0.4 million and $0.4 million, respectively, due to a lien in respect of bank guarantees granted to secure hedging transaction and the Company&#8217;s rent agreements. See &#8220;Note 5- Fair Value Measurement&#8221; and &#8220;Note 10-Operating Lease&#8221; for more information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095093672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. The Company commenced capitalizing inventory for AMZEEQ upon FDA approval of AMZEEQ on October 18, 2019 and ZILXI on May 29, 2020. The Company periodically reviews its inventory levels and, if necessary, writes down inventory that is expected to expire prior to being sold, inventory in excess of expected sales requirements and inventory that fails to meet commercial sale specifications, with a corresponding charge to cost of goods sold. There were no inventory write-downs during the three and six months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093329880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text">LONG-TERM DEBTOn July 29, 2019 (the &#8220;Closing Date&#8221;) the Company secured up to $50 million in debt under a credit agreement &#8220;the Credit Agreement&#8221;) from two of its current shareholders, who are considered related parties (the &#8220;lenders&#8221;) and entered into a Securities Purchase Agreement with one of the lenders for gross proceeds of approximately&#160;$14 million, before deducting offering expenses (see &#8220;Note 9- Share Capital&#8221; for more information). On March 9, 2020, the Company entered into an Amended and Restated Credit Agreement and Guaranty (the &#8220;Amended and Restated Credit Agreement&#8221;), whereby the Company has guaranteed the indebtedness obligation of Foamix Pharmaceuticals Inc. and granted a first priority security interest in substantially all of our assets for the benefit of the lenders. The Amended and Restated Credit Agreement provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $50.0 million, of which $35.0 million was drawn as June&#160;30, 2020 and December&#160;31, 2019.<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Amended and Restated Credit Agreement, the debt comprises of three tranches: (a) $15 million funded at closing (the &#8220;Tranche 1 Loan&#8221;), (b) $20 million funded on December 17, 2019 (the &#8220;Tranche 2 Loan&#8221;) and (c) up to $15 million available after the closing date and prior to September 30, 2020 (the &#8220;Tranche 3 Loan&#8221;). The Tranche 2 Loan was borrowed following the FDA&#8217;s approval of the Company&#8217;s NDA for AMZEEQ (formerly known as FMX101) and listing of AMZEEQ in the FDA&#8217;s &#8220;Orange Book,&#8221; in addition to maintaining its arrangements with a third party for the commercial supply and manufacture of AMZEEQ. The Company shall be permitted to borrow the Tranche 3 Loan only following the achievement of certain revenue targets prior to September 30, 2020. Subject to any acceleration as provided in the Credit Agreement, including upon an event of default (as defined in the Amended and Restated Credit Agreement), the credit facility will mature on July 29, 2024 and bear interest equal to the sum of (A) 8.25% (subject to increase in accordance with the terms of the Credit Agreement) plus (B) the greater of (x) the one-month LIBOR as of the second business day immediately preceding the first day of the calendar month or the date of borrowing (if such loan is not outstanding as of the first day of the calendar month), as applicable, and (y) 2.75%. A fee in an amount equal to 1.0% of the aggregate principal amount of all loans made on any given borrowing date shall be payable to the lenders.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amended and Restated Credit Agreement contains certain financial covenants, including that the Company at all times after the date of FDA approval of AMZEEQ maintain a minimum aggregate compensating cash balance of $2.5 million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as a result of the negative impact on the Company's product sales of AMZEEQ due to the COVID-19 pandemic, the parties entered into Amendment No. 1 to Amended and Restated Credit Agreement (the "Amendment") on August&#160;5, 2020.  The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $6.0&#160;million for the fiscal quarter ending December 31, 2020 to $97.0&#160;million for the fiscal quarter ending June 30, 2024. The Amendment does not modify any of the conditions precedent to borrowing the Tranche 3 Loan, as described above and as set forth in the Amended and Restated Credit Agreement. See "Note 12 - Subsequent Events."</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company is in compliance with all covenants, including&#160;maintaining a minimum aggregate compensating cash balance as mentioned above. In the event where the Company fails to observe or perform any of the financial covenants the lenders may, by notice to the Company, declare the Term Loans then outstanding to be due and payable in whole, together with accrued interest and a Prepayment Premium (as defined in the Amended and Restated Credit Agreement ). Additionally, the Company will continue to monitor ongoing developments in connection with the COVID-19 pandemic, which may have an adverse impact on the Company&#8217;s commercial prospects, projected cash position and ability to remain in compliance with these covenants.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Amended and Restated Credit Agreement, there are no required payments of principal amounts until July 2023. Afterwards, the Company will pay 1.5% of the aggregate principal amount each month. The outstanding amount will be paid in full on July 2024.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, on the Closing Date, Foamix issued to the lenders warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, at an exercise price of $2.09 per share (the &#8220;Warrant&#8221;), which represents the five-day volume weighted average price of the ordinary shares as of the trading day immediately prior to the Closing Date. Following the Merger, the Warrants were exchanged, based on the Exchange Ratio, to 651,640 of the Company&#8217;s common stock, and adjusted the exercise price to $3.53 (See &#8220;Note 3 &#8211; Business Combinations&#8221; for more information relating to subsequent adjustment of warrant following the Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106)). Payment of the exercise price will be made, at the option of the lender, either in cash or as a reduction of common stock issuable upon exercise of the Warrant, with an aggregate fair value equal to the aggregate exercise price ("cashless exercise"), or any combination of the foregoing.&#160;The Warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants' expiration date, if in the money. The Warrants issued were classified as equity in accordance with ASC 815-40. Proceeds received under the Tranche 1 Loan were allocated to the Warrants and the Tranche 1 Loan on a relative fair value basis.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company incurred offering expenses of $1.1 million in connection with transactions contemplated by the Credit Agreement and the Securities Purchase Agreement, which were allocated to the Warrants, shares and debt consistently with the allocation of proceeds. The Company incurred additional expenses in the amount of $0.3 million from the borrowing of Tranche 2 Loan, allocated only to the debt.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Debt issuance costs are recorded on the consolidated balance sheet as a reduction of liabilities.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts allocated to the debt, net of issuance cost, are subsequently recognized at amortized cost using the effective interest method.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the debt as of June&#160;30, 2020 was $35.8 million and is categorized as Level 3. The valuation was performed by applying the income approach, under which the contractual present value method was used. The estimation of risk adjusted discount curve was based on public information reported in the financial statements of publicly traded venture lending companies.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June&#160;30, 2020 the company recorded interest expense of $1.0 million and $0.1 million relating to the interest and discount cost, respectively.  During the six months ended June&#160;30, 2020 the company recorded interest expense of $1.9 million and $0.2 million relating to the interest and discount cost, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093685368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text">SHARE CAPITAL<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Preferred stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company's Certificate of Incorporation, as amended, authorizes the Company to issue 20,000,000 of shares of $0.0001 par value preferred stock.  There were no shares of preferred stock issued and outstanding as of June&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares of preferred stock may be issued from time to time in one or more series.  The voting powers (if any), preferences and relative, participating, optional or other special rights, and the qualifications, limitations and restrictions of any series of preferred stock will be set forth in a Certificate of Designation filed pursuant to the Delaware General Corporation Law, as determined by the Company's Board of Directors.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Common stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company&#8217;s Certificate of Incorporation, as amended, authorizes the Company to issue 300,000,000 shares of $0.0001 par value common stock. See Note 12&#8212;Subsequent Events. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Issuance of stock</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 29, 2019, pursuant to the Credit Agreement and Securities Purchase Agreement, Foamix issued and sold, in a registered offering, an aggregate of 6,542,057 ordinary shares at a purchase price of $2.14 per share, later exchanged to 3,875,514 Menlo common stock at the closing of the Merger. The aggregate gross proceeds of approximately&#160;$14 million, before deducting issuance costs allocated as described in Note 8-Long Term Debt, in the amount of $0.3 million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the completion of the merger, on March 9, 2020, the Company issued 36,550,335 shares to Foamix shareholders.  On April 6, 2020, pursuant to the terms of the CSR Agreement, the Company issued 74,544,413 shares to Foamix shareholders.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 9, 2020, the Company completed an underwritten public offering of 31,107,500 shares of common stock at a price to the public of $1.85 per share.  The net proceeds of the offering were approximately $53.6&#160;million, after deducting underwriting discounts and commissions and other offering expenses.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Warrants</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the Credit Agreement signed on July 29, 2019, on the Closing Date, Foamix issued to the lender Warrants to purchase up to an aggregate of 1,100,000 of its ordinary shares, later exchanged to 1,980,660 of Menlo&#8217;s common stock. Upon the closing of the Merger, each Warrant received one CSR as described in Note 3- Business Combinations.  The warrants were exercisable immediately following the closing of the Credit Agreement and are due to expire on July 29, 2026. Any Warrants left outstanding will be cashless exercised on the Warrants&#8217; expiration date, if in the money.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exchange of Warrants from Foamix warrants to Menlo warrants and the additional CSR, was accounted for as a modification, by analogy, from the modification&#8217;s guidance under ASC 260-10-S99-2. The Company assessed the significance of the modification of the Warrants by comparing the fair value of the Warrants immediately before and after the amendments. In its assessment, it also considered additional qualitative factors. The Company concluded that the change of terms was not </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">significant. Therefore, the incremental fair value, in the amount of $41,000, of the modified Warrants over the original ones (as of modification date) was recognized in retained earnings as deemed dividend to the Warrants holders in the six months ended June&#160;30, 2020.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share-based compensation</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Equity incentive plans:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the Merger, the company adopted Foamix&#8217;s 2019 Equity incentive plan (the &#8220;2019 Plan&#8221;). As of June&#160;30, 2020, 2,849,843 shares remain issuable under the 2019 Plan.  In addition, the Company adopted the 2018 Omnibus Incentive Plan (the "2018 Plan"), effective January 2018.  Pursuant to the terms of the 2018 Plan in January 2020, the 2018 share reserve automatically increased by 976,105 shares of common stock issuable.  As of June&#160;30, 2020, 2,184,769 shares remain issuable under the 2018 Plan.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Employee Share Purchase Plan:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon closing of the Merger, the company adopted Foamix&#8217;s ESPP pursuant to which qualified employees (as defined in the ESPP) may elect to purchase designated shares of the Company&#8217;s common stock at a price equal to&#160;85%&#160;of the lesser of the fair market value of the common stock at the beginning or end of each semi-annual share purchase period (&#8220;Purchase Period&#8221;). Employees are permitted to purchase the number of shares purchasable with up to 15% of the earnings paid (as such term is defined in the ESPP) to each of the participating employees during the Purchase Period, subject to certain limitations under Section 423 of the U.S. Internal Revenue&#160;Code.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, 9,371,258 shares remain available for grant under the ESPP.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June&#160;30, 2020, 61,031 Foamix ordinary shares, later exchanged to 109,892 Menlo common stock, were issued to the employees.  </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Options and RSUs granted to employees and directors:</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the six months ended June&#160;30, 2020 and 2019, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,782,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.95-$3.13</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,589,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,299,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.48-$2.12</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">748,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* All amounts and exercise prices for pre-Merge grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options and RSUs granted to employees and directors during the six months ended June&#160;30, 2020, and the six months ended June&#160;30, 2019 was $11.4 million and $3.7 million, respectively.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of RSUs granted is based on the share price on the grant date.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">60.44%-69.83%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">60.40%-61.40%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">0.44%-1.26%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">2.20%-2.62%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 years</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the Merger, all outstanding options and RSUs granted by Foamix were exchanged to stock options and RSUs of Menlo&#8217;s common stock according to the Exchange Ratio. In addition, for each option and RSU the holder received a CSR as described in Note 3- Business Combination. This transaction was considered by the company to be a modification under ASC 718, Compensation - Stock Compensation. The modification did not affect the remaining requisite service period. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation expense of $60,000 related to the modification in the consolidated statement of operations for the three months ended March 31, 2020.  As described in Note 3 - Business Combination, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  The conversion was considered by the company to be a modification under ASC 718. As a result of the modification, for outstanding options and RSUs granted to Foamix employees and consultants, the Company recorded incremental compensation of $9.3 million for the three and six months ended June&#160;30, 2020.  As of June&#160;30, 2020 there is $6.6 million of unrecognized incremental compensation expense related to the modification which will primarily be amortized using a graded vesting method over the next 2 years.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Awards granted to options and RSU holders who are no longer employed or providing services to the Company are accounted for in accordance with ASC 815-40, Derivatives and Hedging. Under this guidance, the awards are classified as a derivative liability because the award no longer exchanges a fixed amount of cash for a fixed number of shares. Accordingly, as of March 9, 2020 the Company reclassified $1.6 million from additional paid-in capital to derivative liability on the unaudited condensed consolidated balance sheet. Prior to the reclassification of these awards as a liability instrument, the Company recorded an incremental compensation expense of $0.6 million due to the above mentioned modification in accordance with ASC 718. Subsequent to the reclassification of these awards as a liability instrument, the Company recorded incremental compensation expense of $0.5 million and $1.0 million for the three and six months ended June&#160;30, 2020, respectively.  As described in Note 3 - Business Combination, on April 6, 2020, the Company announced that study MTI-105 and study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis.  Accordingly, on April 6, 2020, pursuant to the terms of the CSR Agreement, each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share.  On April 6, 2020, the awards are exchangeable for a fixed amount of cash for a fixed number of shares and were remeasured to fair value and reclassified from derivative liability to additional paid-in capital.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, Menlo recognized all expenses relating to awards outstanding as of the Effective Date. These awards were subject to acceleration upon the change of control per the previous Menlo stock option plan.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:41.548%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095476744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASE</a></td>
<td class="text">OPERATING LEASE<div style="text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Operating lease agreements</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has operating leases for corporate offices, research and development facilities, and vehicles. The properties primarily relate to the Company&#8217;s principal executive office in Bridgewater, New Jersey, corporate offices in Redwood City, California and research and development facility in Israel.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 13, 2019, the Company signed an amendment to the original lease agreement for its principal executive office in Bridgewater, New Jersey (&#8220;The Amendment&#8221;). The Amendment includes an extension of the lease period of the 10,000 square feet previously leased under the original agreement (the &#8220;Original Space&#8221;) and an addition of 4,639 square feet (the &#8220;Additional Space&#8221;). The Company entered the Additional Space following a period of preparation by the lessor completed during September 2019 (the &#8220;Commencement Date&#8221;). The Amendment is due to expire on August 31, 2022.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to The Amendment of the lease on the Current Space, the Company recognized an additional right of use asset and liability in the amount of $0.7 million. The Additional Space was considered a new lease agreement and was recognized as a right of use asset and liability, in the amount of $0.3 million, on the Commencement Date.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s corporate offices in Redwood City, California are under lease through December&#160;31, 2020 with a base rent of approximately $60,000 per month. Given the short-term nature of the remaining lease period, the combined company did not recognize a right-of-use asset and liability and expects to recognize the lease payments in its statements of operations and comprehensive loss on a straight-line basis over the remaining lease term.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease agreement for the research and development facility in Israel is linked to the Israeli consumer price index (&#8220;CPI&#8221;) and due to expire in December 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the Company has entered into operating lease agreements in connection with the leasing of vehicles. The lease periods are generally for three-year terms. To secure the terms of certain of the vehicle lease agreements, the Company has made prepayments to the leasing company, representing approximately 3 months of lease payments. These amounts have been recorded as part of the operating lease right-of-use assets.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June&#160;30, 2020, the Company has a lien in the amount of $0.7 million on the Company&#8217;s cash and marketable securities in respect of bank guarantees granted in order to secure the lease agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095591656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company may periodically become subject to legal proceedings and claims arising in connection with its business. As of June&#160;30, 2020, no claims or actions pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">IPO Lawsuits</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 8, 2018 and January 28, 2019, two purported class actions were filed in the Superior Court of California, San Mateo County, against the Company and certain of our officers and directors. The actions are entitled Savelstrov v. Menlo Therapeutics Inc., et al., and McKay v. Menlo Therapeutics Inc., et al. The underwriters for our initial public offering were also named as defendants in these lawsuits. The complaints contain identical allegations against the same defendants. Both complaints alleged&#160;that the Registration Statement and prospectus for our initial public offering contained false and misleading statements in violation of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 due to allegedly false and misleading statements in connection with our initial public offering. The complaints seek, among other things, an award of damages in an amount to be proven at trial, along with reimbursement of reasonable costs and expenses, including attorneys&#8217; fees and expert fees. The McKay action has been consolidated with the Savelstrov action and the claim for violations of Section 12(a)(2) has been dismissed.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The parties have mediated the consolidated lawsuit and reached a settlement, providing for payment to the class of plaintiffs in the amount of $9.5 million, the vast majority of which will be paid by the Company's insurance carriers, in return for a release of all claims against the defendants, including the Company and its current and former officers and directors. The </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">settlement is subject to final documentation and Court approval. The Court preliminarily approved the settlement on April 24, 2020, and will consider whether to grant final approval of the settlement at a hearing scheduled for August 14, 2020. Menlo accrued for the remaining settlement amount that is not covered by insurance carriers as of December&#160;31, 2019, which did not have a material impact on its financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Merger Lawsuits</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Seven lawsuits (collectively, the &#8220;Merger Lawsuits&#8221;) were filed in various U.S. federal district courts against Foamix and certain other defendants in connection with the Merger. The lawsuits generally alleged that the registration statement on Form S-4 and the prospectus/joint proxy statement included therein included false or misleading information regarding the Merger in violations of Section 14(a) and Section 20(a) of the Exchange Act and/or Rule 14a 9 promulgated under the Exchange Act. In addition, one of the lawsuits alleged that the members of Foamix&#8217;s board of directors breached their fiduciary duties in connection with the Merger. The plaintiffs sought, among other things, to enjoin consummation of the Merger, or alternatively rescission or rescissory damages; to compel the individual defendants to disseminate a joint proxy statement/prospectus that does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; a declaration that defendants violated Sections 14(a) and/or 20(a) of the Exchange Act; a declaration that the Merger Agreement was entered into in breach of fiduciary duty and is therefore invalid and unenforceable; an order directing the individual defendants to commence a sale process for Foamix and obtain a transaction; and an award of costs, including attorneys&#8217; and experts&#8217; fees and expenses, as well as an accounting of damages allegedly suffered by the plaintiffs. The plaintiffs have agreed the Lawsuits were rendered moot by subsequent disclosure, and on April 22, 2020, each of the plaintiffs and defendants named in the Merger Lawsuits entered into a mootness resolution agreement pursuant to which the plaintiffs agreed to dismiss their lawsuits with prejudice as to the named plaintiff and Foamix agreed to pay a </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">de minimis</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mootness fee to plaintiffs&#8217; counsel. As of May 4, 2020, each of the Merger Lawsuits has been dismissed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093689928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;">Reverse Stock Split Proposal</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the Company's annual meeting of stockholders held on August 3, 2020, the Company's stockholders voted to approve a proposal to adopt an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation to effect (a) a reverse stock split of the Company&#8217;s outstanding shares of common stock, at a reverse stock split ratio ranging from 1-for-2 shares to 1-for-7 shares, which may be determined by the Board at a later date, and (b) a reduction in the number of authorized shares of the Company&#8217;s common stock by a corresponding ratio. The exact timing for selection of the reverse stock split ratio and the effective date of the reverse stock split will be determined by the Board based upon its evaluation as to when such action will be most advantageous to the Company and its stockholders. The Board may delay or abandon the reverse stock split at any time prior to the effective time of the reverse stock split, if the Board determines that the reverse stock split is no longer in the best interests of the Company or its stockholders. The reverse stock split, if implemented, would become effective upon the filing of a charter amendment with the Delaware Secretary of State. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amendment to Amended and Restated Credit Agreement</span></div>On August&#160;5, 2020, the Company and the lenders entered into the Amendment. The Amendment provides for a covenant "holiday" with respect to the minimum net revenue covenant in the Amended and Restated Credit Agreement, such that the compliance with such covenant will commence with the fiscal quarter ending on December 31, 2020, rather than September 30, 2020.  Accordingly, as of the last day of each fiscal quarter commencing on the fiscal quarter ending December 31, 2020, the Company must generate consolidated net product revenue for the trailing 12-month period in amounts set forth in the Amendment, which range from $6.0&#160;million for the fiscal quarter ending December 31, 2020 to $97.0&#160;million for the fiscal quarter ending June 30, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165609320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ReverseMergerPolicyTextBlock', window );">Reverse Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Reverse Merger</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 10, 2019, the Company, Foamix Pharmaceuticals Ltd. (&#8220;Foamix&#8221;) and Giants Merger Subsidiary Ltd. (&#8220;Merger Sub&#8221;), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the &#8220;Merger Agreement&#8221;). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the &#8220;Merger&#8221;) on March 9, 2020 (the &#8220;Effective Date&#8221;).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company&#8217;s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See &#8220;Note 3 &#8211; Business Combination&#8221; for more information on the Merger.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company launched AMZEEQ&#160;in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company&#8217;s activities prior to the commercial launch of AMZEEQ&#160;had primarily consisted of </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the six months ended June&#160;30, 2020, the Company incurred a net loss of $207.7 million and used&#160;$88.1 million of cash in operations. As of June&#160;30, 2020, the Company had cash, cash equivalents and investments of $100.4 million and an accumulated deficit of $518.3 million.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company has revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its other topical minocycline product candidates.  The Company does not currently intend to pursue serlopitant further.  In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes that its existing cash, cash equivalents and investments as of June&#160;30, 2020 and projected cash flows from revenues and the funds that the Company is entitled to receive under the license agreement with Cutia Therapeutics (HK) Limited ("Cutia"), will provide sufficient resources to fund its current ongoing needs for at least the next 12 months from the issuance of these financial statements, though there may be need for additional financing activity if the on-going COVID-19 pandemic continues for an extended duration and as the Company continues to grow.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Basis of Presentation<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial statements. In the opinion of management, the Company has made&#160;all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company&#8217;s condensed consolidated financial position, results of operations, cash flow and statement of stockholders' equity for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These unaudited interim condensed consolidated financial statements should be read in conjunction with Foamix&#8217;s audited consolidated financial statements for the year ended December&#160;31, 2019, included in the Company&#8217;s Current Report on Form 8-K/A filed with the Securities and Exchange Commission ("SEC") on May 7, 2020, and the Company's unaudited consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 11, 2020. </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The results for the three and six months ended June&#160;30, 2020 are not necessarily indicative of the results expected for the year ending December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Principles of ConsolidationThe consolidated financial statements include the accounts of Menlo and its subsidiaries. Intercompany balances and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated upon consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Use of Estimates<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company&#8217;s estimates.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which the pandemic impacts worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. For the three and six months ended June 30, 2020, the Company's product sales for AMZEEQ were negatively impacted by office closures due to the pandemic.  In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June&#160;30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition.  The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information).  The Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Business Acquisition<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s unaudited interim condensed consolidated financial statements include the operations of an acquired business after the completion of the acquisition. The Company accounts for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of In-Process Research and Development and Goodwill be recorded on the balance sheet.&#160;Transaction costs are expensed as incurred.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting.&#160; For example, the Company uses fair value in the initial recognition of net assets acquired in a business combination and when measuring impairment losses.&#160; The Company estimates fair value using an exit price approach, which requires, among other things, that Company determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may use one or all of the following techniques:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Income approach, which is based on the present value of a future stream of net cash flows.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our fair value methodologies depend on the following types of inputs:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Asset Impairment</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company reviews all of its long-lived assets for impairment indicators throughout the year. Impairment testing is performed for indefinite-lived intangible assets annually (or sooner if warranted) and for all other long-lived assets whenever impairment indicators are present. When necessary, the Company records charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Revenue Recognition<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for its revenue transactions under FASB ASC Topic 606,&#160;Revenue from Contracts with Customers. In accordance with ASC Topic 606, the Company recognizes revenues when its customers obtain control of its product for an amount that reflects the consideration it expects to receive from its customers in exchange for that product. To determine revenue recognition for contracts that are determined to be in scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when such performance obligation is satisfied.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s customers include a limited number of national and select regional wholesalers (the &#8220;distributors&#8221;). These distributors subsequently resell the product, primarily to retail pharmacies that dispense the product to patients. Net product revenue is typically recognized when distributors obtain control of the Company&#8217;s products, which occurs at a point in time, typically upon delivery of product to the distributors. The Company evaluates the creditworthiness of each of its distributors to determine whether it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur. The Company does not assess whether a contract has a significant financing component if the expectation is such that the period between the transfer of the promised goods to the customer and the receipt of payment will be less than one year. Standard credit terms do not exceed 90 days. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that would have been recognized is one year or less or the amount is immaterial. Shipping and handling costs related to the Company&#8217;s product sales are included in selling, general and administrative expenses.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net product revenues through&#160;June&#160;30, 2020&#160;were generated through sales of AMZEEQ, which was approved by the FDA in October 2019 and was commercially launched in the United States in January 2020. Product revenue is recorded net of distribution fees, trade discounts, allowances, rebates, copay program coupons, chargebacks, estimated returns and other incentives. These reserves are classified as either reductions of accounts receivable or as current liabilities. The estimates of reserves established for variable consideration reflect current contractual and statutory requirements, known market events and trends, industry data and forecasted customer mix. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net product revenues only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from these estimates. If actual results vary, estimates may be adjusted in the period such change in estimate becomes known, which could have an impact on earnings in the period of adjustment. See &#8220;Note 4 &#8211; Revenue Recognition&#8221; for more information.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 23, 2020, the Company announced that it entered into a license agreement with Cutia for AMZEEQ as well as certain of the Company's other topical minocycline product candidates, once approved, on an exclusive basis in Greater China.  Under the terms of the agreement, Cutia will have an exclusive license to obtain regulatory approval of and commercialize AMZEEQ, ZILXI and, if approved in the U.S., FCD105 in the Greater China territory.  The Company will supply the finished licensed </span></div>products to Cutia for clinical and commercial use.  The Company will receive an upfront cash payment of $10.0 million ($6.0 million received in the three months ended June&#160;30, 2020) and will be eligible to receive an additional $1.0 million payment upon the receipt of marketing approval in China of the first licensed product.  The Company will also receive royalties on net sales of any licensed products.  The license is determined to be a distinct performance obligation of the arrangement, therefore the Company recognizes the revenues from the upfront license fee when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  See "Note 4 - Revenue Recognition" for more information.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Allowance for credit losses</a></td>
<td class="text">Allowance for credit lossesAn allowance for doubtful accounts is maintained for potential credit losses based on the aging of trade receivables, historical bad debts experience and changes in customer payment patterns. Trade receivable balances are written off against the allowance when it is deemed probable that the receivable will not be&#160;collected.&#160;Trade receivables, net are stated net of reserves for certain sales allowances and provisions for doubtful accounts. Provisions for doubtful accounts were not material for the three and six months ended June&#160;30, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative instrumentsThe Company recognizes all derivative instruments as either assets or liabilities in the unaudited condensed consolidated balance sheet at their respective fair values. All gains and losses associated with derivatives are reported as a finance expense (income) in the accompanying condensed consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fair value measurement<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1:&#160;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active market data of similar or identical assets or liabilities.</span></div><div style="text-indent:-72pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Loss per share<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The calculation of the weighted-average number of common stock outstanding during the period in which the reverse merger occurs was based on:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The number of common stock outstanding from the beginning of that period to the merge date was computed on the basis of the weighted-average number of common stock of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The number of common outstanding common stock outstanding from the merge date to the end of that period was the actual number of common stock of the legal acquirer (the accounting acquiree) outstanding during that period.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The basic and diluted loss per share for each comparative period before the acquisition date presented in the consolidated financial statements following the reverse merger was calculated by dividing (a) by (b):</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">a.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">The loss of the legal acquiree attributable to common stockholders in each of those periods.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">b.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.94pt;">The legal acquiree's historical weighted-average number of common stock outstanding multiplied by the exchange ratio established in the merge agreement</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of Ordinary shares outstanding during the period. Diluted net loss per share is based upon the weighted average number </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury share method when dilutive.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,975,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,037,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,082,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,576,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,893,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,272,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the above, the CSR was excluded from the calculation of the diluted net loss per share because its effect would have been anti-dilutive for the periods presented. On April 6, 2020, the Company announced that each of Menlo&#8217;s Phase III PN Trials (study MTI-105 and study MTI-106) did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based upon a 4-point improvement responder analysis. Each CSR was converted into 1.2082 shares of Menlo common stock, resulting in an effective Exchange Ratio in the Merger of 1.8006 shares of Menlo common stock for each Foamix ordinary share. The conversion of the CSR also affected the Exchange Ratio of the pre-Merger Foamix equity awards and warrants outstanding as of March 9, 2020. See "Note 3 - Business Combination" for more information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Newly issued and recently adopted accounting pronouncements<div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Guidance Issued:</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2020-4, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting" (ASU 2020-4), which provides guidance to alleviate the burden in accounting for reference rate reform by allowing certain expedients and exceptions in applying generally accepted accounting principles to contracts, hedging relationships, and other transactions impacted by reference rate reform. The provisions of ASU 2020-4 apply only to those transactions that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. Adoption of the provisions of ASU 2020-4 are optional and are effective from March 12, 2020 through December 31, 2022. The Company is currently evaluating the impact of ASU 2020-4 on its consolidated financial statements.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued Accounting Standards Update No. 2016-13,&#160;&#8220;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;&#160;(ASU 2016-13), which requires companies to measure credit losses of financial instruments, including customer accounts receivable, utilizing a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional Accounting Standard Updates to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. As a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023 or at such time where it is no longer a smaller reporting company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_LiquidityAndCapitalResourcesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Capital Resources</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_LiquidityAndCapitalResourcesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ReverseMergerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Merger</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ReverseMergerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919260-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919272-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093701160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following average stock options, restricted stock units (&#8220;RSUs&#8221;), warrants and incremental shares to be issued under the employee stock purchase plan (&#8220;ESPP&#8221;) were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (share data):</span></div><div style="padding-right:18pt;margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.859%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding stock options, RSUs and shares under the ESPP</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,975,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,037,802&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,082,037&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,576,229&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,893,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,272,336&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660090612408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock', window );">Schedule of Merger Consideration to be transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is the Merger Consideration (as defined in the Merger Agreement) was transferred to effect the Merger:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,757&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deemed (for accounting purposes only) conversion of Menlo equity awards</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total consideration*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">131,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* This amount reflects total consideration prior to reduction in respect of the CSRs (which had a fair value of $19.6 million as of the Merger Date) that were issued to Foamix shareholders and that reduced the Menlo stockholders&#8217; relative ownership in the combined company. If the effect of the CSRs is included, the total consideration deemed paid by Foamix, as the accounting acquirer, to Menlo stockholders and equity award holders in the Merger would be reduced to approximately $111.4 million, as shown in the purchase price allocation table below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of allocation of the purchase price to the fair values of assets acquired and liabilities assumed</a></td>
<td class="text"><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investment in marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In-process research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated purchase price*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div><span></span>
</td>
<td class="text">The Company completed its analysis of the allocation of the purchase price to the fair values of assets acquired and liabilities assumed as follows:<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">March 9, 2020</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,641&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investment in marketable securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,703&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,581&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In-process research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">117,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,827)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Estimated purchase price*</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* Reflects reduction in the purchase price deemed paid to Menlo stockholders in the Merger on the assumption that the CSRs, in an aggregate value of $19.6 million, convert into additional shares of the combined company for the Foamix shareholders, thereby resulting in a lower percentage of the combined company&#8217;s outstanding shares being owned by Menlo stockholders following the Merger.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock', window );">Schedule of the calculation of goodwill from the merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The purchase price of the transaction and the excess purchase price over the fair value of the identifiable net assets acquired, are calculated as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 9, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase price</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: fair value of net assets acquired, including other identifiable intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(107,398)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,045&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock', window );">Schedule of indefinite-lived intangible IPRD assets acquired in the merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The IPR&amp;D recognized relates to Menlo&#8217;s once</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">-</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">daily oral serlopitant for the treatment of pruritus (itch) associated with PN that has not reached technological feasibility as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:83.630%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Intangible asset</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Estimated Fair Value</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acquired indefinite life intangible assets*</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value of identified intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,300&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>* Represents acquired IPR&amp;D assets which are initially recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the research and development period, these assets will not be amortized into earnings; instead these assets will be subject to periodic impairment testing.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of pro forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual Menlo results of operations included in the condensed consolidated statement of operation for the three and six months ended June&#160;30, 2020:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.222%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.598%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss attributable to Menlo</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,637&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:41.713%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.596%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.384%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.601%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands, except per share data)</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Unaudited)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Unaudited)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenues</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,688&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,438&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">308&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">167,441&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,470&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">205,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69,547&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Loss per share - basic and diluted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.21&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Transaction costs</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,931)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acceleration of stock based compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,199)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total Adjustments</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,130)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of consideration to be transferred to effect the Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the calculation of goodwill from the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095215352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s assets and liabilities that are measured at fair value as of June&#160;30, 2020 and December&#160;31, 2019, are classified in the tables below in one of the three categories described in note 2H above:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:48.879%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.730%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.732%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 1</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 2</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Total</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:-9pt;padding-left:27pt;margin-top:10pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.43pt;">The Company&#8217;s debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorized as Level 2.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093343752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s marketable securities:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Israeli mutual funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">591&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,680&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (Loss) on Securities</a></td>
<td class="text">As of June&#160;30, 2020 and December&#160;31, 2019 the fair value, cost and gross unrealized holding gains and losses of the debt marketable securities owned by the Company were as follows:<div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,018&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost or<br/>amortized<br/>cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>unrealized<br/>holding gains</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Government and agency bonds</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,031&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,030&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S Treasury bills</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,475&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660175308776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the Company&#8217;s inventory:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,387&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">954&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,801&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660093363544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock', window );">Schedule of share-based compensation awards granted for options and RSUs during the period</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the six months ended June&#160;30, 2020 and 2019, the Company granted options and RSU as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,782,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.95-$3.13</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,589,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:41.088%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.676%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.679%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Award<br/>amount*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercise price<br/>range*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vesting period</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expiration</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees and Directors:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,299,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">$1.48-$2.12</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">748,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1 year -4 years</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">* All amounts and exercise prices for pre-Merge grants are presented following the exchange to Menlo options and RSUs at the Exchange Ratio described in Note 3-Business Combination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of underlying data used for computing the fair value of the options</a></td>
<td class="text">The fair value of options granted was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended<br/>June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">60.44%-69.83%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">60.40%-61.40%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">0.44%-1.26%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">2.20%-2.62%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table illustrates the effect of share-based compensation on the statements of operations:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:41.548%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.386%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.639%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">384&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,566&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">738&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,004&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,961&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,388&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,337&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095054952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of lease liabilities are as follows:</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:84.363%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">993&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,118&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097328568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>segments</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 167,440<span></span>
</td>
<td class="nump">$ 18,993<span></span>
</td>
<td class="nump">$ 207,673<span></span>
</td>
<td class="nump">$ 34,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,070)<span></span>
</td>
<td class="num">$ (29,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and investments</a></td>
<td class="nump">100,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (518,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (518,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (310,587)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660096061640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationEffectiveExchangeRatio', window );">Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_UpfrontRoyaltyReceipt', window );">Upfront royalty receipt | $</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents', window );">Additional royalty upon receipt of marketing approval in China | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember', window );">Outstanding stock options, RSUs and shares under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,975,385<span></span>
</td>
<td class="nump">11,037,802<span></span>
</td>
<td class="nump">12,082,037<span></span>
</td>
<td class="nump">10,576,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,272,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional royalty receipt upon occurrence of certain event related to licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationEffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationEffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_UpfrontRoyaltyReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront royalty receipt upon delivery of licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_UpfrontRoyaltyReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165477368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 11, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="nump">1.2082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_EffectiveExchangeRatio', window );">Effective Exchange Ratio (CSR per share)</a></td>
<td class="nump">1.8006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders', window );">Ownership percentage of parent by subsidiary stockholders</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders', window );">Ownership percentage of parent by parent stockholders</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss', window );">Contingent Stock Right Remeasurement</a></td>
<td class="nump">$ 84,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,726<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">84,726<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="nump">$ 104,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement', window );">Share issued and delivered upon CSR conversion (in shares) | shares</a></td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">In process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards', window );">Deemed (for accounting purposes only) conversion of Menlo equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationConsiderationTransferredGross', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes', window );">Number of shares deemed (for accounting purposes only) issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix | Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ExchangeRatio', window );">Exchange ratio per ordinary share for common stock (share per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessAcquisitionContingentStockRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of contingent stock right issued in connection with the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessAcquisitionContingentStockRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquiree Common Stock Rights Converted to Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred consisting of the conversion of equity awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationConsiderationTransferredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationConsiderationTransferredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares deemed, for accounting purposes only, to be issued in the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockConsiderationRemeasurementGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Stock Consideration, Remeasurement Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockConsiderationRemeasurementGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_EffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_EffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_PostMergerParentOwnershipByPreMergerParentStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_PostMergerParentOwnershipByPreMergerParentStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660100960392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Consideration Transferred in Merger (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 09, 2020</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders</a></td>
<td class="nump">$ 123,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards', window );">Deemed (for accounting purposes only) conversion of Menlo equity awards</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationConsiderationTransferredGross', window );">Total consideration</a></td>
<td class="nump">131,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, fair value of liability</a></td>
<td class="nump">19,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration net of the effect of CSRs</a></td>
<td class="nump">$ 111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred consisting of the conversion of equity awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationConsiderationTransferredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationConsiderationTransferredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165592824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Purchase Price Allocation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocations of purchase price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="nump">$ 19,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Allocations of purchase price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">38,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="nump">22,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">In-process research and development</a></td>
<td class="nump">50,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="nump">117,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(5,827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="num">(5,827)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">111,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock', window );">Value of CSR converted into additional shares of the combined company</a></td>
<td class="nump">$ 19,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquiree Common Stock Rights Converted to Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660094763080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Goodwill (Details) - Foamix<br></strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationGoodwillAbstract', window );"><strong>Business Combination, Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">111,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets', window );">Less: fair value of net assets acquired, including other identifiable intangibles</a></td>
<td class="num">(107,398,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 4,045,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of net assets acquired including other identifiable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095049336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATION - IPRD and CSR (Details) - Foamix<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>In-Process Research and Development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired indefinite life intangible assets</a></td>
<td class="nump">$ 50,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Fair value of identified intangible assets</a></td>
<td class="nump">$ 50,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097330296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Pro Forma (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Loss attributable to Menlo</a></td>
<td class="nump">7,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenues</a></td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,438<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 167,441<span></span>
</td>
<td class="nump">$ 35,470<span></span>
</td>
<td class="nump">$ 205,082<span></span>
</td>
<td class="nump">$ 69,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Loss per share - basic (in USD per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Loss per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 1.21<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalIncomeStatementElementsAbstract', window );"><strong>Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdjustmentsToSupplementalProformaTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (14,931)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation', window );">Acceleration of stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,199)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations', window );">Total Adjustments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (22,130)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdjustmentsToSupplementalProformaTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdjustmentsToSupplementalProformaTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalIncomeStatementElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalIncomeStatementElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660096472504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 23, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances', window );">Product sales provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_EstimateOfProductReturnRateMinimum', window );">Minimum estimate product return (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_EstimateOfProductReturnRateMaximum', window );">Maximum estimate product return (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,688,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,438,000<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_UpfrontRoyaltyReceipt', window );">Upfront royalty receipt</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents', window );">Additional royalty upon receipt of marketing approval in China</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customers | Revenue from Contract with Customer, Product and Service Benchmark | Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customers | Revenue from Contract with Customer, Product and Service Benchmark | Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customers | Revenue from Contract with Customer, Product and Service Benchmark | Distributor Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Product Sales</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional royalty receipt upon occurrence of certain event related to licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_EstimateOfProductReturnRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum estimate of product sales return rate at reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_EstimateOfProductReturnRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_EstimateOfProductReturnRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum estimate of product sales return rate at reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_EstimateOfProductReturnRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_UpfrontRoyaltyReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront royalty receipt upon delivery of licensed products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_UpfrontRoyaltyReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mnlo_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mnlo_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mnlo_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mnlo_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mnlo_DistributorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mnlo_DistributorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165903032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 2,609<span></span>
</td>
<td class="nump">$ 16,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">15,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660090612408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASURMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DerivateCostsForYear', window );">Currency hedging cost for a year</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DerivativeMaximumTermOfContract', window );">Currency hedging transactions, maximum term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAmountOfHedgedItem', window );">Derivative, Amount of Hedged Item</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions', window );">Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions', window );">Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions</a></td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DerivateCostsForYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction cost of currency hedging for year from the time of occurrence of the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DerivateCostsForYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DerivativeMaximumTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period the derivative contract is outstanding, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DerivativeMaximumTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAmountOfHedgedItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of hedged item in hedging relationship. Excludes hedged asset or liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAmountOfHedgedItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097361128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">$ 2,609<span></span>
</td>
<td class="nump">$ 16,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=mnlo_IsraeliMutualFundsMember', window );">Israeli mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember', window );">U.S Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Marketable securities</a></td>
<td class="nump">$ 2,018<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=mnlo_IsraeliMutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=mnlo_IsraeliMutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097009608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 2,018<span></span>
</td>
<td class="nump">$ 15,660<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or amortized cost</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">15,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or amortized cost</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember', window );">U.S Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,031<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S Treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost or amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095448232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Permanent impairment loss, debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturity of marketable securities</a></td>
<td class="nump">36,400,000<span></span>
</td>
<td class="nump">$ 33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted Investments</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095263736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">3,387,000<span></span>
</td>
<td class="nump">3,387,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">954,000<span></span>
</td>
<td class="nump">954,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,460,000<span></span>
</td>
<td class="nump">1,460,000<span></span>
</td>
<td class="nump">856,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 5,801,000<span></span>
</td>
<td class="nump">$ 5,801,000<span></span>
</td>
<td class="nump">$ 1,356,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660165597640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT - Credit agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>tranches</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($) </div>
<div>shareholders </div>
<div>lenders</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CreditAgreementNumberOfTrenches', window );">Number of trenches | tranches</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Base interest rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DebtInstrumentFeePercent', window );">Debt instrument fee as a percent of the aggregate principal amount</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent', window );">Monthly payment as a percent of the aggregate principal amount beginning July 2023</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DebtCovenantsAbstract', window );"><strong>Debt covenants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval', window );">Minimum aggregate cash balance to maintain after FDA approval</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement | Forecast | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance', window );">Debt covenant, minimum quarterly revenue compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 97,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement | One-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember', window );">Amended and Restated Credit Agreement, Trench 1 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember', window );">Amended and Restated Credit Agreement, Trench 2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember', window );">Amended and Restated Credit Agreement, Trench 3 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnlo_ShareholderLenderMember', window );">Shareholder Lender | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberOfLenders', window );">Number of lenders involved | shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnlo_RegisteredOfferingMember', window );">Registered offering per securities purchase agreement | Shareholder Lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberOfLenders', window );">Number of lenders involved | lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CreditAgreementNumberOfTrenches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trenches of credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CreditAgreementNumberOfTrenches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Minimum Quarterly Revenue Compliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DebtCovenantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DebtCovenantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DebtInstrumentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument, as a percent of the aggregate principal amount of all loans outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DebtInstrumentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required monthly payment as a percent of the aggregate principal amount from Jul 2023 through July 2024.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from issuance of common stock before deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum aggregate cash balance to maintain after FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NumberOfLenders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of lenders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NumberOfLenders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnlo_ShareholderLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnlo_ShareholderLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlo_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlo_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095836520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT - Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2020</div></th>
<th class="th"><div>Jul. 29, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ClassOfWarrantAbstract', window );"><strong>Warrants issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_StockIssuedDuringPeriodSharesWarrantExchange', window );">Shares issued in exchange of warrants</a></td>
<td class="nump">651,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Incurrred expenses related to Credit Agreement and Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember', window );">Amended and Restated Credit Agreement, Trench 2 Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Incurrred expenses related to Credit Agreement and Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember', window );">Amended And Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember', window );">Credit Agreement | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNetAbstract', window );"><strong>Debt offering expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=mnlo_FoamixMember', window );">Foamix | Shareholder Lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ClassOfWarrantAbstract', window );"><strong>Warrants issued</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares that may be purchased by exercise of warrants</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ClassOfWarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ClassOfWarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_StockIssuedDuringPeriodSharesWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period for the exchange of warrants following the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_StockIssuedDuringPeriodSharesWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnlo_ShareholderLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnlo_ShareholderLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660086482168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>votes </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>votes </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Incurrred expenses related to Credit Agreement and Securities Purchase Agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue', window );">Fair value of options and RSUs granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,388<span></span>
</td>
<td class="nump">12,527<span></span>
</td>
<td class="nump">$ 2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_EffectiveExchangeRatio', window );">Effective Exchange Ratio (CSR per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Additional paid in capital reclassified to derivate liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of fair market value used as purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percent of annual earnings that may be used to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,371,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,371,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2018PlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance', window );">Increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">976,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued pursuant to the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessAcquisitionContingentStockRightIssued', window );">Number of contingent stock rights issued (in CSR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification', window );">Deemed dividend to warrants holders due to warrant modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix | Employees and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation costs incurred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost', window );">Incremental compensation costs incurred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod', window );">Incremental compensation costs, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix | No longer employed or providing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation costs incurred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment', window );">Additional paid in capital reclassified to derivate liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost', window );">Incremental compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember', window );">Foamix | CSR Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued pursuant to the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,550,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mnlo_PublicStockOfferingMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (USD/share) | $ / shares</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">31,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received in a transaction | $</a></td>
<td class="nump">$ 53,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CommonStockVotingRightsNumberPerShare', window );">Number of votes entitled to each ordinary share | votes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mnlo_OrdinarySharesMember', window );">Ordinary Shares | Foamix | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mnlo_OrdinarySharesMember', window );">Ordinary Shares | Registered offering per securities purchase agreement | Foamix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,542,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (USD/share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Foamix | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares that may be purchased by exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Number of shares issued for warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,980,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessAcquisitionContingentStockRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of contingent stock right issued in connection with the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessAcquisitionContingentStockRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Increase in Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CommonStockVotingRightsNumberPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitled to each ordinary share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CommonStockVotingRightsNumberPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_EffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_EffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from issuance of common stock before deducting offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of options and equity instruments other than options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Unrecognized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_CSRAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_CSRAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlo_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlo_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mnlo_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mnlo_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mnlo_FoamixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mnlo_FoamixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mnlo_RegisteredOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mnlo_RegisteredOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660195421960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Options and RSU Grants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option, award amount</a></td>
<td class="nump">4,782,444<span></span>
</td>
<td class="nump">2,299,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, minimum (in usd per share)</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, maximum (in usd per share)</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU, award amount</a></td>
<td class="nump">2,589,710<span></span>
</td>
<td class="nump">748,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660098964392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Fair value assumptions (Details) - Options<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based payment assumptions for computing fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">60.44%<span></span>
</td>
<td class="nump">60.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">69.83%<span></span>
</td>
<td class="nump">61.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.26%<span></span>
</td>
<td class="nump">2.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660100271848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Schedule of Share-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 10,768<span></span>
</td>
<td class="nump">$ 1,388<span></span>
</td>
<td class="nump">$ 12,527<span></span>
</td>
<td class="nump">$ 2,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">3,566<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 7,718<span></span>
</td>
<td class="nump">$ 1,004<span></span>
</td>
<td class="nump">$ 8,961<span></span>
</td>
<td class="nump">$ 1,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660097278904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASE - Operating lease costs (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,558<span></span>
</td>
<td class="nump">$ 1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_VehicleLeasePrepaymentPeriod', window );">Vehicles lease prepaid period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_RestrictedInvestmentsToSecureLeaseAgreements', window );">Lien on marketable securities to secure lease agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member] | Redwood City, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_OriginalSpaceMember', window );">Original Space | Bridgewater, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_FacilitySpaceUnderLease', window );">Facility space leased | ft&#178;</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_AdditionalSpaceMember', window );">Additional Space | Bridgewater, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_FacilitySpaceUnderLease', window );">Facility space leased | ft&#178;</a></td>
<td class="nump">4,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_FacilitySpaceUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Size of the facility under lease, in square feet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_FacilitySpaceUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_RestrictedInvestmentsToSecureLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_RestrictedInvestmentsToSecureLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_VehicleLeasePrepaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of prepaid to secure lease of vehicles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_VehicleLeasePrepaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mnlo_RedwoodCityCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mnlo_RedwoodCityCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_OriginalSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_OriginalSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mnlo_BridgewaterNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mnlo_BridgewaterNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_AdditionalSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mnlo_AdditionalSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095590264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASE - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 2,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660095743608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>lawsuits</div>
</th>
<th class="th">
<div>Nov. 08, 2018 </div>
<div>lawsuits</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=mnlo_OfficersAndDirectorsMember', window );">Current and Former Officers and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for settlement | $</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mnlo_InitialPublicOfferingLawsuitsMember', window );">IPO Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberOfClassActions', window );">Number of class actions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mnlo_MergerLawsuitsMember', window );">Merger Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberOfClassActions', window );">Number of class actions</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember', window );">Merger Lawsuits, Breach of Fiduciary Duties Of BOD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberOfClassActions', window );">Number of class actions</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NumberOfClassActions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of class actions lawsuit brought against the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NumberOfClassActions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=mnlo_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=mnlo_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mnlo_InitialPublicOfferingLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mnlo_InitialPublicOfferingLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mnlo_MergerLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mnlo_MergerLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660096476616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2020</div></th>
<th class="th">
<div>Apr. 06, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_ContingentStockRightSharesConversion', window );">Number of common stock shares issued per CSR (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_BusinessCombinationEffectiveExchangeRatio', window );">Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement', window );">Share issued and delivered upon CSR conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,544,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders', window );">Ownership percentage of parent by subsidiary stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Amended And Restated Credit Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance', window );">Debt covenant, minimum quarterly revenue compliance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, consersion ratio (share/share)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, consersion ratio (share/share)</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_BusinessCombinationEffectiveExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_BusinessCombinationEffectiveExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_ContingentStockRightSharesConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued per each contingent stock right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_ContingentStockRightSharesConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Minimum Quarterly Revenue Compliance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mnlo_AmendedAndRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139660094895960">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashAndCashEquivalents</td>
<td class="nump">$ 855,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashAndCashEquivalents</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MYR>$?"+9TFRR4R;5EFV&L3I58:X#U/TY8_)]HO?M\IS6_P=02P,$%     @
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M\HZI7Q-\+I"*,J[EA]ZI."J*7!/_7!<HEVFW:-)80:SW@M_"X>.3Y-[[*G;
MQQ"-YB]](='XH58I0N/Y+)H)E>3F.)?G#L,1$E-G,I]5)PP2J2IY)K44MCY^
M@-54O1PVA:\PS_54<;[K^XJ@ ,QPB'NN*)C-MEHD;6PDUOO(2<&6VT6)>)Q2
MKCOA:*P9N<2:Z3[K]PE.IJ+EJ=-K  #/)RL ,8D)3%5MKE.JC1$C>B/VG"QH
MSJGX%GFC^5:O7V-PB-[@7*"?:C*DK006/0"I"'AILE";[)1L8VJ(WM1,V7N<
MEN\7*=A8!J*W#!<H: %+//!E . 4_2Y+%0(X\&"I>W3:FM%B51US<[1@V[RL
MS]8.;P]'Z;WJ /GL?1_?###P/L W87U0WJ2OS^U?XF*5Y!RE]%4T95R[8JB+
M^BB\?BC9ICKK_<'*DF75[9K&2UI(@/C]E;'RXT$V</B'Q/V_4$L#!!0    (
M +$[!E%_>P PKP,  !\,   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
MI5==<^(V%/TK&L\^)#--_('YR@ S!+R3=!+(Q.SVH=,'80O0Q):H),.VO[Y7
MMO$26SAI^Q);\CGWZARDJYO1D8LWN2-$H1]IPN38VBFUO[-M&>U(BN4MWQ,&
M7S9<I%C!4&QMN1<$QSDI36S/<7IVBBFS)J-\[D5,1CQ3"67D12"9I2D6?]V3
MA!_'EFN=)E[I=J?TA#T9[?&6A$1]V[\(&-E5E)BFA$G*&1)D,[:F[EW@.IJ0
M([Y3<I1G[TA+67/^I@>/\=AR](I(0B*E0V!X',B,)(F.!.OXLPQJ53DU\?S]
M%/UK+A[$K+$D,Y[\1F.U&UL#"\5D@[-$O?+C RD%=76\B"<R_XN.)=:Q4)1)
MQ=.2#"M(*2N>^$=IQ!D!XI@)7DGPZ@3_ J%3$CJ?S>"7!/^S&;HE(9=N%]IS
MX^98X<E(\",2&@W1]$ON?LX&ORC3&R54 KY2X*G);+F8!XLPF"-X"Y=/C_/I
M"@;A"A[/P6(5HN57^/3\\AH\ .[Q>X">EF&(;M"W<(ZNOERC+X@RM-KQ3&(6
MRY&M8%4ZMAV5*[@O5N!=6$$'/7.F=A(%+":Q@3]OY_=:^#:X45GBG2RY]UH#
M_IJQ6]1Q?D&>XSF&]<P^37>')CG_+WOPG[._,Z-3[8].'J]S(5ZHL")0&!3B
M&S3C*52CG2X3!X(>6<13@GZ?KJ42<.#_:$GG5^G\/)U_(=T"2F/"I7$;%<Q>
MSM3U[S!Q>WW?!Y,.Y[^. 388#COO4?,FRG/ZO7X-%C1A'=\=]BO4.Y'=2F2W
MU=/EZB%X-1VJJ\<%S ;7=RU.]JHDO0^=S!C<'0G]F\3H:@N7AKS.S242;01/
MH8R(-Z+P.B%(DB@35%%B=+[(U#USX<:O.34S86J>-R%NS6Y3$,=L=K_RH=_J
MPU,A&.XDHURX[*($2TDW%%RB3''$6O9@O[' N@]-1&V#SIN(FE%!6XQW)@PJ
M$P;_9C.4F^"T)\";F AZP/K.1AO*,(LH3L -.-B9/OQ&+P8?*9TU$6[]''X8
M)&@B;CRS&\/*C6&K&ZOE:OJ$3*?P= #SXVC2/&S=H(7J)F98$]U$=&NB37DN
MJ':=GU>]\PG=S;ICO+,=8[5UZF)-N*'C>#7%!EA>;P<UW08<%-QNMR;=/FMX
M4B*V>:<I4<0SIHJ[K9JMNMEIWL/5YN_=NYEKF)_K[C=OL'Z&+UKG9RRV<#!0
M0C:0RKGMPX\DBFZT&"B^S]NM-5?0O.6O.^C@B=  ^+[A7)T&.D'U/\'D'U!+
M P04    " "Q.P91;,G$B]P'   N*   &    'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;,V::V_;-A2&_PIA%%@+U#5ONA5)@-9VFFQMTL7IAGUD)"86JHLG
MR4G[[T?)JF7Q)KD(T'U)+/OE,<^%? YEG3SEQ==RS7D%OJ5)5IY.UE6U>3N;
ME>&:IZQ\DV]X)CZYSXN45>*R>)B5FX*SJ!F4)C,,H3M+69Q-SDZ:]SX79R?Y
MMDKBC'\N0+E-4U9\?\^3_.ET@B8_WKB)']95_<;L[&3#'OB*5U\VGPMQ-=M;
MB>*49V6<9Z#@]Z>3=^CM.77K 8WBKY@_E0>O0>W*79Y_K2\NH],)K&?$$QY6
MM0DF_CWR.4^2VI*8Q[^MT<G^.^N!AZ]_6#]OG!?.W+&2S_/D[SBJUJ<3?P(B
M?L^V2763/UWPUB&GMA?F2=G\!4^M%DY N"VK/&T'BQFD<;;[S[ZU@3@8@(AA
M &X'X+$#2#N 2 .P9QA VP%4'F#RP6D'.-( D2S] +<=T"1SM@M6$^D%J]C9
M29$_@:)6"VOUBR9=S6@1X#BK*VM5%>+36(RKSN;75XOEU6JY .+5ZOKCY>+=
MK;A8W8I_GY97MRMP?0[F%^^N/BQ7X/)*?' ]_^/B^N-B>;/Z#2S__')Y^P^8
M@B^K!7CYXA5X >(,W*[S;<FRJ#R956**]1?-PG8Z[W?3P8;IW.852S3#YO9A
M\SQ-19F*:(5?-:,7]M'OHBBNRYPE8,/B:"I<"-DFUL]D.6 K#+?I-F$5C^H"
MC\.XTA@Y'V\DK]:\ &&>BHUC7:_H1RYB+*XY>)GD9?FJ;WXF\K\O KPO MQ\
M'S5\WWN6L"SD@%5@P<,W@*#7 $/DZ_*WL^0VENIMZ_$LP,C')[/'PW2I*@3[
MDH4J(=!S,>W+EJILBI%#8=#7G6MTE.PUO;"0?5C(J+"\+->LX.6K,?&9[TPZ
MA_'Q?)>ZKF$R=#\9VHPDIA)OU^#BR\WEU0=P>[$$GY<WE]>+MY8"</;&':NG
M\UYY[>JJK3)=#3B*CU-"D>-(J=/+ D_*G"JC6!\K=^^.:W5G^8T785QRD-^#
M?%,O[1*(_0@\\K**LX?Z;9'/JHC#>H4UNP;89G&EW;!<97IUXGNE;)7T//#V
M'GC'>O!Z>/J-D[MB!7%9;L6GVRP2VP=/-TG^G?-6O-D6X5K@&&Q$@8.78K]K
M*UQ7T)[&.=\[2';/07_OH&]U<%5/9%KW!%&SN8G28[6;N@SXR@PP(5(5+09$
MO4D&^TD&8_?%W[>96/>P6?>!;I*!\OTN),J^& SOBZHA H/ D_:[I2J;8AJX
MT)56ET:']%%!L.L9X-$;XU" YJW-WL[H0T?L"(:U@@YZ&#0V3Y]8L=^?M7EJ
M31U.P_."0-J[YJW,FBF-*0)])Y!T2XUNB@ET$9%RI1&:8M.A'8UC^V&NAH(T
M;VWV*1;X'B4&BJ&.J8@\/\=01TE$GY-DK;7^\@@@Q'(*=3H_")0,:G2!(60=
MG)&=SL^*,Z3B%LMU;9/T?>B(C(Y&\J\"&E)Q[3J!;P :ZI"-[,P^!FE(0U7B
MRTP;4O4GVJ$7V=E[#-:0RE4=UUJ9?;M436G)IM'IT:83FMC6(1^-8_YQ;%,I
M:V<;[EB+Q[%6.GMHD]6:ZF7!<SR9;1J9M(\ML IK@GUQ[I)/9ZIN2A!TY%(^
MUP@-"PYWV,?CL&\ZG^ECI(&V2WU($)7#-$+9G_G!>1L_/P1QQUAL/[@>"<'6
M6O^,+<[BGB]G6SW<[H0R!G5"4[H[M&,[VI\5@U@%-7:56Q1V4=^/#N?X:)S_
M*A1BE?0($@RAH<W#'>^QG??'P!!KSL_8P3(-!V7]J7;<QG9N+SA/Z[MU\6,<
M<1'D*@=/K"A8)H*^SA,1XQ)$6W[P/DCS*+Z/0[-'*KB5VE(E%,GK3=5,J8%P
MN,,_MN-_GK"RW$^_KKA=Y3#A7536;@J7XT=6W_('2<SNXB2NOFO=U  XD'&S
M&%+UW>A C>V@OA2+H-G^]PX4?'?+5'B0\N*!%]HYJZA&@8L\*._^FJ,ZDCW3
MVW(,'3_IH$_LT!_AV]#2)IKC=@!=$@2&!4,Z[I+1Q^V#S@A#7;B)>H[VD(,E
MLLPU,B2O?Z+RV/$#'\EG-8UNZB"?0"E]YQJA87,G'=G)\<?MX2"IQVWD>JY/
M?*4I&27MS_W@=O>X^]W].P2&*:L]@QLX1&XU=3(YK6JO0#&D1+Z+HM%-B0-]
M5TFK1DA-B>VZ#V+O/@;NHVBC-"=J R&V!X@0,<VGZR*(\_PM).GX3>S\/K*%
M)"J;IZ(N*52R:!!2*&=1%1J3V*&>''U;_>=;2**CLWR0&A#U_>@03NP(_Q^U
MD$2ENT.@YQG:%-+QG=CY?DP'230@%N<2^7>:05G_E[D.U]2.Z^?KJ*A*;=>1
M03@@ZCO149W:J7[8<UP749RQXCM8[:JE6A?Y]F$-F*B-NR0.A>9>>)0]O 89
MK^H1+\CK )*FK!HC85[J5PW54%P<JZ6;0'.J-@3RTC)8<@V!Z!!.[0@?$XBC
MPC"TA*C*=()$83K0L.'1#NG4CO2?;)*IBE DD.S*M_VHBG=YS1E,.89NA1[\
M'FX'\C/TR%3%LT<=2BDR_5C?X9G:#_G'],BMJ:$>62-3>F2-1MLC:W3Z'EDC
M-!5EUUM0>V_Q4STRU9S^#3WR*.EN[K.#)Z?J)^E$1_<0BZ8@X?=B+'SC"2/%
M[N&TW465;YJ'J>[RJLK3YN6:,[&]UP+Q^7V>5S\NZN>S]H\(GOT'4$L#!!0
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M@F*Z#:ND7.6//^A!H8'8+\J30OY%CP=9YP1%55'FZ6$Q($A95O\/?Q\,T5@
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M84OG\P@LQ^L//NJ3,M_+;R;N\K+,4WFXHR$PM1" W[<YN-SA1-S@^-G-V?\
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MKD7)<#B'B>2))FR#&[.AFR PSU0B5RI$H@9LOD'$!H(?FXV"H\Z3K$Y;D[1
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MP(0G/@!%KLTA%\AF%N0=VX-KY/W4NG.0D[?I\;;8UZ#+EHC+J%TJ1+1NTT7
ML!37D G$+1=J%_$V$Z\KI+BVW^CXF2G&:NX^-(5>1T[S3LO#BFO0&D+S0YLV
MN>8>F VZ;2 AQQ$SOPG"A9@)VQ4N3N\H24)*#$^;T-#-!L)$TQ<NSH6A9;W(
MVX3X._UYT%DL]1F1P965_CO)#A!'^;%JRBL-V>N2G0>&E"EI:(,CKZFU.!"?
MJ!/O^&ZHDOP6.=/3AMTW<6G[C"R:+9Y<GLES 8(\X6L;6&RDZ'F"FR2L&;PX
MU%=V^OZ ![4MTG%3+<5R]%PS\.2JZDLNXAJKJ]/O0\";+@^MSW\ AR]ZK&R=
MV>:';,T,=1U>X8T(^"0\($X\1)9^?G;8"G[?X=GOC>M_2>,Z#,AIH:SO8*#*
M+6UJ7"N7&K8AAPOGAIN!N#"<T'1UTD".[72&7@=[*BTH[D\&PR:/"XKA1>/.
M.:<'=2YA014C)Y:0&_OK5S4(D"N9=F-EB1K8ZOW9A@?M\!W=N%A\&\;B=X%@
M#EPK]OKFEO>NWNT=LHB;ZQ!(['+; K@-!H2P1S^^)43F<Z"K9'E(/E@DNC4>
M6#Q[!ER 55R2BY"H5;+,BZQ8V,XIH% SMCX]AP_7C<M:7P\RA/>$!G]C-+CP
MF*US;C] >X#N>>CQ#BHHD7!9S/L.FGB@L#EX=U [AG(/EVD'D:(5N7N_[301
M+YK=,= &A!- &2F6 3.CB,0<2!.LY"CC35M'FLJ(S';-ZH0L! ;O\UN.KW"Y
M&4@6N=>7BVU>1SN3.Q3<B&/]'::T;=/M'&D;V.R2II$9NQ3I?Z:"",D)$:CD
M(&I>XA*14J9;1LYH@;.?N"U4N!ET$GHV15E0L<#2#0VM0L@(N4.K&KNI(4#]
M=^X B!5E4D>6N@^$GCO , PQ=44Q!SX;;;GXE81!5L]MZX;BKJO#.A$3[_]D
MHSBG]G,R=>LDI/A>B%^HG!"%HEE&_%@$"VH\KP_><Z9BSN55-N(Y(7)2@WQ@
M8\;:[."'G9</7VARP,HMN>=_%#,H"OR^O_O_-4R>#(-^1Z]IW$.Z_T,ADS:"
M_88P=7IVG3OI[H#_^YT@V>)R79L+XU13_SQM-I!=Y?Q-U<]DQ@T\>[(S%/4X
M]LJC^=NIN%&']* NM\;*!&0716DY-,!(>($8!PWMC2)1V_YEF3(C[+H7=Y?B
M;'AR-(Z/1B='#F::'4C @L<LZ(UB%R3+I+@(Y]V9;7&G"@RP#3BNI$7T*-GL
MH& [@I'1GQCS;63?F</D6E''G, #D#%KQ,/G._TV?MCZ)%_QA3.B<E%1L*"=
MP&:T;IL/;45O$I5+1$#*ON1A!]5:<"3!42?/<L7;.[."LKUM$#[[ 2K4!^43
M:9N46"L'R3>(<0GN"19E<Z_I(7+3' ]F"K"B8'Q/@>G]'L5^/Z7T[W1*Z9]R
M2.E_[8A2N^=A@O8\B=.>9&!-NHC:4V:3>O>7V]VFX817EHC$5;<UNG4KPYX;
M@?<8?X#)47E  2U]5VY!U(*ZP:')?QH_-UPK;Q;GS\%V&Y?]JCH,+6&(!D>[
M8N6O"XA##HCPX+S9(07CQ2S3"]=2!33(I]V<FZ4/9=V*MI--E%X4.UB9G $E
MWME-1/"^)(U\")JQ\[)8B2LF$5G>XQ/Q#HG9 ^\S6[W^1:4+/C+5;GW <#.@
M)&FJ.:+V&S31EO?/)"Q<SW:2BYG:^?[6M&/026UWBI6WEC6WH)&<5YGMYA.Z
MV&KW 5'>-FV;\SI=\PQ!Y5NAL2DF]L\F[2D;HNEVG/YEQ0'GQ4Y^C39:VW+3
M/I.$@@"?OND=CQA.@OWE@P"?FJ-RFWCLR@SNX6QLB<:#R7 C^!WZQGO>*$GS
M"<?<?1[4&%FX]^U/3=V4M#U<KJ0]!F?+!0O2U ]G^?2/CO4/.OZVTTX_7)O9
M+7#&8MMG8=_E0+MY+*'_'0,F*>K%LG\BK&VPV>HXU8D[7S+OE#^VH](T6'@O
MWM:^3TJ6C2K@G< %GYRW!HL@)_AS,SX3D?LCDE[0_9TV2K=A@$N9;L N]Z#:
M;6C<^:O,:TH38OL5#2\F;(1>A+H-RKE 19M'2Y_WK\[P'];CYIDL'OB,XN^^
M81=?O* /Q:V5+[5:V4Y'+X-?'TC8_9,+5C#[8AJ=G$]HJ^@\.AU/GV7J&_RP
M&MI?G=5&W!U<<Z_3^3F$BVHI7$3X^^[+S<V'JX]7G^XO/HB;V\_B_>?;CQ?N
M8ZJK=^+VZN[+A_L[\?F]^'QS=<N?5]V]".40Q]'IV5E'(/$XFHSIUGAX)CYY
M,\3]TVDTF<3TX"2:3(?X,1J>1)0:[XO3<X#6U JQY?Z(4ZS$IIPNZ=JG?)JH
MT,=*]FK,_^)3<=$<I#$^:>\X3>LJC3ML-=IHPVKE#(5$M&'_]QO'&[>9QKXX
MB"?1^3@^#&ZB^%"9-W,"3TZ2+8J3#\)'[#,_P/\_F$;Q^?EA<VT/*H1+W\'#
M:!3%XV'(PSUWM+=!R0XO;<]I>[FUQXO7=):C]%O*65;;*O!!=8\36646C(G\
MH*P< NY&R"ZBV)XT(P_(V9X$L]&4+-O K4C<F=S"'SDO#>IO^>0G ]9FR-K\
M3H%H6F$198)X:5[SV?& *;^5W\B'P54K5Q3\*L'JW'X[S'FP;ZVZ[KV@G,9)
M LD2?S2%8CG1RH="L&_D ^\,L)A6\LD>^Y,9I^)-6*-F[:*UON# Q+:/.X^#
M3V;YN#A]&$Q!NLXK^_5L<[?Y]OC"?G+;OFX_7$8\1;Y++;$YA@X'TY,]VTKT
M%U6QY@]P9T55%2O^N502F2Z]@.?SHJC\!4W0?)']YA]02P,$%     @ L3L&
M42KBU;40#0  :B0  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULI5IK
M<]O&%?TK.ZK<.C,T15&RD[BV9V193I6)'Y'CI)-./RR!);DQ@(5W 5'LK^^Y
M=Q]84)0<MQ^<B,#N?3_.O>2SC;&?W%JI3MS45>.>'ZR[KGUZ=.2*M:JEFYI6
M-7BS-+:6'3[:U9%KK9(E7ZJKH_EL]N2HEKHY>/&,G[VW+YZ9OJMTH]Y;X?JZ
MEG;[4E5F\_S@^" ^N-*K=4</CEX\:^5*?5#=Q_:]Q:>C1*74M6J<-HVP:OG\
MX.SXZ<M3.L\'?M5JX[*_!6FR,.83?;@LGQ_,2"!5J:(C"A+_NU;GJJJ($,3X
M'&@>))9T,?\[4G_-ND.7A73JW%2_Z;);/S_X[D"4:BG[JKLRFW^HH,]CHE>8
MRO%_Q<:?/?WV0!2]ZTP=+D."6C?^__(FV"&[\-WLC@OS<&'.<GM&+.4KV<D7
MSZS9"$NG08W^8%7Y-H33#3GE0V?Q5N->]^+JXM>+MQ\OQ-7%^;L?WE[^<OGN
M[;.C#H3I]5$1B+ST1.9W$'DBWIBF6SMQT92J'-\_@D!)JGF4ZN7\7H(_]LU4
MG,PF8CZ;S^ZA=Y*T/&%Z)W=IJ:Y5TRNQM*86YY#5(AI@Z6XMSMG&RHI_G2T<
M/__W/0Q/$\-39GCZ_YGU7B*4CT]=*POU_  )YY2]5@?[*(OWUI0]%/H@*^72
M)^N5=@*I*[JUPC^KE)!-*9R^$;5WF2*7"1A<)8.+C;)*K%2CK.SPDJWFF+99
MBK,WOU]<_"PV:UVLQ48Z49@:]BNTK*JMJ&3?H'"40C?,\V.CB<2'#I0</?Q1
M-CVRGQE-Q2\X<F[J5C;;O_[EN_GQMW]W(>J5I>-%U9<0652Z9CI-7R_@*XC1
M2,IJ67E].,NA\<H_*S5<J1=]9ZQC)DZ-GJ$&+9SZW*NF@\QDVZIB<5MONPG^
MT"A2&F\[@P.=U)5HUQ)UH-!0I%O+CBBB-CJ5WZ3C+40#97!^BZK:CMTA-&YO
M6UVPN:PJS*K1_X%JF[5JQD*:!=@VL"_B%84!2G=[S!7HNTEPB2F*'I<AGQ2M
MT4W'KD AG61\^Q85L505*B)\ <J9^,1D;,#7HP"Z.W FX<1("UD4IF\XCD#F
M=/Y@(DY/'K#;CA\_R'D'"TW((:WB<EUM!^[W!^V?X?T$O$^^#[Q/_PSO6YEU
MK:D=W4HR\BKYTI)<#;P.TDD2ZCY+I> AU)>2162Q\ #.,!O9%/32J@4ER404
MB+,5/A2?\$$Y^([3$%'86[ FZ0T,8BD_$&<0%>=*Y0IPP[D%==I1:@DXO>@K
MGX*=8P%WPY):&^CZK-VL#?2%SK#@YQXJLPZ%<9V/_"ZGS=)ZPB/C@P)'9S09
MN>"A_F;7"*Q/;@?7(XKEB!B;CP\.UX@<J-<M=)%;X 1D[4,-^KG%V*(4U+^L
MM2T?M=)V6_%>;E%=)C%/H1=>;,'2@2,)07175M9C7V2&CU*D@_P.W,$^5&HO
MH+JA8((H@[G9B=,\ENC@EX.%68S$09$&A*D\ QA,XB,Q(1*D,M]'5"I]+1<5
MD>3(]"Y&52FI>)7TES.5+MED"UFQ!1A13,49ZJ)7>7#D)-1EW:R&F!W;Q0OK
M=<U#8(_(E98+76FXA=HQ2M594=@>;\ETD,]]G< [9HW1G9RRDR;>8B/_A*:Y
MV(K#Q]/O@;FJBN$C%#H\/IT>IR=?VU9W:\NKW.6O8X![K[T:&?(L9<?345HC
M:IU/C5LA1.KJ(M"DMX6RW$U@-9G:UY"L["0P#O4_<J#;'@A0UPB'7.9G8L6U
M$1=O58#;*1J;\9Y\IM@H C3KT<,A*WI\;[UI<Z%\4NVI.)!!2<OALI?'Q->:
M@NHTHA<:E9PPCLDO>P2[K#FO?:_=+RC#(>*]LL:YVY$3ZB.U7%_+AC<<_K'C
M3\55S)[SG2KSCK,I!<'3U&Z\K6L*D1X19O%G@]FI?%3(8*B504MOR-:P(5!,
M06F:RE1$9=,/4Y8&..@/Y=M^2.6I>.-)BG,OKB^A5E'[H'.YC^0*H4^\V/:,
MHB(<H0=!.,'"87"4T)MAF]<RX*DM4K%12]V%\QZ\Y&R\$*(%RB2]5AY)JAM4
MPV:E.,RN3=77;($C0U:QGU#J'!BHZ<BZ_Y,>@TUQ4C6, /,N7&I+1AR ZX[\
MY(8(&LD4R&9%M4-Z;U2(X>',[<Z:NC%AL=\()OK8W"<6E+]3JK:W(.E4IMO:
MFGZUSCF$\'4J*XV:^_((&-@D72YQ+(FE7BXQ0U!=7JANH[S(F8Y4NW1YJ]1D
MAR"&Q[-\&O4^OAW<0I]OJSE&/A$,>#EC-.^V4L1>+"J@NT"P+BJ]XOY">#[4
M1BX#0\& B0:HX>O&EXK#J#9X@4;P,1:&K]> 8^O/J>&1'D\ #,<&7G^CX<M:
MCXE\^'I.C5J93OO4W4%9)/A*<CWU#B)PA1YYDR/* 7MQ^R&2:%-5J :3@)QT
M V.@D&_%6L'=Z,!C,,\0ZSIGC3*]<RD8.$QL5" :54U#01UJ>)PL]PU4M^$@
M+I&U4A7E?II-O8]TX]"HRC3YB1I@A"P2NRXFK94..,=B\$3,UGY$)%='>$Z-
M.TQYDE 02H=GM2L0PB59%T4D&H0N%Y74 8]ZU$2UA=*5GM]&[UF\!!X&.E'$
M\'8DC85T#[4#0:6:?&J5+L;P,"Q=>8S[E#8M)#+%$U-#LB)++0$)VL85&+>R
MFIEV#@0U>"#P<3O 2)]Z 2=*06!*+S7975EM2K8=9=9"P6P^7^6RHV*(:]!4
M6V]C0H[W)=D  D;Z;P#\**N\0*3\UQ>$KRT$@FN<7[Z2Z#YMO&&2VT/$\W28
MT':,<?B!TGP-1QA+X__@AISPD,66[1!B'%E+LT/LU0K\"YEU1^[CP4BML=T2
MP-PX$8O$#:S/"QE*>XZ!@($9+Z;4K:!]E=#),'V.(&U(YE@M[J=-"S, _=;[
M6]41!H\$YVJ"3$2&DN(8(:JEH)V(RWR? %T9,HPDNSMZJ,6WN'K#3Q#)\P<D
MS\EHV[ ;25/Q$[*!5DE7$2N^PR2$5EB)^<FPX,B[98/XHO:<*G\#>_#B#>QH
MKO($$[2)ZT[4<;9$V.,A@3>$=VB1%XK5>-&$IN 116=X>T1;:%-L"]I6)H4*
MF),',AH%J4*Q#:Y5.8DEZ@;!Z&!:*ER:7?V#59*2\QS9+*?B(^-93@IE:Y<*
M891_$F1GVZWEM1J3C?I"^; W0T134:7X\M)(WJ%QYTS%&[D4+#$1OU_^],]+
M>H\)=YDTR#'S1+P^?W4\>QR?C50@N:TF?N/H8(%=W[:T3*0Y ]'F:$4:1"Y'
MH&9P$%F8#3Y(S!][A_![UW>.FGFP4M+>RL8!>EFR?!XOI4%,-::+EH--RE*'
M%2K*)Q<"<ER # S2^^02:2U!;3_"7>Y@[TR ,5/6W"\@V%M]BVI(X$*Z=9P(
M28/#X]ETEN;JAX=/LD_A>G+#EW:0W["Y8H+YOELIWT>2()GNA\<9LR@3MWM?
M57&G92']3$%U(D431/*>#UY8:HMNN^M6'PW10]KQ_@*^HV1=(H>#()?O*0<S
M6_)9&83OG>]G<53BMI)[GK+;]%U<E4#0GHV&P>A:14-GSAG':-I=CEUAEHE^
M:E"Y&[Z\]-B3"K)R@S.LV<JJTW[-0^NI]#T#G;^5(6$[.-P:*FF")$'"@ EX
M<^QI6E@1@U+<D _1/9#CDX\8G_)1C[(0[8H[R5@;PD.44LEXP[:IBJ";R.\-
ML1+G.,SN#[&=_!J:K71A4>JQ2@@KY+\F9#+H=BVMYB"*4>?;_:I'N:9\]R?/
M/IR+)[,G$['WFS(W_JH,J#5]AW;FG K=-#W[*:STR*"YO= AQB4H#AD$.XG*
MP[[!Q8HMF;:6W^3F;$=[$,F!LK-DD\,W2!S^?@,R(,O@_8 18=X<BH'<X$2.
MJ/UNE^+P]%:1(G$G0S30L29,'L.!;)UYQQ)SPK'A'<#-8(^:83;6;M@P^XF/
MQVIDP,\G>]+O;@=4F<ONLFJWAU),XQ#5W-=E>>T[R9)6:DLR$1Q $/BN/A-V
MA]D([[]O ;=:.[_-]4^*[,G.P-!YI!CBA),?*;(&)HV[%@.-MDK:.!S9,";@
M7U@VAV_A@)QI#"ZG=W -R)H-3<LBZ#>)HOBIHZRIR7>4;->).GV3AF[1<$"2
M)2$04G<WME18CY-]"<J5?\ N.^D;RX):+GE\HWJ)2HQX70(C@.@R,2H2H\U:
MC4ICOIJ)P,%3HJ6M)G.L#(U5-JZ38T5+"<:]-I)-3_U>FD5$<NW2B"4[N0/O
MZ+NB*7U+W)280D0!XZ/)>2!8&C8%%6%(]/T,0'R+PU=<M+<#8L[M2(F!'MA5
M880,9U.8[HX+0]=))::DF<2TBA<1,J\I,&E5R84)OF!:H\Z:1 JM:)@G#V?3
M>:H:_#5[*A=E;^,.Y:[F2N_W_3CA*/O]!T1<\:]<*&S!U?\4)#U-/Z0Y\[\?
M&8[[7^&\D7:E&_KR;HFKL^FWCP^$];]L\1\P!?"O21:F@SWXS[62"$PZ@/=+
M8[KX@1BDGQ>]^"]02P,$%     @ L3L&49%U2CG!!   Q0H  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULI591;]LV$/XK!Z\84L"S93EQT\8)X+0I
MFJ')@KC-'H8]T-+9XDR1*DG%27_][DZRZK1),*PO(D7QOOONN].1TXWSZU @
M1K@KC0W'O2+&ZLUP&+("2Q4&KD)+7Y;.ERK2JU\-0^51Y6)4FF&:))-AJ;3M
MG4QE[<J?3%T=C;9XY2'49:G\_2D:MSGNC7K;A6N]*B(O#$^FE5KA'./GZLK3
MV[!#R76)-FAGP>/RN#<;O3G=Y_VRX4;C)NS,@2-9.+?FE_/\N)<P(3281490
M--SB6S2&@8C&EQ:SU[EDP]WY%OV]Q$ZQ+%3 M\[\J?-8'/<.>Y#C4M4F7KO-
M!VSC.6"\S)D@3]@T>\?[/<CJ$%W9&A.#4MMF5'>M#CL&A\D3!FEKD KOQI&P
M?*>B.IEZMP'/NPF-)Q*J6!,Y;3DI\^CIJR:[>/)^=GX--[./G\_@XFPV_WQ]
M=G%V^6DZC(3-.X99BW/:X*1/X$S@PME8!#BS.>8/[8?$J2.6;HF=IL\"_E[;
M 8R3/J1)FCR#-^X"'0O>^*E E?9PHTR-\$Z'S+A0>PSPUVP1HJ?:^/L9'_N=
MCWWQL?_38OX?'/A4(+QU9:7L_:^_'*:C5T<!5 @8:; Y&*T6VNBH*:Q8J C*
M(Y2H.- <Z'W)$MR*!"J 6P)IC)W&@O$.,RP7Z&$\XM71Z[Z@9(;\Z*4F'&T)
M'"&JA2$_"_ZK><T1$B'*I\(CF:B(*^>93(XA\WK1&%L7$=(/H!;N%M]\1V%/
MT%T=B$MX"1_Q%@V,VC%MQS%\<E$9N%!^C<(# F:U;R+?&[V$%W#P>D3/M)^,
M#FD4M=(C69DDKW^,\B<\C?I,G,:#_F22/' VFO0GAXGL>RQU.2[B+AX+3:68
M-SJ5XG,GDR0<9(ZZ88Z<S^A(_+:I]6%1-YLDN[GTJ9QR E]JDCMOP:#R.L-
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MVB/3@NZ9Z'D#?5\Z:F;M"SOH;JXG_P)02P,$%     @ L3L&40S\R3_#!0
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M]P__6>!I PP1X'ZFT:CZAQ2T5\CSOP%02P,$%     @ L3L&41(<AQT;!
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MV= 3'!\.TT[UHE5-GE$]ACNC?>'@6F>8?:L_)!H]EV3+Y2)Y$?#76A_".!Y
M$B?Q"WCCWK=QP!L_YYM>H_;&;N!*NE095UN$O\^7SELJAG]>L##I+4R"A<G_
MB=Z+JMQL9ZX2*<XCZB:'=HW1#@^VW"4Z$$3;>>$Q ^'!%PC42FC!Y) :YT'H
M##3U+S6EDE_$4B&LA:J12LD7K4B&'BV5#T%P*T NK?,'4@^Z%;4K%[=TL-Q
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MNL-35$ ? "JV<BVINV^;&!%\ D!!&_U1:\OG.1OO&6!LNX-Q G]T%AK4\?0
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M$4E'39NH)D)N4,CY# 6-T#!DH4=><#>_W:RYB^1>(.CMS6'Y-1C%[PL[==[
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M4LP!K1+CJ*FKZ=??C97KY<U-IQS;;S52G&^=R2_\Z<ZM8K5F;_'(I]TO>1K
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M)8X:Q[SDP#V]+"2V^ ['$7F\;:@-0FW"4X& _9^U=U45O >MDE@,Q'/^@ZM
M7UAY9V@FGU!=.1WTQ^/GO>FB/Q\]YZL!KH;T(6ZU_=Q;HQL%C&B>9]$J4_?N
MM@S[X?2Y"/LA-H3]:=BBSTEMZAVD^CPN[JKBAJ:C[7[U40"B;*LZ2]=CMX*\
MGZ0>;WUR2L"=9LYG>I:Z;G14^Y*M7#;>%14@*3@7]8RZ&23(_WB,0" !1@O(
M:J7+Q@YA=8OG1]%1,[)'4]_MC5M][FPX#SBOU$U*3_ CO\Y-!\UN@X7JA%H_
MR34Z'^DR.>DI1RVGK2[X4= =^8Z+PEP3T.37EDEQJE]VZOLJ,S<CP&ZX(56
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MT?AQ15Q-;O9;PXDQ,R(Q&0'0&R467&T9)$(ZSX<K6\_ JVZ:DFIGX$AHY[S
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M?&K=GWK@4C7Q55%NNU7Y*YSSH!SW@>J)F=,+QB?XA];LRU8_W7R[A;8X8_(
M1"'*F1W[:&V)9V(4#"8#^IR/^6HRG>)S-IJ+I4)8I;=A-OZ5,7[L%Z=HKES8
M@5EF =*#H"=F8S$/%M,AOD\6"_'14!A_)H:#8#:=TY=@-.?/,)B$,WP)>4YU
MZIW-\]9KL/QN"+WL2[X.^+LW8NN[]?O$%^XUVF:Y>QD9]0+J'?>8^<W9H#^;
MG+F7GJJ+PNSXI=J5*0J3\M>M0NV7TP+\OC;( ?Z"#JC?LG[[;U!+ P04
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M<VAE970R,"YX;6RE5FUOVS80_BL'#=@ZP(T<)6VRSC%@IQG6 2VRN.D^#/M
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MF$2J41O.21TN9>4M3B7T_'QUNUQ=_7E[]>DS77W!N)JE'K#A,"U&B.4 D1V
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MSMXD9(>W?%AXT\;W,S<>KW&<UOC]81L$<%X9],IQ$0SL?JCFWP!02P,$%
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MD<-$"&T2*9(S.P+:9DG&'"70>/.&2_%*B5GFMRE(IX@"2,8J:JMCQG!+5S'
M >XB]0D:BDK#<4'>UHF,N@XKXEM CP7$J/MBU[,0NY[M#35?:@BUR-2@9%<-
MK3X4L7X'&!)R\"R@4 TGS.#W5KB/'$4FIT#/E@4GN+ORA:Y= ]F;&?!)Z]I
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MAY+M2+\E*DWT!H03Z"YF*"878LM"-R?( 2!N(%[N&H@TRF43V6#B&B*-]/=
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MWZ!GH3%CL)&'+1R*C@@</7 7*U-4]2?..3+ZPC'J<NJ"G1;*-(;T.K!P0[1
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M/C-+Y>=PEVBXJ.(CN:8BO2(2H4W&YR<G9WO!Q[!";KBT'9_!IH^Q=HE(XGZ
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M8^32/L:<X0A%&_#[7$I3O9" ^N\-%_\!4$L#!!0    ( +$[!E$:&:[D;0,
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M&R8*;$"J3*GHI29V4$A*G^#_8@8K)3*GD"5Q-]Y$D$59&8>2N;=P4AF@MI(
MYKMC,<$6-0(SE?8.\JGHOA/.5\=QY,@I#8^>V^-[AJ>K^;:F'VOK3@^_^_/#
M[&/._B^U<_J]\LK=CQ\COM.T2S7U-YF2AI5[):6XW1@=WL(IL9<B=V.K-FS6
M5X];C78[JB:M]ALJMR=5'A[UB1SUTG=#0YHII"U;1KU;-]Q!V6<.YF6WIB_:
MTNE(X()<HYL[4KDN.V"YL&KMN\Y<6>IA?KJB/PVHG0&=+Q35N%JX /7?D/Y_
M4$L#!!0    ( +$[!E%SUG$SDP(  # %   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;'U4;6_:,!#^*Z=LFEJ)-B$!2BD@E;YHG=2NHJS5-.V#20YB
MU;$SVRGEW^_L0,:DPI?8]_(\]Y([#U=*OYH<T<)[(:09!;FUY2 ,39ICP<RI
M*E&29:%TP2R)>AF:4B/+/*@081Q%O;!@7 ;CH=<]ZO%0559PB8\:3%443*\G
M*-1J%+2#K6+*E[EUBG \+-D2G]#^*!\U26'#DO$"I>%*@L;%*+AL#R8=Y^\=
MGCFNS,X=7"5SI5Z=<)>-@L@EA )3ZQ@8'6]XA4(X(DKCSX8S:$(ZX.Y]RW[K
M:Z=:YLS@E1(O/+/Y*.@'D.&"5<).U>HK;NKI.KY4">._L*I]DSB M#)6%1LP
M95!P69_L?=.''4 _V@.(-X#8YUT'\EE>,\O&0ZU6H)TWL;F++]6C*3DNW4]Y
MLIJLG'!V?/?P?/,P^S[]"4<S-A=HCH>A)5YG#=,-QZ3FB/=P].!>29L;N)$9
M9O_C0\JG22K>)C6)#Q)^J^0I)%$+XBB.#O E39&)YTOV%2G?4%JEUW#-32J4
MJ33"K\NYL9JFXO>!")TF0L='Z.R)\$3+DE4"02V ;Z)Q-!_U\B"1V\&!*5F*
MHX"6S*!^PV \RQ$62M "<;D$Z_X3&+2&E-KF8,E\I8J2R?673_VX?79AFB36
M Z!N(G43KC'%8HX:DC8<<4DP51DF,W/L^TR?]CE,V8K&RZ+F3!CX#$DKZ9_1
MV8TB>*'].N'RI-0J16/@O-L!'S"^@%LN.4UA!DNE,@/M5J<70;_;@YFR3#B"
M5C]JT]EN):3]J.7ASA07J)=^5PVDJI*V'NA&VSP'E_46_'.OWY)[II=<&A"X
M(&AT>M8-0-?[60M6E7XGYLK2AOEK3D\::N= ]H52=BNX ,TC.?X+4$L#!!0
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MPNBG+^CW]T/.A//_W9G(B^9S+YO/K3-)-CZ*_##ZAC.S)//B>/9-5WZ$A1#
M*MG6IC, /[-;.\11#Q_?H-I@EVLB5/8=-?:@M%G>0Q"?\I+51&LDW& MY)>
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M-QAZMN=>YNV]H7V9L!HNUW<]KW^9KS:N(A#6R7U*7\AOL3A0)E%"]H"Q;WP
MB^*.6TP4S\P5ZX$KN+"980S?!41H UC?<ZY>)_K65GUI3/X'4$L#!!0    (
M +$[!E'!SEUP/ 8  &P9   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;+59;4_C.!#^*U:U)[$2U\9.^K8")"BPL#I81)>]#Z?[X"8NM3:QL[9#0=H?
M?[9CDI0FIJN#+^ DGIG',^-GQN[!FHL?<D6( H]9RN1A;Z54_FDPD/&*9%CV
M>4Z8_K+D(L-*/XK[@<P%P8D5RM(!"H+1(,.4]8X.[+L;<73 "Y521FX$D$66
M8?%T0E*^/NS!WO.+6WJ_4N;%X.@@Q_=D3M1=?B/TTZ#2DM",,$DY X(L#WO'
M\--%.#0"=L9W2M:R,09F*0O.?YB'R^2P%QA$)"6Q,BJP_O= 9B1-C2:-XZ=3
MVJML&L'F^%G[N5V\7LP"2S+CZ=\T4:O#WJ0'$K+$1:IN^?J"N 59@#%/I?T+
MUFYNT -Q(17/G+!&D%%6_L>/SA$-@7#<(8"< -I5('0"X0L!!#L$(B<0[2HP
M= +#705&3F"TJ\#8"8Q?"G2Y=>($)C:Z93AL+$^QPD<'@J^!,+.U-C.P"6&E
M=0@I,[D[5T)_I5I.'9W<S2^OS^9S,/MZ=7)Y??SM\NLU^!-<8R&PR2JP=TH4
MIJG\"#Z  9 K+(@$E($[1I7<UR_U^-N*%Q*S1!X,E,9D- ]B9_^DM(\Z[!_G
MH@^"T3Y  0KNYJ=@[\/'VE#YMT7KS*_U"ANMT]_5>NK7^J5@?1 &&UI;M)SM
MK 5.N[6<OPF6SV^"Y>(U;S\!"#U0!CHIJ\Q$568BJS7LRLQ"ZC=2@N/X9T$E
MM53WSU_Z';A4))/_>FR$E8W0VH@Z;%P7V8((P)<@YEFF]>O]%O^HLES*@B0@
MUS-F\UNPIS.]_-+FHY/2TM1:,A7CX0CV43!!!X.'%H11A3#R(CQ;+HFE=W#V
M&*\PNR?@5F],#O8,) /-0FI%%+4@FNB:UHYH6"$:>A%]73,BY(KFQGI,F-(E
MSG@PUS"8 HLG70<7DB94E\+2GRN>)EJD#:+?U 3U@^ /3YQ'%>;1_\3L1J_A
M]9N!DU?PCBN\8Z^B6<IU\M^7L06YH#&QZ5?(I!%S\*O!R6UH2R.3C02(VJ,_
MJ9!-O,@^<YZL:9H"FN68BLPX38-M9=-2TZAA/@J"H+)?TMPKDS9 3BN04R_(
M[S@M;'S-'HDY>R!"Z8U,F>( )XFE$IP^;W,]3ZV(88"%UI.808[94UO5F6Z!
MA=-1%UH8U#4X\(>;,Z7#;7PYMP1D6TAP2S*"92&(\7)K:0VV\$RB\4L7G[II
MP\UI:+0Y[:Q%V\M@[:;ILU?3IH\:?0K<U4<ZHII?B&E0.-L'2YV'X.$YY"G%
M"YI2U1:_$V=C(X!!%'5&L*Y5$'G1S>U&=05#=T*Z?4XU:0O]5.2ZKM2):)O^
M1BG1F[A[ SNK37^/HV$413#L0%Q7/N@O?9<,W @>FP)[2R3!(EY9X*?D01]H
M\NV4V[13UR\8O5L9AW5-@OY*H5>3N]6(YFJ2>C4-QFIM_89;J3$,PBVZ<M.&
MG=,V%U 7*.@O'><<9_31YXNZ=L#Q^WF\K@/07PB:K5.U,\OV21CVJMHGD^LZ
M_=LZE)FST?0F[/!DS?W03_[?!&82ER?CF$O5MK$NX#:3(SCI"B.JF1SYF?R4
M:++6:UYRH8_E,2^L:T!>B)Q+4VM8^O31>@:SV/)5&?CG6J0+U!5A*7^M$9FA
M;8J%*!P/QQTKJ'D6^7EVMQ4TN$ROH81,=+:I)X#76+2>!&?.\@:;A:BC04:-
M<X*?>V?-<@"4"?^2"$V]K1C0MM]"&(RG'2AJ/D5^/GV;EFWFK#1[-M2?=J&K
M61CYCQ'U;G6)ENR<J&X+[U"N9@Y$,\ 1-.U<Y\:J"1[Y"?[=6CJTS?N>G@[5
MA([\A/X6_<K,V=@57%TBD/]\X4CG%SC+\I0_$0(6A)$E?4F6F^KKVH F[U:!
M4$WTR$_T3>6"I%C90+<3_KG3M=&YPBY'AC7?AWZ^KQPY)ZG^=K\/=,1UI%/;
M?> DHXQ*55ZE^>XK:GH.X?O=BM24&OHI];=<&[90*AQW^K9Q-_,*HS:O9'Z!
M5SNDL&;#\/UZTK"FK-!/6=6%C=WXM@APD5!F[T5LE3#DNW'QM.>JA^]:9^;,
M-N]U@OYPBEZ>[ >-6V'S.\05%O>429"2I18,^F.M1Y17^^6#XKF]*%YPI7AF
MARN"-7&9"?K[DG/U_&#NGJL?6([^ U!+ P04    " "Q.P91L1XCK0$#  !0
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RU5LENVS 0_96!T$,"
MM-'B+2YL ['3H@::!7'2'HH>&'ED$:%(E:3LY.\[I!S5A66WA_9B<7OSWCPN
MX]%&Z2>3(UIX+H0TXR"WMGP?AB;-L6#F3)4H:293NF"6NGH5FE(C6WI0(<(D
MBOIAP;@,)B,_=JLG(U59P27>:C!543#],D6A-N,@#EX'[O@JMVX@G(Q*ML(%
MVH?R5E,O;*(L>8'2<"5!8S8.+N+WLSAR +_B"\>-V6F#2^51J2?7F2_'0>04
MH<#4NA",/FN<H1 N$NGXL0T:-)P.N-M^C?[1)T_)/#*#,R6^\J7-Q\%Y $O,
M6"7LG=I\PFU"/1<O5<+X7]ALUT8!I)6QJMB"24'!9?UESULC=@!Q]P @V0*2
MOP5TMH".3[16YM.Z9)9-1EIM0+O5%,TUO#<>3=EPZ;9Q837-<L+9R?1A,;_^
ML%C [.9J.K^^N)_?7,,[F"G:J"5JYKV^UTR:#+7&)7 )5ZA7J.'D$BWCPIS2
M^H?%)9R\.84W;OX^5Y5A<FE&H26)CBA,MW*FM9SD@)PKIL\@&KZ%)$JB%OCL
M./RB=/!^&SPD8QIWDL:=Q,?K''*G,C1B#%RD/RINN'?CVV<:@[G%PGP_PM%I
M.#J>HWN @ZRV7*Y06DAW77\+&>,:UDQ4""H#P=DC%]R^M-E24_0]A;NYZTD<
M=;L1>;!ND=9MI'6/2ONH6,&?C^38:P+U_IN/_8:C?U3L)6)!Y_.$GC9Z'%)5
M>5NAK'2I#!I04KR< C>F8C+UCM;I@<F9IGFKZ&!+H8#N7/J4*T$;T7J"^_M>
M)YU!;]#N]:"1/_@'\NF$K$F6LX\2J/4B66I?@&V8;K]R-7%O1_"@DR3M<L\;
MN>='Y=XKR\3O![:-^GR/.N[$T6#83CYLR(?__<I,A_O2AOU#-R:.?KVGT9^T
M[;R<D@HQ";$Y F89E2[7FRWNVI_&:/]DQ?'^+0YWGGM7:^G17'%I0&!&P.AL
M0$GINGS5':M*7P$>E:5ZXILYE7S4;@'-9TK9UXXK*LV?B,E/4$L#!!0    (
M +$[!E&VH<^<1P,   0*   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;,56RV[;,!#\%4+HH06:Z&')C\(V$#M]^)#4B)/V3$OKB @EJB1E.W_?):7(
M+B(IZ*'HQ28E[LSL<CGB]"#DDTH!-#EF/%<S)]6Z^.2Z*DXAH^I2%)#CFYV0
M&=4XE8^N*B30Q 9EW T\;^AFE.7.?&J?K>5\*DK-60YK2529950^+X"+P\SQ
MG9<'=^PQU>:!.Y\6]!$VH!^*M<29VZ D+(-<,9$3";N9<^5_6OB1"; K?C X
MJ+,Q,:ELA7@RDU4R<SRC"#C$VD!0_-O#$C@W2*CC5PWJ-)PF\'S\@O[%)H_)
M;*F"I> _6:+3F3-V2 ([6G)])P[?H$[("HP%5_:7'*JUH] A<:FTR.I@5)"Q
MO/JGQ[H09P&!WQ$0U &!U5T169775-/Y5(H#D68UHIF!3=5&HSB6FUW9:(EO
M&<;I^>)AL[K]O-F0Y?>;Q>KVZG[U_99<D'4IXQ23)6O)8B!7G(N8VC*^OP9-
M&5<?R#O"<G*?BE+1/%%35Z,< ^K&-?6BH@XZJ&^HO"3>Y",)O,![V%R3]^\^
M_(GB8C)-1D&346!A!QVP)ZV*B!TI7C(I3"8]^(,&?V#QPP[\'Y278)"7FSL2
MBWP/4D."M=""T"1AAIERHE(JP2K0*>"Z;(LXB1D4-']NJU9%.[2TYC#MY_YD
MZ'E3=]^B-FS4AKUJOPB:L6-/VE$#%/V3L@X;_&&OT"55*<%&(K$9P*^2[2F'
M7+<V5@45G95J,!Z&?GNI1HV"4:^"%6ZETN@XVC0V>M03=OJ6 U$0EQ+W%5JU
MC%YI"8*1-VC7,FZTC'NUK"44E"4$CFB_"OO(5$9@)TDT!2F-1JH4M%=G_$J1
M'XT[BC-I!$W>*,Y%(44,2J$7*Z"X^U93 GMT]L)4K4W*Y)64R!MT];3OG4S+
MZU7S58CDP#AO-1WO%6?HA5$'Y9E/^KV4]T+CJ>XN>AW^1]7]$79"!_')SOR@
M_V#4^\T9W3+>V88URCG_130.1AWT)[?S^^VNROLM\L%?D9_,R^]WKW6/R]3,
M84O9_3#L.'_^R>[\Z/_8?,W[EL^[9]]T<S_"K^4C0^_EL,,X[W*$,+*Z<E03
M+0K[F=\*C9<&.TSQF@;2+,#W.R'TR\3<')J+W_PW4$L#!!0    ( +$[!E%0
M4)DG@ (  )\%   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(U46V_;
M(!3^*\C:0RNU]25.>I%CJ4G7+5(O4;-N#],>B'T<HV)P 2?9O]\!NUZF)M5>
M;#CP7<Z!0[*1ZD67 (9L*R[TV"N-J:]\7V<E5%2?R1H$KA125=3@5*U\72N@
MN0-5W(^"8.17E DO35QLKM)$-H8S 7-%=%-55/V> )>;L1=Z;X$GMBJ-#?AI
M4M,5+, \UW.%,[]GR5D%0C,IB()B[%V'5Y.1W>\V?&>PT3MC8C-92OEB)[-\
M[ 76$'#(C&6@^%O#%#BW1&CCM>/T>DD+W!V_L=^ZW#&7)=4PE?P'RTTY]BX\
MDD-!&VZ>Y.8K=/D,+5\FN79?LNGV!A[)&FUDU8'10<5$^Z?;K@X[@"@\ (@Z
M0.1\MT+.Y0TU-$V4W!!E=R.;';A4'1K-,6$/96$4KC+$F73RO)@]?%XLR/3Q
M?C)[N/XV>WP@I^2+E/F&<4Z.;L!0QO4Q!F\EK=@V\0WJ6K2?=1J35B,ZH'%/
MU1D)+D](%$3!\^*&''TZ_I?%1]>]]:BW'CG:P2'KC<:(UF0JJR43U)[RR5_G
M/Z^7VB@\]5\?: UZK8'3B@]H]:PYY U>I"4'@AU!F,AD!<30+:D;54L->E]]
M6O*1([=MLDZ#Q%_O\1/W?N(/_<P;E95X&4FM6 ;[)%O\<$<R#,,X'@3! >EA
M+SW\4/H.2WY%"LH465/> )$%$?AZ4*W!:&RSUX8IR$]L;7B3,[$BTI2 M<I!
M&%8P:HO'A*%B9>NXMV##=^Y/P^!\<'EQT/ZHMS_ZKY/<ISIZ=TQQ$ _?2_H[
M_6:?+KS@*R8TX5 @,C@[1^.J?0[:B9&U:\&E--C0;ECB"PK*;L#U0DKS-K%=
MW;_)Z1]02P,$%     @ L3L&42*MXU@S @  E00  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&ULC53=3]LP$/]73A$/( T2T@(;2B/U8VA] *J&;L]N
M<FDL'#O83MO]]SL[)>HDBGA)?/;=[\,^.]DI_6HJ1 O[6D@S"BIKF_LP-'F%
M-3-7JD%)*Z72-;,4ZDUH&HVL\$6U".,HN@UKQF60)GYNH=-$M59PB0L-IJUK
MIO].4*C=*+@.WB>6?%-9-Q&F2<,VF*%=-0M-4=BC%+Q&:;B2H+$<!>/K^\G0
MY?N$WQQWYF@,SLE:J5<7S(M1$#E!*#"W#H'1;XM3%,(!D8RW V;04[K"X_$[
M^H/W3E[6S.!4B3^\L-4H^!Y @25KA5VJW2\\^+EQ>+D2QG]AU^7>10'DK;&J
M/A23@IK+[L_VAWTX*HBO3Q3$AX+8Z^Z(O,H9LRQ-M-J!=MF$Y@;>JJ\F<5RZ
M0\FLIE5.=3:=K++YT\\L@^GSXV3^-'Z9/S_!)<P7RQDP6< T6\+Y#"WCPES0
MPH-B-=_#&7 )+Y5J#269)+0DQ0&&^8%VTM'&)V@?F;Z"Z,<WB*,X6F4S.#^[
M^!\E)".]F[AW$WO8P0G8N;Q<:)6C,;!$@TSGE7<QPRVU7T/-9#]A&?0L \\R
M/,$RSM]:KK&@/:#SYY);!,%+I-@RN>%K@<",0?OAQG38MQ[;79EM>A,-HB@)
MMQ](&O:2AI]*>F!<PY:)%D&5P LRRDON)7Y!TO!+DL*C+G,7ELYPPZ4!@275
M15=W-P'H[A)T@56-;[RULM3&?EC1NX':)=!ZJ91]#UPO]R]1^@]02P,$%
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MC9J!6QGP]S1Y0)Y]AUS;M0WU#+_L[K1-</Y?]O$O9_] AE?L$T_'\S[;)ZF
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M.5:9"J/5IUR<*0&G\B#IAW^#W@ 1*(4ZZN2>@'P\'"A14YBB V@"K4Q1H.\
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MF_#"*KS0RG.K8A ZE@CH@CPFT!1 N%4Y@=M487O:76W;M91@KPJB9PWB'A;
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M9Q+"!"-M&!A]=CC")#%$E,;?DM.I) WPN'U@_VR]DY<E4S@2R2\>ZTW/^>A
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MKF",2PTLBV'R-^?Z"188Y9)KC@I^#Y9*2[IL?QI$VY5HVXJVSXC.D"Y>1IK
MTRWCTLA#(A2E$)L45*5[!6Q'9X@M$P0J5:!8@G6'J- +K9XI6+L^;<WN>%F;
M(DY,="H3G6834D2(L8*5%*E-S"X=5123^Q.(%;7E ]T!D_RSI;KT"Z7.47)!
MV/;,[]3%J//*11!XIX$G9L+*3-AH9DZ'0/)(8PQ')Z(NU?!5!G6)CO\;5J3I
M'A6@%.7:%G(%D<@S75S):K1Z*P:V1+X8'[9N1D7)?Z8I'J!;)M<\4Y#@BBB]
MZP^TAK(HZD5'BZTM<TNAJ6C:YH;>090F@.970NA#QPA4+VO_'U!+ P04
M" "Q.P91ZW?MQ<$"  "4"   &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6RE5FMOFS 4_2L6VH=66@KA%5HED=K2:IO4KDI?FJ9]<. FL0IV9IO0_OO9
MAK"T$!9I7X(?YYQ[SS7Q95PR_B)6 !*]YAD5$VLEY?K,MD6R@AR+$[8&JG86
MC.=8JBE?VF+- :>&E&>VZSBAG6-"K>G8K-WQZ9@5,B,4[C@219YC_G8!&2LG
MUM#:+LS(<B7U@CT=K_$2[D$^KN^XFMF-2DIRH((PBC@L)M;Y\"R.--X G@B4
M8F>,M),Y8R]Z\C6=6(Y."#)(I%; ZK&!2\@R+:32^%UK6DU(3=P=;]6OC7?E
M98X%7++LF:1R-;$B"Z6PP$4F9ZS\ K6?0.LE+!/F%Y45UG,ME!1"LKPFJPQR
M0JLG?JWKL$-0.MT$MR:XAQ*\FN!])/A["'Y-\$UE*BNF#C&6>#KFK$1<HY6:
M'IAB&K:R3Z@^]GO)U2Y1/#G]>OMT=?OP??8#'<4@,<G$,1J@Q_L8'7TZ'MM2
MA=! .ZGE+BHY=X^<AVX8E2N!KF@*:0?_LI\?]O!M9:WQYV[]7;B]@M\*>H(\
MYS-R'=?IRN?_Z'$_/89$T8>:/CSM<>,UI^49/6_?:=$-4,GX&XJ)2#(F"@[H
MY_E<2*[^0+]Z(OA-!-]$\/\9H>1$PB!E)>UZ#2J5T*CHJV4S5>79[!:V#_$N
MM:!)+>A-;89+]>9+X 1GHBNGBA[L1/2\:.0X'S,[$!<'+0>!X^S"WMD(&QMA
MKXUG=0\."!VL.4M =!H)6PF>!G[;QV&PN W;XV#4.!CU.K@FE*@;)T5+QM).
M Z-6R*$?.FT'!^+B-BX*PKTG$34^HEX?#TSBK"O]J'WPD3-LIW\@+F[CAEY7
M_O;./9X#7YI^*%#""BJK*[U9;5KNN>DT]E]XU:]O,%\2*E &"T5U3D:J>+SJ
M@=5$LK7I"G,F58\QPY7Z; "N 6I_P9C<3G2 YD-D^@=02P,$%     @ L3L&
M480W@/MH!0  51<  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULM5C;
M;MLX$/V5@;$+M$!BBY3E2^$8B.-<NDC:(FEWGVF9MHE*HDI23@/TXW<H*Y(2
MR[3]X#S$NG".AF>&AS,</4OU4Z\X-_ [CA)]T5H9DW[J='2XXC'3;9GR!-\L
MI(J9P5NU[.A4<3;/C>*H0SVOUXF92%KC4?[LFQJ/9&8BD?!O"G06QTR]3'@D
MGR]:I/7ZX%$L5\8^Z(Q'*5OR)VY^I-\4WG5*E+F(>:*%3$#QQ47KDGRZ\WO6
M(!_QK^#/NG8-=BHS*7_:F\_SBY9G/>(1#XV%8/BSYE<\BBP2^O&K &V5W[2&
M]>M7])M\\CB9&=/\2D;_B;E97;0&+9CS!<LB\RB?[W@QH<#BA3+2^7]X+L9Z
M+0@S;61<&*,'L4@VO^QW043-@ YW&-#"@+XW(#L,_,+ /]2@6QAT#S4("H/@
M4(->8= [U*!?&/3?&71WT3HH# 9Y=#?AR&,Y98:-1TH^@[*C$<U>Y F16V,(
M16)S]\DH?"O0SHSOOWZY/?]^_?@ T^O)=SB'*\7GP@!;*LXQ1PU\F'+#1*0_
MCCH&/VC-.F$!/MF TQW@#TRUP1N> ?6H]^-I"A_^^F@42W !Z@:T*S?:E(=M
M\,D;M :4J1OEGRQ!%"]'Z>Y&N3X<Q>'+S<$S(L/=*+<'H)#^/I2[?3.*VD"'
M;U#TBBF^DM&<*QWQQ/Z\!>Y@MI4I1\N4H_F7NCN^5&38Y6N&.2#]$M+/(?V=
M%,P,B$0;E>4Y*Y*-JJ,Z.M"[)7K7Z?"7+)YQ!7(!1O$\>>$/./)XLH$+<CB[
M>:S'_JBS;O @*#T(G!Y<QI;].5PF<WCDVC"#-T?PV"N_TSL!C_T2O>^<18[^
MN40_@QL6<KB,9?;>^0V-&[1>C<; V_PULSDH_1@X_;B7R?+<<!7C)C=#-Y9*
MZJ8X7@^V'/"#=PYLEOD! ]]X.BP]'3H]G>"NC$% 7S'HH##L33RY,09M&OSM
MB![QJJW"VQ^_6G8L. >F@4'*56@?V!6RPF=+3,DE.@NI$DDH4A8!VQGE/1\E
M;<]SNE_;Z8@3Z4$F9A6]0,I><O>/<QUF?"F21"1+0*E\L<+O-T['[01I!^[I
M5"I*Z/ZU&LHU3UAB7+I,*A4EOILAD8@XBVLLA$ROL#:,4.LX& FV&L9J &O.
M!28EW$PO@:6IDFL6-9+A;RT,&CC6!:DDF;@U^2!%1)G& I?C).SE4S;3_%=F
MGU^OW7I)*F$FP0D4DU2"3'K[U]QKE,]L!9A'Z%?&% 8 \U!Q?)=AI&2<1L+&
MJ;&RZFT%HM>D9-.&@<.^2\I(I?[$+?^'ANQKPL]CNU;A_O/DZZ.+QDKQR> 4
M8:ITFNP5:J%ATSX"MF1KI@2;17RG9N_!H^V^4[1I)=K4K9^OK#,7ZV?P/:]L
M@,"]9"Y*:"6WE)R <EJK(MUEY)'5Q%T!5\]LXMRD::6;U*V;QW%,]W)<J2#M
MGH+C2MVHN^X\DN/; NZ-WCM+-EH)(74+X7$<^WLYKF2+]D_!<25-U%V-3J1"
M&UM7A"QEH3 O3:4HW2XQ]V1OI5W4K35/59<']WF7AR)\3)-6:9'OG8!*OY(<
MWUU<'43E70%R>%_A5YKDNS6IZA2+=AFGN);1&E/U#]2[Z4:_Z%;;2'<X5.N+
MW<KTB$6KMNT#[DJ+!5>6&RQY0?,P4\((;&733(4KVV>PVAZ\G1.N %5ZY9]"
MK_Q*KWRW7CGY;SS!**@/MJ@G.ZBO!,MW"]:M[2JQC9 AYW,-"R5C$%IG>2F-
M'F+!AE4.:"/#GXT^;5=BI-N8IIW:\9\]<'Y@"EL5C1->H*F'I40+U.8,=W-C
M9)J?",ZD,3+.+U=8N'!E!^#[A93F]<8>,I8GZ>/_ 5!+ P04    " "Q.P91
M<PK&KBX$   ]#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6S%5UMO
MXC@4_BM':!Y:J25Q0BB, *DM[>Z,.K-5+SO/)C'$FL1F;:>TTO[X/;F0,$TP
M2%-I7R!QSG?RG8N_'$\V4OW4,6,&7M-$Z&DO-F;]V7%T&+.4ZKY<,X%/EE*E
MU."M6CEZK1B-"E":.)[K#IV4<M&;38JU>S6;R,PD7+![!3I+4ZK>KE@B-],>
MZ6T7'O@J-OF",YNLZ8H],O.\OE=XY]1>(IXRH;D4H-ARVKLDGV^] E!8_,W9
M1N]<0Q[*0LJ?^<V7:-IS<T8L8:')75#\>V'7+$ER3\CCG\IIKWYG#MR]WGJ_
M+8+'8!94LVN9_."1B:>]40\BMJ198A[DYD]6!13D_D*9Z.(7-I6MVX,PTT:F
M%1@9I%R4__2U2L0.@ SV +P*X!T+\"N ?RQ@4 $&QP*""A <"QA6@&&1^S)9
M1:;GU-#91,D-J-P:O>471;D*-":8B[RS'HW"IQQQ9G;WU_<_SI]N'K[!_.;J
M"<[A!U6*"J/A9,X,Y8D^Q<7GQSF<?#J%3^" CJEB&KB 9\&-/L-%O'Z*9::I
MB/3$,4@K=^Z$%86KDH*WA\(WJOK@CL_ <SVW WYMAW_-DCYX!9R,.^#S0W#1
M!]_=^_:;WX/?VN%S%B*<=)%WL))U.;VZG%[AS]_CKZX>USICD<6C7WOT"X\#
MNT=@KTR%7#-8*QXR.,&:1S))J-*P9JKLBM.NXI?N1X7[7.=>9GX_\"?.2P>I
M04UJ8"7U6/5@$63>?NPUC*E8,9!+V%0YZ")3N@UVR P#,ARXW72"FDY@S?J<
M+0R^><D4%ROD@K*OF;8D?U@['EKC_"+"3"F%,6Z=HIHGU.""D7"-#[B!RY5B
M#,7> .X_>&0(X8:CZ7VF,"M8LMJB:W>5#(8[*2'$;1)2;H*VD>_N2=I%'=O%
M@=@,PR*:;6A=6_>BS<UM<;MHU92,]Y$;U>1&5G)SKD.984I#J;NR-A^U7]HB
MUK;Q]O$:U[S&5EZ76,4(JY]7^@&35[3"^SXX@R?%1!B#!W>2"DL?$K?Y3+@?
MV^)DYPM$_O<FKR@<U<"D$5OB'56-2ULU;#EJ1)CXA]//A38J*Y+ 13E4XG!F
M\]_H*;$+ZIT4JW/<CRE.90MLH)62NDM YZ2MH'[0WI/'F=U69L.]9K^&T^@Q
M":SAM)KF7[AC+RP!WY:M1I7)\(,W0R.*Q*Z*[PI]!DO*%;S0).L42-)62#\8
MM<MQR.Q7MHU*$KM,WDJ:\E?,;O%!CF42X2APEV\*9<M&HW9D_$'CC-<HF>=:
M.7_/T@6RQ$%!JH@+/$YM1UH34X.S]1LL<,JI9"6"Q5LS^QR8+JHW!^^^I7L;
MVFLTTK-KY&]/897_W3',Z[OC=[R<G8-$?K#$T7R%S0@)6R+,[5]@:*H\JY4W
M1JZ+L\5"&CRI%)<QGF^9R@WP^5)*L[W)CROUB7GV'U!+ P04    " "Q.P91
M,0'N.VH)   Q+P  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU6FMO
MV[@2_2N$L0NT0!OK14E>) '2.&G3;+M&O-W]<'$_,!)M"]7#2U%Y7.R/OT-)
M%B5+I)6T+M#6EH?#,\/AF1E2IX\9^YYO*.7H*8G3_&RRX7S[VW2:!QN:D/PD
MV](4?EEE+"$<OK+U--\R2L)R4!)/+<-PIPF)TLGY:?ELP<Y/LX+'44H7#.5%
MDA#V_('&V>/9Q)SL'MQ%ZPT7#Z;GIUNRIDO*OVT7#+Y-&RUAE- TC[(4,;HZ
MFUR8O]UZAAA02OP5T<>\]1D)4^ZS[+OX<A.>30R!B,8TX$(%@?\>Z"6-8Z$)
M</Q3*YTT<XJ![<\[[=>E\6#,/<GI91;_'85\<S;Q)RBD*U+$_"Y[_$1K@[#0
M%V1Q7OZ+'FM98X*"(N=94@\&!$F45O^3I]H1K0&VIQA@U0.LO0&FHQA@UP/L
MO0&6:@:G'N",A83K 7AO@&,I!KCU '<?DJD8X-4#O+$#_'J /Q;2K!XP&SN#
M:>Q6SMCWDW*MF\6N@JZ*DC+$YH23\U.6/2(FY$&?^%#&:3D>(BM*Q99:<@:_
M1C".GR\_7=Q=H<N+Q<V?%[^C]^@K88R(*$=OYI23*,[?HE_0%.4;PFB.HA1]
M2R.>OX.'\/G/35;D) WSTRD',$+E-*@G_E!-;"DF_ERD)\B8O4.681G?EG/T
MYI>W<J+JWP&MEWJM%UL&6MU*Z\#PN7[X%\)ZH)10K@X9&)\@J]1ESL8;>#W"
M;;;10?B0<9J/4/UQA/&VV5$]H.73:("-V0-:;HYGYN>? O!6KV5.@YVSS)D>
MU!2V9+,OK69?6J5^6Z'_,B9YCK(56O(L^([^\SO\CFXX3?+_:K3;C7:[U.XH
MM"\@;U'&:(ARH?[=;GN3@F\R%OT/?G@#V[MZ.N2=ZTH_+O6+M/UP#DF\_',Z
M?6BO\UC!VQ&"'5N=QE;G9;9N"4,/)"Z XF#YIZ61;]&_+9H;,KB:Q&O!,TX
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M3-3U"[@V4-\WC,GC1#NH+G2C?U!+ P04    " "Q.P91,$_*/YX#   T#
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M%LPY<Z@Q:)8;O-*YI<'>9P-G"C>V5&)77E)X8>:FU>N"(^WB$]+1 X>G[F.
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M    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;+5676_:,!3]*U=1'UJI(A]
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M&^8RO4PF."%S!6/.U$K"D$4X>HUW=<A%W,$N[EY02O@E916H>I<0>('W.!_
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MD&8 ]N^$T*>&N7'5=_C97U!+ P04    " "Q.P91C90<K.D!  #T!   &0
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M0]BX:PF,+W#KM=:X3_S)GR^Z_!=02P,$%     @ L3L&44I)\Y%, @  P L
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M/_7.Y;1+^=KSO<;G_R?5Y7QONC[^LOP^.7I[+S@'^)/@\0M02P,$%     @
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M]W' Y!-02P$"% ,4    " "Q.P91!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +$[!E&PH'#%[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( +$[!E&97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ L3L&48:=KXAF!0  $18  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( +$[!E'.\P//. <  !0>   8              " @:D-  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "Q.P918.1:X^L"  "S
M"0  &               @($7%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ L3L&431<>)7R!0  G!@  !@              ("!.!@
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( +$[!E%_>P P
MKP,  !\,   8              " @6 >  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "Q.P91;,G$B]P'   N*   &
M@(%%(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ L3L&
M41RF/:!U @  @@4  !@              ("!5RH  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( +$[!E%F1")3&0D  ((C   8
M      " @0(M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "Q.P91N&,Q+;H,  "9(   &               @(%1-@  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ L3L&4=+R>EM%&P  3%(  !D
M             ("!04,  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "Q.P917#!S#& 2  "=/0  &0              @(&]7@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +$[!E$JXM6U$ T
M &HD   9              " @51Q  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ L3L&49%U2CG!!   Q0H  !D              ("!
MFWX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "Q.P91
M#/S)/\,%  !.#@  &0              @(&3@P  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( +$[!E$2'(<=&P0  (H(   9
M      " @8V)  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ L3L&4?+Q.884#0  K2(  !D              ("!WXT  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "Q.P91&U 7%',/  !Q+0
M&0              @($JFP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( +$[!E'L>Y9A_P4  /<.   9              " @=2J  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ L3L&46"-T].Z
M"   2A4  !D              ("!"K$  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "Q.P91?/&^$?D#  !<"0  &0
M@('[N0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( +$[
M!E%I-!01NA\  .%D   9              " @2N^  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ L3L&42 @R#1M P  X@8  !D
M         ("!'-X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " "Q.P91W+FPXA@(  ![&   &0              @(' X0  >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +$[!E$:&:[D;0,  %P'
M   9              " @0_J  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ L3L&4>O(7,F< P  D@@  !D              ("!L^T
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "Q.P91<]9Q
M,Y,"   P!0  &0              @(&&\0  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( +$[!E&TNN'IQP0  ($+   9
M  " @5#T  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
ML3L&43)/[XMY @  ) 4  !D              ("!3OD  'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "Q.P91]'ZQDCD#  #E"0  &0
M            @('^^P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( +$[!E'_DTXSQ@,  '4,   9              " @6[_  !X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ L3L&4<'.77 \!@
M;!D  !D              ("!:P,! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " "Q.P91L1XCK0$#  !0"   &0              @('>
M"0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( +$[!E&V
MH<^<1P,   0*   9              " @18- 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ L3L&45!0F2>  @  GP4  !D
M     ("!E! ! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +$[!E&W+4$FP@(  #P'   9              "
M@:,A 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ L3L&
M4?E,>6L= P  L L  !D              ("!G"0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " "Q.P91?^0#P $$  #;$0  &0
M        @('P)P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( +$[!E%#R97]T@(  &4'   9              " @2@L 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ L3L&4>MW[<7! @  E @
M !D              ("!,2\! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " "Q.P91A#> ^V@%  !5%P  &0              @($I,@$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( +$[!E%S"L:N
M+@0  #T/   9              " @<@W 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ L3L&43$![CMJ"0  ,2\  !D
M ("!+3P! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "Q
M.P91-JB2L;0#   #$   &0              @('.10$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +$[!E$\T![BSP(  $<)   9
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M970U,BYX;6Q02P$"% ,4    " "Q.P916?R;%,(#  #/"P  &0
M    @(&X60$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M +$[!E&-E!RLZ0$  /0$   9              " @;%= 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ L3L&44I)\Y%, @  P L   T
M             ( !T5\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "Q.P91
MEXJ[',     3 @  "P              @ %(8@$ 7W)E;',O+G)E;'-02P$"
M% ,4    " "Q.P91.ZC8R*($  #D(P  #P              @ $Q8P$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ L3L&40^45$C: 0  62   !H
M         ( ! &@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ L3L&42%=IR;- 0  )"   !,              ( !$FH! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #X /@#I$   $&P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>373</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIES</Role>
      <ShortName>MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - LONG-TERM DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/LONGTERMDEBT</Role>
      <ShortName>LONG-TERM DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITAL</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - OPERATING LEASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASE</Role>
      <ShortName>OPERATING LEASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables</Role>
      <ShortName>MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/MARKETABLESECURITIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/INVENTORY</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SHARECAPITAL</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2339307 - Disclosure - OPERATING LEASE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASETables</Role>
      <ShortName>OPERATING LEASE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/OPERATINGLEASE</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails</Role>
      <ShortName>BUSINESS COMBINATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails</Role>
      <ShortName>BUSINESS COMBINATION - Consideration Transferred in Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails</Role>
      <ShortName>BUSINESS COMBINATION - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails</Role>
      <ShortName>BUSINESS COMBINATION - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails</Role>
      <ShortName>BUSINESS COMBINATION - IPRD and CSR (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails</Role>
      <ShortName>BUSINESS COMBINATION - Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/REVENUERECOGNITION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - FAIR VALUE MEASUREMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/INVENTORYDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/INVENTORYTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - LONG-TERM DEBT - Credit agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails</Role>
      <ShortName>LONG-TERM DEBT - Credit agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - LONG-TERM DEBT - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails</Role>
      <ShortName>LONG-TERM DEBT - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - SHARE CAPITAL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails</Role>
      <ShortName>SHARE CAPITAL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails</Role>
      <ShortName>SHARE CAPITAL - Options and RSU Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails</Role>
      <ShortName>SHARE CAPITAL - Fair value assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails</Role>
      <ShortName>SHARE CAPITAL - Schedule of Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - OPERATING LEASE - Operating lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails</Role>
      <ShortName>OPERATING LEASE - Operating lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>OPERATING LEASE - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mnlo-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - mnlo-20200630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - mnlo-20200630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mnlo-20200630.htm">mnlo-20200630.htm</File>
    <File>ex101cutia-licenseagre.htm</File>
    <File>ex102agreementno1toarc.htm</File>
    <File>mnlo-20200630.xsd</File>
    <File>mnlo-20200630_cal.xml</File>
    <File>mnlo-20200630_def.xml</File>
    <File>mnlo-20200630_lab.xml</File>
    <File>mnlo-20200630_pre.xml</File>
    <File>mnlo-20200630xexx311.htm</File>
    <File>mnlo-20200630xexx312.htm</File>
    <File>mnlo-20200630xexx321.htm</File>
    <File>mnlo-20200630xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mnlo-20200630.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "mnlo-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mnlo-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mnlo-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mnlo-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnlo-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mnlo-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 491,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 7
   },
   "keyCustom": 59,
   "keyStandard": 314,
   "memberCustom": 26,
   "memberStandard": 32,
   "nsprefix": "mnlo",
   "nsuri": "http://www.menlotherapeutics.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.menlotherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - BUSINESS COMBINATION",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.menlotherapeutics.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - MARKETABLE SECURITIES",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIES",
     "shortName": "MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - INVENTORY",
     "role": "http://www.menlotherapeutics.com/role/INVENTORY",
     "shortName": "INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - LONG-TERM DEBT",
     "role": "http://www.menlotherapeutics.com/role/LONGTERMDEBT",
     "shortName": "LONG-TERM DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - SHARE CAPITAL",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITAL",
     "shortName": "SHARE CAPITAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - OPERATING LEASE",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASE",
     "shortName": "OPERATING LEASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ReverseMergerPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ReverseMergerPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - BUSINESS COMBINATION (Tables)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - MARKETABLE SECURITIES (Tables)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables",
     "shortName": "MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - INVENTORY (Tables)",
     "role": "http://www.menlotherapeutics.com/role/INVENTORYTables",
     "shortName": "INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - SHARE CAPITAL (Tables)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALTables",
     "shortName": "SHARE CAPITAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339307 - Disclosure - OPERATING LEASE (Tables)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASETables",
     "shortName": "OPERATING LEASE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - NATURE OF OPERATIONS (Details)",
     "role": "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ib1f7bee6f856461cb5df3d54f47f4a78_I20200406",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ContingentStockRightSharesConversion",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i80a470217c3a4272adc3535da6eb3922_D20200401-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ib1f7bee6f856461cb5df3d54f47f4a78_I20200406",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ContingentStockRightSharesConversion",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - BUSINESS COMBINATION - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
     "shortName": "BUSINESS COMBINATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i30bc8898298941ccab04367f96cd0e7a_D20200406-20200406",
      "decimals": "2",
      "lang": "en-US",
      "name": "mnlo:PostMergerParentOwnershipByPreMergerParentStockholders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ib1f7bee6f856461cb5df3d54f47f4a78_I20200406",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - BUSINESS COMBINATION - Consideration Transferred in Merger (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
     "shortName": "BUSINESS COMBINATION - Consideration Transferred in Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "mnlo:ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i4486b08f7c0c48b6ab9b0a78c0be8865_D20200309-20200309",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i4294414ce48b417a90b94bbd93daf454_D20200309-20200309",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
     "shortName": "BUSINESS COMBINATION - Purchase Price Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "id8d2dac9a2a445dfae26312379d3050b_I20200309",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "id8d2dac9a2a445dfae26312379d3050b_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - BUSINESS COMBINATION - Goodwill (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
     "shortName": "BUSINESS COMBINATION - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "id8d2dac9a2a445dfae26312379d3050b_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlo:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "id8d2dac9a2a445dfae26312379d3050b_I20200309",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - BUSINESS COMBINATION - IPRD and CSR (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
     "shortName": "BUSINESS COMBINATION - IPRD and CSR (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlo:ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "id8d2dac9a2a445dfae26312379d3050b_I20200309",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)",
     "role": "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails",
     "shortName": "BUSINESS COMBINATION - Pro Forma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - REVENUE RECOGNITION (Details)",
     "role": "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
     "shortName": "REVENUE RECOGNITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:RevenueRecognitionDistributionTradeDiscountsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:DerivateCostsForYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - FAIR VALUE MEASUREMENT - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:DerivateCostsForYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - MARKETABLE SECURITIES - Marketable Securities (Details)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails",
     "shortName": "MARKETABLE SECURITIES - Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
     "shortName": "MARKETABLE SECURITIES - Fair Value, Cost and Gross Unrealized Holding Gains of Securities Owned (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - MARKETABLE SECURITIES - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails",
     "shortName": "MARKETABLE SECURITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - INVENTORY (Details)",
     "role": "http://www.menlotherapeutics.com/role/INVENTORYDetails",
     "shortName": "INVENTORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i4fa0d91fe20746dc801522cdb641699a_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:CreditAgreementNumberOfTrenches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranches",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - LONG-TERM DEBT - Credit agreement (Details)",
     "role": "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
     "shortName": "LONG-TERM DEBT - Credit agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i4fa0d91fe20746dc801522cdb641699a_I20200309",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:CreditAgreementNumberOfTrenches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tranches",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i665aac50c21e4c9382a4dedf21e3a6d4_I20200309",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - LONG-TERM DEBT - Warrants (Details)",
     "role": "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
     "shortName": "LONG-TERM DEBT - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i665aac50c21e4c9382a4dedf21e3a6d4_I20200309",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - SHARE CAPITAL - Narrative (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
     "shortName": "SHARE CAPITAL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mnlo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - SHARE CAPITAL - Options and RSU Grants (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
     "shortName": "SHARE CAPITAL - Options and RSU Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mnlo:ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - SHARE CAPITAL - Fair value assumptions (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
     "shortName": "SHARE CAPITAL - Fair value assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i8c0e54e4b2b64c84aa162bfc96944b34_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - SHARE CAPITAL - Schedule of Share-based Compensation (Details)",
     "role": "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails",
     "shortName": "SHARE CAPITAL - Schedule of Share-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i875e9e1345164d94bc58815365779517_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - OPERATING LEASE - Operating lease costs (Details)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails",
     "shortName": "OPERATING LEASE - Operating lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - OPERATING LEASE - Maturities of Lease Liabilities (Details)",
     "role": "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "OPERATING LEASE - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i62013cb8bd8344108941648a67adfc5b_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i62013cb8bd8344108941648a67adfc5b_D20200101-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ib1f7bee6f856461cb5df3d54f47f4a78_I20200406",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mnlo:ContingentStockRightSharesConversion",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i25c54cc3ee9d4ef7bbd258d135e18074_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i25c54cc3ee9d4ef7bbd258d135e18074_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i74f696343f7b4319b954654fee16542a_D20200401-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS",
     "role": "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "ic89e3a3486e547a8b29ed1304d9f351d_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - mnlo-20200630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - mnlo-20200630.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mnlo-20200630.htm",
      "contextRef": "i55514fe802bc4047841713151110e3e1_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mnlo_A2018PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2018 Plan",
        "label": "2018 Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "A2018PlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_A2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Plan",
        "label": "2019 Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "A2019PlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of additional royalty receipt upon occurrence of certain event related to licensed products",
        "label": "Additional Royalty Receipt Upon Occurrence Of Certain Events",
        "terseLabel": "Additional royalty upon receipt of marketing approval in China"
       }
      }
     },
     "localname": "AdditionalRoyaltyReceiptUponOccurrenceOfCertainEvents",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_AdditionalSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the additional leased facility space.",
        "label": "Additional Space [Member]",
        "terseLabel": "Additional Space"
       }
      }
     },
     "localname": "AdditionalSpaceMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": 1.0,
       "parentTag": "mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of acceleration of stock based compensation as adjustment to pro-forma results of the combined operation after business acquisition.",
        "label": "Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation",
        "negatedLabel": "Acceleration of stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of adjustments to supplemental proforma combined results of operations of the combined operation after business acquisition.",
        "label": "Adjustments to Supplemental Proforma Combined Results of Operations",
        "negatedTotalLabel": "Total Adjustments"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_AdjustmentsToSupplementalProformaTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails": {
       "order": 2.0,
       "parentTag": "mnlo_AdjustmentsToSupplementalProformaCombinedResultsOfOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount pertaining to transaction costs as adjustment to pro-forma results of the combined operation after business acquisition.",
        "label": "Adjustments To Supplemental Proforma Transaction Costs",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "localname": "AdjustmentsToSupplementalProformaTransactionCosts",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_AmendedAndRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Amended and Restated Credit Agreement entered into on March 9, 2020.",
        "label": "Amended And Restated Credit Agreement [Member]",
        "terseLabel": "Amended And Restated Credit Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_AmendedAndRestatedCreditAgreementTrench1LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents trench 1 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench1 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 1 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench1LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_AmendedAndRestatedCreditAgreementTrench2LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents trench 2 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench2 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 2 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench2LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_AmendedAndRestatedCreditAgreementTrench3LoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents trench 3 loan of the Amended and Restated Credit Agreement.",
        "label": "Amended And Restated Credit Agreement Trench3 Loan [Member]",
        "terseLabel": "Amended and Restated Credit Agreement, Trench 3 Loan"
       }
      }
     },
     "localname": "AmendedAndRestatedCreditAgreementTrench3LoanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_BridgewaterNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the location in Bridgewater, New Jersey.",
        "label": "Bridgewater New Jersey [Member]",
        "terseLabel": "Bridgewater, New Jersey"
       }
      }
     },
     "localname": "BridgewaterNewJerseyMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_BusinessAcquisitionContingentStockRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of contingent stock right issued in connection with the business acquisition.",
        "label": "Business Acquisition, Contingent Stock Right Issued",
        "terseLabel": "Number of contingent stock rights issued (in CSR)"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentStockRightIssued",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mnlo_BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Acquiree Common Stock Rights Converted to Common Stock",
        "label": "Business Combination, Acquiree Common Stock Rights Converted to Common Stock",
        "terseLabel": "Value of CSR converted into additional shares of the combined company"
       }
      }
     },
     "localname": "BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of net assets acquired including other identifiable intangible assets.",
        "label": "Business Combination Assets Acquired Including Other Identifiable Intangible Assets",
        "negatedLabel": "Less: fair value of net assets acquired, including other identifiable intangibles"
       }
      }
     },
     "localname": "BusinessCombinationAssetsAcquiredIncludingOtherIdentifiableIntangibleAssets",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": 1.0,
       "parentTag": "mnlo_BusinessCombinationConsiderationTransferredGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred consisting of the conversion of equity awards.",
        "label": "Business Combination Consideration Transferred Conversion Of Acquirer Equity Awards",
        "terseLabel": "Deemed (for accounting purposes only) conversion of Menlo equity awards"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_BusinessCombinationConsiderationTransferredGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer prior to the reduction in respect of the contingent stock rights issued to acquired shareholders.",
        "label": "Business Combination Consideration Transferred Gross",
        "terseLabel": "Consideration transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredGross",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_BusinessCombinationEffectiveExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective exchange ratio of ordinary shares for shares of common stock from the merger as adjusted for the conversion of contingent stock rights.",
        "label": "Business Combination, Effective Exchange Ratio",
        "terseLabel": "Effective exchange ratio of Foamix ordinary shares into Menlo common stock (share/share)"
       }
      }
     },
     "localname": "BusinessCombinationEffectiveExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mnlo_BusinessCombinationSharesDeemedIssuedForAccountingPurposes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares deemed, for accounting purposes only, to be issued in the merger.",
        "label": "Business Combination Shares Deemed Issued For Accounting Purposes",
        "terseLabel": "Number of shares deemed (for accounting purposes only) issued (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationSharesDeemedIssuedForAccountingPurposes",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mnlo_CSRAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CSR Agreement",
        "label": "CSR Agreement [Member]",
        "terseLabel": "CSR Agreement"
       }
      }
     },
     "localname": "CSRAgreementMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_ClassOfWarrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "n/a",
        "label": "Class Of Warrant [Abstract]",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantAbstract",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mnlo_CommonStockIncreaseInCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock, Increase in Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Increase in Capital Shares Reserved for Future Issuance",
        "terseLabel": "Increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockIncreaseInCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mnlo_CommonStockVotingRightsNumberPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of votes entitled to each ordinary share.",
        "label": "Common Stock Voting Rights Number Per Share",
        "terseLabel": "Number of votes entitled to each ordinary share"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberPerShare",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mnlo_ContingentStockConsiderationRemeasurementGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Stock Consideration, Remeasurement Gain (Loss)",
        "label": "Contingent Stock Consideration, Remeasurement Gain (Loss)",
        "negatedTerseLabel": "Contingent Stock Right Remeasurement"
       }
      }
     },
     "localname": "ContingentStockConsiderationRemeasurementGainLoss",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ContingentStockRightSharesConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued per each contingent stock right.",
        "label": "Contingent Stock Right Shares Conversion",
        "terseLabel": "Number of common stock shares issued per CSR (in shares)"
       }
      }
     },
     "localname": "ContingentStockRightSharesConversion",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mnlo_CreditAgreementNumberOfTrenches": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of trenches of credit agreement.",
        "label": "Credit Agreement, Number of Trenches",
        "terseLabel": "Number of trenches"
       }
      }
     },
     "localname": "CreditAgreementNumberOfTrenches",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mnlo_DebtCovenantMinimumQuarterlyRevenueCompliance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Covenant, Minimum Quarterly Revenue Compliance",
        "label": "Debt Covenant, Minimum Quarterly Revenue Compliance",
        "terseLabel": "Debt covenant, minimum quarterly revenue compliance"
       }
      }
     },
     "localname": "DebtCovenantMinimumQuarterlyRevenueCompliance",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_DebtCovenantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "n/a",
        "label": "Debt Covenants [Abstract]",
        "terseLabel": "Debt covenants"
       }
      }
     },
     "localname": "DebtCovenantsAbstract",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mnlo_DebtInstrumentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument, as a percent of the aggregate principal amount of all loans outstanding.",
        "label": "Debt Instrument Fee Percent",
        "terseLabel": "Debt instrument fee as a percent of the aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFeePercent",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_DebtInstrumentPeriodicPaymentPrincipalPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Required monthly payment as a percent of the aggregate principal amount from Jul 2023 through July 2024.",
        "label": "Debt Instrument Periodic Payment Principal Percent",
        "terseLabel": "Monthly payment as a percent of the aggregate principal amount beginning July 2023"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipalPercent",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_DeemedDividendToWarrantsHoldersDueToWarrantModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from modification of warrants that is deemed dividend",
        "label": "Deemed Dividend To Warrants Holders Due To Warrant Modification",
        "negatedTerseLabel": "Deemed dividend to warrants holders due to warrant modification",
        "terseLabel": "Deemed dividend to warrants holders due to warrant modification"
       }
      }
     },
     "localname": "DeemedDividendToWarrantsHoldersDueToWarrantModification",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_DerivateCostsForYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The transaction cost of currency hedging for year from the time of occurrence of the transaction.",
        "label": "Derivate Costs For A Year",
        "terseLabel": "Currency hedging cost for a year"
       }
      }
     },
     "localname": "DerivateCostsForYear",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_DerivativeMaximumTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum period the derivative contract is outstanding, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Currency hedging transactions, maximum term",
        "terseLabel": "Currency hedging transactions, maximum term"
       }
      }
     },
     "localname": "DerivativeMaximumTermOfContract",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mnlo_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_DistributorThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents distributor three.",
        "label": "Distributor Three [Member]",
        "terseLabel": "Distributor Three"
       }
      }
     },
     "localname": "DistributorThreeMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document And Entity Information [Abstract].",
        "label": "DOCUMENT AND ENTITY INFORMATION [Abstract]",
        "terseLabel": "DOCUMENT AND ENTITY INFORMATION [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "xbrltype": "stringItemType"
    },
    "mnlo_EffectiveExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Exchange Ratio",
        "label": "Effective Exchange Ratio",
        "terseLabel": "Effective Exchange Ratio (CSR per share)"
       }
      }
     },
     "localname": "EffectiveExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mnlo_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_EstimateOfProductReturnRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum estimate of product sales return rate at reporting date.",
        "label": "Estimate of Product Return Rate, Maximum",
        "terseLabel": "Maximum estimate product return (as a percent)"
       }
      }
     },
     "localname": "EstimateOfProductReturnRateMaximum",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_EstimateOfProductReturnRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum estimate of product sales return rate at reporting date.",
        "label": "Estimate of Product Return Rate, Minimum",
        "terseLabel": "Minimum estimate product return (as a percent)"
       }
      }
     },
     "localname": "EstimateOfProductReturnRateMinimum",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_ExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the exchange of ordinary shares of acquiree for common stock of the entity.",
        "label": "Exchange Ratio",
        "terseLabel": "Exchange ratio per ordinary share for common stock (share per share)"
       }
      }
     },
     "localname": "ExchangeRatio",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mnlo_FacilitySpaceUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Size of the facility under lease, in square feet.",
        "label": "Facility Space Under Lease",
        "terseLabel": "Facility space leased"
       }
      }
     },
     "localname": "FacilitySpaceUnderLease",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "mnlo_FairValueMeasurmentsNarrativeDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurements Narrative",
        "terseLabel": "Fair Value Measurements Narrative"
       }
      }
     },
     "localname": "FairValueMeasurmentsNarrativeDetailsAbstract",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "xbrltype": "stringItemType"
    },
    "mnlo_FinancialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the total financial expenses during the reporting period.",
        "label": "Financial Expenses",
        "terseLabel": "FINANCE EXPENSES"
       }
      }
     },
     "localname": "FinancialExpenses",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_FinancialIncomeNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the total financial income during the reporting period.",
        "label": "Financial Income Net",
        "negatedLabel": "FINANCE INCOME"
       }
      }
     },
     "localname": "FinancialIncomeNet",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_FoamixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the merger of Foamix.",
        "label": "Foamix [Member]",
        "terseLabel": "Foamix"
       }
      }
     },
     "localname": "FoamixMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions.",
        "label": "Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions",
        "terseLabel": "Foreign exchange risk lien on checking account for bank guarantees granted to secure hedging transactions"
       }
      }
     },
     "localname": "ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions.",
        "label": "Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions",
        "terseLabel": "Foreign exchange risk lien on marketable securities for bank guarantees granted to secure hedging transactions"
       }
      }
     },
     "localname": "ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross proceeds from issuance of common stock before deducting offering expenses.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash increase (decrease) in employee severance benefit liability net of profit from retirement fund.",
        "label": "Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits",
        "terseLabel": "Changes in accrued liability for employee severance benefits, net of retirement fund profit"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_InitialPublicOfferingLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents initial public offering related lawsuits",
        "label": "Initial Public Offering Lawsuits [Member]",
        "terseLabel": "IPO Lawsuits"
       }
      }
     },
     "localname": "InitialPublicOfferingLawsuitsMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_InterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest received.",
        "label": "Interest received",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceived",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_IsraeliMutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Israeli Mutual Funds",
        "label": "Israeli Mutual Funds [Member]",
        "terseLabel": "Israeli mutual funds"
       }
      }
     },
     "localname": "IsraeliMutualFundsMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_LiquidityAndCapitalResourcesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liquidity and Capital Resources",
        "label": "Liquidity and Capital Resources [Policy Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesPolicyTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents lawsuit related to the merger alleging that the members of Foamix's board of directors breached their fiduciary duties in connection with the Merger.",
        "label": "Merger Lawsuits Breach Of Fiduciary Duties Of B O D [Member]",
        "terseLabel": "Merger Lawsuits, Breach of Fiduciary Duties Of BOD"
       }
      }
     },
     "localname": "MergerLawsuitsBreachOfFiduciaryDutiesOfBODMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_MergerLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents merger related lawsuits",
        "label": "Merger Lawsuits [Member]",
        "terseLabel": "Merger Lawsuits"
       }
      }
     },
     "localname": "MergerLawsuitsMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_MinimumAggregateCashBalanceMaintainAfterFdaApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum aggregate cash balance to maintain after FDA approval.",
        "label": "Minimum aggregate cash balance to maintain after FDA approval",
        "terseLabel": "Minimum aggregate cash balance to maintain after FDA approval"
       }
      }
     },
     "localname": "MinimumAggregateCashBalanceMaintainAfterFdaApproval",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_NonCashAcquisitionOfBusinessCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash as part of a non-cash business acquisition.",
        "label": "Non Cash Acquisition Of Business, Cash Acquired",
        "terseLabel": "Less cash acquired"
       }
      }
     },
     "localname": "NonCashAcquisitionOfBusinessCashAcquired",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net assets acquired in non-cash acquisition, net of cash acquired included in the acquisition.",
        "label": "Non Cash Acquisition Of Business, Net Assets After Cash Acquired",
        "terseLabel": "Merger net of cash acquired"
       }
      }
     },
     "localname": "NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_NumberOfClassActions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of class actions lawsuit brought against the entity.",
        "label": "Number of Class Actions",
        "terseLabel": "Number of class actions"
       }
      }
     },
     "localname": "NumberOfClassActions",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mnlo_NumberOfLenders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of lenders.",
        "label": "Number Of Lenders",
        "terseLabel": "Number of lenders involved"
       }
      }
     },
     "localname": "NumberOfLenders",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mnlo_OfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The member pertaining to Officers and Directors.",
        "label": "Officers And Directors [Member]",
        "terseLabel": "Current and Former Officers and Directors"
       }
      }
     },
     "localname": "OfficersAndDirectorsMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_OrdinarySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ordinary shares of legal entity.",
        "label": "Ordinary Shares [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_OriginalSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the original leased facility space.",
        "label": "Original Space [Member]",
        "terseLabel": "Original Space"
       }
      }
     },
     "localname": "OriginalSpaceMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_PostMergerParentOwnershipByPreMergerParentStockholders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of post-merger Menlo ownership held by pre-merger Menlo stockholders, as a percent.",
        "label": "Post Merger Parent Ownership By Pre Merger Parent Stockholders",
        "terseLabel": "Ownership percentage of parent by parent stockholders"
       }
      }
     },
     "localname": "PostMergerParentOwnershipByPreMergerParentStockholders",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_PostMergerParentOwnershipByPreMergerSubsidiaryShareholders": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of post-merger Menlo ownership held by pre-merger Foamix shareholders, as a percent.",
        "label": "Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders",
        "terseLabel": "Ownership percentage of parent by subsidiary stockholders"
       }
      }
     },
     "localname": "PostMergerParentOwnershipByPreMergerSubsidiaryShareholders",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mnlo_ProceedsFromBusinessMerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash inflow from business merger.",
        "label": "Proceeds From Business Merger",
        "terseLabel": "Cash acquired through merger"
       }
      }
     },
     "localname": "ProceedsFromBusinessMerger",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_RedwoodCityCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the location in Redwood City, California.",
        "label": "Redwood City California [Member]",
        "terseLabel": "Redwood City, California"
       }
      }
     },
     "localname": "RedwoodCityCaliforniaMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_RegisteredOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of entity stock pursuant to a Securities Purchase Agreement.",
        "label": "Registered Offering [Member]",
        "terseLabel": "Registered offering per securities purchase agreement"
       }
      }
     },
     "localname": "RegisteredOfferingMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_RestrictedInvestmentsToSecureLeaseAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lien on marketable securities in respect of bank guarantees granted in order to secure lease agreements.",
        "label": "Restricted Investments To Secure Lease Agreements",
        "terseLabel": "Lien on marketable securities to secure lease agreements"
       }
      }
     },
     "localname": "RestrictedInvestmentsToSecureLeaseAgreements",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_RevenueRecognitionDistributionTradeDiscountsAndAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate of fee the entity pays for distribution services and certain date that distributors provide to the entity and sales discounts given by the entity, including, but not limited to, early payments of accounts",
        "label": "Revenue Recognition, Distribution, Trade Discounts and Allowances",
        "terseLabel": "Product sales provisions"
       }
      }
     },
     "localname": "RevenueRecognitionDistributionTradeDiscountsAndAllowances",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ReverseMergerPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reverse Merger",
        "label": "Reverse Merger [Policy Text Block]",
        "terseLabel": "Reverse Merger"
       }
      }
     },
     "localname": "ReverseMergerPolicyTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_ScheduleOfBusinessAcquisitionConsiderationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of consideration to be transferred to effect the Merger.",
        "label": "Schedule of Business Acquisition Consideration [Table Text Block]",
        "terseLabel": "Schedule of Merger Consideration to be transferred"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionConsiderationTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_ScheduleOfBusinessCombinationGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the calculation of goodwill from the business combination.",
        "label": "Schedule Of Business Combination Goodwill [Table Text Block]",
        "terseLabel": "Schedule of the calculation of goodwill from the merger"
       }
      }
     },
     "localname": "ScheduleOfBusinessCombinationGoodwillTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of in-process research and development indefinite lived intangible assets acquired in the merger.",
        "label": "Schedule Of In Process Research And Development Assets Acquired Through Business Combination [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible IPRD assets acquired in the merger"
       }
      }
     },
     "localname": "ScheduleOfInProcessResearchAndDevelopmentAssetsAcquiredThroughBusinessCombinationTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the share-based compensation awards granted during the period, exercise price range, vesting period and expiration of awards.",
        "label": "Schedule Of Share Based Compensation By Share Based Payment Award Grants In Period [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation awards granted for options and RSUs during the period"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationByShareBasedPaymentAwardGrantsInPeriodTableTextBlock",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mnlo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the total fair value of options and equity instruments other than options granted during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options And Equity Instruments Other Than Options Grants in Period Total Grant Date Fair Value",
        "terseLabel": "Fair value of options and RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalGrantDateFairValue",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Plan Modification, Unrecognized Cost",
        "label": "Share-based Payment Arrangement, Plan Modification, Unrecognized Cost",
        "terseLabel": "Incremental compensation costs incurred"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationUnrecognizedCost",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period",
        "label": "Share-based Payment Arrangement, Plan Modification, Unrecognized Costs, Recognition Period",
        "terseLabel": "Incremental compensation costs, recognition period"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationUnrecognizedCostsRecognitionPeriod",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mnlo_ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification pertaining grantees not employed or providing services after the modification and reclassified from additional paid-in capital to derivative liabilities.",
        "label": "Share-based Payment, Modification of Terms, Incremental Compensation, Modification of Terms, Incremental Compensation Cost, Reclassified Adjustment",
        "negatedLabel": "Classification of stock awards to derivative liability",
        "terseLabel": "Additional paid in capital reclassified to derivate liabilities"
       }
      }
     },
     "localname": "ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share options RSUs and Shares Under ESPP [Member]",
        "label": "Share Options Restricted Stock Units R S U And Shares Under Espp [Member]",
        "terseLabel": "Outstanding stock options, RSUs and shares under the ESPP"
       }
      }
     },
     "localname": "ShareOptionsRestrictedStockUnitsRSUAndSharesUnderEsppMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_ShareholderLenderMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to shareholders that are also lenders of debt.",
        "label": "Shareholder Lender [Member]",
        "terseLabel": "Shareholder Lender"
       }
      }
     },
     "localname": "ShareholderLenderMember",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mnlo_SharesIssuedUponConversionOfCommonStockRightsPerAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number shares issued upon conversion of common stock rights arising form the certain events as provided for in the commons stock rights agreement.",
        "label": "Shares Issued Upon Conversion of Common Stock Rights, Per Agreement",
        "terseLabel": "Share issued and delivered upon CSR conversion (in shares)"
       }
      }
     },
     "localname": "SharesIssuedUponConversionOfCommonStockRightsPerAgreement",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mnlo_StockIssuedDuringPeriodSharesWarrantExchange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued during the period for the exchange of warrants following the merger.",
        "label": "Stock Issued During Period Shares Warrant Exchange",
        "terseLabel": "Shares issued in exchange of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantExchange",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mnlo_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for warrants exercised during the current period.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Number of shares issued for warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mnlo_UpfrontRoyaltyReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of upfront royalty receipt upon delivery of licensed products",
        "label": "Upfront Royalty Receipt",
        "terseLabel": "Upfront royalty receipt"
       }
      }
     },
     "localname": "UpfrontRoyaltyReceipt",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mnlo_VehicleLeasePrepaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period of prepaid to secure lease of vehicles.",
        "label": "Vehicle Lease, Prepayment Period",
        "terseLabel": "Vehicles lease prepaid period"
       }
      }
     },
     "localname": "VehicleLeasePrepaymentPeriod",
     "nsuri": "http://www.menlotherapeutics.com/20200630",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r136",
      "r208",
      "r212",
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r134",
      "r208",
      "r210",
      "r356",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r135",
      "r208",
      "r211",
      "r358",
      "r366",
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r182",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r137",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r8",
      "r42"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r29",
      "r138",
      "r139",
      "r209"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r68",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Recognition and Exercise",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r221",
      "r234",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r80",
      "r94",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Discount cost"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r325",
      "r347"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r59"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r144",
      "r160"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost or amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r141",
      "r145",
      "r160"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r223",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued pursuant to the merger (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "negatedLabel": "Loss per share - basic (in USD per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "negatedTerseLabel": "Loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Acquisition, Pro Forma Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL PRO FORMA COMBINED RESULTS OF OPERATIONS:"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of pro forma"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r252",
      "r253",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration net of the effect of CSRs"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails": {
       "order": 2.0,
       "parentTag": "mnlo_BusinessCombinationConsiderationTransferredGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Deemed (for accounting purposes only) issuance of Foamix shares to Menlo stockholders"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r251",
      "r254",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, fair value of liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS COMBINATION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Goodwill [Abstract]",
        "terseLabel": "Business Combination, Goodwill [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Loss attributable to Menlo"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Acquired indefinite life intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "totalLabel": "Fair value of identified intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTotalLabel": "Total liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Allocations of purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r102",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsIncurred": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in lease obligation from new lease.",
        "label": "Lease Obligation Incurred",
        "terseLabel": "Additions to operating lease liabilities"
       }
      }
     },
     "localname": "CapitalLeaseObligationsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r40",
      "r96"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r89",
      "r96",
      "r101"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD",
        "totalLabel": "TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r89",
      "r284"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of ordinary shares that may be purchased by exercise of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r181",
      "r333",
      "r352"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (USD/share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (shares)",
        "periodStartLabel": "Balance (shares)",
        "terseLabel": "Common stock shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock: $0.0001 par value; 300,000,000 shares authorized at June\u00a030, 2020 and December\u00a031, 2019, respectively; 167,683,814 and 36,480,314 shares issued and outstanding at June\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "TOTAL COMPREHENSIVE LOSS",
        "terseLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r281",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r281",
      "r282",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r281",
      "r282",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Product Sales"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r124",
      "r125",
      "r281",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r121",
      "r124",
      "r125",
      "r126",
      "r281",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r281",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r262",
      "r265",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).",
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate notes"
       }
      }
     },
     "localname": "CorporateNoteSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "TOTAL EXPENSES"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "EXPENSES"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customers"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r22",
      "r24",
      "r25",
      "r326",
      "r327",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r25",
      "r191",
      "r327",
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt instrument, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Base interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt instrument information"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r106",
      "r198",
      "r201",
      "r202",
      "r203",
      "r285",
      "r286",
      "r287",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Issuance Costs, Net [Abstract]",
        "terseLabel": "Debt offering expenses"
       }
      }
     },
     "localname": "DeferredFinanceCostsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r131"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAmountOfHedgedItem": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of hedged item in hedging relationship. Excludes hedged asset or liability.",
        "label": "Derivative, Amount of Hedged Item",
        "terseLabel": "Derivative, Amount of Hedged Item"
       }
      }
     },
     "localname": "DerivativeAmountOfHedgedItem",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r109",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "LOSS PER SHARE BASIC AND DILUTED (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r276",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r273",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "verboseLabel": "FAIR VALUE MEASURMENTS [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r273",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r273",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r214",
      "r215",
      "r217",
      "r273",
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r102",
      "r278",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r174",
      "r175",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r171",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (Loss) on Securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss from disposal and sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r166",
      "r168"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and in-process research &amp; development impairments"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r94",
      "r167",
      "r169",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r94",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "In process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r111",
      "r321",
      "r337",
      "r355"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "LOSS BEFORE INCOME TAX"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r132",
      "r241"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "INCOME TAX"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "(Decrease) increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effects of businesses acquired:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Increase in other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Increase in trade receivables, prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "CHANGES DURING THE PERIOD:"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r80",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r88",
      "r90",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r1",
      "r57",
      "r163"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory (Note 7)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/INVENTORYDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r322",
      "r341",
      "r365"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASE"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r328",
      "r350"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "One-month LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note 8)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/FAIRVALUEMEASUREMENTAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r45"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investment in marketable securities (Note 6)"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r116",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r89",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "verboseLabel": "Cash used in operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r69",
      "r72",
      "r76",
      "r95",
      "r114",
      "r338",
      "r354"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "negatedTerseLabel": "Net Loss",
        "negatedTotalLabel": "NET LOSS FOR THE PERIOD"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS -"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net acquired (See \u201cNote 3- Business combination\u201d)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "terseLabel": "Less liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEMaturitiesofLeaseLiabilitiesDetails",
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities (Note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities (Note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets (Note 10)",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r60",
      "r63"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "negatedTerseLabel": "Net unrealized losses (gains) on derivative financial instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r70",
      "r73",
      "r260",
      "r261",
      "r263"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "negatedTotalLabel": "TOTAL OTHER COMPREHENSIVE (INCOME) LOSS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE LOSS (INCOME):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r154"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Losses on marketable securities reclassified into net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r61",
      "r63"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "negatedLabel": "Net unrealized (gains) losses from marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r46"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Non-cash finance (income) expenses, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r58",
      "r335",
      "r353"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-term Investments",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction, Value of Consideration Received",
        "terseLabel": "Cashless exercise of warrants and restricted stock units"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Permanent impairment loss, debt securities, available for sale"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "verboseLabel": "Incurrred expenses related to Credit Agreement and Securities Purchase Agreement"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for settlement"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r223",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (USD/share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.0001 par value; 20,000,000 shares authorized at June\u00a030, 2020 and December\u00a031, 2019, respectively; no shares issued and outstanding at June\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r21",
      "r324",
      "r346"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "terseLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds related to issuance of ordinary shares through offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r82",
      "r83",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale and maturity of marketable securities and bank deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r237"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds related to issuance of stock for stock-based compensation arrangements, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r178",
      "r351"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r216",
      "r297",
      "r299",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r240",
      "r368"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r13",
      "r96",
      "r101",
      "r323",
      "r348"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r13",
      "r96",
      "r101"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "terseLabel": "Restricted Investments"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Current",
        "terseLabel": "Restricted investment in marketable securities (Note 6)"
       }
      }
     },
     "localname": "RestrictedInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r204",
      "r349"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/NATUREOFOPERATIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "TOTAL REVENUES",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r293",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Additions to operating lease right of use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.menlotherapeutics.com/role/REVENUERECOGNITIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received in a transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (USD/share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONConsiderationTransferredinMergerDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONGoodwillDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONIPRDandCSRDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r221",
      "r233",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r221",
      "r233",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/INVENTORYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of allocation of the purchase price to the fair values of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r223",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of underlying data used for computing the fair value of the options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r51",
      "r105",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r79",
      "r162"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALScheduleofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of fair market value used as purchase price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSU, award amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Share-based payment assumptions for computing fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percent of annual earnings that may be used to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Option, award amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation costs incurred"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r220",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price range, minimum (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Exercise price range, maximum (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost",
        "terseLabel": "Incremental compensation cost"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r219",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees and consultants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r218",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "No longer employed or providing services"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Closing share price (in usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALOptionsandRSUGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r230",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALFairvalueassumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r23",
      "r329",
      "r330",
      "r331",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeasePayments": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.",
        "label": "Short-term Lease Payments",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "ShortTermLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/OPERATINGLEASEOperatingleasecostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r27",
      "r28",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of stock related to merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r27",
      "r28",
      "r197",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued during the period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r197",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Ordinary Shares through public offering, net of $3,903 issuance costs (in shares)",
        "verboseLabel": "Number of shares issued (in usd per share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r197",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of options, vesting of restricted stock units and shares issued under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r53",
      "r197",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of stock related to merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r197",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Ordinary Shares through a public offering, net of $3,903 issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r204",
      "r222",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of options and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r32",
      "r33",
      "r140"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHARE CAPITAL"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, consersion ratio (share/share)"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails",
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalIncomeStatementElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Income Statement Elements [Abstract]",
        "terseLabel": "Adjustments to the supplemental pro forma combined results of operations, included in the above, are as follows:"
       }
      }
     },
     "localname": "SupplementalIncomeStatementElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.",
        "label": "Supplemental Unemployment Benefits, Severance Benefits",
        "terseLabel": "Liability for employee severance benefits"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).",
        "label": "US Government Agencies Short-term Debt Securities [Member]",
        "terseLabel": "U.S Government"
       }
      }
     },
     "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S Treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESFairValueCostandGrossUnrealizedHoldingGainsofSecuritiesOwnedDetails",
      "http://www.menlotherapeutics.com/role/MARKETABLESECURITIESMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Changes in marketable securities and bank deposits, net"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/LONGTERMDEBTCreditagreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/SHARECAPITALNarrativeDetails",
      "http://www.menlotherapeutics.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.menlotherapeutics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919260-210447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919272-210447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=SL116886442-113899"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4549-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r371": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r372": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r373": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r374": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r375": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001566044-20-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001566044-20-000011-xbrl.zip
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M,H5UP&#O3'])8X;UC/%8X??*HE3[Z!B57I3GI53YK!1*I\-E:VQ@N=,L]T[
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MKL.%,W\128G&ZL7E0#N17M>F/M@FL81ZVD&LM8-M3PFF^M#I/*C@@=^/>>S
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M#0,,IAL1ZQ(N?D:U[UVA^O8AM&",A8(*JA[%*Q7E$Z198&P8'BI\<.$YT.W
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M)-@($#,@Y7ZF@HF4=U@)U(-F:N08)O[S+E;J_D.=%8!?4R/4DA,^4;YL3 ,
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M@(,RY\VGY^!C2HHE8W:Y?L5>TM$[Z<?B?6EM43]&OT=%D:^4@LH!J.(:8-G
MYT RM$2: ).0&:8->R?G_W6*WQFEL.EO1?@F*L2XQE2#4&3>_Y2PPS)CIG!L
M/"$<$D\05!)38OP+]I]J.,&8+.69"$/6#_((7@][6HC/>"DKIKD7ED3"ED]4
MQ 0*'M_P"KPHI_8&]%&W!4IU(XA8MC*,'2)ES*7OS*5_,>;2C[GT!\]HY8 8
MK79'9+*A?4\WRO)')IC)?\K 0(I@'1^I^0&(ZIR+YHLR2W:QQ@/=\-D -[RQ
MW0S.E8+<!;F7*1F)<\A-=Z%CV]?YD/8U07)%% MTU.5</[L08&Q/I4PTS!A9
M0^QP87<A&>>9!)J62P.I5B9!2H ,A%8D@H"JD>?XZU5 #B#\]-&TACC!EY,J
M/Q4A/&I:N,Y$UN>G*H> 7V*U=N4R K4^2FET#!!'3W/G@X-<9YB[B_QH=CH:
M:?\V(\UQZ8$D:.Q,M[U6K%-KKUW\"_;:P2:!="S\N[3 U:'F*[K$'XOJYRFE
M^UFA;5%K=D81_-W0,[IE>I?E@R_&?*S6(,7.I]?.B>5'^$K$#BH+ SQC3PFF
M%G*%?YF8H(7J28=+(]DS'?$/<&S.P&C,&/,1+D.+CLYB*.$@H1,2[C%/Y[/=
MF*;A6!6N2#WUU@LXGTTG]<09L>5WS"N5;$4,&^*DY,>BPZ^;ZZB^.+:]+%Z/
M,#B\'IUQH5U+3OUU]%/-4C>:\&  5P'62<PC;1MJ*]\GT,D<??KQQG#W]K?4
M0#@KN7"@?BP))B)-X@TONX(Y0E@F<T)$'&CH2_>$P-+7J 4F4BR4O.*SE129
MR#9.$8FFI&I@ E= TY89@YM&!XN;*S78.PDIS Y*@B>F*:P\2BBZX->25P3(
M$WT/_QI-AIP#B:.$Q5SZAO^J1^OQUL^LBNN:9=+Q2$/C9J0-=GL(^$K]&/U>
MXC6: 5/TLG0C8G9=P3FB6*H^-;:4:<NFJ4OY&& GK!4?P5E)3J[6,P,GFA-
MCTV^WF&?-8P?S&2FT7+:P'E%8HG5=^G2MW@X;G;KR>=3UL8[(-B R*7(L >
M \M)/$ E_A-T7#,WV(V420T#AQ>;1NEW621B!+\\V9QRLQ)7]F'D+0(V3[C%
MW"@M55CJN5BN8L6)3GX#7E;@:63K3\FM,)JK86J?JVIH@DG'*7<KH.YQU,L
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MU[3+.ZG<%"&%D%<Q;@H,3(H24\B7RRCGFAH$< NBV!I2%61TSK7V;0X"*(?
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M+6EG</!Q1ERI8RH'J5JL=F\;3+9>A#9X,ISDB3S=UTBJMRK1]%C)G/?5TK7
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MA PBV%*9S,5<Z@Q7UX.;9A5NXJA%VW')C2CA@R+1UQ"A5</XU]J)ZL#P@V(
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M2J\4!#L#9SC6)J=^=[>3F% J"PM7EVSV-M/UB$Q7FZQAF^G:]$S78(R6'FN
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M7U-&9I[:=O:HN3X^>%'TG#\?Z]QE$JS](%OVZ@YI%PMJW.8M;1H6338@CX7
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M]U&Z)U>HB+B=CXVSWN>D=[A9?;I9)7;3E-IT0$KMK*A10+&03,EU4%ROM!:
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M-\*T6^LUL#<4%:<&%.SS.KCS]AS[":X34.U$_H>Q6I"IA4%M.:2>EI>=E[,
MTZ7RP9_D0B<I6<].,@$*.*.%@[P#+N9"<1U;>P8'9K;,;"#&3X+UT4IV0A@M
MIW0/EK$C8[PJ7IXT/#$!W8=&N/7S;N%"EV1OC5 78:_!'^$I?,MBHAE&RG;,
M B/[>,_N4,8)4:I$'"DLK-1M81?_L:QX2?%>]1/NCKJR&;O-UU['YAIN'G7(
MD"I0\(CZ?9;I='E7$5:.947%\J4L3<65H;"_E?<F;^_?X9;;^U#<(C,2'D(N
MQGQ2J]*Y>21_4S.1M/'?^%;%C\&"'7^[3L=@Z+Y]4O/HV=TX2#K['%C^;N]P
M(APV/8\./Q[Z?]O5GHTM9:#0E$51@5>%[%5>-^YN?ZR;'F#']9*BJE^8!EAB
MR$*3BJ-8)3-38Q.6&L0._SM.M =/ L[D7:5T\INF8LR05$R_$1SM*,$86I=I
MCH@1N<H=>(2:*#.F!3^%,8EI,=^KBSWM625LS)5)RLGU+B/X6M?5+!K-_VG,
M/V 4KW]Z^8M>:4*9%ES+TOOF!%QSE,1."(V-Q'9>@IVOJK"R0MX'JK7Q&2EC
M5X8:W^21[[,W'UC0\"HRA71 7@-JYH@CRI7 DI>E7F%VB6?D^^A;>I9&\I7,
M+%BH9D/NC_Y:#P9ILM)/7<723I*WMCF-??*N"H=0VF9%'Y$5_6F;%=UF19]9
M5K3#"?Z3;[*.'O+_0@B;F5L%7F*;1+A(!<%AV3R)?1+:&,V!H./%I+/C16=@
M0J; (3:)H#464==NVEZ\J3!:K%Z])O=L'"2A']Z[H_M6Z FN"*JP?_\?,X.-
M=!>NK-V2[S7[[G! $07*K=)@B@CO"[ ')[]269*#&D@3E8Y)$/S>8]/AX6XA
MUT[<KAU&\;-MGC,0@<(L*B>2HH6A<J)8R7=62EI]3;WN<JKA9Z9MVW6UJY-0
MV"P(F86R&Z& Z1 OROTV%>=FHJ73=OW/0)150)%:<XV@4CXXUG3Z=<RU@QWI
MO*;IX<'VP_(8C]U=P0T6 *%PZ[#D",>A@U/(@C^RVM+6>V3^>DFSK81-;DKJ
M/H.0 +*5Z.4:&GS8@,+R B\UZ4CM6R5!+9;[!JT:#Z#K?1NIJO\84" Q9$3!
MAH-Y2(I"PI)+38)\NK\>@0+;45=S-BV2*<J*T=V<P);,F9!*EC>@CJV+P?4U
MT>UUL7Z=@QK\*PL=XL[F2SC.E""*?@Z]BZ/=(76T,><--YAR>9ZQ@4%@6/TV
M<6B&J5:BA'.86#2%N_#N^VRP0MS)"P=LE]"Q]?7N51.5H5IHS46P.!*F+)]C
M(2T\U[5OLTE>2R#IFIO2=R8F$>3')%E*9Q0[OC5%"0/9^)AH)ZD\W,EN+/)%
MMH9^ 0?!!844#J^U)ZERK<MR8M97JLGI3[JF:XO%IBF\KQNK\&+_3RU!52@2
MTG!?$7:8\3U6>MD.(*)]+E7M0?Z,I>%N9Z#$3_EAFYL '@0'@7L,,6(!B_GY
M7TCLS1EG^_1540]40DVVV-5*5(Z0IZ#;EE% _#HVRL*/2X@45D0E@%QA*>ER
M>)QOV.$YFN=.T_@P4R6[.CC8/^@8)Y<W:3&Q0$I4%EP<*.[;]"ZM=-]F;UQ;
MGH,7^Z_N*PZ(_<H SGOH@53VWB&HELW#XPRIE8\VZ.RMX/!0<*OJ./2*Z,BY
M]W^)7VXC[P*_8^N-4^SJ;3K<';P(VYD),C:=(ZH>D?G(5XWP.\+WX_\;OSV+
MA<AN4X"/2 '^O$T!;E. SUYM#Z\73I>A[J.6U5+G3S\F,N'WAWK6H0E>HB<0
MF>"!_'F!"7Y^7US" <#\P(3WG<?&)3Q!>E)QB8V#E VI!\MWU7*Q(HNM>(;-
M[Z21WC>00*'FP\)304]V-:-4]21JHIH4"_L/6P,*SX-34&5WZ^4@-DX<AU2[
M\)W%<1L=^Q>B8WY7GL<'QQ32U!T=>_F8Z)@R'GS'X-CFQ<9>-RN+64;0*AR"
MNMB&O)[FOK!4>43P#^VC>[]_%'/9^%UWT?@(-/3>85$B@2]J%!3H6&IM,?Q%
M=L5GJ:J4NB,,8R6W'161/@32PH;6*I&L?%;H/IKE;MWK;@RJ6#G\$$?O#S_#
M?TX_2YD4]4!=9@E!*D/J[AY:LVN39#46F)18)UZ H32OHNN$X$E-QO0.8C9O
M.VK%<L9<LP+^!?6+A=L WCK5>]!OG+)Y9W5(<8[F6>WR61N]&J)TIO0@C-?V
MK"&T^:M%.K%H(B(QL3(2$I&2T4\,OD[HNP[P;I<Y0[SHW@'K.DW1 ZK%.ST0
MRV.Z'YVT(AIBACI6&"$*GC+CB<EI+0PU%H(7R-3%%&SK@]@E"?07MQYQ5>D9
MQ+ <UHJ"NQPNA]CG"Z,X F&[; &]0A<K[MX-6RS>O1A: HA4J-=L63H:4"&O
MJ/AH%Q/L]@C3V+QS/23/OMF(D#A\B])0M98H;T]:X#(P#L\71\L%%0%;Z6'_
MHU$Y081WSO/P5(1W=>!-!<<!6X2#FQY=%TMD#:$>!M.T[OWBN"B^*DL^TC%4
M'2'%Q#M@+<72H4C <S332OBATOS&@"1>T8'=Z;OX= %BZCZRQVV(7?/5W?WH
M@EJ;TERLLR35K5SRV?%<F;I)YF3,P 7,*L+%;ND3A%:[+GASO!(66'PW+W!B
M*&"W_Y?*YHOU9/-I,0;T#/(=<Y.5W"V..SB0DYLJ>GQ&';;]\^&DB?#A(H/.
MBVVH:U3G].-XMS/@W"&\L1.O*=YN( C;<LM'Y%I?MWNR;7.MFYYK'8QITJ.R
M+!=((VX6MOY)D :4+E&D(../XN4M=0<%L1RE.1?B!=_N8$6R&NW5_NL-#*"]
ML34KG\AZ:?+.@H(?7/^^_ST\_GP9C2[@)VSK>''Z>W1Q.;H\/HI.SJ++#R<7
MT>C]^?'QQ^.SRS@Z^Q0UNS]^.O>:/T:_?1A=7GPZ_O7X/(:?CR\_')_K@_&3
M)Q\_GYX<'\7P[,/3+T<G9^_]+W]Z%WT\/C_\ /\<O3TY/;G\/8[>G5R>X9??
MP;='T><1-MG\<CHZCSY_.?_\Z>(8QW2V=W+V[AP>1J/$]^#O/IY<C#Y_/O_T
M^?R$AHJ/A_F<']%3?H<A7!Z?GAX?7GX9G4;XN6/\[?G)^P^7%W$T.C^./HZ.
MCO%I[T]^/3Z+WOZ./\-SWAY_&)V^P\>-Y%$XLTM8J'?O8-2P=OC]LZ-H='K:
M6JZP6:9;I-'YR04N![X%1F)'?#KZC5Z+'_KM!.>+(X-_',,GW9;!-L)Z'A_M
MTT(=P@+!ZO'+3BX_?/IR&9V>?#RYQ#? D_!#Q^\_P;]@@3^-/I[\+\SU[[ #
MK?WUMO?WZ/#3V>'Q^9D^Y/3D\/CL @0%%N_HR^$E[; \[O+X\,/9I]-/[W_O
MEK#C2QS#Y0<G9+9[ZGTNYN#[I]JI'CSSB9Z<'1U_/#MY=W)(LK1M!>OND@-M
M!7LB63,%LU@D^#"NCP!./S4S@X3.-A,HQ8A%IIE%0@FMD0 HB"L98P:<'BWP
M1S^CAX8-9_5VT+1!)_OEBU^>U)KU;#TOA&Q[;89A)]#Z'ORR&UTGY3S#D(YD
MOJ>V!)H@4Y)9R8A3#KG>YHFPBB=CV' TB["ERX)1'-P,DKC%72S8\Z^925H^
MS@^'$U[FYLZRU\TP0[0SH.T_I:5Y4B.];\_!1^".NKC%3?&5*#\"_&QK3<P1
MX&G&MG@2%"%V<"1-@7%AK?1$,P<<!O1*ZL=W;4#%I"!N$&)!C0=UV'':P]KM
MI$PK8M98XN;%$7(U(L6M( 5Q4_'/=/XQJ/4X!IE>]I@FHT^T8[Y-S*)6& S<
M_BX4K&A%#^6"V<X@$MLDQ[5(T.8]5$G/J;H'(8.,A&.>KW.X):O3X)1X2,*W
M\=6UTT&.DQ7S52GOCV6=QE%BC!_ID^=I9;N)EE%NKF!P%!V8.&XE679WKIGV
MV28/]$X/Z,H]4@'$F]YU[9&2.+:NO6B6I!FS0E)FW[(=I V+B'3#%*2I"GEH
M/4C1*Z^TSZXD62.5Q0Z6)C,WB":B,XD8:H]_ -;\#]B.B1>\Q^&I"!-5$FD_
M^BX>$<F,Q?B@CB-2.6B8""=+(N71L+\[5=6P6I6J92LVC&9T<"KO6/CKQX(E
MJ\"[CNBJC0O+'&A#H Y3>D#E?#[T;I4A+9*PM:3_;_M,/*E1?Q]3FNW%T 9K
M37Q-(XRMD;_LAG_ 95R$,/*(;45.P76 8;^WC=!+H'^_D=!$__IV;,#9-F)H
MQBJK(BS]?(A1T6#+Z;<IXON,"K H'(J$V(1L,P58C,:5FQ5(_%TZH!IIEAYB
MP'B;R7Q,)K,=--QF,K>9S('8<#UW(IK84U:"#W%:FC[%]_99.HSN[^ZTA)IZ
M,#Z+5C2N=%K:/E^WSW*P@3[+JVZ?Y;.5FZ>M*_W>4(W^?^[4^59*6:>3S(#<
M#\[-L%MDQ(Y[4H.^S\M@=7>%IG(#R"F*CW>/3O[M-?S';1]J"4.%U,42'CW8
MC;NS<)<G->K[=@ZND/FB)@9,='NP=2O5:"L;MNAU6V3#9"U4X59DKLK>7BC>
MEV3KVPO$![HE\?(&+JTW/=]53*,#GU=5BE#D"38DKGN^9:\^2?-T5C$V9D)W
M"TW$74B]8MLW)729L>-J.DD73+).:SDO<O1.>+7TG30([-):F<R"^&]AG-=%
M0:ZTU#5AO:1.)*3U_6LECE[\M[2&>W.RC@S*1D_CZ+JX!<^_?!K3N*]75H]<
MXDZ#+"[GT@19S,I>H>K:;=AIT)FA+'FO<$8E6'MU9CS#2ULCX?-#0#VV]A+V
M]KI+1&.FZR7@^C+WVB+B(Z]-!MNSS"F"Q'PA^&(![B$--85-,K;$%LF=$L6#
M@!LXYQ<%>.O<PJ5GV> <)=IYD .2BOD7:S0G>'Q$\/BX>PKMA1%"$M!MJ519
M>WKIP6OE:ZZ3OC\Y*JR'2 &&>N081,FXN '-I,&P;F7":Z1!O-@.61T,T,MW
MZKF X7YER9$I[."8HKV-;*+$O:4*F116C<K,_9::?N.%'8D8=WP5BR9HR7 6
M&$*T9"%<G:[U\31#=BKZQ"A0YU09AL_:Y="S;7?<\VV6G]+,\9U^'7K+V6C/
MP=]!"D$%=NA^U*R6@2G5!(W%.Y0K\"5RY5Q*V4RN(\<8%HLJO*5B!*A#_?^\
M_T:M+RK0;(K:.M'!_<@1&6+JNY?\%RO13,95,3!&E44]7O>\AZ:1!RD(W'O0
M.SW>G;QU)EP+$EBF:!U_=)VW\@U9)B@3L;5%,4#+0X#_EL:3>9CA/ZCYZ0:Z
MBU*Z?PHN5NV%V!E5,PB[%L[;\0E!71DS>_$!X;%O$48Z>GMZ'%U^(E I 5T9
M[7L&'_I\?'@R.HT1>GIQ_/]^.3Z[I'^>G!V>'"%&%7[^_.7LY/+DU^.88+AG
M1R?GQX>7T='HX^C]\87%U;X[__01/W!^?#IB&.PG>L/;\^/1X0?!!@=8Y_/C
M]Z/SHU-"+K^CSYY]NCPY/.;/'D>?/UU<G#!,&7]U\04>(V_=1UCKV:?H^%?$
M(_]V A/UYRXV[P6, 69 "\"/^7)V!)\)!T+XV>,C>N7HXZ<O\)O/HY,CG,OG
MT>^T=&]_CPZ_P,+@G 1_V_6D?9P PH$O+D=G1QU08/CS!_RU8G(O8"%//IW9
M.,WK"'Z)L&EX^!&^#,; VTC@8E[>B\OS$UA_?'0#_RG8:H(SOST]>:\ <EY<
ME@H>=_/%!_@=3/3&"KFV2_C^_!,ABL^.W\,C!?Y-8\0GP.KV;S!\T$K)KZ.3
M4UI+AS-W[W"/0)0W0:TO3GZE???F :LFXXY>[O^@F' 0W'<DJB"W_=^0F:Y(
MWF]3(OTID9?;E,@V);(!1L ;C1E7RQ+#*D];=FR%49-L G,CVG04[7KR)U*=
ME)_&7@@C@\*'[_R/)5,T!VLF/D0+N\6U8HD<U./#>)3UJW(DD<A<D?K"$L2
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M&REPPXJ07@S^:$0?8,"<8-J+NP[!(]EX3Z1J=" R'WCCQ]E1QK[L7^RC#&F
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M57"URGBY*7$7?RYP&_5+IM&T.[M#(OQ:LD+>XPE!/H8K,&O']H(P?6P7%NW
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M/?CUE\J'HXO[+U;',KM&3J\ :T<L%/\>@])"F?#$XV+QC;+]AO\6A.@#:H7
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MYCC2Q$B,!JS&*;(9T"IP?9@=FOYHN8]&83 *7<09]T9/O"\H)\2"$,R83<3
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M&N-1X"_[^HVD7D=1KQ\DPC\Q3:@5\S.U7E8"7TGX_D02##P$Y.+:I!(&(#4
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M:KL LA^FK;XD*C7;1VDRK_-<DNA.DQ;DZ.EN*N1W+S?7)*&=).3A?7 +ME'
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M2!C]@601WG<I53@^=8FT<8?R*F\ITS(5OZ4D*6&PH)Y_F_#8B(1' 5.U4'$
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M,C R,# V,S N:'1M[+UI5QO)LB[\_?X*O>S[GM.]%F7G/-C=W$4;[$U?2]B
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MTB]=.C7Z&:>""T9[PT3$2C 9&.+<&N:(C8^@3RTH_6:FUUVCGPP8&>V\Q52
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M'#FH.XOIB7G X(2YSP_Z-<?/Y2K'::]_VQ)'=>K>ZQL$"U"4*?7,.!9C5$X
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M0HSJ6,(ET'4O"?XVT7LGC<)V_%"&:K&AAOM[P?WAI+++!9;66)D%+G'&I)<
M]R$%B7/!$2;6A KN.5=UN$T=7%C#W^-LF53#WS3A[TK;]<Y8X0W-;-!@ZW/L
M,@W$RX3GT?%4I].Y%&TH=%V9<TZUW:?@QZUSP)=5L?U>^F.KUW5U&,W](?[X
M6AJXE=)(1D-FO309"RIFQJ1<<$:0Y0Q3'E2JRXD5K1T:M3NWQL&'J\M9@]W#
M@-U$NG>4' &=,D.BRP#ATH;V5&<V4AMEB"32:HND>G^D.=5F'\#PGZ, K6'N
MS+=A6O/AHGVR0>&SRI^I,?XG,?Y:/CB.3G/D?$:D"JD*,TJJK<\"Y91Y[I0B
M:;/G5--C_C9[7K:X\"?KT'VR8#FK#)H:+'\>+"=*UG.,&#<N(]2QC"$+JK$D
M,C-.2Q:Q<I*D?>56)9N_G>66#2M_*?Q[MC'Q4^S+8^;0//E!JTVTGS/1;C;+
M9C9J(_*/&J3  ;XW2!OGWLH"\P5^__O1A<:/AVX)5+%9V:VU G8O!>S]I+7J
MD'?",)SY*#58JRF07@N<$1^PY<A@K%(]'XI6%9M;<_6NLVG^D&@^3=9:D-2"
M9)X$R:QL^EJ0W%>03!2&XP89@TD6)3,9LS1D&B.441-(J@S'!/$K:PJO8JYK
M.3(K<_YY/^U+ Y\^/UW[ _Z,^SLQ,"[ 7"M>=DQQF'>'-AWZ]@7OV)7K_;_S
M:__ JFKGW9"-[5=28=G>46@8YWH=Z.-%2C7H]OK0O"G@<+>1PRL=%J;=.#%%
MM4ER_RB4 4#&#'S>#TG$=GU:Y:Z^5?:K28=CWC5=E\.-91\.5+NK/[L<UJ\'
M\:17YHE_7Q2A;?KY:7AYEOO^$;P#=''474:>23X<SION-!8>/NB'ER/>0Y--
MK/R 9/-"(O;_V'O3IC:2+FWXKRB8B??ICE#2N2_V'42H0;;I,9(;1'OP%T>N
M1EA(C"3:QK_^S9*$$09L%BTE<>X%"TI5E95YZKK.EN?<OD3B^L1-_SSN7[W=
MGR)R_6@_(YOR0[VPG2_V8K#QQ[5G/\V2^<.$WIBGITY&2O.;C-':9>[I%7G"
M>=FS)&; *;Y6#-ZNWJ KQ_V"F_^K[0PEUE*2B/5<,.XT-\9380)S7D7\4>5W
MM0"AXBT<T7JW2(VT6[<)QSH!U%Z]\;99:;VI[]?>U0];N]L'E=W&]MU@LG*O
M]W:SL5-O'-1W*OG30?/M[DZME7_YL_:VUMBN5P[>U*=]5*N[OG<\_F^'FP>;
M64_H=&Q_D DG4TSO/%\Q#*J5^-7'K$2<Q0QSQP4E97:QOZ_/TO]V>$FD=S_4
MU'(6<#WY=4)S$T8<:2??'W*LA/EB1L\&\<7EAY>A/3CKV(L7[>YH**.3?E3D
M\FTFC&#,IL)J1 H3S_+D^A/"V!P3Q@]*YOB@-)O&\+N/__3DGQ\DFY+)1YZ,
M-\G/#@K&'GGNKX>L[GGR+SSY]Q3@!45"'F-1_'+ DS=W3>(,?YUW8X7AQWBF
M8&G+O;0[T<=3EZF)D8?$?Y_[.L\@YEDB(2A"+_!R/[M%)V8)&_[6"S[?MJUK
M=]K#=N%MZH:Q@G_<ZV0Y&8SZ$:N7HVINPXOY;[R9;_+*LA-62C(YD*3RT%?D
M<O? V]W:G[MO=UN[]4=6>EUL\<SG<__GF>H'8REEI=?UKX?5ZML0*V?VHO!<
MW:@+L#P>*=<L+3&98HUR)1:0=.=]'O-P\&XLSR/A7JM^(B?A].CTG\X>?75Z
M1/?8AY/]D[V=XSS6(]K<J='&SJO.7JM&C[[]>2.!HD$_M#^\/_QV]/[#21[+
M:>/UWI?FZU?'C9,COK=SA/?>'W[=V_EPLO?ZG]2XS,([P%\^4L.B9Y0BF2A&
M7'.);+0*V>"T]-YR9MG&EJF:$FX:*SO\/O,D.X#]9P#["TB1 ]B?%>Q_^P[[
M,G*B%>6(IJ 0=\8AQX-!E 2*A1$2F["Q14R5 >Z7M2;$^E<XRZ]^_SR&2AQ7
MAH'*9NNAQ1=K.N7-!C!_!)BWIW1XJRW'0CDDJ!EU!(S(D6B048XSYK&,L4B!
MKFJR""Q?^_H^90I: /"MDAX+P#<+X+O28H4SU@L=$349[KAT%%E*',(Q".R)
M,]+2C2U691I:\I14B5U_)WS]]*S3NXBQ,MJLD;79GLO/-,ILGYM""T78%Z?0
M7J[O_GAY =^?AN\74XHM)Q0G&2W2F@G$,2'(62=0"E8:C#VE*155>O!"\'WM
MG10E<$X# *Z>8@L .&, O%)P<=)1<N:1TRH@[@5%A@>+K%>,16RDB7)C*PL'
M P LJ8*[_E[:'[NN=:825>?>;0T\&,OJMG:)\Q> \@]'^>;VE)J+74PX&H:(
M,K%P8S!D3,*(<D:H),%@RXMN0W0AQ2C7WHT!_MLU1+]%-UL#]'L:^EWIN-FV
MYP8;@JC#!G'C*;*.^XQ^BA,A;?!"%>B'#42O2JKCKK\3=]21!KRUI=5A?X#J
M8K7 #_$DC-YK76N7YJTUPC&-O+ 2<4(BTL0%9 *Q0GEM+!89I4M8J[/LT *.
MV.>!;3-JE@;8-B-LNRHAZ001GBJ+-+<,<<X5<EH'A"5A)K.0X5IN;%&% =O*
MJ7_.P5(OT:[F<>G]6_8VE\.G^FP[_LS?X0HP_T28O]8@#2>!J?8!2>XTXJ;H
M^6,D186?07&KG<$DPSRO4E8^3\.Z-?UYMD[89PN7\_?0 EP^'2ZOM&)L)';2
M<H0-QMGB+[(0G#-(64<BL2QI'#-<FBJCY6L;O&YP^:3"*8NM)C/#L2RS1]JS
MGS0PU![ZWKYM-EZC5GU_[^D%J%:JX-D*W?]YXBB,I90%J-8_-?![ED2AQ%?B
MY4Z80<S/:+L^5ESLQM0>PL[N\GJKKMM8!^=G9YU1?QK;.>R.5[3X[<_)0AY<
M+NWE'\ $>Y )=G3-8Z65QBQ()(C*)IB(%&E./6+Y4]0R$B/PQA;'K'3V5]F!
M"3Q2SP/U9A1T!=2;.^I-.YYTD)9RI!E/B#N+D7$FHL23P9HD$@+)J$<YH%XY
MP['/(!UPF5M>(*5FZ5M>&KVNAPC#(X#>3ZNW-$A%!,=(:J<0YR0B&[! RB?&
ML4N!8U]D?C.L(?,&L@H! N>850@X-VN<NU)HJ>):Y/\BR0PM\@LSSD4I4(C8
M1\X5#<1N;$FQ"#-^[5$.'+6/<M3VBCF)_=.,$FXXT6$U[-I> Q6V6-I67MF=
MO+" YX_$\T_3>BLQRE)A">+"6L23(,B9Z)&/@IAD==2:;6PQ6C4$-FR#9Q:
M;TGI@ !\,P&^*4461Z4-<R@HHA%WTB&-E4-4*N6%U@[+, (^10'X2JK+/@/G
M;+%#;MHE"X[8TFJQ/]_;"%C](*S^/*VD1H:Q32XKJ306'3Z21S82CHQGT2H2
M\^K(C2TN%I&[O?9.!W"MKB&HS6G#-H#:0T'M2@'51"9"I$>8)(RX90)9SP,2
M6F7J(8GJQ #42JQ]KO<&@/%.[5NW 93#D_IL-Q\N=*\V.!L>A_4GM6M>UB"M
MTI8C+TRQ_] F9(+CB.B$/?5,6I<56":J6,-V[;(HN&OG@GVVB+G0[=J F(]'
MS*G$64\8-IPC9B1#7/F 7.04!><3]XFE;/9GQ.19)A:14/6\$;-DOMO5T9[G
MKS,_S')[M@RP4)T9</]!N'^M-F=,-F&I\]IK;A O.B09GBPBQI* )549G#:V
MA*DRLH@]$W-XO58(]Y^M*_C9XN1"-67 R8?BY)5^3)+7(;&(8M$LF1,>D<Z0
MB&)6C@45RCHJ-K8DJPH-.+F*^O%Z>Y>WFWM[NZV]>J-U<+G)C)0D0_?98O],
M=.1OL=\+=G#\(^QO]TY/V\-BG_&@U@W;^<9YUF+7 PT\E :NU0$-F8P#(Q1A
M4W05M9H@+9U&E&D7J7(T>EE EJ:$O@0_24GT9? LKPMFSD1?!LQ< &9>J<XQ
M+Q+1W"&3P;'(_,59=4X4:4\CMCY:H1U@YBKKSNOM6SYH-;?_YTWS[4Y]_^#_
M5>I_'^ZVCAY7F7&QQ>Z>S_U7Q!X,[7\OAS2Z;+L;,M>\0&;JA-$5*-T4-U^#
M>PKL=2F_]\OQ"Z3JM+L1799/Q",=XET_IMCOQP*->_[SB\I__XS)W\7^P;'M
MQYE80;N-5S^2]_?1'!2#>6?[S?[!L.@I_H_MG,>KNT]X' ./WX_')\UF&SMY
M3!<&?_C?8^Q/_^G:]^:\>?JATWA_Q(Y:QY\;K__^=M3:/]W;J?&]D\;G#ZW\
MO">O3C^T\G/M?/C\O]]VOS9;G[_LG11S=\CV6I\^!BD],X$C[)-''%N)G)0:
M":$"8R%A;<7/U<.[A.I1:B((U3H(563$29XM=$*U0CS:@(S0'ID0&,_'%)99
MJ#)28GRS[_V-/U3.;+_R;['8+RMW"N*@$(+![&3PWK[]Z^(YDL5![7QXW.MG
M' \@EF41RY/Z1\-Q*)0?%/._B&O)D,4L(*<-B58%D[SZ"=;=+F*/YTX0L?43
M,<^"Q@93A$51\368B*RU^1.W!CLJ.-=T8XOB:H:^XO_W0+^QV%7L]P6OV&'E
MK_-N'!N6#%<KA8A5;#=4=J*/IR[V)X=(<8B8:B5?X"SFZ_T;.Q?+ =&LX?I"
MRK]D4WX0N_<1\>;Y<##,3Y55<I#QTLBX_X@9S21.+5*)D2S9CB$7O4=$!H$)
MRQ*.TW)@]!%"MCL8G .&EDJ^2'2.<TY1RFB6,33#I\-9W&+D+!$6M3!\9>0+
M0*R<0F:UP)8X@H(KNF-A;I&-SB"LF=:<QZ3TPT%L64P)(%8Z^4H>XX291)H*
M4[2HE-G,2#+;P5$P+TT*1>G_;N_7"N#]5<3V2 Q&BF#O"G:>J"Y^=[*']K_+
M#KFN<U1UKIDHUT%CY#B#:.HC,U R6HCFWQ]Q$$Q9FE!2,2!NB4+:489DRN\W
M3X3+0,L;45W!H.FS33199]2;:RX)H-[L<D@*U&M\^BB]H3P$C0R+ O$H BJ,
MM6RE115ILIH9 ZCW_%)%UBRL7F2A];JEB*F/AP*QS]F!VM_?#;^];_5O^5J=
M^&;_XL/[<.8HE_D[)\W7N]GPJUTT=SQNO-[]MO?^KY,/K4:G^;[1R?. &W17
MY'L6C8_R/.S2QK>_\5[K,VW4/G)A&<'9VC,A6<0)+:*>4J/DC;?.:^\P6VX\
M'01JI01*6I:\T G1( GBQ391EP4L_QHDC0H'QO1"8ND+"'1.B29$.<LIDJ3Q
M]T?*-!-:&I27FQ?[E3/:<1]0$%XR); *CW#0+R!5 \1K)<3+9=,B.%N400D2
M\0PUR%"?R52RJ&P@SH^J5..5"J(O STA+% >T3ZI?=W[^R-/U J+'7*<^"S0
MV9!V0@9DA>?:^N15"F7,0+HA6A#6+*5\)1>TY5@@:Q-#W$>&G$L1*<9D4(*X
M2-+&%I&J*C6KZEO*B=R$S@(25X#+ >S*)(P7>U\^:H.-3)P@*I3)/*X=*OK_
M(B*MCT0ZI=QJJ(D =J64+Y.-#DR512H;(T5;/HVT8@%AFK)QG(1E5&4]45:Y
MQK>63EJG0#J4?9]Q+XLI%(#(T:/>_*N*#4IRI4QRB&&=LMI+/=)<*$2-=%I%
MHK@V62U1I2O:LX(!HV7O P5,*U.8'#!MMI@VU4O-2!VM-B@E$A'/AA5R+ 5$
MC"(D<<6R29^U#X"T<L; U[\E<"T/KY XVZF<V79 [6[%V[/VT';*47-LG?%Z
M_J5WKU;W75[<W>[V>&D!T1^$Z(?36JH0F5=9Q,AS*Q#W1;4<5W0H"AQ3'1A6
MDFYL"6VJFI2O8T79X0@R.I\'],V_FBY WXR@[TJ9Y<'K5-0=%R;KL5EYU1GZ
M!$461ZPT,2)S6=$86%>)6$1IW;6'OI*E=:Z*2NO]^>EYI\A7R^"1VKX]+$>/
MB54#]-\6HLP.\@SE3P^ ]OTXM.UN#'7;[^;I&TPM^,YXO0'E'X3R1]<4W!"#
MP"XBF1<1<4,-TLQ'I*7.*RDH9M%E!9?H*KLEE_!&J6KP68 ;]IE!X:.56X#"
M,D#AE<+K))8!9^/>&Y6A,&F6%=YD$";12.FX]4YDA9?@JM WPU( A<O6=9^!
M^W9*U^T5+<CSW)V>]>-Q[ [:_\9*NYM_C^#*70E7[ET[5*<6>=1F?GMZB7='
M*_RV-Q@TXK"96O8K(/Z#$-]/*[^>)Y>X,D@8:K/R2V36>ZU!A'IADA%2:@4[
M5\&["VBX@$0$P+TYX]Z5IIM,<CPH@223 G&1(<^D9%$,.EJCE+2D,/H!\<JI
MZ*YW6X=QR^"#-[7]^@_-'<KAUWVV/7[FG\ PRD([[G7R_ [J_W?>'EX RC\(
MY3]-:[=&<.FLH2BH0!''*B#KHT DBN0L98P)L[&E2%701;2.?]ZM,9^M[_?9
MPN7\DQX +I\.EU=*L<1)FJ):G] ,(QZ]039R6I0Q&#60M(G*8D-"5:A%:,;/
M&RY+YA]>&;7Y[6[MS]VWNZW=^D&EUMBYID:/_%CJY1W*],)F]J>B.CDXN1O+
MQT/OW'7BW8Q1+E'^[Y(V1+SWO*X!\<[?3GG;MJ[=:0_;L6A("C3\1!K^/&VU
M$$HBUUZA1%Q 7"B";&(.L41$LEE@;/29AAFN:EZ^C.M9OH3E0[=R>O2!N8"Y
MUH.YYF\R G/-FKFN#$BA@XHL)628](BK3%].$(-XH%Y'$RQE:6-+DRH1!HAK
MV<0ULC#_&-K\&)?U-WXL6#R>(!_S*]I_>6K[G]K=\03A$E4K5C]6*Z8C"&P=
MQXKU17J0[5X4A4JZO6%1[*Z?_]RMM/,C?>J/=H'VAY5>J@R/XR!F;++GH5UD
M%V5<"K$[&'\:"<,HZ2BUN[;KV_G$05$A]C1/S6#S>A&3J4D\ZPU&FW)>]&/'
M%@5/7GYIA^'QN*#R9+B<;BIQHU[T]S.MRS<_'\:7$]G#TY>XI<;TM24KRQ+=
M*"@]7B+Y0_67J9_%8XW@UQE*K*4D$>NY8-QI;HRGP@3FO(KX(Z4;ER<=]Z_P
MXE-$KA_MYZP[YYEX83M?[,5@XX]K$W::Q?F'5;@QN4^=P93F-X.C!<\\U^O;
MD:QD\<TH57RM&+Q=O4%7CON%'O!?OUYUE5_P KF*5W>D0N3W\#]_V*W;)&HE
M7I$[4&ROWGC;K+3>U/=K[^J'K=WM@\IN8_MNQ"GO ]Z! =O-QDZ]<5#?J>1/
M!\VWNSNU5O[EH)7_R0_?.J@T7U6:[_+SMW;S%Q[PX&7EJSLFXK?#S8/-K%9T
M.K8_R/R4&:EWGJ\8!M5*_.ICUCG.8G]<C*N2R<C^OCY"\-OA)>_>_5!3RUD
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M8,J+[)+F(4,\HE8SQ(O,$IT_(H\Q#0HK2WVV%0BI2KT(&IC#V[A"'%&F^J<
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M8X>LY QQFY=)<T*0\EPQSIDV)(TW#DA(PRPQK4"D9[&1'F!?8-\2L.]2=E0
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M;['?"W9P#!!;4HB]<H>3P%*T7J.@5(98[D31*"PBS9W/-IDV0L@"(C0E]"4
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M  0<!!P$' 1\505\L9YLT'U71_>=]H(KC!,+/"*5&$5<I*S]1N(189H:KK)
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MXN+#XO.W0A_HRP\+T6?HBTPHHY1!"AN!N.0.:2<P8DQ'5BQ;"FECBRRBS"5
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M<9&&,I2X2.NY2,/*=,^;)@<#7])G_;)8B2\C-8PT]SO,9'^(:6S;O_UHV_K
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M+18';U:=Y$)PX[35R'!E$:44(ZDH1=:I%%MK!,WQUG;.>*ST$JDG4D^DGBB
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M0%XIZWR'!U=^],'I< ;.*G>F2AL.Q]339<Q=71N=[L:FN\O.ZU?-LC]WA:L
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M5CN'J*0:"0%"<NH*9C#F&1=R:UN(4<K3(1F$;W04!XIXT5H<(?4N0XTCI X
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M\ZC-H^O^'"[M_C:MDMX53?)=$)G#I5T&7E*"W)W49\Z#].P\.3M1U:DRX<&
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M%R#,>8/IW(O%(&/-01BJ73WJ+QW(2[/*==M$=5-5M4"BEGZS3D(,QIWDV$U
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MD[[*UD:[^[G50^&>IV6PV !*O-E]MM46)#I/>&?+Z&RZ2RUK)3_J*^][S4O
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MECY)_FRJ1[=%)J[J)UJWS4,OSLDUT7%=?G03>NWI:QFYVG>BU8WI)+!N,+S
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MH\&K]$AUM.;TPJ)A]#_W8V(P^!JKO#(.1GX/YB+F\?374I4JM2YO&58DY#*
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M!%MP]AVX<$3=-\RO3F6 (Y#R9#3RK-:6';M*;&._T'-3&?I663=BXC^:7@/
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M;[+FC[3KJU8AE,\XM"NL\HV@$8'M5*UGYHFJI![WN*KMD]>#@8KN1D$F,\P
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MKK '@QT_K3(6W"3PWC2EUN=<+CLO9<HO9LY.<WD[52;SDB3\SO+8A <5:;A
M@NJ+V8BV[]"B['0EAC^1Y?FS>L;/G\*EJ@9]NL?O<OMB;_,HLFED34A)'(7H
M&S:<",YR0BT-(VUU&"<&\SSIQA+\JSK1$XBP.($C<$5".*(_ZQ(=U:4N*-L?
MGB]!X[RBJ=*Z)YC\694SS.6=(]*E0W9Q,$Q^K6X2:E4KM7L1;FS^Z+BA7=[6
MTZVSO=S!@Y&8/-<Z9B13FH,6;5+B0 . C<4\3&T2QYCCMR$65>CED%97)A5-
M;E%9XPLD5IK[_IR5]_38+_SO^ @A495F8)S%-",\E*#Q1)D@&<VH4(JQ7'-G
MJUV3\MSQBD+AZ.2..O&*BN5;QX*?(-G0W<TCGJ@,D^%)DAG,V+2:*)E+D@!K
MTA$0CZ'*172OR4">5EC=.0/F;J 2OY/Y>)@)'RKT5/1F.&KTZ"G?\0G3TWMG
M>!F6@M)D22(BT (Y2XG(PH2H)).9X)(E NB)7Z<$SJ5%25CL4U]K!L;48!A,
MSLH67:[ S^,9@TP[E<96A1)S$#G>ML(AAI6IY.MW5XW!/5C<\>E1XX<+X&Y&
MITF84$MT*CFZ 21H79DFH:(9_%$H&9^]2C>6X)G,\[99;]&R6M;;<3_?BF4.
M[&M9"[IFESM?V^:@0LO>-LVBWX7*7NQK4%THQ^-13TV\M02/ LOC&UH'M=-L
MODQY4E2%G>6L6MMB)0G\^+R[><1 1N?(9)5$W%_!$I)%8&K(.,R4I"G\G=_!
MMG"H#FA[GTUJ +L_^V #!P?Z9(CMD4IP6=CNTZ&Q?;S(6%\%MZS('#\I*?')
MU"D%F[63XM&6?S]P.X]I!=:^U</C 4S-[.!B]?(>J.]%8<=%55@(RGSE N_9
M8A.U!6O:PJQ&85;W_$@:SE242&+3/ &U+.0D,Y$FQJ:,89E\SMA"H\24IRP/
MP3[(,AXJJ6RL4Z/B2&2*6Q"<<X5<S>9=TUX//5?DZK%]*X[0\.)5_<5FW7PE
MZYGR$H\,X/:]\DK[-A+]Z=9[3=%#T_@BK.+E]7U'%K&$KR%K6*-$)!&/\E3Q
M"#0'$7.PDG)K*?S#IHA0+5D_#%GO'7X(P<)0H-$)SBEP-K18!<U)%@-E)XFB
M.;>A#",U3\I2\RC23)LH23D-(VE !5%:I#EE*>S80DWB-2[D%F/Z>HQIT6),
MMQC3/X\Q?2-F]-P1IS%< HPXUB*"]PI51+6.103FNDDUX\^N:KA[DY2[XKX;
M64I;B]O6XK:UN&TM[E(I.6-UMS6Y#Z:-O);%B0=_PA_0OP;FA)=%JYN,W>9:
M/_&ZVA_,+_S)<MI%FQ1UBUM8I7C(X(OMZ>EZ+"G7O'MX''</W[/NX9]?G9WZ
M!>9[^,]7N)KM??P,]BI\MW5RLIAR?4SW$%I]ZQ/=?;O_%>S:B]TO7[]W/\+U
M7S[%GT]WP\];G\*]MW,5MC$6T=HL)0DHL(1S,'%58AE1BN7*ICFC/'GV*LHZ
M"5^,XZ]TQO6Z)E2W!;;WT*C^FRTCM:!Z@O'SU9;&#N+=.5;2%L^VDF6)9$&<
MV,'87[E;T\U!33:MH+F+H&D6UHI$&)9H11*>&<*3G!)AA20\S%,JHB31$48.
M62<-%Z/C;67M2LB2IVC1O1M95[A@OY_9 :953!%4M><699SH827*W12C5J*L
MI$0I:6G;DQ)<OX=TY+]K)<M=)$NS:M1F*HXS8T@4\X3P2%@BI,V)3:3.F<IC
MH[ K7B?.5L^":07+$S92R-EHJ('/8.FH=0Y:WP/OF^T/S]!Z:8V45J3<(%*<
M!&EEQQUD1_=U0W9DL559$@LB4Y41GB:"J) E6#45FRQU316>O8K#3A2&K56R
MFL+C*5HE;X=#<][K+X/7;8V.M900U8ZVO/PNO+P9RE#<,&LH)U*&DO"$8D6B
M2HA-;2@9CU1N];-7O!/RN+4#5I.5/T4[P$.W_0H?TMVTB[NE#+2\_C=9 ZWW
MZ.Y2HQF7".-$,B%RPK@"J1&E.5$FBD@LPPP((.(BI@@CDG98NGHF0!L!;^V#
MI7EH96BB4:ZR2J;"HY(MSQ^O<"G)J/%%*VCN(FB:88HT,6',THR(1*:$*\:(
MI"PG"3.18B+)4Y8\>Q5W,K;8R6 A:7K%CNH3ES!/UVSY9?+E"=LNCUB^M(+E
MQP3+7C.&$1IEDUQD1-/<$ [2!%&3<_2 Y3R*.4J=7R)86M.E-5U^7K!L%V,'
M%&CFBO3;?@9/L,;F"?4S6%W1786FEHKPKAVWHOLNHGNF^D9)Q4QNB34Z(IR!
M_%8ART@B$V-2D[(H3!V&<8?S7Y$5W38\>$H-#_:K)@<S?0R6P.,T =R7([//
M K /_6\.'^?,@V<CEF*%&M_!RV%AY/'QR!XC!MP/=47@#&%9N+8\4YRF4H1*
M<*6,B(S,><P?$B"Q9(T6/CH=#@YP*?9Q<8O7%7[>X;#QW9/%1>QN[83=XZ-,
MQ3**K"5<&T&XT(((ICB)=<2%Y2I/>'I#>X1.!4WH$0R1>>#WLE_A=I;(3O/=
M"VI Q24]$QRT]<BJ"\S G/0=?"*29M ?G@,9G]D15O?+8WO5X#4>^G R+L9R
M8&K<PB)0UJ$:G^/E\(0EA\:#1E7HA_[L+(&6GT6,6OQDE5G079'MEN<U_3(@
M.T99S,2O2-S"SADC!+TQ0![GO?%)V0MC"J&. &2!*EF/RPR&6X"+Z$G?64=E
M^PS3RW.@8<0W5G9\;NU@820'L[F(DSC;I&,\17DM6XG8"@H-^#A(?=]'H^3K
MM\%%VPB:+SL8CK&Y#N@1EW@@)F/\<&P+?!4\HCTX4+V1J]D$4=&WLH ?!D#D
M_?[%QM6XS?>E1^]TW\R( ]A@C2+A'':HL(.K-.G-Z3)7H(P.DW$*R5BM 19]
M:)0+\ON6%[>H9[MN0T\65!0^I[OOCZA1>9B;D,2,4<*3E!,9@E*<F5321&5Q
MK+-GK[K#@5V4#B4MUY0VJNT9I"];+GJ)@FOJA?<D-P V;H.Q_%Z#YE9\9Y45
MM_HTW#<:IE-VIIB!2]2>:IF?-"[@%.[RZSFBVG<WC]($<9]M0J(LS C/,PUV
MG$S@IY3%-@-5QRQ@!,8\$7&26@NZ#Y="BCB2H83=BC@+4[H4[G).+R^)W['N
MDC%6K-M^=Y4E\S>  G4%:FZO8?X' SN>Y_*= -&89^7/[5 O[PA+MA3][,;%
M:N',6CBS)P5G5N*._8)53G^!LV4Y/MD:A556R''U;H;G/ZQ[L(4<:R''VFC'
M6NF]/MIQNGW^>>OK][TM#3KM+NBY^U\_'7[@<&]_]W3G_-/'?T[W/OYSTMW:
M66CO_.GPSZ][A]N\>]F'9WT][[Z%YQV>@,[\X>+3ES]=B^C/'[=#>/=9K+&(
M9;&B84J,T"GA<:Y(IBS':$>2(^YNDJHUC7:LNDQ8WT2X%5K$OX&9O)PSG99:
M2KXEKG/_.J"8&=NJ-QC+P3$Z(8HK=<>VLG_U\^&N# W-2).=BA1<H7Y3ZNS4
M=/"82GA^E5QIEO#$8<:D$8S 7X*@@X!D.L\(T\;8D,=)GF)T*4P[D5CL*O@;
M4^!6G>&M;Y;;"BWB0DAKI0RQ-G%M)=)?5D[(KH:,?9S@"+]*1C:KC\(\YEQQ
M0X1*%<I(36082F)9*'*6*QFBC%Q-<(0GGF>VF +RV+K[[0V"S;-1KQ\DS9;S
M56\W.1C 5#5&<3&+S$KL-EJV1*T3<-XYC^?.SD[PKAL<CGK 8X+GQ7AB+H+=
MPQU"P]B%QIJ?)"\" X2$B0FGUKKTM!YVLR\P9MS[YORGL) 7@1V8LR&8;?A4
M8T^'@V(\\OU]BS'\6SB2[5\$F"4!RKV6<.E,2MW9".&#)RY-[@SN0,CZ8#RR
M+H[FDC]@Y?K#L]X8;W6Y12,?M#[K2VW5,%#P=B:8G&&$+^#$3Z=W>C8:?K,N
M9P*G/<3&277S.]_/M5I$,[0^!Z.'O9'\V)-1,;%E(^T:<\XU=)W.9B,(-@O7
MX75V4^K<%1GD$\SPF*9OZ!.@OCMG\_U0W/H'^[E7XF2GGO3?P^()-R\^_ 3S
MV&$P-MO= N$!)I6-F:6Q(5&><L(IM40RFI"$44.E3&&S\CLI"3_4S;#=W@?:
M7BG".$YB3:Q!V+M,*)+Q5)!4Q'D62Q4FL05M8&,1\.+JQM6N/:'G6L=UWM?
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M"3M,XZMVN"$32LG504%Y!G(6A$;_8B.HQ<*\AK%,*)2RXVI1$-R-DK1*,I:
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M%/ 4NS%#JC_T,M/-ARL;F7:5'\/T1KC;M\F9J])RA]Z,?NGF ]+PC_.>&9_
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MPD$ #/A[;DAYAZ8FJV'_?%'_0#,XKQKC]$[&35@OC7WS2Q[7L-K%I2(O'Q-
MZ-&K@V[8S:3;Z_1_VP I^QL&_JX_/!G"GMD)9O#<#;V[4^2GEMR?]F11!"^]
M18%X,-=2P2A8TP010@55)&"%P\J;%(.YW*'$P3SF]B2C?L$@<6 <@/0\>'^$
M^17VIX-K5AA$O6E^M+NGW>TPZ&[%4>.:U[?$I+F^AS6Q,,\46>-QZNMHD25!
M(Q$%<9@X+@->>3/J13NO.RLL2[VPPB#A2NX04#;!]>/I+C=\UQR"-%C3.\I8
M6F(:*/0K^@6LEFVDRRY*RX(4(Z]P(DKKN1'85OR?#..;@.*O&#0<!HER(EAI
M A@!10B(X]1&0W&)9+#*1X]UX<SBID:5*BQ[J_VL>_$S-DRN%?F97M>FT6GG
MINGW:#KWB(6U&58K^_)]95Y^!NOR3QCT5F]1Z 0^_!80X..I 7O@)(3AQ_RO
MA]?_I[0ZMJ<,A65I2/</;*7]LZU/>\I(KT40J(A8(,XX1=IBC9R5"DOJF,7\
M)TWHKK!&NXOR+K-!MU#DGH6\O3L([@@D*+F(,.A:U&XJ:JRUOZ>XB%@6#N%
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M..(.8']F,R#+*XQAO]_WPSS,/&OP!-D;N(6%6/ HM62<Q<)R  FK!9<"W(-
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MZJD&XG@*")Q.A+PY;[0!+GP['Z;"Y@*%[T>[N3SW29^I+D_+W_-F4/;M:52
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M S]<(%UPK^6),_Z53>VV^ZM\P+]&SU8''R_V:?/37A&5$88HI',['%9H9+@
MX>8%=2DIGVB6@H^+SF=^'GS,[ECV>4I#8>9 H_Q(%ID<<&QGG(NGJ1"F-Y8V
M_G+W[DS08H2/4[7HJZ."H_9P>%H>+4_KK[-\O'V2->'QJ.RSS""9J=>Y+DTQ
M5Z;.)REZS:E3IN"%C#QHIVSA-8U.4>Q$=&3Q,>FMB&_>@=,^W(K?RT?8&GQ.
M\S+*59R4L[X#!1;\V_/J<\/J@Z\WB[&UL<Y:ZWO@<_%8&(D4EP9Q31TR$O:O
MCM@%3@S7KDA\-P3C5;R@E=6H0#F'4\S@O*Q0!C!/L>E>(_Q(*GF8-_0-8LB
MI;E&\$'$B-Y(5-Y7(_PK#7#\YE@^R"L6D/?IW)V!ITZ,ULAZH1'W*B4]2HZ(
MD$2QR%T0,L6*L;XL&V!*E_(PDTI43?%T.64.2P5PYH9A9%O']M\!I5C<W_T.
MZ-]&"8#)*@%CT.Q/250^=9\5OZF8WLG ^/)0:OZTO4J#F<?*-<#*Z;2:9ACL
MAT%IG8RD T8##Q5^ %+V]H,'XQ\0TX^0]WWU>N-S2IQ9O?:T="%L<JHY)S"U
M7%E.P!?'5G-KO6;>1"[X30[,;Q8BR>70FUDI;)RF M[2RLF;<%@][>AQ7O%.
M:/+F_AZ3*MJ<T4EMV@F1(A.I1YZ1(!T3!J>S="G(JN2+@?(JMZ6?# M8B#+!
MPOC#T^%)54,\!Z _"[5= :!2"F.<P(Z2P)UFBAH.%GZ$/YF1_HITI1I [RDV
M,'ZPBZG@3$N!N&(!P:8&*"TP1\[AR 3SV$2PB]F:8)=EYI<O<T7T+/]%R.^-
MMZ,T(A H"]B7XV'7U=27U"!5G&$XB565XC;*&JQ,P;G4PF8 L!B+[%_9/MS<
MW&S\U6ILYX:BC5^&)Z?^O-'<WD0$BRS'TZ_(7W]=:U2>TV@GS(GVR'Q/F079
M?,BX?CRJF)_8JZN-T,YAD.2M)Z<^'5.5!W69CJ#\_/2^RF9O#J;DI,3Q%U>W
MK41VM8JK3%N\T;0'C;]-YS3,)@Y./C'W%+^LI"%UTL*,WED!%9>&"%ZMFZS5
M.+8$RY3C)6ME_&M[@9K)]RF#05,:;':)1IF]5R2NE<@R"*-CR/#CN'TY85*"
M0P[#'']_(CB=<;5&BW3I(<?*;W3M?Y5?43ZKSSY(.X["3[ RX;QTY,;?5;DF
M^9%= IIV;(<<GTVAA8H]8"Y?;_W+NX8BL+4P2->(I22%A,%X\!6WTG0LF%09
MRCEP ;/GS,G$&QJ/)$W5@JM2U*@QJC2=E@R;\L]>KG,YG:8,7GEB(O(+"#]N
MFQ\27$&"!DM'P_\;;82S48G4;EU8XFBR<<HZ)K2PH.DV/F(%/%OQ0QG([>VG
M!L@CTR>)T[O^<,H7?&U'0,W#]V)K>_V\>;%)TUA:8.Q$!\:.]D@'X1$GWB/C
MF4:1*<X8+I23)D5S+C-\3U.<70KYPHX:EI\;EN+0/2[YJD9L*HM@*[UQ+3'5
MR(6X?E^OCIV#GA\58/9@YZ:"V,[Y)"9=W:#"Z!'YT6RZ_G@?F'%\?+(3*I";
MI,W=JK[/9 H+76 C.27,"DV"=[3PX.T2HWZV+VY#BE#OB]OLBYVSYMF>9P9@
MRS(DB*4(-HA%.@J)5*%P2'T+*%$K;_#: F-N?"B:,B\R'<_XO!)D9+:(9G5*
MC'.I1R7+26Q?KJ9) ??25DL:WB79RS;+()7 ^XF-,9,P,SK^&QZ$<++ $.RT
MRW,>@(ZYF5O,!EQS2]R(6T+6W!(UM\3]N25>%U?$>G4,>LE&2;B^FG/_4CQ]
M&@%7,P)._'70!0D.]WOPO;F2',R,P4G^(WV\<3H<>80!3'17IJJ.4@2ZX>2@
M[U^N DDFVI1C5OG"V=8S5V2LY'+5VQAHDA<<*P]6@-'<:F.<]=&+$ R)(A+\
MX-1C'^"!OJ7G>;5V6.MP_4?K; _S:)7R&A&O'.(*8V1-C,C)Y$(J*RUEF:E*
M75,4#;9_&WP/V'S[_4&YAX:-/U.J2H.5-GZ2G1*ADFA4Z4"EBY)JX<Y'^PM\
M@'XWE!46QAVL5O&&TA6IS)23-(#3G)*2SS8JP2SW8;[_Z3#X\GMA@[:[8[]C
MT!X>34+!OCUTV9L MP,V="ZQ'ATY')_:3MO-A?J. 10FZ3Z3!*:<S3%)T,B7
M)O-R8))]E=*D4AUMI\K0<]G=N6PYO2#(*(\]RJ.BQ-52)AFD)/PT(0OP8I3!
MGMS L6$Z*2\NG<#;>GT%CU)+QEDL+&>)U45P*7@,@< _U%0G/GRFY<*=6\64
M8WU?#C6!S2M&ED]GZ12<8IM84Q#@N4#<\P)9L$H0$X+)B*,1A5A<.#<#+,NZ
MXNNEB9"Q82NF!=^H\*1*$7S-ZY]H6XSE5' %;GSP$7&L"V2<(@@P0H9T2B93
MPC.^+MHU?;I2:H>IM,P)?&>+KBJ= =.L<[[6:$Q!T+#]XY\!H#OU?*D!Z '8
M#79@')NT=?$)PS/0YOJ>];APH;"I8;$"80P.64\BPHH[(8*T0>5$N@4)%W<%
MHZ=<_1J,;BP+9WN22N:H)4C+Q">E$@L0YPIA$PA3A38V,2SC-?H(P'238-G-
M6F<5^*6TSM+C\_=';J"5H_!5HX_W^?PSG?^GG=+I#\%$7Y*F6JPYWB/?#G<N
MCG[L?F]UFQ__.-K: +F^Z+1;&SML9QOVR,>OY[N'N^T6W127]LCWUN'6]H?.
M#MTYV^E^XJV/S8NM[YNX=>@/6JD)X/8?W59WD^T<=J:;:O&M[:.48"$9(&)!
M0&5C42!>"(LT*03"#@-2)LXU?8FBE!@"7GOTA(+U!6Z[(KBPX-%'HXH0HYUO
MJO7E?]8_OV^\6_]K<WO]S^M[:BT,<_W\^V;'I[QQ7FI3,# ! ?)MH3 3/MJB
MB%PIN[+<.RE_\6^IRT/;W<0) ^2/(9^GY7R-%^MLWJALZK^&C7>IHV-LNRKI
M>K,'5MYQ%:DMJ]++$@WX_?3D(,<QAC/E$XGG*.53W#+Q\&Y-N&_72F&\UAGB
MRDS#]=%3^&7)%GMZ8)LH?]+:./JQM;ZGG#&<>8$H3\!&&4<*6X>HM(GXU3K!
M72*33(G95R9G5V?>=\R\OH= 7+?J?YG!UJ"D.,N1S<FWUZN?5O\<U!J."@<P
MJI"FA0?33UID#3BF6#H?1#H=HMDGA=\6N*7'9A0$/Y[%UI+N81#*9(E;PL.=
M^AC?D'/Z.GPH,Y1KZ:BDHP72X2S#A <$=H4%Z1 *7 3J$#=26P,VAD_LT\]D
M>;<F&8;U&D_66'D,/AY.!-,NP,HJAHPL# K2%(61TH%5>.LU?A -7V_A!UA>
MYPIFG!3(>\Y!O5.1@HX.$1H*Z@IX6^)GL[SU%EZXQC&:0+&1* HO$8^)&=P3
MAY15P5"L+:%^Y4WO<N//.[PP9>K-Z?Q1;G6*^%QF KUM>YX7ZIM]N7+V$A>!
M#:-)+-/WX*MS0"W]VTZYX9D[(M=<I &$846K]7<_Q]Z.^V>IT#9QLX)[]NMJ
M]1V)XJK,1QUEF:V6+&"I]CE=N%I50"0"OT&CG\L>4H@N'>4.<GW-ZCA%-M4G
ME$YC2J]=;73:7?# RUS;\BN&)X-VE7S;SP.IQKKHH4>9_C/D*&;>,]T(P_9^
M5= 0VYU4_W\Z2-DK8UZP#7BPLY3"\C'3777 11V[LHT_S5E%S))8=S-!Q6Q;
M1?"%W_;-P.?O:@^".^E?QQVY=")WVT#(NZFJE1>[TVX4!1E7&[WD6,A43]HZ
M$+)8BUXTU_><DAJK&,#\-13QHB#(ZL0TD2K 12R4)7+E#</71$*6) PRM>!U
M#.1G"Y^R[1F+W!1(1/C!%=;(BI :% ;,P2-UX*?>) 8R70Q8\G95M%T99>CO
MEZF[&B\6?=\G)I6R*O]RF63B'FV?=,K$U"LW"A@UE^#2PE;T8-+BPD9.O#5:
MI+(NIXQFWI)X+\^C[$<VV3O?LE55%AB77!_U[CG<_+%'I"2"@@\9,&&(XTB0
MIL$C(JT,IB@\N)97=']/:UKF(5:GCI>DP^3BJF%_1D:J8LL&;) V; D_3"QK
MO? WV*FIDU%9O]$)^V5GZDE'&K!'TP?+?,PXHD@;FW]V9/3YD=&WVICJX9#9
M<C.!0VD$IT].#3LSS*42TL6F[90+-%O5E7IXEV,?CR>]/'FV?F\62EZN(3HJ
M ,M'""_:&MV:*8$F\'/>A5E8E/B3@L19OJ5<#@_RN5HZ48.PG\H.I^MH5^_)
MM$2)I!PSYKEQ/,:HG,3$4!DMC]SYGY73WLYLO98U!-8EO[4TU$I/#L6MBW6\
M)U7J3$,\4LH %'N+D2J<0S)8[!DAS'*S\D:N"DY7L2@6G-W-4]J W$W8N>[%
MIV244XJ W4H(YX7U!@Q9^"?%J RU5"[N(7F)#N0+K.Y6+(W9-)Q7KX/!<J5[
MQ!>*"7!6P#'1R5D!$? V(B(P58E6EUN;"),(OX8P:;71R8V%QA1#MR<1LEPX
M+HF5S$0><:&CP51X30TAP3'Y("1"-2+<4#"<V!-<AA"M0R:$1+6F(SBP6*1J
M%I%H>(2+@ AL515B52R2CLS",F>3G2PB_R@IJTK;9J)30.D.A^-Z]FPGI=*5
M'ZGH)'3.RUC,K4K5"\.#YMY8A;E67 7I"PJN<631!G&?5K39X/^8!CRB]?@P
MZ'='1LE6G/(%EB5=],F%:FO#L3T1."66%<@[IQ#GND"*48>\8*E42@GI4YO(
M!=)4Y8>N-FQ('#2P0KEH.C4\G*O 'A<KSE!H@R63G6B%_NS#19G8>".7,=Z+
M_^"^J<@OF/_@'_ I)_P'"<)2BRF *BJT1-&E,VEN&8"8M$AR,"*"IPILBNOY
M#U[N"=)?<WY#II(.TV1/W8I+$%YI&K#D&GHQ;7IV&FZG[@NO@W-,$P[[QL 2
M*=@]1G#F91$D)0^J[D?D8^ONWZ?MDNV@3%(>E794Q_U;@\V*>6O,R%HG W1&
M_<0E\=X&[I'0EJ2J,X^T=!*%B$40%HQ&F*,W#'P$@5<96]"-J7(-0-XJ?S._
M4$5"UAH-\&W7P5/H-.1(SN9]V]ENEU\^SQ%\WT\F><I:PRH6#CNNK#166VP*
MY; -2LD;-7ZL9?+)H^_P[]<?B?J5.RQ)C$@Y#;9%Q %IBB5RU EF@\8LR)4W
M!0<?EJ]RL@#RKY?/%ZL(<DBI%Q:C>Z45<E2H+!D_&Z2&S^-"[C&UVAV"0$6P
MG..H.>,Q@L5DP.%D08!NIK&PU7Z3H_TF[^7R3;S_11MIL[<](?NJ=U7>59]8
MZVS/.$8-I1:1:,""L@#]AHN /+8%MA1T=4K[8HERNU@5UY]ESON"9D(3FT/D
M(X&Z4Y1(4T=\X0HF$ENL,QH,/&(=O&2Q-$*,3G1^0AI;1XFNEPG>6M]30@4+
M6A)%7CBPJA4@+<$>,6:U ;7)25"IY%,ML '&,:,JXZAJ(#=V\C.-Z@A22H:\
M:;?_5L[9/0'F5L[9E-R\2SQ]ONI#_[FB]]Q:"#"OSD6;5=MGS?4]FC(,%7$H
M\>6#,'$ &$\YLA$;)ARQ)O"5-X*MR>N[=ZU6+64G@8&QMLJ$ZE7I:)E<EI (
M;,1QLEF9JG:))11D].6>F8V()E^L73/59N3*L[&4#UCRTLR=JMVV+<F$C_>A
MNY)$FD@W4LEH8<%)Q@IT+E?.A!BI59@NCEOBU]>4Y!] LR8'QT-@:S25 2GM
M/.)2>S"1/.@4)1+?EL8JI?W<H2G)O0]5L/-48$58Q)@3':VG06&F:2@")L7/
MCEEO(D,W[LLP'#'OUTYK*S_')PKF-=&,%E84"$>P0KA0%&E%"R15<$9Q1E0A
MD^QHA5>E7"P[LW3WL\EC7X]')*2+SEQ6RT95U0I-J,AOV<5,>>I!S@T8WESX
M5$,@&:&LT)YAV!R+VS7<)I=J0;#D72Y WP<,S\*7D>C5QT2^_FB>[2E8"@8^
M#RJ$X:D."ZQS\-80EA(6A4<I4F>SA5E5*:*V\-2$H<4='"HC_NP%= "H-M#/
M^P"\6'LIL_J-F@'!LHQG-=>05+;/=/.U\H3W;+X1P13). C4:J;_2ZT0P/I.
M!2FC_A>Y4VY5_Y'[D1JXHK]_OCJAG)[^R!C@]D_;94^%DL P-56@$B."T1<-
M>FPV1RYGU0VK[C3)V,OWZTU:,4U_Q5R'C6$:5*:N&A->76;KG#2$F)+TZHPR
MBW!V2LH#QJI9\# W>DT:OQQ=&;X&X<_IBJ[R'F?9VG.US,FHET-95S+SH'!9
M:DR;GW1TS#Y>R3)LGM8AM2BN::4?C%:ZJ&FE:UKI^]-*_Y0_9YX/2%.>.HF3
M5. 1/ =]'ZV+A2LXTUJR)>?;N7Y335#Z9*TD?TA@NCHBL1UD\P @<8+%]\SA
MN.>YWXWHY*H.O3!VOU'E9V_W1[KC?\H3IHW3,'ZM.:667J]!>_B)-S_M11.#
M4)8@Q10&@S9F?KD"^:@LK)S3/AWL<;+0N5Z=5?2@'\<:N_]WI9G[@S9LD%2T
M"@9N[C\.U\P8!LD2_#4KT"DV\W9BJTO-W^'W8 :I!_RP-)_3,H_S\"\U;!JE
M_E=">P,2S1><N9]C!*ADATZV5N@-\Y0_GR>^LU)\/VH4EHR=9-@==^";?GNQ
M_D6.15P1AYAFB36^?YP\A=+C&-O]*4+56#AG,_U:\\?^@E=''5O!1;RR@O>6
M24O862JBPH40'/M"!T.]%(I(3:+F-RP:NW&-[3MSG/91&47['&#:_P[^0W_P
MX32QGH]R_EZQ=G"BN;Z7&E):FKKJ69'.CV@!VH$9Y(40F'BN@A9@J:^"T0;_
M79WU 78%0/E4[\5Q.[ZQ1*TU&C.MRZ?S)$9"6UV@&EO=7MN>#E,%>"6J?XU%
M=25_(OV=NBU..E_\8< L')SG&\"7S6?HS60_C6^1],CDPE'^1GZ[K)L<E**3
M"L[[B7'?Y>JV;$IEV 4O]Y9]TKW01J96RAISRJ)BVG!I-.=14!KOM0_F:R<W
MJV%N]NKM<(O@LJ.M3WN%5\2*PB.LL$%<Z @.:"%1 8X#Y]*#E0N&DR[D*L%7
MI^M=U9T4!/2A@/4Q!:H&UOM)4C-1&B@CN+2*(N)!B#@U#FE+ ^):QLBB(U+J
M!+)$\=5"+J#ZO@G(JA'(O@;;KWO<Z9^'T,A".*G)3#-06X!76(#OO_SUUTQ*
M<-F\IF(22EY8-:NE$^=#S+Y9Y6>EJW_-[$BA4Q5FC\_I?44,E(JNQZCWL_[G
MTRELHW;+)0[>[OP,X\01P@D!]Y8[XS5L)^L-F#.T,"28F^0=SR4CI6=XFY3[
MNRF7:CWYG_LY?/+V?/*1JJQD_<P,_(C;/I4O-<W@*)R427#5/*4LB#$L(OK:
M</'B/=]:W[/86R8]1DIBCCB)'MF"8@0O8T:YH2;$E3<+<M_^LQ2.<7?PX3#G
M'$T.%KIYQF?/%Q;5S]D F[Z7]] @Q0S29_-![C!TV\CT>DD62]MO4H&;3^0;
MOU1>T@1P\NL37^G]> OERQ//U4G5^6U\KS2&4I*G*'NK=S.LY^:T9>[+[;:"
M#(6)ACHF%.7!:ATH[ B88VJD92(N/DJ^G,1Y5_EOFA_M[FEW- F):,4-VIG3
M[/,KE_U/J:>9!T\KZH*@J*P#CXNR9%%R% MGN1.&2<Y7WI %LC^2YW&@[-BT
M?8;IX6EJ0);J\=I78'8Z_DWB7=UBAG)N"O/]I#'-G'C/L'&X,$A!NQG"N=(.
M^5(U?P83=/1=7]>^I-,Z&%Z*#WX.?X?>:67LONO[\'(/@Q_*M!?@:00&.LT'
MS,&"5!CVN%92*.$");PV[9]V&^_@Q%!&"@9;V2"M4^#$@W<(1@=#7F-".*,Q
M* >.X2HK",C>@OZ$L^;\A"@G'>[OYURBB66?]O#+W2>WZX9UV]WCB F",?"R
MB.:VT"8$32QL(1)==(+]I+SX 5D1QBHQ5T94\)J\E5><_GGASEOK>X8KY0@8
MYSH*CSB7%"F* V)@SGMJN8\1=*(DJY@M8'VKTFH>/O>34"69\LH*XD$U!U5P
M')V#K6VMX$'7HO//B@X#'"[ VV,X%B@P#>94D RI2"*R#M2E"TH0G.@0L%Y5
M>D'/K,L,&ZME!MYL@OK80GI6H97;'B1N'4^X@S]_^3HL]5 Y"Q,;L>PB5I&T
M_7:I%=(CM,@J$Z3=0?"GN4)HH6MRE3_R,9\8;_;*[9233.I66E4K+?#$G50$
M_!$$2P&>N+88@>\MD"@4UT1[SF*<;XWUDFR/S1LG$&2Y+PM;I@^M1END/[MW
M4A)#F:Q[S6GTU%R)R=1527Y5/N!)-@I'LY=:?P[2S'7,\3#\-OKE=]\>'G?,
M^6_M7G[&?-'O?R<>95 .53X@?$V5#J?U&B<B9\2=#. _/[I_E2VW5F;+_>O$
M7WZ3P[M*7?W^M1=?_R99DX6\X\5XC5SWIF#BCM?60UZ.(>L;7ORO+-&E5,/V
M2#OO_ZRPE5OBSU0:;<J'G]]*Y1;]_3B=8_?V4?K(;P3VZ^B%00DQY0X>C7D\
M&B+&PQE=D"" 'O\8WZ#"@/32[4=<)?[>9\S3D/V3QIDW!N=93+_A8ZV\^;((
MFALC5!YCZ_PD3Y9\A(U@F(2%Z[%$'UT&\?SG1_,,]C#[![=P905D$^OX)-',
MMGUCM*^>W?[.1OI_V\&_WI2IQ__[!EOZ027@ ::S%H]'$X]1R6MY2)SE)!]!
MU6)2B\F4F'P+P[+M4O;RGUHVGN'R/[L5?C\N*IU9W9_8"G>9V/]P+H08'W3M
M;SB1_"DF<B:2MW$YDG>+37.[J7I<"'V2=:PGIYZ<ESHYCP&E,?_?2X72ZL#D
M2N2D#SUY>2+N-GMEC&R))N]V9['*X2!XX)9:R9WBQA!);71:ZL1)S1_V+/:N
MR6^50,R>.656^^=^3GNPT_W1V3H\8KO?=[NMBZ\4OH?#N#H[] /<>Q_O=-_#
MN'?.6Q<[?'=CMSNZ!K[K=)=^E5O;OK/;W6&M[5UXIOV+UD?X_N]_',+WMG>V
MC\Y;AYNL=7APU.KNQN8Y_O'G]ON3YA=\MA>)Q4%*BF@H/.+*$:0#4TA&8PG5
MA H;5M[PU4+15<XO\]Y7^<1S>_3I]^6R@MCB^;F1FGH$=']@)^DQAKB8;J,4
M@:4][BP9,.[""GM/Y+UA9O%\-]2O*?DMI[N4F)J374;!H)Q1_SF!\9^IS7+Y
M6\I%K5'V=BA[4:'LQ=;&5SR?6@#C$ZWMHQ^MBW7>/%RGK8^M@]W#@\.M[]^Z
M.Q<[/YJ'CNUTO_*=[=8,*RG\GBAN&2Y 0FB!+ \1<8,5TI88Y!TFRA"EK"H2
MQ:V^G.J,7IR<?CT^KN5T^>149&X,)8+5 1FB&>)!.)#8J%"T!8LJ\$*:N/*&
MK2V@NY]CIZE5YPM6G=?EMAD7"9,%CBP:3I4P)'*?:+(E-=85BZ%GGKC1GP[.
M@QD\F"^2?U1Q\=(1(378W 1LR!38L'FP:1TZTMQN_FA]_WJQ]1$4W<=//[:^
M;[+FQC=XCDV^0S_] - Y:VX<7%**6P VD0=#8T#2*XYXC")U@#%(81T<\X56
MU(!2'"%-)6UO&DDR&N@Z&:0^4*TCEJH0W!1)[KP249N">V($K66PED%0>%OK
M>YQQS".SB!%K$'?:(,V]!+'@D=!""B9!X?&%,CA\;2KO'A&WY7/UK\./.YG/
MM\$/^W/\L//X,3GT*]&C!H^;@ <;Q\Y8M"0J%U,KB )Q(N W03C" 4L*&HA$
M9U-UQ$_V>GW0>I?=EDHH'NMHX/+,O=ZC 4&CM]8:&0H/>LRI*(FF/@IML&6!
M+,?1P*@UW?!D<)HIC+=2PY3M ]-;>&A01PAN@7FM=U/G!8GZH+ N50^F8D*9
MBL$48)ZBA8W$>#"/22+:$4JO%N0RW>7#GQ?<;;,N*ZS=X[S@*8[5:V"]=NT4
M)?3W6L2?M8@OG]7U0N-Z1"CG&":J<(93HN%'<HZ]5EZ S;&X9K6.J2RIB3 5
M4]GY,1]3:7;AWH<'[5;W/6L>'IVE0X36Q3[?^K[;V?VX@YLP!SOT/6E=?%X4
MUY/1:FJ$0TDL$!?!( 6>%_)4*^LLYP4F=XOK!5-X X(5 DUQ&V>QXU23@DE1
M,&I#+8.U#)9Q/:Q,80&=D/':(*X41@9$(GG\I+!&*VG98\3U:JON'S=7:JON
M;E9=#FK]*Y?+U_7Y+[1RO!YR79]?U^?_(_7Y1-?U^75]_FLKK7Q9E;5U?7XM
M'G5]?BTF=7U^;0?6]?EU??ZSF<>E&LMH[9;^1/&?%Z%Z<NK)J5D,:A:#YW'V
M<LMF!"X:S3R/PA!>>&*)=-X5DDE/9'"949[HZC 7?JE9#![EN->W=[;7Z6[W
M#[C?YZ/=0W@=KMGI?A6M[9TS&.N/YL8?1[L?WY_/'_>VZ!\'S8W=[DX7QO[Q
M<[?U\</AUO<_VKO;1Z1U^/:PM?'^K-G]?+2S_<<LBX$)5$E+*8H42\0]=\BF
MR@MB+7.I49GA1<I*I#HQU5]N_U>S&-0L!G7*UMU9#.Z)O#6+P1*C[*@Z_$>J
M_KY4'=[]=-[::+*MC?6+5G?S1^OC^XO=PZ/SYL8GUOJ^>;[S'<:^O<F;VQ\6
ML1AH*J)3.*6/>XPX]09IP1EB3CHB1/1"R,1BP"^W>+H3B\%2R^G+9#%X]G(J
MFOM[M.#1!ED@I8-" )P<&6T54CX5Q?#(A/5@7ZR1RTUP7EM)YVM6G==6D!MI
M9(&ILX%P+*()Q',BJ#.18!?50NBI,TV7%&Q&F:9GEZK'-]X#T.RG#D'MYO81
MAWNUFQ?[I+FQ+G8.=^ >FWAWXRMO77Q;F.D<HG84,V28)8G6AX(C4P#08(4M
MXSS@J.^6Z0Q 90LBC'=4<<.)<M(46(50T$(7VM;R]]KE+V4Y"X,%"05'@2LP
MR*(ID#:4H93@S"D-@7)1LQ>\-O:".YG--7O!,@+'A+U \L(5 52-<,& 3>LX
MTIAJ%*5BC#BA"J)K]H*:O6#)9NYV1P*FL-I)*J-PCH.=HXI$P5)88870FA;+
M<23P.MD+G@;S9M@+ M;<,BF09@68-RQQ@R4;1[K@02:4%IZOO"FX6F6LJ+D+
M7E9A=PVK=97;"Q?QY;.Y7F@TCP0CO'41.T(YX<P2KBQESDDE8Q2XCJ8\)P/A
MZFC*X=%YXHC<Z<)<;!S =4>XN='IPK,>P?T.=NC[\]T-?]"B"Z-Y12#!!T*1
M2 S(W'.+E,4%V!R2T1"XXIS>+9KGN'1:XNB+2#DG3&F?0GH%-U)9ZTDM?Z]=
M_E(TSX?"%SQ81$WB(B6R0-87!#D3+)6&,)# FK.@MN9J:^[VG 5YP$MKP= L
MDO^[L=[I-,K*PK+@(<P4E V32H!? VJ&P7YH[.<P0P.P/;TX3!4T'C[2Z?3/
M4GG1R4& &[B#I <:)_U&,_0Z_4:_#%'DVZ>P5L.<Y$^^'WWR<](?#1^&;M"V
M<,-VK]'JGX0&0V]/AS#HX; !BL:V>UG/K,WASBPT7;(GVST/P_R-R0F%Q'-9
MG6V8I&C:@\;?IG,:&OUX>2KS@L"4P62'F<(5/RI<:8 2'ZW-<%&Q>"GCHX[N
MJ_GJ&WV8Z,:9&3:N3;.93Z]1.C #6D4&P0L#%K$.GC#,O8Y,D,6,7I-H&Q(W
M"+9U0>;NG7R[WKMMS&V[?V(Z^:4-<Q(^P+)]2ZLV#L7)YVGIS%@;<,WAUO:'
MS@X%ZZ;[B;<^-B^VOF^FL\2#UN'^V>[V']U6=Y/M''9B:V.3M<[V@@0](XU!
MFC*%N#4"P7\>"1ZHH4875"5F+K)VN7-8 _94)PE4DLC;2)D2)%!I,?4F<NJT
MT@070:2AL.!++OYK8KJUE#TK*4MI@H4@!O."(>HD1YP6-J5W"T1M0:*!I:.%
M2$UD+H=L1T*VV@!]=@R0V?X[=,[G=,R+UBDS>J0];.1SU ;LL*P$#DI=#[;
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M08#Z4>KJCN/&.O/#4(]MTV*<LSCE#$C67$FR*^1I'P*[*W9-5GW2TY)S+</
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MC(Z@1@,:_X7<B1++\Q/:XK@D;LC&M$WUTOEG_)O*[^\"!^4:L<D,VW%\-W7
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MPG4KB4S=87:BAYX7Z*8!YGD$YQEY_I/GOAWTXO:!Q>U6]ZCX(9MXPL=CF-]
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M.I'])GIM77#9%,<TX #D83C6T)?]=U8]R2(0^O,9?R;%O-$>8NTEE)"W&TZ
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M/,OB,^ *XS%Q,)8E"EA9RNS_00("<Y_E,9 7*\L,Y.) >'MF\S(G*F38:D3
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M%)7H"L@46N9\.@7S*CXCR/RJFG/\@< ,0H>2N%\B8DW77!IY4S :$"\.GI6
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MUGA.# ;$"*7]BA^_)@E$CK2<#;6_ZLR[3@B3-;%+06K$-$7B4GML19Z8Q"(
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M/3P@01U% Z!;8>B(?7F:7?S2RA%.L 97Y0KAO&4764UU;*$24)"*N'7WA28
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M&]L$5%\X6_Q,-BBK9.S]FD>P!+$IN<<?R%0M^>->E=[$J:Y1HY9-)1%>;H6
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M/#8)_YAYA^,%/>_8:-U@MTU[$4'@BS6HO0Y_ASTTO3[8UQORO9A_U$S [7G
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MU+2.IO8SHED>MK2C^M-N6^)64_2FC="8S?/X3/3<^X/E<U9>J5>91HN_X[N
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MK4L7[, $SCJX!N29ZB70U 4CI>R[5!8&#55CYU_A1QA@!!LK+XRT0+4Q#*Z
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M$RFGJ'1[S[9SKLM2$CSFG@DPKBZIU?A_I\Z-LGC.+>*D!GYB..%D0C O*%U
M)*#P4#')C2I$!R-$I=F([D!HT),IL3[=;(XR)\I* ]B5NSJ;.M%-GSI+JG$\
M5A7<,I)[<5Y%&HY>>LY;05+G<UZNP&U#P<'@Q-8>0(@)@T'IN&^DF(KPLTH6
M8<7> 8E7F\]6<R"W"4@)0Z>YP#6"19L.KZT5Z\9-4SPF HR !X0YW$(ND_V:
M786)$.09=!5)72P:@4' ^D&HH2(>:1;5$*K,7QBB-VB1.I"&5TU!2!(^Y;08
MLXRWF#,\3M'=.$5-CU/D<8J^"J?(B]T5$[L&-VY6 _/D"?929H=/:.#0!5:C
M,]5"&P($U)YK.U<EA&F-CDP5Q4\A!5-/K;A)A!#*.$D:E8[L$OA#PT.3W:$1
M2!^B 3R3KB*3@M679K#-8(:"A8 P400!#A9 42*B/[#NMF%,AVW(?(@I-%_A
M( =OTKA!GB=6D=3%/)&4-/  S<(451 &\A)XIO%S0<[$N&=Q?R)%&#U$00;.
M$;?B)7[L=WT%25V\Z[-:JA\/C4.;I3@4A/')R;E%=36,>T[QA5%J-0J>:PU'
MR*D(K]JS/R9-$ZF^XE!=>!6BR %O(XQ'.0=D^AA<%Z&2A03@WL71-'$6T9B:
M6,D, PW3;4=XI5IU<DS(Z,6ND564)AF').ST%"A<HYS3\/H9/(!EB##Q94AH
MWV.%G_*U:Q1)OC^0.@6.C\NE@1ZK-H0;.G60MLOD<Y+>))Q^L@"-%/*7&TT%
M^.?%:0DX'*\C]'(:P$+0Y0@ C:#0#GRY1@%WL;^1] 2'C)GA<9*%R\P8.<D9
M$_MU"YMB=[A&<DBU0.<K:*R1NB*PRN$P[*:ZY*@*J&[PXG'ZW)5^H4N\B?,8
M?#M93>"Z* :/%GUP?$-,# [2(<]*BD?:\<55)V(U*+*,K%,Z[V?'%3EO@6.#
MLK@WA;'NK+\&('[\#,9F:P-F,![3K W8OB,[">9=.D0T?]B%2V?NR:]E=&4G
M!G[@8H57@FJ_,84I-+8-> 9QD"AX.6_*@(#[*TQT(Q]*>AR'Z601&87D-A#X
M$ _OHYE5/9PD1O%0L]0R,HH PX%W_W5T]([K3OB^+GCL@HD'6H#DF/>&8S0*
M/RLS;$!<I.EQ W(,>#H(IM959)0%1D-YHA9KE["+PZYB9Y!$%.<"E*[]=*DR
M7?0[?E)$PP_Z,OAQWN@&)VI;(6UV*JP#&<]7T5K*Q!T:O>>L0*;G, CH[2 &
M49,1T]M!DJS"D^ ZA)N4.KFJ!;V>FJ%'=> ]L2P(!!^&*VRZM1=GO7*$@\IZ
M&@/>P3=GW'1*L]"HLC"/V66 3<,W^&2/6#<M"ZF(R[()?HG3:]0=VV/@BW&>
M$1 7854'6"DA3=_@$FE7P->QK*SD01)$(.6(8LSKFWJFW&4E?DN^0K;;L%6:
M5<;U3$\UH0R5P_4B8(B5RIR,&[";;W@ZII9(J$L)+K\(655.;9Z3](1=) ![
M6/6:L ^ZY_HQG(C0-88CU*ON1*<0MU),/T[DZQ$W9JK IXKP,VNR43:06?AY
M.Q426G8.UW3M23J6T2X7= ;QT]?(VP?;O^T<H?GL#+P(+E\=XP5GP&3[7(:T
M,8OWQR >\FR6"E?=NXJ2BWJ;XNE"4QS-PKF2\6;.>;+(SO=NW C'_J)%E='$
MJYF#13QMIV,A'4;X6H)$3I!^^BZG2VL<$Z4CRNAE#/2ZP6:G$<"9Y'5N[2U!
MK_:Q(FW.<!]M6T^K3"-[-5@ZFOU%H3)'R,;)0!G;7W#BUXBA'UQH*<#UZ_.&
M]_<83<\S,>#\#+N?SQTOH]V&J0$E-EQ<*;1)RI'*T)PPH6=M43A%-UW@-M39
M>@A/D;[@DQ3"(2JPAXB"3,XH 4UI38J'9^>RC/5\ ?TN-VDVC&XP3#4*>UF*
M X'2467(GCO.S0Q>S3B?KN!0I>QM9>9D\BPBC)8":6A"H8.6P=E^R?6&8SQ>
M<M3LO&WTW.C""47)G-E HM+-"H/<T/Y;6GDI' >8K=*\(-@<-4ODS"0^/0VH
M7V8<G\%&-6K\DC%*CORN"!SK0VA!2(6:D;(L@<&"7IA7)79LQ_I(N07&'JU.
M=K\WYBP8C==A/-0U[M-CC*C\5J(=8GUI'G,X<^%XV\I0^JI;$.>B==@#FK,8
M9L&DN2[BP\,[53E!\_<:QQC>$*OB/D=IV2WZY; Z9IN+,J6+L$:ET GGIRCH
M,!06QD&HBN,4TG3'5;<I!A?C:YK1;,QT/=8).1_/- U$?>\L+'Z1(==.W:[2
M ZBY!$/'L,?PIO(D##8F5S%L6/XR&.BQ6FP#NS>D=2H3_1*RN7:^I=F\9SA(
M2D9)HW42M.FO9O-E\+,^G4!Z%QA-CY1JP7?DR:19A:^>5U[4[(1P#F^HKL)9
M5N@Y?F+%3:O)-!4;7S(EN4:DIW,9XWZ/WPYVG74XUT<I/ECMZ_J7][2*1[U>
M!A[CQ@1[CBOE/9("(!^4VH1E,.:"=EN)2@2AC4N0XQOB(K&$,8$+YDC2_^2'
M.Q%+]JI1-&>LJ%$XF[HC\W2W (UC1<<7YS+6W#(L#BG/;;S(WI6F$MHA1F:@
M--V,S89KS'X2>?IG>@@A_9OKX=S@K8Z_\L084E0R31F.G;9#I&F;BMCY.?I,
M4M! YDDS@;KYBR,XJ3'KXYPW@@;6LCF!*=DQW 7]#MH[O1NQ'JQ[WX$&+4YD
MZCB2>TNS;T93\GO@W?DE+-WHL$@2F6:JWO*825+_9)VA_O #[!Y;&-;RA6&^
M,.RQA6%KIH["Z)J,4U-W3[&;D$L+0A3X-7$Q)DY;1U=9\]%81&Q\:M'N7@?F
MU1>^TD@YS/&Y<CBC*:4HP\ATNSAW%(EU133 Q1B>M:TM^KY2]_BV-;>,1I-0
MTPWL5_@YW05>-0M!VVJMC XUO=HHSGM@_86)0L>:OB6]:P<L8RQ3*]!03!:;
M F#[S?0M1CH(;:K0S6]Y%&ZBAL;QP;4(K3\JA<6DR KQ8ZJ%Q>2DDK:KTLA&
M0E39 ZQ0"V&WNN&0V" ?*%6P?[2\5M-O21%"5OWH.KAIB8"=MU :,+!.CS5N
MM=I9+QVJ7XYHR,QWJ@VH!>58'D.CP\>%GA4[9%<)?HW&NVLOFRYI,EW6QXA\
MJ-5\(>[>A77WUN=E[VU[9&%C?%K#<2'U)L)BJ3%X@9$:SDN).EGF2XP^AUF$
MKF1$P6(Z-,^VCBZ/MYX'>XV]&H<.]'(2^QQ7#>5C/42;+Z4?XT^WGML@T;%;
MM6 [(<7REA_4*E5=8O+IG))KL-?@,*"9C26I?+IA/3E0A=E<2D -<>QUH?29
M%6-Z^D(C1A8]B$,'(K+EJ/%2W P4K!367^3/[[@''EV$$\K[,4CS#>+!93;*
M!(F(4T2"AF;WG9R'$C6YZ$:4M8FQ*P3GNWZ0WG/;'9=FNOA%? "Y;<0E@9I;
M8E8'NDX&&]_"L;9JN@K/A'Z* RCAT$%%6YD.I.*9DY 0,[_KG,+;[7 V9*J9
MBKN$"^4Z-Y6R'GI$0M$V#*N6X_$0/:6D1&U24O+=:?JCEY_JDN&3MV@Q30;%
M,*9T. ./T"$LBWBH^3U.QF! C%0Q2*-*)(UBA<:8Z4Z<P?.<]1Y2SCS4O\44
M#J%><=&%Z.TBO0$!9, (A"0YHZ2]@=;Y+T+JG+U"?'4*S5['P.&I4WP06?^W
M7[E/14T;<E@@D0W@%%%I;4K]G7HNJPW:8?C003*[]]$DJ;&><2S>-54A;(QP
M.(N'L 1I,F5%AZ:Y%0L\Z-!50^A2<U+YD5/:0L8.; RF8$W3($94T*:B920_
MOQXL>+[=%L;7$,DD4FE6-9" OU$578/-LM0O"[O7Y?"\Y((12@=-?+2TN_BR
M;OX5CTR6P^E$X[0<E1QFF(Y)?Y&:5U-/L6:1S;NYXF)1$$\W2YM&%?@D'G7+
M+%=V\_BT$@OHP!GF "@1IIM5^N5PN$TM+YPK4UQK"9J P1\DFO[Z_2N)EC^7
M<TTE.&E9;*?][7':^XSH7NS3P+4ZVX;B$KYP"&'$A[P0,T'\/*=""<-9M^QL
M],,XX_*A>O 665,<$_/R#@^@QB('A?Q +%(E3HOU+X:@W&C=9$$Y]H5<B<R7
MESWLHX#%6"/6>:AY;U(@1PB-DV^4?7^^H 3%>/MDDUC40>Z=-AA!-CN.83C=
MSSWE#X=VV73 W.BVF3M17:.)T=I?.HK=)@IUO$.71-:PJA$+6@0I!2N0:U(-
MC&==I^CT0V<J%['"C8K3*J$3DKFQJ^;M"=.>_#2Y?*@HC*#K=\QO\/K39/N=
M 'Q6A-5)U:@+_J4S@F[81PR)2N"@'KQWM(I-;4C$(:KD+3:%?8^DB-7F4V=!
M!C2_RL: CM0Y#0$XTB5$2 1#74S798J6))7/JL/4 )E*6;XOV(4#%5X3P%:R
MN"QW8S;@#ZTY;)^)H,W:(H>%5<+V1-0T2@GI.LQU<Y&-B:=@R WE!5I@\"Q5
MK;=+,QMUJK-S1#Z)N@UQ:]G-R"M'4"RQN8_J$^+OM+# 5[$"KV?3X:*05>*X
M'#8-+Y4%FBPW*.B0PS(/82ENP>9CFY!4.MB@#Y!R4Q:DTH$'^HYRY5V)WUWK
M-A,J-N"7I<81 54C$Q5+@T.S:X0LAN!3.$&8G$1$R^"@L7ZJR=Y77R7.C?F-
MTE,[NQAPU6X)%=WA#:W/2]5\^G=:)PR _;!2B4J'\!\"'8VHS%:36::KB;]N
M.*_&!Y'O)[(YB_//^B:N\Z0E+]4WA2,TMZA+AXZS47EZK3;G5",S"YMR$9L]
MJ!P:IE/'1PCVO,QTYS=)4NHX$I6H^<HPD8$GHGU+J(@3X;YUIX"I<BU4;Y#$
M<-9SCTVUBJ3.;ZT\99ST:=D5Y],Q$ 8RLTT.!F^JR%0XTD*8 !^IX. ><$'/
M!"O$!&<LR.]B BWK,U-5P>K,+5$D/2$7.B$3M[B< \,8BY1:\# C_U7D?U7R
M>Q9:15+GL] Q^6OW2!$*X&"NO"?M MS+5V0$TC'-#;5@R(7<4W6A?3#FI:=5
MPNBF6CK%4AN5][!C;&.T._G\UO1DQQH>?D4=6J:6?4H;3\;L&U&(_@Z5[ N<
M[BYP:OL")U_@Y)&O-D5/_5ZF@JO>D^R -4GF&B%<)4$N+YLV>?#L#0;]@J;(
MUN?>3EE%4I?=_SR&9X?9LKM/M=U_W<%%R]Q2<U*E)YR?4V-\&60L%T&\^D3S
MNRI*L/VKBP6#*+#<V]E?$=)PI-$-*#V.QGN-+;(L2ZG:@#+W->=FVKB/PB+D
MI'[&5@,'_*3^3\&>Z3/2\F=DE4F=?T8^),Z6N[RC2_P7PU?(MK?OW_8UV]*C
M ".^0[>,M>]:Y3Y-\6V3ND<4F#PU8?KU>=,E"C:I,$F"JC1<8J9+D52,S5&@
MJ.^% GU"E=VZ)1Y'3^C:)RJI<7ZED9/[K"P6-2G:8'Q2,C!.PE,:B4*2\;,$
M8CX%"UD64,GM0Q1#!.HP7&T0'2G +$6K>OQC]747=&[J6BN!U@=]9/NKW<Q1
MSG$$4J/S$5NX&XMO^Q5X4[L;@#=UWN]O_RQYZDLJ<#]R\,(VZ-1IJXN!] QR
M;'^[6M[OHJ6Q$D1L*3*4*B!#$S#Q/BL>E,=7A+:[57#H*"DJ,E^0*Y(I4!'3
M[E^SU3].HV+-12NR91XU.XZF9I#GN-,M+J@!'NTZ^1S^%("AQW/ZP09P^BGB
M "2FL'U36/LH1]%/-<215*R>@(U^@]P*_Y'ZQIG"?X+<F\ %C&8S7200RV)-
M&/F9X!6D!)F=#A3R5&LL501BU*!7T&/V1[_EAI!X"A[$A[<@I$.Y 4IJ^-\;
MW>Y$.!<"T1B.PQYP-]<C8?9RF*?VZ,;5K;15Y+E].4/F%/K5=*$/5QE4[R?@
MFV1MV5L#N2/0H".:0$S+B18BZS.9/54XK5_)I.(%BO;*EWW:G8 -)Z!,"12W
MW93AB(\^VZWF!ISM7\]_OD3X-+>?Y=60JXPVY:!C&<>O8/GG!1P#Z@\SA8^7
M^%$YSFD)@&N (UJDLI"Y]=K41$Y0AD7*7X'7< VN] CCGL5A0  )C3C*2(8X
M)B:@GL@BO%*FB*1@?!=* '*!CC1G4[?Z"-L5Z% B9#,5 ET3>JY3'I2;SB,!
M\=7C/!DNE8G"_*"6!KU!FG(18JK?),6&M[+0E&L $VIASZ4(J.:"3M&QI?J1
M!Q.96U%)944$B452*DH14!)+;JA)K\>/1B@Q)D\+G#M6S6(7&J:&>\4@4:]3
M6IFO..J=#3CJ%ZK'326GX =+C>@1KWL%,S5+DQ3=ZXVR8QT<&%Z'Q:^L3P*H
M5(2,824"4D%^[B+)SH&:=7Y=@<3[D(1E1)W#IYC-BZD!,.("UF.W&_:U,7$O
M;=$R.95N?R^-1Y/]E,-316-UW\AMO)GS+6K?"5KP?)^:;A*.V9PFJ"C=IC-M
MAAML8^YIFF-R+PZU^(3JW0G5SN*$ZD-DU_Z63\/Z-.QZXTPL\DQ!/@;M>O![
MB;UK!?>#H22"#X;Z[Q.#\JS#R5+%=1'GGS=%OVEO+\C!RQHJIVQ<FZ9H?5$D
MD]M,+TI@CF:KN]W2IM6K6\'W/Q*0)%K=9@._OV"D"Q3TE]N_@1>7DXEK/&!V
MX)R1# R -(/-AZ%I;+,:L'Y$^PP>\GC#K-W8 ,,,UYFMC$Z=80'2(>ML:J2)
MD'/7CD\7O.LK >=E$\8>S8UY[SM*TRQ><,W!XS)]\+(FU \YB%4?C"^:U"(B
MS=I<.JA4<_OS#<@O7$^NK1YL:Y>XYR[QV"QQS94,<"Q1,N1!LQUN-W>?*>[N
M;.Y&\I?ULEQY45L8=>$N"NRAT ;T$A1I(_HI".,L>^5)9MRJ/(_+M+6<=)+_
MV'W, DTE1##W+E? 1JW0ZYJ) BQB[2UCC2_#@#VZ QJ!Q1ESI^Q2?&'^.VB,
M@(QP0L?<7(?_S,L1' -NY>-!(HQT[<!$4".O;J#'EI28@ KDV\M7QP8Y,BOU
ML%A\N[SN'LX%^Z1[*9F=4;,2.E+(8?E%/UJE945L'VHDER5$4(D2(2 <6-'>
M%,2F>XP=H.$BMU4B4T?7?C[O$(>Y"]E7HPP+%J=J#"(=#4$FN HS=]9.Y!SO
M.I@UFC#;Y*EK69+)XN.?I()+BY"K#$AJ]HB."_ERR'"88]>J/4T(*L*,CL#L
M.J,G4R<K @Q(9U/L0"#J<<2&4IW=E!D/0ZK[*2R2.D%!6$1W71R]W04IUX^+
M0)?5Y(-XS)/.P$$65(1YKUL/?G8+K55%'RTG,!='F.?);AV_)_:B[V:8 !\D
M. JX6UJ84A Q(IY8DC#"Q;7SGW'CYV_1$(M/UJ@(XAYP5XL:0L$5+'@7>X(A
M66Q,Y4*;Q6OW[HN#VPB:P<#1+GX*LDRL5\,P#"V'B_:NO01G$,T2".0:MRB>
MWYD\=;*,M#)^!^OPJ*+#X:]YGHA))9LL\5"/OT*1=%=Z>>8'M;FKLG!1?.CJ
ML:&KW2<)7;7;/G3E0U>;&;IZA[G(T]-Z</[^EU<7P>G;U^<79T?O3\_?/CX8
MLK<AP9"@60_>@*T[Y$" 0I-WR1['=2R"/L=$TS67)1Q05<(!Z<5?PZ1$*/,6
M?XA#4FXPMYN)F]<;AMCU)ZVC9 +PJ"KMW97D^&5@"Y49ST4 )0).5A*'M> R
MQ!E6A4KQZP3KH?3TUNE!&;I210SD^34M>M2%!1I$ Z% <BX1_38'37L=7(.7
MHI)ABA=GX5B!B=S+P6CKU6L!9J"&=<X^G?5^"R=+7$T/)2ESD\4T64/#6&G\
M"STY%&>]H8%#RT1%,4DX8O 8GE\;RG $+C7!^IXREAE1G.C&8F,.)-#L"ML,
M,QPJ [#H+"'!*MA[@^.12J& W(I^J"*VK QBPX6ZBFE0*05;=0K0#._%?%QY
M_VL*F83H,\S9#1W%^1"GZ7%.WID'<1VG0^,#72K9PV:S%C1;S\+GSUK:3M,&
M&EQ39ER=(X43S<-V6P^/D??"5HG[GSUM.M[Q4C-[@:-DYV.&8"LL(2+BR-5P
M%(I-C!]S#2S'%="750P@C'8B I[BO8B0"GP:YUN-(V61G%W<9QT* %\:SIB:
MY!(R8"QI?36<1/R;7X;Y7*"-!L"+-(JS@HYLY\[98R0_T&#.-&Z96,+L9.YL
MI=U%\P3P)6%'P \6])8-E*W-75W[(U.FQ8D ;6(BII6%EB,OH;2P-T#I@!D+
M$&(<[>'0ARX,UU,C=)B(I#%&((@[XWY?BQ/-<_#=W_XWOGV1I,GK3+:P!%:_
M0,.HS*,M/=>(/HCW0.:W>]V#;G30[G2:C8/#3G.O<Q#N[8=1O[?;_<\)>F*-
M9J.Y3?_8:S>V*%@T@E/WSZWMW:V  VIPK]OB15*.HK20[[=(^N%3MZ_"</SB
MG4 \ODXS4KR7YJWSK2 '*0?7[FVQ(1*U_V_2/4FOW[0NKC^VS\KHTZOK/_]U
M^.E\=+I[]NGUX./[T]L_\;]??F^>?;F(ST]^WSW_XVSR]OWP\UGKUT]O6Q]N
MWK3?#C]^&<?G<.W'/UY-SO[X"/\]:[Q]?];X^.FJ<?Y^^.GLTX?=/T_>QA^_
M1,.SUP>W9U\^7O^9_#KX\\MX=-;ZO?WQ2Z_SY_M7K8^CC_";WV\_?OIS>/;^
MPY>WH[,O;T].=]]^ZNU^C \;?_Y[T.B-_B\)_S@LST<?O_QY$GUZ^V4 U_X9
M__GI(GY[\CI^._IP"\]N??QRUCC[]+GU]LLP_O>7J\G;$_CD2V]R]OZH<_[^
MU7_"9M@_/.QTMW?!'-L&,VQON]MN];8/.U&CV=UK'$:JN?7381W\G^I&_P02
M<#@T [2NPQR'BWQ*,X&4J<+;$U91=^)JXK_G[GRR,,MBGBZ-WG519HF4B""N
M8<BX0=B$((/87;5D-9(KLZ9U/H;@=#&VC@FKNW6_/2F$UFQGM*!G/0RBM%?2
M<#0CNM@LH=CGM=;E_-D87B-&T"4=%D0YS4?6>0IB8(_ABJ#5T7/1"+"*2],8
M7 GKS%@SI,%5AC4[3(U^JM9HSFTI:C90(>G1',5 B58,#50KKTI8QF9'YS;8
M/-$8^+K/(E,C6&_ZN7-;43P4I.:B&YH>QV&1V;V5(* N6)7X2U.;@LPP$? )
MWHE$6S@])0I7"#=R'@[B5^1<#S? S6@>U2G_'[SFB5OK%PN](]%HL-RJYU!/
MA$9,L#E==%5QD.;N@%<::FRAV!QL5HZTN7/HC5D"9@.<EFQBAPW=:,A-50\^
MIF60#PBZ#5A>(>SLQ!Y;ML*)TIEQVK-X.A+N/*(^K.DAOLW&]F\R1>^KIOQR
M\/!W<,D*0HF;?<SO1@+\Q5=)_/2,0##Y[.)]%C^JV70E&15(W/E =\\6#=TU
M^Z''Y26I[HB4C.S9["#;$UMJ2'6B(#,G..,;))(-IA_K'ARZYL)6_YW;ZC^=
MRD7A;AL<--ZWKNHU/1 .I'$^S7\R%&]:UH41PD)/=PII;ES8"#2WE4A[6((9
M7Z2]S]Q)7@^.9 (F!HCG'R#NDN+>/=@N'DZ"(XISKBCGLR-:E1)["KL.S8L@
M=AQYIMS05WF->Z(?'!S^!,<M[D]6ST9_: _K'S3R1<Y_X(QYE$FM:AS3:%(W
MG8\C8?,QCHO'>G$*$.<ZA!A>D> #KP>-(_?0V%F,+*&(N>"ZK+2EL+@OC*#.
M_JV#28Z[R!>S='  A<F*$C5<9G.F3V^@SZ7[Q6R;#1LKB*TI>\*>=#Z.,QZ<
M!,8:PXZ&I<GO8_B#XTU)RH.3,CAWUW%6PKFU.]8%3X5D_S%X_2$5I5%:%C9%
M3\D-"_M@='Z'S$9FFC%L:Q];9U$'T9@\/5RX.D.8A-2'A,JW*23C,AZ555/G
M^HWDXH*T>GCM) H4-0CAY91'LV341%8'"6O(V9Q:2!*V]O-QBE,W6 RBN!B$
MT112/O,=K!!&G-A,EW8V_J.&4M(!IM:E#RKKJ6F5@D+,);<"/XL7+)P[[*04
M[QEO')B\XD-F%<\9A#XV,XMYGJ0, 9"Y% YT=V7!T49F[9%/JP^G ,($-NV8
M="RYF 18NT7ZBK:DAZ930KH ;2Y$9Q;XMB+L:<!MEF,]9U9DEAL)E)LA8]A4
M(W=')T/3 _="E4>PXZ<.2T@D0K^;[:]C[M%Q7!QL1#T)>=A75R6%R7#6A\#]
MPQFKDM?GI0MU]52I 4PT6\]A"L,,/8G_4<DMHY^&(]YF<)/(K3.HN?U8#;GD
M1+<TX"4"-P['GR8,\)T) B:>,5O!^]V.%+SED$'457>;<?5 J\,:9,P*X2BO
MW%)S,'AZ/5VG2J_,#C;! C, -('X\F[KX%ZB5(354D[^'%'V(F,#4EL9BB.]
M_B,2C:9"SUTJVBUDZ1&%\;=Y<!L]& .;;#,NW!UI&@T_4Q32&0,ZQI':I8:8
M#&BHDYUA0P]5M$PX*AW,'3GJO^@)S'32[$TP*2&2J<95*OP.F1+K)Y12'T(]
M17<<2!G$7>)IVFV57(57(EOMS'"]I=I6PDB]F> M ,754_XV=8I:L#JIJ^<,
M2C@]5T(;'CXT&'2()<S=0IE</![206-*FDP=ILI8Z30S_6OB[$>\T=/[:0'N
M(T6G"\>I:DQ]\[IS?NC:&UW'(N&R-L1NJ+"ZR\["\?J%+6A23XU%DB[B( -A
M[#Z>!R46BL$A]+05 HDP[4'BWCW /I^QAUPO;R +"M=IA&X25SC4:&(8!L,G
M2>@D93CUA;\ZYMGG9D1:Q;RC"'@X8O7#418.['",95<'=[!G;(ORD;OUX)PD
MWJEU.K<XXF:] J<[RQ;J<?@7'N6&BJ>I VT%8ES?JJ9GE&@V)S3Q.-=M8$[K
MJ)XJ3C5\=Q\$$]TS!T!Z1?ME1J]&5 I'\Q;;]14+:(9N7Q_SR/J8/8^5Z2M=
MG@(K<QW]0]V+;@(A9<*H&Q(4,II#M)X>&4BV%8_Q0Y'-3@99B^Z/JIVJH,M'
M:*[0[V(U!6JA[6,<@(;.1>P$ZC&3)W:A'6X6B1,#AC/H)(X/B?;.PAMG(CRJ
M*W@DQNLH.2B11Y#G&B.*Z4>,)S3:;AZY)F0WT)K4YK^O]D6Q08['+49<6([N
M377HH5'$QK7]K":8M^(Y<&P=@&Y!:P+=!KBE4B:N9>:V49([IB@?5S [%,M*
MBE\VQX$S)I:U\4[[BPTQK1FY$4V<DV(09]$V8YZ8H:7.X,<LK]G/S?RO-+L*
M$QDN*6Z67AC02"HGN\AYMZG7LHSI^L12M4'_AI6+*-6<:S1NK-R6J2I@93BP
MD^B5)U0"H>L\9N=?2L/U_&EP<]TC'AABW+0JPY+E*]MCUXJ" )57RA>\4XTR
MZSV&&@]D"F=J.=$^H3+5F@=MTGP6<"_,@A= ,-/.4R1[%+;KD]TMR&496ZI=
MQ)^"8T8E'EU%820B.;E*D7H>ZT9G!0PL'I;I<%,].(+3I0,.6G@8HZD2/)*6
M 6V1:JO=G#2G[]&NJ][ >S@"KZ)4KB0.34QAP8)Q*%QX< &'Z%>O\+*>B&WY
M@U>4;RBVNBF8GC;!@=L2;1\BWBG9X<X8=)-694M50YD8PE1E+5SN 2[-.'-M
MPZBX?::^!N_V2-?B*8+G/_UO-]OYZ=%)TTYK Y*FY NUZL&')*,B-4I>7Y+7
M"H?AU5\E<HE3&X9;]H&/HQ1R;DP_)TZ??'P*O;,) (BZ^?Y$]4.R&S[@B+-+
ME6#TQ'+!QF36OW++-P()$+>\@[.!$ZQ')"/8@5?8H*TN'$2MQV_Z[B9 Q$D$
MC(-C,V&PS4UCGB?SPH(U-YA6"UZG\.Q;_=_@W2"$=>E1I3J::5RKCK\88L0N
MRS44(]JO1<I6S3M,NXW)_I0(VR_ID'H>@M/36O#F'0?@(\10Y,IPM(*NG("B
MW+QFHIH,E18SBO&1#G5RD49!/N!T+(^^_1=[=?!>7!++P5$N7SG4[S\NLQSQ
M5OCA8"CK>.R1B7.^3>M!$[]_^*.#9TB[%*:8.^I1TYPMM0\2>UL#9.F(9; U
MH++>R9:NY::J#KU<!$99CF@.VW2PLQI++O33[GL'R8,8QX&JU&.+&LK@G/H9
M&CUOI,P%G/_"4ENW>$BF$4ZA5N(N !N8D0>7&-CG[PWJ0A5HTX[R'6+E*:P,
M_DVNU=1#A:I8E\$OIFL.46Z<>825DB9W4*FT3F@^&OL >OUUY12F_BFCT6QM
M4YY8P_O%NG8_GT:1<1C"3!2E]E%*-?UMK][0Q;?F*4N^$3+,WP[WE[Z!F\ON
M,*_JXG.*2S-Z>%JEV9E%A?T)3J457C;MFBZ*DVCO]'@*K:":G;=Q,[/>2V;F
MZ\'**_?6<G(]J/S?ZH^>X"8&3'YR1(.KXL;N('++2U&JZ]"X34SRAS*[G#<:
MF.LOQ,?2W=M4_I 4<8;F7!=!'?J*J_2F6;5&,G;L5*PCAD91<+,$77U?Q2**
MHE>WE R&O^NM.7QUM\/M,TQ+99CVGZ0#>]<"GWZ+O)2^%EZSMPU+C!'9%XQJ
M,_GZ%?99JU7*6DUKB6^SY]_!%=K3$\]%C&V.V_N^,AA3-^QP"0G5K-=X,$,&
M?LB W0/K)9.1B=:.@9"^4P_<,_JZ(FM7=1D78=R)>L.Y";?+\,:N=8Y%%8G6
M*NB<Z=>D.C1\Q6$XSM4+_0\$5!L/P\F+."%BZ$<OKU5&/JBL)#Q&Q._A87V_
ML4\2N,C@_R-]?Y'.=9;..T4T^^5^_:#56?SUG;]MU)MW?;G;;C_RMW<^M=.L
M=QJ/_?%_A^3U6^1FL[[7WELKDM=OD9'B9==XATXVGVX0$RB!_KG5W@JR](;_
MW=JRQAP/MD,YU!K?FD%W(HCPHR7EJR.W<4K>/ E4G:+G###,6'[.RO9[I._2
M4KPJ_)=\(RO*WY88%S"R7#; 7=J'Z:)[UHH7?\GE\M0\@)KF[K?E?+%8-H'W
M3Q-P%,9FO"D8<1(66.(8:),D2=DA6N5+5X$MVYXKE^3*U^B'5#APD;+SG+#9
MG*!U\XF-AZZ=@O[.>RPN)#G2XR*@C$R@%W[M& !C"=][QY]@!3T[?!MV. %#
MQ;.#9P=AAS5UV;S6OWM;?P$?! L3'F("?M<8Q_<[19WOL-SM>M,?H6^\W2O<
MH-=8QU3G/417$H^*G0B3_QP4Q?C%SL[-S4T=+JM?I=<[1UEO@.WL.RJZ"K.=
M*"S"G>;NWEZCT]F!MVCNM0Y:!XWF ?Q[KW.P(W=L-^N#8K3UT_SJ,>0C&F-,
M650;:>&"RIE<Z@]]\E;!8/D>HO9@^S<O:G^D#6_NM YW$.W;;_N/M.WK:%*M
MI--\C]6OS0&LI5BMU?24><H\99XR3]F/0-DJ!:?6T%AJK9VQM(([ZD-,:QUB
M:C8Z>[N'K49C]["YV]HI1N U[AZV]Z/F?]1M>[MU1ZCIYPG.-?%!I:6<S0>1
MO$)2$@OJO9C<O'W=W6DV=[#[TF_NYFWN.IHV*YMZ_AX;ME*T:,Y9/@N^"KZ0
MIVQ=I=5*T3*'^5=R_SQEGC)/F:?,1PV_MS]<;_YC[8SK%=Q3'S=<G;BANFTV
MFKVRB,/M8=Q#5-SP*E,<^GO#'[AX9"Z"FXQ)-3A=71[RVE7%#<["6 !>]Z:(
MZCRH%1]:'<+^[)??G@=O>$Q1);BX$L ,<]=]ZZ=@32.@WNM>%5J6=CP\ ZW.
MIJT2+9Z!/ /]B STG2M&UX['_KV2_4SK&JQ$8$E_1)Z$8.\!KI8'V JUBY>D
MS2(-LYY3_/&UX-O::V3<\V!WRE\,1VER%9RI9)A6O4&&.;_#C7PL0/IR^.B+
MX-'7N>K%4^.I\=2L@8;]48W054B2>,H\99XR3YFG[,>E;%5B)6NI\=O--6Q&
M7L$M]5&2U8F2C))ANHUQB\9>NW&K;F_;3<%BL; K,COG>!"K?O#J5F%:_5H%
MYS@$7&5!IOXJXTQ@;\NAXH$/S7:XW>P\"Y_SGVE&WP7-W8@_]N$&3XVGQE/C
MPPT^W. I\Y1YRCQEGK(-H\R'&[XNW.#K,GRX8=V(?FBXH75GN.%UG(1)+PZ'
M/MS@J?'4>&I664_Y<(,W@CUEGC)/F:?,4^;##6NE\=NM>O,?'@? !QS6C>@'
M!AQ:3UK?T)T?<.@^IV:,2]6CNS?;NPU^1#@&#R'8:^-?[^,"?W& _\:FC@\)
M @0$E]A[D@?'::2"9_#MA_IE_;@>X'/V7^*=?###4^.I\=3X8(8/9GC*/&6>
M,D^9IVS3*//!C*\+9K1\,,,',]:.Z(<&,YZT>J+[/)B)8_ %3C!#_\)'-#PU
MGAI/S?HH0A_1\':VI\Q3YBGSE'G*?$1CK31^L]&LG[Z]]"&-C=K5?_]\\28X
M3?("W'05G*2]DF FM\E[CO7GD?X\2H& )"V"<#Q68097T(6G:->&/:I:. F+
M$/Q^<,.[JA>6.=RFR -Z3A%>Y4&8J4"-NBI"L,N;N!B8>V#\@2_4SUL[9O/4
M>&H\-6L@P+TK[@U$3YFGS%/F*?.4>5=\K30^NN*7Q[^LG7?D=_5>5_Q]>)LF
MZ6@2O+HM5))C,OVR-U"CT/CF];7;=D^-I\93LP:BU#O%WE3SE'G*/&6>,D^9
M=XK72N.C4WQ\]&;MO"._JX]QBH_#8:\<<K7YFSCYW USY5UD3XVGQE/C763O
M(GO*/&6>,D^9IVRS*/,N\E>ZR">O7J^==^1W]3$N\HGJQTGL/61/C:?&4^,]
M9.\A>\H\99XR3YFG;(,I\Q[R5WK(;XY^7COOR._J8SSD-V%7#;US[*GQU'AJ
MO'/LG6-/F:?,4^8I\Y1M*&7>.?Y*Y_C=Q:NU\X[\KC[&.7Z7J1RL55]B[:GQ
MU'AJO(_\-#[R3A%VA^HGF3$ _V/6,LVI6.=%IK"OY5J]O(FC8L #&\1VZK3J
M^[O\EO-^&7;S=%@6ZJ6L?\.]1?4WL^M=&?R0EZ-1F$VFEW/)%Z^NUC>98M&B
M-^H<3(UL</YWD%DNO5+;W4R%G[?#/KSJBW!X$T[RK9W*BHSB9'MJF1>NWK=9
MJV\U\:.UCF-*[B-:)I+\3]P];#7#L-7L-\->9[?=Z1YT#@][K=W#J-WM[:O&
M?_:W?GJ/9PYG@O3@D<#N^9QI']/G$?;T"E@"11OR@OPI)TL.(9UELW9I!M3A
MN@W#<:Y>Z'^\C.)\/ PG+V)".-VF'\T3;\QNAX?U_<8^<9PX*G)_X<8Z<Z.6
MRI4O]^L'K<[BK^_\;:/>O.O+W7;[D;^]\ZF=9KW3>.R/_SLDK]\B-YOUO?;>
M6I&\?HN,%"^[QCY:[BGSE'G*/&6>LA6FS$?+ORI:WEF[&*G?T;MV]/U P:+!
MFP0844!W\DPEPS2 S[-PK$IXP3PX37KUO^?![V68%>"K3H(+-4ZS(DB3X'6:
MC8)F8_OWH)]F-//B+[XJ4 D.P_BU3%30;M0"G+!9PXM&88'C*^.D,AWC69ST
MAJ4S/N,5C^F$>S<#^$78&V"(/G^^=OSGJ?'4>&HV@YJ[H]WTN!C$7E*\V&X>
M.'?B6Q_8D!LJ(Y+W*QZ,_L_C_J\:AGS@$JWXDOP/SVH^32)@)9S #+<$U4FC
MI# 4B_%SG/C<2T=CE>1AD6:38#P,D_I7K<J:,<X_>)7>@9D0ITG.LZOC/)#I
MV\$@O,9A6BH)TE&L#8*PUTNSB*9SH140G!9J%.PUFL^ZSY\U&\^?Q=?/\487
MZDK#I%UN__9C+:NL*YEM*,WT>/)<C"18R##7QA-?VV[5F[#X84'K.X*WF_!>
M+++G9!@Y&G4XV Q'HT4*&#P*^O%0+#0R]2Y5K\SB(H87Q%GFKVY[@S !*_(X
M'8WBG"HN\'-]DR*%'8=]ADT>8_J#!Z9GJJ\RA7L>)W %4@>/@5V:;XSJT]>K
M<^9DFI C/'W]H'G8;M=P*<(1&:*U()VYU-!K?].I_N9FH. W&1SQ"+D5K%>%
M]Z&,&]TM@K<PO'W_>M:".,M4/E8\5@Y^B*][I1)XOZ&S,KAR(#&N2K3)4:B$
MP IT1/*R-Y#U6<SX/NWZB+3KX>*T*[YL'/USZ_Z\7'-W?^M;)FM].G:3TK&S
M)V=5U='^_$-S":2'10DB;:$L6M4W6B &WI597H8)*2L4\)GZJXPSLN[(B+E$
MT0W2N=E&1=#<?18]9_F_A&;A^UW%.0C&!$V@/(A*T!8T431B'9*QYF!5F</R
MPA?P.!PWVE6#<-A'E8DW(C[E"^C.F2I1?=(-P[(8I!F\=K181ZS9OIR@N? B
M."JORESLFCT.*@7+O.+:5#MT]NL'NW?D<N_.B=_U9:M^T#[X%C?NM.OMQJ'/
M$O_(E-VSK:NP8'O?/R/P((*73 KL?X>DP((4P!*A=RTHDY2MOH><^<[*GBQ/
MV9J>>9\%7.[ _SQYL<3A7FNY^3V6<2??"4["ZS@*3M+1EW"8?XX?TE"^6B=F
MM:CYWKPGK@"Y1^,BR-,A[*IFB.7>Y@G"-=_*IVJ(3S6?5;4?]=^FGA[\(BY@
M8WK+O,_Q(%9]\+W!#Z?PZGF_'_=4-A6$\0=QK0[BMU$"LZSU#=7"LW=9G/3B
M<3B<9<[GCT$<\?;H>E&V5N+&6\K>4OXNEO)1$F5PS\LP_NRMY#4[NS^0E3R/
M3=?:0N;LR>LX"<$H"8?\IY@C5*_Q/E-A7F;><E[OP[E9EK/AU\!E5?O]4:\'
M-RRP;FBQ:;VR0 4KGGW=;2PNCMGIIM$$_C,H1L.?_A]02P,$%     @ L3L&
M4:,T,)FZ$@  ];T  !$   !M;FQO+3(P,C P-C,P+GAS9.U=;7?JN+7^/K_"
MY<MMURHG&,A)<M;D=!%P$EJ"*9 S[:=9PA:@>XQ%)3LO_?5W2[;!Q%C8#M3<
M0M=T)MC:CUX>:6MK:TO^]2]O"T=[P8P3ZMY6]"^UBH9=B]K$G=U6GL?WU>O*
M7[[_\LNO?ZA6_W$W[&D=:OD+['I:FV'D85M[)=Y<^\W&_*<V972A_4;93_*"
MJM7O4JA-E^^,S.:>5J_5:Q_?LF_UJZ_-FQN,JM;5E5UM7MM6=7(YG51KEW8-
M7NBH<?GUS[-OC5KS$EU=7E?K5\UK2-:85B>3&ZL*Z6LW5_5+NW%Y*4'?^#=N
MS?$":5 QEW][X[>5N><MOUU<O+Z^?GEM?*%L=E&OU?2+?SSU1C)I)4SK$/?G
M1NJW"7.B](T+\7J".(Z2+UR';B2'=G&H-\<,+;'O$8M_L>CB0M2[]K51B\0$
M*%%D0USN(==:9>-2U_47VP5LCUUX[TM\ 8FJD HS8JWD=@M% LCS&)GX'KZG
M;-'!4^0[WFW%=__E(X=,";:A4SA8T+Z1(/;:0VR&O3Y:8+Y$%L[3+-]_T31!
M&UDL*?,T-X$Q17PB"\Z9!V+Z3;6F5QMZ10N([E$+>;+WANEE11-"%]CQN/A5
M74-\>>-VY2)[ 7Q>G2&TS%^(N&!0D/!)_L+$>K%^<W-S\2:Z96HQDMU+IJ^*
M/ZMZ/5^V:?TT>][PJQK)[:,,ZR&9KPR1W"?+L'WX92E*7+(?"(JRW(BRZ%\_
M5Y9BY2A:" G%L?5E1E\N;$QV#@Z>)B3^2!T/R'6I)U'$D_#9<DG<*0T>P"/!
MZK>(VB&>1@HWH=>WC!_YGV^(68PZ.P;;Q9+1)68>P3P^)TB .</3VXJ8&:J1
M@OO=0LX7*$F4))'!9O\4KR] Q/(=6=W>NCX1@B#LML*!$@<'+73,U;?Q-&_U
M082XY+^B]@Z:Y*T]B&#G_WW%EPSGK3B(<+ QBG1[(3^&]QJQ;RMM"@9M11//
MGH?=#+:(S#V0BF CX'57_%X#HQ'^T:IK([BJ2:E?+SZF_8#B<VR;[G?Y]\=:
MAL)A$H7@!Z6066YS-&T5"Q]&K:AJ6[/?,?HCHP-_C,Q>M],:&YV[5J_5;QNC
M1\,8C_(W_&Y(!2NZ9*4.5(R@37%$2X2IQ4&U$%4+8,^TQ=IX@!A4;XZ!&^0<
M@,--?#6A0B44(53[XT8N?SIU@D=C^/>3T1^/S'MS8 Q;XRZ\W0^Y*=AJ8ANU
M6C,;L6MXS;S7UAF<*5TW>]M\&@R-1TC3_6'TS-$!F$UFH2:X6:M=%B%X(Q]-
M9'0F.L;"8ZO_8(RZ_='8;/_MT>QUC.'(^/MS=_S/ U"NR$Q-_B58?H7(#W+4
MNGTMGN?_:$&NYYZ0B9P#3."%<E;WD:^UVM4!^LAYYE<PUQH]WO?,WPXQ/:R@
MU:Q?U6K7A5@'?$UF<$*$]EOCYZ'Q*8MM"X2"H+I>T_5@84NXY5#N,PP_ I"3
M-;^2;=C!'B(.WP,;$9**E&8-_LE$BO;'$.^4U-ZH^]#OWG?;K?ZXU6Z;S_UQ
MM_\P #W2[AKY!XP:33UV&KIT/VS0%,/3UH!:A'CF*6B' 76(17#^(94-5<5;
MO=:L)X?7#M[ S BQST,M;)(QFCC[)C#$5-'7J%TV"M 7()_)"QNDZ(R6"50]
MN7UMYM::)SG/W3W#FLL8C=KFTUVW+R?\W'1MPU#/:5>Z],!NL!.A:#&8TR:B
MH.Y+1U)KO.M&<LAL(^44U=R6-NTCQJ!4+[BHELN"J59R-\ULPT@8]A'R6<L%
M;=*F+B<V9K)D8X9</L6,89NX3YC-,-LCJUFS4I*MUYIR<R,+V1L9:K$<->)J
M09[G;A"TUL!GUAQQ/&#$PBW'"6.)]LC^CAS4I.M-N>&1A?0H'TUFI*US.E,=
MM-$#I?8K<9P]<OL14DVF,$LSDAD!G[D+FJ0[&':0:[='PSVREP15\]=HRLV%
M+/P): VP-0 _<Q@J0D9%?#?:IV[] *GFK]F4VP29E"FCFD0^2?*&Q@^C_VP,
MC;8)*^9":\(M$,HEH7ZI)\V;$$2+H9PT"T5'3CJ2>L!\A25&!DY.<HS<M[K#
M'ZW>L_%DM$;/0[FIF)N8K2#J<7*E)RU" :-)'"T&=.)D%/2>**"4[A/]NI%<
MC&\GYA0=*-N:M<4Y]CA823V")L0A(OC["2/1=C;R[A%A/Y#C%_:O["%+M7J\
M@45Y1L:K6I"SM EC>6M1YAKR-)&])O,_:]2PX3[M9,L$JJ2Y7H-E>&::3]O/
M]M0:_LT8M^YZQLAH TOC(IOE6T&4DR),B\F5]1I&6^.<.!<%YT0%E').K-<;
M2:-^*R^G."5N:]4GQ'Z"VH"F&&'+9W*.**KZ\N*KM6"CJ2=VA[93"<]7N6CK
M;,X*,6R@E971IN*HLOW *.?/+L/((?_&]B-UQ/4(#XBXG$[7[6>^NMC>9U_8
M1SG4?:;9U!,F<5J?61L_?]9$@:2E)(NDK<NDA8729*DT.HWW+UFP<R\+F_33
MEE,F4#7_ETT]H_H_=<.IV_\!]J,YS'_@8BVI-I&^ZDGG]4KV%%NZH"WT45YM
M %TUDMZ:%<(I&CVKRA=52PD M0JZ;NHJ DY0U?3,_L/8&#YUC+O\#LL-8;7"
MN=&3NRU"O"KD-0%PHHW>%J$?'IHQ+ ^K%!T(&2"50P.69GIBT;Q)D @ED<C:
M"OKDA\QOPDYQO<*K,A66FB^]J2=F\ 1?$>1)\C1Z; V-=FO0';=Z^8..X\)*
MU=:HZ\E],2FNA?(GVN9%@_63$$JK"OZ7=/=MM/\I6E;Q5OSTXD\)IE93L.A/
MS/N;Y)SZ8B_>N.92@(H=J>'H^>%3,TM&6#5[L&17JS;X'8)+#PW :P_G&4>T
MC/!@O0@'%N+<7P1MM \N5;AJ,K\VZXD-RH]D2K^;A-=B^"=/IKBZU?8=3*>C
M.6)8W!5FM^EBB6%0B>SV06S6/-0D7S7KR8-J'TB.<I(>4Y%756:FQ7,[2<K#
M4\[]AY[1&AFYV?P@KK8:K_5DN, *0),()]OR!2W'K2!JV_&FD?2#?F#A%*W'
MS98TE_+PB#MS8-+!%N7%K9+,P$HMUZPUZXGMQX^T"<LDA-<DOB8S."LVXPEY
MX2X9G?9$R\1"D/9#;)8<U SKS7IBLS#)\#H?,9?)G#;BJ<Y<9V#B=_WP;$,>
M9[X/PW?;?'KJCN4M1JV^N#Q)M)C1+W0SB0I+:<Z U9D,BXNA:0"G;>"=&?K,
MG0@9(-7CK=&L)S;CE7R=Y-@:/=^):^>@1<0YAP+7#2< U*.HJ2?#JM806H!Q
MPNU?>)V=@J,>(Y?->F*W.,'&?_NX^/5B\^,'P>^-#R2(SR.$GVR1K(F[V7]O
MP4\;VRW7'F(NKN*S@\W#5K1W.&;8M>9ZCR+W"2\FXA)U-.$>0Y9W6_&8CROR
M Q"WE2)(+G$<L6J+D.1W<+[!>H!0>RRO=K?]X$!\1>,^9$L\7_QZ8-1?WE:"
MY,3#BXH6W 0??!CGFTT7B+A=>"%0UE^,2%1_B,5WCG!PO%[>X_0^QF_>G4.M
MG_&*3I'#5S55"QVJ3EZ4189JR1"\ :,6QC:_9W31Y=P7'U@QIVVZ6%!WY*DJ
MF%5\=U6##[MXT:L)<@0,- &>$"]C_8,GD"L,8/:>H?;&8NG0=XQE*5<G^9U=
M'7BG6.F]U0#(!8PL<PKDV+[E#3$8VNX0'CVA-[+P%ZF49A'-06>VZD'=0-J"
M.F2H7.3N-*=W/B<NYKQE_<LG7"K#S=LX1"%W#]/B@,<PA&4O%.,.VQU83+FS
M@<Q>.H)Y&#!@O$$?=6<XO0ER@>R]VL$3+G/+4F61\$[XN ?H7;QJB0+.9"HY
M#JE-IB2X'T.$%UMTYHH 8Q%YS(?!3_$NJ&1ZH^PYFP,U6R24H>&B_@W*>4)<
M*26[.DR\,7T]%)_<@S0NS%XP.X]IEJE@']!Y&NC#/&%)$^)@$X5"*8(55E2?
M1J+EZM,AME\IM=O$>V^+;_)1YA*DG@&5(N7/?M,IMD3\0:2QAB*W=(92DA]H
MN"YAX9&A$C_PG%@.ECZQ </+0 /MT%AJH?+U3]Q4C!1&8!VG5DDE\@E]<5"[
M\AX4H&L1Y'1=6++B/O92J[<MZ=&JP9;]OS[WQ#,^IB-_N0P2( =(FHK[5 +E
MC\7"SG<\;D[#+1NPH5);X'.@1]M6H7)OS6!5.P-EWT9\?A=D_01JS(/_MZ8>
M9O<V:BV7C+Z([RZD-%$AK*-MF0Z>>.++9ZZ(*VJ%-4Z;:5(2'\H"]83MFZ$.
M,;,%!BX3^K;KMM&20+\-C&;HK9B]8/N>LGO?$SH_7!JGLOPIS'V;$#DM\D C
M]] K]XG'[Z#PUMR<WA,P> CTBHXOSQ9.[\R.VK#(CU.ZM;$Z:!E<]B 5V<>@
MREV]/!]&Z9U_TUW7]P43YC1PV^%T3;]3[C"=&!0DADZ5R1(6;6#!PJ0+"Y3U
MI"1.H09&U:KPZ;7,!W*DGK'/+'T/LIX^7F//G$*9,>,MU^[ :M?R*.-J):>2
M*%V=M6Q;.BV0,Z3OR/'>A]C"9.D]+ZEK6M"'Q6@5_EU8P .B\:(<# 71CI7K
M/G6%[15S#ZY]AJL7#*<OT+(#'&L3[#37Y87$4'/I.^7*OI$;Z6AMVH1JB^LR
MF.(P6W!IU 4UC$?F9D\I&@'&CX,X!PELKQLPN\K]3Y?K6+OQ%G=EVD7>@;>2
MRV8(QR<SX#_>>^L5,3N]@^\UCZ/M^FW!NSD--PEV6;IIJ<NV:3<7'GD6*4<S
M<S\OIXRZWN9$F]HY4U(?ZWB]IVA!WM2\;*8IG8_8>OX'%6'+P>9'L.P98"9U
M<Q9O@$JZ["63R<@,=)LS6B(+[S![MR4MG:65 ]9X$Q.:8OFZ)>6QCI:=IE7+
MLD"(A9.[[&5W'P\H%3?<LJ$?[8PFA]:<.C!/]T2H$E/WZ]3DY?=MRC"9N:M]
M+<)_]@AV3;<]Q]9/T"E %/5=#]+=(??G@X_$I(PQEV<^I9_Q$=LP:&<Q4UPQ
M0 Z477$?R6'[R;8M;WD/;+2* WO9\<6-9J8(8^S:( T&LJA*%X:+.R/P5R"1
M:UN]<!Y'ZFSJ<H:P0YY\ST?.O>_:.^RO]/2ECSBPX\5<#<^DUMLP]X>05EX'
M+$3$%7<]RA7.TOQ(1ZM0.U"$%[%O)5;Q,,K_B5'ZAN_VQ$?:=>^1)<ZJO$N;
MYMF54P#BZ59=:OK]]USHMC OH4STP .[0UZ@@[GVF$:WS#S*.8UW?+QZ%G<*
M*!@LB'>LYI3)0,%"TF 7;I>5NRUMZ8HI2X ?-]XPLPA7^"_SPI0=*3C$,\(]
M#-K-G$ZQ*/"NP*:T]*4S^&%"D,O!H-W7SJ.LLTF*\&$6DQD#GEKUFGZS._@Z
MD:QT8CK4\N5NEFL;T,K>>]>5JR!IJ^T*;\@D6[9S+.@IP; 7.S=Q;V4BN!,T
MPFJ#4^V7+H98MDJ)MJVE)[.U8TFT/7'93IMDP'ML>1%]G*YP\'P&K&.(F^\0
MT?\GOD?9^)6JE<[VM*5K'G&^R/5Q+-1\5=!@>\'&XK";6'.+S6;QT<A782ZI
M@A<*(QZK\1;CSG1WN"BWIRV=YYTGYCYYX.YH*AH?9W,H7/91&4]=>C76.K'K
MROAE+D/W$+/F(N8#QIA#EW+:WW#E0"6H/YMOT:.Y=?&!\CT&O1W%1G9P%".Y
M.H\GCEL*C1)=(?'>QYXY'6*/!*X2X2L2/FJB<+CM"_Y8U:&PGZ^SF=G71V5F
MKSOW.J@AOJ%P]YZ,+Q-[Y\']A=WP%%;ND;3/S(YA^.0(2I"G>_<1W1 "';%_
M<AUD'L;:_]U'S,/,>0\M(D&^0Y3QVSE1CK8U!I1[X9%UZ.*N)[Z\POB<+._>
M!PS'W\@U6K#SE=Y/BL(=Q".:_51<QEL*&GN[[Z!Q5/<=M$?#C-;EMI2E%S]+
MIQM!QL0FD:]V'_TX#;+DOJR*.@4;)K0&Q0FB3P>QJN".U202BKOK0E6E*^X>
MXT'0LDI-OUV@9**[KO!=RVA,3%X4%"83'BLYZPCR#"%&*8E+5T?;C<C8\8<T
M>S*\C%NXAV4TZ+K7<;G?/YXC-TSSP?2D'G+DHP[,.*OS11D"A4LOX;'VQ,B7
M&P3Y[/;YKM*5[>[M$6#&%K'$KAV>)P1+A/J@57C6JXQR81S#.B<,(P#E%EY;
M(R+8Q>:"F]B0V19^D"Y7_BGZC 9E?6^F:?VH3-/ME_0DMC>#S:6=R]>,**5N
MC0[\"8PP6:ALV]@*@=+ID]-(.".LSTK*LCZ[Q./#T3/TQV"#4$;(&'RYS!"!
M612R] ;IBHT6Y 2<171E.XF02;3T"J;&A6[[7O&A8U'WD>?1!J0R8L_P*^AQ
MUL>O?Q5W#[ZK.Y!*HO1^D_'ZGKRW]AQ046_QB09:)PB)"R83Z%5A(+2(G_+9
MDJI.'7P&LNQ0B<UU<F#V$RM</0Q 5UED"=HKUVI[)TK)2_ M?.6\CRH'PG^F
ML\LK8KDUQPOT_9?_ U!+ P04    " "Q.P91D=^I[J@A  !)60$ %0   &UN
M;&\M,C R,# V,S!?8V%L+GAM;.5]:U?;.9+W^_D4V>S;54?W2Y_IV4.(D^8L
M 19(]\XK'UU*B;>-G<<V2=A/_Y2,(=PQMF3^R<R9TXF)D>KR4ZFJ5"K]_3^_
MG0Q??(')=# >_?:2_4)?OH!1'*?!Z.-O+S\<OR7VY7_^XV]_^_N_$?(_KP]W
M7[P9Q],3&,U>;$_ SR"]^#J8?7KQ9X+I7R_R9'SRXL_QY*_!%T_(/^:_M#W^
M?#89?/PT>\$IIS?_=?(K-UHZ!YY$8Q*1-D425 Z$JD3Q'Y@72O_'QU\%E<H;
M90DWTN+71"8AN$CP^]09KI)0:C[H<##ZZ]?RG^"G\ *9&TWG'W][^6DV^_SK
MJU=?OW[]Y5N8#'\93SZ^XI2*5Q???KGX^K=;W_\JYM]FSKE7\W^]_.IT<-<7
M<5CVZG_>[Q[%3W#BR6 TG?E1+!-,![].YS_<'4<_F\O\4;I>W/N-\HE<?(V4
M'Q'&B6"_?)NFE__XVXL7Y^*8C(=P"/E%^?/#X<ZU*5&7P_'L$TS\9SB=#>+T
MES@^>56^^6I[C+A FN=CS,X^PV\OIX.3ST.X^-FG">3?7I[@ *0HEVI!R\S_
M?OZ+K[X3$/TPG@[G_.[BY\6OETG6H 6^S6"4(%V=:%5.]_?>]/:.>F_P+T?[
MNSMOMHY[;UYO[6[M;?>.?N_UCH]6$L/CH]:5T1.YN!1@(>*"C.$X7OO2L.!T
M?"GZH0\PG/^T?SHE'[W_W-^:3F$VW1N/XNED@I:AG[+T)CM%>'29R(1+VD65
M"?6*"XT#!"&NRV[!WQS<V4_#'.&+\1'IS+V"X6QZ\1-2?D(H6P#]W^\CY%RZ
MJS-V,!E_ALGL[&#H1[.M4>K]O]/!YV+[]F#6EU)+IJ@B0)DGTC,@KGQD"926
MRGAM4@LF'R+J.L-7 +4UB2_&DP03M/ O7WR%8H\7QOZ<0C^)MY!VW=0LOO%J
M>GIR,A^3#&9P<O'[Q?)71,5LW$@3YZI'7M;'!GSV@]3[]AE&4T"2]LN:O,4T
M6.$$MY1P80.11BL2C &BM58J.YIH,FU0L@QYR^"%_YAXJ:Z=:LC91R2C0$8?
M=P$W[<,BVOW\ :DLU/5=2*"=01SC-H)^CG+$>Z:1?P6.42Z%"BT \R!5R^!$
M_(@XJ:>+:O#8'?@P& YF YAN+SC,("*@>TPHYT"D0L#ZS!AQW'@>111.^A:8
MN$W*NLQMQ3@^'<VF!_[,AR$<3WR""RY%B Z]>$#>/"-2H*"]*6X^SS1%HX57
ML8G7<#]-7=I/U\3%3>37TD0UW"-!DU-(=[#I(*/FJ"/.EM!/&T&<"VBJLU9!
M9Q6L;N-.WD=1E[;-^K"HH(5JH.AAF#4^ PSIAB77< =9//M,.6[<FB%MT@M&
M0@!/M W9:FIMD*P%.!ZEK$M[9F60U-5*(\?J@JJS"YI4MH&%Y$A.&O?P&"QB
MUQOB'0N6.Y"B3<#V,%G+P$3^F#"IJ(]Z&"EQP!U\&BH \2H)#5HBGQ+YU%$4
M/IT!@9XD:^)BW4//,JA0/R@J*FB@A;-]-:(0P )3",JL#)&.*6(E,NH"YSXI
M%6-J[6_72V(=G7[^/(22*_'##R.8F^[RZ36,( ]FTR/X@LMT%.'B!WUAJ4J,
M192_PIT>=W?D'*61%;.XY=-@:!-#^61*.^J>KXBDFPNEK>):[[I7A."-T2%E
M2U)R2!;:"!+ HN<8G;4NQNAB$__]4<HZZL=7PD]=Q=0SN>/1QV.8G+R!,+M"
MBS6")85Z](%3I"5*$A*UA*D8DG(2HG5-;.Z=Y'34>:^$C HJ:.:0]:7)BFK+
M2!(B$RDQS@Q"2,)%=HDE@ZZ%W80GUE''O)9Q6$?L+=RO?J VQP(\P2BR)!(0
MB[$B,=)KJ84)GC5)_]VK\EK>I%#1"@QG"-=9%<8"<> 348Q'',,D'?0S>9.=
M<9F>I/U;YFQML;=,WN/TQ@#S)$I JVK1H%HTID3[Y$*00JG49F/[4=*6M72_
MBL"K*?YH-HY_?1H/48C3<C@].^L;(7QTI40I6TXDI9$$'BP! \8QJR.8)F[O
M;5+696Y[?'(R'LW'_<,/3Z&/(;Y7((& A7(<Y@()%CQ1 ;QD @)(VH*UFX1T
MR9JMB8";P%Y+YO4.95(:%-[]\, /TLYHVW\>8#C:=UZI+&A XVHED0Q=#T^!
M$Q%UB-'+@(NXR9',W?1TR;)5QD$-#52#PR',_& $J><G(PPLIULQGIZ<S@\!
MWD >Q,&L[ZS)6L2$=$6TOHXS8JG61#N5?/+!1-O$VWF<M"[%=)5!4EDO-<]T
M+^B8!QQHU#Y/X!.,IH,OL#.*XQ/8'4^G>S#;S\?^&WH"SFG&T:@E1\N1 $K#
M"=2UA9 QP'$VJ48GO4^ALTNA86USTU!C-6OO,J"SEZYLC\XPYEAV)!F.P3"G
MF3C'(XDQ"F4Q&':N2=K@#EJZ='A3&1[K2KY%H+4U2G=QF7.*NL1["=$IK<W$
M"G2<%,: WMFL>&P==MU)6,V4B64Y^F0,"3KY$CA)XE,(1+/(O9+4F=S$#7]B
MENP9\@GK8^*!0/-)<F\983HI&*B,LV<+1$J.D2XP2@)N]LP;!A2:Z/\Q5'<F
MM5 ?!FMJH1H:2G@XF)7CP,+D]GA4#GI@%.>I7(HD!9>( )Z)#%P21UTFN$TS
MJJR67#;9"A^@J4N^=U-\U-)+/1=\7B[=Y]9H+\&2K$N1M $@GJ/)LIP*G0'P
MIVT"]OGT=9BXK#Y)0#47!AV.5*X"2D5LR$!8T-ED'X4-#:\7=; T> 4=W_+[
M5Y9P9:1>R> SI($9I8CPI0Q91Z1"8X"A4X@I62N4;))*Z/XMF0JJ7E'.E;5]
M 3@9M1::F7(1QQ$)C!'+C"99:(5!I(\Y-*FX>F!)K[ G^^FG8O3QC[*3?/'#
M^38PV_:3R1EN ^?A$FB,MJ04)"N-NXM&)3HK$D%V&9699=^FNFHIZKIGU59!
MR*U-N;IB*F94I[/)(,X@+4>D .D\^B6EI@N=362;>$<]"=YGSYTP$)N<DC^1
MSNZ9S!HX:JFL!HC:&7W!O\]]T<NS49<UE8D1%FU)UW%*7,#0!9">J&6BF3=Q
M Q\BJDNQ00NLK*F&:L!X[R=_P:Q<]CH"W/JOG9E;S;S,:/%\5 %#$YDPFBWQ
MB0.T?#PEFIJ$C _0U*4D>SU8U%)"S2.:^3W 0XB =@P)VX/9!45)!2:24^5.
MAD0#1AVQ*2CB>&:29^L8EXW.8^XEJDO9]7JXJ*:&:L H9FN$7SDK+19XE-Q'
MJ3$,]+94!U)B%2A",40PP8@L0I-;=E>)6$;Q^H=3_,IBWD@GBTL. T@SOYS%
MA2JGQ^@;IY"(DIFKY"U3J8G^EZ!M&5B8'PX6M952MU[[Z--X,BL5Y%=\FSYG
M%DP6ED"D&=G5B80LD#J@T@ID7[7I^G,O1<L@P_YPR*BC@+IX^+YK3:]L6YY3
MB')>R&G0GX%8KI>(0*B1#-U<);5J8C3N)VD91+@?$Q'KJ^ &)/[^ZJ:0=O'S
M!CJM'?A"^B? W_/#Z\35:KMV?8H-]V![@+_6'>V.CO&_[WM[QT?[;_</>H=;
MQSOXK]5D?,_P[>6[#%^5FMUMCZ?SH[W%SCSM P0,VX0C.=)2;EZ66''<7(S>
M)<N<:=.VYB8AZY\H3V?[^=UXG.;'HC#Y,H@P/1H/4S]PF2G#[23F"$0R*XFU
M"MU2GT$H/^_1V8K%NTGJ4IYZ+43</C^NHH6:V43 84JR\PU\@>%XWG5OP6I?
M&VZ0GTR2]DA2C)H$)P.Q-*8@T>M@/C=*)]Y/59=RSU6Q44\7]8J28(C_]/$=
MC-!6#Y&PK70R& VFLW+S^ M<T!:<HS:H1!++XOSN@@M&(6TL@XE2N=S$1BY'
M7I<2T%4!TT [U9!33-S7P;!0M3.:^='' ;JN<Y]XYP0CW\G)O [!916I#B1$
M]&&E1KOG@":2J0%-03()3;IG+D-<E_+355%373-K8Z:XG_W+6JK9O&0+/TX'
M:=[A8#PZA!/PT]/)O%O&.S\8E1KU/HM"!YLIT:$T&,JVU#7H2&BPBDI&/;UY
M2>FVG[O:U$_,49/N@V,#*JB8N;ZXIO 6A7%.]"G2O6B(@52_ACR>+*XS'/MO
M,.U]0YN(BAF,_.1L!\4YKX_!WT1)%Q.*"P$F,)WUG9;(CXG$&9^(#!EW65NZ
MTEO%-;@(P)J4E3?D::U5^19''\6!'UZBBS(9P&1+6,@<_1#$F8W*$Q.T 6Y]
M1$]DJ55W:^@G.OUM5U570'9M@:ZGC3IV^I*&<\[+L8:3BAD7.#&:(S\T:>)$
MBJ7C3,@9 NI=/@T2EV-WR=GO-B164T?]-E'?I=0O;W9X*B,QT:'C*3)&*S%B
M!)-D4DX8%E.3^PMWT-*E&*!K.*JEPJ984BI%):@D^ <R)A7Z,]E9DDRF4? (
M7C;)43V*I0HIQFBI9A(=*.-CN6\D)(;VQA!A;<2P'OE,?/,IQF?>@-<%P5V9
MMY6E7C'?]@5&IW"Q\"<^SOX<S#YMGTYGR.2D]RT.3\O33"4>P_^G<@>7LI0R
M4XPH5<Z!+<58C'-)LDR9"L%BU$V*IU>@M4O;=6T M59=-8RA#W"%Y9P@1XOA
M7XH9?8!R.N@RRT0XW">$CBF8)J5_UZCH<LB'4:LV%I6B1&E,FTTF/J/WY+22
MT2>;6:O:IPV%?,][?+(Z&F^74G4#!)43&4CH8D]:-'KM&QT,..,(V@XD)D L
M695$%#54!ZH"\(9)B%OT/-&HMW4+:L-I/>D_8TW%U3/Q[?WW!X>]W_$[.W_T
M=O>/VASYWYYELR?_CW!9K0#@5D>4RVXHB24J/"O%VSH3J4,B%H(G21IMA-,^
MNB8W%A^@J:ZS(+QTB'5D2Y1Z(@.!>$_1<U%4.\$%1GQ-"L(?<!:>^_"_#AIN
M&I_5Q5ZWLN^1_C\'X\E<\+/99!!.Y_<:CL?G!4Y]'R$&A[NE%AI)I0QW2_1W
M">Z4SN7RGJMI$K6N27>70I16Z-JD:CN#1Z43;F52(&28())%06R.G&1</MY%
MJ81K8KNJXK&>V#Z,)N"'@_^#]/MX6.+2BT.[_='WJTE;D\$4_^D-?AQ]/(#)
M8)PN >@4UY(74=+YXXE>$"<Y)59*JKG%4)JV*^]MP%"7MI5-8GU9X[!1P&S$
M:AQ"'/KI=) 'YT]Q;Z7_/3TOIB\!Y-;^]L[;\>3(#V$_?^?PDIVHA:.:HHQ=
M*9L12A#/T1Y343I :>U%:)-Q;L51I^*X+JZ S6)F(TN@W&!_.QQ__1W21[A8
MT%MY-K]0<)W1T3QC:80,0BH,II4N=]JY(;X(-Z6<2G-MC(?;O$];D8DN'?9U
M%>=-@=&5M,CO6WOO>D<[>T?'^]O_]?O^[IO>X5'OOS_L'/^S38+D@?DVG"I9
MEO--WDAY@*@V=X)6FKPSBNK(/:+MK:/?W^[N_]DHIW@Y^H;E?C=7M7*(:%QO
M](ZYU5OF^@^N?//<JT9+/2GO>KV!\S\OCQ?Q+Y_\Z",<^AGT<H8XZPM@*'(>
MR?P]%'2VH;SMDPE723*!SCAE32+?S;)9(=-92#B8C+\,4,6OSSY,2_.6RV/B
MK3@;?#EO  M,,Z \$Y9$*"V/:<G'"0( P5!3*@>:G+@O3V*7@MD.H_V.M&L+
M#-0\NK^+OO-;X-?I8YPJ]/Y221=;(J.TY?TC3E02)@+*AIHFAX3+D]BI3.L/
MC]%U,= :HXM"U&OT1>8BE3H0IA1'(E.YA. ,,<Q&DR/^E34))I<GL4NAXH^/
MT74Q4*]]]CJB[&?IC$PJXSJ2&.H:%TGIX$RR%T+;S%40;:Y\KT-UZTZ5?9:"
M5;D40HB2VS(.B#5"D,QE2D%JY6RC,L2'"?MI7*$GX>ZIO2N?I+ZJZW")/IJJ
MF*(HB;)9EKTLEQ::B=C HXD4/2[=;+W]4*U.GP]>]17Y'#YS#-$IPQ/)-BHB
MO0DDX,:''VG,!D1RODE[U%5]YJ<+X\#/WY"?'H^W(NJI%$-^;R"E:4;%)$-L
ME(Q(22WQ4I04K@B.2AFU:&+!'R*J4W<.&D'I5O.W6DJJUR/P)D4H HR)9V<'
M0S^:E5L3^--Y.XJ^HSDXKP)1P!V1MCPT9\ 0IK46+#D-JDD;N.5)[-0YYW-!
MJHX"ZUP915HB0)J7;;\^G0Y&,)V^A\E'F/0%^O_"(;P-9\@SE^5->MP[M'4\
MYFR4@!O=\N^Y.GK_'%T*\1JCH::T*_8?_4Y/.3A',+[WLW)R?K:?[^J7W'?
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M.9"D6"!21D4<HYP8X8RP,:B0]7-*Y)+2+J7)F^#M9DJLK2ZK94V7(O,03OP
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M'EYVMW8N")\-,!GK9NMKU4>HI04-;9L:M;.E36GY=5#NWDKI4<.+1]_-U-/
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M^/>JR2 &BJ<BG. ,':0:S2%8D/7X,F4HSEH)MFE7DBX@GSR=>M!-@XOHM0_
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M[WXKFK=PBD?E!J;+=@,=0*UAQG12^DHTN[59^E#3N)6,>]QK[@:'67D,4;'
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MAFFC:H@>*&:B,DI@$;Q3-Y#U3?I5B)Z<.=^+Z%MPXEK..YS2E]>..RX;B'=
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MT 9>ZEQZ662E')&4*O1F2F&.5:*\=AAP X[4J4/4+^T_E(8T>&'9F;7='W_
M?'$U6)2-0%G&-9>$"\>)+!6%GBE%<J0N2NYR3.I164#W$/%+NX?2@ :UY!W0
M\# MX8[%]N?Y>-;]SRN33"1N!/6:@$P&"1&46.0R<2'3D@Z266CGQ-:@X*^I
MQX/+OD'YX[47WH<X.E_'TN5[,+<JY%+-+9571$:TK*RQDBBGJ1(Z"1V:M VO
M1L%0\RP.K;H'D?AC&96QA(__<_>4R5B4: ^5,L72BB_Z7":^.!(UE0R4=T8W
MJ>:\@>(1)'<,J0BW9QKO+)#!@A-]&/&3C+-T*S^J#TU-^_$V(.HPB2A[Z,JV
M=NA0@GXJ2JR,IX8Y21PKK5L"FMF6\TPT3U0&)H7QC8>B/7;E?2"/YI'K[C;R
M;3&)YGJV_#*DL7JB=SI"RMH2%0(EDC--@DZ*1&64C!E<9$T*2]8B>H2^3G.!
MWYYB4T5:#9[?2N. V3@N('70/J%DYB>GGU;@))?>!Y-(*AG[4DA9VA4)PKVA
MP4MC&6WB9F]$]4N=*DJM117Y,N<QJ!QU%(1)AN<UVK2HUQ3_2I7'7U&M19]N
MD4^NQ\,!'(/=&5_QO>9V178?&,^T(\16$EC33& 7]C7L",%!>JKP-'%)J_($
M'DF0R/]8VB8H#II"'V/V<4BQ5T>(&D+<AFNU.T(@IWXV-M#)LQ0MD B4E]&O
M@@0G@1AKG+(*LHA]7G[Z=82XOO+A.D)LQ?MI#<95;I=TLS4%>C=4HTE ) ML
MJ8X.D/$R1>&E55[H:BU9'DE/CYTEN#/C#IBP_)L?S[[YR07X^?SBZS(-J5+&
M\J9/MTI9[DW.K9QE"E*K1$$P)B2-U@>4#PB:,AK%^/=1WT4.GK3L; )IO2=)
M IX<-!9#7WE"!15,!,J@UY'[5TI:+O+\H\CSZ*<\T6]Z!XLOTS2=3#__. KH
M]_BX&-D0HY6TZX;,RL08(!:HPP,B\B1EXKEU;4@SVAZA>UM7VZME.#32E\>4
MY'P?B:__/(?B^K\:?QLG/#Q/_ )&UD,)&W&2A=5$\NB(E8+B96FERDF(1O-,
MFU/VA+9#*WULN5_V5J9#/,?L0N ?TPE^9C)>_"@DKJS\D07@7K% $G>!R" ,
M\18DH4Z@!)35*K89"SL8B;_VSR#[9W_U&BQWNBZE2V=KA!:[H%0IHC.'DE]#
MB>4Y$6J""5Y'9Q]9C=[6)/[:2(?82#NHUV-*P[Z/TI/Q_']_FP&\.2NS3N>+
MZP=&R-I(RB3)6CLB,\]X\RI'/-4F4\ZBNV_\Y"/;1AL(_+6)FFZB6JK5*O>[
M*9VKH\(DF10>#L2Y,E=!BTP\6+1E*:4.F--:-,E0'(K 7UMH^"VT@VJUR#S?
M-85^TWW[$69?V<A%FZ73E@3:C850HC222\39)!D(40++CZJ>XD&2?FV3:A48
M==6GXA2*^ND7)C+%#!=$<8O\C<83SR+>E-GJJ%GRX%.3?? 7+,G8*V9\$(D_
MSI(,GW"+Y91(HH"&G:" ]Y.2A$=JL@O">-[DI>F9E61LI0@;2S*V$<A3R6;O
M0].ODHSM2S*VTI4ATMIW$?1346)NE5*:"<*2E@2MI42\!$4$:, ?LI1RP&8G
MCU%YMRK)>'2ZNXU\!RW)H-DH9P(EVL=0&GY'XE+I JM%TLB\;&B3F,1S+\G8
M2N"]2S*VD=;:9('V*6.7IL\TW^_954H?Z[M,JU2RG<B\TPHS*,>"I#9(&<N,
M+U *8M39LN!#&NVR8*7# F;?QA'6;(])]R'\Z3B?0)Q^/BNM;)9]$%Y.YXOY
M3V\J>.YP%4O 0222>TZ"38&PH",$GE403;R RG3L[1HM5X)T/Y 2MCB;PRAJ
MQU7(E(0D9 E8E%;\-!'NHDY41:>%:.(S]8(W_.E\2&V\XTS5%V&+E*XKQ[,.
M[Y9.J(* ]QF28D+A6_2,A(SWF_?2.1M2CKI/U=0>\:>*U P5BWI,RGMXM7@L
M0:HW9WB==VW*N^^^7='9>0["%T>!6Y)E3LCA@*1(JTB*!G#WBHB7=0LUWX#I
M\ &L@RG,M(W@&GA8:Z!=SE'O :YEC&HCNL,$FZK)LI^.["&(P;6%E>%8P2>B
M5)G&),ICKN5H3D0;?;!>Z38%&@?0D@>B.H=1DFWXWT Y3F .^,$O1V?I%7R#
MR?2\8%P9EZM @)7"<^W*+%)>AN%I36PIUF=1&J&,=Y+K%BK2 ]OP+D)%:=[M
M9E!5%"VL?9C@KS[_#F<P\Q,$>I2^(L?+J_QB_ U66.>7DTJ-, 84[A+ERDC;
MF(F+5*&DM7+*I0RR36._;5 ^)PUJ)YZ!2T*//[P^.?KXYOWO;U\?G;[>)71W
MZPLUHW*;P-T.N&F+(HM!,*6E-,PZ&IER%FBVUB<W6@^S"N<Z*WBGT.>]WVG'
MQ?N WN(E=P9P)T00EDLIRPB?P$%DP7UPG.?10Y"K</08?1I?>@E/ 'V26%R-
M/0+,O;_=CO-]";HE#:&4HB)KFH*0@0<;HU ,F+%&L<3YJ/<J^]U(;V$^!WA;
MOOH*YG$V/E]QYC*(P;+*>$\2S4NK9ZZ V$@=48(JKFBDT.:M\P%<>PT(_LW'
MKC+@]-Q'Z!JZ=^N,LA3,&:>(5XJA<: ""8$%PH/4BDJK)5,/:>2F!8:_*FM*
M]\8$X1HL;&!?76V3#LW)^/.7Q7'^-"\9A[ 8"<Y$8(D1I;TMG9$B<30+M 6=
MXEQ)$=HTG=V(ZGDH17T!-$D&F<X6)=.T [=Z&YZ/LL)KD $2F,K,:[3J2- E
MZQ0)1K] )'E[FGNM=([[X#PO?:C \@8%C3>U].W8A^XP&VEK:'2HE4I20:0%
M/+V4,80EHT0 JK1N4OV^!L_S4H4:3&]0D[<D^2:XHK#'^>7T;)DM#TXK9:P@
MS):.>LE)XG4*!+0)U(*)ILWTX8>A/2\-J2R*BM5GG<WS!WP9Q\F2]@\S.%\>
M9JMI$C+G!#1$HCV4L(/%PRR[2**/26A#T=<RO6S'3:L\#W'796;% JD.V,^>
MJ&_.ON'/W87U<7H*\6*VA'OT>0;+5+.1S3S39?4C]VCNBD!<$L@([VAR()17
MH9?4MUGU&6E!,V8WJ ZZGPG+=U(6S;()KZ%E+(@/MK@]>*6!L#Y%D66;/E(;
M, V5-='^0MB?Y8\EE^'#;(J7V^)'23]=')UU$T3/EU5./[.A=?;.X(GG8^GU
M 3Z38'4D FQP65D61)/'HA[8#I7;4$T-IFW%T<!E70NQ +PLM>@!L66^0@^,
MA\E:J"[?OOJSIW .I$<Y.!MDHB2GS(B4>,D&9X!P[G-D:*XDUV32R,'TYX%\
MAL>@/MO(I(':O+@83Q*Z8JL7S\1=!LL\H5'C70[HKWN>2S<=)17GW(30Q!&^
M"6-X^[>ZI*;5V%PQB-Y9Y,>S\>?QF9]T@?T5'A_1!2LHA,B(1TE& M62A*PX
M4HTVN-2]O)Q[/CZ\,/=A]K0BIRINUP[/44H=YVXB4BK0(*(G,7)'9"E'LB4)
M&:QRG)D8$Z.]9'?OYY^N]/;G5N6A%U?Y++_#]//,GW\91S_I[AANJ;<:T&]B
M:-A*EA3Q'OW>E+U,6=J899^H=*^>[6M1/!?;OQZK:\M_Z6)>AW15G?@PJ-HC
M4-:B&7X@2B5I35NQNO+$C?7@,A=)IL#1N,R^5"KAY0(\$"U,Y%8JJTV?5(S'
M*/\-HU2&%/\V'*Y]?;^8C=-G^([$SM[#]_^&V1Q^7-U*#B0K>=/1XJVD%+H;
MKMB7/$)*T5@N>*\[?/T:PX[GJ"2!:7WVU3:G3R!]GT[3R_'BQTL_&>?I[&SL
M+W.1>4C66C1;=,0_9'#$"X\[T0%7RC#IC>PEU@V+/'FYUF+@01-PW_G%Q0P_
M#O-IOO'ZC?]2+?NQSR+MTB"W)O%6/F14H$3,.J6 @I34\<R,*X\#3/#DPF@O
M8G>4XLOC=^_>?'SW^OW'TZ/WKUX>OR_KOW[_\LWKTUWDM>ES-273&_8M&7BI
MP(=,I;3HN0KA G5:6<4<[E JV:@G ?6YO<<FZ?'5@7C?*RU8"L\LLQ2Y+QD5
M-G#!( H*UE,\-3>)H%)"\'0^+^D6Z&/#6<3M]/,ICWGG8E:&>-K-F V,6*$%
MB>"R=>AU@6TR$7@]I+WNYO<7Y18YSB\G?CX_BET_RA%C5F<5(H$@1>F,Z8E3
M%FF4H$P,(J7;+[EK+N7[OGZ E_LZTKQQ)>_-MP:)OY>9A;]-9V_ALY^<PF(Q
M6>4-!!$":*=("*4C'_H()48?B*/*)E"@16[R.+\!TY-7A-I\;_!V<8?B9="(
M&A^B59$PK4KNB''$*AX)WGO.2,ZX=4U:8]P/9[ LC3;BK\#C0^=F%+_E+?+\
M<U=$^+*D'"V#"[9X+([H:'*9%*&)Y]W#'GC+ J=!5QMU>G?Y@T5;*\AS6HVO
ME2-K-]%<>[KK@ZEV@'4=F.'CJ_L*::V\]^3P4-)/6GO.G4#+A1D\_VPL RTH
MH4D[SV3I*MUGY- CE/J&J.H00M^&L;6CJ6\*__SDPT68C.-QSC K">7^^_QB
MO+BLWP:?@#&#^*A%?'B4$9^2( DII5P&D6^7UZ\Q]7LL-FP<KHY(I@WY63O.
M^@YFGV%V"Y"F*4D'GF0%0&1$V].K8$EDTB5O&'K4_>+F]WW]J4MT;X[5WK(W
M ;V8@8]?CO-OXW01QW[VX]5%B>T=YQ?'KZ[ZJS*K<NGED4O&33::..T8T=0C
M!ZA06?8KU]UVY>%$7TE2Z^5>F<V5[^R/XT7I:/;F+)6QHA>K=[\<5(J<>J)L
M1(<EV$ "7E)$>*<0J!%HJM:ZL.]%\$RL\_VY6SD%X@Z@_QDOOIS I#OWYE_&
MYQ^GKY'ZQ8^KE+N'H=:VV[?$.+PY7T&JFW2D@4A:'QH/0.;!QZPS1VE3M'NY
M-,25Y@4I9I%3R#JZ/K-ZGH[V;' +#JL\VTBBMO6!-NTXPJP,S'HUGD'$__7R
MJK5>10_2$H:'*9&&(ZR8,V$BVQ"S9)GV>Q)8O\:PQF13N4SK,W7HYOB?7IR^
M_M>GU^\_OOZCO+/M\NIXYQM5V]IO!'CK1=&4# L#TC,59' F.&5IUIRE#,GH
M.-H$M1(']QDAL.93+?G9YZ$VA.19--DX**ZM\#HPIC1:8,)9:MT=MM9YG3V]
M"'/XOXO2U_!;Z7UW%<77N*QEFA'KG"522[32<XG>,#"9.RD];U*:L0[0WKU:
MRCB-+],);O=Y*;=8_'@_72R';)R>3\8+M(._X:]0Z"?EV&(C(:AS98J,#=D1
M*<M/V3#B.'K"$FC,H<U0GBV!'F!D2@V=N=/8I:5\:D>'KIRF10>P:TO4]<6>
M_X0YHH$RG;4A(,IL< 61>%8F"HKL@XCE=;M?+7^?U9ZX%K3A:O64VHLY4EE\
MYJ]A?+:<^I SFB%=+\_XI8P,ZK1S))A,0B'14@>-*$LFH3*2F,P,1".4O)W9
MLB[#MN^2ST$!VO"W8E"A0[E4R3?S^06D3^?3LY_*6?K*?/TZ/?NIOO,/,+OJ
M.#$*@27/<XFL^1+YXHD$G3)1/H-P*0:F72^MV!G"<]"28?A?L3-4A_K#=+Y8
MADH_(/RSQ?'W,P2-OM&+'Q]FL/Q-X=4XE:AI1^/J-APEK_&BTP)=&P?E'225
MAE9(1512)YZ%Z]E&<G<,ST%O!I) [2Y1KR"@\8,\\&>+=\CVKQ=?_W7A9PN8
M37Z< /[[!91!').Q/XLP<D:&!,J3G!FZU@B..&U+U3 /*H;,H:?1L=6RST$]
MVO&Y8D>I->0OX_:"!:?!6,(8"T0&M(I"C(GD&%P4 KW(W*3?PGU@!IOWW<07
MV9>[A\Y!6T?(99<)30-G3'N2N$;?B69*'&2+'$H6(*<<H,F8N35X#C;C:&\Y
M/Z XN_"[19_:N[!6D=@^P)J.SUZ'[# -?JK([V&=V(/Y@VJ'E3)[IC51295"
M1Z.(!V=("CE2IP(ZVT,=$P=LVS.L4FS#\_;*<)F)%5AT+@MB%%-X)K*2O!'1
M\<8S46DEE;=-^AC?B^;@QN:NTMJL SNPNF)8LSSCG93XRC)U,T?.,UY_@7:I
MFP%!>.?1_5%>6L9C='TZF/=ZPKY:]<E; ;OSL'+>2P=BI4]]8-3.:;FV_O#Y
M*CM*X+8,]V!?Y?R3ZW 43S9J5L;),XYJF1WQE@G"F9,^>,'Q!GHR4MR0-U)7
MB-MPK;+P5I&$%1!<SFJ/]P.3AA(I%.!UD0SA(6CFC$\J]3&H>HGOQLK#YH/L
MS/MI#<95OA7?^3^O >&1*B:,0U,O>C3Z\(ZV#J_GZ WG(5*:7;5<T1LK/T$)
M[LRX!G9MB>Z].9LO9A<EKM*=+$9G'GEBA"9?YD0@24Y80Z(.(1LN(O--QK3<
MA?+D+9]*7*[XYG(_HO?^ZZ7EW@=7R\C'.F"'"7SL*[B->K GUYN?!M?P.655
MR"D0:VDLM0F&6(4WCE9&"RI99+>?VIZB-CP0\!A*&;9A=O7FIE^[Y+NCLU1&
M1O@%I)<S2./%U6/QZMJ27KJD(),D A)>VL'YTGC ,@W>>NV$>##E<)L%AP]N
MU!'/M#%O*QMU5TT 3R.<^=EXNM3R"(B$4J*23*CE:*B@V4F)S4Y$)%<HX6H9
M=_<B>/*&0!W>5GQ"[P"M<'PZFY]#'.<QI,OKJ >HZIU0UZ$Y8"?4W24U;<7F
MVEU0UX(#H4K/1D\TM4 D,$]"\I[PQ -XXV1B]3;]L++OTP6UL>BWX6XCD?\V
MG:'+.;^\=8+2CFM:^M&4]C1*9>(D'FL PF2A@O*Q6FS[?@@#]]"L(YM[I+T'
M8[>MP%G]<_DC^#G\Y[_]/U!+ P04    " "Q.P91SG:41>[S  "$E0D %0
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M LL4D4UY9?Q^QR "^LS9;,)OQ>@-IQ,U[&5>J!*6RPC4ZT4QRB2DB1M0U6K
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M@893DQ!+>@%=)?AL(T&J8\9[EU72,T)[QKYGZ;,KA>D,K"S&^?IB])!(?P2
M-BW=+F0,:@H?@=.FK7S,4!TO+S,5.9$7[[_GQ9]7V5U],S>6\HX0ZGG0$=2'
MB),$XB!.8.)3X2$6^(R%1G>5.Z<Y-5FGB(-I!IO[2<.[Q]U(:EXU'HU/WS>+
M<P+/@"(1I!EHB#RKXS<MWB:V8F'U\G#W3,/>%;9RNW4UV/YT-QEP(RG%Y?-M
M<8>+:?./*G&N3)6HJ1H*WXJYQ%'AE])0>^','7NQXT:8>= GGJK;*QR(8T]
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M3_4Q1P>7TU663E,\N9N124IOA9 C9D_7^'LY2Z=EXR<(/%<PX@20<H(@HKZ
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MI@6FT]_3Z?/YK)Q*ZZRX^-%$FHQ4NGS)F<H\YT[BHI@3R(DO[2@>QY 0E\#
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M'N]J>&6J$5E=0O0^+?_\S#/ZK/JP-#7S>1"X"8XHC!QUX^^'TAIP.(:^QZE
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M-<O B4#[N-Q.^-G[I'GIA&L)_^3N.<_XS:R*M64A<U'H4XB8)__PG03&3IQ
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M'(61IMEB5_71TSW6G@N3S1Q7@)4K.E^JMA_Z2$Y^F*8?^+MO^6)GQ[U4)>5
M)Z%> %673EU97Z7)@/]Z*9L,.SEJ_6!76S.?$]B[<?,R\'C;.I^X[6WZO XT
MP,:X$T*^K=7J<L&NY?:2RG>K[9^:451D(8L@"3(*$6<9+-(LDY-?Q&$4LXR'
M1K7"3XPSM?6^J6FC/]7/R^I9;@=:X>NJWJWX%KS>@[+!(NP&.\]+Z1:CRRY&
M0YJ!]X!EL92Y 6U$)^"S%DXM%)T.X8??/%>KQ6F,>CF_Y_;QF/NT#GO\:W#Y
MN9&ZEXMUR<KY1K6LVFT0;W[5?MG/4GQ%^)OZG;H3-[A2L[WZKNK92NK?&6XB
M"?( J]:[,440T3"'6!08AIBF'*<H*=#  %]7(DZ-N[M[M:Z.76].JR50+Q+H
MZ*EN:C55UGQM]0\-)';V%AA&OGSHW(ZU37,WK3;[M#-"GUU/AI^(:6=2?E"@
MM6N4C\=G.Q]IV&*CMP0J@.'R5[F:818E+$ICF&<1@2B*.2PX"F!>T"1F(HOB
MV*JIS][3IT;QM=M%20?^KN2SS/381\Z,6P?CX9D6S:&P9K"#*KLDG_T!1N6-
M@[J]_>0/7W36F:O.[?A2+OCMFC^KD]18\(B'D. H@0BG&20%*6":I4&:9B)+
M>3[@)'5_E*E]O=NCMSK[Z.]*4* EM?R.#V-J=9(Y'*FQSB<M0!IZW'@8! ^'
MB&\&^HBCP<.Z'CGP.W+Q !?;O_,?)9USW4?P>\5?:J]>[<B;D4+D3"0,QH@'
M$*%80!QG(4QCADF2%C@I(F,G6]](4V."1M95TU+T18E;,ON3L5YT#9QKKC#S
MS F-F&WGT)VDS;F3*\0L/&RND!O1Q]:<PDAJ;=^W]1*LE!W/F_=0_NIG\V:Z
M\K*9X-3K9^M]P'B>-A,]]GQM1C<,(-1K^82?>,VOEJOUZO.R4G5%9B@10O4P
MA7$011"% 84XH@32),UYS%,1!>81U8=&F!J!UN<4]!7(O>F3<A=3*:R./,#@
M5<IKP0@' 37@SG-A\LR9K7A RZ<.<\"E+O1S+C06)'DN1".28[<$C'Z75&SQ
MVY=,O5_J[:K=;.K\>UT^:]I<TN;B[6%ZYX&NN+0/SEX./7CC>-S9)_<>9_9>
MZ"9-=5OV+Z>8DI#'$&>2+5$4(KD7C3%,",I$'D5A5%CM0(\--#7F/)"!>;H2
MH!VTADY[!X#Y=KT/P>KL7%6O-1./C?6AF:HGZR6>NGYHT69),Y<+=O-+1:#P
MW0M,>)J'%(<0$VE$H3#)8!$4,<P9*<($HY1P9E>P^?! 4^.&F__S_>;;PXUE
MWOI1& T=4@[ \>V3TB:4BD)HA?1"!*>0<%N!^<A8(U=?[M?X?>7E$]<//%&2
MUMOS9BXM#Z9;ZZICK(K_D$.4/_GM@BZ?^9>ESDNZ$X_XUZS@(LWE!@O2(N 0
M94Q%D.<)Q$%:%'%4I$5LE,L^</RIT49'?+#47:)I5P&5E2<UL#RJLIP2P\,L
M?T#[/N[J8%QWXMZ3'=3"@]^4^+_7R:RJ1!'^Y?!8;!AX3@_.+$48]VAM&#[O
M#M\&/L:^5L>#W%CKTD!_\.53A5]^E!3/]=%PGK*8Q83KO21$E&-8T#2!/(XX
MC7.>I9%11]_>4:9&8UWYK([7^['L9R9G"'GF'QMPK*ITG%3^W#(=QP<8K4['
M21V[A3I.7SRTP:X*K>6L#<MIHHHYCQ"A:0$%9R%$I,AAD6<,4A$)6J2"HLBJ
M.<WA8:;VK7>74\9%2<OC?5QMT#0S0\['R//7W@JXBQT\&<H^H-MM'PANF]H>
M'&GDWK5]VKYO4=M[]8!CH[:V@K0F2+FH>P76116X_-'S<J&/_.NTW:OEXB>O
MY*?QN.S\;I;&K,@(QI %2091&F!(.(L@C8H\S<*"%)%1(PE'\DR-4NK^H*K)
MU<.]W  U(JLFLDN &=,U+N3:V51$:$X)J%:_R;?#BU>+PQD',VIPRC7N/'FF
MM589T-'FHBWQHT[*E-!-X%&M$MCJI [+NQ>,.U,6AV[CSMA(1W2CS)S=:9P[
MG'O/[AP,,]Y)GSM,]LX%'3[6R2EBIPYC@O(,89%#$F,&$0LYS%E(8))D+!<B
M3[AEQ]IC(TUMN7M[-M:$8EM5N#P-[Z"CQ$G6NAR(U[FGB59E+\\]3AR[!J:Q
MSB<.%,^NAGGDN5^VL=E%@1-,< YQQ#!$64HA1IG\&R$9SSAE69Z<01-?IAKR
M_NZM'Q[T?A3;01PQ"+&Q*<)/\/LI)#P2Q)>/"8$_I?$)>GA__9!^),N%JH4B
M'W>H(_4SQZH2BW;[21I2#OY9&N0\82F!\L613)%(NLACFL.$8XH$3Q$.\MF"
M/RDGUJ-IHQ);*8P^CZ+^/-[)XO-$OM6C:_2#/15L^G)83X[!UMD/UJ/UH-['
M=T_ZBWV@@5*@.7KT"KI->Q2?X(^TZ74_"98M5(9BV-]4Q?JI([99&:KQ?N.5
MP4\99G5^D5MCSN]>]!"+)YURT.D>@IA(,\)RF!*<0A3S%!*6<)@R$<:$\80P
MHRPKL^&F9H'>?;^YOWR\_?8'^')S^7!C9W.>0-;,\G2'EV?2KP6] %M1ZX0K
M7SU:S'!Q:8V>&'%4F]1,^[>6J>%=0^JM*JJJ>WA>Z_I^=:I2W=NS*>QZ\XO^
M4)7]9D7(@IB00-JB)($H""*(PT3N:7-IIK(HIWED44?58N2IL<O#VU;"O!'4
MOJ"U_2P8V*"^L/6]$];F3M,GN!:\+3':(-Y6KVZ%]X6Q3?U03UB/F 6U.-(C
M^UW%3YT*I?YYZ'V7OYS/EW^U=SSKWB;.BGP.0+F_>*?- T<LRCE S_UBFT,>
M8+=P=+O<UT^_6;!KO.:S,"SR/,4%S&,>080$@464,,BS@/."Q91PHP7BZ A3
M6PA:(5N:NE$E"Z6<9KQT',A^CG<"CV<NMT;&F ].:K^S'5>M\;CB]%^?EC__
M3=Y;VXWR+V_-Q>//'>7S/ZE6^YF?OG#@*48;@=BT6H^3/$U%!".*!419&$(2
M8@(YB5&<B#"0G[35V<7>XZ?V(6^E&]A,?1\[P[.)P8AXM\-,P; _A3BHL].S
MA_T1QCUQ.*C=NW.&PU>=U2WC=O&]6E*Y3;SG*RX?\D,5>^4_^7SYHNMIUXV5
MFGY*CS^JY>;IQX'XBC=E]!.6IDD8JP(380X130JYUTL09"0EL8H*+ JCC,@Q
MA)T<HW0*>)8+%6V\*-<<SLN?=7B@O+94U3AOO]]?'^I_MK.A!S53\/-"F.P]
MIS/-OFFRTTE#-<.HE06MMG55\)V^VS:#[20W*H-#46ZN>FKX>0T&M=?X\-?A
M0SMME OXTKP@5?N"J-1BUGE!=C0!WM%$+T.X;Z7A=;(,NVKXD>$C&FQX1?-(
MKPV_8]I[#&X6ZW+]>L^?2I6\O5A_DY_0K$A8GC(>P3PH$HC"B$"<X0P*:6 P
MCC#+*35U&!P:8&I&02TCV D)E)3FWH*#()YV%IP+C>>%U!(5*T]!G^IG. H.
M/G8T/T&?4ETW0>]UP[P$+45T6KA*GE%-8_#;RM_7JF@X9S.I'8ZRD,&"Y00B
ME$80<\X@Y5F2AYP2DD86$4W#)9EH5).*!5 .]MK[#B!@M;C@-[G(L^5<&A.=
MWQO&VIPQ7V;>"T_PCYP2U)%>51A=ZO9'^$#SA O0:.'.%S(<09?^D@%2C.I3
M&8[26[_+&4\:XILYV.OLLM)-\I0%=JSMV5W=1%/5NY%RKE]O%Y*\]<9EI2M#
M//[ B^::-QW2EFL\US]2WN#/N*QT<N*,X#QFD;2OB%!E0M,@@]+NXI $/,ZB
M-!8Q,L_@G(Q:4S/ME&#@9YL-^JX3:M-%T683/Q6DC;P^4Q%V0HO,T>ZJ'5A4
MA^WCG58;Q;4GJ88'=/!I*@(IA+97-KU9RVUO5@U3_6-]_@;T>ZJA^J=\%VU<
M3U,1>H).JGO^HMQ0ZEW196OU6R*.4ABO7[ZR\_+5);_6ZN5KKSS0*;;B+\NJ
MTPW6F:=J:G/;[].:C+0C>K\FH_-!/]GDI!NV'?]CN61_E?.YE.=VZRS6OKW;
MYQ<YAA)L1FB>X"R4!F#$4[D!SR.8QRB$!49)2-*8$+NV.R:#3LT\:V76=';(
M&?_?\//+_]AWQV^5,8SEM)H4LUVV:Z@]FSQ[*.\$KH^^P$YD=YMH&X!<;IN-
MQAUUHVR#Q-NML=6] S;#?U3+U4J?1W"V4BT#580BEFK=B6Z]DZ! &0\8@TF(
M HAPEL.<2.QI%A%$6)H69A68+<:<'$]5VAO8B%VW'"@;P75W@KJDR<JR&(WA
M!!CL]-S#ZIN3-**MQ$")#%J9U=']P/(^AHA:[%?<(SMB#/F3Q7L+"!=+N>5E
MG&VHWAPLA>!ZS\";$L^N]@EVF/8:\8:/&L_"MM-MS_RUO-6^R.Q7_*M\WCPW
M]1&QP!G&JN]CK"IG\X! G!,!PX3F!2$9$851M<EW3YX:>S?"F1>0W<>IGW[/
MTMXSR39R.2P8>53;<RO#[C]TM&JP!W7I5H ]?,&P;>'-\\M\^<KY Z]^EI0?
MV>W.-?JZ:_,]I\NG1?E?<K.K=ZNZY/Z7;;$5%:.1\E1%9T29BM- ,*=";B-3
MAM0WS TK0WN2;VHTT#0JL-LUNIXSLPWF!\[$&.YW2/;=ZCL'ST7;U8/IS>H5
M?BG7>*[TN@"7S\N-MT(\GA!WN;EU+>*H^V!/^+[=,OL:QETQB"\E)N6\7+\V
M;__J>L-5;[5'^:KPF4 %)21.5<M( 1%C A*""QBBC.91&M.@, J]&RS!U$A;
M6OSQ^74B^D$WXV2O4'IFW2/5)"[ 5H&+EHU7%T JH;M3 JV&WR(31@CZKCO1
M+\2'EZ(PPLBD.H79@X:V-- 5_+_C:OW:% R-1)0&J!"049I %#$*,0DSR!,2
MI4E2Y$$>V+4S>#O$U-BJD1!H$0<68#T I!E!G0>/9P:R1&9 !X-CRKOM7O!N
ME)$[%QS3\GW7@J-7#DQ$WN8PN+&QZIS<7$28"40@0YQ+BBABB(,P@0&)(RPR
M1GE(K/*9?4@Y-99QL(<:E$[MY0TPX[8/G]?I;XN=)X7[A-QI;KD70<=-4?>)
M];M,=Z^##5M=MI$W30;<@K6V:LE77^LJC>QN(<??5.I(2E[P;;FHVG]*H<O5
MFW38C'!<I F&1*BR-S&+(%$!UJE@7(A(Q#$W"K#V)^+4UI5=$"KXNBN,N5+%
M31LE-/MTM;);03S,LMGR\;%SYWGM&#!M-HGLU@N'/[!=KAH>I!QUR?"'\MOU
MPN-( [<B:IWZ7LD5:X80R0J6Y#!+,G4$%N2JET,.@RR@22%(@&D\^\DKLC3>
M06P?;O.)=X?P]Z5?S9<K]?76*8DO2DB=CKA9L<&IB!TP#4WQ00"-83\#+95#
M"_B=ID[-UMW3Q[4UWVGUSD!\?\6 Z,)K3M97RY]\@1?KK^5"G:+_[PVNI"$S
M?[WG\N<;U3#J95ZJ")<9CR*1"Y3!,,]S=?"!8)X&%!:(%%&(J,B(D:_0?NBI
M66%*>$ ;Z2_ <RT_^'^M J"J-=!M"FL5+ +D[&:EGQ'\8NV9,33,5UN8&]'!
M5G;0" ^N_,-L$8[H#>Z1HA)=PFX7=#@(N=[80[LGCA>".$C3O4C$84\89LU=
M_L3E7)F'GY?5 Y[S!V4X:MM22;'[URP61<P"&D*&0@)1AA.8XY3 B(LTHX0)
M8=<[P73@J2T0NYQF.TO/&&@S.] '?&-P_DZR"[#5 8IE!5=2"W?6HRT^+FU+
MX[%'M3QM$7EKEUK?/\1J;99!E4JHZ_3<+H2J1:$]H405[*'K610F0<Y)#GG&
M.$0B1A G/(1YEF4DQ&F0A:FYL6HPXM0HZ/KNZL^O-]\>P>6W:R#_O'W\3W#[
M[?/=_=?+Q]N[;^#OK> V]1&-H#>Q2!T#ZIN4/@Q+&[/3,:9C69MMO7-=JZ$N
M:-:1O(.MJ]06&Z#ZC4N3!XUH4UKHM6]*VMPX@+ OY<,99_+Q]WRE:CBSJXJS
M<GWY5''M"&^R.+(@#(.<!; H*(8H1@+F',42>9(0DC,<%D9=7VT&G1IM-V+K
MKZ$5'-22@ZWH%BQCBKT!:7M U#-O&X%Y.O5F.*H6].T!W?%+HK2 XU[ Y?]Y
M78IWO022XK_J.@+%!5 4ZXKE+?'L)7K39XW']9;:[=&][;T#?09R)='U&,N?
MG5V *J391$QBFL:L* HHBD! E$<$%B(/81 '+(N#4*2Q51S]J0$GQ_0=>?=V
MO$KD@8&I)T$W]!LXA-(WQ9^'HKW+P! :IZZ"4V..ZR(P1."=:\#TOJ'![6OY
M$,[:BI275"Y^&QUA>\U%2<OUC/(XY#%G,$@S:5]2D<,\IS$D(J$B)4$:<J-L
M:O,A)\<Y.PD!JT6TC7P_B;(9Q;C%SC/)M,+NRMO^UD6R$=A!'VE[=-R&SI\<
M=>10>E,4WH?6&]]Y;JC]<8]G'3P=()[R($=0A!2I&$<$29C%,*1QF*$X945F
ME0%N//+4N*?;U^>]4[^S=I\;^GYJ1LP(R@O.GGG*'<1GA*(;PN4GO/S4X!\4
M,FZ(R?$P<-,'#/#.?:I*]L3_DMQ8?>-__4_%!*^-^R+$+,F+G$%I'#&(4J+Z
MC004)CC,LQ!G21Z8]ZT^/L[4F*HCJ=Q'\+] +:R%?Z@'4P-'FQND/'--1\@.
M1D.<:3U@6?C/W( VDLOL.Z^4@:*+_2YUO=\V@4-5H#[R_KGRC)U&JM<9UG/[
M>/ZOTSKLN;P,+A_:F.D1_[IE\HTII5FI9_";;@H^"UA"@D"N5223UA["*(=%
M@#+YGP13P@."0Z/<EI,C38T]FS,\*2W8%Q?4\MHV;3H&<#^1.H7-,Y4.1FQ
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MG-W\HNIXO\[CR((X0H@2F,9%#A'EZG@]DX9HE&:J<F.89E957P=),35>54J
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M?][??OL#//[M1GEF;^^N_[MMQK+=-)AQF$=P/5/9MO7-;]?=%BD'*[+^7:D
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M6>]PTG0(2(MS.P_P=+USNX-,FXH=AR!R.'?S %5/1VQW1>%:O;6EC\5J+<S
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MO(O\R-(,4$LH,(8 8PFX!P_@&S@SK0G-F!A[@#8(_%:89!D4<_+ N-9+[7Z
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M(C,N)$4R]UIA$)*EJE+#^ PMC5P?Z29KL*NL=[8P.Z-F849O:^Z6;)1!ZL#
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M_.,;=*V%(_=.<-2E#AHP.W^'X?DWI/N@#)TZAR]7I3SK."]8NW>QZ3&7WK%
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M(QY6S62\5LHX*XFE@A%IDB66<4TXE ,;H$+%*M[8L]0T IS=M?VX6F5GT3>
MGWL==U?M@X2WE/(D"(VE_9BC0&S E:8Q5J+ .$;JM;NS]]GEK4/MOMS<> M1
M-X"5%Z86KYA18+FRPI,L10DTV&)2E"':<A>U%<&I*KAYE:I^4]C=8Z@[%32
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MO-X!>@.=]'_R_6P9R@G$R3@.1_" L[/)FH*^&UDI?&)6)B+!HU MNB0!2A&
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M6*;1R%*RQD(H76""),$)1Y1GP0)JHE) 61^\U2X"M@K>#3392B?S)4^/.#G
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MB9**=@@518F3VMO2E"K6Z4U1,UGX:O0W^^7ZWK^6U40<F:2X9HCQM @A.>+
M 3$8!5JM)1/&U U[UB.TX5!]$QR]'-=4T%<#F^WM** R4VI^70Z))N/%9*!2
M;^NI*O&7)MR (1(@D6 =+Y+C@EEM ZURL>%5JEJYKE@#$(_1UYEV&H#:(QY6
MA;\I1QND+-?87*EPB [C+V3'Z605MU)H5\5[>Y::GJ'5G;8?=[G:6?0-X ?)
MOYB,%Y4,JW)O:;U&.C,!)CTN+:I)8*5-5ZEH *UCSI7:MC^BI%_<=*#=)VW:
M=Q%U UAYQC8O%E&2,NB<8[EA@-%'D&7<2F)$<<&#]L""JU(H_P(]K=S,VL-6
MUH5&&@76,A]S<]'1 D474QK">=8EVV*)MR&1S(/QUGL=8Q6?Z4W*VO#0=]+_
M&IC:7AE]IW@?W&3BC(7 DB!9F])54"[ZTK,RZ<XRZPPSCY-:S=[UJJ2M%R^!
M;2*Z!BS*<@SZK>_WN?S"S>) >TI=S!YIYZ48#Q0)- >B*)49>,[&56D%^PI-
MK5S5VL.6U95FV@79:MUQ*:FP@,X=M6B#);)E%:Y 3KW0%JP6H4JB[56J^C56
MG>E^/4QMH8@&4'4*(_S1^:\PAJD?'8S30;H8CH<E[;:L^KV$\0QF*[MLC&,V
M*4]X*-;=EA8?OO2"4&BG)4BCZZ1S-Z*R2=1M@X['F:1JJFH AXMF,U=Q?C5%
M%C],9G/DKYR@3K_#8L%"0N.?0R#,4E]\3$H"T$PR1.]!65RP54J'WJ"KW[/L
MO6ZE76JH <"=X>=*I=,]IE9KU*AH,^1,-(NX1HUFI R8(L)(JDT2V;,J*:D7
M*>K7H'6J]TD-)32 IL.+R]'D&N"T# KVXP@W@8QC4I<+.,:6GE@V ,'_HZRD
M3HXZY7.E01#/T],ODCK2]N/$> >B;P!!GW KG\-GW,C3$>ID?#Y$@[VL%OKE
M^C?_'Y/IAY&?+<\1=-11207$,?Q#!JJ)*\EAJ03-7BGG?!4W; ,:^RV5V>O&
M6$MS;8/RCK%['>*B+^,K@B*1!U/JVSFQ3A<H!>V"EC[)*N9N0SK[-8/5\+(^
M+G=67@/8?*/0\J:=5 83K5>$9^[+.9HMIZV9!,Y<"")DYU@-1*Y%7;,XW!T?
M3W(F72NK 00^L[=\OKV$719L,$P3YLJ8GXS;BK,L$)&U]H9E+ER=J?>O$-7O
M9."^SRJWTTW?1TH/[]UKS3GU/A"7R[W[Z#*Q*2>2G5%,)::E6.\ZW^9]#_9Y
MJ+2EJB:=R*UOC3]_I_!)%Y"CV>P*TL %1Y/%@"E'M;@9$(F7$O"?4?)$M;1^
MLRX9:[VVC2MPW2*FGMS[1M1:362TXQEX&4["BX/I*&[OS 3B%7=4NQ18RFL!
MJ;.V/M7OKW6+G\ZEW#=L7NC]DJQBB5E&N+(8D^B,5I5E2Q3ZA<K0J/.:=0T[
M-.&I?CVLX\UH=TDVY._>J]"_)Z83&/DYI)(AG@U2="DS;HF/693]5I"@;23:
M(Y,900ZLRI6']4ELXRY79S"KK*.&T/=@>Y[-C_/-9<IE,^JSJ1_/?+SY\6Q@
M@I+6>$NX2.6*,)4D9$J)%=XZDYGS7->$XH;T]ANC5<=E3>WUO5]^18I_@^DY
M3+\NA'W\QQ@?_&UX^<OUURDL?W)Z%6;#-/33ZX5K\&TR0H7.!MX)]!H])X*6
M^[U>.^00&<[!JV@D-V;-N]O;T[ 6\,R[ =X^-?(>@+?\R<(SO6&1):&<YH*D
MK V1)=/FO $T9,S+$*Q+R78&NJ?O7PMP]L<#W(Z::&@KON=D/.QZ5*SXDK+E
MQ9:C,;X<T)XO@^>#<2I?+))\VD+@AFIB?#GZ92X1QYTAR1B0RG!A:)5JBPYY
M6 O([MT N6\M]VU--^#[+K"_=62F2UD<_.&G"=T7Z@)C*']K%N.MHB6!*KM(
M80M&N0ITO:1*AT2ME^VE[P:OO2KM'8'UU^ED-AM80'>:&T\H9QQ78LC$9^25
M1I8LE1ZX7R][L^F;UX/=.SMEJ"K^!G;ZA4O\=3J,,%@T=BY#'6$QWHFB+^R4
M1Y<E>,N3,,Q#E9/T.Q+60]#[.7784<A;PP.M7YA4,C[+A/='@ M(2S?@TV1Z
M;T+ZU?027ST;R*R3#[@$!$"Y,R@4">!+6MSJQ*QPR?IMS=":-*P'IW=V"+$G
ME31@FFXZ AY=7/KA='G7 @VL<\93,)JDZ(N!90:W<<^(BT(+9BFD5*5']_/D
MK(>Q]W.:T:'P&X#0'?6E;]_#$JAE==2H5$<-4@P^>5^Z=11)>:Z)!T-19D$J
MG25G=5H.K$G?>B![?V<9-=33H+]^<X/Z7L>.Q=GQZMAX#NEL<N]G@\B4=XK:
M<H1<.MW+,E6+*J(T%U9HXQC=>B[*AK2LA[SW<UK1AXKZ1N2CLH4'X<L)^@R^
MS%DHB_!7/QPOK+S-WC-N*;& @8P4G)/@-*XWY)I)J:EPZ_EN&[]Z/;R]LT.*
MN@K8'%YN":\QG)>SXK/*6>,5ZP^XOFDM?CTPSB0M<6<T616?- MBT=83Y[+F
MZ%_P9*I<^]R"UO6P^7[.,_:EMK[MWS(\6@9&98CE_?3@$WO_%:8'YU-8+,=!
M5E89K3BA&40YM0G$6E#$&,J9$09R6K,!_+8DK(>Y]W/TL$>%O,?&Q"^E%H?C
MY<EBM_V*UWU;]3;&6[&]C^[&9=(B) 1VC#1@X&$,\5P@X@4$'V1 +.YK=^JO
MNS%U20:&QCT#=26C'3#<CY%@K"^B2* 9JSS4Y=UW-]X$1SMW-]Y$7PWD:%YJ
M.B>X%)%J15 ^Z&*48>>6R4 RS5Y&"I)#U1%?V[2!;*>C\48@6+,-Y"8::118
M#WO9:>>%B@K#=JMP69ID2*!,$J\H+)K0";:ORM'WT 9R(_UOW 9R$V7T'5(\
MZF4HN4P)5YE&B4B'7_GB# LFM8XV2?LX>?P#M('<2%NOM(%<7W1M6I1[X9#,
M0@61D(/ <(]'7FS@Y6XK6*%Y-JI.'_Z=[P.WT[NXXTUK.]TTA+,N"O-L\LA$
M3,2Z:(CD$0B*V!!6KC7&K+/352<O[:O\LJ>ZHDV 5;'\<A,M][UY=EK)!RIG
M+DK[IU+)%S+R[1TCT5-I>3)>VLZ+W3HIO^RIB&D+N/:JLW>$U67YG\F2&NXR
M 8W.$7)HB)76$XJ4"9]EM)"Z!N3ZU9<]U3KM 76;2W][:$WF?M3;@9F.#EAI
MFAY<.1H,.9' O2 J*8>N=,! K$KY4ZT#LYY*HSK?M[O3VOMR0-E T)B9892
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M^W0^7MP.8G&6FHP*@0>T\<)@6.(3]4"5XXD*F2BI,Y5Z.TVMA(R] JIO630
MJ]\__S;]D6:3PJNSJS0):.,_?YW.%OB*;\7!O#?]ZP5*E5,HDR4M+@8$12_
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MW_:MDF@: ]UZ(UJ>.:7(F40]*1VI(MC$)7!!A'"9>,6J7$1]2LJP.JN6T%_
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M4SKX: 4!I[P;UIUL[GH1W/AYF(V7$[DO"Q^4=#Z$9$&51(*(5H"SRH+7PM/
M?6:A2@UPK05UJQH^@2.=IB3?P YX<(3UVGT?+]SURCV_1 G/?J3X=CI[>[.X
MF:7;XX>1M892%24HC:&?<,X#>N[EOA(ZZEK*H$V5N5@[4]H-LR=T-E175D.[
MP0]6]VX29@DWWKM)QW7FY)2EKN1M2V?DK!48S0-0*S&D],I[I3JYP@<0T0UN
M)W"V<U1I-* "7TQ3;.TV-!]%FQEN(P9>QM*_KGRGDP+J#:,^)0PUZPP(W(_>
M;O@\I3.>(\AM:*6XMYMRL?1(YF>3>'L>>]OG=WZQ^)IF7[ZZR?IWEI>2Y^\F
M*_9]F>(.7_ZH./1OW7BVK/\=$2ZY)KB5<?MF$*1X]B($D$(+8HQ*@71K4M;,
MDKIMB!,X=&J+K3LAI0'U?W:]_)T4G^?@^5_E6XQL/:6Z3%V/AHJB-01XPR-8
M)W7T/B::JQSC=R.O&Y9/Z&RJ@E2&UN7/I:M7Q@H_^8'O*.E$IZ55F9:I(-J!
M4!A(&I<M6)]"Z;L>8^QV\-3E;=U0<RK'3;WS=VC G.><PF+\(YW_A>X+KNRR
MR&9DJ U4! 5!E#DR4D1<@M9%@1 M%>K>S:;CV]J%/OO\;J XE6.C'GC8@(W:
MV[@O&^H].*Y8QG+E4W?]\$FEIG2D N=&E$+27"8Q8!2'?G$.8%64QL5,/*G<
M-ZK>XKJ!^@3.JII%Q-#*\J562)MK_GTR2V%Z-2E79I<+#5P)3TR $$N>+/L
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M\ 1M/2\G_;583D?\OWHXKORZJDI<9>P_3A?IS,\7,X39B,;DI74!\&NY&(J
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M'"-<9M'M8MVN;QY&B?0DY>V8Z9GE SLH7\:+,OO@W22.?^""UET2LI<Q,.)
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MQ'V:EDBC7#7_M.3SQ9\3?/#7\?=7/S_-TNJ3PMMQ++?.ESQ96_Q1= J-N>)
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MB>8\G0$[P\1YE2N4:'5XK=4[@&!%JR?"4WB41.;3@'K2SRB[;@1# "?9LO-
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MZ#\D50?>-Q"N9VN!E744ZP&KM%EQ'/\ *I-$6,OY*V5KHL"BW'LF8)]7LH<
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MDLRQBDI)_;IJ[1]^X5U_5N_?]5\">G\#4$L#!!0    ( +$[!E'D,>9OG 4
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M;G-E86=R92YH=&U02P$"% ,4    " "Q.P91_N3Q7?LB  !T, $ &@
M        @ $"W@  97@Q,#)A9W)E96UE;G1N;S%T;V%R8RYH=&U02P$"% ,4
M    " "Q.P91H080-+LX @#  AH $0              @ $U 0$ ;6YL;RTR
M,#(P,#8S,"YH=&U02P$"% ,4    " "Q.P91HS0PF;H2  #UO0  $0
M        @ $?.@, ;6YL;RTR,#(P,#8S,"YX<V102P$"% ,4    " "Q.P91
MD=^I[J@A  !)60$ %0              @ $(30, ;6YL;RTR,#(P,#8S,%]C
M86PN>&UL4$L! A0#%     @ L3L&48%&_4;690  5S0$ !4
M ( !XVX# &UN;&\M,C R,# V,S!?9&5F+GAM;%!+ 0(4 Q0    ( +$[!E'.
M=I1%[O,  (25"0 5              "  >S4 P!M;FQO+3(P,C P-C,P7VQA
M8BYX;6Q02P$"% ,4    " "Q.P91$567;1"1  ##908 %0
M@ $-R00 ;6YL;RTR,#(P,#8S,%]P<F4N>&UL4$L! A0#%     @ L3L&4=3.
M(U,W"   "RP  !@              ( !4%H% &UN;&\M,C R,# V,S!X97AX
M,S$Q+FAT;5!+ 0(4 Q0    ( +$[!E'N'U"!+0@  /\K   8
M  "  ;UB!0!M;FQO+3(P,C P-C,P>&5X>#,Q,BYH=&U02P$"% ,4    " "Q
M.P91U6Q4R*8%  !D&   &               @ $@:P4 ;6YL;RTR,#(P,#8S
M,'AE>'@S,C$N:'1M4$L! A0#%     @ L3L&4>0QYF^<!0  51@  !@
M         ( !_' % &UN;&\M,C R,# V,S!X97AX,S(R+FAT;5!+!08
..#  , #(#  #.=@4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
